ANTI-CANCER PHOSPHONATE ANALOGS

This non-provisional application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Serial Nos. 60/465,588; 60/465,594; 60/465,465; 60/465,569; 60/465,467; 60/465,631; 60/465,714; 60/465,589; 60/465,586; 60/465,607; 60/465,668; 60/465,287; 60/465,343; 60/465,471; 60/465,567; 60/465,545; 60/465,394; 60/465,603; 60/465,614; 60/465,339; 60/465,325; 60/465,377; 60/465,415; 60/465,575; 60/465,844; 60/465,559; 60/495,387; and 60/465,531; all filed April 25, 2003; and to U.S. Provisional Patent Application Serial Nos. 60/493,303 and 60/493,310; both filed August 7, 2003; and to U.S. Provisional Patent Application Serial Nos. 60/495,382; 60/495,685; 60/495,527; 60/495,686; 60/495,525; 60/495,629; 60/495,484; 60/495,644; 60/495,297; 60/495,682; 60/495,784; 60/495,751; 60/495,565; 60/495,789; 60/495,736; 60/495,769; 60/495,647; 60/495,645; 60/495,362; 60/495,339; 60/495,534; 60/495,669; 60/495,425; 60/495,524; 60/495,426; 60/495,393; 60/495,387; and 60/495,416; all filed August 15, 2003; and to U.S. Provisional Patent Application Serial Nos. 60/514,462; 60/513,971; 60/513,969; 60/514,394; 60/514,393; 60/513,944; 60/513,956; 60/513,923; 60/514,202; 60/514,247; 60/514,461; 60/514,369; 60/514,452; 60/514,439; 60/513,948; 60/514,424; 60/513,972; 60/513,925; 60/513,926; 60/513,927; 60/514,368; 60/514,207; 60/514,115; 60/513,980; 60/514,131; 60/514,105; 60/514,280; 60/513,963; 60/514,145; 60/514,159; 60/514,083; 60/513,949; 60/514,144; 60/51,4481; 60/513,974; 60/514,108; 60/513,979; 60/514,084; 60/514,161; 60/514,304; 60/514,235; 60/514,325; 60/514,359; 60/514,113; 60/514,114; 60/514,112; 60/513,968; 60/514,345; 60/514,346; 60/513,564; 60/513,588; 60/514,298; 60/514,330; 60/513,932; 60/513,976; 60/513,562; 60/514,258; and 60/514,258; all filed October 24, 2003; and to U.S. Provisional Patent Application Serial No. 60/519,476 and 60/519,476; filed November 12, 2003; and to U.S. Provisional Patent Application Serial No. 60/524,340; filed November 20, 2003; and to U.S. Provisional Patent Application Serial Nos. 60/532,230; 60/531,960; 60/532,160;

and 60/531,940; all filed December 22, 2003; and to U.S. Provisional Patent Application Serial No. 60/532,591; filed December 23; 2003; and to U.S. Provisional Patent Application Serial Nos. 60/536,007; 60/536,006; 60/536,005; 60/536,054 and 60/536,054; all filed January 12; 2004. The entirety of all Provisional Applications listed above are incorporated herein by reference.; which is incorporated herein by reference.

FIELD OF THE INVENTION

The invention relates generally to compounds with anti-cancer activity.

BACKGROUND OF THE INVENTION

Improving the delivery of drugs and other agents to target cells and tissues has been the focus of considerable research for many years. Though many attempts have been made to develop effective methods for importing biologically active molecules into cells, both *in vivo* and *in vitro*, none has proved to be entirely satisfactory. Optimizing the association of the drug with its intracellular target, while minimizing intercellular redistribution of the drug, e.g., to neighboring cells, is often difficult or inefficient.

Most agents currently administered to a patient parenterally are not targeted, resulting in systemic delivery of the agent to cells and tissues of the body where it is unnecessary, and often undesirable. This may result in adverse drug side effects, and often limits the dose of a drug (e.g., glucocorticoids and other anti-inflammatory drugs) that can be administered. By comparison, although oral administration of drugs is generally recognized as a convenient and economical method of administration, oral administration can result in either (a) uptake of the drug through the cellular and tissue barriers, e.g., blood/brain, epithelial, cell membrane, resulting in undesirable systemic distribution, or (b) temporary residence of the drug within the gastrointestinal tract. Accordingly, a major goal has been to develop methods for specifically targeting agents to cells and tissues. Benefits of such treatment includes avoiding the general physiological effects of inappropriate delivery of such agents to other cells and tissues, such as uninfected cells.

Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells.

Many of the current treatment regimes for cell proliferation diseases such as psoriasis and cancer utilize compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on rapidly dividing cells such as tumor cells can be beneficial. Alternative approaches to anti-proliferative agents which act by mechanisms other than the inhibition of DNA synthesis have the potential to display enhanced selectivity of action.

In recent years it has been discovered that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene i.e. a gene which, on activation, leads to the formation of malignant tumor cells (Bradshaw, Mutagenesis 1986, 1, 91). Several such oncogenes give rise to the production of peptides which are receptors for growth factors. The growth factor receptor complex subsequently leads to an increase in cell proliferation. It is known, for example, that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden et al., Ann. Rev. Biochem., 1988, 57, 443; Larsen et al. Ann. Reports in Med. Chem. 1989, Chpt. 13).

Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research, 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine kinases such as the EGF, TGF.alpha., NEU, erbB, Xmrk, HER and let23 receptors, Class II receptor tyrosine kinases comprising the insulin family of receptor tyrosine kinases such as the insulin, IGFI and insulin-related receptor (IRR) receptors and Class III receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor

tyrosine kinases such as the PDGF.alpha., PDGF.beta. and colony-stimulating factor 1 (CSF1) receptors. It is known that Class I kinases such as the EGF family of receptor tyrosine kinases are frequently present in common human cancers such as breast cancer (Sainsbury et. al., Brit. J. Cancer, 1988, 58, 458; Guerin et al., Oncogene Res., 1988, 3, 21 and Klijn et al., Breast Cancer Res. Treat., 1994, 29, 73), non-small cell lung cancers (NSCLCs) including adenocarcinomas (Cerny et al., Brit. J. Cancer, 1986, 54, 265; Reubi et al., Int. J. Cancer, 1990, 45, 269; and Rusch et al., Cancer Research, 1993, 53, 2379) and squamous cell cancer of the lung (Hendler et al., Cancer Cells, 1989, 7, 347), bladder cancer (Neal et. al., Lancet, 1985, 366), oesophageal cancer (Mukaida et al., Cancer, 1991, 68, 142), gastrointestinal cancer such as colon, rectal or stomach cancer (Bolen et al., Oncogene Res., 1987, 1, 149), cancer of the prostate (Visakorpi et al., Histochem. J., 1992, 24, 481), leukaemia (Konaka et al., Cell, 1984, 37, 1035) and ovarian, bronchial or pancreatic cancer (European Patent Specification No. 0400586). As further human tumor tissues are tested for the EGF family of receptor tyrosine kinases it is expected that their widespread prevalence will be established in further cancers such as thyroid and uterine cancer. It is also known that EGF type tyrosine kinase activity is rarely detected in normal cells whereas it is more frequently detectable in malignant cells (Hunter, Cell, 1987, 50, 823). It has been shown more recently (W. J. Gullick, Brit. Med. Bull., 1991, 47, 87) that EGF receptors which possess tyrosine kinase activity are overexpressed in many human cancers such as brain, lung squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynaecological and thyroid tumors.

Accordingly it has been recognized that an inhibitor of receptor tyrosine kinases should be of value as a selective inhibitor of the growth of mammalian cancer cells (Yaish et al. Science, 1988, 242, 933). Support for this view is provided by the demonstration that erbstatin, an EGF receptor tyrosine kinase inhibitor, specifically attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma which expresses EGF receptor tyrosine kinase but is without effect on the growth of another carcinoma which does not express EGF receptor tyrosine kinase (Toi et al., Eur. J. Cancer Clin. Oncol.,

1990, 26, 722.). Various derivatives of styrene are also stated to possess tyrosine kinase inhibitory properties (European Patent Application Nos. 0211363, 0304493 and 0322738) and to be of use as anti-tumor agents. The *in vivo* inhibitory effect of two such styrene derivatives which are EGF receptor tyrosine kinase inhibitors has been demonstrated against the growth of human squamous cell carcinoma inoculated into nude mice (Yoneda et al., Cancer Research, 1991, 51, 4430). Various known tyrosine kinase inhibitors are disclosed in a more recent review by T. R. Burke Jr. (Drugs of the Future, 1992, 17, 119).

Cancer is a major health problem worldwide. Although drugs targeting tumors and cancerous cells are in wide use and have shown effectiveness, toxicity and side-effects have limited their usefullness.

Assay methods capable of determining the presence, absence or amounts of cancer are of practical utility in the search for anti-cancer compounds as well as for diagnosing the presence of cancer.

Inhibitors of tumor growth are useful to limit the establishment and progression of cancer, as well as in diagnostic assays for cancer.

There is a need for anti-cancer therapeutic agents, i.e. drugs, having improved anti-cancer, as well as pharmacokinetic properties, including enhanced activity against development of cancer, improved oral bioavailability, greater potency and extended effective half-life *in vivo*. Such anti-cancer compounds should be active against various cancers, have distinct resistance profiles, fewer side effects, less complicated dosing schedules, and orally active. In particular, there is a need for a less onerous dosage regimen, such as one pill, once per day.

SUMMARY OF THE INVENTION


Intracellular targeting may be achieved by methods and compositions that allow accumulation or retention of biologically active agents inside cells. The present invention provides novel analogs of anti-cancer compounds. Such novel anti-cancer compound analogs possess all the utilities of anti-cancer compounds and optionally provide cellular accumulation as set forth below. In

addition, the present invention provides compositions and methods for treatingcancer or therapeutic activity against cancer.


The present invention relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of phosphonate-containing molecules in cancer cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.

Accordingly, in one embodiment the invention provides a compound of the invention which is a conjugate comprising a chemotherapeutic agent linked to one or more phosphonate groups.


In another embodiment, the invention provides a compound of any one of formulae **500-601:**




500




501




502




503




504




505




506




507




508




509




510




511




512




513




514




515




516



517




518



519




520




521


5




522




523




524




525




526




527




528




529




530




531




532




533




534




535




536




537




538




539




540




541




542




543




544




545




546




547




548




549




550




551




552




553




554




555




556




557




558




559




560




561




562




563




564




565




566




567




568




569




570




571




572




573




574




575




576




577




578




579




580




581




582




583




584




585




586




587




588




589




590




591




592




593




594




595




596




597




598



599



600




601

that is substituted with one or more groups A^0,

wherein:


A^0 is A^1, A^2 or W^3 with the proviso that the conjugate includes at least one A^1;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$; and when Y^2 joins two phosphorous atoms Y^2 can also be $C(R^2)(R^2)$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12

In another embodiment, the invention provides a compound of the formula:

$$[DRUG]-(A^0)_{nn}$$


or a pharmaceutically acceptable salt or solvate thereof wherein,

DRUG is a compound of any one of formulae **500-601**;

nn is 1, 2, or 3;


A^0 is A^1, A^2 or W^3 with the proviso that the conjugate includes at least one A^1;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$; and when Y^2 joins two phosphorous atoms Y^2 can also be $C(R^2)(R^2)$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;


M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;


M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.


In another embodiment, the invention provides a compound of any one of formulae **1-336**:




1




2




3




4




5




6




7




8




9




10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32





33





34



35



36



37



38



39



40



41



42



43



44



45


46



47


48



49




50




51




52




53




54




55




56




57




58




59





60





61



62



63



64



65



66



67


68



69


70



71




72




73




74



75




76




77


5




78




79




80




81




82




83




84




85




86



87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108




109



110




111




112


5




113




114




115




116




117




118




119




120




121




122




123




124



125




126




127


5




128




129




130




131




132




133




134




135




136




137




138




139




140




141




142




143




144




145




146




147




148




149




150




151




152




153




154




155




156




157




158




159




160




161




162




163




164




165




166




167




168




169




170




171




172




173




174




175




176




177




178




179




180




181




182




183




184




185




186




187




188




189




190




191




192




193




194




195




196




197




198




199




200




201




202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226




227




228




229




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248




249




250




251




252




253




254




255




256




257




258




259




260




261




262




263




264




265




266




267




268




269




270




271




272




273




274




275




276




277




278




279




280




281




282




283




284




285




286




287




288




289




290




291




292




293




294




295




296




297




298




299




300




301




302




303




304




305




306




307




308




309




310




311




312




313




314




315




316




317




318




319




320




321




322




323




324




325




326




327




328




329




330




331




332




333



334



335




336

wherein:


A^0 is A^1;

A^1 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$; and when Y^2 joins two phosphorous atoms Y^2 can also be $C(R^2)(R^2)$;

R^x is independently H, R^2, W^3, a protecting group, or the formula:



;

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

R^{5a} is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

X^{50} is H F, or Cl; and

X^{51} is H or Cl.

The invention provides a pharmaceutical composition comprising an effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.

This invention provides a method of increasing cellular accumulation and retention of drug compounds, thus improving their therapeutic and diagnostic value, comprising linking the compound to one or more (*e.g.*, 1, 2, 3, or 4) phosphonate groups.

This invention also pertains to a method of increasing cellular accumulation and retention of a chemotherapeutic agent comprising linking the compound to one or more phosphonate groups.

The invention also provides a method of treating cancer in a mammal, comprising administering a compound of the invention to the mammal.

The invention also provides a compound of the invention for use in medical therapy preferably for use in treating cancer, as well as the use of a compound of the invention for the manufacture of a medicament useful for the treatment of cancer.

In another aspect the invention also provides a method for inhibiting cancer activity comprising contacting a sample in need of such treatment with a compound or composition of the invention.

The invention also provides processes and novel intermediates disclosed herein which are useful for preparing compounds of the invention. Some of the compounds of the invention are useful to prepare other compounds of the invention. The invention also provides novel methods for syntheses of the compounds of the invention.

DETAILED DESCRIPTION

Reference will now be made in detail to certain claims of the invention, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated claims, it will be understood that they are not intended to limit the invention to those claims. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

DEFINITIONS

Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings:

When tradenames are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.

"Bioavailability" is the degree to which the pharmaceutically active agent becomes available to the target tissue after the agent's introduction into the body. Enhancement of the bioavailability of a pharmaceutically active agent can provide a more efficient and effective treatment for patients because, for a given dose, more of the pharmaceutically active agent will be available at the targeted tissue sites.

The terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to a heteroatom , 3) single-bonded

to a heteroatom, and 4) single-bonded to another heteroatom, wherein each heteroatom can be the same or different. The terms "phosphonate" and "phosphonate group" also include functional groups or moieties that comprise a phosphorous in the same oxidation state as the phosphorous described above, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having the characteriatics described above. For example, the terms "phosphonate" and "phosphonate group" include phosphonic acid, phosphonic monoester, phosphonic diester, phosphonamidate, and phosphonthioate functional groups. In one specific embodiment of the invention, the terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to an oxygen, 3) single-bonded to an oxygen, and 4) single-bonded to another oxygen, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having such characteriatics. In another specific embodiment of the invention, the terms "phosphonate" and "phosphonate group" include functional groups or moieties within a molecule that comprises a phosphorous that is 1) single-bonded to a carbon, 2) double-bonded to an oxygen, 3) single-bonded to an oxygen or nitrogen, and 4) single-bonded to another oxygen or nitrogen, as well as functional groups or moieties that comprise a prodrug moiety that can separate from a compound so that the compound retains a phosphorous having such characteriatics.

The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the drug substance, i.e. active ingredient, as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), photolysis, and/or metabolic chemical reaction(s). A prodrug is thus a covalently modified analog or latent form of a therapeutically-active compound.

"Prodrug moiety" refers to a labile functional group which separates from the active anti-cancer compound compound during metabolism, systemically, inside a cell, by hydrolysis, enzymatic cleavage, or by some other process

(Bundgaard, Hans, "Design and Application of Prodrugs" in A Textbook of Drug Design and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191). Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphases. Prodrug moieties can serve to enhance solubility, absorption and lipophilicity to optimize drug delivery, bioavailability and efficacy. A prodrug moiety may include an active metabolite or drug itself.

Exemplary prodrug moieties include the hydrolytically sensitive or labile acyloxymethyl esters $-CH_2OC(=O)R^9$ and acyloxymethyl carbonates $-CH_2OC(=O)OR^9$ where R^9 is C_1–C_6 alkyl, C_1–C_6 substituted alkyl, C_6–C_{20} aryl or C_6–C_{20} substituted aryl. The acyloxyalkyl ester was first used as a prodrug strategy for carboxylic acids and then applied to phosphates and phosphonates by Farquhar et al. (1983) *J. Pharm. Sci.* 72: 324; also US Patent Nos. 4816570, 4968788, 5663159 and 5792756. Subsequently, the acyloxyalkyl ester was used to deliver phosphonic acids across cell membranes and to enhance oral bioavailability. A close variant of the acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester (carbonate), may also enhance oral bioavailability as a prodrug moiety in the compounds of the combinations of the invention. An exemplary acyloxymethyl ester is pivaloyloxymethoxy, (POM) $-CH_2OC(=O)C(CH_3)_3$. An exemplary acyloxymethyl carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC) $-CH_2OC(=O)OC(CH_3)_3$.

The phosphonate group may be a phosphonate prodrug moiety. The prodrug moiety may be sensitive to hydrolysis, such as, but not limited to a pivaloyloxymethyl carbonate (POC) or POM group. Alternatively, the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.

Aryl esters of phosphorus groups, especially phenyl esters, are reported to enhance oral bioavailability (De Lombaert et al. (1994) *J. Med. Chem.* 37: 498). Phenyl esters containing a carboxylic ester ortho to the phosphate have also been described (Khamnei and Torrence, (1996) *J. Med. Chem.* 39:4109-

4115). Benzyl esters are reported to generate the parent phosphonic acid. In some cases, substituents at the *ortho*-or *para*-position may accelerate the hydrolysis. Benzyl analogs with an acylated phenol or an alkylated phenol may generate the phenolic compound through the action of enzymes, e.g., esterases, oxidases, etc., which in turn undergoes cleavage at the benzylic C–O bond to generate the phosphoric acid and the quinone methide intermediate. Examples of this class of prodrugs are described by Mitchell et al. (1992) *J. Chem. Soc. Perkin Trans. II* 2345; Glazier WO 91/19721. Still other benzylic prodrugs have been described containing a carboxylic ester-containing group attached to the benzylic methylene (Glazier WO 91/19721). Thio-containing prodrugs are reported to be useful for the intracellular delivery of phosphonate drugs. These proesters contain an ethylthio group in which the thiol group is either esterified with an acyl group or combined with another thiol group to form a disulfide. Deesterification or reduction of the disulfide generates the free thio intermediate which subsequently breaks down to the phosphoric acid and episulfide (Puech et al. (1993) *Antiviral Res.*, 22: 155-174; Benzaria et al. (1996) *J. Med. Chem.* 39: 4958). Cyclic phosphonate esters have also been described as prodrugs of phosphorus-containing compounds (Erion et al., US Patent No. 6312662).

"Protecting group" refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. Chemical protecting groups and strategies for protection/deprotection are well known in the art. *See e.g.*, Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.

Protected compounds may also exhibit altered, and in some cases,

optimized properties *in vitro* and *in vivo*, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug *in vivo*. Because active prodrugs may be absorbed more effectively than the parental drug, prodrugs may possess greater potency *in vivo* than the parental drug. Protecting groups are removed either *in vitro,* in the instance of chemical intermediates, or *in vivo*, in the case of prodrugs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g., alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

Any reference to any of the compounds of the invention also includes a reference to a physiologically acceptable salt thereof. Examples of physiologically acceptable salts of the compounds of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX_4^+ (wherein X is C_1–C_4 alkyl). Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound of an hydroxy group include the anion of said compound in combination with a suitable cation such as Na^+ and NX_4^+ (wherein X is independently selected from H or a C_1–C_4 alkyl group).

For therapeutic use, salts of active ingredients of the compounds of the invention will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base. However, salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts,

whether or not derived form a physiologically acceptable acid or base, are within the scope of the present invention.

"Alkyl" is C_1-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl (Me, -CH_3), ethyl (Et, -CH_2CH_3), 1-propyl (n-Pr, n-propyl, -$CH_2CH_2CH_3$), 2-propyl (i-Pr, i-propyl, -$CH(CH_3)_2$), 1-butyl (n-Bu, n-butyl, -$CH_2CH_2CH_2CH_3$), 2-methyl-1-propyl (i-Bu, i-butyl, -$CH_2CH(CH_3)_2$), 2-butyl (s-Bu, s-butyl, -$CH(CH_3)CH_2CH_3$), 2-methyl-2-propyl (t-Bu, t-butyl, -$C(CH_3)_3$), 1-pentyl (n-pentyl, -$CH_2CH_2CH_2CH_2CH_3$), 2-pentyl (-$CH(CH_3)CH_2CH_2CH_3$), 3-pentyl (-$CH(CH_2CH_3)_2$), 2-methyl-2-butyl (-$C(CH_3)_2CH_2CH_3$), 3-methyl-2-butyl (-$CH(CH_3)CH(CH_3)_2$), 3-methyl-1-butyl (-$CH_2CH_2CH(CH_3)_2$), 2-methyl-1-butyl (-$CH_2CH(CH_3)CH_2CH_3$), 1-hexyl (-$CH_2CH_2CH_2CH_2CH_2CH_3$), 2-hexyl (-$CH(CH_3)CH_2CH_2CH_2CH_3$), 3-hexyl (-$CH(CH_2CH_3)(CH_2CH_2CH_3)$), 2-methyl-2-pentyl (-$C(CH_3)_2CH_2CH_2CH_3$), 3-methyl-2-pentyl (-$CH(CH_3)CH(CH_3)CH_2CH_3$), 4-methyl-2-pentyl (-$CH(CH_3)CH_2CH(CH_3)_2$), 3-methyl-3-pentyl (-$C(CH_3)(CH_2CH_3)_2$), 2-methyl-3-pentyl (-$CH(CH_2CH_3)CH(CH_3)_2$), 2,3-dimethyl-2-butyl (-$C(CH_3)_2CH(CH_3)_2$), 3,3-dimethyl-2-butyl (-$CH(CH_3)C(CH_3)_3$.

"Alkenyl" is C_2-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp^2 double bond. Examples include, but are not limited to, ethylene or vinyl (-$CH{=}CH_2$), allyl (-$CH_2CH{=}CH_2$), cyclopentenyl (-C_5H_7), and 5-hexenyl (-$CH_2CH_2CH_2CH_2CH{=}CH_2$).

"Alkynyl" is C_2-C_{18} hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. a carbon-carbon, *sp* triple bond. Examples include, but are not limited to, acetylenic (-C≡CH) and propargyl (-$CH_2C{\equiv}CH$),

"Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two

different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to, methylene (-CH_2-) 1,2-ethyl (-CH_2CH_2-), 1,3-propyl (-$CH_2CH_2CH_2$-), 1,4-butyl (-$CH_2CH_2CH_2CH_2$-), and the like.

"Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene radicals include, but are not limited to, 1,2-ethylene (-CH=CH-).

"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical of 2-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene radicals include, but are not limited to, acetylene (-C≡C-), propargyl (-CH_2C≡C-), and 4-pentynyl (-$CH_2CH_2CH_2$C≡CH-).

"Aryl" means a monovalent aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, radicals derived from benzene, substituted benzene, naphthalene, anthracene, biphenyl, and the like.

"Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp^3 carbon atom, is replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, , naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The arylalkyl group comprises 6 to 20 carbon atoms, e.g., the alkyl moiety, including alkanyl, alkenyl or alkynyl groups, of the arylalkyl group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.


"Substituted alkyl", "substituted aryl", and "substituted arylalkyl" mean alkyl, aryl, and arylalkyl respectively, in which one or more hydrogen atoms are each independently replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -R, -O^-, -OR, -SR, -S^-, -NR_2, -NR_3, =NR, -CX_3, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO_2, =N_2, -N_3,

NC(=O)R, -C(=O)R, -C(=O)NRR -$S(=O)_2O^-$, -$S(=O)_2OH$, -$S(=O)_2R$, -$OS(=O)_2OR$, -$S(=O)_2NR$, -S(=O)R, -$OP(=O)O_2RR$, -$P(=O)O_2RR$ -$P(=O)(O^-)_2$, -$P(=O)(OH)_2$, -C(=O)R, -C(=O)X, -C(S)R, -C(O)OR, -$C(O)O^-$, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR, -C(NR)NRR, where each X is independently a halogen: F, Cl, Br, or I; and each R is independently -H, alkyl, aryl, heterocycle, protecting group or prodrug moiety. Alkylene, alkenylene, and alkynylene groups may also be similarly substituted.

"Heterocycle" as used herein includes by way of example and not limitation these heterocycles described in Paquette, Leo A.; Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; The Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and *J. Am. Chem. Soc.* (1960) 82:5566. In one specific embodiment of the invention "heterocycle" includes a "carbocycle" as defined herein, wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S).

Examples of heterocycles include by way of example and not limitation pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazoly, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl,

isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bis-tetrahydrofuranyl:



.

By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

"Carbocycle" refers to a saturated, unsaturated or aromatic ring having 3 to 7 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 20 carbon atoms as a polycycle. Monocyclic carbocycles have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of

monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl.

"Linker" or "link" refers to a chemical moiety comprising a covalent bond or a chain or group of atoms that covalently attaches a phosphonate group to a drug. Linkers include portions of substituents A^1 and A^3, which include moieties such as: repeating units of alkyloxy (e.g., polyethylenoxy, PEG, polymethyleneoxy) and alkylamino (e.g., polyethyleneamino, Jeffamine™); and diacid ester and amides including succinate, succinamide, diglycolate, malonate, and caproamide.

The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

"Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

The term "treatment" or "treating," to the extent it relates to a disease or condition includes preventing the disease or condition from occurring, inhibiting the disease or condition, eliminating the disease or condition, and/or relieving one or more symptoms of the disease or condition.

Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of

Organic Compounds (1994) John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

Protecting Groups

In the context of the present invention, protecting groups include prodrug moieties and chemical protecting groups.

Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthetic procedures, i.e. routes or methods to prepare the compounds of the invention. For the most part the decision as to which groups to protect, when to do so, and the nature of the chemical protecting group "PG" will be dependent upon the chemistry of the reaction to be protected against (e.g., acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups do not need to be, and generally are not, the same if the compound is substituted with multiple PG. In general, PG will be used to protect functional groups such as carboxyl, hydroxyl, thio, or amino groups and to thus prevent side reactions or to otherwise facilitate the synthetic efficiency. The order of deprotection to yield free, deprotected groups is dependent upon the intended direction of the synthesis and the reaction conditions to be encountered, and may occur in any order as determined by the artisan.

Various functional groups of the compounds of the invention may be protection. For example, protecting groups for -OH groups (whether hydroxyl, carboxylic acid, phosphonic acid, or other functions) are claims of "ether- or ester-forming groups". Ether- or ester-forming groups are capable of functioning as chemical protecting groups in the synthetic schemes set forth herein. However, some hydroxyl and thio protecting groups are neither ether- nor ester-forming groups, as will be understood by those skilled in the art, and are included with amides, discussed below.

A very large number of hydroxyl protecting groups and amide-forming groups and corresponding chemical cleavage reactions are described in Protective Groups in Organic Synthesis, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN 0-471-62301-6) ("Greene"). See also Kocienski, Philip J.; Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994), which is incorporated by reference in its entirety herein. In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184. For protecting groups for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid and other protecting groups for acids see Greene as set forth below. Such groups include by way of example and not limitation, esters, amides, hydrazides, and the like.


Ether- and Ester-forming protecting groups

Ester-forming groups include: (1) phosphonate ester-forming groups, such as phosphonamidate esters, phosphorothioate esters, phosphonate esters, and phosphon-bis-amidates; (2) carboxyl ester-forming groups, and (3) sulphur ester-forming groups, such as sulphonate, sulfate, and sulfinate.

The phosphonate moieties of the compounds of the invention may or may not be prodrug moieties, i.e. they may or may be susceptible to hydrolytic or enzymatic cleavage or modification. Certain phosphonate moieties are stable under most or nearly all metabolic conditions. For example, a dialkylphosphonate, where the alkyl groups are two or more carbons, may have

appreciable stability *in vivo* due to a slow rate of hydrolysis.

Within the context of phosphonate prodrug moieties, a large number of structurally-diverse prodrugs have been described for phosphonic acids (Freeman and Ross in Progress in Medicinal Chemistry 34: 112-147 (1997) and are included within the scope of the present invention. An exemplary phosphonate ester-forming group is the phenyl carbocycle in substructure A_3 having the formula:



wherein R_1 may be H or C_1–C_{12} alkyl; m1 is 1, 2, 3, 4, 5, 6, 7 or 8, and the phenyl carbocycle is substituted with 0 to 3 R_2 groups. Where Y_1 is O, a lactate ester is formed, and where Y_1 is $N(R_2)$, $N(OR_2)$ or $N(N(R_2)_2$, a phosphonamidate ester results.


In its ester-forming role, a protecting group typically is bound to any acidic group such as, by way of example and not limitation, a $-CO_2H$ or –C(S)OH group, thereby resulting in $-CO_2R^x$ where R^x is defined herein. Also, R^x for example includes the enumerated ester groups of WO 95/07920.


Examples of protecting groups include:


C_3–C_{12} heterocycle (described above) or aryl. These aromatic groups optionally are polycyclic or monocyclic. Examples include phenyl, spiryl, 2- and 3-pyrrolyl, 2- and 3-thienyl, 2- and 4-imidazolyl, 2-, 4- and 5-oxazolyl, 3- and 4-isoxazolyl, 2-, 4- and 5-thiazolyl, 3-, 4- and 5-isothiazolyl, 3- and 4-pyrazolyl, 1-, 2-, 3- and 4-pyridinyl, and 1-, 2-, 4- and 5-pyrimidinyl,

C_3-C_{12} heterocycle or aryl substituted with halo, R^1, R^1-O-C_1-C_{12} alkylene, C_1-C_{12} alkoxy, CN, NO_2, OH, carboxy, carboxyester, thiol, thioester, C_1-C_{12} haloalkyl (1-6 halogen atoms), C_2-C_{12} alkenyl or C_2-C_{12} alkynyl. Such


groups include 2-, 3- and 4-alkoxyphenyl (C_1-C_{12} alkyl), 2-, 3- and 4-methoxyphenyl, 2-, 3- and 4-ethoxyphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-diethoxyphenyl, 2- and 3-carboethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-4-hydroxyphenyl, 2- and 3-ethoxy-5-hydroxyphenyl, 2- and 3-ethoxy-6-hydroxyphenyl, 2-, 3- and 4-O-acetylphenyl, 2-, 3- and 4-dimethylaminophenyl, 2-, 3- and 4-methylmercaptophenyl, 2-, 3- and 4-halophenyl (including 2-, 3- and 4-fluorophenyl and 2-, 3- and 4-chlorophenyl), 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-biscarboxyethylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dimethoxyphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- and 3,5-dihalophenyl (including 2,4-difluorophenyl and 3,5-difluorophenyl), 2-, 3- and 4-haloalkylphenyl (1 to 5 halogen atoms, C_1-C_{12} alkyl including 4-trifluoromethylphenyl), 2-, 3- and 4-cyanophenyl, 2-, 3- and 4-nitrophenyl, 2-, 3- and 4-haloalkylbenzyl (1 to 5 halogen atoms, C_1-C_{12} alkyl including 4-trifluoromethylbenzyl and 2-, 3- and 4-trichloromethylphenyl and 2-, 3- and 4-trichloromethylphenyl), 4-N-methylpiperidinyl, 3-N-methylpiperidinyl, 1-ethylpiperazinyl, benzyl, alkylsalicylphenyl (C_1-C_4 alkyl, including 2-, 3- and 4-ethylsalicylphenyl), 2-,3- and 4-acetylphenyl, 1,8-dihydroxynaphthyl (-$C_{10}H_6$-OH) and aryloxy ethyl [C_6-C_9 aryl (including phenoxy ethyl)], 2,2'-dihydroxybiphenyl, 2-, 3- and 4-N,N-dialkylaminophenol, -$C_6H_4CH_2$-$N(CH_3)_2$, trimethoxybenzyl, triethoxybenzyl, 2-alkyl pyridinyl (C_{1-4} alkyl);



;


;


; C_4 - C_8 esters of 2-carboxyphenyl; and C_1-C_4 alkylene-C_3-C_6 aryl (including benzyl, -CH_2-pyrrolyl, -CH_2-thienyl, -CH_2-imidazolyl, -CH_2-oxazolyl, -CH_2-isoxazolyl, -CH_2-thiazolyl, -CH_2-isothiazolyl, -CH_2-pyrazolyl, -CH_2-pyridinyl and -CH_2-pyrimidinyl) substituted in the aryl moiety by 3 to 5 halogen atoms or 1 to 2 atoms or groups selected from halogen, C_1-C_{12} alkoxy (including methoxy and ethoxy), cyano, nitro, OH, C_1-C_{12} haloalkyl (1 to 6 halogen atoms; including -CH_2CCl_3), C_1-C_{12} alkyl (including methyl and ethyl), C_2-C_{12} alkenyl or C_2-C_{12} alkynyl; alkoxy ethyl [C_1-C_6 alkyl including -CH_2-CH_2-O-CH_3 (methoxy

ethyl)]; alkyl substituted by any of the groups set forth above for aryl, in particular OH or by 1 to 3 halo atoms (including $-CH_3$, $-CH(CH_3)_2$, $-C(CH_3)_3$, $-CH_2CH_3$, $-(CH_2)_2CH_3$, $-(CH_2)_3CH_3$, $-(CH_2)_4CH_3$, $-(CH_2)_5CH_3$, $-CH_2CH_2F$, $-CH_2CH_2Cl$, $-CH_2CF_3$, and $-CH_2CCl_3$);  ; -N-2-propylmorpholino, 2,3-dihydro-6-hydroxyindene, sesamol, catechol monoester, $-CH_2-C(O)-N(R^1)_2$, $-CH_2-S(O)(R^1)$, $-CH_2-S(O)_2(R^1)$, $-CH_2-CH(OC(O)CH_2R^1)-CH_2(OC(O)CH_2R^1)$, cholesteryl, enolpyruvate ($HOOC-C(=CH_2)-$), glycerol;


a 5 or 6 carbon monosaccharide, disaccharide or oligosaccharide (3 to 9 monosaccharide residues);

triglycerides such as α-D-β-diglycerides (wherein the fatty acids composing glyceride lipids generally are naturally occurring saturated or unsaturated C_{6-26}, C_{6-18} or C_{6-10} fatty acids such as linoleic, lauric, myristic, palmitic, stearic, oleic, palmitoleic, linolenic and the like fatty acids) linked to acyl of the parental compounds herein through a glyceryl oxygen of the triglyceride;

phospholipids linked to the carboxyl group through the phosphate of the phospholipid;

phthalidyl (shown in Fig. 1 of Clayton et al., *Antimicrob. Agents Chemo.* (1974) 5(6):670-671;

cyclic carbonates such as (5-R_d-2-oxo-1,3-dioxolen-4-yl) methyl esters (Sakamoto et al., *Chem. Pharm. Bull.* (1984) 32(6)2241-2248) where R_d is R_1, R_4 or aryl; and



;


The hydroxyl groups of the compounds of this invention optionally are substituted with one of groups III, IV or V disclosed in WO 94/21604, or with isopropyl.


Table A lists examples of protecting group ester moieties that for example can be bonded via oxygen to -C(O)O- and $-P(O)(O-)_2$ groups. Several amidates also are shown, which are bound directly to -C(O)- or $-P(O)_2$. Esters of


structures 1-5, 8-10 and 16, 17, 19-22 are synthesized by reacting the compound herein having a free hydroxyl with the corresponding halide (chloride or acyl chloride and the like) and N ,N-dicyclohexyl-N-morpholine carboxamidine (or another base such as DBU, triethylamine, $CsCO_3$, N,N-dimethylaniline and the like) in DMF (or other solvent such as acetonitrile or N-methylpyrrolidone). When the compound to be protected is a phosphonate, the esters of structures 5-7, 11, 12, 21, and 23-26 are synthesized by reaction of the alcohol or alkoxide salt (or the corresponding amines in the case of compounds such as 13, 14 and 15) with the monochlorophosphonate or dichlorophosphonate (or another activated phosphonate).


TABLE A


1. $-CH_2-C(O)-N(R_1)_2$ *
2. $-CH_2-S(O)(R_1)$
3. $-CH_2-S(O)_2(R_1)$
4. $-CH_2-O-C(O)-CH_2-C_6H_5$
5. 3-cholesteryl
6. 3-pyridyl
7. N-ethylmorpholino
8. $-CH_2-O-C(O)-C_6H_5$
9. $-CH_2-O-C(O)-CH_2CH_3$
10. $-CH_2-O-C(O)-C(CH_3)_3$
11. $-CH_2-CCl_3$
12. $-C_6H_5$
13. $-NH-CH_2-C(O)O-CH_2CH_3$
14. $-N(CH_3)-CH_2-C(O)O-CH_2CH_3$
15. $-NHR_1$
16. $-CH_2-O-C(O)-C_{10}H_{15}$
17. $-CH_2-O-C(O)-CH(CH_3)_2$
18. $-CH_2-C\#H(OC(O)CH_2R_1)-CH_2-(OC(O)CH_2R_1)$*


19. 


20. 


21. 

22. 

23. 

24. 


25. 


26. 

- chiral center is (R), (S) or racemate.

Other esters that are suitable for use herein are described in EP 632048.

Protecting groups also includes "double ester" forming profunctionalities

such as $-CH_2OC(O)OCH_3$,  $-CH_2SCOCH_3$, $-CH_2OCON(CH_3)_2$, or alkyl- or aryl-acyloxyalkyl groups of the structure $-CH(R^1 \text{ or } W^5)O((CO)R^{37})$ or $-CH(R^1 \text{ or } W^5)((CO)OR^{38})$ (linked to oxygen of the acidic group) wherein R^{37} and R^{38} are alkyl, aryl, or alkylaryl groups (see U.S. Patent No. 4968788). Frequently R^{37} and R^{38} are bulky groups such as branched alkyl, ortho-substituted aryl, meta-substituted aryl, or combinations thereof, including normal, secondary, iso- and tertiary alkyls of 1-6 carbon atoms. An example is the pivaloyloxymethyl group. These are of particular use with prodrugs for oral administration. Examples of such useful protecting groups are alkylacyloxymethyl esters and their derivatives, including -

$CH(CH_2CH_2OCH_3)OC(O)C(CH_3)_3$,  ; - $CH_2OC(O)C_{10}H_{15}$, $-CH_2OC(O)C(CH_3)_3$, $-CH(CH_2OCH_3)OC(O)C(CH_3)_3$, - $CH(CH(CH_3)_2)OC(O)C(CH_3)_3$, $-CH_2OC(O)CH_2CH(CH_3)_2$, - $CH_2OC(O)C_6H_{11}$, $-CH_2OC(O)C_6H_5$, $-CH_2OC(O)C_{10}H_{15}$, - $CH_2OC(O)CH_2CH_3$, $-CH_2OC(O)CH(CH_3)_2$, $-CH_2OC(O)C(CH_3)_3$ and - $CH_2OC(O)CH_2C_6H_5$.

In some claims the protected acidic group is an ester of the acidic group and is the residue of a hydroxyl-containing functionality. In other claims, an amino compound is used to protect the acid functionality. The residues of suitable hydroxyl or amino-containing functionalities are set forth above or are found in WO 95/07920. Of particular interest are the residues of amino acids, amino acid esters, polypeptides, or aryl alcohols. Typical amino acid, polypeptide and carboxyl-esterified amino acid residues are described on pages 11-18 and related text of WO 95/07920 as groups L1 or L2. WO 95/07920

expressly teaches the amidates of phosphonic acids, but it will be understood that such amidates are formed with any of the acid groups set forth herein and the amino acid residues set forth in WO 95/07920.

Typical esters for protecting acidic functionalities are also described in WO 95/07920, again understanding that the same esters can be formed with the acidic groups herein as with the phosphonate of the '920 publication. Typical ester groups are defined at least on WO 95/07920 pages 89-93 (under R^{31} or R^{35}), the table on page 105, and pages 21-23 (as R). Of particular interest are esters of unsubstituted aryl such as phenyl or arylalkyl such benzyl, or hydroxy-, halo-, alkoxy-, carboxy- and/or alkylestercarboxy-substituted aryl or alkylaryl, especially phenyl, ortho-ethoxyphenyl, or C_1-C_4 alkylestercarboxyphenyl (salicylate C_1-C_{12} alkylesters).

The protected acidic groups, particularly when using the esters or amides of WO 95/07920, are useful as prodrugs for oral administration. However, it is not essential that the acidic group be protected in order for the compounds of this invention to be effectively administered by the oral route. When the compounds of the invention having protected groups, in particular amino acid amidates or substituted and unsubstituted aryl esters are administered systemically or orally they are capable of hydrolytic cleavage *in vivo* to yield the free acid.

One or more of the acidic hydroxyls are protected. If more than one acidic hydroxyl is protected then the same or a different protecting group is employed, e.g., the esters may be different or the same, or a mixed amidate and ester may be used.

Typical hydroxy protecting groups described in Greene (pages 14-118) include substituted methyl and alkyl ethers, substituted benzyl ethers, silyl ethers, esters including sulfonic acid esters, and carbonates. For example:

- Ethers (methyl, *t*-butyl, allyl);
- Substituted Methyl Ethers (Methoxymethyl, Methylthiomethyl, *t*-Butylthiomethyl, (Phenyldimethylsilyl)methoxymethyl, Benzyloxymethyl, *p*-Methoxybenzyloxymethyl, (4-Methoxyphenoxy)methyl, Guaiacolmethyl, *t*-Butoxymethyl, 4-Pentenyloxymethyl, Siloxymethyl, 2-Methoxyethoxymethyl, 2,2,2-Trichloroethoxymethyl, Bis(2-

chloroethoxy)methyl, 2-(Trimethylsilyl)ethoxymethyl, Tetrahydropyranyl, 3-Bromotetrahydropyranyl, Tetrahydropthiopyranyl, 1-Methoxycyclohexyl, 4-Methoxytetrahydropyranyl, 4-Methoxytetrahydrothiopyranyl, 4-Methoxytetrahydropthiopyranyl *S,S*-Dioxido, 1-[(2-Chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-Dioxan-2-yl, Tetrahydrofuranyl, Tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-Octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl));

- Substituted Ethyl Ethers (1-Ethoxyethyl, 1-(2-Chloroethoxy)ethyl, 1-Methyl-1-methoxyethyl, 1-Methyl-1-benzyloxyethyl, 1-Methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-Trichloroethyl, 2-Trimethylsilylethyl, 2-(Phenylselenyl)ethyl,
- *p*-Chlorophenyl, *p*-Methoxyphenyl, 2,4-Dinitrophenyl, Benzyl);
- Substituted Benzyl Ethers (*p*-Methoxybenzyl, 3,4-Dimethoxybenzyl, *o*-Nitrobenzyl, *p*-Nitrobenzyl, *p*-Halobenzyl, 2,6-Dichlorobenzyl, *p*-Cyanobenzyl, *p*-Phenylbenzyl, 2- and 4-Picolyl, 3-Methyl-2-picolyl *N*-Oxido, Diphenylmethyl, *p,p'*-Dinitrobenzhydryl, 5-Dibenzosuberyl, Triphenylmethyl, α-Naphthyldiphenylmethyl, *p*-methoxyphenyldiphenylmethyl, Di(*p*-methoxyphenyl)phenylmethyl, Tri(*p*-methoxyphenyl)methyl, 4-(4'-Bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-Tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4"-Tris(levulinoyloxyphenyl)methyl, 4,4',4"-Tris(benzoyloxyphenyl)methyl, 3-(Imidazol-1-ylmethyl)bis(4',4"-dimethoxyphenyl)methyl, 1,1-Bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-Anthryl, 9-(9-Phenyl)xanthenyl, 9-(9-Phenyl-10-oxo)anthryl, 1,3-Benzodithiolan-2-yl, Benzisothiazolyl *S,S*-Dioxido);
- Silyl Ethers (Trimethylsilyl, Triethylsilyl, Triisopropylsilyl, Dimethylisopropylsilyl, Diethylisopropylsilyl, Dimethylthexylsilyl, *t*-Butyldimethylsilyl, *t*-Butyldiphenylsilyl, Tribenzylsilyl, Tri-*p*-xylylsilyl, Triphenylsilyl, Diphenylmethylsilyl, *t*-Butylmethoxyphenylsilyl);
- Esters (Formate, Benzoylformate, Acetate, Choroacetate, Dichloroacetate, Trichloroacetate, Trifluoroacetate, Methoxyacetate, Triphenylmethoxyacetate, Phenoxyacetate, *p*-Chlorophenoxyacetate, *p*-poly-

Phenylacetate, 3-Phenylpropionate, 4-Oxopentanoate (Levulinate), 4,4-(Ethylenedithio)pentanoate, Pivaloate, Adamantoate, Crotonate, 4-Methoxycrotonate, Benzoate, *p*-Phenylbenzoate, 2,4,6-Trimethylbenzoate (Mesitoate));


- Carbonates (Methyl, 9-Fluorenylmethyl, Ethyl, 2,2,2-Trichloroethyl, 2-(Trimethylsilyl)ethyl, 2-(Phenylsulfonyl)ethyl, 2-(Triphenylphosphonio)ethyl, Isobutyl, Vinyl, Allyl, *p*-Nitrophenyl, Benzyl, *p*-Methoxybenzyl, 3,4-Dimethoxybenzyl, *o*-Nitrobenzyl, *p*-Nitrobenzyl, *S*-Benzyl Thiocarbonate, 4-Ethoxy-1-naphthyl, Methyl Dithiocarbonate);
- Groups With Assisted Cleavage (2-Iodobenzoate, 4-Azidobutyrate, 4-Nitro-4-methylpentanoate, *o*-(Dibromomethyl)benzoate, 2-Formylbenzenesulfonate, 2-(Methylthiomethoxy)ethyl Carbonate, 4-(Methylthiomethoxy)butyrate, 2-(Methylthiomethoxymethyl)benzoate); Miscellaneous Esters (2,6-Dichloro-4-methylphenoxyacetate, 2,6-Dichloro-4-(1,1,3,3 tetramethylbutyl)phenoxyacetate, 2,4-Bis(1,1-dimethylpropyl)phenoxyacetate, Chlorodiphenylacetate, Isobutyrate, Monosuccinate, (*E*)-2-Methyl-2-butenoate (Tigloate), *o*-(Methoxycarbonyl)benzoate, *p*-poly-Benzoate, α-Naphthoate, Nitrate, Alkyl *N,N,N',N'*-Tetramethylphosphorodiamidate, *N*-Phenylcarbamate, Borate, Dimethylphosphinothioyl, 2,4-Dinitrophenylsulfenate); and
- Sulfonates (Sulfate, Methanesulfonate (Mesylate), Benzylsulfonate, Tosylate).

Typical 1,2-diol protecting groups (thus, generally where two OH groups are taken together with the protecting functionality) are described in Greene at pages 118-142 and include Cyclic Acetals and Ketals (Methylene, Ethylidene, 1-*t*-Butylethylidene, 1-Phenylethylidene, (4-Methoxyphenyl)ethylidene, 2,2,2-Trichloroethylidene, Acetonide (Isopropylidene), Cyclopentylidene, Cyclohexylidene, Cycloheptylidene, Benzylidene, *p*-Methoxybenzylidene, 2,4-Dimethoxybenzylidene, 3,4-Dimethoxybenzylidene, 2-Nitrobenzylidene); Cyclic Ortho Esters (Methoxymethylene, Ethoxymethylene, Dimethoxymethylene, 1-Methoxyethylidene, 1-Ethoxyethylidine, 1,2-Dimethoxyethylidene, α-Methoxybenzylidene, 1-(*N,N*-Dimethylamino)ethylidene Derivative, α -(*N,N*-

Dimethylamino)benzylidene Derivative, 2-Oxacyclopentylidene); Silyl Derivatives (Di-*t*-butylsilylene Group, 1,3-(1,1,3,3-Tetraisopropyldisiloxanylidene), and Tetra-*t*-butoxydisiloxane-1,3-diylidene), Cyclic Carbonates, Cyclic Boronates, Ethyl Boronate and Phenyl Boronate.

More typically, 1,2-diol protecting groups include those shown in Table B, still more typically, epoxides, acetonides, cyclic ketals and aryl acetals.

Table B



wherein R^9 is C_1-C_6 alkyl.

Amino protecting groups

Another set of protecting groups include any of the typical amino protecting groups described by Greene at pages 315-385. They include:

- Carbamates: (methyl and ethyl, 9-fluorenylmethyl, 9(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-di-*t*-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl, 4-methoxyphenacyl);
- Substituted Ethyl: (2,2,2-trichoroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenylyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(*N,N*-dicyclohexylcarboxamido)ethyl, *t*-butyl, 1-adamantyl, vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, *N*-

hydroxypiperidinyl, alkyldithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl, diphenylmethyl);


- Groups With Assisted Cleavage: (2-methylthioethyl, 2-methylsulfonylethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, *m*-choro-*p*-acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, 2-(trifluoromethyl)-6-chromonylmethyl);
- Groups Capable of Photolytic Cleavage: (*m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, phenyl(*o*-nitrophenyl)methyl); Urea-Type Derivatives (phenothiazinyl-(10)-carbonyl, *N'*-*p*-toluenesulfonylaminocarbonyl, *N'*-phenylaminothiocarbonyl);
- Miscellaneous Carbamates: (*t*-amyl, *S*-benzyl thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, *p*-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(*N,N*-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(*N,N*-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-Iodoethyl, Isobornyl, Isobutyl, Isonicotinyl, *p*-(*p'*-Methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1-(*p*-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium)benzyl, 2,4,6-trimethylbenzyl);
- Amides: (*N*-formyl, *N*-acetyl, *N*-choroacetyl, *N*-trichoroacetyl, *N*-trifluoroacetyl, *N*-phenylacetyl, *N*-3-phenylpropionyl, *N*-picolinoyl, *N*-3-pyridylcarboxamide, *N*-benzoylphenylalanyl, *N*-benzoyl, *N*-*p*-phenylbenzoyl);
- Amides With Assisted Cleavage: (*N*-*o*-nitrophenylacetyl, *N*-*o*-nitrophenoxyacetyl, *N*-acetoacetyl, (*N'*-dithiobenzyloxycarbonylamino)acetyl, *N*-3-(*p*-hydroxyphenyl)propionyl, *N*-3-(*o*-nitrophenyl)propionyl, *N*-2-methyl-2-(*o*-nitrophenoxy)propionyl, *N*-2-

methyl-2-(*o*-phenylazophenoxy)propionyl, *N*-4-chlorobutyryl, *N*-3-methyl-3-nitrobutyryl, *N*-*o*-nitrocinnamoyl, *N*-acetylmethionine, *N*-*o*-nitrobenzoyl, *N*-*o*-(benzoyloxymethyl)benzoyl, 4,5-diphenyl-3-oxazolin-2-one);

- Cyclic Imide Derivatives: (*N*-phthalimide, *N*-dithiasuccinoyl, *N*-2,3-diphenylmaleoyl, *N*-2,5-dimethylpyrrolyl, *N*-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3-5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridonyl);
- *N*-Alkyl and *N*-Aryl Amines: (*N*-methyl, *N*-allyl, *N*-[2-(trimethylsilyl)ethoxy]methyl, *N*-3-acetoxypropyl, *N*-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), Quaternary Ammonium Salts, *N*-benzyl, *N*-di(4-methoxyphenyl)methyl, *N*-5-dibenzosuberyl, *N*-triphenylmethyl, *N*-(4-methoxyphenyl)diphenylmethyl, *N*-9-phenylfluorenyl, *N*-2,7-dichloro-9-fluorenylmethylene, *N*-ferrocenylmethyl, *N*-2-picolylamine *N*'-oxide);
- Imine Derivatives: (*N*-1,1-dimethylthiomethylene, *N*-benzylidene, *N*-*p*-methoxybenylidene, *N*-diphenylmethylene, *N*-[(2-pyridyl)mesityl]methylene, *N*,(*N*',*N*'-dimethylaminomethylene, *N*,*N*'-isopropylidene, *N*-*p*-nitrobenzylidene, *N*-salicylidene, *N*-5-chlorosalicylidene, *N*-(5-chloro-2-hydroxyphenyl)phenylmethylene, *N*-cyclohexylidene);
- Enamine Derivatives: (*N*-(5,5-dimethyl-3-oxo-1-cyclohexenyl));
- *N*-Metal Derivatives (*N*-borane derivatives, *N*-diphenylborinic acid derivatives, *N*-[phenyl(pentacarbonylchromium- or -tungsten)]carbenyl, *N*-copper or *N*-zinc chelate);
- N-N Derivatives: (*N*-nitro, *N*-nitroso, *N*-oxide);
- N-P Derivatives: (*N*-diphenylphosphinyl, *N*-dimethylthiophosphinyl, *N*-diphenylthiophosphinyl, *N*-dialkyl phosphoryl, *N*-dibenzyl phosphoryl, *N*-diphenyl phosphoryl);
- N-Si Derivatives, N-S Derivatives, and N-Sulfenyl Derivatives: (*N*-benzenesulfenyl, *N*-*o*-nitrobenzenesulfenyl, *N*-2,4-dinitrobenzenesulfenyl, *N*-pentachlorobenzenesulfenyl, *N*-2-nitro-4-methoxybenzenesulfenyl, *N*-triphenylmethylsulfenyl, *N*-3-nitropyridinesulfenyl); and *N*-sulfonyl Derivatives (*N*-*p*-toluenesulfonyl, *N*-benzenesulfonyl, *N*-2,3,6-trimethyl-4-

methoxybenzenesulfonyl, *N*-2,4,6-trimethoxybenzenesulfonyl, *N*-2,6-dimethyl-4-methoxybenzenesulfonyl, *N*-pentamethylbenzenesulfonyl, *N*-2,3,5,6,-tetramethyl-4-methoxybenzenesulfonyl, *N*-4-methoxybenzenesulfonyl, *N*-2,4,6-trimethylbenzenesulfonyl, *N*-2,6-dimethoxy-4-methylbenzenesulfonyl, *N*-2,2,5,7,8-pentamethylchroman-6-sulfonyl, *N*-methanesulfonyl, *N*-β-trimethylsilyethanesulfonyl, *N*-9-anthracenesulfonyl, *N*-4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonyl, *N*-benzylsulfonyl, *N*-trifluoromethylsulfonyl, *N*-phenacylsulfonyl).

More typically, protected amino groups include carbamates and amides, still more typically, $-NHC(O)R^1$ or $-N=CR^1N(R^1)_2$. Another protecting group, also useful as a prodrug for amino or $-NH(R^5)$, is:



See for example Alexander, J. et al. (1996) *J. Med. Chem.* 39:480-486.

Amino acid and polypeptide protecting group and conjugates

An amino acid or polypeptide protecting group of a compound of the invention has the structure $R^{15}NHCH(R^{16})C(O)$-, where R^{15} is H, an amino acid or polypeptide residue, or R^5, and R^{16} is defined below.

R^{16} is lower alkyl or lower alkyl (C_1-C_6) substituted with amino, carboxyl, amide, carboxyl ester, hydroxyl, C_6-C_7 aryl, guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxide, and/or alkylphosphate. R^{10} also is taken together with the amino acid α N to form a proline residue (R^{10} = $-CH_2)_3$-). However, R^{10} is generally the side group of a naturally-occurring amino acid such as H, $-CH_3$, $-CH(CH_3)_2$, $-CH_2-CH(CH_3)_2$, $-CHCH_3-CH_2-CH_3$, $-CH_2-C_6H_5$, $-CH_2CH_2-S-CH_3$, $-CH_2OH$, $-CH(OH)-CH_3$, $-CH_2-SH$, $-CH_2-C_6H_4OH$, $-CH_2-CO-NH_2$, $-CH_2-CH_2-CO-NH_2$, $-CH_2-COOH$, $-CH_2-CH_2-COOH$, $-(CH_2)_4-NH_2$ and $-(CH_2)_3-NH-C(NH_2)-NH_2$. R_{10} also includes 1-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl, indol-3-yl, methoxyphenyl and ethoxyphenyl.

Another set of protecting groups include the residue of an amino-

containing compound, in particular an amino acid, a polypeptide, a protecting group, $-NHSO_2R$, NHC(O)R, $-N(R)_2$, NH_2 or -NH(R)(H), whereby for example a carboxylic acid is reacted, i.e. coupled, with the amine to form an amide, as in $C(O)NR_2$. A phosphonic acid may be reacted with the amine to form a phosphonamidate, as in $-P(O)(OR)(NR_2)$.

In general, amino acids have the structure $R^{17}C(O)CH(R^{16})NH-$, where R^{17} is -OH, -OR, an amino acid or a polypeptide residue. Amino acids are low molecular weight compounds, on the order of less than about 1000 MW and which contain at least one amino or imino group and at least one carboxyl group. Generally the amino acids will be found in nature, i.e., can be detected in biological material such as bacteria or other microbes, plants, animals or man. Suitable amino acids typically are alpha amino acids, i.e. compounds characterized by one amino or imino nitrogen atom separated from the carbon atom of one carboxyl group by a single substituted or unsubstituted alpha carbon atom. Of particular interest are hydrophobic residues such as mono-or di-alkyl or aryl amino acids, cycloalkylamino acids and the like. These residues contribute to cell permeability by increasing the partition coefficient of the parental drug. Typically, the residue does not contain a sulfhydryl or guanidino substituent.

Naturally-occurring amino acid residues are those residues found naturally in plants, animals or microbes, especially proteins thereof. Polypeptides most typically will be substantially composed of such naturally-occurring amino acid residues. These amino acids are glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, methionine, glutamic acid, aspartic acid, lysine, hydroxylysine, arginine, histidine, phenylalanine, tyrosine, tryptophan, proline, asparagine, glutamine and hydroxyproline. Additionally, unnatural amino acids, for example, valanine, phenylglycine and homoarginine are also included. Commonly encountered amino acids that are not gene-encoded may also be used in the present invention. All of the amino acids used in the present invention may be either the D- or L- optical isomer. In addition, other peptidomimetics are also useful in the present invention. For a general review, see Spatola, A. F., in Chemistry and Biochemistry of Amino Acids,

Peptides and Proteins, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983).

When protecting groups are single amino acid residues or polypeptides they optionally are substituted at R^3 of substituents A^1, A^2 or A^3 in Formula I. These conjugates are produced by forming an amide bond between a carboxyl group of the amino acid (or C-terminal amino acid of a polypeptide for example). Similarly, conjugates are formed between R^3 (Formula I) and an amino group of an amino acid or polypeptide. Generally, only one of any site in the parental molecule is amidated with an amino acid as described herein, although it is within the scope of this invention to introduce amino acids at more than one permitted site. Usually, a carboxyl group of R^3 is amidated with an amino acid. In general, the α-amino or α-carboxyl group of the amino acid or the terminal amino or carboxyl group of a polypeptide are bonded to the parental functionalities, i.e., carboxyl or amino groups in the amino acid side chains generally are not used to form the amide bonds with the parental compound (although these groups may need to be protected during synthesis of the conjugates as described further below).

With respect to the carboxyl-containing side chains of amino acids or polypeptides it will be understood that the carboxyl group optionally will be blocked, e.g., by R^1, esterified with R^5 or amidated. Similarly, the amino side chains R^{16} optionally will be blocked with R^1 or substituted with R^5.

Such ester or amide bonds with side chain amino or carboxyl groups, like the esters or amides with the parental molecule, optionally are hydrolyzable *in vivo* or *in vitro* under acidic (pH <3) or basic (pH >10) conditions. Alternatively, they are substantially stable in the gastrointestinal tract of humans but are hydrolyzed enzymatically in blood or in intracellular environments. The esters or amino acid or polypeptide amidates also are useful as intermediates for the preparation of the parental molecule containing free amino or carboxyl groups. The free acid or base of the parental compound, for example, is readily formed from the esters or amino acid or polypeptide conjugates of this invention by conventional hydrolysis procedures.

When an amino acid residue contains one or more chiral centers, any of

the D, L, meso, threo or erythro (as appropriate) racemates, scalemates or mixtures thereof may be used. In general, if the intermediates are to be hydrolyzed non-enzymatically (as would be the case where the amides are used as chemical intermediates for the free acids or free amines), D isomers are useful. On the other hand, L isomers are more versatile since they can be susceptible to both non-enzymatic and enzymatic hydrolysis, and are more efficiently transported by amino acid or dipeptidyl transport systems in the gastrointestinal tract.

Examples of suitable amino acids whose residues are represented by R^x or R^y include the following:

Glycine;

Aminopolycarboxylic acids, e.g., aspartic acid, β-hydroxyaspartic acid, glutamic acid, β -hydroxyglutamic acid, β-methylaspartic acid, β-methylglutamic acid, β, β-dimethylaspartic acid, γ-hydroxyglutamic acid, β, γ-dihydroxyglutamic acid, β -phenylglutamic acid, γ-methyleneglutamic acid, 3-aminoadipic acid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid;

Amino acid amides such as glutamine and asparagine;

Polyamino- or polybasic-monocarboxylic acids such as arginine, lysine, β -aminoalanine, γ -aminobutyrine, ornithine, citruline, homoarginine, homocitrulline, hydroxylysine, allohydroxylsine and diaminobutyric acid;

Other basic amino acid residues such as histidine;

Diaminodicarboxylic acids such as α, α'-diaminosuccinic acid, α, α'-diaminoglutaric acid, α, α'-diaminoadipic acid, α, α'-diaminopimelic acid, α, α'-diamino- β-hydroxypimelic acid, α, α'-diaminosuberic acid, α, α'-diaminoazelaic acid, and α, α'-diaminosebacic acid;

Imino acids such as proline, hydroxyproline, allohydroxyproline, γ-methylproline, pipecolic acid, 5-hydroxypipecolic acid, and azetidine-2-carboxylic acid;

A mono- or di-alkyl (typically C_1-C_8 branched or normal) amino acid such as alanine, valine, leucine, allylglycine, butyrine, norvaline, norleucine, heptyline, α-methylserine, α-amino-α-methyl-γ-hydroxyvaleric acid, α-amino- α-methyl-δ-hydroxyvaleric acid, α-amino- α-methyl-ε-hydroxycaproic acid,

isovaline, α-methylglutamic acid, α-aminoisobutyric acid, α-aminodiethylacetic acid, α-aminodiisopropylacetic acid, α-aminodi-n-propylacetic acid, α-aminodiisobutylacetic acid, α-aminodi-n-butylacetic acid, α-aminoethylisopropylacetic acid, α-amino-n-propylacetic acid, α-aminodiisoamyacetic acid, α-methylaspartic acid, α-methylglutamic acid, 1-aminocyclopropane-1-carboxylic acid, isoleucine, alloisoleucine, *tert*-leucine, β-methyltryptophan and α-amino- β-ethyl-β-phenylpropionic acid;

β-phenylserinyl;

Aliphatic α-amino-β-hydroxy acids such as serine, β-hydroxyleucine, β-hydroxynorleucine, β -hydroxynorvaline, and α-amino-β-hydroxystearic acid;

α-Amino, α-, γ-, δ- or ε-hydroxy acids such as homoserine, δ -hydroxynorvaline, γ-hydroxynorvaline and ε-hydroxynorleucine residues; canavine and canaline; γ -hydroxyornithine;

2-hexosaminic acids such as D-glucosaminic acid or D-galactosaminic acid;

α-Amino-β-thiols such as penicillamine, β-thiolnorvaline or β-thiolbutyrine;

Other sulfur containing amino acid residues including cysteine; homocystine, β-phenylmethionine, methionine, S-allyl-L-cysteine sulfoxide, 2-thiolhistidine, cystathionine, and thiol ethers of cysteine or homocysteine;

Phenylalanine, tryptophan and ring-substituted α-amino acids such as the phenyl- or cyclohexylamino acids α-aminophenylacetic acid, α-aminocyclohexylacetic acid and α-amino-β-cyclohexylpropionic acid; phenylalanine analogues and derivatives comprising aryl, lower alkyl, hydroxy, guanidino, oxyalkylether, nitro, sulfur or halo-substituted phenyl (e.g., tyrosine, methyltyrosine and o-chloro-, p-chloro-, 3,4-dichloro, *o*-, *m*- or *p*-methyl-, 2,4,6-trimethyl-, 2-ethoxy-5-nitro-, 2-hydroxy-5-nitro- and p-nitro-phenylalanine); furyl-, thienyl-, pyridyl-, pyrimidinyl-, purinyl- or naphthyl-alanines; and tryptophan analogues and derivatives including kynurenine, 3-hydroxykynurenine, 2-hydroxytryptophan and 4-carboxytryptophan;

α-Amino substituted amino acids including sarcosine (N-methylglycine), N-benzylglycine, N-methylalanine, N-benzylalanine, N-methylphenylalanine, N-

benzylphenylalanine, N-methylvaline and N-benzylvaline; and

α-Hydroxy and substituted α -hydroxy amino acids including serine, threonine, allothreonine, phosphoserine and phosphothreonine.

Polypeptides are polymers of amino acids in which a carboxyl group of one amino acid monomer is bonded to an amino or imino group of the next amino acid monomer by an amide bond. Polypeptides include dipeptides, low molecular weight polypeptides (about 1500-5000 MW) and proteins. Proteins optionally contain 3, 5, 10, 50, 75, 100 or more residues, and suitably are substantially sequence-homologous with human, animal, plant or microbial proteins. They include enzymes (e.g., hydrogen peroxidase) as well as immunogens such as KLH, or antibodies or proteins of any type against which one wishes to raise an immune response. The nature and identity of the polypeptide may vary widely.

The polypeptide amidates are useful as immunogens in raising antibodies against either the polypeptide (if it is not immunogenic in the animal to which it is administered) or against the epitopes on the remainder of the compound of this invention.

Antibodies capable of binding to the parental non-peptidyl compound are used to separate the parental compound from mixtures, for example in diagnosis or manufacturing of the parental compound. The conjugates of parental compound and polypeptide generally are more immunogenic than the polypeptides in closely homologous animals, and therefore make the polypeptide more immunogenic for facilitating raising antibodies against it. Accordingly, the polypeptide or protein may not need to be immunogenic in an animal typically used to raise antibodies, e.g., rabbit, mouse, horse, or rat, but the final product conjugate should be immunogenic in at least one of such animals. The polypeptide optionally contains a peptidolytic enzyme cleavage site at the peptide bond between the first and second residues adjacent to the acidic heteroatom. Such cleavage sites are flanked by enzymatic recognition structures, e.g., a particular sequence of residues recognized by a peptidolytic enzyme.

Peptidolytic enzymes for cleaving the polypeptide conjugates of this

invention are well known, and in particular include carboxypeptidases. Carboxypeptidases digest polypeptides by removing C-terminal residues, and are specific in many instances for particular C-terminal sequences. Such enzymes and their substrate requirements in general are well known. For example, a dipeptide (having a given pair of residues and a free carboxyl terminus) is covalently bonded through its α-amino group to the phosphorus or carbon atoms of the compounds herein. In claims where W_1 is phosphonate it is expected that this peptide will be cleaved by the appropriate peptidolytic enzyme, leaving the carboxyl of the proximal amino acid residue to autocatalytically cleave the phosphonoamidate bond.

Suitable dipeptidyl groups (designated by their single letter code) are AA, AR, AN, AD, AC, AE, AQ, AG, AH, AI, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RE, RQ, RG, RH, RI, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NE, NQ, NG, NH, NI, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DD, DC, DE, DQ, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CE, CQ, CG, CH, CI, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, EA, ER, EN, ED, EC, EE, EQ, EG, EH, EI, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, QA, QR, QN, QD, QC, QE, QQ, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, GA, GR, GN, GD, GC, GE, GQ, GG, GH, GI, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HE, HQ, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IE, IQ, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LE, LQ, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KE, KQ, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, ME, MQ, MG, MH, MI, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FE, FQ, FG, FH, FI, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PE, PQ, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SE, SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TE, TQ, TG, TH, TI, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WE, WQ, WG, WH, WI, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA,

YR, YN, YD, YC, YE, YQ, YG, YH, YI, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VE, VQ, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY and VV.

Tripeptide residues are also useful as protecting groups. When a phosphonate is to be protected, the sequence -X^4-pro-X^5- (where X^4 is any amino acid residue and X^5 is an amino acid residue, a carboxyl ester of proline, or hydrogen) will be cleaved by luminal carboxypeptidase to yield X^4 with a free carboxyl, which in turn is expected to autocatalytically cleave the phosphonoamidate bond. The carboxy group of X^5 optionally is esterified with benzyl.

Dipeptide or tripeptide species can be selected on the basis of known transport properties and/or susceptibility to peptidases that can affect transport to intestinal mucosal or other cell types. Dipeptides and tripeptides lacking an α-amino group are transport substrates for the peptide transporter found in brush border membrane of intestinal mucosal cells (Bai, J.P.F., (1992) *Pharm Res.* 9:969-978). Transport competent peptides can thus be used to enhance bioavailability of the amidate compounds. Di- or tripeptides having one or more amino acids in the D configuration are also compatible with peptide transport and can be utilized in the amidate compounds of this invention. Amino acids in the D configuration can be used to reduce the susceptibility of a di- or tripeptide to hydrolysis by proteases common to the brush border such as aminopeptidase N. In addition, di- or tripeptides alternatively are selected on the basis of their relative resistance to hydrolysis by proteases found in the lumen of the intestine. For example, tripeptides or polypeptides lacking asp and/or glu are poor substrates for aminopeptidase A, di- or tripeptides lacking amino acid residues on the N-terminal side of hydrophobic amino acids (leu, tyr, phe, val, trp) are poor substrates for endopeptidase, and peptides lacking a pro residue at the penultimate position at a free carboxyl terminus are poor substrates for carboxypeptidase P. Similar considerations can also be applied to the selection of peptides that are either relatively resistant or relatively susceptible to hydrolysis by cytosolic, renal, hepatic, serum or other peptidases. Such poorly cleaved polypeptide amidates are immunogens or are useful for bonding to

proteins in order to prepare immunogens.


Specific Embodiments of the Invention

Specific values described for radicals, substituents, and ranges, as well as specific embodiments of the invention described herein, are for illustration only; they do not exclude other defined values or other values within defined ranges.

In one specific embodiment of the invention, the conjugate is a compound that is substituted with one or more phosphonate groups either directly or indirectly through a linker; and that is optionally substituted with one or more groups A^0; or a pharmaceutically acceptable salt thereof, wherein:


A^0 is A^1, A^2 or W^3;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, R^1, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

R^{5a} is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;


M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;


M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.


In another specific embodiment of the invention A^1 is of the formula:




In another specific embodiment of the invention A^1 is of the formula:



In another specific embodiment of the invention A^1 is of the formula:




In another specific embodiment of the invention A^1 is of the formula:



;


In another specific embodiment of the invention A^1 is of the formula:



;


and W^{5a} is a carbocycle or a heterocycle where W^{5a} is independently substituted with 0 or 1 R^2 groups. A specific velue for M12a is 1.

In another specific embodiment of the invention A^1 is of the formula:




;

In another specific embodiment of the invention A^1 is of the formula:



;


In another specific embodiment of the invention A^1 is of the formula:



;


wherein W^{5a} is a carbocycle independently substituted with 0 or 1 R^2 groups;

In another specific embodiment of the invention A^1 is of the formula:



wherein Y^{2b} is O or N(R^2); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


In another specific embodiment of the invention A^1 is of the formula:



;

wherein W^{5a} is a carbocycle independently substituted with 0 or 1 R^2 groups;


In another specific embodiment of the invention A^1 is of the formula:



;

wherein W^{5a} is a carbocycle or heterocycle where W^{5a} is independently substituted with 0 or 1 R^2 groups.


In another specific embodiment of the invention A^1 is of the formula:



M12d


wherein Y^{2b} is O or N(R^2); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

In a specific embodiment of the invention A^2 is of the formula:



M12b


In another specific embodiment of the invention A^2 is of the formula:



In another specific embodiment of the invention M12b is 1.

In another specific embodiment of the invention e M12b is 0, Y^2 is a bond and W^5 is a carbocycle or heterocycle where W^5 is optionally and independently substituted with 1, 2, or 3 R^2 groups.

In another specific embodiment of the invention A^2 is of the formula:




;

wherein W^{5a} is a carbocycle or heterocycle where W^{5a} is optionally and independently substituted with 1, 2, or 3 R^2 groups.


In another specific embodiment of the invention M12a is 1.

In another specific embodiment of the invention A^2 is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, pyridyl and substituted pyridyl.

In another specific embodiment of the invention A^2 is of the formula:




In another specific embodiment of the invention A^2 is of the formula:




In another specific embodiment of the invention M12b is 1.

In a specific embodiment of the invention A^3 is of the formula:




In another specific embodiment of the invention A^3 is of the formula:



M12a


In another specific embodiment of the invention A^3 is of the formula:



M12a ;

wherein Y^{1a} is O or S; and Y^{2a} is O, N(R^x) or S.


In another specific embodiment of the invention A^3 is of the formula:



M12a ;

wherein Y^{2b} is O or N(R^x).


In another specific embodiment of the invention A^3 is of the formula:



M12d ;

wherein Y^{2b} is O or $N(R^x)$; and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

In another specific embodiment of the invention A^3 is of the formula:




M12d ;

wherein Y^{2b} is O or $N(R^x)$; and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


In another specific embodiment of the invention M12d is 1.

In another specific embodiment of the invention A^3 is of the formula:



M12b


In another specific embodiment of the invention A^3 is of the formula:



M12b

In another specific embodiment of the invention W^5 is a carbocycle.


In another specific embodiment of the invention A^3 is of the formula:



M12b

In another specific embodiment of the invention W^5 is phenyl.


In another specific embodiment of the invention A^3 is of the formula:



;

wherein Y^{1a} is O or S; and Y^{2a} is O, N(R^x) or S.


In another specific embodiment of the invention A^3 is of the formula:



;

wherein Y^{2b} is O or $N(R^x)$.

In another specific embodiment of the invention A^3 is of the formula:




;

wherein Y^{2b} is O or $N(R^x)$; and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


In another specific embodiment of the invention R^1 is H.

In another specific embodiment of the invention A^3 is of the formula:




wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.


In another specific embodiment of the invention A^3 is of the formula:




In another specific embodiment of the invention A^3 is of the formula:




In another specific embodiment of the invention A^3 is of the formula:



In another specific embodiment of the invention A^3 is of the formula:




In another specific embodiment of the invention A^3 is of the formula:



M12a

wherein Y^{1a} is O or S; and Y^{2a} is O, $N(R^2)$ or S.


In another specific embodiment of the invention A^3 is of the formula:



M12a

wherein Y^{1a} is O or S; Y^{2b} is O or $N(R^2)$; and Y^{2c} is O, $N(R^y)$ or S.


In another specific embodiment of the invention A^3 is of the formula:



M12d

wheren Y^{1a} is O or S; Y^{2b} is O or N(R^2); Y^{2d} is O or N(R^y); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


In another specific embodiment of the invention A^3 is of the formula:



M12d ;


wherein Y^{2b} is O or N(R^2); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

In another specific embodiment of the invention A^3 is of the formula:




wherein Y^{2b} is O or N(R^2).

In another specific embodiment of the invention A^3 is of the formula:




In another specific embodiment of the invention A^3 is of the formula:



M12a ;


In another specific embodiment of the invention A^3 is of the formula:



M12a ;

wherein Y^{1a} is O or S; and Y^{2a} is O, $N(R^2)$ or S.


In another specific embodiment of the invention A^3 is of the formula:



M12a ;


wherein Y^{1a} is O or S; Y^{2b} is O or $N(R^2)$; and Y^{2c} is O, $N(R^y)$ or S.

In another specific embodiment of the invention A^3 is of the formula:



wherein Y^{1a} is O or S; Y^{2b} is O or N(R^2); Y^{2d} is O or N(R^y); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


In another specific embodiment of the invention A^3 is of the formula:



;


wherein Y^{2b} is O or N(R^2); and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

In another specific embodiment of the invention A^3 is of the formula:



wherein Y^{2b} is O or N(R^2).


In another specific embodiment of the invention A^3 is of the formula:



;


wherein: Y^{2b} is O or $N(R^x)$; and M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

In another specific embodiment of the invention A^3 is of the formula:




wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.

In another specific embodiment of the invention A^3 is of the formula:




wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.

In another specific embodiment of the invention A^3 is of the formula:




In a specific embodiment of the invention A^0 is of the formula:



wherein each R is independently (C_1-C_6)alkyl.

In a specific embodiment of the invention R^x is independently H, R^1, W^3, a protecting group, or the formula:



;


wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;


In a specific embodiment of the invention R^x is of the formula:



;

wherein Y^{1a} is O or S; and Y^{2c} is O, N(R^y) or S.


In a specific embodiment of the invention R^x is of the formula:



;

wherein Y^{1a} is O or S; and Y^{2d} is O or N(R^y).


In a specific embodiment of the invention R^x is of the formula:



.


In a specific embodiment of the invention R^y is hydrogen or alkyl of 1 to 10 carbons.

In a specific embodiment of the invention R^x is of the formula:



.


In a specific embodiment of the invention R^x is of the formula:



M12a

.


In a specific embodiment of the invention R^x is of the formula:



In a specific embodiment of the invention Y^1 is O or S

In a specific embodiment of the invention Y^2 is O, N(R^y) or S.

In one specific embodiment of the invention R^x is a group of the formula:



;

wherein:

m1a, m1b, m1c, m1d and m1e are independently 0 or 1;

m12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

R^y is H, W^3, R^2 or a protecting group;

provided that:

if m1a, m12c, and m1d are 0, then m1b, m1c and m1e are 0;

if m1a and m12c are 0 and m1d is not 0, then m1b and m1c are 0;

if m1a and m1d are 0 and m12c is not 0, then m1b and at least one of m1c and m1e are 0;

if m1a is 0 and m12c and m1d are not 0, then m1b is 0;

if m12c and m1d are 0 and m1a is not 0, then at least two of m1b, m1c and m1e are 0;

if m12c is 0 and m1a and m1d are not 0, then at least one of m1b and m1c are 0; and

if m1d is 0 and m1a and m12c are not 0, then at least one of m1c and m1e are 0.

In another specific embodiment, the invention provides a compound of the formula:

$$[DRUG]\text{-}(A^0)_{nn}$$


or a pharmaceutically acceptable salt thereof wherein,

DRUG is a compound of any one of formulae **500-601:**

nn is 1, 2, or 3;


A^0 is A^1, A^2 or W^3 with the proviso that the compound includes at least one A^1;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, R^1, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

R^{5a} is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;


M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;


M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and


M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

In another specific embodiment, the invention provides a compound of the formula **1-336**:



1
2
3
4
5
6
7
8
9
10




11




12




13




14




15




16




17




18




19




20




21




22




23




24




25




26




27




28




29




30




31




32





33





34



35



36



37



38



39



40



41



42



43



44



45


46



47


48



49




50




51




52




53




54




55




56




57




58




59





60





61



62



63



64



65



66



67


68



69


70



71




72




73




74



75




76




77


5




78




79




80




81




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108




109



110




111




112


5




113




114




115




116




117




118




119




120




121




122




123




124




125




126




127




128




129




130




131




132




133




134




135




136




137




138




139




140




141




142




143




144




145




146




147




148




149




150




151




152




153




154




155




156




157




158




159




160




161




162




163




164




165




166




167




168




169




170




171




172




173




174




175




176




177




178




179




180




181




182




183




184




185




186




187




188




189




190




191




192




193




194




195




196




197




198




199




200




201




202




203




204




205




206




207




208




209




210




211




212




213




214




215




216




217




218




219




220




221




222




223




224




225




226




227




228




229




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248




249




250




251




252




253




254




255




256




257




258




259




260




261




262




263




264




265




266




267




268




269




270




271




272




273




274




275




276




277




278




279




280




281




282




283




284




285




286




287




288




289




290




291




292




293




294




295




296




297




298




299




300




301




302




303




304




305




306




307




308




309




310




311




312




313




314




315




316




317




318




319




320




321




322




323




324




325




326




327




328




329




330




331




332




333



334



335




336

or a pharmaceutically acceptable salt thereof wherein:


A^0 is A^1;

A^1 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, W^3, a protecting group, or the formula:



;

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

R^{5a} is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;


M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

3. A compound of any one of formulae **1-336** wherein:


A^0 is A^1;

A^1 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, W^3, a protecting group, or the formula:



;

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

R^{5a} is independently alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2-18 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

In another specific embodiment, the invention provides a compound of the formula:

$$[DRUG]-[L-P(=Y^1)-Y^2-R^x]_{nn}$$


or a pharmaceutically acceptable salt thereof wherein,

DRUG is a compound of any one of **500-601**;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, W^3, a protecting group, or the formula:



;

R^y is independently H, W^3, R^2 or a protecting group;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

M2 is 1, 2, or 3;

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

nn is 1, 2, or 3; and
L is a linking group.

In another specific embodiment, the invention provides a compound of which is a compound of the formula:

$$[DRUG]-(A^0)_{nn}$$


or a pharmaceutically acceptable salt thereof wherein,

DRUG is a compound of any one of formulae **500-601**;

nn is 1, 2, or 3;


A^0 is A^1, A^2, or W^3 with the proviso that the compound includes at least one A^1;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, W^3, a protecting group, or the formula:



;

R^y is independently H, W^3, R^2 or a protecting group;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$,
$-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and


M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

In compounds of the invention W^5 carbocycles and W^5 heterocycles may be independently substituted with 0 to 3 R^2 groups. W^5 may be a saturated, unsaturated or aromatic ring comprising a mono- or bicyclic carbocycle or heterocycle. W^5 may have 3 to 10 ring atoms, e.g., 3 to 7 ring atoms. The W^5 rings are saturated when containing 3 ring atoms, saturated or mono-unsaturated when containing 4 ring atoms, saturated, or mono- or di-unsaturated when containing 5 ring atoms, and saturated, mono- or di-unsaturated, or aromatic when containing 6 ring atoms.


A W^5 heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S). W^5 heterocyclic monocycles may have 3 to 6 ring atoms (2 to 5 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S); or 5 or 6 ring atoms (3 to 5 carbon atoms and 1 to 2 heteroatoms selected from N and S). W^5 heterocyclic bicycles have 7 to 10 ring atoms (6 to 9 carbon atoms and 1 to 2 heteroatoms selected from N, O, and S) arranged as a bicyclo [4,5], [5,5], [5,6], or [6,6] system; or 9 to 10 ring atoms (8 to 9 carbon atoms and 1 to 2


hetero atoms selected from N and S) arranged as a bicyclo [5,6] or [6,6] system. The W^5 heterocycle may be bonded to Y^2 through a carbon, nitrogen, sulfur or other atom by a stable covalent bond.

W^5 heterocycles include for example, pyridyl, dihydropyridyl isomers, piperidine, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl. W^5 also includes, but is not limited to, examples such as:




W^5 carbocycles and heterocycles may be independently substituted with 0 to 3 R^2 groups, as defined above. For example, substituted W^5 carbocycles include:






Examples of substituted phenyl carbocycles include:



Conjugates of Formula I

In one embodiment, the invention provides a conjugate of Formula I:



I

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X is selected from O, $C(R^y)_2$, $C{=}C(R^y)_2$, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,

Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or N–NR_2;


Y^2 is independently a bond, O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, N–NR_2, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, R, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, $-SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($-NH_2$), ammonium ($-NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone ($-SO_2R$), arylsulfone ($-SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($-SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($-C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($-N_3$), nitro ($-NO_2$), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8

alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group (PG), or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



;

wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and


W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

For a conjugate of Formula I, in one specific embodiment, C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, –NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, –SOAr, –SAr, $-SO_2NR_2$, –SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8

trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

For a conjugate of Formula I, in one specific embodiment, "protecting group" is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

For a conjugate of Formula I, in one specific embodiment, W^5 is selected from the structures:



For a conjugate of Formula I, in one specific embodiment, X is O and R^y is H.


For a conjugate of Formula I, in one specific embodiment, X is $C{=}CH_2$ and R^y is H.

For a conjugate of Formula I, in one specific embodiment, Z^1 is OH.


For a conjugate of Formula I, in one specific embodiment, Z^2 is C_1–C_8 alkyl or C_1–C_8 substituted alkyl.

For a conjugate of Formula I, in one specific embodiment, Z^2 is CH_3.


In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:



In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




wherein, in a more specific embodiment, Z^1 is OH; Z^2 is C_1–C_8 alkyl or C_1–C_8 substituted alkyl; and Z^2 is CH_3.

In one specific embodiment, the conjugate of formula I has the following


formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:



In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




wherein R^2 is H or C_1–C_8 alkyl.

In one specific embodiment, the conjugate of formula I has the following formula:




In one specific embodiment, the conjugate of formula I has the following formula:




wherein Y^{2c} is O, N(R^y) or S.

In one specific embodiment, the conjugate of formula I has the following formula:




wherein, in a more specific embodiment, Y^{2c} is O; Y^{2c} is N(CH_3); and R^y is H or C_1–C_8 alkyl.

For a conjugate of Formula I, in one specific embodiment, the substituted triazole has the structure:



In one specific embodiment, the conjugate of Formula I is a conjugate of the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


R^y is independently H, F, Cl, Br, I, OH, R, -C(=Y^1)R, -C(=Y^1)OR, -C(=Y^1)N(R)$_2$, -N(R)$_2$, -$^+$N(R)$_3$, -SR, -S(O)R, -S(O)$_2$R, -S(O)(OR), -S(O)$_2$(OR), -OC(=Y^1)R, -OC(=Y^1)OR, -OC(=Y^1)(N(R)$_2$), -SC(=Y^1)R, -SC(=Y^1)OR, -SC(=Y^1)(N(R)$_2$), -N(R)C(=Y^1)R, -N(R)C(=Y^1)OR, or -N(R)C(=Y^1)N(R)$_2$, amino (–NH_2), ammonium (–NH_3^+), alkylamino, dialkylamino,

trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone (–SO_2R), arylsulfone (–SO_2Ar), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide (–SO_2NR_2), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido (–C(=O)NR_2), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido (–N_3), nitro (–NO_2), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group (PG), or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, -$C(Y^1)R^y$, -$C(Y^1)W^5$, -SO_2R^y, or -SO_2W^5; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.



In one specific embodiment, the conjugate of Formula I has the following formula:



wherein PG is a protecting group selected from an ether-forming group, a thioether-forming group, an ester-forming group, a thioester-forming group, a silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, a



urea-forming group, an amino acid conjugate, and a polypeptide conjugate.

In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:



or a pharmaceutically acceptable salt or solvate thereof; wherein B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, or pyrazolo[3,4-D]pyrimidine. In an additional embodiment, the compound is isolated and purified.

In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:



or a pharmaceutically acceptable salt or solvate thereof; wherein B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 2,6-diaminopurine, 5-fluorocytosine, or c-propyl-2,6-diaminopurine. In an additional embodiment, the compound is isolated and purified.

In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:



or a pharmaceutically acceptable salt or solvate thereof. In an additional embodiment, the compound is isolated and purified.

In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:


or a pharmaceutically acceptable salt or solvate thereof; wherein B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, or pyrazolo[3,4-D]pyrimidine. In an additional embodiment, the compound is isolated and purified.

In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:

or a pharmaceutically acceptable salt or solvate thereof; wherein B is adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 2,6-diaminopurine, 5-fluorocytosine, or c-propyl-2,6-diaminopurine. In an additional embodiment, the compound is isolated and purified.


In one specific embodiment, the invention provides a conjugate of Formula I having one of the following formulae:



or a pharmaceutically acceptable salt or solvate thereof. In an additional embodiment, the compound is isolated and purified.

Conjugates of Formula II

In one embodiment, the invention provides a conjugate of Formula II:



II

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine,

N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or N–NR_2;

Y^2 is independently a bond, O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, N–NR_2, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, R, -$C(=Y^1)R$, -$C(=Y^1)OR$, -$C(=Y^1)N(R)_2$, -$N(R)_2$, -$^+N(R)_3$, -SR, -S(O)R, -$S(O)_2R$, -S(O)(OR), -$S(O)_2(OR)$, -$OC(=Y^1)R$, -$OC(=Y^1)OR$, -$OC(=Y^1)(N(R)_2)$, -$SC(=Y^1)R$, -$SC(=Y^1)OR$, -$SC(=Y^1)(N(R)_2)$, -$N(R)C(=Y^1)R$, -$N(R)C(=Y^1)OR$, or -$N(R)C(=Y^1)N(R)_2$, amino ($–NH_2$), ammonium ($–NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone ($–SO_2R$), arylsulfone ($–SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($–SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($–C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($–N_3$), nitro ($–NO_2$), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and


R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

For a conjugate of Formula II, in one specific embodiment, C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, –NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, –SOAr, –SAr, $-SO_2NR_2$, –SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.


For a conjugate of Formula II, in one specific embodiment, "protecting group" is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

For a conjugate of Formula II, in one specific embodiment, W^5 is selected from the structures:




For a conjugate of Formula II, in one specific embodiment, X is O and R^y is H.

In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




wherein, in a more specific embodiment, Z^1 is OH; and Z^2 is CH_3.

In one specific embodiment, the conjugate of Formula II has the following formula:




wherein, in a more specific embodiment, Z^2 is C_1–C_8 alkyl or C_1–C_8 substituted alkyl.


In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:



In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




wherein R^2 is H or C_1–C_8 alkyl.

In one specific embodiment, the conjugate of Formula II has the following formula:




In one specific embodiment, the conjugate of Formula II has the following formula:




wherein Y^{2c} is O, $N(R^y)$ or S.

In one specific embodiment, the conjugate of Formula II has the following formula:




wherein, in a more specific embodiment, Y^{2c} is O; Y^{2c} is $N(CH_3)$.

In one specific embodiment, the substituted triazole has the structure:



In one specific embodiment, the conjugate of Formula II has the following formula:



wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X^a is selected from O, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


R^y is independently H, F, Cl, Br, I, OH, R, -C(=Y^1)R, -C(=Y^1)OR, -C(=Y^1)N(R)$_2$, -N(R)$_2$, -$^+$N(R)$_3$, -SR, -S(O)R, -S(O)$_2$R, -S(O)(OR), -S(O)$_2$(OR), -OC(=Y^1)R, -OC(=Y^1)OR, -OC(=Y^1)(N(R)$_2$), -SC(=Y^1)R, -SC(=Y^1)OR, -SC(=Y^1)(N(R)$_2$), -N(R)C(=Y^1)R, -N(R)C(=Y^1)OR, or -N(R)C(=Y^1)N(R)$_2$, amino (–NH_2), ammonium (–NH_3^+), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone (–SO_2R), arylsulfone (–SO_2Ar), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide (–SO_2NR_2), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido (–C(=O)NR_2), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido (–N_3), nitro (–NO_2), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, -C(Y^1)R^y, -C(Y^1)W^5, -SO_2R^y, or -SO_2W^5; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

In one specific embodiment, the conjugate of Formula II has the


following formula:



wherein PG is a protecting group selected from an ether-forming group, a thioether-forming group, an ester-forming group, a thioester-forming group, a silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, a urea-forming group, an amino acid conjugate, and an olypeptide conjugate

Conjugates of Formula III

In one embodiment, the invention provides a conjugate of Formula III:



III

or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;


Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or $N–NR_2$;

Y^2 is independently O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, $N–NR_2$, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, $-SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($–NH_2$), ammonium ($–NH_3^+$), alkylamino, dialkylamino, trialkylammonium, $C_1–C_8$ alkyl, $C_1–C_8$ alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, $C_1–C_8$ alkylsulfonate, $C_1–C_8$ alkylamino, 4-dialkylaminopyridinium, $C_1–C_8$ alkylhydroxyl, $C_1–C_8$ alkylthiol, alkylsulfone ($–SO_2R$), arylsulfone ($–SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($–SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($–C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($–N_3$), nitro ($–NO_2$), $C_1–C_8$ alkoxy (–OR), $C_1–C_8$ alkyl, $C_1–C_8$ substituted alkyl, $C_1–C_8$ alkenyl, $C_1–C_8$ substituted alkenyl, $C_1–C_8$ alkynyl, $C_1–C_8$ substituted alkynyl, $C_6–C_{20}$ aryl, $C_6–C_{20}$ substituted aryl, $C_2–C_{20}$ heterocycle, $C_2–C_{20}$ substituted heterocycle, polyethyleneoxy, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



;

wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and


R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

For a conjugate of Formula II, in one specific embodiment, C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, –NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, –SOAr, –SAr, $-SO_2NR_2$, –SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.


For a conjugate of Formula II, in one specific embodiment, "protecting group" is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

In one specific embodiment, for a conjugate of Formula III, W^5 is selected from the structures:




In one specific embodiment, for a conjugate of Formula III, X is O and each R^y is H.


In one specific embodiment, the conjugate of Formula III is a resolved enantiomer having the structure:




In one specific embodiment, the conjugate of Formula III is a resolved enantiomer having the structure:




In one specific embodiment, the conjugate of Formula III has the following formula:




In one specific embodiment, the conjugate of Formula III has the following formula:




In one specific embodiment, the conjugate of Formula III has the following formula:




In one specific embodiment, the conjugate of Formula III has the following formula:



In one specific embodiment, the conjugate of Formula III has the following formula:




In one specific embodiment, the conjugate of Formula III has the following formula:




wherein R^2 is H or C_1–C_8 alkyl.

In one specific embodiment, the conjugate of Formula III has the following formula:




In one specific embodiment, the conjugate of Formula III has the following formula:



wherein in a more specific embodiment, Z is H and B is adenine .


In one specific embodiment, the conjugate of Formula III has the

following formula:




wherein Y^{2c} is O, N(R^y) or S.

In one specific embodiment, the conjugate of Formula III has the following formula:




wherein, in a more specific embodiment, Y^{2c} is O or N(CH_3).

In one specific embodiment, for a conjugate of Formula III, substituted triazole has the structure:



In one specific embodiment, the conjugate of Formula III has the following formula:



wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Y^2 is independently O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, $N–NR_2$, S, S–S, S(O), or $S(O)_2$;

R^y is independently H, F, Cl, Br, I, OH, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, $-SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($–NH_2$), ammonium ($–NH_3^+$), alkylamino, dialkylamino, trialkylammonium, $C_1–C_8$ alkyl, $C_1–C_8$ alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, $C_1–C_8$ alkylsulfonate, $C_1–C_8$ alkylamino, 4-dialkylaminopyridinium, $C_1–C_8$ alkylhydroxyl, $C_1–C_8$ alkylthiol, alkylsulfone ($–SO_2R$), arylsulfone ($–SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($–SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($–C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($–N_3$), nitro ($–NO_2$), $C_1–C_8$ alkoxy (–OR), $C_1–C_8$ alkyl, $C_1–C_8$ substituted alkyl, $C_1–C_8$ alkenyl, $C_1–C_8$ substituted alkenyl, $C_1–C_8$ alkynyl, $C_1–C_8$ substituted alkynyl, $C_6–C_{20}$ aryl, $C_6–C_{20}$ substituted aryl, $C_2–C_{20}$ heterocycle, $C_2–C_{20}$ substituted heterocycle, polyethyleneoxy, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

PG is a protecting group selected from an ether-forming group, an ester-forming group, a silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, an amino acid, and a polypeptide.

Linking Groups and Linkers

The invention provides conjugates that comprise an anti-cancer compound that is linked to one or more phosphonate groups either directly (e.g. through a covalent bond) or through a linking group (i.e. a linker). The nature of the linker is not critical provided it does not interfere with the ability of the phosphonate containing compound to function as a therapeutic agent. The phosphonate or the linker can be linked to the compound (e.g. a compound of Formula **500-601**) at any synthetically feasible position on the compound by removing a hydrogen or any portion of the compound to provide an open valence for attachment of the phosphonate or the linker.

In one embodiment of the invention the linking group or linker (which can be designated "L") can include all or a portions of the group A^0, A^1, A^2, or W^3 described herein.

In another embodiment of the invention the linking group or linker has a molecular weight of from about 20 daltons to about 400 daltons.

In another embodiment of the invention the linking group or linker has a length of about 5 angstroms to about 300 angstroms.

In another embodiment of the invention the linking group or linker separates the DRUG and a $P(=Y^1)$ residue by about 5 angstroms to about 200 angstroms, inclusive, in length.

In another embodiment of the invention the linking group or linker is a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain,

having from 2 to 25 carbon atoms, wherein one or more (e.g. 1, 2, 3, or 4) of the carbon atoms is optionally replaced by (-O-), and wherein the chain is optionally substituted on carbon with one or more (e.g. 1, 2, 3, or 4) substituents selected from (C_1-C_6)alkoxy, (C_3-C_6)cycloalkyl, (C_1-C_6)alkanoyl, (C_1-C_6)alkanoyloxy, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=O), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy.

In another embodiment of the invention the linking group or linker is of the formula W-A wherein A is (C_1-C_{24})alkyl, (C_2-C_{24})alkenyl, (C_2-C_{24})alkynyl, (C_3-C_8)cycloalkyl, (C_6-C_{10})aryl or a combination thereof, wherein W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl.

In another embodiment of the invention the linking group or linker is a divalent radical formed from a peptide.

In another embodiment of the invention the linking group or linker is a divalent radical formed from an amino acid.

In another embodiment of the invention the linking group or linker is a divalent radical formed from poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-lysine or poly-L-lysine-L-tyrosine.

In another embodiment of the invention the linking group or linker is of the formula W-$(CH_2)_n$ wherein, n is between about 1 and about 10; and W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl.

In another embodiment of the invention the linking group or linker is methylene, ethylene, or propylene.

In another embodiment of the invention the linking group or linker is attached to the phosphonate group through a carbon atom of the linker.

Intracellular Targeting

The phosphonate group of the compounds of the invention may cleave *in vivo* in stages after they have reached the desired site of action, i.e. inside a cell. One mechanism of action inside a cell may entail a first cleavage, e.g. by esterase, to provide a negatively-charged "locked-in" intermediate. Cleavage of a terminal ester grouping in a compound of the invention thus affords an unstable intermediate which releases a negatively charged "locked in" intermediate.

After passage inside a cell, intracellular enzymatic cleavage or modification of the phosphonate or prodrug compound may result in an intracellular accumulation of the cleaved or modified compound by a "trapping" mechanism. The cleaved or modified compound may then be "locked-in" the cell by a significant change in charge, polarity, or other physical property change which decreases the rate at which the cleaved or modified compound can exit the cell, relative to the rate at which it entered as the phosphonate prodrug. Other mechanisms by which a therapeutic effect are achieved may be operative as well. Enzymes which are capable of an enzymatic activation mechanism with the phosphonate prodrug compounds of the invention include, but are not limited to, amidases, esterases, microbial enzymes, phospholipases, cholinesterases, and phosphatases.

In selected instances in which the drug is of the nucleoside type, such as is the case of zidovudine and numerous other antiretroviral agents, it is known that the drug is activated *in vivo* by phosphorylation. Such activation may occur in the present system by enzymatic conversion of the "locked-in" intermediate with phosphokinase to the active phosphonate diphosphate and/or by phosphorylation of the drug itself after its release from the "locked-in" intermediate as described above. In either case, the original nucleoside-type drug will be convened, via the derivatives of this invention, to the active phosphorylated species.

From the foregoing, it will be apparent that many different drugs can be derivatized in accord with the present invention. Numerous such drugs are specifically mentioned herein. However, it should be understood that the

discussion of drug families and their specific members for derivatization according to this invention is not intended to be exhaustive, but merely illustrative.

Anti-cancer compounds

The compounds of the invention include those with anti-cancer activity. In particular, the compounds include anti-cancer compounds. The compounds of the inventions bear one or more (e.g. 1, 2, 3, or 4) phosphonate groups, which may be a prodrug moiety.

Typically, compounds of the invention have a molecular weight of from about 400 amu to about 10,000 amu; in a specific embodiment of the invention, compounds have a molecular weight of less than about 5000 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 2500 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 1000 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 800 amu; in another specific embodiment of the invention, compounds have a molecular weight of less than about 600 amu; and in another specific embodiment of the invention, compounds have a molecular weight of less than about 600 amu and a molecular weight of greater than about 400 amu.

The compounds of the invention also typically have a logD(polarity) less than about 5. In one embodiment the invention provides compounds having a logD less than about 4; in another one embodiment the invention provides compounds having a logD less than about 3; in another one embodiment the invention provides compounds having a logD greater than about -5; in another one embodiment the invention provides compounds having a logD greater than about -3; and in another one embodiment the invention provides compounds having a logD greater than about 0 and less than about 3.

In one specific embodiment the invention provides compounds that may fall within the generic definition of the term anti-cancer compound but which further comprise a phosphonate group, e.g., a phosphonate diester, phosphonamidate-ester prodrug, or a phosphondiamidate-ester (Jiang et al., US 2002/0173490 A1).

Selected substituents within the compounds of the invention are present to a recursive degree. In this context, "recursive substituent" means that a substituent may recite another instance of itself. Because of the recursive nature of such substituents, theoretically, a large number may be present in any given claim. For example, R^x contains a R^y substituent. R^y can be R^2, which in turn can be R^3. If R^3 is selected to be R^{3c}, then a second instance of R^x can be selected. One of ordinary skill in the art of medicinal chemistry understands that the total number of such substituents is reasonably limited by the desired properties of the compound intended. Such properties include, by of example and not limitation, physical properties such as molecular weight, solubility or log P, application properties such as activity against the intended target, and practical properties such as ease of synthesis.

By way of example and not limitation, W^3, R^y and R^3 are all recursive substituents in certain claims. Typically, each of these may independently occur 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0, times in a given claim. More typically, each of these may independently occur 12 or fewer times in a given claim. More typically yet, W^3 will occur 0 to 8 times, R^y will occur 0 to 6 times and R^3 will occur 0 to 10 times in a given claim. Even more typically, W^3 will occur 0 to 6 times, R^y will occur 0 to 4 times and R^3 will occur 0 to 8 times in a given claim.

Recursive substituents are an intended aspect of the invention. One of ordinary skill in the art of medicinal chemistry understands the versatility of such substituents. To the degree that recursive substituents are present in an claim of the invention, the total number will be determined as set forth above.

Whenever a compound described herein is substituted with more than one of the same designated group, e.g., "R^1" or "R^{6a}", then it will be understood that the groups may be the same or different, i.e., each group is independently selected. Wavy lines indicate the site of covalent bond attachments to the adjoining groups, moieties, or atoms.

The term "anti-cancer compound" includes not only the generic disclosures cited above but also each and every species set forth therein. The phosphonate group may be a phosphonate prodrug moiety. The prodrug moiety

may be sensitive to hydrolysis, such as, but not limited to, a pivaloyloxymethyl carbonate (POC) or POM group. Alternatively, the prodrug moiety may be sensitive to enzymatic potentiated cleavage, such as a lactate ester or a phosphonamidate-ester group.

The term "anti-cancer compound" also includes gefitinib, imatinib, erlotinib, vatalanib, fosteabine, camptosar, irinotecan, hycamtin, femara, letrozole, fadrozole, temozolomide, etopophos, anastrozole, arimidex, carboplatin, paraplatin, exemestane, atamestane, epirubicin, adriamycin, taxotere, taxol, vinorelbine, ospemifene, troglitazone, etoposide, everolimus, vincristine, sirolimus, raltitrexed (tomudex), aminopterin, alvocidib, bortezomib, VX-148, vinblastine, tipifarnib, mitoxantrone, vindesine, lonafarib, merimepodib, brequinar, amsacrine, CEP-701, decitabine, teniposide, midostaurin, MLN-518, PD-184352, emetrexed (ALIMTA), 10-propargyl-10-deaza-aminopterin (PDX), tacedinaline, thalidomide, TLK-286, pixantrone, pentostatin, enocitabine, clofarabine, BCX-1777, rubitecan, suberanilohydroxamic acid, revimid, MS-275, dexamethasone, LAQ-824, fludarabine, pirarubicin, teriflunomide, cerubidin HCL, idarubicin HCL, exatecan, sardomozide, adriamycin, methopterin, mizoribine, tamoxifen citrate/toremifine citrate, raloxifene hydrochloride, mycophenolate, dexamethasone, methotrexate, GLEEVEC, PNP-405, MDL-74428, 9- (3,3-dimethyl-5-phosphonopentyl) guanine, DADMe-IMMG, camptosar, idarubicin, leflunomide, BAY-43-9006, bicyclo nucleobase compounds, 2-fluoro, 2', 3' didehydro, 4' phosphonate nucleoside compounds, gemcitabine, cladribine, rofecoxib, ANA-245, and halobetasol propionate.

In one embodiment of the invention, the compound is not a kinase inhibitor, an IMPDH, a PMP, an anti-viral agent, or an autoimmune system enhancer. In another embodiment of the invention, the compound is not a compound of formula **501**, **519**, **597**, **541**, **518**, **558**, **591**, **593**, **592**, **503**, **504**, **505**, **506**, **542**, **544**, **545**, **546**, **516**, or **512**.

Cellular Accumulation

In one embodiment, the invention is provides compounds capable of accumulating in human PBMC (peripheral blood mononuclear cells). PBMC refer to blood cells having round lymphocytes and monocytes. Physiologically, PBMC are critical components of the mechanism against infection. PBMC may be isolated from heparinized whole blood of normal healthy donors or buffy coats, by standard density gradient centrifugation and harvested from the interface, washed (*e.g.* phosphate-buffered saline) and stored in freezing medium. PBMC may be cultured in multi-well plates. At various times of culture, supernatant may be either removed for assessment, or cells may be harvested and analyzed (Smith R. etal (2003) *Blood* 102(7):2532-2540). The compounds of this claim may further comprise a phosphonate or phosphonate prodrug. More typically, the phosphonate or phosphonate prodrug can have the structure A^3 as described herein.

Typically, compounds of the invention demonstrate improved intracellular half-life of the compounds or intracellular metabolites of the compounds in human PBMC when compared to analogs of the compounds not having the phosphonate or phosphonate prodrug. Typically, the half-life is improved by at least about 50%, more typically at least in the range 50-100%, still more typically at least about 100%, more typically yet greater than about 100%.

In one embodiment of the invention the intracellular half-life of a metabolite of the compound in human PBMCs is improved when compared to an analog of the compound not having the phosphonate or phosphonate prodrug. In such claims, the metabolite may be generated intracellularly, *e.g.* generated within human PBMC. The metabolite may be a product of the cleavage of a phosphonate prodrug within human PBMCs. The phosphonate prodrug may be cleaved to form a metabolite having at least one negative charge at physiological pH. The phosphonate prodrug may be enzymatically cleaved within human PBMC to form a phosphonate having at least one active hydrogen atom of the form P-OH.

Stereoisomers

The compounds of the invention may have chiral centers, e.g., chiral carbon or phosphorus atoms. The compounds of the invention thus include racemic mixtures of all stereoisomers, including enantiomers, diastereomers, and atropisomers. In addition, the compounds of the invention include enriched or resolved optical isomers at any or all asymmetric, chiral atoms. In other words, the chiral centers apparent from the depictions are provided as the chiral isomers or racemic mixtures. Both racemic and diastereomeric mixtures, as well as the individual optical isomers isolated or synthesized, substantially free of their enantiomeric or diastereomeric partners, are all within the scope of the invention. The racemic mixtures are separated into their individual, substantially optically pure isomers through well-known techniques such as, for example, the separation of diastereomeric salts formed with optically active adjuncts, e.g., acids or bases followed by conversion back to the optically active substances. In most instances, the desired optical isomer is synthesized by means of stereospecific reactions, beginning with the appropriate stereoisomer of the desired starting material.

The compounds of the invention can also exist as tautomeric isomers in certain cases. All though only one delocalized resonance structure may be depicted, all such forms are contemplated within the scope of the iinvention. For example, ene-amine tautomers can exist for purine, pyrimidine, imidazole, guanidine, amidine, and tetrazole systems and all their possible tautomeric forms are within the scope of the invention.

Salts and Hydrates

The compositions of this invention optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example, Na^+, Li^+, K^+, Ca^{+2} and Mg^{+2}. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. Monovalent salts are preferred if a water soluble salt is desired.

Metal salts typically are prepared by reacting the metal hydroxide with a

compound of this invention. Examples of metal salts which are prepared in this way are salts containing Li^+, Na^+, and K^+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound.

In addition, salts may be formed from acid addition of certain organic and inorganic acids, e.g., HCl, HBr, H_2SO_4, H_3PO_4 or organic sulfonic acids, to basic centers, typically amines, or to acidic groups. Finally, it is to be understood that the compositions herein comprise compounds of the invention in their un-ionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids. Any of the amino acids described above are suitable, especially the naturally-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

Methods of Treating Cancer

Another aspect of the invention relates to methods of treating cancer. Compositions of the invention may treat cancer, may act intermediates for such treatment or have other utilities as described below. The anti-cancer compounds will bind to locations on the surface or in a cavity of a cancer cell having a geometry unique to the anti-cancer compound. Compositions binding the anti-cancer compound may bind with varying degrees of reversibility. Those compounds binding substantially irreversibly are ideal candidates for use in this method of the invention. Once labeled, the substantially irreversibly binding compositions are useful as probes for the detection of cancer. Accordingly, the invention relates to methods of detecting cancer in a sample suspected of containing cancer comprising the steps of: treating a sample suspected of containing cancer with a composition comprising a compound of the invention bound to a label; and observing the effect of the sample on the activity of the label. Suitable labels are well known in the diagnostics field and include stable

free radicals, fluorophores, radioisotopes, enzymes, chemiluminescent groups and chromogens. The compounds herein are labeled in conventional fashion using functional groups such as hydroxyl or amino.

Within the context of the invention samples suspected of containing cancer include natural or man-made materials such as living organisms; tissue or cell cultures; biological samples such as biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, and the like); laboratory samples; food, water, or air samples; bioproduct samples such as extracts of cells, particularly recombinant cells synthesizing a desired glycoprotein; and the like. Typically the sample will be suspected of containing cancer. Samples can be contained in any medium including water and organic solvent/water mixtures. Samples include living organisms such as humans, and man made materials such as cell cultures.

The treating step of the invention comprises adding the composition of the invention to the sample or it comprises adding a precursor of the composition to the sample. The addition step comprises any method of administration as described above.

If desired, the activity of cancer after application of the composition can be observed by any method including direct and indirect methods of detecting cancer activity. Quantitative, qualitative, and semiquantitative methods of determining cancer activity are all contemplated. Typically one of the screening methods described above are applied, however, any other method such as observation of the physiological properties of a living organism are also applicable.

Organisms that contain cancer include mammals such as humans. The compounds of this invention are useful in the treatment or prophylaxis of cancer in animals or in man.

However, in screening compounds capable of treating cancer it should be kept in mind that the results of enzyme assays may not correlate with cell culture assays. Thus, a cell based assay should be the primary screening tool.

Screens for Anti-Cancer Compounds

Compositions of the invention are screened for activity against cancer by

any of the conventional techniques for evaluating enzyme activity. Within the context of the invention, typically compositions are first screened for activity against cancer *in vitro* and compositions showing activity are then screened for activity *in vivo*. Useful *in vitro* screens have been described in detail and will not be elaborated here. However, the examples describe suitable *in vitro* assays.

Pharmaceutical Formulations

The compounds of this invention are formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. All formulations will optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.

While it is possible for the active ingredients to be administered alone it may be preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.

The formulations include those suitable for the foregoing administration routes. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by

uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.

A tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets may optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.

For administration to the eye or other external tissues e.g., mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base.

If desired, the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably include a compound which

enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulphoxide and related analogs.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

Emulgents and emulsion stabilizers suitable for use in the formulation of the invention include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils are used.

Pharmaceutical formulations according to the present invention comprise one or more compounds of the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When

used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long

chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.

Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions (weight:weight). The pharmaceutical composition can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion may contain from about 3 to 500 μg of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/hr can occur.

Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert

basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns (including particle sizes in a range between 0.1 and 500 microns in increments microns such as 0.5, 1, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of cancerous infections as described below.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

The formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described. Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients particularly

mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

The invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier therefor.

Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.

Compounds of the invention can also be formulated to provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provided compositions comprising one or more compounds of the invention formulated for sustained or controlled release.

Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active cancerous infection, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies. It can be expected to be from about 0.0001 to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about .01 to about 5 mg/kg body weight per day. More typically, from about .05 to about 0.5 mg/kg body weight per day. For example, the daily candidate dose for an adult human of approximately 70 kg body weight will range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses.

Routes of Administration

One or more compounds of the invention (herein referred to as the active ingredients) are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and

sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with for example the condition of the recipient. An advantage of the compounds of this invention is that they are orally bioavailable and can be dosed orally.

Combination Therapy

Active ingredients of the invention are also used in combination with other active ingredients. Such combinations are selected based on the condition to be treated, cross-reactivities of ingredients and pharmaco-properties of the combination. For example, when treating cancer, the compositions of the invention can be combined with other chemotherapeutic agents. The second chemotherapeutic agent can be any suitable compound that has biological activity against one or more forms of cancer.

It is also possible to combine any compound of the invention with one or more other active ingredients in a unitary dosage form for simultaneous or sequential administration to an cancer patient. The combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations. Second and third active ingredients in the combination may have chemotherapeutic activity and include any of the additional chemotherapeutic agents described herein. Exemplary active ingredients to be administered in combination with compounds of the invention are described below.

Suitable additional chemotherapeutic agents include, e.g., antracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone); (b) other DNA intercalators (e.g., actinomycins C, D, B, etc.; podophyllotoxins, and epipodophyllatoxins (etoposide, teniposide, ctoposide)); (c) alkylating agents (e.g., mechlorethamine, melphalan, cyclophosphamide, chlorambucil, ifosfamide, carmustine, lomustine, busulfan, dacarbazine, cisplatin, carboplatin, oxaliplatin, iproplatin, and tetraplatin); (d) hormonal agents (e.g., antiestrogens / estrogen antagonists (tamoxifen and other SERMs); LHRH agonists and antagonists (leuprolide acetate, goserelin, abarelix); aromatase inhibitors; and

antiandrogens; (e) chemoprevention agents (e.g., NSAIDs and cis-retinoids); and (f) cell-cycle chemopreventative agents.

Alternatively, the additional chemotherapeutic agent can include, e.g., antineoplasts. Representative antineoplasts include, e.g., adjuncts (e.g., levamisole, gallium nitrate, granisetron, sargramostim strontium-89 chloride, filgrastim, pilocarpine, dexrazoxane, and ondansetron); androgen inhibitors (e.g., flutamide and leuprolide acetate); antibiotic derivatives (e.g., doxorubicin, bleomycin sulfate, daunorubicin, dactinomycin, and idarubicin); antiestrogens (e.g., tamoxifen citrate, analogs thereof, and nonsteroidal antiestrogens such as toremifene, droloxifene and roloxifene); antimetabolites (e.g., fludarabine phosphate, interferon alfa-2b recombinant, methotrexate sodium, plicamycin, mercaptopurine, and thioguanine); cytotoxic agents (e.g., doxorubicin, carmustine [BCNU], lomustine [CCNU], cytarabine USP, cyclophosphamide, estramucine phosphate sodium, altretamine, hydroxyurea, ifosfamide, procarbazine, mitomycin, busulfan, cyclophosphamide, mitoxantrone, carboplati, cisplati, cisplatin, interferon alfa-2a recombinant, paclitaxel, teniposide, and streptozoci); hormones (e.g., medroxyprogesterone acetate, estradiol, megestrol acetate, octreotide acetate, diethylstilbestrol diphosphate, testolactone, and goserelin acetate); immunomodulators (e.g., aldesleukin); nitrogen mustard derivatives (e.g., melphalan, chlorambucil, mechlorethamine, and thiotepa) and steroids (betamethasone sodium phosphate and betamethasone acetate).

Suitable additional chemotherapeutic agents include, e.g., alkylating agents, antimitotic agents, plant alkaloids, biologicals, topoisomerase I inhibitors, topoisomerase II inhibitors, and synthetics.

Representative alkylating agents include, e.g., asaley, AZQ, BCNU, busulfan, bisulphan, carboxyphthalatoplatinum, CBDCA, CCNU, CHIP, chlorambucil, chlorozotocin, cis -platinum, clomesone, cyanomorpholinodoxorubicin, cyclodisone, cyclophosphamide, dianhydrogalactitol, fluorodopan, hepsulfam, hycanthone, iphosphamide, melphalan, methyl CCNU, mitomycin C, mitozolamide, nitrogen mustard, PCNU, piperazine, piperazinedione, pipobroman, porfiromycin, spirohydantoin mustard, streptozotocin, teroxirone, tetraplatin, thiotepa, triethylenemelamine,

uracil nitrogen mustard, and Yoshi-864.

Representative antimitotic agents include, e.g., allocolchicine, Halichondrin B, colchicine, colchicine derivatives, dolastatin 10, maytansine, rhizoxin, paclitaxel derivatives, paclitaxel, thiocolchicine, trityl cysteine, vinblastine sulfate, and vincristine sulfate.

Representative plant alkaloids include, e.g., actinomycin D, bleomycin, L-asparaginase, idarubicin, vinblastine sulfate, vincristine sulfate, mitramycin, mitomycin, daunorubicin, VP-16-213, VM-26, navelbine and taxotere.

Representative biologicals include, e.g., alpha interferon, BCG, G-CSF, GM-CSF, and interleukin-2.

Representative topoisomerase I inhibitors include, e.g., camptothecin, camptothecin derivatives, and morpholinodoxorubicin.

Representative topoisomerase II inhibitors include, e.g., mitoxantron, amonafide, m-AMSA, anthrapyrazole derivatives, pyrazoloacridine, bisantrene HCL, daunorubicin, deoxydoxorubicin, menogaril, N, N-dibenzyl daunomycin, oxanthrazole, rubidazone, VM-26 and VP-16.

Representative synthetics include, e.g., hydroxyurea, procarbazine, o,p'-DDD, dacarbazine, CCNU, BCNU, cis-diamminedichloroplatimun, mitoxantrone, CBDCA, levamisole, hexamethylmelamine, all-trans retinoic acid, gliadel and porfimer sodium.

Alternatively, the additional chemotherapeutic agent can include tubulin-binding drugs and drugs that affect tubulin dynamics and function. This includes a variety of drugs that are chemically unrelated to vinca alkaloids and taxanes (e.g. CP-248 [a derivative of exisulind] and ILX-651). These drugs have distinctive effects on cells at G2M-phase and may have functionally independent effects on cells in G1 and /or S phase.

Alternatively, the additional chemotherapeutic agent can include selective apoptotic anti-cancer drugs (SAANDs), which include sulindac, aptosyn, CP-461, CP-248 and related sulindac derived compounds that inhibit one or more of the following isozymes of cyclic GMP phosphodiesterase (cGMP PDE): 1, 2, 5.

Alternatively, the additional chemotherapeutic agent can include drugs

that inhibit proteosomes (bortezomib or Velcade). Proteosomes degrade many ubiquitinated proteins that have been marked for active destruction. Ubiquitinated proteins include many critical cell cycle regulatory molecules and molecules that regulate apoptosis at specific stages of the cell cycle. While proteosomes may degrade proteins throughout the cell cycle, the proteins that are degraded by proteosomes include some of the most critical cell cycle regulatory proteins. The so-called "cell cycle active rationale" may be applied to the treatment of diseases in various categories, including cancer, inflammatory/autoimmune diseases, and neurological diseases that involve disorderly cell cycle and/or apoptosis.

Alternatively, the additional chemotherapeutic agent can include drugs that inhibit heat shock protein 90 (HSP90), a 'chaperonin' that participates in the degradation of 'client' proteins in the ubiquitin mediated proteosome pathway. Several drugs seem to exert their antitumour effect by inhibiting the intrinsic ATPase activity of HSP90, resulting in degradation of HSP90 "client proteins" via the ubiquitin proteosome pathway. Examples include: geldanamycin, 17-allylamino geldanamycin, 17-demethoxygeldanamycin and radicicol.

Suitable cell-cycle dependent biological agents or schedule-dependent biological agents include drugs, proteins or other molecules that block, impede, or otherwise interfere with, cell cycle progression at the G1-phase, G1/S interface, S-phase, G2/M interface, or M-phase of the cell cycle. These drugs are cell cycle-dependent or schedule-dependent.

Specifically, suitable cell-cycle dependent biological agents or schedule-dependent biological agents include:

(1) Analogues of uridine nucleosides, analogues of thymidine nucleosides, and analogues of uridine and thymidine nucleosides. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., 5-fluorodeoxyuridine (floxuridine, FUDR); 5-flurouracil (5-FU); prodrugs of 5-FU (e.g. capecitabine, 5'-deoxy-5-fluorouridine, ftorafur, flucytosine); bromodeoxyuridine; and iododexoyuridine.

(2) Modulators of fluoropyrimidines. These compounds act at the S-

phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., leurovorin, methotrexate and other folates; levamisole; acivicin; phosphonacetyl-L-aspartic acid (PALA); brequinar; 5-ethynyluracil; and uracil.

(3) Cytidine analogues and cytidine nucleoside analogues. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., cytarabine (Ara-C, cytosine arabinoside); gemcitabine (2',2'-difluorodeoxycytidine); and 5-azacytidine.

(4) Purine analogues and purine nucleoside analogues. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., 6-thioguanine; 6-mercaptopurine; azathioprine; adenosine arabinoside (Ara-A); 2',2'-difluorodeoxyguanosine; deoxycoformycin (pentostatin); cladribine (2-chlorodeoxyadenosine); and inhibitors of adenosine deaminase.

(5) Antifolates. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., methotrexate; aminopterin; trimetrexate; edatrexate; N10-propargyl-5,8-dideazafolic acid (CB3717); ZD1694, 5,8-dideazaisofolic acid (IAHQ); 5,10-dideazatetrahydrofolic acid (DDATHF); 5-deazafolic acid (efficient substrate for FPGS); PT523 (N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine); 10-ethyl-10-deazaaminopterin (DDATHF, lomatrexol); piritrexim; 10-EDAM; ZD1694; GW1843; PDX (10-propargyl-10-deazaaminopterin); multi-targeted folate (i.e. LY231514, permetrexed); any folate-based inhibitor of thymidylate synthase (TS); any folate-based inhibitor of dihydrofolate reductase (DHFR); any folate-based inhibitor of glycinamide ribonucleotide transformylase (GARTF); any inhibitor of folylpolyglutamate synthetase (FPGS); and any folate-based inhibitor of GAR formyl transferase (AICAR transformylase).

(6) Other antimetabolites. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., hydroxyurea and polyamines.

(7) S-phase specific radiotoxins (deoxythymidine analogues). These

compounds act at the S-phase in all cells undergoing DNA synthesis. The compounds are incorporated into chromosomal DNA during S-phase. These compounds include, e.g., [125I]-iododeoxyuridine; [123I]-iododeoxyuridine; [124I]-iododeoxyuridine; [80mBr]-iododeoxyuridine; [131I]-iododeoxyuridine; and [211At]-astatine-deoxyuridine.

(8) Inhibitors of enzymes involved in deoxynucleoside/deoxynucleotide metabolism. These compounds act at the S-phase in tumor cells, and possibly neovascular endothelial cells. These compounds include, e.g., inhibitors of thymidylate synthase (TS); inhibitors of dihydrofolate reductase (DHFR); inhibitors of glycinamide ribonucleotide transformylase (GARTF); inhibitors of folylpolyglutamate synthetase (FPGS); inhibitors of GAR formyl transferase (AICAR transformylase); inhibitors of DNA polymerases (DNA Pol; e.g. aphidocolin); inhibitors of ribonucleotide reductase (RNR); inhibitors of thymidine kinase (TK); and inhibitors of topoisomerase I enzymes (e.g. camptothecins, irinotecan [CPT-11, camptosar], topotecan, NX-211 [lurtotecan], rubitecan, etc.).

(9) DNA chain-terminating nucleoside analogues. These compounds act specifically on S-phase cells and are incorporated into chromosomal DNA during S-phase; terminate growing DNA strand. These compounds include, e.g., acyclovir; abacavir; valacyclovir; zidovudine (AZT); didanosine (ddI, dideoxycytidine); zalcitabine (ddC); stavudine (D4T); lamivudine (3TC); Any 2' 3'-dideoxy nucleoside analogue; and any 2' 3'-dideoxy nucleoside analogue that terminates DNA synthesis. These compounds include, e.g., inhibitors of growth factor receptor tyrosine kinases that regulate progression through the G1-phase, G1/S interface, or S-phase of the cell cycle (e.g. EGF receptors, HER-2 neu/c-erbB2 receptor, PDGF receptors, etc; [e.g. trastusumab, iressa, erbitux, tarceva]); inhibitors of non-receptor tyrosine kinases (e.g. c-src family of tyrosine kinases; [e.g. Gleevec]); inhibitors of serine-threonine kinases that regulate progression through the G1-phase, G1/S interface or S-phase of the cell cycle (e.g. G1 cyclin-dependent kinases, G1/S cyclin-dependent kinases, and S cyclin-dependent kinases [e.g. CDK2, CDK4, CDK5, CDK6]; mitogen-activated kinases; MAP kinase signaling pathway); inhibitors of G1-phase, G1/S interface

or S-phase cyclins [e.g. cyclins D1, D2, D3, E, and A]); inhibitors of G-proteins and cGMP phosphodiesterases that positively regulate cell cycle progression at the G1-phase, G1/S interface or S-phase of the cell cycle; drugs that inhibit the induction of immediate early response transcription factors (e.g. N-terminal c-jun kinase, c-myc); and drugs that inhibit proteosomes that degrade 'negative' cell cycle regulatory molecules (e.g. p53, p27/Kip1; [e.g. bortezomib]).

(10) Cytokines, growth factors, anti-angiogenic factors and other proteins that inhibit cell cycle progression at the G1-phase or G1/S interface of the cell cycle. These compounds act at G1, G1/S or S-phase of the cell cycle in tumor cells, and in some cases, neovascular endothelial cells. These compounds include, e.g., interferons; interleukins; somatostatin and somatostatin analogues (octreotide, sandostatin LAR); and many anti-angiogenic factors inhibit cell proliferation of endothelial cells at the G1 or G1/S phases of the cell cycle.

(11) Drugs and compounds that inhibit cell cycle progression at the G2/M interface, or M-phase of the cell cycle. These compounds act at G2/M interface or M-phase of the cell cycle in tumor cells, and in some cases, neovascular endothelial cells. These compounds include, e.g., (a) microtubule-targeting drugs – taxanes (e.g., taxol, taxotere, epothilones, and other taxanes and derivatives); (b) microtubule-targeting drugs – vinca alkaloids (e.g., vinblastine, vincristine, vindesine; vinflunine, vinorelbine, vinzolidine, nocadazole, and colchicines); (c) microtubule-targeting drugs – others (e.g., estramustine, CP-248 and CP-461); (d) inhibitors of serine-threonine kinases that regulate progression through the G2/M interface or M-phase of the cell cycle (e.g., inhibitors of G2/M cyclin-dependent kinases (e.g. CDC2); inhibitors of M-phase cyclins (e.g. cyclin B) and any drug that blocks, impedes, or otherwise interferes with, cell cycle progression at the G2/M interface, or M-phase of the cell cycle).

(12) Radiopharmaceuticals useful in radiation therapy and/or diagnosis. A suitable class of radioisotopes decay by a nuclear disintegration process known as the "Auger Process" or "Auger Cascade". Auger emitting isotopes generate short acting electrons that efficiently cleave duplex DNA. Suitable Auger-emitting radionuclides include, e.g., 125-Iodine, 123-Iodine and 80m-

Bromine. Suitable corresponding halogenated pryimidine and purine nucleosides include, e.g., 5-125Iodo-2'-deoxyuridine, 5-123Iodo-2'-deoxyuridine, 5-80mBromo-2'-deoxyuridine and 8-80mBromo-2'-guanidine.

Growth Factors

Many growth factors and cytokines have the capacity to stimulate malignant cells to traverse specific points in the cell cycle. For example, G-CSF or GM-CSF can stimulate leukemic blasts in acute myeloid leukemia to traverse the G1/S interface. This increases the cells' susceptibility to cell-cycle specific drugs, such as cytarabine. Similar strategies have been tested using EGF and cytotoxic drugs for solid tumors. In order to respond the the growth factor, cells must be at a specific stage of the cell cycle, e.g., at the G1/S interface. The continuous presence of a growth factor could be beneficial, because at any given time, only a subset of the blasts are at G1/S. Thus, the growth factors act in a cell cycle specific fashion. Similar logic can be applied to the use of hematopoietic growth factors used to treat neutropenia, anemia and thrombocytopenia.

As such, peptide / protein growth factors can be employed in the present invention to promote survival of normal non-malignant cell lineages. One benefit in using such substances is the ability to protect proliferating cells in bone marrow, skin, oral and gastrointestinal mucosa, and hair follicles.

Examples of substances within this category include, e.g., hematopoietic growth factors: G-CSF, GM-CSF, erythropoietin, thrombopoietin and biologically active derivatives of these peptides; keratinocyte growth factor (KGF) for mucositis; B-lymphocyte stimulating pepdie (BLys); platelet derived growth factor (PDGF), epithelial growth factor (EGF), TGF-alpha and related growth factors; interleukins (e.g. IL-2, IL-6); other cytokines, growth factors and peptides that stimulate proliferation of non-malignant cells that need to be protected.

Therapeutic Growth Factors / Cytokines

Some therapeutic growth factors / cytokines can inhibit cell proliferation

of cancer cells and/or neovascular cells at specific stages of the cell cycle. For example, interferons, somatostatin, octreotide and analogues thereof, thrombospondin and troponin-I inhibit neovascular endothelial cell proliferation by reducing the rate at which the cells enter S-phase. As such, any one or more of these substances can be employed in the present invention.

The combination therapy may provide "synergy" and "synergistic effect", i.e. the effect achieved when the active ingredients used together is greater than the sum of the effects that results from using the compounds separately. A synergistic effect may be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect may be attained when the compounds are administered or delivered sequentially, e.g., in separate tablets, pills or capsules, or by different injections in separate syringes. In general, during alternation therapy, an effective dosage of each active ingredient is administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.

Metabolites of the Compounds of the Invention

Also falling within the scope of this invention are the *in vivo* metabolic products of the compounds described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products typically are identified by preparing a radiolabelled (e.g., C^{14} or H^3) compound of the invention, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood

or other biological samples. These products are easily isolated since they are labeled (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites is done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found *in vivo*, are useful in diagnostic assays for therapeutic dosing of the compounds of the invention even if they possess no anti-cancer activity of their own.

Recipes and methods for determining stability of compounds in surrogate gastrointestinal secretions are known. Compounds are defined herein as stable in the gastrointestinal tract where less than about 50 mole percent of the protected groups are deprotected in surrogate intestinal or gastric juice upon incubation for 1 hour at 37 °C. Simply because the compounds are stable to the gastrointestinal tract does not mean that they cannot be hydrolyzed *in vivo*. The phosphonate prodrugs of the invention typically will be stable in the digestive system but are substantially hydrolyzed to the parental drug in the digestive lumen, liver or other metabolic organ, or within cells in general.

In one embodiment of the invention, the compound is in an isolated and purified form. Generally, the term "isolated and purified" means that the compound is substantially free from biological materials (e.g. blood, tissue, cells, etc.). In one specific embodiment of the invention, the term means that the compound or conjugate of the invention is at least about 50 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 75 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 90 wt.% free from biological materials; in another specific embodiment, the term means that the compound or conjugate of the invention is at least about 98 wt.% free from biological materials; and in another embodiment, the term means that the compound or conjugate of the invention is at least about 99 wt.% free from biological materials. In another specific embodiment, the invention provides a

compound or conjugate of the invention that has been synthetically prepared (e.g., ex vivo).

Exemplary Methods of Making the Compounds of the Invention.

The invention also relates to methods of making the compositions of the invention. The compositions are prepared by any of the applicable techniques of organic synthesis. Many such techniques are well known in the art. However, many of the known techniques are elaborated in Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., Advanced Organic Chemistry, Third Edition, (John Wiley & Sons, New York, 1985), Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9 Volumes, Barry M. Trost, Editor-in-Chief (Pergamon Press, New York, 1993 printing).

A number of exemplary methods for the preparation of the compositions of the invention are provided below. These methods are intended to illustrate the nature of such preparations are not intended to limit the scope of applicable methods.

Generally, the reaction conditions such as temperature, reaction time, solvents, work-up procedures, and the like, will be those common in the art for the particular reaction to be performed. The cited reference material, together with material cited therein, contains detailed descriptions of such conditions. Typically the temperatures will be -100°C to 200°C, solvents will be aprotic or protic, and reaction times will be 10 seconds to 10 days. Work-up typically consists of quenching any unreacted reagents followed by partition between a water/organic layer system (extraction) and separating the layer containing the product.

Oxidation and reduction reactions are typically carried out at temperatures near room temperature (about 20 °C), although for metal hydride reductions frequently the temperature is reduced to 0 °C to -100 °C, solvents are

typically aprotic for reductions and may be either protic or aprotic for oxidations. Reaction times are adjusted to achieve desired conversions.

Condensation reactions are typically carried out at temperatures near room temperature, although for non-equilibrating, kinetically controlled condensations reduced temperatures (0 °C to -100 °C) are also common. Solvents can be either protic (common in equilibrating reactions) or aprotic (common in kinetically controlled reactions).

Standard synthetic techniques such as azeotropic removal of reaction by-products and use of anhydrous reaction conditions (e.g., inert gas environments) are common in the art and will be applied when applicable.

Schemes and Examples

General aspects of these exemplary methods are described below and in the Examples. Each of the products of the following processes is optionally separated, isolated, and/or purified prior to its use in subsequent processes.

Generally, the reaction conditions such as temperature, reaction time, solvents, work-up procedures, and the like, will be those common in the art for the particular reaction to be performed. The cited reference material, together with material cited therein, contains detailed descriptions of such conditions. Typically the temperatures will be -100°C to 200°C, solvents will be aprotic or protic, and reaction times will be 10 seconds to 10 days. Work-up typically consists of quenching any unreacted reagents followed by partition between a water/organic layer system (extraction) and separating the layer containing the product.

Oxidation and reduction reactions are typically carried out at temperatures near room temperature (about 20 °C), although for metal hydride reductions frequently the temperature is reduced to 0 °C to -100 °C, solvents are typically aprotic for reductions and may be either protic or aprotic for oxidations. Reaction times are adjusted to achieve desired conversions.

Condensation reactions are typically carried out at temperatures near room temperature, although for non-equilibrating, kinetically controlled condensations reduced temperatures (0 °C to -100 °C) are also common. Solvents can be either protic (common in equilibrating reactions) or aprotic

(common in kinetically controlled reactions).

Standard synthetic techniques such as azeotropic removal of reaction by-products and use of anhydrous reaction conditions (e.g., inert gas environments) are common in the art and will be applied when applicable.

The terms "treated", "treating", "treatment", and the like, when used in connection with a chemical synthetic operation, mean contacting, mixing, reacting, allowing to react, bringing into contact, and other terms common in the art for indicating that one or more chemical entities is treated in such a manner as to convert it to one or more other chemical entities. This means that "treating compound one with compound two" is synonymous with "allowing compound one to react with compound two", "contacting compound one with compound two", "reacting compound one with compound two", and other expressions common in the art of organic synthesis for reasonably indicating that compound one was "treated", "reacted", "allowed to react", etc., with compound two. For example, treating indicates the reasonable and usual manner in which organic chemicals are allowed to react. Normal concentrations (0.01M to 10M, typically 0.1M to 1M), temperatures (-100 °C to 250 °C, typically -78 °C to 150 °C, more typically -78 °C to 100 °C, still more typically 0 °C to 100 °C), reaction vessels (typically glass, plastic, metal), solvents, pressures, atmospheres (typically air for oxygen and water insensitive reactions or nitrogen or argon for oxygen or water sensitive), etc., are intended unless otherwise indicated. The knowledge of similar reactions known in the art of organic synthesis are used in selecting the conditions and apparatus for "treating" in a given process. In particular, one of ordinary skill in the art of organic synthesis selects conditions and apparatus reasonably expected to successfully carry out the chemical reactions of the described processes based on the knowledge in the art.

Modifications of each of the exemplary schemes and in the examples (hereafter "exemplary schemes") leads to various analogs of the specific exemplary materials produce. The above-cited citations describing suitable methods of organic synthesis are applicable to such modifications.

In each of the exemplary schemes it may be advantageous to separate reaction products from one another and/or from starting materials. The desired

products of each step or series of steps is separated and/or purified (hereinafter separated) to the desired degree of homogeneity by the techniques common in the art. Typically such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can involve any number of methods including, for example: reverse-phase and normal phase; size exclusion; ion exchange; high, medium, and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography.

Another class of separation methods involves treatment of a mixture with a reagent selected to bind to or render otherwise separable a desired product, unreacted starting material, reaction by product, or the like. Such reagents include adsorbents or absorbents such as activated carbon, molecular sieves, ion exchange media, or the like. Alternatively, the reagents can be acids in the case of a basic material, bases in the case of an acidic material, binding reagents such as antibodies, binding proteins, selective chelators such as crown ethers, liquid/liquid ion extraction reagents (LIX), or the like.

Selection of appropriate methods of separation depends on the nature of the materials involved. For example, boiling point, and molecular weight in distillation and sublimation, presence or absence of polar functional groups in chromatography, stability of materials in acidic and basic media in multiphase extraction, and the like. One skilled in the art will apply techniques most likely to achieve the desired separation.

A single stereoisomer, e.g., an enantiomer, substantially free of its stereoisomer may be obtained by resolution of the racemic mixture using a method such as formation of diastereomers using optically active resolving agents (Stereochemistry of Carbon Compounds, (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) *J. Chromatogr.*, 113:(3) 283-302). Racemic mixtures of chiral compounds of the invention can be separated and isolated by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods,

(2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure stereoisomers, and (3) separation of the substantially pure or enriched stereoisomers directly under chiral conditions.

Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, α-methyl-β-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.

Alternatively, by method (2), the substrate to be resolved is reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched xanthene. A method of determining optical purity involves making chiral esters, such as a menthyl ester, e.g., (-) menthyl chloroformate in the presence of base, or Mosher ester, α-methoxy-α-(trifluoromethyl)phenyl acetate (Jacob III. (1982) *J. Org. Chem.* 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers of atropisomeric compounds can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). By method (3), a racemic mixture of two enantiomers can be separated by chromatography using a chiral stationary phase (Chiral Liquid Chromatography (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) *J. of Chromatogr.* 513:375-378). Enriched or purified enantiomers can be distinguished by methods used to distinguish other

chiral molecules with asymmetric carbon atoms, such as optical rotation and circular dichroism.

Examples General Section

A number of exemplary methods for the preparation of compounds of the invention are provided herein, for example, in the Examples hereinbelow. These methods are intended to illustrate the nature of such preparations are not intended to limit the scope of applicable methods. Certain compounds of the invention can be used as intermediates for the preparation of other compounds of the invention. For example, the interconversion of various phosphonate compounds of the invention is illustrated below.

INTERCONVERSIONS OF THE PHOSPHONATES R-LINK-P(O)$(OR^1)_2$, R-LINK-P(O)(OR^1)(OH) AND R-LINK-P(O)$(OH)_2$.

The following Schemes **32-38** described the preparation of phosphonate esters of the general structure R-link-P(O)$(OR^1)_2$, in which the groups R^1 may be the same or different. The R^1 groups attached to a phosphonate ester, or to precursors thereto, may be changed using established chemical transformations. The interconversion reactions of phosphonates are illustrated in Scheme **S32.** The group R in Scheme **32** represents the substructure, i.e. the drug "scaffold, to which the substituent link-P(O)$(OR^1)_2$ is attached, either in the compounds of the invention, or in precursors thereto. At the point in the synthetic route of conducting a phosphonate interconversion, certain functional groups in R may be protected. The methods employed for a given phosphonate transformation depend on the nature of the substituent R^1, and of the substrate to which the phosphonate group is attached. The preparation and hydrolysis of phosphonate esters is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 9ff.

In general, synthesis of phosphonate esters is achieved by coupling a nucleophile amine or alcohol with the corresponding activated phosphonate electrophilic precursor. For example, chlorophosphonate addition on to 5'-hydroxy of nucleoside is a well known method for preparation of nucleoside phosphate monoesters. The activated precursor can be prepared by several well

known methods. Chlorophosphonates useful for synthesis of the prodrugs are prepared from the substituted-1,3-propanediol (Wissner, et al, (1992) *J. Med Chem.* 35:1650). Chlorophosphonates are made by oxidation of the corresponding chlorophospholanes (Anderson, et al, (1984) *J. Org. Chem.* 49:1304) which are obtained by reaction of the substituted diol with phosphorus trichloride. Alternatively, the chlorophosphonate agent is made by treating substituted-1,3-diols with phosphorusoxychloride (Patois, et al, (1990) *J. Chem. Soc. Perkin Trans. I*, 1577). Chlorophosphonate species may also be generated in situ from corresponding cyclic phosphites (Silverburg, et al., (1996) *Tetrahedron lett.*, 37:771-774), which in turn can be either made from chlorophospholane or phosphoramidate intermediate. Phosphoroflouridate intermediate prepared either from pyrophosphate or phosphoric acid may also act as precursor in preparation of cyclic prodrugs (Watanabe et al., (1988) *Tetrahedron lett.*, 29:5763-66).

Phosphonate prodrugs of the present invention may also be prepared from the free acid by Mitsunobu reactions (Mitsunobu, (1981) *Synthesis*, 1; Campbell, (1992) *J. Org. Chem.* 57:6331), and other acid coupling reagents including, but not limited to, carbodiimides (Alexander, et al, (1994) *Collect. Czech. Chem. Commun.* 59:1853; Casara et al, (1992) *Bioorg. Med. Chem. Lett.* 2:145; Ohashi et al, (1988) *Tetrahedron Lett.*, 29:1189), and benzotriazolyloxytris-(dimethylamino)phosphonium salts (Campagne et al (1993) *Tetrahedron Lett.* 34:6743).

Aryl halides undergo Ni^{+2} catalyzed reaction with phosphite derivatives to give aryl phosphonate containing compounds (Balthazar, et al (1980) *J. Org. Chem.* 45:5425). Phosphonates may also be prepared from the chlorophosphonate in the presence of a palladium catalyst using aromatic triflates (Petrakis et al (1987) *J. Am. Chem. Soc.* 109:2831; Lu et al (1987) *Synthesis* 726). In another method, aryl phosphonate esters are prepared from aryl phosphates under anionic rearrangement conditions (Melvin (1981) *Tetrahedron Lett.* 22:3375; Casteel et al (1991) *Synthesis*, 691). N-Alkoxy aryl salts with alkali met al derivatives of cyclic alkyl phosphonate provide general synthesis for heteroaryl-2-phosphonate linkers (Redmore (1970) *J. Org. Chem.* 35:4114). These above mentioned methods can also be extended to compounds

where the W^5 group is a heterocycle. Cyclic-1,3-propanyl prodrugs of phosphonates are also synthesized from phosphonic diacids and substituted propane-1,3-diols using a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC) in presence of a base (e.g., pyridine). Other carbodiimide based coupling agents like 1,3-disopropylcarbodiimide or water soluble reagent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) can also be utilized for the synthesis of cyclic phosphonate prodrugs.

The conversion of a phosphonate diester **S32.1** into the corresponding phosphonate monoester **S32.2** (Scheme **32**, Reaction **1**) is accomplished by a number of methods. For example, the ester **S32.1** in which R^1 is an aralkyl group such as benzyl, is converted into the monoester compound **S32.2** by reaction with a tertiary organic base such as diazabicyclooctane (DABCO) or quinuclidine, as described in *J. Org. Chem.* (1995) 60:2946. The reaction is performed in an inert hydrocarbon solvent such as toluene or xylene, at about 110 °C. The conversion of the diester **S32.1** in which R^1 is an aryl group such as phenyl, or an alkenyl group such as allyl, into the monoester **S32.2** is effected by treatment of the ester **S32.1** with a base such as aqueous sodium hydroxide in acetonitrile or lithium hydroxide in aqueous tetrahydrofuran. Phosphonate diesters **S32.1** in which one of the groups R^1 is aralkyl, such as benzyl, and the other is alkyl, is converted into the monoesters **S32.2** in which R^1 is alkyl by hydrogenation, for example using a palladium on carbon catalyst. Phosphonate diesters in which both of the groups R^1 are alkenyl, such as allyl, is converted into the monoester **S32.2** in which R^1 is alkenyl, by treatment with chlorotris(triphenylphosphine)rhodium (Wilkinson's catalyst) in aqueous ethanol at reflux, optionally in the presence of diazabicyclooctane, for example by using the procedure described in *J. Org. Chem.* (1973) 38:3224, for the cleavage of allyl carboxylates.

The conversion of a phosphonate diester **S32.1** or a phosphonate monoester **S32.2** into the corresponding phosphonic acid **S32.3** (Scheme **32**, Reactions **2** and **3**) can be effected by reaction of the diester or the monoester with trimethylsilyl bromide, as described in *J. Chem. Soc., Chem. Comm.*, (1979) 739. The reaction is conducted in an inert solvent such as, for example,

dichloromethane, optionally in the presence of a silylating agent such as bis(trimethylsilyl)trifluoroacetamide, at ambient temperature. A phosphonate monoester **S32.2** in which R^1 is aralkyl such as benzyl, is converted into the corresponding phosphonic acid **S32.3** by hydrogenation over a palladium catalyst, or by treatment with hydrogen chloride in an ethereal solvent such as dioxane. A phosphonate monoester **S32.2** in which R^1 is alkenyl such as, for example, allyl, is converted into the phosphonic acid **S32.3** by reaction with Wilkinson's catalyst in an aqueous organic solvent, for example in 15% aqueous acetonitrile, or in aqueous ethanol, for example using the procedure described in *Helv. Chim. Acta.* (1985) 68:618. Palladium catalyzed hydrogenolysis of phosphonate esters **S32.1** in which R^1 is benzyl is described in *J. Org. Chem.* (1959) 24:434. Platinum-catalyzed hydrogenolysis of phosphonate esters **S32.1** in which R^1 is phenyl is described in *J. Am. Chem. Soc.* (1956) 78:2336.

The conversion of a phosphonate monoester **S32.2** into a phosphonate diester **S32.1** (Scheme **32**, Reaction **4**) in which the newly introduced R^1 group is alkyl, aralkyl, haloalkyl such as chloroethyl, or aralkyl is effected by a number of reactions in which the substrate **S32.2** is reacted with a hydroxy compound R^1OH, in the presence of a coupling agent. Typically, the second phosphonate ester group is different than the first introduced phosphonate ester group, i.e. R^1 is followed by the introduction of R^2 where each of R^1 and R^2 is alkyl, aralkyl, haloalkyl such as chloroethyl, or aralkyl (Scheme **32**, Reaction **4a**) whereby **S32.2** is converted to **S32.1a**. Suitable coupling agents are those employed for the preparation of carboxylate esters, and include a carbodiimide such as dicyclohexylcarbodiimide, in which case the reaction is preferably conducted in a basic organic solvent such as pyridine, or (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PYBOP, Sigma), in which case the reaction is performed in a polar solvent such as dimethylformamide, in the presence of a tertiary organic base such as diisopropylethylamine, or Aldrithiol-2 (Aldrich) in which case the reaction is conducted in a basic solvent such as pyridine, in the presence of a triaryl phosphine such as triphenylphosphine. Alternatively, the conversion of the phosphonate monoester **S32.2** to the diester **S32.1** is effected by the use of the


Mitsunobu reaction, as described above (Scheme 7). The substrate is reacted with the hydroxy compound R^1OH, in the presence of diethyl azodicarboxylate and a triarylphosphine such as triphenyl phosphine. Alternatively, the phosphonate monoester **S32.2** is transformed into the phosphonate diester **S32.1**, in which the introduced R^1 group is alkenyl or aralkyl, by reaction of the monoester with the halide R^1Br, in which R^1 is as alkenyl or aralkyl. The alkylation reaction is conducted in a polar organic solvent such as dimethylformamide or acetonitrile, in the presence of a base such as cesium carbonate. Alternatively, the phosphonate monoester is transformed into the phosphonate diester in a two step procedure. In the first step, the phosphonate monoester **S32.2** is transformed into the chloro analog $RP(O)(OR^1)Cl$ by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17, and the thus-obtained product $RP(O)(OR^1)Cl$ is then reacted with the hydroxy compound R^1OH, in the presence of a base such as triethylamine, to afford the phosphonate diester **S32.1**.

A phosphonic acid R-link-$P(O)(OH)_2$ is transformed into a phosphonate monoester $RP(O)(OR^1)(OH)$ (Scheme **32**, Reaction **5**) by means of the methods described above of for the preparation of the phosphonate diester R-link-$P(O)(OR^1)_2$ **S32.1**, except that only one molar proportion of the component R^1OH or R^1Br is employed. Dialkyl phosphonates may be prepared according to the methods of: Quast et al (1974) *Synthesis* 490; Stowell et al (1990) *Tetrahedron Lett.* 3261; US 5663159.

A phosphonic acid R-link-$P(O)(OH)_2$ **S32.3** is transformed into a phosphonate diester R-link-$P(O)(OR^1)_2$ **S32.1** (Scheme **32**, Reaction **6**) by a coupling reaction with the hydroxy compound R^1OH, in the presence of a coupling agent such as Aldrithiol-2 (Aldrich) and triphenylphosphine. The reaction is conducted in a basic solvent such as pyridine. Alternatively, phosphonic acids **S32.3** are transformed into phosphonic esters **S32.1** in which R^1 is aryl, by means of a coupling reaction employing, for example, dicyclohexylcarbodiimide in pyridine at ca 70 °C. Alternatively, phosphonic acids **S32.3** are transformed into phosphonic esters **S32.1** in which R^1 is alkenyl,

by means of an alkylation reaction. The phosphonic acid is reacted with the alkenyl bromide R^1Br in a polar organic solvent such as acetonitrile solution at reflux temperature, the presence of a base such as cesium carbonate, to afford the phosphonic ester **S32.1**.

Scheme 32



Preparation of phosphonate carbamates.

Phosphonate esters may contain a carbamate linkage. The preparation of carbamates is described in Comprehensive Organic Functional Group Transformations, A. R. Katritzky, ed., Pergamon, 1995, Vol. 6, p. 416ff, and in Organic Functional Group Preparations, by S. R. Sandler and W. Karo, Academic Press, 1986, p. 260ff. The carbamoyl group may be formed by reaction of a hydroxy group according to the methods known in the art, including the teachings of Ellis, US 2002/0103378 A1 and Hajima, US 6018049.

Scheme **33** illustrates various methods by which the carbamate linkage is synthesized. As shown in Scheme **33**, in the general reaction generating carbamates, an alcohol **S33.1**, is converted into the activated derivative **S33.2** in which Lv is a leaving group such as halo, imidazolyl, benztriazolyl and the like, as described herein. The activated derivative **S33.2** is then reacted with an amine **S33.3**, to afford the carbamate product **S33.4**. Examples **1** – **7** in Scheme **33** depict methods by which the general reaction is effected. Examples **8** - **10** illustrate alternative methods for the preparation of carbamates.

Scheme **33**, Example **1** illustrates the preparation of carbamates employing a chloroformyl derivative of the alcohol **S33.5**. In this procedure, the alcohol **S33.5** is reacted with phosgene, in an inert solvent such as toluene, at about 0 °C, as described in Org. Syn. Coll. Vol. 3, 167, 1965, or with an equivalent reagent such as trichloromethoxy chloroformate, as described in Org. Syn. Coll. Vol. 6, 715, 1988, to afford the chloroformate **S33.6**. The latter compound is then reacted with the amine component **S33.3**, in the presence of an organic or inorganic base, to afford the carbamate **S33.7**. For example, the chloroformyl compound **S33.6** is reacted with the amine **S33.3** in a water-miscible solvent such as tetrahydrofuran, in the presence of aqueous sodium hydroxide, as described in Org. Syn. Coll. Vol. 3, 167, 1965, to yield the carbamate **S33.7**. Alternatively, the reaction is performed in dichloromethane in the presence of an organic base such as diisopropylethylamine or dimethylaminopyridine.

Scheme **33**, Example **2** depicts the reaction of the chloroformate compound **S33.6** with imidazole to produce the imidazolide **S33.8**. The imidazolide product is then reacted with the amine **S33.3** to yield the carbamate **S33.7**. The preparation of the imidazolide is performed in an aprotic solvent such as dichloromethane at 0°, and the preparation of the carbamate is conducted in a similar solvent at ambient temperature, optionally in the presence of a base such as dimethylaminopyridine, as described in *J. Med. Chem.*, 1989, 32, 357.

Scheme **33** Example **3**, depicts the reaction of the chloroformate **S33.6** with an activated hydroxyl compound R"OH, to yield the mixed carbonate ester **S33.10**. The reaction is conducted in an inert organic solvent such as ether or

dichloromethane, in the presence of a base such as dicyclohexylamine or triethylamine. The hydroxyl component R"OH is selected from the group of compounds **S33.19 - S33.24** shown in Scheme **33**, and similar compounds. For example, if the component R"OH is hydroxybenztriazole **S33.19**, N-hydroxysuccinimide **S33.20**, or pentachlorophenol, **S33.21**, the mixed carbonate **S33.10** is obtained by the reaction of the chloroformate with the hydroxyl compound in an ethereal solvent in the presence of dicyclohexylamine, as described in *Can. J. Chem.*, 1982, 60, 976. A similar reaction in which the component R"OH is pentafluorophenol **S33.22** or 2-hydroxypyridine **S33.23** is performed in an ethereal solvent in the presence of triethylamine, as described in *Syn.*, 1986, 303, and *Chem. Ber.* 118, 468, 1985.

Scheme **33** Example **4** illustrates the preparation of carbamates in which an alkyloxycarbonylimidazole **S33.8** is employed. In this procedure, an alcohol **S33.5** is reacted with an equimolar amount of carbonyl diimidazole **S33.11** to prepare the intermediate **S33.8**. The reaction is conducted in an aprotic organic solvent such as dichloromethane or tetrahydrofuran. The acyloxyimidazole **S33.8** is then reacted with an equimolar amount of the amine $R'NH_2$ to afford the carbamate **S33.7**. The reaction is performed in an aprotic organic solvent such as dichloromethane, as described in *Tet. Lett.*, 42, 2001, 5227, to afford the carbamate **S33.7**.

Scheme **33**, Example **5** illustrates the preparation of carbamates by means of an intermediate alkoxycarbonylbenztriazole **S33.13**. In this procedure, an alcohol ROH is reacted at ambient temperature with an equimolar amount of benztriazole carbonyl chloride **S33.12**, to afford the alkoxycarbonyl product **S33.13**. The reaction is performed in an organic solvent such as benzene or toluene, in the presence of a tertiary organic amine such as triethylamine, as described in *Synthesis.*, 1977, 704. The product is then reacted with the amine $R'NH_2$ to afford the carbamate **S33.7**. The reaction is conducted in toluene or ethanol, at from ambient temperature to about 80 °C as described in *Synthesis.*, 1977, 704.

Scheme **33**, Example **6** illustrates the preparation of carbamates in which a carbonate $(R"O)_2CO$, **S33.14**, is reacted with an alcohol **S33.5** to afford the

intermediate alkyloxycarbonyl intermediate **S33.15**. The latter reagent is then reacted with the amine $R'NH_2$ to afford the carbamate **S33.7**. The procedure in which the reagent **S33.15** is derived from hydroxybenztriazole **S33.19** is described in *Synthesis*, 1993, 908; the procedure in which the reagent **S33.15** is derived from N-hydroxysuccinimide **S33.20** is described in *Tet. Lett.*, 1992, 2781; the procedure in which the reagent **S33.15** is derived from 2-hydroxypyridine **S33.23** is described in *Tet. Lett.*, 1991, 4251; the procedure in which the reagent **S33.15** is derived from 4-nitrophenol **S33.24** is described in *Synthesis*. 1993, 103. The reaction between equimolar amounts of the alcohol ROH and the carbonate **S33.14** is conducted in an inert organic solvent at ambient temperature.

Scheme **33**, Example **7** illustrates the preparation of carbamates from alkoxycarbonyl azides **S33.16**. In this procedure, an alkyl chloroformate **S33.6** is reacted with an azide, for example sodium azide, to afford the alkoxycarbonyl azide **S33.16**. The latter compound is then reacted with an equimolar amount of the amine $R'NH_2$ to afford the carbamate **S33.7**. The reaction is conducted at ambient temperature in a polar aprotic solvent such as dimethylsulfoxide, for example as described in *Synthesis*., 1982, 404.

Scheme **33**, Example **8** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and the chloroformyl derivative of an amine **S33.17**. In this procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 647, the reactants are combined at ambient temperature in an aprotic solvent such as acetonitrile, in the presence of a base such as triethylamine, to afford the carbamate **S33.7**.


Scheme **33**, Example **9** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and an isocyanate **S33.18**. In this procedure, which is described in Synthetic Organic Chemistry, R. B. Wagner, H. D. Zook, Wiley, 1953, p. 645, the reactants are combined at ambient temperature in an aprotic solvent such as ether or dichloromethane and the like, to afford the carbamate **S33.7**.

Scheme **33**, Example **10** illustrates the preparation of carbamates by means of the reaction between an alcohol ROH and an amine $R'NH_2$. In this

procedure, which is described in *Chem. Lett.* 1972, 373, the reactants are combined at ambient temperature in an aprotic organic solvent such as tetrahydrofuran, in the presence of a tertiary base such as triethylamine, and selenium. Carbon monoxide is passed through the solution and the reaction proceeds to afford the carbamate **S33.7**.


Scheme 33. Preparation of carbamates.

General reaction





Examples

(1)




(2)







(3)





(4)





(5)

















PREPARATION OF CARBOALKOXY-SUBSTITUTED PHOSPHONATE BISAMIDATES, MONOAMIDATES, DIESTERS AND MONOESTERS.

A number of methods are available for the conversion of phosphonic acids into amidates and esters. In one group of methods, the phosphonic acid is

either converted into an isolated activated intermediate such as a phosphoryl chloride, or the phosphonic acid is activated in situ for reaction with an amine or a hydroxy compound.

The conversion of phosphonic acids into phosphoryl chlorides is accomplished by reaction with thionyl chloride, for example as described in *J. Gen. Chem. USSR*, 1983, 53, 480, *Zh. Obschei Khim.*, 1958, 28, 1063, or *J. Org. Chem.*, 1994, 59, 6144, or by reaction with oxalyl chloride, as described in *J. Am. Chem. Soc.*, 1994, 116, 3251, or *J. Org. Chem.*, 1994, 59, 6144, or by reaction with phosphorus pentachloride, as described in *J. Org. Chem.*, 2001, 66, 329, or in *J. Med. Chem.*, 1995, 38, 1372. The resultant phosphoryl chlorides are then reacted with amines or hydroxy compounds in the presence of a base to afford the amidate or ester products.

Phosphonic acids are converted into activated imidazolyl derivatives by reaction with carbonyl diimidazole, as described in *J. Chem. Soc., Chem. Comm.* (1991) 312, or *Nucleosides & Nucleotides* (2000) 19:1885. Activated sulfonyloxy derivatives are obtained by the reaction of phosphonic acids with trichloromethylsulfonyl chloride or with triisopropylbenzenesulfonyl chloride, as described in *Tet. Lett.* (1996) 7857, or *Bioorg. Med. Chem. Lett.* (1998) 8:663. The activated sulfonyloxy derivatives are then reacted with amines or hydroxy compounds to afford amidates or esters.

Alternatively, the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a diimide coupling agent. The preparation of phosphonic amidates and esters by means of coupling reactions in the presence of dicyclohexyl carbodiimide is described, for example, in *J. Chem. Soc., Chem. Comm.* (1991) 312 or *Coll. Czech. Chem. Comm.* (1987) 52:2792. The use of ethyl dimethylaminopropyl carbodiimide for activation and coupling of phosphonic acids is described in *Tet. Lett.*, (2001) 42:8841, or *Nucleosides & Nucleotides* (2000) 19:1885.

A number of additional coupling reagents have been described for the preparation of amidates and esters from phosphonic acids. The agents include Aldrithiol-2, and PYBOP and BOP, as described in *J. Org. Chem.*, 1995, 60, 5214, and *J. Med. Chem.* (1997) 40:3842, mesitylene-2-sulfonyl-3-nitro-1,2,4-

triazole (MSNT), as described in *J. Med. Chem.* (1996) 39:4958, diphenylphosphoryl azide, as described in *J. Org. Chem.* (1984) 49:1158, 1-(2,4,6-triisopropylbenzenesulfonyl-3-nitro-1,2,4-triazole (TPSNT) as described in *Bioorg. Med. Chem. Lett.* (1998) 8:1013, bromotris(dimethylamino)phosphonium hexafluorophosphate (BroP), as described in *Tet. Lett.*, (1996) 37:3997, 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinane, as described in *Nucleosides Nucleotides* 1995, 14, 871, and diphenyl chlorophosphate, as described in *J. Med. Chem.*, 1988, 31, 1305.

Phosphonic acids are converted into amidates and esters by means of the Mitsunobu reaction, in which the phosphonic acid and the amine or hydroxy reactant are combined in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The procedure is described in *Org. Lett.*, 2001, 3, 643, or *J. Med. Chem.*, 1997, 40, 3842.


Phosphonic esters are also obtained by the reaction between phosphonic acids and halo compounds, in the presence of a suitable base. The method is described, for example, in *Anal. Chem.*, 1987, 59, 1056, or *J. Chem. Soc. Perkin Trans., I*, 1993, 19, 2303, or *J. Med. Chem.*, 1995, 38, 1372, or *Tet. Lett.*, 2002, 43, 1161.

Schemes **34-37** illustrate the conversion of phosphonate esters and phosphonic acids into carboalkoxy-substituted phosphonbisamidates (Scheme **34**), phosphonamidates (Scheme **35**), phosphonate monoesters (Scheme **36**) and phosphonate diesters, (Scheme **37**). Scheme **38** illustrates synthesis of gem-dialkyl amino phosphonate reagents.

Scheme **34** illustrates various methods for the conversion of phosphonate diesters **S34.1** into phosphonbisamidates **S34.5**. The diester **S34.1**, prepared as described previously, is hydrolyzed, either to the monoester **S34.2** or to the phosphonic acid **S34.6**. The methods employed for these transformations are described above. The monoester **S34.2** is converted into the monoamidate **S34.3** by reaction with an aminoester **S34.9**, in which the group R^2 is H or alkyl; the group R^{4b} is a divalent alkylene moiety such as, for example, $CHCH_3$, $CHCH_2CH_3$, $CH(CH(CH_3)_2)$, $CH(CH_2Ph)$, and the like, or a side chain group present in natural or modified aminoacids; and the group R^{5b} is C_1–C_{12} alkyl,

such as methyl, ethyl, propyl, isopropyl, or isobutyl; C_6–C_{20} aryl, such as phenyl or substituted phenyl; or C_6–C_{20} arylalkyl, such as benzyl or benzyhydryl. The reactants are combined in the presence of a coupling agent such as a carbodiimide, for example dicyclohexyl carbodiimide, as described in *J. Am. Chem. Soc.*, (1957) 79:3575, optionally in the presence of an activating agent such as hydroxybenztriazole, to yield the amidate product **S34.3**. The amidate-forming reaction is also effected in the presence of coupling agents such as BOP, as described in *J. Org. Chem.* (1995) 60:5214, Aldrithiol, PYBOP and similar coupling agents used for the preparation of amides and esters. Alternatively, the reactants **S34.2** and **S34.9** are transformed into the monoamidate **S34.3** by means of a Mitsunobu reaction. The preparation of amidates by means of the Mitsunobu reaction is described in *J. Med. Chem.* (1995) 38:2742. Equimolar amounts of the reactants are combined in an inert solvent such as tetrahydrofuran in the presence of a triaryl phosphine and a dialkyl azodicarboxylate. The thus-obtained monoamidate ester **S34.3** is then transformed into amidate phosphonic acid **S34.4**. The conditions used for the hydrolysis reaction depend on the nature of the R^1 group, as described previously. The phosphonic acid amidate **S34.4** is then reacted with an aminoester **S34.9**, as described above, to yield the bisamidate product **S34.5**, in which the amino substituents are the same or different. Alternatively, the phosphonic acid **S34.6** may be treated with two different amino ester reagents simulataneously, i.e. **S34.9** where R^2, R^{4b} or R^{5b} are different. The resulting mixture of bisamidate products **S34.5** may then be separable, e.g. by chromatography.

Scheme 34



An example of this procedure is shown in Scheme **34**, Example **1**. In this procedure, a dibenzyl phosphonate **S34.14** is reacted with diazabicyclooctane (DABCO) in toluene at reflux, as described in *J. Org. Chem.*, 1995, 60, 2946, to afford the monobenzyl phosphonate **S34.15**. The product is then reacted with equimolar amounts of ethyl alaninate **S34.16** and dicyclohexyl carbodiimide in pyridine, to yield the amidate product **S34.17**. The benzyl group is then removed, for example by hydrogenolysis over a palladium catalyst, to give the monoacid product **S34.18** which may be unstable according to J. Med. Chem. (1997) 40(23):3842. This compound **S34.18** is then reacted in a Mitsunobu reaction with ethyl leucinate **S34.19**, triphenyl phosphine and

diethylazodicarboxylate, as described in *J. Med. Chem.*, 1995, 38, 2742, to produce the bisamidate product **S34.20**.

Using the above procedures, but employing in place of ethyl leucinate **S34.19** or ethyl alaninate **S34.16**, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained.

Alternatively, the phosphonic acid **S34.6** is converted into the bisamidate **S34.5** by use of the coupling reactions described above. The reaction is performed in one step, in which case the nitrogen-related substituents present in the product **S34.5** are the same, or in two steps, in which case the nitrogen-related substituents can be different.

An example of the method is shown in Scheme 34, Example 2. In this procedure, a phosphonic acid **S34.6** is reacted in pyridine solution with excess ethyl phenylalaninate **S34.21** and dicyclohexylcarbodiimide, for example as described in *J. Chem. Soc., Chem. Comm.*, 1991, 1063, to give the bisamidate product **S34.22**.

Using the above procedures, but employing, in place of ethyl phenylalaninate, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained.

As a further alternative, the phosphonic acid **S34.6** is converted into the mono or bis-activated derivative **S34.7**, in which Lv is a leaving group such as chloro, imidazolyl, triisopropylbenzenesulfonyloxy etc. The conversion of phosphonic acids into chlorides **S34.7** (Lv = Cl) is effected by reaction with thionyl chloride or oxalyl chloride and the like, as described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976, p. 17. The conversion of phosphonic acids into monoimidazolides **S34.7** (Lv = imidazolyl) is described in *J. Med. Chem.*, 2002, 45, 1284 and in *J. Chem. Soc. Chem. Comm.*, 1991, 312. Alternatively, the phosphonic acid is activated by reaction with triisopropylbenzenesulfonyl chloride, as described in *Nucleosides and Nucleotides*, 2000, 10, 1885. The activated product is then reacted with the aminoester **S34.9**, in the presence of a base, to give the bisamidate **S34.5**. The reaction is performed in one step, in which case the nitrogen substituents present

in the product **S34.5** are the same, or in two steps, via the intermediate **S34.11**, in which case the nitrogen substituents can be different.

Examples of these methods are shown in Scheme 34, Examples 3 and 5. In the procedure illustrated in Scheme **34**, Example **3**, a phosphonic acid **S34.6** is reacted with ten molar equivalents of thionyl chloride, as described in *Zh. Obschei Khim.*, 1958, 28, 1063, to give the dichloro compound **S34.23**. The product is then reacted at reflux temperature in a polar aprotic solvent such as acetonitrile, and in the presence of a base such as triethylamine, with butyl serinate **S34.24** to afford the bisamidate product **S34.25**.

Using the above procedures, but employing, in place of butyl serinate **S34.24**, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained.

In the procedure illustrated in Scheme 34, Example 5, the phosphonic acid **S34.6** is reacted, as described in *J. Chem. Soc. Chem. Comm.*, 1991, 312, with carbonyl diimidazole to give the imidazolide **S34.32.** The product is then reacted in acetonitrile solution at ambient temperature, with one molar equivalent of ethyl alaninate **S34.33** to yield the monodisplacement product **S34.34.** The latter compound is then reacted with carbonyl diimidazole to produce the activated intermediate **S34.35**, and the product is then reacted, under the same conditions, with ethyl N-methylalaninate **S34.33a** to give the bisamidate product **S34.36**.

Using the above procedures, but employing, in place of ethyl alaninate **S34.33** or ethyl N-methylalaninate **S34.33a**, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained.

The intermediate monoamidate **S34.3** is also prepared from the monoester **S34.2** by first converting the monoester into the activated derivative **S34.8** in which Lv is a leaving group such as halo, imidazolyl etc, using the procedures described above. The product **S34.8** is then reacted with an aminoester **S34.9** in the presence of a base such as pyridine, to give an intermediate monoamidate product **S34.3**. The latter compound is then converted, by removal of the R^1 group and coupling of the product with the aminoester **S34.9**, as described above, into the bisamidate **S34.5**.

An example of this procedure, in which the phosphonic acid is activated by conversion to the chloro derivative **S34.26**, is shown in Scheme **34**, Example **4**. In this procedure, the phosphonic monobenzyl ester **S34.15** is reacted, in dichloromethane, with thionyl chloride, as described in *Tet. Letters.*, 1994, 35, 4097, to afford the phosphoryl chloride **S34.26**. The product is then reacted in acetonitrile solution at ambient temperature with one molar equivalent of ethyl 3-amino-2-methylpropionate **S34.27** to yield the monoamidate product **S34.28**. The latter compound is hydrogenated in ethylacetate over a 5% palladium on carbon catalyst to produce the monoacid product **S34.29**. The product is subjected to a Mitsunobu coupling procedure, with equimolar amounts of butyl alaninate **S34.30**, triphenyl phosphine, diethylazodicarboxylate and triethylamine in tetrahydrofuran, to give the bisamidate product **S34.31**.

Using the above procedures, but employing, in place of ethyl 3-amino-2-methylpropionate **S34.27** or butyl alaninate **S34.30**, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained.

The activated phosphonic acid derivative **S34.7** is also converted into the bisamidate **S34.5** via the diamino compound **S34.10**. The conversion of activated phosphonic acid derivatives such as phosphoryl chlorides into the corresponding amino analogs **S34.10**, by reaction with ammonia, is described in Organic Phosphorus Compounds, G. M. Kosolapoff, L. Maeir, eds, Wiley, 1976. The bisamino compound **S34.10** is then reacted at elevated temperature with a haloester **S34.12** (Hal = halogen, i.e. F, Cl, Br, I), in a polar organic solvent such as dimethylformamide, in the presence of a base such as 4, 4-dimethylaminopyridine (DMAP) or potassium carbonate, to yield the bisamidate **S34.5**. Alternatively, **S34.6** may be treated with two different amino ester reagents simulataneously, i.e. **S34.12** where R^{4b} or R^{5b} are different. The resulting mixture of bisamidate products **S34.5** may then be separable, e.g. by chromatography.

An example of this procedure is shown in Scheme **34**, Example **6**. In this method, a dichlorophosphonate **S34.23** is reacted with ammonia to afford the diamide **S34.37**. The reaction is performed in aqueous, aqueous alcoholic or alcoholic solution, at reflux temperature. The resulting diamino compound is

then reacted with two molar equivalents of ethyl 2-bromo-3-methylbutyrate **S34.38**, in a polar organic solvent such as N-methylpyrrolidinone at ca. 150 °C, in the presence of a base such as potassium carbonate, and optionally in the presence of a catalytic amount of potassium iodide, to afford the bisamidate product **S34.39**.

Using the above procedures, but employing, in place of ethyl 2-bromo-3-methylbutyrate **S34.38**, different haloesters **S34.12** the corresponding products **S34.5** are obtained.

The procedures shown in Scheme **34** are also applicable to the preparation of bisamidates in which the aminoester moiety incorporates different functional groups. Scheme **34**, Example **7** illustrates the preparation of bisamidates derived from tyrosine. In this procedure, the monoimidazolide **S34.32** is reacted with propyl tyrosinate **S34.40**, as described in Example **5**, to yield the monoamidate **S34.41**. The product is reacted with carbonyl diimidazole to give the imidazolide **S34.42**, and this material is reacted with a further molar equivalent of propyl tyrosinate to produce the bisamidate product **S34.43**.

Using the above procedures, but employing, in place of propyl tyrosinate **S34.40**, different aminoesters **S34.9**, the corresponding products **S34.5** are obtained. The aminoesters employed in the two stages of the above procedure can be the same or different, so that bisamidates with the same or different amino substituents are prepared.

Scheme **35** illustrates methods for the preparation of phosphonate monoamidates.


In one procedure, a phosphonate monoester **S34.1** is converted, as described in Scheme **34**, into the activated derivative **S34.8**. This compound is then reacted, as described above, with an aminoester **S34.9**, in the presence of a base, to afford the monoamidate product **S35.1**.

The procedure is illustrated in Scheme **35**, Example **1**. In this method, a monophenyl phosphonate **S35.7** is reacted with, for example, thionyl chloride, as described in *J. Gen. Chem.* USSR., 1983, 32, 367, to give the chloro product **S35.8**. The product is then reacted, as described in Scheme **34**, with ethyl alaninate**S3**, to yield the amidate **S35.10**.


Using the above procedures, but employing, in place of ethyl alaninate **S35.9**, different aminoesters **S34.9**, the corresponding products **S35.1** are obtained.

Alternatively, the phosphonate monoester **S34.1** is coupled, as described in Scheme **34**, with an aminoester **S34.9** to produce the amidate**S34.5**. If necessary, the R^1 substituent is then altered, by initial cleavage to afford the phosphonic acid **S35.2**. The procedures for this transformation depend on the nature of the R^1 group, and are described above. The phosphonic acid is then transformed into the ester amidate product **S35.3**, by reaction with the hydroxy compound R^3OH, in which the group R^3 is aryl, heterocycle, alkyl, cycloalkyl, haloalkyl etc, using the same coupling procedures (carbodiimide, Aldrithiol-2, PYBOP, Mitsunobu reaction etc) described in Scheme 34 for the coupling of amines and phosphonic acids.


Scheme 34 Example 1




Scheme 34 Example 2




Scheme 34 Example 3





Scheme 34 Example 4






Scheme 34 Example 5






Scheme 34 Example 6



Scheme 34 Example 7



Examples of this method are shown in Scheme **35**, Examples **1**, **2** and **3**. In the sequence shown in Example **2**, a monobenzyl phosphonate **S35.11** is transformed by reaction with ethyl alaninate, using one of the methods described above, into the monoamidate **S35.12**. The benzyl group is then removed by catalytic hydrogenation in ethylacetate solution over a 5% palladium on carbon catalyst, to afford the phosphonic acid amidate **S35.13**. The product is then reacted in dichloromethane solution at ambient temperature with equimolar amounts of 1-(dimethylaminopropyl)-3-ethylcarbodiimide and trifluoroethanol **S35.14**, for example as described in *Tet. Lett.*, 2001, 42, 8841, to yield the amidate ester **S35.15**.

In the sequence shown in Scheme **35**, Example **3**, the monoamidate **S35.13** is coupled, in tetrahydrofuran solution at ambient temperature, with equimolar amounts of dicyclohexyl carbodiimide and 4-hydroxy-N-methylpiperidine **S35.16**, to produce the amidate ester product **S35.17**.

Using the above procedures, but employing, in place of the ethyl alaninate product **S35.12** different monoacids **S35.2**, and in place of

trifluoroethanol **S35.14** or 4-hydroxy-N-methylpiperidine **S35.16**, different hydroxy compounds R^3OH, the corresponding products **S35.3** are obtained.

Alternatively, the activated phosphonate ester **S34.8** is reacted with ammonia to yield the amidate **S35.4**. The product is then reacted, as described in Scheme **34**, with a haloester **S35.5**, in the presence of a base, to produce the amidate product **S35.6**. If appropriate, the nature of the R^1 group is changed, using the procedures described above, to give the product **S35.3**. The method is illustrated in Scheme **35**, Example **4**. In this sequence, the monophenyl phosphoryl chloride **S35.18** is reacted, as described in Scheme **34**, with ammonia, to yield the amino product **S35.19**. This material is then reacted in N-methylpyrrolidinone solution at 170° with butyl 2-bromo-3-phenylpropionate **S35.20** and potassium carbonate, to afford the amidate product **S35.21**.


Using these procedures, but employing, in place of butyl 2-bromo-3-phenylpropionate **S35.20**, different haloesters **S35.5**, the corresponding products **S35.6** are obtained.

The monoamidate products **S35.3** are also prepared from the doubly activated phosphonate derivatives **S34.7**. In this procedure, examples of which are described in *Synlett.*, 1998, 1, 73, the intermediate **S34.7** is reacted with a limited amount of the aminoester **S34.9** to give the mono-displacement product **S34.11**. The latter compound is then reacted with the hydroxy compound R^3OH in a polar organic solvent such as dimethylformamide, in the presence of a base such as diisopropylethylamine, to yield the monoamidate ester **S35.3**.


The method is illustrated in Scheme **35**, Example **5**. In this method, the phosphoryl dichloride **S35.22** is reacted in dichloromethane solution with one molar equivalent of ethyl N-methyl tyrosinate **S35.23** and dimethylaminopyridine, to generate the monoamidate **S35.24**. The product is then reacted with phenol **S35.25** in dimethylformamide containing potassium carbonate, to yield the ester amidate product **S35.26**.

Using these procedures, but employing, in place of ethyl N-methyl tyrosinate **S35.23** or phenol **S35.25**, the aminoesters **34.9** and/or the hydroxy compounds R^3OH, the corresponding products **S35.3** are obtained.


Scheme 35



R-link—P(=O)(OR1)—OH
S34.1
S34.9
R-link—P(=O)(OR1)—N(R2)—(R4b)—CO2R5b
S35.1
R-link—P(=O)(OH)—N(R2)—(R4b)—CO2R5b
S35.2
S35.3
R2NH(R4b)CO2R5b
S34.9
R-link—P(=O)(OR1)—Lv
S34.8
R-link—P(=O)(OR1)—NH2
S35.4
Hal(R4b)CO2R5b
S35.5
R-link—P(=O)(OR1)—NH—(R4b)—CO2R5b
S35.6
R-link—P(=O)(Lv)—Lv
S34.7
S34.9
R-link—P(=O)—N(R2)—Lv—(R4b)—CO2R5b
S34.11
R3OH
R-link—P(=O)(OR3)—N(R2)—(R4b)—CO2R5b
S35.3

Scheme 35 Example 1




Scheme 35 Example 2






Scheme 35 Example 3




5

Scheme 35 Example 4



Scheme 35 Example 5



Scheme **36** illustrates methods for the preparation of carboalkoxy-substituted phosphonate diesters in which one of the ester groups incorporates a carboalkoxy substituent.

In one procedure, a phosphonate monoester **S34.1**, prepared as described above, is coupled, using one of the methods described above, with a hydroxyester **S36.1**, in which the groups R^{4b} and R^{5b} are as described in Scheme **34**. For example, equimolar amounts of the reactants are coupled in the presence of a carbodiimide such as dicyclohexyl carbodiimide, as described in *Aust. J. Chem.*, 1963, 609, optionally in the presence of dimethylaminopyridine, as described in *Tet.*, 1999, 55, 12997. The reaction is conducted in an inert solvent at ambient temperature.

The procedure is illustrated in Scheme **36**, Example **1**. In this method, a monophenyl phosphonate **S36.9** is coupled, in dichloromethane solution in the presence of dicyclohexyl carbodiimide, with ethyl 3-hydroxy-2-methylpropionate **S36.10** to yield the phosphonate mixed diester **S36.11**.

Using this procedure, but employing, in place of ethyl 3-hydroxy-2-methylpropionate **S36.10**, different hydroxyesters **S33.1**, the corresponding products **S33.2** are obtained.

The conversion of a phosphonate monoester **S34.1** into a mixed diester **S36.2** is also accomplished by means of a Mitsunobu coupling reaction with the hydroxyester **S36.1**, as described in *Org. Lett.*, 2001, 643. In this method, the reactants **S34.1** and **S36.1** are combined in a polar solvent such as tetrahydrofuran, in the presence of a triarylphosphine and a dialkyl azodicarboxylate, to give the mixed diester **S36.2**. The R^1 substituent is varied by cleavage, using the methods described previously, to afford the monoacid product **S36.3**. The product is then coupled, for example using methods described above, with the hydroxy compound R^3OH, to give the diester product **S36.4**.

The procedure is illustrated in Scheme **36**, Example **2**. In this method, a monoallyl phosphonate **S36.12** is coupled in tetrahydrofuran solution, in the presence of triphenylphosphine and diethylazodicarboxylate, with ethyl lactate **S36.13** to give the mixed diester **S36.14**. The product is reacted with tris(triphenylphosphine) rhodium chloride (Wilkinson catalyst) in acetonitrile, as described previously, to remove the allyl group and produce the monoacid product **S36.15**. The latter compound is then coupled, in pyridine solution at ambient temperature, in the presence of dicyclohexyl carbodiimide, with one molar equivalent of 3-hydroxypyridine **S36.16** to yield the mixed diester **S36.17**.

Using the above procedures, but employing, in place of the ethyl lactate **S36.13** or 3-hydroxypyridine, a different hydroxyester **S36.1** and/or a different hydroxy compound R^3OH, the corresponding products **S36.4** are obtained.

The mixed diesters **S36.2** are also obtained from the monoesters **S34.1** via the intermediacy of the activated monoesters **S36.5**. In this procedure, the monoester **S34.1** is converted into the activated compound **S36.5** by reaction

with, for example, phosphorus pentachloride, as described in *J. Org. Chem.*, 2001, 66, 329, or with thionyl chloride or oxalyl chloride (Lv = Cl), or with triisopropylbenzenesulfonyl chloride in pyridine, as described in *Nucleosides and Nucleotides*, 2000, 19, 1885, or with carbonyl diimidazole, as described in *J. Med. Chem.*, 2002, 45, 1284. The resultant activated monoester is then reacted with the hydroxyester **S36.1**, as described above, to yield the mixed diester **S36.2**.

The procedure is illustrated in Scheme **36**, Example **3**. In this sequence, a monophenyl phosphonate **S36.9** is reacted, in acetonitrile solution at 70 °C, with ten equivalents of thionyl chloride, so as to produce the phosphoryl chloride **S36.19**. The product is then reacted with ethyl 4-carbamoyl-2-hydroxybutyrate **S36.20** in dichloromethane containing triethylamine, to give the mixed diester **S36.21**.

Using the above procedures, but employing, in place of ethyl 4-carbamoyl-2-hydroxybutyrate **S36.20**, different hydroxyesters **S36.1**, the corresponding products **S36.2** are obtained.

The mixed phosphonate diesters are also obtained by an alternative route for incorporation of the R^3O group into intermediates **S36.3** in which the hydroxyester moiety is already incorporated. In this procedure, the monoacid intermediate **S36.3** is converted into the activated derivative **S36.6** in which Lv is a leaving group such as chloro, imidazole, and the like, as previously described. The activated intermediate is then reacted with the hydroxy compound R^3OH, in the presence of a base, to yield the mixed diester product **S36.4**.

The method is illustrated in Scheme **36**, Example **4**. In this sequence, the phosphonate monoacid **S36.22** is reacted with trichloromethanesulfonyl chloride in tetrahydrofuran containing collidine, as described in *J. Med. Chem.*, 1995, 38, 4648, to produce the trichloromethanesulfonyloxy product **S36.23**. This compound is reacted with 3-(morpholinomethyl)phenol **S36.24** in dichloromethane containing triethylamine, to yield the mixed diester product **S36.25**.


Using the above procedures, but employing, in place of with 3-(morpholinomethyl)phenol **S36.24**, different alcohols R^3OH, the corresponding products **S36.4** are obtained.

The phosphonate esters **S36.4** are also obtained by means of alkylation reactions performed on the monoesters **S34.1**. The reaction between the monoacid **S34.1** and the haloester **S36.7** is performed in a polar solvent in the presence of a base such as diisopropylethylamine, as described in *Anal. Chem.*, 1987, 59, 1056, or triethylamine, as described in *J. Med. Chem.*, 1995, 38, 1372, or in a non-polar solvent such as benzene, in the presence of 18-crown-6, as described in *Syn. Comm.*, 1995, 25, 3565.


The method is illustrated in Scheme **36**, Example **5**. In this procedure, the monoacid **S36.26** is reacted with ethyl 2-bromo-3-phenylpropionate **S36.27** and diisopropylethylamine in dimethylformamide at 80 °C to afford the mixed diester product **S36.28**.

Using the above procedure, but employing, in place of ethyl 2-bromo-3-phenylpropionate **S36.27**, different haloesters **S36.7**, the corresponding products **S36.4** are obtained.

Scheme 36



HOR1 (1 equiv.)
HO-R4b-COOR5b
S36.4
Hal-R4b-COOR5b
S33.7
S34.1
S36.1
S36.2
S36.3
S36.5
S36.6
S36.4

Scheme 36 Example 1




S36.9 S36.11

Scheme 36 Example 2




S36.12 S36.14 S36.15 S36.16


Scheme 36 Example 3




S36.9 **S36.19**




Scheme 36 Example 4



S36.22 **S36.23**




S36.24



S36.25

Scheme 36 Example 5



S36.26 **S36.27** **S36.28**

Scheme **37** illustrates methods for the preparation of phosphonate diesters in which both the ester substituents incorporate carboalkoxy groups.

The compounds are prepared directly or indirectly from the phosphonic acids **S34.6**. In one alternative, the phosphonic acid is coupled with the hydroxyester **S37.2**, using the conditions described previously in Schemes **34-36**, such as coupling reactions using dicyclohexyl carbodiimide or similar reagents, or under the conditions of the Mitsunobu reaction, to afford the diester product **S37.3** in which the ester substituents are identical.

This method is illustrated in Scheme **37**, Example **1**. In this procedure, the phosphonic acid **S34.6** is reacted with three molar equivalents of butyl lactate

S37.5 in the presence of Aldrithiol-2 and triphenyl phosphine in pyridine at ca. 70 °C, to afford the diester **S37.6**.

Using the above procedure, but employing, in place of butyl lactate **S37.5**, different hydroxyesters **S37.2**, the corresponding products **S37.3** are obtained.

Alternatively, the diesters **S37.3** are obtained by alkylation of the phosphonic acid **S34.6** with a haloester **S37.1**. The alkylation reaction is performed as described in Scheme 36 for the preparation of the esters **S36.4**.

This method is illustrated in Scheme **37**, Example **2**. In this procedure, the phosphonic acid **S34.6** is reacted with excess ethyl 3-bromo-2-methylpropionate **S37.7** and diisopropylethylamine in dimethylformamide at ca. 80 °C, as described in *Anal. Chem.*, 1987, 59, 1056, to produce the diester **S37.8**.

Using the above procedure, but employing, in place of ethyl 3-bromo-2-methylpropionate **S37.7**, different haloesters **S37.1**, the corresponding products **S37.3** are obtained.

The diesters **S37.3** are also obtained by displacement reactions of activated derivatives **S34.7** of the phosphonic acid with the hydroxyesters **S37.2**. The displacement reaction is performed in a polar solvent in the presence of a suitable base, as described in Scheme 36. The displacement reaction is performed in the presence of an excess of the hydroxyester, to afford the diester product **S37.3** in which the ester substituents are identical, or sequentially with limited amounts of different hydroxyesters, to prepare diesters **S37.3** in which the ester substituents are different.


The methods are illustrated in Scheme **37**, Examples **3** and **4**. As shown in Example **3**, the phosphoryl dichloride **S35.22** is reacted with three molar equivalents of ethyl 3-hydroxy-2-(hydroxymethyl)propionate **S37.9** in tetrahydrofuran containing potassium carbonate, to obtain the diester product **S37.10**.

Using the above procedure, but employing, in place of ethyl 3-hydroxy-2-(hydroxymethyl)propionate **S37.9**, different hydroxyesters **S37.2**, the corresponding products **S37.3** are obtained.


Scheme **37**, Example **4** depicts the displacement reaction between equimolar amounts of the phosphoryl dichloride **S35.22** and ethyl 2-methyl-3-hydroxypropionate **S37.11**, to yield the monoester product **S37.12**. The reaction is conducted in acetonitrile at 70° in the presence of diisopropylethylamine. The product **S37.12** is then reacted, under the same conditions, with one molar equivalent of ethyl lactate **S37.13**, to give the diester product **S37.14**.

Using the above procedures, but employing, in place of ethyl 2-methyl-3-hydroxypropionate **S37.11** and ethyl lactate **S37.13**, sequential reactions with different hydroxyesters **S37.2**, the corresponding products **S37.3** are obtained.

Scheme 37




Scheme 37 Example 1




S34.6 **S37.6**

Scheme 37 Example 2




S34.6 **S37.8**

Scheme 37 Example 3




S35.22 **S37.10**

Scheme 37 Example 4



S35.22 **S37.12**




S37.14


2,2-Dimethyl-2-aminoethylphosphonic acid intermediates can be prepared by the route in Scheme **5**. Condensation of 2-methyl-2-propanesulfinamide with acetone give sulfinyl imine **S38.11** (*J. Org. Chem.* **1999**, *64*, 12). Addition of dimethyl methylphosphonate lithium to **S38.11** afford **S38.12**. Acidic methanolysis of **S38.12** provide amine **S38.13**. Protection of amine with Cbz group and removal of methyl groups yield phosphonic acid

S38.14, which can be converted to desired **S38.15** (Scheme 38a) using methods reported earlier on. An alternative synthesis of compound **S38.14** is also shown in Scheme **38b**. Commercially available 2-amino-2-methyl-1-propanol is converted to aziridines **S38.16** according to literature methods (*J. Org. Chem.* **1992**, *57*, 5813; *Syn. Lett.* **1997**, *8*, 893). Aziridine opening with phosphite give **S38.17** (*Tetrahedron Lett.* **1980**, *21*, 1623). Reprotection) of **S38.17** affords **S38.14**.

Scheme 38a



Scheme 38b




The invention will now be illustrated by the following non-limiting Examples.

Examples

Example 1: Preparation of exemplary compounds of the present invention


Scheme **1.1**




Schemes **1.1-1.3** illustrate the synthesis of target molecules of types **1-12** and **1-56**, in which the link is a heteroatom and carbon chain. The preparation of **1-1** is described in U.S. Patent No. 5,770,596. Diether **1-1** is converted into mono ether **1-2** as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) p. 246, or by the method described in U.S. Patent No. 5,770,596. Preferably diether **1-1** in methanesulfonic acid is treated with L-methionine at reflux to give the phenol **1-**

2. Phenol **1-2** is then protected as the acetyl compound **1-3** and then converted to the chloride **1-4**. These procedures are described in U.S. Patent No. 5,770,596. The acetoxy compound is then treated with the aniline **1-5** to give the amine **1.6** followed by deprotection of the acetyl group to give **1-7** as described in U.S. Patent No. 5,770,596. Treatment of **1-7** with epibromohydrin **1-8** (Aldrich) in DMF with potassium carbonate present then affords the epoxide **1-9.** Treatment of epoxide **1-9** with morpholine in a non-protic solvent at reflux in the presence of a base such as triethylamine affords the alcohol **1-10**. The alcohol **1-10** is treated with one equivalent of the phosphonate alkylating agent, in which Lv is a group such as mesyl, trifluoromethanesulfonyl, Br, I, Cl, tosyl etc, in the presence of base e.g. potassium or cesium carbonate in DMF, to give the ether **1-12**, in which the link is an oxygen and carbon chain. Alternatively, the alcohol **1-10** is oxidized to the ketone **1-13** as described in *Comprehensive Organic Transformations*, by R. C. Larock, 2nd Edition, (1999), p.1234ff. Preferably the alcohol **1-10** is treated with Dess-martin periodinone to give the ketone **1-13**. Ketone **1-13** is then reacted with an amino alkyl phosphonate **1-14** under reductive amination conditions to give the phosphonate **1-56** in which the link is a nitrogen and carbon chain. The preparation of amines by means of reductive amination procedures is described, for example, in *Comprehensive Organic Transformations*, by R. C. Larock, 2nd edition, p. 835. In this procedure, the amine component and the aldehyde component are reacted together in the presence of a reducing agent such as, for example, borane, sodium cyanoborohydride or diisobutylaluminum hydride, to yield the amine product.

Scheme **1.2**




Scheme **1.3**




For example, the alcohol **1-10** is treated with triflate **1-15**, prepared as described in *Tetrahedron Lett.* **1986**, 27, 1497, and potassium carbonate in DMF, to give the ether **1-16**. Alternatively, for example, the ketone **1-13** is treated with amine **1-17** (Acros) in methanol and then after a period of time sodium borohydride is added to give the amine **1-18**. Using the above procedures, but employing, in place of the triflate **1-15**, or the amine **1-17**, phosphonates **1-11** and **1-14**, respectively, the corresponding products **1-12** and **1-56** are obtained.

Scheme **1.4**



Scheme **1.5**




The reactions shown in Schemes **1.4-1.5** illustrate the preparation of the compounds **1-22** in which the phosphonate is linked through a carbon chain and a heteroatom. Phenol **1-7** (Schemes **1.1-1.3**) is treated with dibromide **1-19** using the conditions described in Schemes **1.1-1.3** for the preparation of **1-9** from **1-7**, to give bromide **1-20**. Bromide **1-20** is then treated with the dialkyl hydroxy, thio or amino-substituted alkylphosphonate **1-21** to give the product **1-22**. The reaction is performed in the presence of a base, in a polar aprotic solvent such as dioxan or *N*-methylpyrrolidinone. The base employed in the reaction depends on the nature of the reactant **1-21**. For example, if X is O, a strong base such as, for example, lithium hexamethyldisilylazide or potassium tert. butoxide is employed. If X is S, NH or N-alkyl, an inorganic base such as cesium carbonate and the like is employed.


For example, **1-7** is treated with dibromoethane **1-23**, as described in Schemes **1.1-1.3** to give the bromide **1-24**. Bromide **1-24** is then treated with amine **1-25**, prepared as described in *J. Org. Chem.* **2000**, 65, 676, in DMF and potassium carbonate at ca 80 °C to give the phosphonate **1-26**. Alternatively bromide **1-24** is then heated at reflux with an equimolar amount of a dialkyl 2-

mercaptoethylphophonate **1-27**, the preparation of which is described in *Aust. J. Chem.*, **1990**, *43*, 1123, in the presence of sodium carbonate, to afford the thioether product **1-28**. Using the above procedures, but employing, in place of the dibromoethane **1-23**, different dibromo compounds **1-19** and/or different alkyl phosphonates **1-21** in place of **1-25** or **1-27**, the corresponding products **1-22** are obtained.

Scheme **1.6**



Scheme **1.7**




Scheme **1.6** illustrates the synthesis of target molecules **1-32**, in which A is Br, Cl, [OH], [NH], or the group link-P(O)(OR^1)$_2$. The preparation of **1-4** is illustrated in Scheme **1.1**. Treatment of chloride **1-4** with amine **1-29** in reluxing isopropanol gives amine **1-30**. The preparation of **1-29** in which A is group link-P(O)(OR^1)$_2$ is described below in Schemes **1.8-1.12**. Treatment of amine **1-30** according to conditions described in U.S. Patent No. 5,770,599 then affords the final product **1-31**.

The reactions shown in Scheme **1.6** illustrate the preparation of the compounds **1-31** in which the substituent A is either the group link-P(O)(OR^1)$_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **1.7** depicts the conversion of the compounds **1-31** in which A is [OH], [SH], [NH], Br etc, into the phosphonate esters **1-32**. In this procedure, the compounds **1-31** are converted, using the procedures described in Schemes **1.1-1.6** into the compounds **1-32**.


Schemes **1.8-1.12** describe the preparation of phosphonate-containing derivatives **1-29** which are employed in the preparation of the phosphonate ester intermediates **1-32**.

Scheme **1.8**




Schemes **1.8-1.10** illustrates the preparation of **1-29** in which the phosphonate is attached through a heteroatom e.g. O, S, or N, and a carbon linker. In this procedure an optionally protected aniline is reacted with an alkylphosphonate **1-34** in which Lv is a leaving group such as triflate, Br, Cl, Mesyl, etc, in the presence of a suitable base. The base required for this transformation depends on the nature of the heteroatom X. For example, if X is N or S, an excess of an inorganic base such as, for example, potassium carbonate, in the presence of an organic solvent such as dimethylformamide, is suitable. The reaction proceeds at from ambient temperature to about 80° C to afford the displacement products **1-35**. If X is O, an equimolar amount of a strong base, such as, for example, lithium hexamethyldisilylazide and the like, is employed, in the presence of a solvent such as tetrahydrofuran. Deprotection, of the amine group as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7, affords the amine **1-36**.

Scheme **1.9**



For example, the diamine **1-37** (Aldrich), protected as the CBZ carbamate (*Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), page 531ff) is treated with an equimolar amount of triflate **1-38**, the preparation of which is described in *Tetrahedron Lett.* **1986**, *27*, 1497, in dimethylformamide containing excess potassium carbonate, at about 60 °C to afford the phosphonate product **1-39**. Deprotection by reduction over palladium on carbon in the presence of hydrogen then affords the amine **1-40**.


Scheme **1.10**



Alternatively, the aminophenol **1-41**, protected as the CBZ carbamate as described above, is reacted with one equivalent of triflate **1-38** to give phosphonate **1-42**. Removal of the CBZ group by catalytic reduction over palladium on carbon in the presence of hydrogen, as described above, then affords the amine **1-43**.


Using the above procedures, but employing, in place of the aniline **1-37** or phenol **1-41**, different anilines **1-33**, and/or different alkylphosphonates **1-34**, in place of **1-38**, the corresponding products **1-36** are obtained.

Scheme **1.11**



Schemes **1.11-1.12** illustrates the preparation of **1-29** in which the phosphonate is attached through a unsaturated or saturated carbon linker. In this procedure, an optionally protected halo-substituted aniline **1-44** is coupled, by means of a palladium-catalyzed Heck reaction with a dialkyl alkenyl phosphonate **1-45**, to afford the coupled product **1-46**. The coupling of aryl halides with olefins by means of the Heck reaction is described, for example, in *Advanced Organic Chemistry*, by F. A. Carey and R. J. Sundberg, Plenum, (2001), p. 503ff, and in *Acc. Chem. Res.*, **1979**, *12*, 146. The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxane, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine) palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate, to afford the coupled product **1-46**. Protection of anilines is described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7. Preferably the aniline is treated with a BOC reagent such as BOC chloride, or BOC anhydride in the presence of DMAP and a base e.g. triethylamine to afford the protected aniline. Optionally, the product **1-46** can be reduced to afford the saturated phosphonate **1-47**. Methods for the reduction of carbon-carbon double bonds are described, for example, in *Comprehensive Organic Transformations*, by R. C. Larock, VCH, (1989), page 6. The methods include catalytic reduction, and chemical reduction, the latter for example employing diborane or diimide.

Scheme **1.12**




For example, BOC protected 3-chloro-4-fluoro aniline **1-50** (Aldrich) is reacted with a dialkyl propenyl phosphonate **1-51**, the preparation of which is described in *J. Med. Chem.*, **1996**, *39*, 949, in the presence of bis(triphenylphosphine) palladium(II) chloride , as described in *J. Med. Chem.*, **1992**, *35*, 1371, to afford the coupled product **1-52**. The BOC protection of the aniline is performed by treating the corresponding aniline with BOC anhydride in the presence of DMAP. The product **1-52** is reduced, for example by reaction with diimide, as described in *J. Org. Chem.* **1965**, *30*, 3965, to afford the saturated product **1-53**. Boc removal by treatment of **1-52** and **1-53** with TFA in THF or dioxane affords the products **1-54** and **1-55** respectively. Using the above procedures, but employing, in place of the halo aniline compound **1-50**, different anilines **1-44**, and/or different phosphonates **1-45** the corresponding products **1-48** and **1-49** are obtained.


The procedures described for the introduction of phosphonate moieties (Schemes **1.1-1.12**) are, with appropriate modifications known to one skilled in the art, transferable to different chemical substrates. Thus, the methods described above for the introduction of phosphonate groups onto **1-12, 1-56** and **1-22** are also applicable to the introduction of phosphonate moieties onto anilines **1-29** and vice versa.

Example 2: Preparation of exemplary compounds of the present invention

Scheme **2.1**



Scheme **2.2**



Scheme **2.1** illustrates the preparation of compounds **2-4** in which A is Br, I, [SH], [NH] etc or the group link-P(O)(OR^1)$_2$. The amine **2-1** is prepared as described in U.S. Patent No. 5,521,84. Amine **2-1** is coupled with the acid **2-2** to give the amide **2-3**. The preparation of amides from carboxylic acids and derivatives is described, for example, in *Organic Functional Group Preparations*, by S.R. Sandler and W. Karo, Academic Press, 1968, page 274. The carboxylic acid is reacted with the amine in the presence of an activating agent, such as, for example, dicyclohexylcarbodiimide or diisopropylcarbodiimide, optionally in the presence of, for example, hydroxybenztriazole, in a non-protic solvent such as, for example, pyridine, DMF or dichloromethane, to afford the amide.


Alternatively, the carboxylic acid may first be converted into an activated derivative such as the acid chloride or anhydride, and then reacted with the amine, in the presence of an organic base such as, for example, pyridine, to afford the amide.

The conversion of a carboxylic acid into the corresponding acid chloride is effected by treatment of the carboxylic acid with a reagent such as, for example, thionyl chloride or oxalyl chloride in an inert organic solvent such as


dichloromethane. Preferably, the acid **2-2** is treated with oxalyl chloride in an inert solvent such as dichloromethane followed by the addition of a few drops of DMF and then treated with the amine **2-1** to give the amide **2-3**. The acid, **2-2** is prepared according to Schemes **2.7-2.8** shown below.

The reactions shown in Scheme **2.1** illustrate the preparation of the compounds **2-3** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **2.2** depicts the conversion of the compounds **2-3** in which A is [OH], [SH], [NH], Br etc, into the phosphonate esters **2-4**. In this procedure, the compounds **2-3** are converted, using the procedures described below, Schemes **2.7-2.12**, into the compounds **2-4**.

Scheme **2.3**



Scheme **2.4**




Scheme **2.3** illustrates the preparation of compounds **2-6** in which A is Br, I, [SH], [NH], etc., or the group link-P(O)$(OR^1)_2$. The amine **2-1** is treated with acid **2-5** as described above, Scheme **2.1**, to give the amide **2-6**. The preparation of acid **2-5** is described in Schemes **2.9-2.10** below.


The reactions shown in Scheme **2.3** illustrate the preparation of the compounds **2-6** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br, etc. Scheme **2.4** depicts the conversion of the compounds **2-6** in which A is [OH], [SH], [NH], Br etc, into

the phosphonate esters **2-7**. In this procedure, the compounds **2-6** are converted, using the procedures described below, Schemes **2.7-2.12**, into the compounds **2-7**.

Scheme **2.5**




Scheme **2.6**




Schemes **2.5-2.6** illustrates the preparation of compounds **2-10** in which A is Br, I, [SH], [NH], etc., or the group link-P(O)$(OR^1)_2$. The amine **2-1** is treated with acid **2-8** as described above, Scheme **2.1**, to give the amide **2-9**. The preparation of acid **2-8** is described in Schemes **2.11-2.12** below.

The reactions shown in Schemes **2.5-2.6** illustrate the preparation of the compounds **2-9** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br, etc. Scheme **2.6** depicts the conversion of the compounds **2-9** in which A is [OH], [SH], [NH], Br, etc., into the phosphonate esters **2-10**. In this procedure, the compounds **2-9** are converted, using the procedures described below, Schemes **2.7-2.12**, into the compounds **2-10**.

Scheme **2.7**




Scheme **2.8**



Schemes **2.7-2.8** describe the preparation of phosphonate-containing derivatives **2-2**, in which A is Br, Cl, [OH], [NH], or the group link-$P(O)(OR^1)_2$ that are employed in the preparation of the phosphonate ester intermediates **2-4**. Piperazine **2-11** is protected with a BOC group according to methods described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) p. 518ff. Preferably piperazine is treated with 1 equivalent of BOC anhydride in methanol or DMF and one equivalent of triethylamine to give the BOC amine **2-12**. Treatment of **2-12** with an alkylphosphonate **2-13** in which Lv is a leaving group such as triflate, Br, Cl, Mesyl, etc., in the presence of a suitable base, affords the product **2-14**. The base required for this transformation is typically an inorganic base such as, for example, potassium carbonate, in the presence of an organic solvent such as dimethylformamide. The reaction proceeds at from ambient temperature to about 80 °C to afford the displacement products **2-14**. Deprotection, of the BOC-amine group as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) p520ff., affords the amine **2-15**. The amine **2-15** is then reacted with the acid **2-16** (Aldrich) in the presence of a base to give the product acid **2-17**. For example, **2-12** prepared from piperazine as described above, is treated with bromophosphonate **2-18**,

prepared as described in *Syn.* **1999**, *9*, 909, and potassium carbonate in THF to give the amine **2-19**. The BOC amine **2-19** is then deprotected by treatment with trifluoroacetic acid in dichloromethane to give the amine **2-20**. The amine **2-20** is then reacted with the bromomethyl benzoic acid **2-16** in THF or dioxane in the presence of triethylamine, or aqueous potassium carbonate, to give the acid **2-21.** Using the above procedures, but employing, in place of the bromo phosphonate compound **2-18**, different phosphonates **2-13**, the corresponding products **2-17** are obtained.

Scheme **2.9**




Schemes **2.9-2.10** describes the preparation of acids **2-5** in which the phosphonate is attached to the scaffold through a heteroatom and carbon linker. The benzyl protected ketone **2-22**, prepared from the corresponding acid by treatment with benzyl alcohol in the presence of DCC and DMAP in DMF, as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and

P.G.M. Wuts, Wiley, Third Edition (1999), p. 373ff., is treated with a brominating agent to give the bromo ketone **2-23**. Protection of the ketone as the cyclic dioxalone as described in T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), p. 312ff., gives **2-24**. Dioxalone **2-24** is then treated with the dialkyl hydroxy, thio or amino-substituted alkylphosphonate **2-25** to give the dioxalone **2-26**. The reaction is performed in the presence of a base, in a polar aprotic solvent such as dioxane or *N*-methylpyrrolidinone. The base employed in the reaction depends on the nature of the reactant **2-25**.


For example, if X is O, a strong base such as, for example, lithium hexamethyldisilylazide or potassium tert. butoxide is employed. If X is S, NH or N-alkyl, an inorganic base such as cesium carbonate and the like is employed. Deprotection of the dioxalone as described in in T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), p. 317ff., gives ketone **2-27** which is then treated under reductive amination conditions with *N*-methyl piperazine to give the amine **2-28**. The preparation of amines by means of reductive amination procedures is described, for example, in *Comprehensive Organic Transformations*, by R. C. Larock, 2nd edition, p. 835. In this procedure, the amine component and the aldehyde component are reacted together in the presence of a reducing agent such as, for example, borane, sodium cyanoborohydride or diisobutylaluminum hydride, to yield the amine product. Deprotection of the ester group as described in in T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) p. 373ff then affords the acid **2-29**.

Scheme **2.10**



For example, 4-acetyl benzoic acid is treated with benzyl bromide in the presence of potassium carbonate in aqueous THF to give the ester **2-22**. Treatment of the ester **2-22** with bromine in acetic acid, or NBS and AIBN in CCl_4 affords the bromide **2-23**. Bromide **2-23** is then reacted with 1,2-ethane diol in toluene at reflux under a dean stark head with a catalytic amount of p-TsOH present to give the dioxalone **2-24**. Dioxalone **2-24** is reacted with dialkyl 2-aminoethyl phosphonate **2-30**, prepared as described in *J. Org. Chem.*, **2000**, *65*, 676, in dimethylformamide at about 80 °C, in the presence of potassium carbonate, to afford the amine **2-31**. Treatment of the dioxalone **2-31** with 1N hydrochloric acid in THF then yields the ketone **2-32**. Ketone **2-32** is reacted with N-methyl piperazine in the presence of triethylamine followed 30 minutes later by the addition of sodiumcyano borohydride to give the amine **2-33**. Removal of the benzyl ester by hydrolysis using sodium hydroxide in aqueous THF gives the acid **2-34**. Using the above procedures, but employing, in place of the amino phosphonate compound **2-30**, different phosphonates **2-25**, the corresponding products **2-29** are obtained.


Scheme **2.11**



Schemes **2.11-2.12** illustrates the preparation of acid **2-8** in which the phosphonate is attached through a unsaturated or saturated carbon linker. In this procedure, the acid **2-16** (Aldrich) is treated with N-methyl piperazine as described in Schemes **2.7-2.8** for the preparation of **2-17**, to give the acid **2-35**. Acid **2-35** is then brominated with bromine or NBS to give the bromide **2-36**. Bromide **2-36** is optionally protected as the benzyl or t-butyl ester, as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), page 373ff., to give **2-37**. Ester **2-37** is then coupled, by means of a palladium-catalyzed Heck reaction with a dialkyl alkenyl phosphonate **2-38**, to afford the coupled product **2-39**. The coupling of aryl halides with olefins by means of the Heck reaction is described, for example, in

Advanced Organic Chemistry, by F. A. Carey and R. J. Sundberg, Plenum, (2001), p. 503ff., and in *Acc. Chem. Res.*, **1979**, *12*, 146. The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxane, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine) palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate, to afford the coupled product **2-39**. Optionally, the product **2-39** can be reduced to afford the saturated phosphonate **2-40**. Methods for the reduction of carbon-carbon double bonds are described, for example, in *Comprehensive Organic Transformations*, by R. C. Larock, VCH, (1989), page 6. The methods include catalytic reduction, and chemical reduction, the latter for example employing diborane or diimide.


Scheme **2.12**



For example, amine **2-35** is then treated with NBS and AIBN in carbon tetrachloromethane at reflux to give the bromide **2-43**. Bromide **2-43** is then reacted in t-butanol with DCC and DMAP to give the t-butyl ester **2-44**. Ester **2-44** is then reacted with dialkyl propenyl phosphonate **2-45**, the preparation of which is described in *J. Med. Chem.*, **1996**, *39*, 949, in the presence of bis(triphenylphosphine) palladium(II) chloride , as described in *J. Med. Chem.*, **1992**, *35*, 1371, to afford the coupled product **2-46**. This product **2-46** is then treated with aqueous HCl in dioxane to give the acid **2-48**. Optionally, the alkene **2-46** can be reduced by reaction with diimide, as described in *J. Org. Chem.*, **1965**, *30*, 3965, to afford the saturated product **2-47**. Hydrolysis of the ester as described above through treatment with aqueous HCl in dioxane gives the acid **2-49**. Using the above procedures, but employing, in place of the phosphonate compound **2-45**, different phosphonates **2-38**, the corresponding products **2-41** and **2-42** are obtained.


Example 3: Exemplary compounds of the present invention

Scheme **3.1**




Scheme **3.1** illustrates exemplary compounds of the present invention, wherein the phosphonate group can either be linked through a carbon atom, or a heteroatom, respectively.

Scheme **3.2**



Scheme **3.3**




Schemes **3.2-3.3** illustrates the synthesis of target molecules of type **3-11**, in which A is Br, Cl, [OH], [NH], or the group link-P(O)$(OR^1)_2$. The preparation of **3-4,** in which is A is a phosphonate is described below. Conversion of **3-4** into **3-9** in which A is methoxymethyl is described in EP 0817775 B1 and similar conditions can be used to prepare **3-9** in which A is the group link-P(O)$(OR^1)_2$. Nitration of the diether **3-4** gives nitro compound **3-5**, which, followed by reduction under standard reducing conditions as described in *Comprehensive Organic Transformations*, by R. C. Larock, 2nd Edition, (1999), p821., affords the amine **3-6**.

For example, **3-4** is treated with cold nitric acid in acetic acid, followed by catalytic hydrogenolysis of the nitro product in acidic ethanol over platinum oxide at high pressure to give the amine **3-6**. The hydrochloride salt that is isolated is then heated at about 160 °C with ammonium formate and formamide to generate the quinazoline **3-7**. The quianzoline is converted to the chloride, **3-8**, as described in EP 0817775 B1. Preferably, the quinazoline, **3-7**, is treated with oxalyl chloride in chloroform and DMF to give the chloride **3-8**. Displacement of the chloride by the amine, **3-10**, then affords the product **3-9**.

For example, heating the chloride **3-8** with 3-ethynyl-aniline in isopropanol at reflux gives **3-9**.


The reactions shown in Scheme **3.2** illustrate the preparation of the compounds **3-9** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br, etc. Scheme **3.3** depicts the conversion of the compounds **3-9** in which A is [OH], [SH], [NH], Br, etc., into the phosphonate esters **3-11**. In this procedure, the compounds **3-9** are converted, using the procedures described below, Schemes **3.10-3.21**, into the compounds **3-11**.

Scheme **3.4**



3-12 **3-13**

Scheme **3.5**




3-13 **3-14**

Schemes **3.4-3.5** illustrates the synthesis of target molecules of type **3-14**, in which A is Br, Cl, [OH], [NH], or the group link-P(O)$(OR^1)_2$. Conversion of **3-12** into **3-13** is completed using the conditions described above, Scheme **3.2**, for the conversion of **3-4** into **3-9**. The preparation of **3-12,** in which is A is a phosphonate is described below in Schemes **3.14-3.17**.


The reaction shown in Scheme **3.4** illustrates the preparation of the compounds **3-13** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **3.5** depicts the conversion of the compounds **3-13** in which A is [OH], [SH], [NH], Br etc, into the phosphonate esters **3-14**. In this procedure, the compounds **3-13** are

converted, using the procedures described below, Schemes **3.10-3.13**, into the compounds **3-14**.

Scheme **3.6**




Scheme **3.7**




Schemes **3.6-3.7** illustrates the synthesis of target molecules of type **3-20**, in which A is Br, Cl, [OH], [NH], or the group link-P(O)$(OR^1)_2$. The preparation of **3-15** is described in EP 0817775 B1. Diether **3-15** is converted to the chloride **3-16** using conditions described in EP 0817775 B1 or as described above, Scheme **3.2**. Treatment of chloride **3-16** with amine **3-18,** in reluxing isopropanol gives **3-17**. The preparation of **3-18,** in which A is group link-P(O)$(OR^1)_2$ is shown below in Schemes **3.18-3.19**.

The reactions shown in Scheme **3.6** illustrate the preparation of the compounds **3-17** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **3.7** depicts the conversion of the compounds **3-17** in which A is [OH], [SH], [NH], Br etc, into the phosphonate esters **3-20**. In this procedure, the compounds **3-17** are converted, using the procedures described below, Schemes **3.10-3.21**, into the compounds **3-20**.

Scheme **3.8**




Scheme **3.9**




Schemes **3.8-3.9** illustrate the synthesis of target molecules of type **3-24**, in which A is Br, Cl, [OH], [NH], or the group link-P(O)(OR^1)$_2$. The preparation of **3-16** is described in Scheme **3.6**. Chloride **3-16** is converted to the amine **3-23** by treatment with amine **3-22** in refluxing isopropanol. The preparation of **3-22** in which A is group link-P(O)(OR^1)$_2$ is shown below in Schemes **3.20-3.21**.

The reaction shown in Scheme **3.8** illustrates the preparation of the compounds **3-23** in which the substituent A is either the group link-P(O)(OR^1)$_2$ or a precursor such as [OH], [SH], [NH], Br, etc. Scheme **3.9** depicts the conversion of the compounds **3-23** in which A is [OH], [SH], [NH], Br, etc., into the phosphonate esters **3-24**. In this procedure, the compounds **3-23** are converted, using the procedures described below in Schemes **3.10-3.21**, into the compounds **3-24**.

Scheme **3.10**




Scheme **3.11**




Schemes **3.10-3.13** describe the preparation of phosphonate-containing derivatives **3-19, 3-30, 3-69, 3-70** which are employed in the preparation of the phosphonate ester intermediates **3-11** (Scheme **3.3**). The dihydroxybenzoic acid **3-25** is treated with one equivalent of the phosphonate alkylating agent, in which Lv is a leaving group such as mesyl, trifluoromethanesulfonyl, Br, I, Cl, tosyl, etc., in the presence of base as described in EP 0817775 B1, to give the ether **3-26**. The ether is then subjected to the same alkylating conditions in the presence of 2-bromoethylmethyl ether (Aldrich) to give the diethers **3-19**, **3-30**, **3-69**, and **3-70**. For example, ester **3-25,** prepared from the corresponding acid (Aldrich) by refluxing in concentrated HCl and ethanol in acetone, is treated with dialkyl 4-bromobutylphosphonate **3-28**, prepared as described in *Syn.* **1999**, *9*, 909, potassium carbonate and tetrabutylammonium iodide to give the ether **3-29**. Ether **3-29** is then treated with 2-bromoethylmethyl ether (Aldrich), potassium carbonate and tetrabutyl ammonium iodide to give the diether **3-30**. Using the above procedures, but employing, in place of the bromobutylphosphonate **3-28**, different phosphonates **3-27**, and **3-37**, the corresponding products **3-4, 3-19, 3-69, 3-70** are obtained.

Scheme **3.12**



Schemes **3.12-3.13** also describe the preparation of phosphonate-containing derivatives **3-69, 3-70** which are employed in the preparation of the phosphonate ester intermediates **3-11** (Scheme **3.3**). The dihydroxybenzoic acid **3-25**, is treated with one equivalent of alcohol **3-31**, as described in Schemes **3.10-3.11** to give ether **3-32**. This ether **3-32** is then further treated with one equivalent of 2-bromoethylmethyl ether (Aldrich), and one equivalent of base as described in Schemes **3.10-3.11**, to give the diether **3-33**. Treatment with an phosphonate alkylating agent **3-27**, in which Lv is a group such as mesyl, trifluoromethanesulfonyl, Br, I, Cl, tosyl, etc., in the presence of base then affords ether **3-69**.

Scheme **3.13**




For example, **3-25** in acetone is treated with 2-bromoethanol, as described above in Scheme **3.10** for the preparation of **3-26** from **3-25**, to give **3-35**. Reaction with 2-bromoethylmethyl ether (Aldrich), and one equivalent of sodium hydride in DMF, then affords the diether **3-36**. Reaction of diether **3-36** with triflate **3-37**, prepared as described in *Tetrahedron Lett.* **1986**, *27*, 1497, and potassium carbonate in DMF, gives the ether **3-70**. Using the above procedures,


but employing, in place of the bromobutylphosphonate **3-28**, different phosphonates **3-27**, and in place of alcohol **3-34**, different alcohols **3-31**, the corresponding products **3-69** are obtained.

Schemes **3.14-3.17** describe the preparation of phosphonate-containing derivatives **3-12, 3-75, 3-76** which are employed in the preparation of the phosphonate ester intermediates **3-14** (Scheme **3.5**).

Scheme **3.14**




Scheme **3.15**




The dihydroxybenzoic acid **3-25** is first treated with 2-bromoethylmethyl ether (Aldrich), as described in Schemes **3.10-3.11** to give the ether **3-38**. Ether **3-38** is then treated with one equivalent of the phosphonate alkylating agent, in which Lv is a group such as mesyl, trifluoromethanesulfonyl, Br, I, Cl, tosyl, etc., in the presence of base, as described in EP 0817775 B1, to give the ether **3-75**. For example, ether **3-38** is treated with triflate **3-37**, prepared as described in *Tetrahedron Lett.* **1986**, *27*, 1497, and potassium carbonate in DMF, to give the ether **3-39**. Using the above procedures, but employing, in place of the phosphonate **3-37**, different phosphonates **3-27**, the corresponding products **3-75** are obtained.

Scheme **3.16**




Scheme **3.17**




Schemes **3.16-3.17** describe the preparation of phosphonate-containing derivatives **3-76** which are employed in the preparation of the phosphonate ester intermediates **3-13** (Scheme **3.4**). Ether **3-38** (Schemes **3.14-3.15**) is reacted with 2-bromoethanol, as described above, Schemes **3.13**, for the preparation of **3-35** from **3-25**, to give **3-40**. Treatment of diether **3-40** with an phosphonate alkylating agent **3-27**, in which Lv is a group such as mesyl, trifluoromethanesulfonyl, Br, I, Cl, tosyl, etc., in the presence of base then affords ether **3-76**. For example, **3-38** in acetone is treated 2-iodoethanol, **3-66**, as described above, Schemes **3.13**, for the preparation of **3-35** from **3-25**, to give **3-41**. Reaction with bromobutylphosphonate **3-28**, as described above (Schemes **3.10-3.11**) then affords **3-42**. Using the above procedures, but employing, in place of the bromobutylphosphonate **3-28**, different phosphonates **3-27**, and in place of alcohol **3-66**, different alcohols **3-63**, the corresponding products **3-76** are obtained.

Scheme **3.18**




Schemes **3.18-3.19** describe the preparation of phosphonate-containing derivatives, which are employed in the preparation of the phosphonate ester intermediates **3-20** (Schemes **3.6-3.7**). Aniline **3-43** is first protected using methods described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7. Bromination of **3-44** by treatment with bromine in acetic acid or NBS in tetrachloromethane at reflux, in the presence of AIBN then affords the bromophenol **3-45**. Alkylation with a phosphonate alkylating agent **3-77** as described above, Schemes **3.10-3.11**, then affords the phosphonate **3-46**. Coupling with TMS acetylene by palladium mediated reaction affords the alkyne **3-47** which can then be deprotected using conditions described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7, gives the amine **3-48**. The coupling of aryl halides with alkynes is described, for example, in *Comprehensive Organic Synthesis*, Eds. Trost and Fleming, Oxford, (1991), 3, part 2.4, page 521.

Scheme **3.19**




For example, 3-aminophenol, **3-49**, is treated with one equivalent of mesyl chloride in the presence of pyridine to afford **3-50**. The mesyl compound **3-50** is then treated with bromine in acetic acid to give the bromide **3-51**. Bromide **3-51** is alkylated with **3-37** as described above (Schemes **3.12-3.13**) to give the phosphonate **3-52**. Treatment of **3-52** with TMS-acetylene in a polar solvent such as dimethylformamide or acetonitrile, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate and copper (I) iodide, affords the coupled product **3-53**. Deprotection of the mesyl group by treatment with potassium hydroxide in THF and water gives the amine **3-54**. Using the above procedures, but employing, in place of the phosphonate **3-37**, different phosphonates **3-77**, and in place of alcohol **3-49**, different alcohols **3-43**, the corresponding products **3-48** are obtained.

Scheme **3.20**



Schemes **3.20-3.21** describes the preparation of phosphonate-containing derivatives **3-58**, which are employed in the preparation of the phosphonate ester intermediates **3-24** (Scheme **3.9**). 3-Iodoaniline is first protected using methods described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7. Coupling with propargyl alcohol by palladium mediated reaction, as described above (Schemes **3.18-3.19**) affords the alkyne **3-56**. Alkylation with a phosphonate alkylating agent **3-27** as described above, Schemes **3.10-3.11**, then affords the phosphonate **3-57**. Finally, deprotection using conditions described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7, gives the amine **3-58**.

Scheme **3.21**




For example, 3-iodoaniline (Aldrich) is treated with BOC anhydride in the presence of pyridine and DMAP to afford **3-59**. Treatment of **3-59** with

propargyl alcohol in a polar solvent such as dimethylformamide or acetonitrile, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine) palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate and copper (I) iodide, affords the coupled product **3-60**. Alkylation of **3-60** with triflate **3-37**, as described above, Schemes **3.12-3.13,** then affords the phosphonate **3-61**. Deprotection of the BOC group by treatment with TFA in THF or dioxane gives the amine **3-62**. Using the above procedures, but employing, in place of the phosphonate **3-37**, different phosphonates **3-27**, and in place of iodoaniline **3-59**, different anilines, **3-55**, the corresponding products **3-58** are obtained.

The procedures described for the introduction of phosphonate moieties (Schemes **3.10-3.21**) are, with appropriate modifications known to one skilled in the art, transferable to different chemical substrates. Thus, for example, the methods described above for the introduction of phosphonate groups onto the aryl rings of **3-18** and **3-48**, are also applicable to the introduction of phosphonate moieties onto the alkynes **3-22** and **3-58**, and vice versa.


Example 4: Exemplary compounds of the present invention

Scheme **4.1**



Scheme **4.1** illustrates the preparation of compounds **4-52** in which A is Br, I, [SH], [NH], etc., or the group link-P(O)(OR^1)$_2$. The preparation of these compounds follows procedures described in *J. Med. Chem.* **2000**, 43, *12*, 2310. The phthalic anhydride **4-1** is melted with a methyl pyridine **4-2** in which A is Br, I, [SH], [NH], etc., or the group link-P(O)(OR^1)$_2$, under high temperature to give **4-3**. The synthesis of **4-2** is described below. The product **4-3** on treatment with hydrazine in water and optionally ethanol, then rearranges to afford the ketone **4-4**. Ketone **4-4** is then converted to the chloride **4-5** by treatment with a phosphorous oxychloride in an inert solvent such as acetontrile at about 50 °C. The amine, **4-7,** is introduced by heating the chloride **4-5** in the presence of the amine, optionally in a high boiling solvent such as xylenes or DMF to give the amine **4-6**. Alternatively the pyridinone **4-4** can be directly converted to the product **4-6** in a one step procedure involving melting the aniline, **4-7**, with the pyridinone in the presence of a dehydrating agent such as phosphorus pentoxide as described in *J. Med Chem.* **2000**, 43, *12*, 2310.


Scheme **4.2**



4-6 **4-52**


The reactions shown in Scheme **4.1** illustrate the preparation of the compounds **4-6** in which the substituent A is either the group link-P(O)(OR^1)$_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **4.2** depicts the conversion of the compounds **4-6** in which A is [OH], [SH], [NH], Br, etc., into the phosphonate esters **4-52**. In this procedure, the compounds **4-6** are converted, using the procedures described below, Schemes **4.5-4.15**, into the compounds **4-52**.

Scheme **4.3**



Scheme **4.3** illustrates the preparation of compounds **4-12** in which A is Br, I, [SH], [NH], etc., or the group link-P(O)$(OR^1)_2$. The chloride **4-8**, described in *J. Med. Chem.* **2000**, *43*, 12, 2310, is treated with an aniline **4-9**, in which A is Br, I, [SH], [NH], etc., or the group link-P(O)$(OR^1)_2$, as described above in Scheme **4.1**, to give amine **4-10**. Alternatively the pyridinone **4-11**, described in J. Med. Chem. 2000, 43, 12, p2310 is treated with an aniline **4-9** in which A is Br, I, [SH], [NH] etc or the group link-P(O)$(OR^1)_2$ as described above, Scheme **4.1**, to give amine **4-10**.

Scheme **4.4**




The reactions shown in Scheme **4.3** illustrate the preparation of the compounds **4-10** in which the substituent A is either the group link-P(O)$(OR^1)_2$ or a precursor such as [OH], [SH], [NH], Br etc. Scheme **4.4** depicts the conversion of the compounds **4-10** in which A is [OH], [SH], [NH], Br etc, into the phosphonate esters **4-12**. In this procedure, the compounds **4-10** are converted, using the procedures described below, Schemes **4.5-4.15**, into the compounds **4-12**.

Schemes **4.5-4.10** describe the preparation of phosphonate-containing derivatives **4-2**, in which A is Br, Cl, [OH], [NH], and the group link-


$P(O)(OR^1)_2$, which are employed in the preparation of the phosphonate ester intermediates **4-52**.

Scheme **4.5**



4-13 **4-15**


Scheme **4.6**



4-16 **4-17**


Schemes **4.5-4.6** describes the preparation of **4-2** (Scheme **4.1**) in which the phosphonate is attached directly to the ring. The halo pyridine **4-13** is treated with a dialkyl phosphite **4-14** to give the phosphonate **4-15**. The coupling reaction is conducted in the presence of a palladium (0) catalyst, for example as described in *J. Med. Chem.*, **1992**, *35*, 1371. For example 2-bromo-4-methyl pyridine (Aldrich) **4-16** is reacted with an equimolar amount of a dialkyl sodium phosphite **4-14a**, in the presence of tetrakis(triphenylphosphine)palladium(0) and triethylamine, in toluene at reflux, to yield the phosphonate **4-17**. Using the above procedures, but employing, in place of the halo pyridine compound **4-16**, different pyridines **4-13**, and/or different dialkyl sodium phosphites **4-14** the corresponding products **4-15** are obtained.

Scheme **4.7**



4-13 **4-19** **4-20**

Scheme **4.8**




4-16 **4-22** **4-23**

Schemes **4.7-4.8** illustrates the preparation of **4-2** in which the phosphonate is attached through a unsaturated or saturated carbon linker. In this procedure, a halo-substituted pyridine **4-13** is coupled, by means of a palladium-catalyzed Heck reaction with a dialkyl alkenyl phosphonate **4-18**. The coupling of aryl halides with olefins by means of the Heck reaction is described, for example, in *Advanced Organic Chemistry*, by F. A. Carey and R. J. Sundberg, Plenum, (2001), p. 503ff., and in *Acc. Chem. Res.*, **1979**, *12*, 146. The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxane, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or a palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate, to afford the coupled product **4-19**. Optionally, the product **4-19** can be reduced to afford the saturated phosphonate **4-20**. Methods for the reduction of carbon-carbon double bonds are described, for example, in Comprehensive Organic Transformations, by R. C. Larock, VCH, (1989), p. 6. The methods include catalytic reduction, and chemical reduction, the latter for example employing diborane or diimide.


For example, 2-bromo-4-methyl pyridine **4-16** is reacted with a dialkyl butenyl phosphonate **4-21**, the preparation of which is described in *J. Med. Chem.*, **1996**, *39*, 949, in the presence of bis(triphenylphosphine) palladium(II) chloride, as described in *J. Med. Chem.*, **1992**, *35*, 1371, to afford the coupled product **4-22**. Optionally, the product **4-22** is reduced, for example by reaction

with diimide, as described in *J. Org. Chem.*, **1965**, *30*, 3965, to afford the saturated product **4-23**. Using the above procedures, but employing, in place of the halo pyridine compound **4-16**, different pyridines **4-13**, and/or different phosphonates **4-18** the corresponding products **4-19** and **4-20** are obtained.

Scheme **4.9**



Scheme **4.10**




Schemes **4.9-4.10** illustrates the preparation of **4-2** in which the phosphonate is attached through a heteroatom e.g. O, S or N, and a carbon chain. In this procedure, a halo-substituted pyridine **4-13** is reacted with a dialkyl hydroxy- or thio-alkylphosphonate **4-24**. The preparation of alkoxypyridines by the reaction of alkoxides with halopyridines is described, for example, in *J. Am. Chem. Soc.*, **1960**, *82*, 4414. The preparation of pyridine thioethers by reaction of halopyridines with thiols is described, for example, in *Chemistry of Heterocyclic Compounds, Pyridine and its derivatives*, E. Klingsberg, Ed., part 4, page 358. The alcohols and thiols are transformed into metal salts, for example sodium or potassium salts, and then reacted with the halopyridine substrates at elevated temperatures, optionally in the presence of copper powder catalyst, to afford the ether or thioether products **4-25**. For example, a tetrahydrofuran solution of 3-bromo-4-methylpyridine **4-26** (Aldrich) is heated at reflux with an equimolar amount of a dialkyl 2-mercaptoethylphophonate **4-27**, the preparation of which is described in Aust. J. Chem., 43, 1123, (1990), in the presence of sodium carbonate, to afford the thioether product **4-28**. Using

the above procedures, but employing, in place of the halopyridines **4-26**, different halopyridines **4-13**, and/or different hydroxy or thio-alkyl phosphonates **4-24**, the corresponding products **4-25** are obtained.


Schemes **4.11-4.15** describe the preparation of phosphonate-containing derivatives **4-10**, in which A is Br, Cl, [OH], [NH], and the group link-$P(O)(OR^1)_2$ which are employed in the preparation of the phosphonate ester intermediates **4-12** (Schemes **4.3-4.4**).

Scheme **4.11**




Schemes **4.11-4.13** illustrates the preparation of **4-9** (Scheme **4.3**) in which the phosphonate is attached through a heteroatom e.g. O, S, or N, and a carbon linker. In this procedure an optionally protected aniline is reacted with an alkylphosphonate **4-30** in which Lv is a leaving group such as triflate, Br, Cl, Mesyl, etc, in the presence of a suitable base. The base required for this transformation depends on the nature of the heteroatom X. For example, if X is N or S, an excess of an inorganic base such as, for example, potassium carbonate, in the presence of an organic solvent such as dimethylformamide, is suitable. The reaction proceeds at from ambient temperature to about 80 °C to afford the displacement products **4-31**. If X is O, an equimolar amount of a strong base, such as, for example, lithium hexamethyldisilylazide and the like, is employed, in the presence of a solvent such as tetrahydrofuran. Deprotection, of the amine group as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) chapter 7, then affords the amine **4-32**.

Scheme **4.12**




For example, the diamine **4-33** (Aldrich), mono-protected as the CBZ carbamate as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), 531ff,, is treated with an equimolar amount of triflate **4-34**, the preparation of which is described in *Tetrahedron Lett.* **1986**, *27*, 1497, in dimethylformamide containing excess potassium carbonate, at ca 60 °C to afford the phosphonate product **4-35**. Deprotection by reduction over palladium on carbon in the presence of hydrogen then affords the amine **4-36**. Using the above procedures, but employing, in place of the aniline **4-33**, different anilines **4-29**, and/or different alkylphosphonates **4-30**, the corresponding products **4-32** are obtained.

Scheme **4.13**



Alternatively , the aminophenol **4-37**, protected as the CBZ carbamate as described above, is reacted with one equivalent of an alkylphosphonate **4-34**, as described above, to give phosphonate **4-38**. Removal of the CBZ group by catalytic reduction over palladium on carbon in the presence of hydrogen then affords the amine **4-39**.


Scheme **4.14**



Schemes **4.14-4.15** illustrates the preparation of **4-9** in which the phosphonate is attached through a unsaturated or saturated carbon linker. In this procedure, an optionally protected halo-substituted aniline **4-40** is coupled, by means of a palladium-catalyzed Heck reaction with a dialkyl alkenyl phosphonate **4-18**, as described above (Schemes **4.7-4.8**), to afford the coupled product **4-41**. Protection of anilines is described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999), chapter 7. Preferably the aniline is treated with a BOC reagent such as BOC chloride, or BOC anhydride in the presence of DMAP and a base, e.g., triethylamine, to afford the protected aniline.

Optionally, the coupled product **4-41** can be reduced, as described above (Schemes **4.7-4.8)** to afford the saturated phosphonate **4-42**. Removal of the protecting groups, as described in *Protective Groups in Organic Synthesis*, by T.W. Greene and P.G.M. Wuts, Wiley, Third Edition (1999) chapter 7, affords the anilines **4-43** and **4-44**.

Scheme **4.15**




For example, BOC protected 3-bromo-4-fluoro aniline **4-45** (Aldrich) is reacted with a dialkyl propenyl phosphonate **4-46**, the preparation of which is described in *J. Med. Chem.*, **1996**, *39*, 949, in the presence of bis(triphenylphosphine) palladium(II) chloride , as described in *J. Med. Chem.*, **1992**, *35*, 1371, to afford the coupled product **4-47**. The BOC protection of the aniline is performed by treating the aniline with BOC anhydride in the presence of DMAP. The product **4-47** is reduced, for example by reaction with diimide, as described in *J. Org. Chem.*, **1965**, *30*, 3965, to afford the saturated product **4-48**. Treatment of **4-47** and **4-48** with TFA in THF or dioxane, affords the products **4-49** and **4-50** respectively. Using the above procedures, but employing, in place of the halo pyridine compound **4-45**, different pyridines **4-40**, and/or different phosphonates **4-18** the corresponding products **4-43** and **4-44** are obtained.


The procedures described for the introduction of phosphonate moieties (Schemes **4.5-4.15**) are, with appropriate modifications known to one skilled in the art, transferable to different chemical substrates. Thus, the methods described above for the introduction of phosphonate groups onto the pyridyl ring of **4-2** are applicable to the introduction of phosphonate moieties onto the aniline **4-9** and the reverse is also true.

Example 5: Preparation of exemplary compounds of the present invention

Scheme **5.1**




Scheme **5.2**




The desired phosphonate substituted analogs for conversion into the prodrugs are prepared by reaction of arabinofuranosylcytosine, **5-1** (obtained as described in U.S. Patent No. 3,116,282, col. 26 line 65 to col. 28 line 25) with the respective alkylating reagents, **5-2**. Schemes **5.1-5.2** shows the preparation of phosphonate linkage to **5-1** through the 5' hydroxyl group. Triol **5-1** is dissolved in a solvent such as DMF, THF and is treated with a phosphonate reagent bearing a leaving group, for example, bromine, mesyl, tosyl, or trifluoromethanesulfonyl in the presence of a suitable organic or inorganic base.

For example, **5-1** dissolved in DMF, is treated with 8 equivalents of sodium hydride and two equivalents of (toluene-4-sulfonylmethyl)-phosphonic acid diethyl ester **5-5**, prepared according to the procedures in *J. Org. Chem.* **1996**, *61*, 7697, to give phosphonate **5-6** in which the linkage is a methylene group. Using the above procedure but employing different phosphonate reagents **5-2** in place of **5-5** the corresponding products **5-3** bearing different linking groups are obtained.

Scheme **5.3**



Scheme **5.4**




The desired phosphonate substituted analogs for conversion into the prodrugs are prepared by first reacting glycal **5-7** (obtained as described in *J. Am. Chem. Soc.* **1972**, *94*, 3213) with phenylselenyl chloride followed by treatment with the respective phosphonate alcohols **5-8** in the presence of silver perchlorate (*J. Org. Chem.* **1991**, *56*, 2642-2647). Oxidation of the resulting chloride using hydrogen peroxide followed by dihydroxylation of the resulting double bond with MCPBA and water generates the anti-diol (**Synth. Commun. 1989**, *19*, 1939) which upon aminolysis of uracil using triazole, 2-chlorophenyldichlorophosphate, pyridine and ammonia (*Bioorg. Med. Chem. Lett.* **1997**, *7*, 2567) provides the desired product **5-3**. Alternatively, the anti-diol

can be accessed through an osmium tetroxide oxidation followed by selective protection and inversion using Mitsunobu conditions.

Schemes **5.3-5.4** show the introduction of different phosphonate linkages. For example, **5-7** dissolved in CH_2Cl_2, is treated with one equivalent of phenyl selenyl chloride at –70 °C followed by silver perchlorate in the presence of diethyl(hydroxymethyl) phosphonate to generate **5-12**. The phosphonate is transformed into the desired analog by first oxidation with hydrogen peroxide, followed by an MCPBA oxidation and finally conversion of uracil to cytosine to the desired product **5-13**. Using the above procedure but employing different phosphonate reagents **5-8** in place of **5-11** the corresponding products **5-10** bearing different linking groups are obtained. In some cases conversions to desired prodrugs may require the use of suitable protecting groups for the amino group of cytosine as well as the diol. Other bases could also be used to generate similar analogs of both **5-3** and **5-10** classes.

Example 6: Preparation of exemplary compounds of the present invention




For example:
X = Cl, Br, I, OMs, OTs, OTf
where R_1 = Alkyl, Aryl

R_1 = H, alkyl, aryl, haloalkyl, alkenyl, aralyl, aryl
R_2 = H, alkyl, aryl, haloalkyl, alkenyl, aralyl, aryl

Bases = thymine, adenine, guanine, cytosine, uracil, inosine, diaminopurine.
Bases requiring protecting groups are to be suitably protected using protecting groups and conditions well known to thoses skilled in the art

Representative compounds of the invention can be prepared as illustrated above. The desired phosphonate substituted analogs are prepared by reaction of intermediate **6-5** (obtained as described in US Patent 5,464,826) with the respective alkylating reagents **6-6**. Illustrated above is the preparation of


phosphonate linkage to 2'2'-difluoronucleosides through the 5'-hydroxyl group. The appropriately protected base as described in US Patent 5,464,826 is dissolved in a solvent such as DMF, THF and is treated with a phosphonate reagent bearing a leaving group, for example, bromine, mesyl, tosyl, or trifluoromethanesulfonyl in the presence of a suitable organic or inorganic base.



For instance, **6-1** (obtained as described in US Patent 5,464,826) dissolved in DMF, is treated with two equivalents of sodium hydride and one equivalent of (toluene-4-sulfonylmethyl)-phosphonic acid diethyl ester **6-8**, prepared according to the procedures in *J. Org. Chem.* **1996**, *61* , 7697, to give the corresponding phosphonate **6-9** in which the linkage is a methylene group. Using the above procedure but employing different phosphonate reagents **6-6** in place of **6-8** the corresponding products **6-2** bearing different linking groups are obtained.


Example 7: Preparation of exemplary compounds of the present invention

Scheme **7.1**




Compound **7-3** (X = $-CH_2CH_2-$) is prepared as outlined in Scheme **7.1**. Camptosar (U.S. Patent No. 4,604,463) is activated with *p*-nitrophenyl chloroformate in DMF and triethyl amine, followed by reaction with an aminophosphonate to furnish compound **7-3**.

Scheme **7.2**




Compound **7-4** is obtained by a published procedure (*J. Chem. Soc. Perkin Trans. 2,* **1972**, 2035). Activation of the 10-OH of **7-4**, followed by reaction with amine **7-21** (as its acid chloride) gives **7-5** (U.S. Patent No. 4,604,463). Compound **7-6** is prepared by refluxing **7-5** and an aminoethylphosphonate in DMF and DIPEA.

Scheme 7.3




A key intermediate is 7-hydroxymethyl-10-hydroxycamptothecin **7-7**, which is prepared according to Dallavele, S. et al. (*J. Med. Chem.* **2000**, *43*, 3963-3969). 7-Aldehyde derivative **7-10** is prepared by refluxing **7-7** in glacial acetic acid. Further oxidation of **7-10** gives acid **7-11**. Treating **7-10** with triphenylphosphoranylidene acetaldehyde, and t-butoxycarbonylmethylene triphenylphosphorane gives **7-12** and **7-13**, respectively. (*J. Med. Chem.* **2000**, *43*, 3963).

Scheme **7.4**



Compound **7-7** is reacted with **7-22** (U.S. Patent No. 4,604,463), followed reaction with a triflated phosphonate and NaH, to give compound **7-8**.

Scheme **7.5**




Syntheses of **7-19, 7-18, 7-17**, and **7-16** are illustrated in Scheme **7.5**. Aldehyde **7-10,** acid **7-11**, extended aldehyde **7-12**, and ester **7-13** (compounds **7-14**) are reacted with **7-22** to furnish **7-15a, 7-15b, 7-15c**, and **7-15d**. Compound **7-19** is prepared by reductive amination of **7-15a** with aminoethylphosphonate, $NaBH_3CN$, and AcOH. Compound **7-15b** is activated with BOP reagent, then reacts with aminoethylphosphonate to give compound **7-18**. Reductive amination of **7-15c** with aminoethylphosphonate, followed by hydrogenation in the presence of 10 % Pd/C furnishes desired **7-17**. Hydrogenation of **7-15d**, followed by treating with aminoethylphosphonate in the presence of coupling agent e.g, BOP reagent. DIC give the desired product **7-16**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.

Example 8: Preparation of exemplary compounds of the present invention


Scheme **8.1**



Derivatives of hycamtin at C-10 and O-20 are readily prepared from hycamtin (topotecan) (U.S. Patent No. 5,004,758), as illustrated in Schemes **8.1-8.5**. Hycamtin is reacted with appropriate triflated phosphonate to yield analogs of **8-2**. Activation of hycamtin with p-nitrophenyl chloroformate , followed by


reaction with appropriate aminophosphonate nucleophile furnishes the desired analog **8-4** containing a carbamate linkage.

Scheme **8.2**




Conversion of OH group at C-10 to Triflate derivative, followed by CO insertion, and then reaction with aminophosphonate to give analog **8-7**. The triflate is converted to an aldehyde by CO insertion, followed by reductive amination with aminophosphonate to give analogs of **8-6**. Protection of OH at C-10 and activation of OH-20, followed by reaction with an aminophosphonate furnishes the desired analogs of **8-8**.

Scheme **8.3**




Scheme **8.4**




Analogs **8-12** are synthesized from Pd-catalyzed reduction of triflated **8-10**, followed by activation of O-20 with *p*-nitrophenyl chloroformate, and reaction with an aminophosphonate. Methylation of hycamtin by treating hycamtin with NaH, CH_3I in DMF affords 10-OCH_3 hycamtin. Analogs **8-14** are furnished from OCH_3 hycamtin derivative in the same manner as **8-12**.

Scheme **8.5**




Preparation of analogs **8-17** is performed by reaction of 10-hydroxycamprtothecin with paraformaldehyde, methylamine and acetic acid, followed by reductive amination with an aldehyde-phosphonate.

Scheme **8.6**




As depicted in Scheme **8.6**, hycamtin is reacted with diethylphosphonate in the presence of Cs_2CO_3 in acetonitrile to afford compound **8-18**. Activation of OH-10 by reaction with p-nitrophenyl chloroformate in CH_2Cl_2 in the presence of DIPEA, followed by reaction aminophonate furnishes carbamate **8-20**.

Scheme **8.7**




As shown in Scheme **8.7**, tirflation of the 10-OH of hycamtin (*J. Am. Chem. Soc.*, **1984**, *106*, 7500), followed by CO insertion gives the aldehyde intermediate. (*J. Org. Chem.* **1999**, *64*, 178). Reductive amination of aldehyde with aminophosphonate, followed by acid treatment, produces amine **8-21**. Triflation and CO insertion of hycamtin gives the carboxylic acid, (*J. Org. Chem.* **1994**, *59*, 6683). The resulting carboxylic acid is activated with BOP-reagent, followed by reaction with aminophosphonate in the presence of DIPEA to produce compound **8-22**. Protection of the 10-OH with TMS-Cl, activation of the 20-OH with *p*-nitrophenyl chloroformate, followed by reaction with an aminophosphonate furnishes phosphonate **8-23**.

Scheme **8.8**




Syntheses of **8-24** and **8-25** (see **8-12** and **8-14**) are described in Schemes **8.8** and **8.9**. Dehyroxylation of **8-10** is performed in DMF with dppp, $Pd(OAc)_2$, and Et_3SiH to yield **8-11**. Compound **8-24** is prepared from **8-11** by activation with *p*-nitrophenyl chloroformate, followed by coupling with aminophosphonate and acid work up.

Scheme **8.9**



Hycamtin is treated with NaH in DMF, and reacts with CH_3I to give 10-methoxy derivative (Scheme **8.9**). This 10-methoxy intermediate is activated with *p*-nitrophenyl chloroformate, followed by reaction with aminophosphonate and acid work up to furnish desired phosphonate **8-25**.

Scheme **8.10**




Scheme **8.10** describes the synthesis of compound **8-26** (an example of analogs **8-17**), reductive amination of 9-methylaminomethyl-10-hydroxycamptothecin **8-16** (prepared as hycamtin described in U.S. Patent No. 5,004,758, using methylamine instead of dimethylamine) with phosphonate with aldehyde functional group gives desired product **8-26**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 9: Preparation of exemplary compounds of the present invention

Scheme **9.1**




Exemplary compounds of the invention are illustrated above.

Scheme **9.2**



Syntheses of examples of analogs **9-2** to **9-8** are illustrated in Schemes **9.2**, **9.3** and **9.4**. Reaction of ketone **9-9** (*Chem. Lett.* **1980**, 51) and 1,2,4-triazole with *n*-BuLi in THF at –78 °C gives alcohol **9-10**. Compound **9-10** is reacted with triflated phosphonate and NaH, to yield **9-12**, an example of **9-7**, where X = -CH_2-. Compound **9-10** is activated with *p*-nitrophenyl chloroformate, followed by reaction with aminoethylphosphonate in the presence of diisopropylethylamine (DIPEA) to furnish the desired produce **9-11**, an example of analogs **9-8**, where X = -CH_2CH_2-.


Scheme **9.3**



For example, 1,2,4-tetrazole ester derivative is stirred with alpha-bromo-4-tolunirile in CH_2Cl_2 to finish **9-13** (U.S. Patent No. 4,978,672). Compound **9-13** is first saponified with LiOH to generate acid **9-14**. The acid is reacted with 4-fluorbenzonitrile according to procedure described in U.S. Patent No. 4,978,672 to give the key intermediate **9-15**. Reaction of **9-15**, DIC, HOAt, and aminoethylphosphonate furnishes **9-16**, an example of analogs **9-2**, where X = -CH_2CH_2-. Reduction of **9-15** with borane in THF, followed by reacting with

triflated phosphonate and NaH gives the desired product **9-18**, an example of analogs **9-4**, where X = - CH_2CH_2-.

Scheme **9.4**




Oxidization of **9-17** with MnO_2 affords aldehyde derivative **9-19**. Treatment **9-19** with aminoethylphosphonate generates **9-22**, an example of analogs **9-5**, where X = - CH_2CH_2-. Aldehyde **9-19** is reacted with hydroxyamine, followed by reacting with triflated phosphonate to furnish **9-21**, an example of analogs **9-6**, where X = - CH_2CH_2-. Compound **9-20** is obtained by reductive amination of **9-19** with an aminoethylphosphonate, $NaBH_3CN$, and AcOH.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 10: Preparation of exemplary compounds of the present invention

Scheme **10.1**




Exemplary compounds of the invention are illustrated above. Syntheses of new compounds containing phosphonate with various linker X are illustrated in Schemes **10.2, 10.3** and **10.4**. Examples are synthesized as depicted in Schemes **10.2, 10.3** and **10.4**.

Scheme **10.2**



Compound **10-14** is prepared as previous published procedure (*J. Med. Chem.* **1991**, *34*, 725) from **10-12** (*J. Heterocyclic Chem.* **1975**, *2*, 577) and **10-13** (*Bioorg. Med. Chem. Lett.* **2001**, *11*, 1257). Compound **10-14** is protected with benzyl group by reaction with benzyl bromide and Cs_2CO_3, followed by treating with thionyl chloride, then cyclization with KO*t*-Bu (*J. Med. Chem.* **1991**, *34*, 725) to furnish compound **10-15**. Hydrogenation to remove benzyl group gives **10-16**. Compound **10-16** is stirring with triflated phosphonate , Cs_2CO_3 in CH_3CN to give the desired product **10-17** (an example of analogs **10-8**, X = $-CH_2-$). Compound **10-16** is activated with p-ntirophenyl chlorofromate in the presence of TEA, followed by teacting with aminoethylphosphonate to yield **10-18** (an example of analogs **10-7**, where X = $-CH_2CH_2-$).


Scheme **10.3**



Compound **10-20** is prepared in the same fashion as compound **10-14**, from **10-12** and **10-19**. Compound **10-21** is synthesized according to the procedure described above for **10-15**, followed by hydrogenation in the presence of 10 % Pd/C to furnish the key intermediate **10-22**. Reductive amination of **10-22** with aldehyde phosphonate, $NaBH_3CN$, and AcOH gives desired product **10-23** (an example of analogs **10-9**, where X = $-CH_2CH_2-$). Compound **10-22** is reacted with phosphonate chloroformate in the presence of TEA to give product **10-25** (an example of analogs **10-11**, where X = $-CH_2CH_2-$). Example of analogs **10-10** (where X = $-CH_2-$), compound of **10-24** is furnished by reaction **10-22** with phosphonate carboxylic acid and DIC. Formylation of fadrozole with *n*-BuLi, DMF gives intermediate aldehyde **10-26** (*J. Med. Chem.* **2000**, *43*, 2165). Further oxidation of **10-26** to give acid, followed by reaction with aminoethylphosphonate, DIC, and HOAt furnishes the desired product **10-31** (an example of analogs **10-5**, where X = $-CH_2CH_2-$). Reductive amination of **10-26**

with aldehyde phosphonate, $NaBH_3CN$, and AcOH give desired product **10-27** (an example of analogs **10-2**, where X = $-CH_2CH_2-$). Treating **10-26** with aminoethylphosphonate yield **10-30** (an example of analogs **10-6**, where X = $-CH_2CH_2-$).

Scheme **10.4**




Reduction of **10-26** with $NaBH_4$ generates alcohol derivative, followed by reaction with triflated phosphonate and NaH to provide product **10-29** (an example of analogs **10-4**, where X = $-CH_2-$). The condensation between compound **10-26** and hydroxyamine in the presence of TEA to give the oxime. The alkylation of the oxime with a triflated phosphonate and NaH furnishes the desired compound **10-28** (an example of analogs **10-3**, where X = $-CH_2-$).

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 11: Preparation of exemplary compounds of the present invention

Scheme **11.1**



Exemplary compounds of the invention are illustrated above.


Scheme **11.2**



Temozolomide, mitozolomide and their derivatives have been synthesized by several different synthetic routes (Scheme **11.2**). 5-Aminoimidazole-4-carbozamide is reacted with alkyl isocyanate to give the 1-(*N*-alkylcarbamoyl) derivative. This derivative is treated with sodium nitrite to generate **11-10** (*J. Org. Chem.* **1997**, *62*, 7288). Alternatively, 5-aminoimidazole-4-carbozamide is treated with sodium nitrite to generate a diazonium salt, followed by the reaction with alkyl isocyanate to furnish amide **11-10** (U.S. Patent No. 5,260,291). Hydrolysis conditions can be selected to hydrolyzed amide **11-10** to acid **11-13** (*J. Med. Chem.* **1990**, *33*, 1393). The acid **11-13** is converted to an aldehyde, followed by reductive amination with an aminophosphonate to furnish analogs **11-31**, by the reaction with an aminophosphonate to give analog **11-41**, and reaction with hydroxylamine, triflate phosphonate to give **11-51**. Compound **11-13** is reacted with an aminophosphonate and a coupling agent to give analogs **11-30**.

Compounds **11-15, 11-17, 11-18,** and **11-19**, which are examples of **11-30, 11-51, 11-41,** and **11-31**, respectively, can be prepared as illustrated below (Scheme **11.3**).


Scheme **11.3**



Temozolomide **11-10** is prepared stepwise, from the reaction of 5-aminoimidazole-4-carbozamide with methyl isocyanate in acetonitrile, followed by the nitrosoation with sodium nitrite in 50 % acetic acid , and cyclization to give **11-10** (*J. Org. Chem.* **1997**, *63*, 7288). Temozolomide is converted to acid **11-14**, by the reaction of **11-10** with sodium nitrite in concentrated sulfuric acid. The acid chloride is obtained by treating acid **11-14** with thionyl chloride and a catalytic amount of DMF (*J. Med. Chem.* **1990**, *33*, 1393). The reaction of the acid chloride with an aminoethyl phosphonate affords **11-15**. The acid chloride can be reacted with a hydroxymethylamine, followed by reduction with DIBAL in THF to give aldehyde **11-16**. The aldehyde is further reacted with aminoethyl phosphonate, and reductively aminated with an aminoethyl phosphonate, $NaBH_3CN$, and AcOH to give **11-18**, and **11-19**, respectively. Aldehyde **11-16**

can be reacted with hydroxylamine hydrochloride in the presence of TEA followed by reaction with a triflated phosphonate and NaH to generate **11-17**.


Scheme **11.4**



Compound **11-21** and **11-23**, which are examples of analogs **11-6** and **11-7**, are synthesized as illustrated above in Scheme **11.4**. Compound **11-10** is lithiated with *n*-BuLi in THF at –78 °C, followed by reaction with DMF, to give aldehyde derivative **11-20**. The reductive amination of aldehyde **11-20** with aninoethylphosphonate, $NaBH_3CN$, AcOH affords the desired product **11-21** (an example of analog of **11-6**, where X = $-CH_2CH_2-$). Temozolomide **11-10** can also be lithiated with *n*-BuLi in THF, followed by the reaction with CO_2 to afford acid derivative **11-22**. Acid **11-22** is reacted with an aninoethyl phosphonate in the presence of coupling agents, e.g., DIC, HOAt, to furnish the desired product **11-23** (an example of analog of **11-7**, where X = $-CH_2CH_2-$). Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 12: Preparation of exemplary compounds of the present invention

Scheme **12.1**



Exemplary compounds of the invention are illustrated above.


Scheme **12.2**



Syntheses of compounds, **12-10**, **12-14**, **12-16**, **12-15**, and **12-13**, containing phosphonate moieties, which are examples of analogs **12-2** (X = -CH_2-), **12-3** (X = -CH_2CH_2-), **12-4** (X = - CH_2CH_2-), **12-5** (X = -CH_2-), and **12-6** (X = -CH_2CH_2-), respectively, are illustrated above in Scheme **12-2**. Etoposide is obtained as previous described procedure (U.S. Patent No. 3,408,441). Etoposide is reacted with triflated phosphonate with Cs_2CO_3 in acetonitrile to afford phosphonate **12-10**. Etoposide is activated with *p*-nitrophenyl chloroformate, followed by reaction with aminoethyl phosphonate in the presence of TEA to give **12-13**. Triflation of **12-9** with $PhN(Tf)_2$, followed by the CO insertion in the presence of $Pd(OAc)_2$, pdpp, TEA in DMF-H_2O gives carboxylic acid derivative **12-12.** Compound **12-12** is reacted with an


aminoethyl phosphonate, DIC, and HOAt to afford **12-16**. Triflation of etoposide, followed CO insertion in the presence of $Pd(OAc)_2$, pdpp, TEA, and triethyl silane in DMF gives aldehyde intermediate **12-11**. Aldehyde **12-11** is reacted with hydroxylamine hydrochloride and diisopropylethyl amine (DIPEA), followed by the reaction with a triflated phosphonate and NaH to furnish phosphonate **12-15.** The reductive amination of **12-11** with an aminoethyl phosphonate, $NaBH_3CN$, and AcOH affords the desired compound **12-14**.

Scheme **12.3**



As depicted in Scheme **12.3**, compound **12-18** is prepared by the glycosylation of **12-17** (*Bioorg. Med. Chem. Lett.* **1994**, *4*, 2567) with proper propected β-d-glucopyranose, BF_3-Et_2O in dichloroethane at –20 °C (*J. Med. Chem.* **1989**, *32*, 1418). Deprotection of 3'-sugar hydroxyl group using zinc dust in 2:1 THF-AcOH, followed the deprotection of 2'-sugar amino group, and benzyl groups of phosphosate by hydrogention in the presence of 10 % Pd/C gives free amine **12-19**. The reductive amination of amine derivative **12-19** with an aminoethyl phosphonate, $NaBH_3CN$, and AcOH affords phosphonate **12-20,** an example of analog **12-8**, where X = $-CH_2CH_2-$.


Scheme **12.4**



As in Scheme **12.4**, compound **12-21** is prepared by the described procedure in *Bioor. Med. Chem. Lett.* **2001**, *11*, 2667 and *J. Med. Chem.* **1999**, *42*, 4640. Compound **12-22** is furnished by the glycosylation of **12-17** with **12-21**, BF_3-Et_2O in dichloroethane at –20 °C (*J. Med. Chem.* **1989**, *32*, 1418). Deprotection of 2'-and 3'-sugar hydroxyl group using zinc dust in 2:1 THF-AcOH, followed the deprotection of the CBZ-group of the terminal amino group and benzyl groups of phosphate by hydrogenation in the presence of 10 % Pd/C gives free amine **12-23**. The reductive amination of amine **12-23** with an animoethyl phosphonate, $NaBH_3CN$, and AcOH affords the desired compound **12-24,** an example of analog **12-7**, where X = -CH_2CH_2-, and n = 1. Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 13: Preparation of exemplary compounds of the present invention

Scheme **13.1**




Exemplary compounds of the invention are illustrated above. Analogs **13-15, 13-16,** and **13-9** are prepared as outlined in Scheme **13.2.**

Scheme **13.2**



Scheme **13.3**




Compound **13-13** is a precursor of analogs **13-15, 13-16,** and **13-9.**

Syntheses of examples are illustrated in Scheme **13.3**. Compound **13-13** is synthesized according to procedure described in U.S. Patent No. Re. 36,617, by alkylation of triazole with benzyl bromide **13-12**, followed by hydrogenation of the NO_2 group in the presence of 10 % Pd/C. The reductive amination of **13-13** with an aldehyde phosphonate, $NaBH_3CN$, and AcOH yields **13-40** (an example of **13-9**, where X = -CH_2-). A solution of **13-13**, carboxylic phosphonate, DIC, HOAt is stirred at room temperature generates product **13-42** (an example of **13-8** and **13-16**, X = -CH_2-). Activation of the hydroxymethylphosphonate with phosgene, followed by reaction with amine **13-13** in the presence of


diisopropylethyl amine in CH_2Cl_2 affords **13-41** (an example of **13-7** and **13-15**, where X = -CH2-).

Scheme **13.4**




Analogs **13-2** and **13-4** are prepared as outlined in Scheme **13.4**. Compound **13-18** is prepared as described procedure (U.S. Patent No. Re. 36,617). Ester **13-18** is saponified to give acid **13-19**, which is the key precursor of analogs **13-2** and **13-4**.

Scheme **13.5**




As depicted in Scheme **13.5**, compound **13-18** is first saponified with LiOH, gives **13-19**. Compound **13-19** is reacted with aminoethyl phosphonate in the presence of coupling reagent DIC, HOAt to furnish **13-21** (an example of **13-2**, where X = -CH_2-). Acid **13-19** is reduced to alcohol with BH_3-THF, followed by the reaction with triflated phosphonate, NaH in THF at RT to furnish **13-20** (an example of **13-4**, where X = -CH_2-).

Scheme **13.6**




Compound **13-22** is obtained from the reduction of ester **13-18**. Aldehyde derivative **13-22** is an important intermediate for analogs **13-5** and **13-24**. (Scheme **13.6**).

Scheme **13.7**




As shown in Scheme **13.7**, aldehyde **13-22** is reacted with aminoethylphosphonate to afford the desired product **13-25** (an example of **13-3** and **13-52**, where X = $-CH_2CH_2-$). Aldehyde **13-22** is reacted with hydroxylamine, followed by the reaction with triflated phosphonate to furnish **13-50** (an example of analogs **13-6** and **13-24**, where X = $-CH_2CH_2-$). Compound **13-23** is obtained by the reductive amination of **13-22** and aminoethylphosphonate, $NaBH_3CN$, AcOH.

Scheme **13.8**



Bromo derivative **13-27** is prepared by the described procedure for anastrozole (U.S. Patent No. Re. 36,617). Compound **13-27** is reacted with Grignard reagent R^2MgBr, or $R^2CH{=}CH_2$ in the presence of a Pd catalyst, to give the vinyl derivative, followed by ozonolysis to furnish aldehyde **13-28**. Aldehyde **13-28** is converted to analogs **13-36** and **13-10** using the procedures described in Schemes **13.6** and **13.7**.

Scheme **13.9**




As shown in Scheme **13.9**, compound **13-27** is coupled with CH_2=CH_2 in the presence of $Pd(OAc)_2$, *n*-Bu_3P, K_2CO_3 in DMF at 100 °C (*Tetrahedron Lett.* **2002**, *43*, 3401), followed by ozonolysis to furnish aldehyde **13-28**. The reductive amination of **13-28** with animoethyl phosphonate, $NaBH_3CN$, AcOH gives desired product **13-32** (an example of analogs **13-10** and **13-36**, where X = -CH_2CH_2-). Reduction of the aldehyde using $NaBH_4$ gives an alcohol derivative. Reaction of the alcohol derivative with NaH and a triflated phosphonate in THF generates compound **13-31** (an example of analogs **13-11** and **13-10**, where X = -CH_2-).

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 14: Preparation of exemplary compounds of the present invention

Scheme **14.1**




Exemplary compounds of the invention are illustrated above.

Scheme **14.2**



Syntheses of new compounds containing phosphonate are illustrated in Scheme **14.2.** Diethyl 3-nitrocyclobutane-1,1-dicarboxylate (*J. Org. Chem.* **1989**, *54*, 2869) is readily converted to the 3-amino derivative in 2 steps. Compound **14-12** is obtained from the reaction between 3-aminocyclobutane-1,1-dicarboxylic acid sodium salt and $PtCl_2(NH_3)_2$ (U.S. Patent No. 4,625,927). Compound **14-12** is readily converted to analogs **14-2, 14-3**, and **14-5** by reaction with the proper phosphonate in one or two steps.


Scheme **14.3**



As outlined in Scheme **14.3**, 3-amino-1,1-dicarboxylic acid is obtained from 3-nitro derivative in 2 steps; first saponification with NaOH, then hydrogenation in the presence of 10 % Pd/C. This dicarboxylic acid is first


converted to its disodium salt, then is reacted with $PtCl_2(NH_3)_2$ according to the previously reported procedure (U.S. Patent No. 4,657,729) to give carboplatin analog **14-12**. The reaction between **14-12** and phosphonate carboxylic acid, HOAt, and DIC gives **14-13** (an example of **14-2**, where X = $-CH_2-$). The reductive amination of **14-12** with aldehyde phosphonate, $NaBH_3CN$, and AcOH affords the desired compound **14-14** (an example of **14-3**, where X = $-CH_2CH_2-$). The hydroxymethyl phosphonate is activated with triphosgene to form chloroformate derivative, which is reacted with compound **14-12** in the presence of TEA to furnish the desired product **14-15** (an example of **14-5**, where X = $-CH_2-$).

Scheme **14.4**




Diethyl 3-oxocyclobutane-1,1-dicarboxylate (*J. Med. Chem.* **1990**, *33*, 2905) is saponified with sodium hydroxide, then reacted with hydroxylamine hydrochloride in the presence of TEA to yield the oxime intermediate **14-17**. The oxime dicarboxylic acid is treated with sodium hydroxide (to form the disodium salt), then is reacted with $PtCl_2(NH_3)_2$ according to previous reported procedure (U.S. Patent No. 4,657,729) to give carboplatin derivative **14-18**. Compound **14-18** is readily converted to analog **14-33**. An example of **14-4**, phosphonate **14-19** is prepared by treating **14-12** with NaH and a triflated phosphonate (Scheme **14.4**).

Scheme **14.5**



In Scheme **14.5**, diethyl 3-hydroxycyclobutane-1,1-dicarboxylate (*J. Med. Chem.* **1990**, *33*, 2905) is saponified with sodium hydroxide and the disodium salt of the dicarboxylic acid is reacted with $PtCl_2(NH_3)_2$ according to the previously reported procedure (U.S. Patent No. 4,657,729) to afford the 3-hydroxy carboplatin analog **14-22**. This analog is readily converted to **14-6** by the reaction with a triflated phosphonate. Hydroxyl **14-22** is converted to analog **14-7** by the activation of the hydroxyl group, followed by reaction with an aminophosphonate. 3-Hydroxycyclobutane-1,1-dicarboxylic acid **14-21** is oxidized to its 3-oxo derivative and can be further converted to **14-23** and **14-24**. Compound **14-23** is reacted with $PtCl_2(NH_3)_2$ according to the previously reported procedure (U.S. Patent No. 4,657,729), followed by hydrogenation and the reductive amination to furnish **14-9**. Compound **14-24** is converted to **14-8** in 3 steps, by hydrogenation, carboplatin formation, and reaction with an aminophosphonate.

Scheme **14.6**




As depicted in Scheme **14.6**, diethyl 3-hydroxycyclobutane-1,1-dicarboxylate (*J. Med. Chem.* **1990**, *33*, 2905) is saponified with sodium hydroxide. This dicarboxylic acid disodium salt is reacted with $PtCl_2(NH_3)_2$ according to previous reported procedure (U.S. Patent No. 4,657,729) gives the 3-hydroxy carboplatin analog **14-22**. This analog is readily to convert to **14-25** (an example of **14-6**, where X = $-CH_2-$) by the reaction with NaH and a triflated phosphonate. The activation of the hydroxyl group with *p*-nitrophenyl chloroformate gives **14-26**. The activated acid derivative **14-26** is reacted with aminoethyl phosphonate in the presence of TEA to afford the desired product **14-27** (an example of **14-7**, where X = $-CH_2CH_2-$). 3-Oxocyclobutane-1,1-dicarobxylic acid **14-35** is reacted with $Ph_3P{=}CHCHO$ or $PH_3P{=}CHCOOBn$ in CH_2Cl_2 to afford **14-33** and **14-24**, respectively. The disodium salt of compound **14-33** is reacted with $PtCl_2(NH_3)_2$ to form a carboplatin derivative, followed by hydrogenation in the presence of 10 % Pd/C to reduce the double bond, and

reductive amination with aminoethyl phosphonate, $NaBH_3CN$, and AcOH affords the desired **14-28** (an example of **14-9**, where X = $-CH_2CH_2-$). The disodium salt of compound **14-33** is reacted with $PtCl_2(NH_3)_2$ followed by the reductive amination with aminoethyl phosphonate, $NaBH_3CN$, and AcOH to furnish **14-29** (an unsaturated analog of **14-28**). Compound **14-30** is synthesized from **14-24** by the hydrogenation in the presence of 10 % Pd/C followed by the reaction with $PtCl_2(NH_3)_2$, and the reaction with aminoethyl phosphonate, DIC, AcOH (an example of **14-8**, where X = $-CH_2CH_2-$).

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 15: Preparation of exemplary compounds of the present invention

Scheme **15.1**




15-1

(Exemestane)




15.2

Scheme **15.2**



Phosphonate analogs **15-2** are readily prepared from 1-alkanoyloxymethyl steroid **15-3** (U.S. Patent No. 4,591,585), as illustrated in Scheme **15.2**. The introduction of methylene group at position 6 can be accomplished according to the method reported in literature (*Synthesis* **1982**, 34). Hydrolysis of **15-4** affords the 1-hydroxymethyl steroid **15-5**. Alkylation of **15-5** with the phosphonate reagent affords desired compounds **15-2**.

Scheme **15.3**




Scheme **15.3** shows an example for the preparation of a phosphonate analog of exemestane. 1-Acetyloxymethyl steroid **15-6** is treated with formaldehyde acetal, phosphorus oxychloride and sodium acetate in chloroform

to give 6-methylene compound **15-7**. Hydrolysis of **15-7** with sodium hydroxide give 1-hydroxymethyl steroid **15-5**. Alkylation of **15-5** with phosphonate triflate afford desired product **15-8**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 16: Preparation of exemplary compounds of the present invention

Scheme **16.1**



16-1 (Atamestane) **16-2**


Scheme **16.2**



16-3 **16-4** **16-2**

Phosphonate analogs **16-2** are readily prepared from 1-acetyloxymethyl steroid **16-3** (U.S. Patent No. 4,591,585), as illustrated in Scheme **16.2**. Hydrolysis of **16-3** give 1-hydroxymethyl steroid **16-4**. Alkylation of **16-4** with the phosphonate reagent affords desired compounds **16-2**.

Scheme **16.3**




Scheme **16.3** shows an example for preparation of phosphonate analog of atamestane. 1-Acetyloxymethyl steroid **16-3** is hydrolized with sodium hydroxide to give 1-hydroxymethyl steroid **16-4**. Alkylation of **16-4** with a phosphonate triflate afford desired product **16-5**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.


Example 17: Preparation of exemplary compounds of the present invention

Scheme **17.1**




Exemplary compounds of the invention are illustrated above.

Scheme **17.2**




As illustrated in Scheme **17.2**, phosphonate analogs of type **17-2** are readily prepared from epirubicin (**17-1**) via reductive alkylation of the amine with phosphonate aldehydes.

Scheme **17.3**




For example (Scheme **17.3**), reductive alkylation of epirubicin **17-1** with aldehyde **17-15** (*Synth. Commun.* **1992**, *22*, 2219) give desired compound **17-5**.

Scheme **17.4**




As illustrated in Scheme **17.4**, phosphonate analogs of type **17-3** are readily prepared from protected epirubicin **17-6** (accessible by the methods reported in *J. Org. Chem.* **1997**, *42*, 3653) via alkylation with appropriate phosphonate reagent.

Scheme **17.5**




For example (Scheme **17.5**), alkylation of tri-protected epirubicin **17-7** with phosphonate triflate, followed by basic (0.1N sodium hydroxide) and acidic (80% acetic acid) deprotection, afford compound **17-8**.

Scheme **17.6**



As illustrated in Scheme **17.6**, phosphonate analogs of type **17-4** are readily prepared from epirubicin intermediate **17-9** (accessible by the methods reported in *J. Med. Chem.* **1985**, *28*, 1223) via a displacement of the leaving group X with appropriate nucleophiles.

Scheme **17.7**




For example (Scheme **17.7**), reaction of bromide **17-11** with phosphonate amine, followed by a deprotection, affords desired product **17-12**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in phosphonate interconversion section herein.


Example 18: Preparation of exemplary compounds of the present invention

Scheme **18.1**




Exemplary compounds of the invention are illustrated above.

Scheme **18.2**




As illustrated in Scheme **18.2**, phosphonate analogs of type **18-2** are readily prepared from adriamycin **18-1** via reductive alkylation of the amine with phosphonate aldehydes.

Scheme **18.3**




For example (Scheme **18.3**), reductive alkylation of adriamycin **18-1** with aldehyde **18-15** (*Synth. Commun.* **1992**, *22*, 2219) give desired compound **18-5**.

Scheme **18.4**




As illustrated in Scheme **18.4**, phosphonate analogs of type **18-3** are readily prepared from protected adriamycin **18-6** (*J. Org. Chem.* **1997**, *42*, 3653) via alkylation with appropriate phosphonate reagent.

Scheme **18.5**




For example (Scheme **18.5**), alkylation of tri-protected adriamycin **18-7** with phosphonate triflate, followed by basic (0.1N sodium hydroxide) and acidic (80% acetic acid) deprotection, afford compound **18-8**.

Scheme **18.6**



As illustrated in Scheme **18.6**, phosphonate analogs of type **18-4** are readily prepared from adriamycin intermediate **18-9** (*J. Med. Chem.* **1985**, *28*, 1223) via a displacement of the leaving group X with appropriate nucleophiles.

Scheme **18.7**




For example (Scheme **18.7**), reaction of bromide **18-10** with phosphonate amine, followed by a deprotection, affords desired product **18-11**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in phosphonate interconversion section herein.


Example 19: Preparation of exemplary compounds of the present invention

Scheme **19.1**




19-1


(Taxotere)




19-2



19-3



19-4




1 A = O
2 A = NH

19-5


Exemplary compounds of the invention are illustrated above. Analogs of type **19-2**, **19-3** and **19-4** are readily prepared from taxotere **19-1**.

Scheme **19.2**




Direct alkylation of **19-1** with the phosphonate reagents give analogs of type **19-2** as major products (*Tetrahedron* **1993**, *49*, 2805). Selective protection of taxotere position at C-2' (*J. Org. Chem.* **1995**, *60*, 761) give **19-6**, which are then alkylated with the phosphonate reagents, followed by deprotection, to afford analogs of type **19-3** and **19-4**.

Scheme **19.3**



For example (Scheme **19.3**), treatment of taxotere **19-1** with *tert*-butyldimethylsilyl chloride and triethylamine in DMF give mono-TBS protected taxotere **19-7**. Alkylation of **19-7** with phosphonate triflate, followed by deprotection with tetrabutylammonium fluoride, afford desired product **19-9** and **19-8**. Direct alkylation of taxotere **19-1** with phosphonate triflate can afford analogs of type **19-2**.


Scheme **19.4**



As illustrated in Scheme **19.4**, analogs of type **19-5** can be obtained from taxotere analogs **19-12**, which are accessible from β-lactam **19-10** and baccatin

III (**19-11**) according to the methods reported in literature (*Bioorg. Med. Chem. Lett.* **1994**, *4*, 479; *Synlett* **1992**, 761).

Scheme **19.5**




For example (Scheme **19.5**), using 4-nitrobenzaldehyde (in place of benzaldehyde) as starting material, β-Lactam **19-14** is prepared by literature procedure (*Synlett* **1992**, 761). Reaction of **19-14** with baccatin III **19-15** in the presence of 4-dimethylaminopyridine affords compound **19-16**. Reduction of **19-16** with zinc in acetic acid affords amino compound **19-18**. Alkylation of **19-18** with a phosphonate triflate reagent produces desired compound **19-17**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the phosphonate interconversion section herein.

Example 20: Preparation of exemplary compounds of the present invention

Scheme **20.1**




Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.


As illustrated in Scheme **20.2**, phosphonate analogs of type **20-2**, **20-3** and **20-4** are readily prepared from taxol **20-1**. Direct alkylation of **20-1** with the phosphonate reagents gives analogs of type **20-2** as major products (*Tetrahedron*, (1993), *49*, 2805). Selective protection of taxol at C-2' position (*J. Org. Chem.* (1995), *60*, 761) give 7, which are then alkylated with the phosphonate reagents, followed by deprotection, to afford analogs of type **20-3**. Full protection of taxol at position C-2' and C-7 give **20-8**, then the C-10 hydroxyl of **20-8** is revealed and alkylated with the phosphonate reagents, followed by deprotection, to furnish analogs of type **20-4**. For example (Scheme **20.3**), treatment of taxol **20-1** with excess of *tert*-butyldimethylsilyl chloride and triethylamine in DMF gives bis-TBS protected taxol 8a. Treatment of 8a with

hydrazine in ethanol gives compound **20-11** (*J. Org. Chem.* (1995), *60*, 761). Alkylation of **20-11** with phosphonate triflate, followed by deprotection with tetrabutylammonium fluoride, afford desired product **20-10**.

Scheme **20.2**




Scheme **20.3**




As illustrated in Scheme **20.4**, analogs of type **20-5** can be obtained from taxol analogs **20-14**, which are accessible from β-lactam **20-12** and baccatin III (**20-13, 20-16**) according to the methods reported in literature (*Bioorg. Med. Chem. Lett.* (1994), *4*, 479; *Synlett.* (1992), 761). For example (Scheme **20.5**), using 4-nitrobenzoyl chloride (instead of benzoyl chloride) as starting material, β -Lactam **20-15** is prepared by literature procedure (*Synlett.* (1992), 761). Reaction of **20-15** with baccatin III in the presence of 4-dimethylaminopyridine give compound **20-17**. Reduction of **20-17** with zinc in acetic acid affords amino compound **20-19**. Alkylation of **20-19** with phosphonate triflate reagent produces desired compound **20-18**.

Scheme **20.4**




Scheme **20.5**




As shown in Scheme **20.6** and Scheme **20.7**, analogs of type **20-6** can be prepared in the same fashion as type **20-5**.

Scheme **20.6**




Scheme **20.7**



Example 21: Preparation of exemplary compounds of the present invention


Scheme **21.1**



Further manipulations are performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.


As illustrated in Scheme **21.2**, the strategy for the synthesis of phosphonate analogs of type **21-2** is first to introduce the phosphonate moiety into catharanthine **21-5** to give **21-7**, which then is connected to vindoline **21-10** and converted into final compounds **21-2** using the same methods used in the synthesis of vinorelbine (Bioorg. Med. Chem. Lett. (2002), 12, 505; *Tetrahedron* (1980), *36*, 3053).

Scheme **21.2**



For example (Scheme **21.3**), catharanthine **21-5** is hydrolyzed with sodium hydroxide to give **21-6**. Coupling of **21-6** with phosphonate amine affords **21-9**. The conversion of **21-9**and vindoline **21-10** into compound **21-11** is accomplished by sequential treatments of 3-chloroperoxybenzoic acid (mCPBA), trifluoroacetic anhydride (TFAA) and sodium borohydride. Treatment of **21-11** with N-bromosuccinimide (NBS), followed by silver tetrafluoroborate, affords desired compound **21-12**.


Scheme **21.3**



21-5 **21-6** **21-9** **21-10** **21-11** **21-12**


As illustrated in Scheme **21.4**, a similar strategy is used in the synthesis of phosphonate analogs of type **21-3**. The phosphonate moiety is first introduce into vindoline **21-10** to give **21-14**, which then is connected to catharanthine **21-5** and converted into final compounds **21-3** using the same methods used in the synthesis of vinorelbine.

Scheme **21.4**



For example (Scheme **21.5**), hydrolysis of vindoline **21-10** with sodium hydroxide, followed by reprotection of the hydroxyl, gives **21-20**. Coupling of **21-20** with phosphonate amine affords **21-15**. Finally, **21-15** and **21-5** are converted to desired product **21-17** in the same manner as described above.


Scheme **21.5**




As illustrated in Scheme **21.6**, phosphonate analogs of type **21-4** are readily prepared from vinorelbine **21-1**. Hydrolysis of **21-1** gives **21-18**, which is then alkylated with phosphonate reagents to afford analogs of type **21-4**.

For example (Scheme **21.7**), treatment of **21-1** with sodium methoxide in anhydrous methanol results in compound **21-18**. Alkylation of **21-18** with phosphonate triflate in the presence of sodium hydride affords desired compound **21-19**.

Scheme **21.6**




Scheme **21.7**




Example 22: Preparation of exemplary compounds of the present invention

Scheme **22.1**




Compounds such as these can be made according to the general route outlined in Schemes **22.2-22.3**, with examples depicted in Schemes **22.4-22.6**.


Scheme **22.2**: Modification of the sugar substituent



Scheme **22.3**: Attachment to the epi-podophyllotoxin core




Scheme **22.4**: Modification of the 4,6 glucose acetal moiety



The glucose derived starting material is synthesized from glucose and benzyl glyoxylate (*J. Org. Chem.*, (2002), *67*, 5408-5411) according to the methods described in *Chem. Lett.*, (1987), 799-802. The glycosidation reaction is performed with 4'chloroacetyl protected epipodophyllotoxin (described in the reference above) under catalysis of boron trifluoride (described in the reference above). The product of this reaction is dissolved in an organic solvent such as ethyl acetate and is hydrogenated in the presence of Pd/C under an atmosphere of hydrogen. The crude reaction mixture is filtered through Celite and the solvent is removed in vacuo. The crude reaction product is dissolved in an organic solvent such as DMF or chloroform and is then treated at a temperature of ~ -10 °C with a tertiary amine base such as diisopropylethylamine (DIEA) and isobutyl chloroformate. After the activation is complete, 2-aminoethylphosphonic acid diethyl ester is added. After all starting material is consumed the reaction mixture is washed with aqueous 0.1 M HCl and aqueous bicarbonate solution. After drying and removal of the solvent the crude product of the coupling is obtained. Further purification is achieved by chromatography. The material is dissolved in an organic solvent such as methanol and is treated with zinc acetate at reflux temperature. At the end of the reaction, the mixture is cooled to room temperature and the solvent is removed in vacuo. The crude

reaction product is dissolved in an organic solvent such as chloroform and the solution is washed with aqueous 0.1 M HCl and aqueous bicarbonate solution. After drying and removal of the solvent the crude final product is obtained. Further purification is achieved by chromatography.


Scheme **22.5**: Modifications of the glucose core



22-10 **22-11**

The starting material (synthesis according to *Chem. Lett.*, (1987), 799-804) is treated in an organic solvent such as DCM or THF with diethyl phosphonato ethyl carbaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Further purification is achieved by chromatography.

Scheme **22.6**: Attachment to the epi-podophyllotoxin core



22-12 **22-13**


The amine containing starting material (obtained as described in *J. Med. Chem.*, (1991), *34*, 3346-3350.) is treated in an organic solvent such as DCM or THF with diethylphosphonato-ethylcarbaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Further purification is achieved by chromatography.

All final products are converted to the corresponding 4' phosphate analogs via treatment of these compounds with phosphoryl trichloride in an organic solvent such as MeCN in the presence of an tertiary organic amine base such as DIEA, followed by treatment with aqueous bicarbonate solution as described in *Bioorg. Med. Chem. Lett.*, (1994), *21*, 2567-2572. Final purification is achieved by chromatography.

Example 23: Preparation of exemplary compounds of the present invention


Compounds such as these are made according to the general route outlined in Schemes **23.1-23.6**, with examples depicted in Schemes **23.7-23.12**.

Scheme **23.1**: Modification at C4




23-1 23-2

Scheme **23.2**: Attachment to C23




23-3 **23-4**

Scheme **23.3**: Attachment to N1




23-5 **23-6**

Scheme **23.4**: Attachment to C4'




23-7 **23-8**

Scheme **23.5**: Attachment to C12'




23-7 23-10

Scheme **23.6**: Attachment to C22'



23-11 23-12

Scheme **23.7**: Attachment to C4




23-13 23-14

2-Diethyl phosphonatoacetic acid dissolved in an organic solvent such as benzene, tetrahydrofuran (THF), or chloroform, is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and is stirred at room temperature according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, 4-deacetylvinblastine (prepared from vinblastine according to *J. Med. Chem.*, (2002), *45*, 4706-4715) is added, and the reaction mixture is heated to ~ 80 °C for ~ 4 hrs (*Biochemistry* (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature and is washed with aqueous hydrochloric acid (HCl)

(1N) and aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as acetonitrile and the solution is cooled to – 20°C. A strong inorganic acid such as perchloric acid (2 equiv) is added, followed by ferrous perchlorate and hydrogen peroxide (excess), according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990). At the end of the reaction aqueous ammonium hydroxide is added and the reaction mixture is extracted with an organic solvent such as dichloromethane (DCM). Removal of solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Scheme **23.8**: Attachment to C23



23-15 23-16


The starting material (synthesis published in *J. Med. Chem.*, (1978), 21, 88-96; from vinblastine) is treated in an organic solvent such as DCM or THF with 2-aminoethylphosphonic acid diethyl ester at room temperature, according to the procedure described in *J. Med. Chem*, (1979), 22, 391-400. At the end of the reaction, the solution is washed with water, aqueous bicarbonate and water, and is dried. Evaporation of solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added, followed by acetic anhydride, and the reaction is stirred at room temperature according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as DCM,

washed with water and aqueous bicarbonate solution and dried. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as acetonitrile and the solution is cooled to – 20°C. A strong inorganic acid such as perchloric acid (2 equiv) is added, followed by ferrous perchlorate and excess hydrogen peroxide, according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990). At the end of the reaction aqueous ammonium hydroxide is added and the reaction mixture is extracted with an organic solvent such as DCM. Removal of solvents in vacuo yields the crude product. Further purification is achieved by chromatography.


Scheme **23.9**: Attachment to N1



2-Diethyl phosphonatoacetic acid is dissolved in an organic solvent such as benzene, THF, or chloroform, and is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and is stirred at room temperature, according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, N-1-(β-hydroxyethylthiomethyl)vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in The Alkaloids, Vol. 37, 145, Academic Press San Diego, (1990), from vinblastine via CrO_3-mediated oxidation in the presence of methanol and subsequent methoxy displacement with β-hydroxy thioethanol) is added, and the reaction mixture is heated to ~ 80°C for ~ 4 hrs (*Biochemistry* (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature, washed with aqueous HCl (1N) and aqueous

bicarbonate solution, and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

Scheme **23.10**: Attachment to C4'




23-7 23-21

Vinblastine and diethyl (cyanomethyl)phosphonate (commercially available) are dissolved in conc. sulfuric acid at a temperature of ~ 0°C, according to a procedure from Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990) (described for acetonitrile). When the starting material is consumed the reaction mixture is carefully diluted with water and further neutralized. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as acetonitrile and the solution is cooled to – 20°C. A strong inorganic acid such as perchloric acid (2 equiv) is added, followed by ferrous perchlorate and excess hydrogen peroxide, according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990). At the end of the reaction aqueous ammonium hydroxide is added and the reaction mixture is extracted with an organic solvent such as DCM. Removal of solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Scheme **23.11**: Attachment to 12'




C12'-Iodo-vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990), by iodination of vinblastine with ferrous perchlorate, tetra(*n*-propyl)ammonium periodinate and a catalytic amount of ruthenium dioxide) is added to a mixture of copper(I) iodide and potassium phosphate and 2-aminoethylphosphonic acid diethyl ester (commercially available). The reaction mixture is heated under an inert gas atmosphere to ~ 80°C, according to a procedure from Buchwald in *Org. Lett.*, (2002), *4*, 581-584. At the end of the reaction the material is cooled to room temperature and the solvent is removed in vacuo. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed with aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography. The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added, followed by acetic anhydride, and the reaction is stirred at room temperature according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as DCM and is washed with water and aqueous bicarbonate solution and is dried. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as acetonitrile and the solution is cooled to – 20°C. A strong inorganic acid such as perchloric acid (3 equiv) is added, followed by ferrous perchlorate and excess hydrogen peroxide, according to Pearce, "Medicinal Chemistry of Bisindole

Alkaloids from Catharanthus", *in The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990). At the end of the reaction aqueous ammonium hydroxide is added and the reaction mixture is extracted with an organic solvent such as DCM. Removal of solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Scheme **23.12**: Attachment to 22'



The starting material (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990), by exhaustive hydrolysis of vinblastine in NaOH (5N) under refluxing conditions) is dissolved in an organic solvent such as dimethylformamide (DMF) at room temperature. Methyl iodide (1 equiv) is added, followed by potassium carbonate. Stirring at room temperature is continued. At the end of the reaction, the reaction is filtered and the solvent is removed in vacuo. The desired C24 methyl ester is purified by chromatography. The product of step 1 is dissolved in an organic solvent such as DCM or DMF and the solution is cooled to $-10^{\circ}C$. A tertiary amine base such as DIEA is added, followed by a coupling reagent such as *iso*-butylchloroformate. Stirring at $-10^{\circ}C$ is continued until the activation is complete. Aminoethylphosphonic acid diethyl ester is added and stirring with slow warming to $0^{\circ}C$ is continued. At the end of the reaction, the solution is warmed to room temperature and the solvent is removed in vacuo. The product is further purified by chromatography. The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added, followed by acetic anhydride, and the reaction is stirred at room temperature according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The


crude material is dissolved in an organic solvent such as DCM, washed with water and aqueous bicarbonate solution, and dried. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as acetonitrile and the solution is cooled to – 20°C. A strong inorganic acid such as perchloric acid (2 equiv) is added, followed by ferrous perchlorate and excess hydrogen peroxide, according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990). At the end of the reaction aqueous ammonium hydroxide is added and the reaction mixture is extracted with an organic solvent such as DCM. Removal of solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Example 24: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared according to the general route outlined in Schemes **24.1** and **24.3**, with examples depicted in Schemes **24.2** and **24.4**.

Scheme **24.1**




24-1 **24-2**

Scheme **24.2**



The 2-chloro-2'-deoxyadenosine **24-1** (prepared according to the procedure of Ikehara, M. et al., *J. Am. Chem. Soc.*, (1963), *85*, 2344, also see Ikehara, M. et al., *J. Am. Chem. Soc.*, (1965), *87*, 3, 606) can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **24-2, 24-3**.


Scheme **24.3**



The preparation of compound **24-7, 24-13** is described in Scheme **24.3**. Compound **24-1** (2-chloro-2'-deoxyadenosine) can be prepared as described in Ikehara, M. et al., *J. Am. Chem. Soc.*, (1963), *85*, 2344; see also Ikehara, M. et al., *J. Am. Chem. Soc.*, (1965), *87*, 3, 606. Oxidation of the 5'-OH followed by elimination provides glycal **24-4** (see the procedure of Zemlicka J. et al., *J. Am.*

Chem. Soc., (1972), *94*, 9, 3213). Protection of the chloroadenine at the 6 position followed by selenoetherification provides the protected phosphonate **24-5, 24-10** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642) followed by stereoselective dihydroxylation provides the diol which can then be converted to the 3' monoprotected sugar. Acylation of the 2' alcohol with phenyl chlorothionoformate provides the precursor for Robins deoxygenation. Subsequent deoxygenation provides compound **24-6, 24-12** (Metteucci, M. D. et al., *Tetrahedron Lett.*, (1987), *28*, 22, 2469, see also Robins, M. J. et al., *J. Org. Chem.*, (1995), *60*, 7902). Finally, the protecting groups are removed.

Scheme **24.4**



24-1 **24-8** **24-4** **24-10** **24-11** **24-12** **24-13**


Specifically, 2-chloro-2'-deoxyadenosine, compound **24-1** can be oxidized with PtO_2 to provide carboxylic acid **24-8**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in DMF at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213).

Once the furanoid glycal **24-4** is in hand, it is first protected at the 6-position of the 2-chloroadenosine using PivCl conditions as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, 1999. Treatment of the protected glycal with silver perchlorate in the presence of diethyl(hydroxymethyl)phosphonate (Phillion, D. et al., Tetrahedron Lett., 1986, 27, 1477) provides the phosphonate **24-5, 24-10** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides a diol which can be monoprotected at the 3' position using a THP group. Further acylation of the 2' alcohol with phenyl chlorothionoformate provides the precursor for Robins deoxygenation, performed with tributyltin hydride, to give compound **24-6, 24-12** (Metteucci, M. D. et al., *Tetrahedron Lett.*, (1987), *28*, 22, 2469, also see Robins, M. J. et al., *J. Org. Chem.*, (1995), *60*, 7902). Deprotection of the pivaloyl group by treatment with sodium methoxide (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)) is followed by a final deprotection of the THP group in acetic acid.

Example 25: Preparation of exemplary compounds of the present invention


Compounds such as these can be made according to the general route outlined in Schemes **25.1-25.5**, with specific examples depicted in Schemes **25.2-25.5.** Final compounds, be they diastereoisomers or enantiomers, may be purified by chromatographic means.

Scheme **25.1**: General access to all compound classes



25-1 25-2


Scheme **25.2**:



25-1 **25-3**

The starting carboxylic acid can be treated in a solvent such as dimethylformamide (DMF) or N-methyl pyrrolidinone (NMP) with a coupling reagent such as diethyl cyanophosphonate or *iso*butyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 2-aminoethylphosphonic acid diethyl ester (commercially available) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **25.3**:




25-1 **25-4**

The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, (2-amino-ethylsulfanylmethyl)-phosphonic acid diethyl ester (made by base-catalyzed coupling of 2-aminoethanethiol with diethyl phosphonomethyltriflate, prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The intermediate is then dissolved in a


mixture of water, DMF, and acetic acid and is treated with hydrogen peroxide solution (excess). After removal of the solvents the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **25.4**:



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604.). When the activation is complete, (*L*)-2-amino-6-(diethylphosphonato)-hexanoic acid is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **25.5**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 4-amino-4-(diethylphosphonato)-butyric acid tert butylester (*J. Am. Chem. Soc.*, (1995), *117*, 10879-10888) is added. After consumption of the activated species is observed the solvent is removed in vacuo

and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The crude intermediate is then dissolved in DMF and treated with trifluoroacetic acid (TFA). The product is isolated via chromatography after removal of the solvents. Alternatively, the product can be isolated through precipitation form the reaction solution with an organic solvent like diethyl ether or the like.

Example 26: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general route outlined in Schemes **26.1-26.5**, with specific examples depicted in Schemes 2 - 4. Final compounds, be they diastereoisomers or enantiomers, may be purified by chromatographic means.


Schemes **26.1**: General access to all compound classes



26-1 26-2

In case a direct coupling to aminopterin is hampered by the presence of a free secondary amine in the starting material (R = H), this entity is temporarily protected either with a tert-butoxycarbonyl group (R = Boc) or benzyloxycarbonyl (R = Cbz or Z) according to standard procedures (Green Wutts: Protective groups in organic chemistry)

Scheme **26.2**:




26-1 26-3

The starting carboxylic acid can be treated in a solvent such as dimethylformamide (DMF) or N-methylpyrrolidinone (NMP) with a coupling reagent such as diethyl cyanophosphonate or *iso*butyl chloroformate and a base

such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 2-aminoethylphosphonic acid diethyl ester (commercially available) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

In case R = Z: The compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed by filtration and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

Scheme **26.3**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, (2-amino-ethylsulfanylmethyl)-phosphonic acid diethyl ester (made by base-catalyzed coupling of 2-aminoethanethiol with diethyl phosphonomethyltriflate, prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The intermediate is then dissolved in a mixture of water, DMF, and acetic acid and is treated with hydrogen peroxide

solution (excess). After removal of the solvents the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

In case R = Z: The compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed by filtration and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.


Scheme **26.4**:



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604.). When the activation is complete, (*L*)-2-amino-6-(diethylphosphonato)-hexanoic acid is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

In case R = Z: The compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed by filtration and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

Scheme **26.5**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 4-amino-4-(diethylphosphonato)-butyric acid tert butylester (*J. Am. Chem. Soc.*, (1995), *117*, 10879-10888) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The crude intermediate is then dissolved in DMF and treated with TFA (excess). The product is isolated via chromatography after removal of the solvents. Alternatively, the product can be isolated through precipitation form the reaction solution with an organic solvent such as diethyl ether or the like.

In case R = Z: The compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

Example 27: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general routes outlined in Schemes **27.1** and **27.3**, with exemplifications in Scheme **27.2** and Schemes **27.4-27.6**.

Scheme **27.1**




27-1 27-2

The bis-anisole derivative of flavopiridol (see *Bioorg. Med. Chem. Lett.*, (2000), *10*, 1037) serves as an ideal starting point for attachment of a phosphonate moiety to the piperidine nitrogen. Following protection of the alcohol, the tertiary amine is demethylated and derivatized with the reagent of choice. Removal of the methyl ethers and the protecting group on the alcohol gives the desired analogs.

An example of an alvocidib analog with a phosphonate moiety linked to the piperidine nitrogen in this manner is illustrated in Scheme **27.2**.

Scheme **27.2**




27-1 27-3

The alcohol is protected as the acetate under standard conditions (see Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)). Demethylation of the N-methylpiperidine is achieved through reaction with α-chloroethyl chloroformate in the presence of a base such as *N,N*-diisopropylethylamine (DIEA) followed by brief heating in acidic methanol. The liberated secondary amine is condensed with (2-oxo-ethyl)-phosphonic acid diethyl ester under reductive conditions such as those achieved through the use of sodium cyanoborohydride in a solvent such as methanol or dimethylformamide (see *Tet. Lett.* (1990), *31*, 5595). The alcohol is de-acetylated by treatment with sodium ethoxide in ethanol. Finally, bis-

demethylation is achieved by heating with pyridinium hydrochloride (see *Bioorg. Med. Chem. Lett.*, (2000), *10*, 1037).

Scheme **27.3**




27-4 27-5

The 2-hydroxyacetophenone (see *Bioorg. Med. Chem. Lett.*, (2000), *10*, 1037) is treated with a suitable phosphonate-bearing benzoyl chloride derivative. The flavone ring system is formed by cyclization, and the methyl groups are removed.

Such a synthesis is exemplified in Scheme **27.4**.


Scheme **27.4**



27-4 27-6

Condensation with [4-(2-chlorocarbonyl-phenoxy)-but-2-enyl]-phosphonic acid diethyl ester (synthesis below) is followed by successive treatment with sodium hydride, hydrochloric acid and sodium carbonate, generating the 5,7-dimethoxyflavone. Demethylation to provide the 5,7-dihydroxyflavone final product is achieved as in Scheme **27.2** (see *Bioorg. Med. Chem. Lett.*, (2000), *10*, 1037).

Scheme **27.5**. Synthesis of [4-(2-chlorocarbonyl-phenoxy)-but-2-enyl]-phosphonic acid diethyl ester




27-7 27-8

Salicylic acid methyl ester is treated in a solvent such as dimethylformamide or tetrahydrofuran with a base such as sodium hydride. When bubbling ceases, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The resulting monobromide is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. The methyl ester is saponified with lithium hydroxide and the acid chloride generated by treatment with oxalyl chloride in a solvent such as dichloromethane in the presence of a catalytic amount of dimethylformamide.

A synthesis of another suitable acid chloride is exemplified below.

Scheme **27.6**



27-9 27-10


The phenol is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester.

Similarly, a reagent suitable for generating an analog with a phosphonate moiety attached to the 4-position of the phenyl ring at the flavone 2-position may be generated from 4-hydroxybenzoic acid methyl ester.


Example 28: Preparation of exemplary compounds of the present invention

Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of vinblastine which, upon cleavage inside the target cell, give rise to an agent with an increased intracellular half-life. Such compounds are described below.


Scheme **28.1**




28-1




28-2




28-3



28-4



28-5




28-6

L = linker; 1-8 atoms in length; 2-4 preferred


Compounds such as these can be made according to the general route outlined in Schemes **28.2-28.7**, with examples depicted in Schemes **28.8-28.13**.

Scheme **28.2**: Modification at C4




28-7 28-8

Scheme **28.3**: Attachment to C23




28-9 28-10

Scheme **28.4**: Attachment to N1




28-11 28-12

Scheme **28.5**: Attachment to C4'




28-13 28-14

Scheme **28.6**: Attachment to C12'




28-13 28-15

Scheme **28.7**: Attachment to C22'



28-16 28-17


Scheme **28.8**: Attachment to C4



28-7 28-18

2-Diethyl phosphonatoacetic acid is dissolved in an organic solvent such as benzene, tetrahydrofuran (THF), or chloroform, and is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and is stirred at room temperature, according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, 4-deacetyl vinblastine (prepared according to *J. Med. Chem.*, (2002), *45*, 4706-4715 from vinblastine) is added and the reaction mixture is heated to ~ 80 °C for ~ 4 hours (*Biochemistry*, (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature and is washed with aqueous hydrochloric acid (HCl) (1N) and aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

Scheme **28.9**: Attachment to C23




28-19 28-20

The starting material (synthesis published in *J Med. Chem.*, (1978), 21, 88-96; from vinblastine) is treated in an organic solvent such as dichloromethane (DCM) or THF with 2-aminoethylphosphonic acid diethyl ester at room temperature, according to the procedure described in *J. Med. Chem*, (1979), 22, 391-400. At the end of the reaction, the solution is washed with water, aqueous bicarbonate and water, and is dried. Evaporation of solvents yields the crude product. Further purification is achieved by chromatography.


The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added followed by acetic anhydride and the reaction is stirred at room temperature, according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as DCM and is washed with water and aqueous bicarbonate solution and is dried. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Scheme **28.10**: Attachment to N1



2-Diethyl phosphonatoacetic acid is dissolved in an organic solvent such as benzene, THF, or chloroform, and is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and stirred at room temperature, according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, N-1-(β-hydroxyethylthiomethyl)vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids* Vol. 37, 145, Academic Press San Diego, (1990), from vinblastine, via CrO_3-mediated oxidation in the presence of methanol and consecutive methoxy displacement with β-hydroxy thioethanol) is added, and the reaction mixture is heated to ~ 80 °C for ~ 4 hrs (*Biochemistry* (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature and is washed with aqueous HCl (1N) and aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.


Scheme **28.11**: Attachment to C4'



Vinblastine and diethyl cyanomethylphosphonate (commercially available) are dissolved in conc. sulfuric acid at a temperature of ~ 0 °C, according to a procedure from Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus" in *The Alkaloids* Vol. 37, 145, Academic Press

San Diego, (1990). When the starting material is consumed, the reaction mixture is carefully diluted with water and further neutralized. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed with aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

Scheme **28.12**: Attachment to 12'




28-21 28-22

C12'-Iodo-vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids* Vol. 37, 145, Academic Press San Diego, (1990), by iodination of vinblastine with ferrous perchlorate, tetra(*n*-propyl)ammonium periodinate and a catalytic amount of ruthenium dioxide) is added to a mixture of copper(I) iodide and potassium phosphate and 2-aminoethylphosphonic acid diethyl ester (commercially available). The reaction mixture is heated under an inert gas atmosphere to ~ 80 °C, according to a procedure from Buchwald in *Org. Lett.*, (2002), *4*, 581-584. At the end of the reaction the material is cooled to room temperature and the solvent is removed in vacuo. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed with aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography. The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added, followed by acetic anhydride, and the reaction is stirred at room temperature according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as DCM and washed with water and aqueous bicarbonate solution and dried.

Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Scheme **28.13**: Attachment to 22'




The starting material (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids* Vol. 37, 145, Academic Press San Diego, (1990), by exhaustive hydrolysis of vinblastine in NaOH (5N) under refluxing conditions) is dissolved in an organic solvent such as dimethylformamide (DMF) at room temperature. Methyl iodide (1 equiv) is added, followed by potassium carbonate. Stirring at room temperature is continued. At the end of the reaction, the reaction is filtered and the solvent is removed in vacuo. The desired C24 methyl ester is purified by chromatography. The product of step 1 is dissolved in an organic solvent such as DCM or DMF and the solution is cooled to $-10^{\circ}C$. A tertiary amine base such as DIEA is added, followed by a coupling reagent such as *iso*-butylchloroformate. Stirring at $-10^{\circ}C$ is continued until the activation is complete. Aminoethylphosphonic acid diethyl ester is added and stirring with slow warming to $0^{\circ}C$ is continued. At the end of the reaction, the solution is warmed to room temperature and the solvent is removed in vacuo. The product is further purified by chromatography. The product of this step is dissolved in an organic solvent such as DCM or THF. Pyridine is added, followed by acetic anhydride, and the reaction is stirred at room temperature according to *J. Med. Chem.*, (1979), *22*, 391-400. At the end of the reaction, methanol is added and the solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as DCM and washed with water and aqueous bicarbonate solution and dried. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.

Example 29: Preparation of exemplary compounds of the present invention

Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of tipifarnib which, upon cleavage inside the target cell, give rise to an agent with an increased intracellular half-life. Such compounds are described below.


Scheme **29.1**




Link is 1-8 atoms, with 2-6 preferred

Compounds such as these can be made according to the general routes outlined in Schemes **29.2**, **29.4**, **29.6**, **29.8** and **29.10**, with specific exemplifications illustrated in Schemes **29.3**, **29.5**, **29.7**, **29.9** and **29.11**.

Scheme **29.2**




Scheme **29.3**



29-7 29-8


The quinolone (see U.S. Patent No. 5,968,952) is treated in a solvent such as dimethylformamide (DMF) or tetrahydrofuran (THF) with a base such as potassium carbonate. *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The bromide is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. Subsequently, the tertiary alcohol is converted via the chloride to the amine using methods described in *Bioorg. Med. Chem. Lett.*, (2003), *13*, 1543. The desired enantiomer is isolated by chromatography or by classical resolution using a chiral acid such as camphor sulfonic acid.

Scheme **29.4**



29-9 29-2

Scheme **29.5**




29-9 29-11

The N-methylquinolone (see U.S. Patent No. 5,968,952, made by treating the starting material in Scheme **29.3** with methyl iodide and potassium carbonate


in a solvent such as DMF) is treated with the lithiated imidazole shown (made from 1-(3-tetrahydropyranyloxy)propyl)imidazole by successive treatment with n-butyl lithium, chlorotriethylsilane, and n-butyl lithium; see in *Bioorg. Med. Chem. Lett.*, (2003), *13*, 1543). After hydrolysis of the ether protecting group, the liberated primary alcohol is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester. Subsequently, the tertiary alcohol is converted via the chloride to the amine using methods described in *Bioorg. Med. Chem. Lett.*, (2003), *13*, 1543. The desired enantiomer is isolated by chromatography or by classical resolution using a chiral acid such as camphor sulfonic acid.

Scheme **29.6**



29-12 29-3


Scheme **29.7**




29-13 29-14

The primary amine is condensed with (2-oxo-ethyl)-phosphonic acid diethyl ester under reductive conditions such as those achieved through the use of sodium cyanoborohydride in a solvent such as methanol or dimethylformamide (see *Tet. Lett.* (1990) 31, 5595).

Scheme **29.8**




Scheme **29.9**




The quinolone (see *Bioorg. Med. Chem. Lett.*, (2003), *13*, 1543) is N-methylated under standard conditions such as by treatment with iodomethane and potassium carbonate in DMF, and treatment with boron tribromide liberates the phenol. This is alkylated as in Scheme **29.3** above, and the subsequent steps are also analogous.

Scheme **29.10**



Scheme **29.11**




5-Chloro-1-pentyne is treated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. This acetylene is coupled with the bromo-containing analog of tipifarnib shown (made as in *Bioorg. Med. Chem. Lett.*, (2003), *13*, 1543, but starting from 2-bromo-4-chloro-4'-nitrobenzophenone) under conditions such as those pioneered by Sonagashira (Sonagashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.*, (1975), 4467).

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.

Example 30: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared as generally described in Schemes **30.1-30.3**, with examples depicted in Schemes **30.4-30.6**.

Scheme **30.1**: Replacement of one amino substituent




30-1 30-2

Scheme **30.2**: Attachment at one secondary alkyl amine




30-3 30-4

Scheme **30.3**: Chain extension



30-1 30-5

Scheme **30.4**: Replacement of one amino substituent




30-1 30-6

The starting material (synthesis described in *J. Med. Chem.*, (1999), *42*, 3494-3501) is treated in an organic solvent such as tetrahydrofuran (THF) or dichloromethane (DCM) with diethyl phosphonato ethyl carbaldehyde (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Drying and removal of the solvent yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in trifluoroacetic acid (TFA) and is stirred at room temperature, according to *J. Med. Chem.*, (1999), *42*, 3494-3501. At the end of the reaction, benzene is added and the solvents are removed in vacuo. The crude material is sufficiently pure for the next step.

The crude material is dissolved in a mixture of *N*, *N*, *N'*, *N'* tetramethylethylenediamine, water and *N*-(β-hydroxyethyl)-*N*-(β-aminoethyl) amine, and the mixture is heated to reflux for several hours, according to a procedure from *J. Med. Chem.*, (1999), *42*, 3494-3501. At the end of the reaction, chloroform is added and the reaction mixture is washed with diluted aqueous hydrochloric acid and water and is dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.


Scheme **30.5**: Attachment at one secondary alkyl amine



30-7 30-8

Mitoxantrone is treated in an organic solvent such as THF or DCM with diethyl phosphonato ethyl carbaldehyde (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Drying and removal of the solvent yields the crude product. Further purification is achieved by chromatography.

Scheme **30.6**: Chain extension



The starting material (synthesis described in *J. Med. Chem.*, (1999), *42*, 3494-3501) is treated in an organic solvent such as THF or DCM with chloroacetaldehyde (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Drying and removal of the solvent yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as dimethylformamide or acetonitrile. 3-Aminopropyl phosphonic acid diethyl ester is added, followed by potassium carbonate and sodium iodide. The reaction mixture is heated to an elevated temperature of ~ 50 - 60 °C. At the end of the reaction, the mixture is cooled to room temperature. Chloroform is added and the reaction mixture is washed with diluted aqueous hydrochloric acid and water. Drying and removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in trifluoroacetic acid (TFA) and is stirred at room temperature, according to *J. Med. Chem.*, (1999), *42*, 3494-3501. At the end of the reaction, benzene is added and the solvents are removed in vacuo. The crude material is sufficiently pure for the next step.


The crude material is dissolved in a mixture of *N*, *N*, *N'*, *N'* tetramethylethylenediamine, water, and *N*-(β-hydroxyethyl)-*N*-(β-aminoethyl) amine, and the mixture is heated to reflux for several hours, according to a procedure from *J. Med. Chem.*, (1999), *42*, 3494-3501. At the end of the reaction, chloroform is added and the reaction mixture is washed with diluted aqueous hydrochloric acid and water and is dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.

Example 31: Preparation of exemplary compounds of the present invention


Compounds of the invention can generally be prepared as described in Schemes **31.1-31.6**, with examples depicted in Schemes **31.7-31.12**.

Scheme **31.1**: Modification at C4




31.1 31-2

Scheme **31.2**: Attachment to C23




31-3 31-4

Scheme **31.3**: Attachment to N1




31-5 31-6

Scheme **31.4**: Attachment to C4'




31-1 31-7

Scheme **31.5**: Attachment to C12'




31-8 31-9

Scheme **31.6**: Attachment to C22'




31.1 31-10

Scheme **31.7**: Attachment to C4



2-Diethyl phosphonatoacetic acid is dissolved in an organic solvent such as benzene, tetrahydrofuran (THF), or chloroform, is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and is stirred at room temperature according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, vindesine is added and the reaction mixture is heated to ~ 80°C for ~ 4 hrs (*Biochemistry* (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature, washed aqueous HCl (1N) and aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.


Scheme **31.8**: Attachment to C23



The starting material (synthesis published in *J Med. Chem.*, (1978), 21, 88-96; from vinblastine) is treated in an organic solvent such as dichloromethane (DCM) or THF with 2-aminoethylphosphonic acid diethyl ester at room temperature, according to the procedure described in *J. Med. Chem*, (1979), 22,

391-400. At the end of the reaction, the solution is washed with water, aqueous bicarbonate and water, and is dried. Evaporation of solvents yields the crude product. Further purification is achieved by chromatography.

Scheme **31.9**: Attachment to N1




31-18 31-20

2-Diethyl phosphonatoacetic acid is dissolved in an organic solvent such as benzene, THF, or chloroform, and is combined with a tertiary amine base such as di*iso*propylethylamine (DIEA) and diphenyl phosphorazidate (1.2 equiv) and stirred at room temperature according to *J. Med. Chem.*, (1991), *34*, 1001-1018. After the acyl azide has been formed, N-1-(β-hydroxyethylthiomethyl)vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990), from vinblastine via CrO_3-mediated oxidation in the presence of methanol and subsequent methoxy displacement with β-hydroxythioethanol) is added, and the reaction mixture is heated to ~ 80°C for ~ 4 hrs (*Biochemistry* (2002), *41*, 14010-14018). The reaction mixture is cooled to room temperature, washed with aqueous hydrochloric acid (HCl) (1N) and aqueous bicarbonate solution, and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an anhydrous organic solvent such as methanol and dry liquid ammonia is added. The reaction mixture is heated in sealed reaction vessel to an elevated temperature of ~ 100°C, according to a procedure from *J. Med. Chem.*, (1978), *21*, 88-96. At the end of the reaction, the mixture is cooled to room temperature and the solvents are removed in vacuo. Further purification is achieved by chromatography.


Scheme **31.10**: Attachment to C4'



31-1 31-19

Vindesine and diethyl (cyanomethyl)phosphonate (commercially available) are dissolved in conc. sulfuric acid at a temperature of ~ 0°C, according to a procedure from Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press San Diego, (1990) (described for acetonitrile). When the starting material is consumed the reaction mixture is carefully diluted with water and further neutralized. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed with aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

Scheme **31.11**: Attachment to 12'




31-17 31-21

C12'-Iodo-vinblastine (prepared according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press, San Diego, (1990), by iodination of vinblastine with ferrous perchlorate, tetra(*n*-propyl)ammonium periodinate and a catalytic amount of ruthenium dioxide) is added to a mixture of copper(I) iodide and potassium phosphate and 2-aminoethyl phosphonic acid diethyl ester

(commercially available). The reaction mixture is heated under an inert gas atmosphere to ~ 80°C, according to a procedure from Buchwald in *Org. Lett.*, (2002), *4*, 581-584. At the end of the reaction the material is cooled to room temperature and the solvent is removed in vacuo. The crude reaction mixture is extracted with an organic solvent such as DCM. The combined organic extracts are washed with aqueous bicarbonate solution and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is dissolved in an anhydrous organic solvent such as methanol and dry liquid ammonia is added. The reaction mixture is heated in sealed reaction vessel to an elevated temperature of ~ 100°C , according to a procedure from *J. Med. Chem.*, (1978), *21*, 88-96. At the end of the reaction the mixture is cooled to room temperature and the solvents are removed in vacuo. Further purification is achieved by chromatography.

Scheme **31.12**: Attachment to 22'




Vindesine is suspended in aqueous sodium hydroxide (5N) and is heated to reflux for several hours, according to Pearce, "Medicinal Chemistry of Bisindole Alkaloids from Catharanthus", in *The Alkaloids*, Vol. 37, 145, Academic Press, San Diego, (1990) (described for vinblastine). At the end of the reaction, water is added and the reaction mixture is extracted with an organic solvent such as DCM or chloroform. The combined organic extracts are washed with brine and are dried. Removal of the solvent in vacuo yields the crude acid. Further purification is achieved by chromatography. The product of step 1 is dissolved in an organic solvent such as DCM or dimethylformamide and the solution is cooled to –10°C. A tertiary amine base such as DIEA is added,

followed by a coupling reagent such as *iso*-butylchloroformate. Stirring at –10°C is continued until the activation is complete. Aminoethylphosphonic acid diethyl ester is added and stirring with slow warming to 0°C is continued. At the end of the reaction, the solution is warmed to room temperature and the solvent is removed in vacuo. The product is further purified by chromatography.


Example 32: Preparation of exemplary compounds of the present invention

Scheme **32.1**



32-1 32-2


Scheme **32.2**




32-3 32-4

5-Chloro-1-pentyne is treated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press (1988) to generate the diethyl ester of the desired phosphonic acid. This acetylene is coupled with lonafarnib under conditions such as those pioneered by Sonagashira (Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.*, (1975), 4467).

Scheme **32.3**




Scheme **32.4**




The piperazine shown (see *J. Med. Chem.*, (1998), *41*, 4890) is acylated with an activated diethylphosphonoacetic acid to provide the desired amide linker compound, according to a procedure such as those reported in *J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604. The activated diethylphosphonoacetic acid is obtained by treatment in a solvent such as dimethylformamide with a coupling reagent such as diethyl cyanophosphonate and a base such as diisopropylethylamine at room temperature.

Scheme **32.5**




Scheme **32.6**




4-Allyl-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester is coupled with 2-aminoethylphosphonic acid diethyl ester (commercially available) using standard reagents for the formation of a secondary amide such as dicyclohexylcarbodiimide (DCC) and hydroxybenztriazole (HOBT), in a solvent such as dimethylformamide. The olefin is oxidized with ozone to produce the carboxylic acid, which is then coupled with the piperidine reagent shown (see *J. Med. Chem.*, (1998), *41*, 4890). Finally, the piperidine nitrogen is deprotected under standard conditions with trifluoroacetic acid, and the primary urea formed as described in see *J. Med. Chem.*, (1998), *41*, 4890.

Scheme **32.7**



Scheme **32.8**




4-Carboxymethyl-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester (commercially available) is mono-protected by treatment with acidic methanol. The remaining acid is coupled with 2-aminoethylphosphonic acid diethyl ester

(commercially available) using standard reagents for the formation of a secondary amide such as dicyclohexylcarbodiimide (DCC) and hydroxybenztriazole (HOBT), in a solvent such as dimethylformamide. The methyl ester is then saponified and coupled to the piperazine shown (see *J. Med. Chem.*, (1998), *41*, 4890). Finally, the piperidine nitrogen is deprotected under standard conditions with trifluoroacetic acid, and the primary urea formed as described in see *J. Med. Chem.*, (1998), *41*, 4890.


Example 33: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general route outlined in Schemes **33.1-33.4**, with examples depicted in Schemes **33.5-33.8**.


Scheme **33.1**: Modification of the phenol substituent




Scheme **33.2**: Modification of the amine substituent




Scheme **33.3**: Introduction of a further substituent



Scheme **33.4**: Modifications at the acridine core




Scheme **33.5**



Amsacrine can be treated in a solvent such as dimethylformamide (DMF), acetonitrile (MeCN), or dichloromethane (DCM) with excess iodotrimethylsilane, as described in *Synthesis*, (1985), 274. After quenching the reaction with aqueous sodium bicarbonate and extracting the product with an organic solvent such as ethyl acetate, the free alcohol can be further purified by chromatography. This material is then treated with *tert*-butoxycarbonyl anhydride in an organic solvent such as DMF and in the presence of a tertiary amine base such as pyridine (Green and Wutts: Protective Groups in Organic chemistry). The solvent is removed in vacuo and the product is further purified by chromatography. The alkoxide anion is then generated via treatment with

sodium hydride (NaH) (~ 1 equiv) in an organic solvent such as THF or DMF, and this is then treated with diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477). When the starting material is consumed, the reaction is quenched with water and the product is extracted with an organic solvent such as ethyl acetate. A final chromatographic purification may be included. The tert-butoxycarbonyl protecting group is removed with trifluoroacetic acid (TFA) in DCM according to standard procedures (Green and Wutts: Protective Groups in Organic chemistry).


Scheme **33.6**



33-12 **33-15**

Amsacrine is deprotonated by treatment with NaH (~ 1 equiv) in an organic solvent such as tetrahydrofuran (THF), and is then treated with diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) according to a procedure such as that reported in *J. Med. Chem.*, (2000), *43*, 489. When the starting material has been consumed, the reaction is quenched with water and the product is extracted with an organic solvent such as ethyl acetate. A final chromatographic purification may be included.


Scheme **33.7**



33-16 **33-17** **33-18**

2,5-Dinitrophenol is converted to the sodium salt in an appropriate organic solvent such as THF, by treatment with NaH. The salt is then reacted with carbon dioxide under Kolbe Schmitt conditions (*J. Chem. Soc.* (1954), 3145). The carboxylic acid product is then activated with a suitable coupling reagent such as isobutyl chloroformate in an organic solvent such as DMF and in the presence of a tertiary amine base such as *N,N*-diisopropylethylamine (DIEA) at reduced temperatures of ~ -10°C. The activated intermediate is then reacted with 2-aminoethylphosphonic acid diethyl ester and the reaction mixture is allowed to warm to 0°C and then to room temperature. The solvent is removed in vacuo, and the crude material is dissolved in an organic solvent such as ethyl acetate and washed with diluted hydrochloric acid. The product is purified, as necessary, by chromatography. The material is dissolved in an organic solvent such as THF and is treated with sodium carbonate and methyl iodide or dimethylsulfate. After the reaction is complete, the solids are removed by filtration and the filtrate is concentrated in vacuo. The product is purified, as necessary, by chromatography. This material is then dissolved in a solvent such as ethyl acetate or DMF and is hydrogenated with the aid of Pd/C under an atmosphere of hydrogen. The crude reaction mixture is filtered through Celite and the solvent is removed in vacuo. In case the product purity is not sufficient, further purification can be achieved by chromatography. The amine is then reacted in an organic solvent such as DMF in the presence of a tertiary amine base such as DIEA with 9-chloroacridine according to *J. Med. Chem.* (1999), *42*, 4741-4748. The solvent is removed in vacuo and the crude material is purified by chromatography. The product is then treated with methanesulfonyl chloride in an organic solvent such as DCM or THF in the presence of a tertiary amine base like DIEA. After removal of the solvent, the final product is isolated by chromatography.

Scheme **33.8**




33-19 33-20 33-21

The starting material in Scheme **33.8** is available according to *J. Med. Chem.* (1999), *42*, 4741-4748 via the reaction of the 9-oxoacridan-4-methyl-5-carboxylic acid chloride and 2-aminoethylphosphonic acid diethyl ester. This material is then treated with thionyl chloride to yield the corresponding 9-chloroacridine derivative as described in the above reference. The crude material is then dissolved in an organic solvent such as chloroform, DCM, or THF and treated with 2-methoxy-4-nitroaniline. The crude product is isolated via precipitation and can be further purified by chromatography. This material is dissolved in an organic solvent such as DMF and is reduced in the presence of Pd/C under an atmosphere of hydrogen. After filtration of the reaction mixture through Celite, the solvent is removed in vacuo. The product can be purified further by chromatography. This material is then dissolved in an organic solvent such as THF or chloroform and is treated with methanesulfonyl chloride in the presence of a tertiary amine base such as DIEA. After removal of the solvent, the final product is isolated by chromatography.

Example 34: Preparation of exemplary compounds of the present invention


Compounds such as these can be made according to the general routes outlined in Schemes **34.1-34.3**, with examples depicted in Schemes **34.4-34.6**.

Scheme **34.1**




34-1 34-2

Scheme **34.2**




34-1 34-3

Scheme **34.3**



34-1 34-4

Scheme **34.4**




34-1 34-5

CEP-701 can be treated in a solvent such as dimethylformamide or tetrahydrofuran with two equivalents of a base such as sodium hydride. When bubbling ceases, benzyl bromide is added in excess, yielding the doubly-

protected intermediate. After further treatment with a base such as magnesium *tert*-butoxide, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester. Final deprotection by hydrogenation over a catalyst such as palladium on charcoal in a solvent such as methanol as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999), provides the desired product.


Scheme **34.5**



34-1 34-6

CEP-701 can be treated in a solvent such as dimethylformamide or tetrahydrofuran with one equivalent of a base such as sodium hydride or cesium carbonate. Benzyl bromide is added, yielding the N-benzylated product. After further treatment with a base such as magnesium *tert*-butoxide, diethyl phosphonomethyltriflate is added, yielding the desired phosphonate diester. Final deprotection by hydrogenation over a catalyst such as palladium on charcoal in a solvent such as methanol utilizing the method described in Greene (see above) provides the desired product.

Scheme **34.6**



34-1 34-7


(4-Formyl-phenoxymethyl)-phosphonic acid diethyl ester is generated by treatment of 4-hydroxybenzaldehyde, in a solvent such as dimethylformamide or tetrahydrofuran, with a base such as sodium hydride and diethyl phosphonomethyltriflate. The product is condensed with CEP-701 in a solvent such as toluene, in the presence of a catalytic amount of *p*-toluenesulfonic acid, with azeotropic removal of the water so formed, yielding the desired acetal.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection

Example 35: Preparation of exemplary compounds of the present invention


Compounds such as these can be made according to the general route outlined in Schemes **35.1** and **35.3**, with examples depicted in Schemes **35.2** and **35.4**.

Scheme **35.1**



35-1 **35-2**

Scheme **35.2**




35-1 **35-3**

The appropriately protected 5-aza-2'-deoxycytidine, prepared according to the procedure of Winkley, M. W., Robins, R. K., *J. Org. Chem.*, (1970), *35*, 2,

491 (see also Ben-Hattar J., Jiricny, J. *J. Org. Chem.*, (1986), *51*, 3211), can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. Formation of the pivaloyl compound **35-1** can be accomplished by protecting 5-aza-2'-deoxycytidine with a pivaloyl group (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)). When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the protected product. The pivaloyl group can be removed with sodium ethoxide to provide the desired phosphonate diester **35-2, 35-3**.


Scheme **35.3**



The preparation of compound **35-9** is described in Scheme **35.3**. Compound **35-15** may be the pivaloyl protected 5-aza-2'-deoxycytidine which is described in Winkley, M. W., Robins, R. K., *J. Org. Chem.*, (1970), *35*, 2, 491 and Ben-Hattar J., Jiricny, J., *J. Org. Chem.*, (1986), *51*, 3211. Protection of the 5' hydroxyl group followed by protection of 2' alcohol provides compound **35-4**. Removal of the 5' protecting group provides the free primary alcohol. Corey's

one-step oxidation procedure (Corey, E. J. et al., *J. Org. Chem.*, (1984), *49*, 4735) can be utilized to transform the primary alcohol to the ester **35-6**. Deesterification, followed by oxidative decarbonylation using a modified Hunsdiecker reaction (Chu, C. K. et al., *Tetrahedron Lett.*, (1991), *32*, 3791) converts **35-7** to the acetate **35-8**. The stereochemistry of the Vorbruggen glycosylation under Lewis acid conditions is controlled by protecting group participation at the 4' position. A final deprotection provides the desired pro-drug **35-9**.

Scheme **35.4**




Specifically, compound **35-1** prepared by protection of 5-aza-2'-deoxycytidine (prepared as in Winkley, M. W., Robins, R. K., *J. Org. Chem.*, (1970), *35*, 2, 491 and Ben-Hattar J., Jiricny, J. *J. Org. Chem.*, (1986), *51*, 3211 using pivaloyl chloride, can be protected with a tert-butyldiphenylsilyl (TBDPS) group to provide the 5'-O-TBDPS analog. Further protection of the 3' alcohol with the benzoyl group provides compound **35-10** (Teng, K., Cook, D. *J. Org. Chem.* (1994), *59*, 278). Exposure of the fully protected compound **35-10** to HF-

pyridine reagent selectively deprotects the 5' hydroxyl group, which is then oxidized to the *t*-butyl ester using the Corey-Samuelsson oxidation (Corey, E. J., Samuelsson, B. *J. Org. Chem.*, (1984), *49*, 4735). Deesterification of the oxidized product using trifluoroacetic acid (TFA) provides compound **35-12**. Oxidative decarboxylation using a modified Hunsdiecker reaction (Chu, C. K. et al., *Tetrahedron Lett.*, (1991), *32*, 3791) converts the free acid to the acetate **35-13** which may be a mixture of anomers at 5'. While separation of the anomers may be achieved by column chromatography, it is not necessary to do so. The stereochemical outcome of a Vorbruggen glycosylation is controlled by the stereochemistry of the 4'-benzoyl group due to anchimeric assistance, rendering separation of the isomers is unnecessary. Vorbruggen glycosylation using hydroxymethylphosphonic acid diethyl ester proceeds to provide the protected phosphonate. Final saponification to remove the pivaloate and the benzoate groups completes the synthesis of compound **35-20** (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)).


Example 36: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general route outlined in Schemes **36.1-36.2**, with examples depicted in Schemes **36.3-36.5**.


Scheme **36.1**: Modification of the sugar substituent



Scheme **36.2**: Attachment to the epi-podophyllotoxin core




Scheme **36.3**: Modification of the 4,6 glucose-acetal moiety



The glucose derived starting material is synthesized from glucose and 5-bromomethylthiophene-2-carbaldehyde (available from 5-methylthiophene-2-carboxaldehyde and N-bromosuccinimide using a procedure from Organikum, 17th edition, page 167) according to the methods described in *Chem. Lett.*, (1987), 799-802. The glycosidation reaction is performed with 4'-chloroacetyl-protected epipodophyllotoxin (described in the reference above) under catalysis of boron trifluoride (described in the reference above). The product of this reaction is dissolved in an organic solvent such as methanol and is treated with zinc acetate at reflux temperature. At the end of the reaction, the mixture is

cooled to room temperature and the solvent is removed in vacuo. The crude reaction product is dissolved in an organic solvent such as chloroform and the solution is washed with aqueous 0.1 M HCl and aqueous bicarbonate solution. After drying and removal of the solvent the crude product is obtained. Further purification is achieved by chromatography. The crude reaction product is dissolved in an organic solvent such as dimethylformamide (DMF) or chloroform and is then treated at a temperature of ~ 40 °C with a base such as sodium carbonate and is reacted with aminoethyldiethylphosphonate. After all starting material is consumed the reaction mixture is washed with aqueous 0.1 M HCl and aqueous bicarbonate solution. After drying and removal of the solvent the crude product of the reaction is obtained. Further purification is achieved by chromatography.


Scheme **36.4**: Modifications of the glucose core



36-9 **36-10**

The starting material (synthesis according to *Chem. Lett.*, (1987), 799-804; from glucosamine and thiophene-2-carbaldehyde – commercially available) is treated in an organic solvent such as dichloromethane (DCM) or tetrahydrofuran (THF) with diethyl phosphonatoethylcarbaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Further purification is achieved by chromatography.

Scheme **36.5**: Attachment to the epi-podophyllotoxin core



36-11 **36-12**


The amine-containing starting material (obtained as described in *J. Med. Chem.*, (1991), *34*, 3346-3350) is treated in an organic solvent such as THF or DCM with diethyl phosphonatoethylcarbaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Further purification is achieved by chromatography.

All final products are converted to the corresponding 4'-phosphate analogs via treatment of these compounds with phosphoryl trichloride in an organic solvent such as acetonitrile in the presence of an tertiary organic amine base such as N,N-diisopropylethylamine, followed by treatment with aqueous bicarbonate solution as described in *Bioorg. Med. Chem. Lett.*, (1994), *21*, 2567-2572. Final product purification is achieved by chromatography.

Example 37: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general routes outlined in Schemes **37.1-37.5**.

Scheme **37.1**




Staurosporin

37-1 37-2

Staurosporin is acylated with activated benzoic acid derivatives such as benzoyl chlorides in a solvent such as chloroform, in the presence of a base such as *N,N*-diisopropylethylamine (DIEA) (*Bioorg. Med. Chem. Lett.*, (1994), *4*, 399). Examples of benzoyl chlorides for use in the synthesis of suitable phosphonate-containing midostaurin analogs are illustrated in Schemes **37.2**–**37.3** below.


Scheme **37.2**



37-3 37-4

4-Hydroxybenzoic acid methyl ester is treated with magnesium tert-butoxide and diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) in a solvent such as tetrahydrofuran. The resulting 4-(diethoxyphosphorylmethoxy)benzoic acid methyl ester is saponified with lithium hydroxide in ethanol, and the acid chloride is generated from the benzoic acid by reaction with oxalyl chloride in a solvent such as dichloromethane, catalyzed by dimethylformamide.


Scheme **37.3**



37-10 37-5

3-Hydroxybenzoic acid methyl ester is treated in a solvent such as dimethylformamide or tetrahydrofuran with a base such as sodium hydride. When bubbling ceases, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The bromide is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate 3-[4-(diethoxy-phosphoryl)-but-2-enyloxy]-benzoic acid methyl ester. The remaining steps are similar to those described in Scheme **37.2**.


Scheme **37.4**



37-1 Staurosporin 37-6

Alkylations on the secondary amine of staurosporine have been carried out under a variety of standard conditions: see *Bioorg. Med. Chem. Lett.*, (1994), *4*, 399. An example of the synthesis of a phosphonate-containing alkyl derivative is shown in Scheme **37.5**.

Scheme **37.5**




Staurosporin is alkylated with diethyl phosphonomethyltriflate in the presence of a base such as DIEA.

Example 38: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared as generally described in Schemes **38.1** and **38.4** and Schemes **38.2**, **38.3** and **38.5**.

Scheme **38.1**



Introduction of the phosphonate-bearing entity at the quinazoline 7-position is most conveniently achieved by alkylation of a suitably-protected 4-piperazinylquinazoline, prior to urea formation.


Scheme **38.2**



6,7-Dimethoxy-3,4-dihydroquinazolin-4-one is reacted with boron tribromide to give a mixture of mono-demethylated products. Although these may be separated by chromatography at this stage, the separation may be more conveniently achieved on the mixture of acetates that arises from reaction with and acetylating reagent such as acetyl chloride in the presence of a base such as pyridine. The desired isomer is reacted with thionyl chloride (see *Bioorg. Med. Chem. Lett.*, (2001), *11*, 1911) and the resulting 4-chloroquinazoline is treated with piperazine-1-carboxylic acid benzyl ester. The acetyl protecting group is removed under standard conditions such as by treatment with ammonia in methanol (see Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)) to generate Intermediate A.


Upon treatment with a base such as magnesium *tert*-butoxide and diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477), the phosphonate-bearing moiety is introduced at the quinazoline 7-position. Thereafter, removal of the benzyl carbamate protecting group by hydrogenation over a catalyst such as palladium on charcoal in a solvent such as methanol (see Greene, *ibid*) and condensation with 4-isopropoxyaniline (commercially available) and 4-nitrophenyl chloroformate provides the desired compound.

Scheme **38.3**




Intermediate A may be alkylated on the phenol by reaction with 4-(2-hydroxy-ethyl)-piperazine-1-carboxylic acid tert-butyl ester in the presence of an azodicarboxylate diester such as diisopropyl azodicarboxylate and triphenylphosphine, as described by Mitsunobu (*Bull. Chem. Soc. Japan.*, (1971), *44*, 3427). Following deprotection with trifluoroacetic acid, the liberated secondary amine is condensed with (2-oxo-ethyl)-phosphonic acid diethyl ester under reductive conditions such as those achieved through the use of sodium cyanoborohydride in a solvent such as methanol or dimethylformamide (see *Tet. Lett.* (1990), *31*, 5595). The remaining steps are similar to those described in Scheme **38.2**.

Scheme **38.4**



The route is similar to that shown in Schemes **38.1-38.3**, but exploits a selective demethylation at the 6-position of 6,7-dimethoxy-3,4-dihydroquinazolin-4-one (see *Bioorg. Med. Chem. Lett.*, (2001), *11*, 1911). A specific example of such a synthesis is shown in Scheme **38.5**.

Scheme **38.5**




Following the selective demethylation, the steps are similar to those discussed in previous examples up to the point where a phenol is alkylated. In this example, however, the alkylation is performed with *E*-1,4-dibromobutene, and the monobromide product is reacted with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. Thereafter, the steps are again similar to those described in previous examples.

Example 39: Preparation of exemplary compounds of the present invention

Compounds of the invention can be prepared as generally described in Schemes **39.1** and **39.3**, with exemplifications in Schemes **39.2** and **39.4**.


Scheme **39.1**



The coupling of an aniline with 2,3,4-trifluorobenzoic acid is performed in the presence of a large excess of a base such as lithium diisopropylamide in a solvent such as tetrahydrofuran, and at temperatures at or below ambient, as described in patent application WO 2001-U.S. Patent No.22948. The subsequent introduction of a phosphonate moiety may be achieved by a variety of means, such as those illustrated Scheme **39.2** below. Thereafter, the hydroxamic ester is


generated by treatment of the benzoic acid with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine and diisopropylethylamine in the presence of a coupling reagent such as benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) in a solvent such as tetrahydrofuran or dichloromethane, as described in patent application WO 2000-U.S. Patent No.18347 20000705, followed by treatment with ethanolic hydrochloric acid.

Scheme **39.2**




Having coupled 2,3,4-trifluorobenzoic acid with 2-iodo-5-nitroanisole (commercially available), the methyl ether is removed under standard conditions such as by treatment with hydrobromic acid in acetic acid (see Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)). The benzoic acid is esterified by dissolution in acidic methanol. The phenol is then treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester. Saponification of the benzoic acid (ready for coupling to form the hydroxamate ester – see Scheme **39.1**) is achieved with lithium hydroxide in a solvent such as tetrahydrofuran or ethanol.

Scheme **39.3**



The iodo substituent present in PD-184352 may be used for the introduction of a phosphonate-bearing moiety, as illustrated in Scheme **39.4** below.

Scheme **39.4**




5-Chloro-1-pentyne is treated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. This acetylene is coupled with **39.5** under conditions such as those pioneered by Sonagashira (Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.*, (1975), 4467).

Example 40: Preparation of exemplary compounds of the present invention


Compounds can be prepared as generally described in Schemes **40.1-40.5**, with specific examples depicted in Schemes **40.2-40.4**. Final compounds, be they diastereoisomers or enantiomers, may be purified by chromatographic means.

Scheme **40.1**: General access to all compound classes



In case a direct coupling to aminopterin is hampered by the presence of a free secondary amine in the starting material (R = H), this entity will be temporarily protected either with a tert-butoxycarbonyl group (R = Boc) or benzyloxycarbonyl (R = Cbz or Z) according to standard procedures (Green Wutts: Protective groups in organic chemistry).

Scheme **40.2**: Specific example for class A




40-1 40-3

The starting carboxylic acid can be treated in a solvent such as dimethylformamide (DMF) or N-methylpyrrolidinone (NMP) with a coupling reagent such as diethyl cyanophosphonate or *iso*butyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 2-aminoethylphosphonic acid diethyl ester (commercially available) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

When R = Z, the compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.


Scheme **40.3**: Second specific example for class A



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, (2-amino-ethylsulfanylmethyl)-phosphonic acid diethyl ester (made by base-catalyzed coupling of 2-aminoethanethiol with diethyl phosphonomethyltriflate, prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like. The intermediate is then dissolved in a mixture of water, DMF, and acetic acid and is treated with hydrogen peroxide solution (excess). After removal of the solvents the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

When R = Z, the compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.


Scheme **40.4**



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604.). When the activation is complete, (*L*)-2-amino-6-(diethylphosphonato)-hexanoic acid is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

When R = Z, the compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.

Scheme **40.5**



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 4-amino-4-(diethylphosphonato)-butyric acid tert butylester (*J. Am. Chem. Soc.*, (1995), *117*, 10879-10888) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The crude intermediate is then


dissolved in DMF and treated with TFA (excess). The product is isolated via chromatography after removal of the solvents. Alternatively, the product can be isolated through precipitation form the reaction solution with an organic solvent such as diethyl ether or the like.

When R = Z, the compound is dissolved in an organic solvent like DMF or NMP and a catalytic amount of Pd/C is added. The reaction mixture is stirred under an atmosphere of hydrogen until the starting material is consumed. The Pd/C is removed and the solvent is evaporated in vacuo. The product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent such as diethyl ether or the like.


Example 41: Preparation of exemplary compounds of the present invention

Compounds of the invention can be made according to the general route outlined in Scheme **41.1-41.5**, with specific examples depicted in Schemes **41.2 – 41.4**. Final compounds, be they diastereoisomers or enantiomers, may be purified by chromatographic means.

Scheme **41.1**: General access to compounds of the invention




Scheme **41.2**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or *iso*butyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 2-aminoethylphosphonic acid diethyl ester (commercially available) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **41.3**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, (2-amino-ethylsulfanylmethyl)-phosphonic acid diethyl ester (made by base-catalyzed coupling of 2-aminoethanethiol with diethyl phosphonomethyltriflate, prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The intermediate is then dissolved in a mixture of water, DMF, and acetic acid and is treated with hydrogen peroxide solution (excess). After removal of the solvents the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **41.4**:



The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604.). When the activation is complete, (*L*)-2-amino-6-(diethylphosphonato)-hexanoic acid is added. After consumption of the activated species is observed the solvent is removed in vacuo and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **41.5**:




The starting carboxylic acid can be treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 4-amino-4-(diethylphosphonato)-butyric acid tert butylester (*J. Am. Chem. Soc.*, (1995), *117*, 10879-10888) is added. After consumption of the activated species is observed the solvent is removed in vacuo and the intermediate is isolated via chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The crude intermediate is then dissolved in DMF and treated with TFA (excess). The product is isolated via

chromatography after removal of the solvents. Alternatively, the product can be isolated through precipitation form the reaction solution with an organic solvent like diethyl ether or the like

Example 42: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared as generally described in Scheme **42.1**, with an example depicted in Scheme **42.2**.

Scheme **42. 1**



Preparation of a specific pro-drug of tacedinaline is shown in Scheme **42.1**. The synthesis is planned so that attachment of the pro-drug moiety is performed late in the synthesis. Reduction of the nitro group allows for completion of the synthesis. A number of methods are reported in literature for such a reduction; hydrogenation, Raney Nickel and tin chloride dihydrate are a few of these (Suzuki, T. et al., *J. Med. Chem.*, (1999), *42*, 3001).

Scheme **42.2**




Preparation of a specific pro-drug linked tacedinaline is shown in Scheme **42.2** in more detail. Compound **42-1** can be prepared according to U.S. Patent No. 5,137,918. Compound **42-1** is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **42-2, 42-5**. Reduction of the nitro group is accomplished by hydrogenation or Raney Nickel conditions to provide the desired pro-drug.


Example 43: Preparation of exemplary compounds of the present invention

Compounds of the invention can be prepared as generally described in Scheme **43.1**, with examples depicted in Scheme **43.2**.

Scheme **43.1**



Scheme **43.2**




5-Nitro-isobenzofuran-1,3-dione (commercially available) is converted to 5-amino-2-(2,6-dioxo-piperidin-3-yl)-isoindole-1,3-dione following the procedures reported in *Bioorg. Med. Chem. Lett.*, (1999), *9*, 1625. This amine intermediate is subjected to a reductive amination with diethylphosphonoacetaldehyde (obtained from ozonolysis of diethyl allylphosphonate) in the presence of a reducing agent such as sodium triacetoxyborohydride to generate the desired amine linker analog (*J. Org. Chem.*, (1996), *61*, 3849). Alternatively, the amine is acylated with an activated diethylphosphonoacetic acid to provide the desired amide linker compound, according to a procedure such as those reported in *J. Med. Chem.*, (1982), *25*, 960 and *J. Med. Chem.*, (1984), *27*, 600. The activated diethylphosphonoacetic acid can be obtained by treatment in a solvent such as dimethylformamide with a coupling reagent such as diethyl cyanophosphonate and a base such as diisopropylethylamine at room temperature.

2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid (commercially available) is treated in a solvent such as acetonitrile with triethylamine, 1-hydroxybenzotriazole, 4-methoxybenzylamine, and 1,3-dicyclohexylcarbodiimide. After the reaction is complete, the solvent is removed and the residue is purified by chromatography to generate the desired analog, according to a procedure such as that reported in *J. Med. Chem.*, (2003), *46*, 3793.


Example 44: Preparation of exemplary compounds of the present invention

Compounds of the invention can be prepared as generally described in Scheme **44.1**, with an example depicted in Scheme **44.2**.

Scheme **44.1**



Scheme **44.2**




Synthesis of the pro-drug of TLK-286 is shown in Schemes **44.1** and **44.2**. With two carboxylic acids present in the pro-drug moiety, mixtures of coupled product are separated by HPLC, to provide the desired product. Aminoethyl diethyl phosphonate is commercially available from Fluka as the oxalate salt which can be freed using triethyl amine in the reaction medium. Peptide coupling reactions are typically run in dimethylformamide (DMF) with addition of dichloromethane. Carbodiimide coupling reagents may be used in the presence of dimethylaminopyridine to speed up the reaction. Prevention of racemization may be achieved using hydroxybenztriazole (HOBt).

Example 45: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared as generally described in Schemes **45.1-45.2**, with examples depicted in Scheme **45.3**.

Scheme **45.1**: Modification of one aminoethyl substituent




45-1 45-2

Scheme **45.2**: Quaternization at the pyridine moiety



45-1 45-3


Scheme **45.3**: Modification at the aminoethyl substituent



45-1 45-6

Pixantrone is treated in an organic solvent such as tetrahydrofuran (THF) or dichloromethane (DCM) with (2-oxoethyl)phosphonic acid diethyl ester (1 equiv.) and sodium triacetoxyborohydride, as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Separation of the product, the other regioisomer, and bis-alkylated material is achieved by chromatography.

Scheme **45.4**: Modifications of the pyridine moiety




Pixantrone is dissolved in an organic solvent such as dimethylformamide (DMF), THF, or chloroform and is treated with tert-butoxycarbonyl anhydride according to standard literature procedures (Greene, T.W.: Protective groups in organic chemistry, Wiley-Interscience, (1999). The solvents are removed in vacuo. The crude material is dissolved in an organic solvent such as chloroform and the solution is washed with aqueous 0.1 N HCl and aqueous bicarbonate solution. The solution is dried and the solvent is removed in vacuo. As needed the product is further purified by chromatography. The product of step 1 is dissolved in an organic solvent such as DMF, and bromoacetic acid (1 equiv.) is added. The solution is heated at an elevated temperature such as 50-70 °C under an atmosphere of an inert gas like nitrogen. When the reaction is complete, the solvent is removed in vacuo and the product is further purified by chromatography. This material is dissolved in an organic solvent such as chloroform or DMF and is reacted with 2-aminoethylphosphonic acid diethyl ester (commercially available) in the presence of a coupling reagent such as dicyclohexylcarbodiimide (DCC), an organic tertiary amine base such as diisopropylethylamine (DIEA), and a catalytic amount of N,N-dimethylaminopyridine (DMAP). At the end of the reaction, the reaction mixture is filtered and the solvent is removed in vacuo. The crude material is dissolved in DCM and treated with trifluoroacetic acid at room temperature according to the standard (Greene, T.W.: Protective groups in organic chemistry, Wiley-Interscience (1999). At the end of the reaction the solvents are removed

in vacuo to yield the crude final product, which is further purified by chromatography.

Example 46: Preparation of exemplary compounds of the present invention


Compounds of the invention can be prepared as generally described in Schemes **46.1** and **46.3**, with examples depicted in Schemes **46.2** and **46.4**.

Scheme **46.1**



46-1 **46-2**

Scheme **46.2**




46-3 **46-4**

The appropriately protected 2'-deoxycoformycin prepared according to U.S. Patent No. 3,923,785 (also reported in Chan, E. et al., *J. Org. Chem.*, (1982), *47*, 3457) can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. Formation of the fully protected compound **46-1**, **46-3** can be accomplished utilizing (8R)-6-(t-butoxycarbonyl)-8-[(t-butyldimethylsilyl)oxy]-3,6,7,8-tetrahedroimidazo[4,5-d]-[1,3]diazapine, prepared by Truong, T. V. et al. *J. Org. Chem.* (1993), *58*, 6090,

through the Vorbruggen glycosylation reaction as described in Chan, E. et al., *J. Org. Chem.*, (1982), *47*, 3457. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **46-1**, **46-3**.

Scheme **46.3**




46-1 **46-5** **46-6** **46-7** **46-8** **46-9**

The preparation of compound **46-9** is described in Scheme **46.3**. Compound **46-1**, (8-(tert-butyl-dimethyl-silanyloxy)-3-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7,8-dihydro-3H-imidazo[4,5-d][1,3]diazepine-6-carboxylic acid tert-butyl ester) can be prepared as described in Truong, T. V. et al. *J. Org. Chem.*, (1993), *58*, 6090 and Chan, E. et al., *J. Org. Chem.*, (1982), *47*, 3457. Oxidation of the 5'-OH followed by elimination of the carboxylic acid provides glycal **46-5** (see the procedure of Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Selenoetherification provides the protected phosphonate **46-6** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642).

Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642) followed by stereoselective dihydroxylation provides the diol, which can then be converted to a monotetrahydropyran protected compound **46-7**. Acylation of the 2' alcohol with phenyl chlorothionoformate provides the precursor for Robins deoxygenation. Subsequent deoxygenation provides compound **46-8** (Metteuci, M. D. et al. *Tetrahedron Lett.*, (1987), *28*, 22, 2459, also see Robins, M. J. et al. *J. Org. Chem.*, (1995), *60*, 7902). The order of formation of the 3' protected alcohol and thiocarbonate formation can also be reversed if the first protection proceeds exclusively at the 2' position. In that case, the 2' thiocarbonate is formed first, followed by protection of the 3' hydroxyl group and a final Robins deoxygenation. Trifluoroacetic acid (TFA)-mediated deprotection removed all three protecting groups to provide compound **46-9**.

Scheme **46.4**




Specifically, compound **46-3** (Truong, T. V. et al., *J. Org. Chem.*, (1993), *58*, 6090 and Chan, E. et al., *J. Org. Chem.*, (1982), *47*, 3457) is oxidized with PtO_2 to provide carboxylic acid **2.2**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in DMF at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Once the furanoid glycal **46-11** is in hand, it is treated with phenylselenyl chloride to perform the selenoetherification followed by treatment with silver perchlorate in the presence of diethyl(hydroxymethyl)phosphonate (Phillion, D. et al., *Tetrahedron Lett.*, (1986), *27*, 1477) to give phosphonate **46-12** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides a diol, which is converted to the mono-protected tetrahydropyranyl ether compound **46-13**. Acylation of the 2' alcohol with phenyl chlorothionoformate provides the precursor for Robins deoxygenation, which is performed with tributyltin hydride to give compound **46-14** (Metteuci, M. D. et al., *Tetrahedron Lett.*, (1987), *28*, 22, 2459, also see

Robins, M. J. et al., *J. Org. Chem.*, (1995), *60*, 7902). Removal of all the protecting groups is achieved using TFA to give compound **46-9** (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)).

Example 47: Preparation of exemplary compounds of the present invention


Compounds such as these can be made according to the general routes outlined in Schemes **47.1** and **47.3**, with examples depicted in Schemes **47.2** and **47.4**.

Scheme **47.1**



47-1 **47-2**

Scheme **47.2**




47-1 **47-3**

The N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)docosanamide (U.S. Patent No. 3,991,045, also see Akiyama, M. et

al., *Chem. Pharm. Bull.*, (1978), *26*, 3, 981) is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **47-2, 47-3**.


Scheme **47.3**



The preparation of compound **47-9** is described in Scheme **47.3**. Compound **47-1** is prepared according to U.S. Patent No. 3,991,045. Protection of the 5' hydroxyl group followed by protection of 2' and 3' alcohols provides compound **47-4**. Removal of the 5' protecting group provides the free primary alcohol precursor to the oxidation. Corey's one-step oxidation procedure (Corey, E. J. et al., *J. Org. Chem.*, (1984), *49*, 4735) can be utilized to transform the primary alcohol to the ester **47-6**. Deesterification followed by oxidative

decarbonylation using a modified Hunsdiecker reaction (Chu, C. K. et al., *Tetrahedron Lett.*, (1991), *32*, 3791) converts **47-7** to the acetate **47-8**. A Vorbruggen glycosylation using Lewis acid conditions is controlled by the protecting group participation at the 4' position. A final deprotection provides the desired prodrug **47-9**.

Scheme **47.4**




Specifically, compound **47-1**, N-(1-β-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)docosanamide (U.S. Patent No. 3,991,045) is selectively protected with a tert-butyldiphenylsilyl (TBDPS) group to provide the 5'-O-TBDPS analog. Further protection of the 3' and 4' alcohols as benzoate esters provides compound **47-10** (Teng, K., Cook, D. *J. Org. Chem.*, (1994), *59*, 278). Exposure of the fully protected compound **47-10** to HF-pyridine reagent selectively deprotects the 5' hydroxyl group which can then be oxidized to the *t*-butyl ester using the Corey-Samuelsson oxidation (Corey, E. J., Samuelsson, B. *J. Org. Chem.*, (1984), *49*, 4735). Deesterification of the oxidized product using

trifluoroacetic acid provides compound **47-13**. Oxidative decarboxylation using a modified Hunsdiecker reaction (Chu, C. K. et al., *Tetrahedron Lett.*, (1991), *32*, 3791) converts the free acid to the acetate **47-14** which may be a mixture of anomers at 5'. While separation of the anomers may be achieved by column chromatography, it is not necessary to do so. The stereochemical outcome of a Vorbruggen glycosylation is controlled by the stereochemistry of the 4'-benzoyl group due to anchimeric assistance, rendering separation of the isomers is unnecessary. Vorbruggen glycosylation using hydroxymethylphosphonic acid diethyl ester proceeds to provide the protected phosphonate. A final deprotection using hydrolysis conditions completes the synthesis of compound **47-15**.

Example 48: Preparation of exemplary compounds of the present invention


Compounds such as these are made according to the general route outlined in Schemes **48.1** and **48.3**, with examples depicted in Schemes **48.2** and **48.4**.

Scheme **48.1**



48-1 **48-2**


Scheme **48.2**



48-1 **48-3**

The appropriately protected 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine **48-1**, prepared according to U.S. Patent No. 5,034,518 (also described in WO 03011877) is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. Formation of the pivaloyl compound **48-1** is accomplished by protecting 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine with a pivaloyl group (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)). When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the protected product **48-2, 48-3**. The pivaloyl group is removed with sodium ethoxide to provide the desired phosphonate diester **48-2, 48-3**.

Scheme **48.3**




48-4 48-5 48-6 48-7 48-8

The preparation of compound **48-8** is described in Scheme **48.3**. Compound **48-4**, 9-(2-deoxy-α-D-ribofuranosyl)-2-fluoroadenine, is prepared as described in Montgomery, J. et al., *J. Med. Chem.*, (1969), *12*, 3, 498. Oxidation of the 5'-OH followed by elimination provides glycal **48-5** (see the procedure of Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Protection of the chloroadenine at the 6 position followed by selenoetherification provides the protected phosphonate **48-6** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642) followed by stereoselective dihydroxylation provides the diol which can then be converted to the 2' protected alcohol. Protection of the 3' alcohol followed by removal of the protecting group at the 2' hydroxyl group provides compound **48-7**. Fluorination and inversion of the stereochemistry at the 2' position can be simultaneously achieved by exposing the compound to dimethylaminosulfur trifluoroide (DAST) and pyridine (Pankiewicz, K. W. et al., *J. Org. Chem.*, (1992), *57*, 553, also see Pankiewicz,

K. W. et al., *J. Org. Chem.*, (1992), *57*, 7315). Finally, the protecting groups are removed to provide compound **48-8**.

Scheme **48.4**




Specifically, 9-(2-deoxy-α-D-ribofuranosyl)2-fluoroadenine, compound **48-4** (Montgomery, J. et. al., *J. Med. Chem.*, (1969), *12*, 3, 498), is oxidized with PtO_2 to provide carboxylic acid **48-9**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in dimethylformamide at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Once the furanoid glycal **48-5** is in hand, it is first protected at the 6-position of the 2-chloroadenosine with pivaloyl chloride, using conditions as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999). Treatment of the protected glycal with silver perchlorate in the presence of diethyl(hydroxymethyl)phosphonate (Phillion, D. et al., Tetrahedron Lett., (1986), 27, 1477) provides the phosphonate **48-10** (Kim, C. et al., *J. Org. Chem.*,

(1991), *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides a diol which can be turned into a mono protected acetate **48-12** by first silylating at the 2'-OH group, followed by protection of the 3' alcohol with an acetate group and subsequent deprotection of the silyl group. Conversion of the 2' alcohol to the 2' fluoride with the opposite stereochemistry can be performed with DAST (Pankiewicz, K. W. et al., *J. Org. Chem.*, (1992), *57*, 553, also see Pankiewicz, K. W. et al., *J. Org. Chem.*, (1992), *57*, 7315). Conditions that deprotect the pivaloyl group (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)) also remove the 3' acetate to provide compound **48-13**.

Example 49: Preparation of exemplary compounds of the present invention


Representative compounds of the invention can be made according to the general route outlined in Schemes **49.1** and **49.3**, with examples depicted in Schemes **49.2** and **49.4**.

Scheme **49.1**



49-1 **49-2**


Scheme **49.2**



49-3 **49-4**

The Boc-protected (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol, compound **49-1, 49-3**, is prepared by stirring the (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol (WO 9,919,338 and Evans, G. B. et al., *Tetrahedron*, (2000), *56*, 3053, also reported in Evans, G. B. et al., *J. Med. Chem.* (2003), *46*, 3412) with BOC anhydride as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999). Compound **49-1, 49-3** is then treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **49-2, 49-4** after deprotection of the BOC group using trifluoroacetic acid (TFA).


Scheme **49.3**



The preparation of compound **49-16** is described in Scheme **49.3**. Deprotected compound **49-5** ((1*R*)-1-(9-deazahypoxanthin-9-yl)-1,2,4-trideoxy-1,4-imino-D-*erythro*-pentitol, as the hydrochloride salt) is prepared as described in Evans, G. B. et al., *Tetrahedron*, (2000), *56*, 3053, using di-*t*-butyl dicarbonate in dichloromethane. Oxidation of the 5'-OH followed by elimination provides glycal **49-6** (see the procedure of Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Selenoetherification provides the protected phosphonate **49-7** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*,

(1991), *56*, 2642) followed by stereoselective dihydroxylation provides the desired diol **49-9**. Finally, the protecting group is removed.

Scheme **49.4**




Specifically, (1R)-1-(9-deazahypoxanthin-9-yl)-1,2,4-trideoxy-1,4-imino-D-*erythro*-pentitol, prepared as the HCl salt as described in Evans, G. B. et al., *Tetrahedron*, (2000), *56*, 3053, is first protected and then oxidized with PtO_2 to provide carboxylic acid **49-11**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in dimethylformamide at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Selenoetherification followed by treatment of the protected glycal with silver perchlorate in the presence of diethyl(hydroxymethyl)phosphonate (Phillion, D. et al., Tetrahedron Lett., 1986, 27, 1477) provides the phosphonate **49-13** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides diol **49-15**. Removal of the amine protecting group, according to the procedure of Greene,

T., Protective groups in organic synthesis, Wiley-Interscience, (1999), provides compound **49-16**.


Example 50: Preparation of exemplary compounds of the present invention

Scheme **50.1**




Compounds of the invention can be made according to the general route outlined in Schemes **50.2-50.4**, with examples depicted in Schemes **50.5-50.7**.


Scheme **50.2**: Modification at C10




Scheme **50.3**: Functionalization of the nitro group



Scheme **50.4**: Modification at C7




Scheme **50.5**: Modifications at C10




10-Hydroxycamptothecin (prepared according to *J. Org. Chem.*, (1995), *60*, 5739-5740 from camptothecin, which is commercially available) is dissolved in mixture of sulfuric acid and nitric acid under ice cooling. At the end of the reaction, the crude reaction solution is poured onto ice. The precipitate is collected and washed with water, cold ethanol, and diethyl ether. As needed the product is further purified by recrystallization (*J. Med. Chem.*, (2001), *44*, 1594-602). The product of step 1 is dissolved in an organic solvent such as tetrahydrofuran (THF), acetonitrile, or dimethylformamide (DMF) and is treated with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate ester. The product is further purified by chromatography.

Scheme **50.6**: Modifications of the nitro group at C9



Rubetican is dissolved in an organic solvent such as DMF or ethyl acetate and is hydrogenated in the presence of Pd/C under an atmosphere of hydrogen. At the end of the reaction, the crude suspension is filtered through Celite and the solvent is removed in vacuo. As needed the product is further purified by chromatography. The product of step 1 is dissolved in an organic solvent such as THF, acetonitrile, or DMF and is treated with (2-oxoethyl)phosphonic acid diethyl ester (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is collected as the resultant precipitate. The product is further purified by chromatography.

Scheme **50.7**: Modification at C7



10-Hydroxycamptothecin is converted to the corresponding C7 aldehyde according to literature protocols (*J. Med. Chem.*, (2000), *43*, 3963-3969). The product of this step is dissolved in an organic solvent such as THF, acetonitrile, or DMF and is treated with aminoethylphosphonic acid diethyl ester (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is purified by chromatography. The product of this step is dissolved in mixture of sulfuric acid and nitric acid under ice cooling. At the end of the

reaction, the crude reaction solution is poured onto ice. The precipitate is collected and washed with water, cold ethanol, and diethyl ether. As needed the product is further purified by recrystallization (*J. Med. Chem.*, (2001), *44*, 1594-602).


Further conversion to the C10 reduced product (according to *J. Med. Chem.*, (1991), *34*, 98-107).

The free C10 hydroxy compound synthesized above is dissolved in an organic solvent such as DMF under an inert gas atmosphere. A tertiary organic amine base such as 2,6 lutidine is added, followed by N-phenyltrifluoromethanesulfonimide. The reaction mixture is stirred at room temperature over night. When all starting material is consumed, a second tertiary organic amine base such as triethylamine is added followed by a palladium (II) species such as $Pd(OAc)_2$ and a phosphine such as triphenylphosphine, and concentrated formic acid. The reaction mixture is heated to an elevated temperature of approximately 60 °C. At the end of the reaction, the solvent is removed in vacuo and the crude product is triturated with a small amount of water and dried. The product is further purified by chromatography.

Example 51: Preparation of exemplary compounds of the present invention


Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of BAY-43-9006 which, upon cleavage inside the target cell, give rise to agents with increased intracellular half-lives. Such compounds are described below.

Scheme **51.1**




Compounds such as these are made according to the general routes outlined in Schemes **51.2, 51.4, 51.6** and **51.8**, with specific examples exemplified in Schemes **51.3, 51.5, 51.7** and **51.9**.

Scheme **51.2**



51-5 51-1


Scheme **51.3**



51-5 51-6

The acid is coupled with 2-aminoethylphosphonic acid diethyl ester (commercially available) using standard reagents for the formation of a secondary amide such as dicyclohexylcarbodiimide (DCC) and hydroxybenztriazole (HOBT), in a solvent such as dimethylformamide.

Scheme **51.4**



51-7 51-9 51-8


An aniline bearing a phosphonate moiety is coupled with 4-(4-aminophenoxy)-pyridine-2-carboxylic acid methylamide (U.S. Patent No. 2002/0165394) in the presence of a reagent such as phosgene, in a solvent such as toluene to form a urea (see *Bioorg. Med. Chem. Lett.*, (2001), *11*, 2775).

4-(4-Aminophenoxy)-pyridine-2-carboxylic acid methylamide is formed by alkylation of (4-hydroxypridine-2-carboxylic acid methylamide with 4-

fluoronitrobenzene with a base such as cesium carbonate in a solvent such as dimethylformamide, followed by reduction of the nitro group with tin(II) chloride in a solvent such as ethanol.

The synthesis of a suitable phosphonate-bearing aniline is illustrated in Scheme **51.5**.


Scheme **51.5**



51-10 **51-11**

2-Chloro-5-nitrophenol is alkylated with an excess of *E*-1,4-dibromobutene in a solvent such as dimethylformamide in the presence of a base such as potassium carbonate. The monobromide product is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988). Finally, the nitro group is reduced with tin(II) chloride in a solvent such as ethanol.


Scheme **51.6**



51-12 **51-13** **51-14**

4-Chloro-3-trifluoromethylaniline is coupled with a 4-phenoxy-substituted aniline bearing a phosphonate moiety in a manner similar to that shown in Scheme **51.4** to form a urea. The synthesis of a suitable phosphonate-bearing aniline is illustrated in Scheme **51.7**.


Scheme **51.7**



51-15 51-16

(3-Benzyloxy)phenol is treated with magnesium t-butoxide and diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) in a solvent such as tetrahydrofuran. The benzyl group is removed by hydrogenation over a catalyst such as palladium on charcoal in a solvent such as methanol as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999), and the resulting phenol is alkylated with 4-fluoronitrobenzene with a base such as potassium carbonate in a solvent such as dimethylformamide. Finally, the nitro group is reduced as in Scheme **51.5**.


Scheme **51.8**



51-17 51-18 51-4

4-Chloro-3-trifluoromethylaniline is coupled with a 4-phenoxy-substituted aniline bearing a phosphonate moiety in a manner similar to that shown in Scheme **51.4** to form a urea. The synthesis of a suitable phosphonate-bearing aniline is illustrated in Scheme **51.9**.

Scheme **51.9**




51-19 51-20

2-Chloro-5-nitrobenzoyl chloride is reacted with 2-aminoethylphosphonic acid diethyl ester. Thereafter, displacement of the chloride by reaction with 4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide in the presence of a base such as potassium carbonate in a solvent such as tetrahydrofuran generates the biaryl ether motif, and reduction of the nitro group as in previous examples reveals the aniline ready for coupling in the urea-forming step.


Example 52: Preparation of exemplary compounds of the present invention

Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of SAHA which, upon cleavage inside the target cell, give rise to agents with increased intracellular half-lives. Such phosphonate pro-drug compounds are described below.


Scheme **52.1**




52-1



52-2




52-3




52-4

Compounds such as these are made according to the general route outlined in Schemes **52.2** and **52.4**, with specific examples depicted in Schemes **52.3** and **52.5**.

Scheme **52.2**



Scheme **52.3**




The synthesis of pro-drug **52-3, 52-13** is shown in Scheme **52.2** (WO 118,171 and WO 03,032,921). A differentially-protected octanedioic acid (reported in U.S. Patent No. 23,232) can be monodeprotected to provide **52-6, 52-11**. Coupling of the monoacid with 4-aminophenol using standard peptide coupling conditions provides compound **52-7, 52-12**. Hydrolysis of the remaining ester, followed by formation of the protected hydroxamide, gives compound **52-9**. The phenolic moiety is utilized for attachment of the pro-drug unit late in the synthesis.

Specifically, octanedioic acid tert-butyl ester methyl ester is monodeprotected using trifluoroacetic acid (TFA) to provide compound **52-6, 52-11**. Coupling of the free acid to 4-(methylamino)phenol (Nag, A. et al., *Indian J. Chem. Sect. B.*, (1989), *64*, 1 as well as U.S. Patent No. 2,397,911) provides amide **52-7, 52-12**. Hydrolysis of the methyl ester can be achieved using LiOH to give the acid **52-8**. Formation of the TBDPS-protected hydroxamic acid is performed by peptide coupling conditions using TBDPSO-NH_2, a carbodiimide such as EDC, and N-N-dimethylaminopyridine to form compound **52-9**. Phenol **52-9** can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling


ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the protected phosphonate diester **52-3, 52-13**. Removal of the TBDPS group can be achieved using TFA to yield compound **52-3, 52-13**.

Scheme **52.4**



Compound **52-4, 52-16, 52-17** can be prepared from the advanced intermediate **52-14** reported in WO 0118171. Protection of the hydroxamide followed by removal of the Cbz group provides compound **52-15, 52-19**. A reductive amination using aldehyde **52-18, 52-20** (from Digital Specialty Chemicals), followed by removal of the protecting group at the hydroxamide provides pro-drug **52-4, 52-16, 52-17**.

Scheme **52.5**




The Cbz protected **52-14** can be prepared as described in WO 0118171. Blocking the hydroxamide using TBDPS (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)) followed by removal of the Cbz group provides compound **52-15**, **52-19**. The free amine of **52-15**, **52-19** can undergo a reductive amination with aldehyde **52-18**, **52-20**, available from Digital Specialty Chemicals (also reported in Olson, G. L. et al., J. Med. Chem., (1995), 38, 15, 2866) to form the pro-drug **52-4**, **52-16**, **52-17**.

Example 53: Preparation of exemplary compounds of the present invention

Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of thalidomide which, upon cleavage inside the target cell, give rise to agents with increased intracellular half-lives. Such compounds are described below.

Scheme **53.1**




53-1 **53-2**


link includes 1 or more atoms; 2 or more is preferred

Compounds such as these are made according to the general routes outlined in Scheme **53.2**, with examples depicted in Scheme **53.3**.

Scheme **53.2**



Scheme **53.3**



2-Methyl-4-nitrobenzoic acid methyl ester (commercially available) is converted to 3-(5-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, following the procedures reported in *Bioorg. Med. Chem. Lett.*, (1999), *9*, 1625.


This amine intermediate is subjected to a reductive amination with diethylphosphonoacetaldehyde (obtained from ozonolysis of diethyl allylphosphonate) in the presence of a reducing agent such as sodium triacetoxyborohydride to generate the desired amine linker analog (*J. Org. Chem.*, (1996), *61*, 3849). Alternatively, the amine is acylated with an activated diethylphosphonoacetic acid to provide the desired amide linker compound, according to a procedure such as those reported in *J. Med. Chem.*, (1982), *25*, 960 and *J. Med. Chem.*, (1984), *27*, 600. The activated diethylphosphonoacetic acid can be obtained by treatment in a solvent such as dimethylformamide with a coupling reagent such as diethyl cyanophosphonate and a base such as diisopropylethylamine at room temperature.

2-Methyl-3-nitrobenzoic acid methyl ester (commercially available) is treated in a solvent such as carbon tetrachloride with N-bromosuccinimide under light to produce 2-bromomethyl-3-nitrobenzoic acid methyl ester. This benzylic bromide is treated in a solvent such as dimethylformamide with [2-(3-amino-2,6-dioxo-piperidin-1-yl)-ethyl]-phosphonic acid diethyl ester (for the preparation of this compound , see below) in the presence of a base such as triethylamine. The coupled product is then reduced by hydrogenation (*Bioorg. Med. Chem. Lett.*, (1999), *9*, 1625) to afford the desired analog. [2-(3-amino-2,6-dioxo-piperidin-1-yl)-ethyl]-phosphonic acid diethyl ester is obtained according to a procedure such as that reported in *J. Med. Chem.*, (2003) *46*, 3793. Accordingly, benzyloxycarbonyl-protected glutaric acid is treated in a solvent such as acetonitrile with triethylamine, 1-hydroxybenzotriazole, diethyl 2-aminoethylphosphonate and 1,3-dicyclohexylcarbodiimide. After the reaction is complete, the solvent is removed and the residue is purified by chromatography to generate the cyclic product, which is subjected to hydrogen in the presence of palladium catalysis to afford the desired intermediate.

Example 54: Preparation of exemplary compounds of the present invention


Reduction of the dose and/or improvement of efficacy are achieved by the use of pro-drugs of analogs of MS-275 which, upon cleavage inside the target cell, gives rise to agents with increased intracellular half-lives. Such phosphonate pro-drug compounds are described below.

Scheme **54.1**



Compounds such as these are made according to the general route outlined in Scheme **54.2**, with an example depicted in Scheme **54.3**.


Scheme **54.2**



Preparation of a pro-drug of MS-275 is shown in Scheme **54.2**. Compound **54-4** (prepared according to CH 569714 as well as Chem Abstr. 78, 16049) is transformed to the carbamate **54-5** through activation of the alcohol by formation of a carbonyl imidazole intermediate, followed by addition of 4-(aminomethyl)benzoic acid. Subsequent coupling of the carboxylic acid of **54-5**

with 2-aminoaniline proceeds to provide compound **54-6**. Hydrolysis of the ester followed by coupling of the acid with the amino phosphonate pro-drug completes the synthesis of pro-drug **54-2**.

Scheme **54.3**




Preparation of the pro-drug linked MS-275 is shown in Scheme **54.3** in more detail. Compound **54-7** is prepared according to reported methods (CH 569714 as well as Chem Abstr. 78, 16049). Condensation of **54-7** with 4-(aminomethyl)benzoic acid (from Aldrich) using 1,1'-carbonyldiimidazole gives carboxylic acid **54-8** (Suzuki, T. et al., *J. Med. Chem.*, (1999), *42*, 3001). Acid **54-8** is converted into acyl chloride by treatment with oxalyl chloride, followed by reaction with imidazole to form the acylimidazole intermediate. This is then reacted with 2-aminoaniline in the presence of trifluoroacetic acid (TFA) to form **54-9**. Hydrolysis of the methyl ester followed by coupling with diethyl aminoethylphosphonate (from Fluka) gives pro-drug **54-10**.

Formation of the pro-drug **54-3** follows analogous procedures to those described above. The starting material, 5-hydroxymethylnicotinic acid methyl ester, can be prepared according to Hemel J. V. et al., *Nucleosides Nucleotides*, (1996), *15*, 1203. The subsequent steps are as shown in Scheme **54.3**.

Example 55: Preparation of exemplary compounds of the present invention

Representative compounds of the invention are made according to the general route outlined in Scheme **55.1**, with an example depicted in Scheme **55.2**.


Scheme **55.1**



Preparation of pro-drug **55-7** is shown in Scheme **55.1**. Compound **55-1**, 4-formylcinnamic acid is first esterified to provide aldehyde **55-2** (WO 03039599). The aldehyde undergoes a reductive amination with 3-(2-aminoethyl)-1H-indol-5-ol (available from Aldrich) to provide compound **55-3**. Alkylation of the secondary amine in **55-3** using a protected 2-bromoethanol provides compound **55-4**. Phenol **55-4** can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride.

When bubbling ceases, a dialkyl phosphonate such as diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **55-5**. Formation of the N-hydroxy amide is performed using hydroxylamine in base to provide compound **55-6**. Final removal of the protecting group on the primary alcohol provides the pro-drug **55-7**.

Scheme **55.2**



A detailed synthesis of pro-drug of LAQ-824 is demonstrated in Scheme **55.2**. 4-formylcinnamic acid is first esterified to provide methyl ester **52-14** (WO 03039599). The aldehyde of **52-14** undergoes a reductive amination with 3-(2-aminoethyl)-1H-indol-5-ol (available from Aldrich) to provide amine **55-8**. Alkylation of the amine with (2-bromoethoxy)-tert-butyldimethylsilane yields


compound **55-9**. Alkylation of the phenol **55-9** with phosphonomethyl triflate yields phosphonate **55-10**. Formation of N-hydroxy amide takes place using hydroxylamine in a basic reaction medium. A final TBDMS removal gives the pro-drug **55-12**.

Other syntheses can follows the same synthetic path illustrated above, for example, using 1H-indol-6-ol (available from Toronto Research Chemicals) as the corresponding starting material.


Example 56: Preparation of exemplary compounds of the present invention

Compounds such as these can be made according to the general route outlined in Schemes **56.1** and **56.3**, with examples depicted in Schemes **56.2** and **56.4**.

Scheme **56.1**



Scheme **56.2**




56-1 **56-3**

The arabinofuranosyl-2-fluoroadenine **56-1** (prepared according to the procedure of Montgomery, J. et al., *J. Med. Chem.*, (1969), *12*, 3, 498) is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate

(prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **56.2**.


Scheme **56.3**



56-4 **56-5** **56-6** **56-7** **56-8**

Preparation of compound **56-8** is described in Scheme **56.3**. Compound **56-4** (9-(2-deoxy-α-D-ribofuranosyl)2-fluoroadenine) is prepared as described in Montgomery, J. et. al., *J. Med. Chem.*, (1969), *12*, 3, 498 as well as U.S. Patent No. 4,210,745. Oxidation of the 5'-OH followed by elimination provides glycal **56-5** (see the procedure of Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Protection of the fluoroadenine at the 6 position followed by selenoetherification provides the protected phosphonate **56-6** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642) followed by stereoselective dihydroxylation provides the diol which is converted to a monotriflate. Protection of the 3' alcohol provides compound **56-7**. Conversion of the stereochemistry at the 2' position is achieved by exposing the compound to LiOAc to provide the protected desired stereoisomer of the product. Finally, the protecting groups are removed.

Scheme **56.4**



56-4 56-9 56-5 56-10 56-11 56-12 56-8


Specifically, 9-(2-deoxy-α-D-ribofuranosyl)2-fluoroadenine, compound **56-4**, (Montgomery, J. et. al., *J. Med. Chem.*, (1969), *12*, 3, 498 as well as U.S. Patent No. 4,210,745) is oxidized with PtO_2 to provide carboxylic acid **56-9**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in DMF at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, (1972), *94*, 9, 3213). Once the furanoid glycal **56-5** is in hand, it is first protected at the 6-position of the 2-fluoroadenosine using PivCl conditions as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999). Treatment of the protected glycal with silver perchlorate in the presence of diethyl(hydroxylmethyl)phosphonate (Phillion, D. et al., Tetrahedron Lett., 1986, 27, 1477) provides the phosphonate **56.10** (Kim, C. et al., *J. Org. Chem.*, (1991), *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides a diol which can be turned into a mono protected triflate **56-12**. Reversal of configuration of the 2' alcohol

can be achieved by replacement of the triflate with an acetate group. Deprotection of the pivaloyl group (Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999)) removes the newly installed 2' acetate as well. A final deprotection of the THP group can be achieved in acidic media.

Example 57: Preparation of exemplary compounds of the present invention


Compounds of the invention is prepared as generally described in Scheme **57.1**, with an example depicted in Scheme **57.2**.

Scheme **57.1**



57-1 **57-2**

Scheme **57-2**




57-1 **57-3**

Preparation of the compound is achieved via reductive amination of a phosphonate-containing aldehyde using Pirarubicin itself. Such aldehydes can be prepared according to *Synth. Commun.* (1992), *22*, 2219.


Example 58: Preparation of exemplary compounds of the present invention

Compounds of the invention are prepared as generally descibed in the following Schemes.

Scheme **58.1**




Scheme **58.2**




Daunorubicin is protected on the aminosugar moiety using a Cbz protecting group as described in Greene, T., Protective groups in organic synthesis, Wiley-interscience publication, (1999) to generate **58-7**. The alcohol is treated in a solvent such as dichloromethane, tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **58-6** after purification. Final deprotection by hydrogenation over a catalyst such as palladium on charcoal condition in a solvent such as methanol utilizing the method of Greene et. al. provides the desired product.

Alkyl derivatives of the aminosugar nitrogen have been reported (Farquhar, D. et. al., *J. Med. Chem.*, (1998), *41*, 6, 965). Attachment of the phosphonate prodrug moiety onto this amine via alkylation is shown in Scheme **58.3**. A specific example of the preparation of **58-9** is provided in Scheme **58.4**.

Scheme **58.3**



Scheme **58.4**




Preparation of the prodrug **58-9** is achieved via reductive amination of a phosphonate-containing aldehyde using Daunorubicin itself. Such aldehydes are prepared according to *Synth. Commun.* (1992), *22*, 2219.

Further manipulations may be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described below.


Example 59: Preparation of exemplary compounds of the present invention

Representative compounds of formulae **59-4**, **59-7** can be made according to the general route outlined in Scheme **59.1**, with an example depicted in Scheme **59.2**.

Scheme **59.1**



Scheme **59.2**




Idarubicin is protected on the aminosugar moiety using a Cbz protecting group as described in Greene, T., Protective groups in organic synthesis, Wiley-interscience publication, (1999) to generate **59-5**. The alcohol is treated in a


solvent such as dichloromethane, tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **59-6** after purification. Final deprotection by hydrogenation over a catalyst such as palladium on charcoal condition in a solvent such as methanol utilizing the method of Greene et. al. provides the desired product.

Alkyl derivatives of the aminosugar nitrogen have been reported (Farquhar, D. et. al., *J. Med. Chem.*, (1998), *41*, 6, 965). Attachment of the phosphonate prodrug moiety onto this amine via alkylation is shown in Scheme **59.3**. A specific example of the preparation of **59-9** is provided in Scheme **59.4**.

Scheme **59.3**



Scheme **59.4**



Preparation of the prodrug **59-9** is achieved via reductive amination of a phosphonate-containing aldehyde using Idarubicin itself. Such aldehydes are prepared according to *Synth. Commun.* (1992), *22*, 2219.


Example 60: Preparation of exemplary compounds of the present invention

Representative compounds of the invention can be made according to the general route outlined in Schemes **60.1-60.3**, with examples depicted in Schemes **60.4-60.6**.


Scheme **60.1**: Modification at C7




Scheme **60.2**: Functionalization of the nitro group



Scheme **60.3**: Modification at C10




Scheme **60.4**: Modification at C7



Exatecan is dissolved in an organic solvent such as tetrahydrofuran (THF), acetonitrile, or dimethylformamide (DMF) and is treated (2-oxo-ethyl)-phosphonic acid diethyl ester (1 equiv.) and sodium triacetoxyborohydride as described in *J. Org. Chem*, ((1996)), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. The product is further purified by chromatography.

Scheme **60.5**: Modifications of the nitro group at C9




Exatecan is dissolved in an organic solvent such as carbon tetrachloride. N-Bromo succinimide (NBS) is added followed by azobis*iso*butyronitrile (AIBN), according to a procedure from Organikum, 17th edition, Deutscher Verlag der Wissenschaften, (1988), 167. The reaction is heated to reflux temperature for a few hours. At the end of the reaction the mixture is cooled to room temperature. The reaction is filtered and the solvent is removed in vacuo, yielding the crude product. Further separation from regioisomeric products is achieved by chromatography.

The product of step 1 is dissolved in an organic solvent such as acetonitrile or DMF and is treated with aminoethylphosphonic acid diethyl ester (excess), sodium iodide (1 equiv), and sodium carbonate (1 equiv). The reaction mixture is heated to an elevated temperature of ~ 50 – 60°C. At the end of the reaction, the mixture is cooled to room temperature and is filtered. The crude

reaction product is dissolved in an organic solvent such as dichloromethane (DCM), chloroform or benzene and the solution is washed with aqueous hydrochloric acid (HCl) (0.1N), and dried. Filtration and removal of the solvent in vacuo yields the crude product. The product is further purified by chromatography.

Scheme **60.6**: Modifications at C10



60-1 60-7

Exatecan is dissolved in an organic solvent such as DMF, DCM, or acetonitrile. Tert. butoxycarbonyl anhydride is added, followed by a catalytic amount of 4-dimethylaminopyridine (DMAP) (Green and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons, NY, (1999)). Stirring at room temperature is continued. At the end of the reaction, water is added and the crude reaction mixture is extracted with an organic solvent such as DCM or chloroform and dried. Removal of the solvents yields the crude product. Further purification is achieved by chromatography.


The product of step 1 is dissolved in an organic solvent such as THF, DMF, or chloroform and is treated with aqueous sodium hydroxide (NaOH). Stirring at room temperature is continued until conversion to the opened lactone is observed. The solvent is removed in vacuo and the crude material is dissolved in an organic solvent such as methanol or DMF. Aminoethylphosphonic acid diethyl ester is added and the reaction is heated to reflux for an extended period of time, according to a modification of the procedure from *J. Am. Chem. Soc.*, (1957), *79*, 385-391. At the end of the reaction, the mixture is cooled to room temperature and is acidified with aqueous HCl. Stirring is continued until formation of the lactone is observed, according to *J. Am. Chem. Soc.*, (1966), *88*, 3888-3890. The solvents are removed in vacuo and the mixture is partitioned between an organic solvent such as chloroform or DCM and aqueous HCl (0.1N). The organic layer is isolated and the solvent is removed in vacuo. The crude material is dissolved in an organic solvents such as DCM or chloroform

and is treated with trifluoroacetic acid (TFA) (Green and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons, NY, (1999)). At the end of the reaction, solid sodium bicarbonate is added and the reaction is filtered. The solvents are removed in vacuo. Further product purification is achieved by chromatography.


Example 61: Preparation of exemplary compounds of the present invention

Representative compounds of the invention can be made according to the general route outlined in Schemes **61.1-61.3**, with examples depicted in Schemes **61.4-61.6**.


Scheme **61.1**: Modification at the ω guanidine nitrogen




Scheme **61.2**: Modification at the α guanidine nitrogen



Scheme **61.3**: Attachment to C2



Scheme **61.4**: Modification at the ω guanidine nitrogen



Synthesis of the aromatic starting material (1):

2-Cyanophenylbromide (commercially available) is dissolved in an organic solvent such as N-methylpyrrolidinone (NMP) or dimethylformamide (DMF), under an inert gas atmosphere. Sodium carbonate, triphenylphosphine, and methyl acrylate are added, followed by palladium (II) acetate ($Pd(OAc)_2$). The reaction mixture is heated to an elevated temperature of ~ 100 – 140°C, according to procedures from *Chem. Rev.*, (2000), *100*, 3009. At the end of the reaction, the reaction mixture is cooled to room temperature, and filtered through Celite. Removal of solvents yields the crude product. Further purification is achieved by chromatography.

The crude material from step one is dissolved in a mixture of organic solvents such as benzene and ethanol under an inert gas atmosphere. Wilkinson's catalyst [$RhCl(PPh_3)_3$] is added and the reaction mixture is placed under an hydrogen atmosphere of ~ 60 – 80 psi and is heated to an elevated temperature of ~ 60°C, according to the procedure described in *J. Org. Chem.*, (1969), *34*, 3684-3685. At the end of the reaction, the reaction mixture is cooled to room temperature and the solvents are removed in vacuo. The crude material is triturated with diethylether, and the catalyst is removed by filtration through Celite. Removal of the solvent yields the crude material. Further purification is achieved by chromatography.

The crude material of step 2 is dissolved is dissolved in polyphosphoric acid and is heated to an elevated temperature of ~ 90 °C under an inter gas atmosphere, according to a procedure from *Org. Lett.*, (2001), *3*, 279-281. At the

end of the reaction, the mixture is cooled to room temperature and is poured onto ice and extracted with an organic solvent such as diethylether. The combined organic extracts are washed with brine and dried. Removal of the solvent yields the crude product. Further purification is achieved by chromatography.

Synthesis of the guanidine derivative (2):

Di(imidazol-1-yl)methanimine is dissolved in an organic solvent such as tetrahydrofuran (THF), and is reacted with 2-aminoethyl phosphonic acid diethyl ester at room temperature, according to the procedure described in *J. Org. Chem.*, (2002), *67*, 7553-7556. At the end of the reaction, water is added and the product is extracted with an organic solvent such as dichloromethane (DCM). The combined organic layers are washed with saturated aqueous ammonium chloride solution, water and brine, and dried. Removal of the solvents yields the crude material. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as DMF and reacted with hydrazine at an elevated temperature of ~ 100°C in a sealed vessel, according to a slightly modified procedure from the reference cited above. At the end of the reaction, the mixture is cooled to room temperature and water is added. The product is extracted with an organic solvent such as DCM. The combined organic layers are washed with saturated aqueous ammonium chloride solution, water and brine, and dried. Removal of the solvents yields the crude material. Further purification is achieved by chromatography.


Final elaboration (3):

The products of reaction sequence (1) and (2) are dissolved in an organic solvent such as ethanol and treated with a catalytic amount of concentrated sulfuric acid. This mixture is heated to reflux for a minimal amount of time, as described in *J. Med. Chem.*, (1993), *36*, 46-54. The reaction mixture is cooled to room temperature and the solvent is removed *in vacuo*. The product is dissolved in an organic solvent such as ethylacetate or chloroform and is washed with water. The organic layer is dried and the solvent is removed *in vacuo*. Further purification is achieved by chromatography.

The product of this step is dissolved in a mixture of organic solvents such as diethyl ether and ethanol. The solution is saturated with hydrochloric acid gas

at 0°C and is kept at this temperature for an extended period of time. At the end of the reaction product precipitation is induced by the addition of diethyl ether. The precipitate is collected and dried *in vacuo*. The crude material is dissolved in an organic solvent such as ethanol and ammonium saturated ethanol is added. The mixture is heated to an elevated temperature of ~ 70°C for several hours. At the end of the reaction, the mixture is cooled to room temperature and the solvents are removed *in vacuo*. The product is further purified either by recrystallization from ethanol/diethylether mixtures or by chromatography.

Scheme **61.5**: Modification at the α guanidine nitrogen



Synthesis of the guanidine derivative (1).

Tert. butyl carbazate (commercially available) is treated in an organic solvent such as DCM or THF with diethyl phosphonatoethylcarbaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, (1996), 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as THF, and is reacted with di(imidazol-1-yl)methanimine, according to the procedure described in *J. Org. Chem.*, (2002), *67*, 7553-7556. At the end of the reaction, water is added and the product is extracted with an organic solvent such as DCM. The combined organic layers are washed with saturated aqueous

ammonium chloride solution, water, brine and are dried. Removal of the solvents yields the crude material. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as DMF and reacted with ammonia at an elevated temperature of ~ 100°C in a sealed vessel, according to a slightly modified procedure from the reference cited above. At the end of the reaction, the mixture is cooled to room temperature and water is added. The product is extracted with an organic solvent such as DCM. The combined organic layers are washed with saturated aqueous ammonium chloride solution, water and brine, and are dried. Removal of the solvents yields the crude material. Further purification is achieved by chromatography.

The product of this step is dissolved in an organic solvent such as DCM and is treated with trifluoroacetic acid (TFA), according to a procedure from Green and Wuts, Protective Groups in Organic Synthesis. At the end of the reaction sodium bicarbonate is added and the reaction mixture is filtered. Removal of the solvents in vacuo yields the crude product. Further purification is achieved by chromatography.


Final elaboration (3):

The products of the above reactions are dissolved in an organic solvent such as ethanol and treated with a catalytic amount of concentrated sulfuric acid. This mixture is heated to reflux for a minimal amount of time, according to the procedure described in *J. Med. Chem.*, (1993), *36*, 46-54. The reaction mixture is cooled to room temperature and the solvent is removed *in vacuo*. The product is dissolved in an organic solvent such as ethyl acetate or chloroform and is washed with water. The organic layer is dried and the solvent is removed *in vacuo*. Further purification is achieved by chromatography.

The product of this step is dissolved in a mixture of organic solvents such as diethyl ether and ethanol. The solution is saturated with hydrochloric acid gas at 0°C and is kept at 0°C for an extended period of time. At the end of the reaction product precipitation is induced by the addition of diethylether. The precipitate is collected and dried *in vacuo*. The crude material is dissolved in an organic solvent such as ethanol and ammonium saturated ethanol is added. The mixture is heated to an elevated temperature of ~ 70 °C for several hours. At the

end of the reaction, the mixture is cooled to room temperature and the solvents are removed *in vacuo*. The product isfurther purified either by recrystallization from ethanol/diethyl ether rmixtures or by chromatography.

Scheme **61.6**: Attachment to C2



The product of sequence (1) in Scheme **61.4** is dissolved in an organic solvent such as THF and the solution is cooled to –78°C. Lithium di*iso*propylamide solution is added, and the reaction mixture is stirred for a few minutes. When the deprotonation is complete, *E*-1,4 dibromobutene is added in excess and the reaction is allowed to warm to room temperature. The reaction is quenched with aqueous ammonium chloride solution and the product is extracted with an organic solvent such as ethyl acetate or chloroform. Drying and removal of solvents yields the crude product. Further purification is achieved by chromatography.

The product of this step is heated with triethylphosphite in an organic solvent such as toluene to an elevated temperature of ~ 110°C, according to procedures outlined in Engel, R., Synthesis of carbon phosphorus bonds, CRC press (1988). At the end of the reaction, the mixture is cooled to room temperature and the solvents are removed *in vacuo*, yielding the crude product. Further purification is achieved by chromatography.

The product of this reaction and aminoguanidine are dissolved in an organic solvent such as ethanol and treated with a catalytic amount of concentrated sulfuric acid. This mixture is heated to reflux for a minimal amount of time, according to a procedure from *J. Med. Chem.*, (1993), *36*, 46-54. The reaction mixture is cooled to room temperature and the solvent is removed in vacuo. The product is dissolved in an organic solvent such as ethyl acetate or chloroform and is washed with water. The organic layer is dried and the solvent is removed in vacuo. Further purification is achieved by chromatography.


The product of this step is dissolved in a mixture of organic solvents such as diethyl ether and ethanol. The solution is saturated with hydrochloric acid gas at 0°C and is kept at 0°C for an extended period of time. At the end of the reaction, product precipitation is induced by the addition of diethyl ether. The precipitate is collected and dried in vacuo. The crude material is dissolved in an organic solvent such as ethanol and ammonium saturated ethanol is added. The mixture is heated to an elevated temperature of ~ 70°C for several hours. At the end of the reaction, the mixture is cooled to room temperature and the solvents are removed in vacuo. The product is further purified either by recrystallization from ethanol/diethyl ether mixtures or by chromatography.

Further manipulations are performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.


Example 62: Preparation of exemplary compounds of the present invention

Representative compounds of formulae **62-4, 62-7** are made according to the general route outlined in Scheme **62.1**, with an example depicted in Scheme **62.2**.

Scheme **62.1**



Scheme **62.2**




62-1 **62-5** **62-6** **62-7**


Adriamycin is protected on the aminosugar moiety using a Cbz protecting group as described in Greene, T., Protective groups in organic synthesis, Wiley-interscience publication, (1999). Protection of the primary alcohol to prepare **62-5** using the acetate protecting group has been described (U.S. Patent No. 4,303,785). The alcohol is treated in a solvent such as dichloromethane, tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester **62-6** after purification. Final deprotection by hydrogenation over a catalyst such as palladium on charcoal condition in a solvent such as methanol utilizing the method of Greene et al. followed by exposure of the compound to potassium carbonate provides the desired product.

Alkyl derivatives of the aminosugar nitrogen have been reported (Farquhar, D. et. al., *J. Med. Chem.*, (1998), *41*, 6, 965). Attachment of the phosphonate prodrug moiety onto this amine via alkylation is shown in Scheme **62.3**. A specific example of the preparation of **62-9** is provided in Scheme **62.4**.

Scheme **62.3**



Scheme **62.4**



Preparation of the prodrug **62-9** is achieved via reductive amination of a phosphonate-containing aldehyde using Adriamycin itself. Such aldehydes are prepared according to *Synth. Commun.* (1992), *22*, 2219.

Example 63: Preparation of exemplary compounds of the present invention

Background and Utility of Scaffold Compound


Certain triaryl ethylenes are useful in the treatment of hypercholesterolemia and osteoporosis by acting as selective estrogen receptor modulators. One such derivative, Ospemifene, is described in WO01/36360 page 3 line 5. The present invention provides novel analogs of Ospemifene, **63-1**. Such novel Ospemifene analogs, as described by structures **63-2**, **63-3**, and **63-4**, possess all the utilities of AGI-1067 and optionally provide cellular accumulation as set forth below.

Method of Making New Compound:


The synthesis of Ospemifene, **63-1** is described in WO01/36360. As shown in Schemes **63.1-63.2**, compound **63-1** is treated with a dialkylphosphonoalkyltrifluromethylsulphonate in a solvent such as pyridine or a non basic solvent such as dichloromethane containing a base such as triethylamine to furnish the ether of **63-1**. The alkyl groups are removed from the phosphonate moiety with trimethylsilylbromide in a solvent such as DMF or acetonitrile and the resulting compound is converted to the desired prodrug **63-2, 63-3, 63-4** using the methods of phosphonate ester and amidate formation described below.

Scheme **63.2** describes the synthesis of a compound **63-9**, a particular member of the general class of compounds described by the structure **63-2, 63-3, 63-4**. Compound **63-1** is treated with diethylphosphonomethyltrifluorosulphonate, **63-5**, in pyridine to yield the ether **63-6**. Compound **63-6** is treated with trimethylsilylbromide in acetonitrile to yield the free phophonic acid **63-7**. Compound **63-7** is then treated with dicyclohexylcarbodiimide and phenol in DMF to yield the monophenol ester **63-8**, which is then condensed with the isopropylester of alanine using aldrithiol and triphenylphosphine in DMF to yield the desired prodrug **63-9**

Scheme 63.1


63-1
Ospemifene
n = 1 to 20
DMF $CsCO_3$
63-2
n = 1 to 20
TMSBr/Acetonitrile
63-3
n = 1 to 20
R_1 = O-aryl, O-heteroaryl, alpha or beta amino acid ester
R_2 = lactate ester or alpha or beta amino acid ester
63-4
n = 1 to 20


Scheme 63.2



Example 64: Preparation of exemplary compounds of the present invention


Synthetic sequences to examples of such phosphonates are described in Scheme **64.1**.

Scheme **64.1**.



Rapamycin, a synthetic precursor of everolimus, is *O*-arylated as shown above using an appropriate aryl bismuth reagent according to a procedure such as that reported in *Bioorg. Med. Chem. Lett*, (1995), *5*, 1035. 3-(Dimethyl-t-butylsilyloxy)bromobenzene is treated either with magnesium in diethyl ether or with butyllithium in tetrahydrofuran, and the resulting organometallic reagent is reacted with bismuth trichloride to generate the triarybismuthine. After treating with 1 – 1.2 equivalents of peracetic acid, the bismuth(V) reagent is then mixed with rapamycin and copper(II) acetate. The reaction is allowed to proceed for a day at room temperature or, if necessary, at reflux, affording the desired 3-(dimethyl-t-butylsilyloxy)phenyl ether. After removal of the dimethyl-t-butylsilyl protecting group, *O*-alkylation is achieved with diethyl (bromomethyl)phosphonate in the presence of silver oxide, affording the desired everolimus analog containing the diethylphosphonate. Silver ion-assisted reactions have been used to mediate *O*-alkylations on an immunosuppresive macrolide structurally similar to rapamycin: see *J. Med. Chem.*, (1998), *41*, 1764.

Scheme **64.2**.




A phosphonate derivative of everolimus indolyl ether is prepared as depicted in Scheme **64.2**, in a similar manner to the previous example with the exception that the key triindolylbismuthine intermediate is obtained from 5-bromoindole following the procedure described in *J. Org. Chem.* (1998), *63*, 6721.

Example 65: Preparation of exemplary compounds of the present invention


Synthetic sequences to examples of such phosphonates are described in Scheme **65.1**.

Scheme **65.1**.



Sirolimus is *O*-arylated as shown above using an appropriate aryl bismuth reagent according to a procedure such as that reported in *Bioorg. Med. Chem. Lett*, (1995), *5*, 1035. 3-(dimethyl-t-butylsilyloxy)bromobenzene is treated either with magnesium in diethyl ether or with butyllithium in tetrahydrofuran, and the resulting organometallic reagent is reacted with bismuth trichloride to generate the triarybismuthine. After treating with 1 – 1.2 equivalents of peracetic acid, the bismuth(V) reagent is then mixed with sirolimus and copper(II) acetate. The reaction is allowed to proceed for a day at room temperature or, if necessary, at reflux, affording the desired 3-(dimethyl-t-butylsilyloxy)phenyl ether. After removal of the dimethyl-t-butylsilyl protecting group, *O*-alkylation is achieved with diethyl (bromomethyl)phosphonate in the presence of silver oxide, affording the desired sirolimus analog containing the diethylphosphonate. Silver ion-assisted reactions have been used to mediate *O*-alkylations on an immunosuppresive macrolide structurally similar to sirolimus: see *J. Med. Chem.*, (1998), *41*, 1764.

Scheme **65.2**.




A phosphonate derivative of sirolimus indolyl ether is prepared as depicted in Scheme **65.2**, in a similar manner to the previous example with the exception that the key triindolylbismuthine intermediate is obtained from 5-bromoindole following the procedure described in *J. Org. Chem.* (1998), *63*, 6721.

Example 66: Preparation of exemplary compounds of the present invention


Synthetic methodology towards compounds such as these is described in WO 09/613266, according to the general routes outlined in Schemes **66.1-66.3**.

Scheme **66.1**




Examples of the synthesis of suitable phosphonate-containing phenylalanine derivatives are shown below.

Scheme **66.2**



The protected tyrosine derivative can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester. Subsequent selective hydrolysis of the carboxylate ester using a source of hydroxide ion such as lithium hydroxide in a solvent such as ethanol provides the phosphonate-containing reagent in a form suitable for use in the synthesis of bortezomib analogs.

Scheme **66.3**




66-5 66-7

The protected tyrosine derivative can be treated in a solvent such as dimethylformamide or tetrahydrofuran with a base such as sodium hydride. When bubbling ceases, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. This is then heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. Subsequent selective hydrolysis of the carboxylate ester using a source of hydroxide ion such as lithium hydroxide in a solvent such as ethanol provides the phosphonate-containing reagent in a form suitable for use in the synthesis of bortezomib analogs.


Example 67: Preparation of exemplary compounds of the present invention

Reduction of the dose and/or improvement of efficacy is achieved by the use of pro-drugs of analogs of VX-148 which, upon cleavage inside the target cell, give rise to an agent with an increased intracellular half-life. Such compounds are described below.


Scheme **67.1**



67-1



67-2




67-3

Link includes 0-8 atoms; 2 - 6 is preferred

Compounds such as these can be made according to the general routes outlined in Schemes **67.2**, **67.4** and **67.5**, with syntheses of suitable reagents depicted in Schemes **67.3** and **67.6**.

Scheme **67.2**.




R_1 = 1-carbon substituent;
FG = functional group

67-4

67-5

A 3,5-difunctionalized nitrobenzene derivative provides a suitable starting point for a reagent that contains a phosphonate moiety linked to the phenyl ring at the desired position, ready for incorporation into the fully-crafted VX-148 analog using methods developed for the parent compound.


Scheme **67.3**



67-6 67-7 67-8

3-Hydroxy-5-nitro-benzoic acid is heated briefly in thionyl chloride to generate the acid chloride. This is then condensed with O,N-dimethyl-hydroxylamine in the presence of a base such as triethylamine to produce the Weinreb amide which, upon reaction with methyl lithium, gives the acetophenone derivative. This is then treated with a base such as potassium carbonate in a dipolar aprotic solvent such as dimethylformamide, in the presence of an excess of *E*-1,4-dibromobutene. The monobromide is isolated by chromatography and then subjected to treatment with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, (1988)) to generate the desired phosphonate diethyl ester. Thereafter, the carbonyl of the acetophenone is reduced enantioselectively using an appropriate homochiral oxazaborolidine such as that described by Corey (*J. Am. Chem. Soc.*, (1987), *109*, 5551), and the resulting alcohol is displaced by azide using a method such as that described by Mitsunobu (*Bull. Chem. Soc. Japan.*, (1971), *44*, 3427). The azide is reduced to the amine under Staudinger conditions (*Helv. Chim. Act.*, (1919), *2*, 635) and protected as the t-butyl carbonate. Finally, the desired aniline is generated by tin (II)-mediated reduction of the nitrobenzene.

Scheme **67.4**.




R_1 = 1-carbon substituent;
FG = functional group

67-9 67-10


Reagents suitable for use in the synthesis of phosphonate analogs are made by routes analogous to that shown in Scheme **67.3**, starting from 2-hydroxy-5-nitro-benzoic acid.

Scheme **67.5**.



An example of the synthesis of a suitable reagent for coupling reactions as in U.S. Patent No. 6,054,472 and U.S. Patent No. 6,344,465 is illustrated in Scheme **67.6** below.

Scheme **67.6**




3-tert-Butoxycarbonylamino-3-(3-nitro-phenyl)-propionic acid (commercially available) is coupled with 2-aminoethylphosphonic acid diethyl ester (commercially available) using standard reagents for the formation of a secondary amide such as dicyclohexylcarbodiimide (DCC) and hydroxybenztriazole (HOBT), in a solvent such as dimethylformamide. Subsequent reduction of the nitro group proceeds in a fashion similar to that described in Scheme **67.3**.

Example 68: Preparation of exemplary compounds of the present invention


Compounds such as these can be made according to the general routes outlined in Schemes **68.1**, **68.3** and **68.4**, with syntheses of suitable reagents depicted in Schemes **68.2** and **68.5**.

Scheme **68.1**.



A 3,5-difunctionalized nitrobenzene derivative provides a suitable starting point for a reagent that contains a phosphonate moiety linked to the phenyl ring at the desired position, ready for incorporation into the fully-crafted merimepodib analog using methods developed for the parent compound.


Scheme **68.2**



3-Hydroxy-5-nitro-benzoic acid is heated briefly in acidic methanol to generate the methyl ester. This is then treated with a base such as potassium carbonate in a dipolar aprotic solvent such as dimethylformamide, in the presence of an excess of *E*-1,4-dibromobutene. The monobromide is isolated by chromatography and then subjected to treatment with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R.,

Synthesis of carbon-phosphorus bonds, CRC press (1988)) to generate the desired phosphonate diethyl ester. Thereafter, the benzoate ester is saponified and reduced, and the resulting alcohol displaced by azide using a method such as that described by Mitsunobu (*Bull. Chem. Soc. Japan.*, (1971), *44*, 3427). The azide is reduced to the amine under Staudinger conditions (*Helv. Chim. Act.*, (1919), *2*, 635) and protected as the t-butyl carbonate. Finally, the desired aniline is generated by tin (II)-mediated reduction of the nitrobenzene.

Scheme **68.3**.




R_1 = 1-carbon substituent;
FG = functional group

68-15 **68-7**

Reagents suitable for use in the synthesis of phosphonate analogs of Type II may be made by routes analogous to that shown in Scheme **68.2**, starting from 2-hydroxy-5-nitro-benzoic acid.

Scheme **68.4**. General route to Type III analogs




R_1 = 1-carbon substituent

68-8 **68-9** **68-10**

An example of the synthesis of a suitable reagent for coupling reactions as in U.S. Patent No. 6,054,472 and U.S. Patent No. 6,344,465 is illustrated in Scheme **68.5** below.

Scheme **68.5**




3-Nitrobenzaldehyde reacts with a Grignard reagent to introduce a tether bearing a protected alcohol and simultaneously to generate a benzylic alcohol, as shown. The alcohol is displaced by an azide in a manner similar to that described for Scheme **68.2**. After deprotection, the liberated alcohol is alkylated with diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) using a base such as magnesium tert-butoxide in a solvent such as tetrahydrofuran. Subsequent transformations of the azide and nitro groups proceed in a fashion similar to that described in Scheme **68.2**.

Example 69: Preparation of exemplary compounds of the present invention


Synthetic methodology towards compounds such as these is based on methods described by Batt et al, *Bioorg. Med. Chem. Lett.*, (1995), *5*, 1549. A typical general route is outlined in Scheme **69.1**.

Scheme **69.1**




Examples of the synthesis of suitable phosphonate-containing analogs are shown below.

Scheme **69.2**



The initial Pfitzinger condensation is classically achieved in a single step using potassium hydroxide with acidic work-up, as shown. Alternatively, the initial aldol condensation may be performed using diethylamine in ethanol, and the quinoline ring may be formed is a second step mediated by an acid such as hydrochloric acid in a solvent such as 1,4-dioxane. Following removal of the benzyl protecting group via hydrogenation, the phenol can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate diester. The carboxylate is deprotected by treatment with lithium hydroxide in ethanol.

Scheme **69.3**




The synthesis is similar to that depicted in Scheme **69.2** except that, following deprotonation of the phenol, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The resulting bromide is heated with triethylphosphite in a solvent such as toluene to generate the diethyl ester of the desired phosphonic acid, and the carboxylic acid is deprotected as before.

Example 70: Preparation of exemplary compounds of the present invention

The structures of Dexamethasone **70-1** (U.S. Patent No. 3,007,923) and the phosphonate esters **70-4** are shown in Scheme **70.1**, in which the substituent R^1 is H, alkyl, alkenyl, aryl or aralkyl. The compounds **70-4** incorporate a phosphonate moiety $(R^1O)_2P(O)$ connected to the nucleus by means of a variable linking group, designated as "link" in the attached structures.

Scheme **70.1**



Schemes **70.2**–**70.12** illustrate the syntheses of the phosphonate compounds of this invention and of the intermediate compounds useful for their synthesis.

Protection of reactive substituents.

Depending on the reaction conditions employed, it may be necessary to protect certain reactive substituents from unwanted reactions by protection before the sequence described, and to deprotect the substituents afterwards, according to the knowledge of one skilled in the art. Protection and deprotection of functional groups are described, for example, in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990. The protection and deprotection of steroidal ketones and alcohols is described in Organic Reactions in Steroid Chemistry, Vol. 1, J. Fried and J. A. Edwards, van Nostrand Reinhold, (1972), p. 375ff. Reactive substituents which may be protected are shown in the accompanying schemes as, for example, [OH], [O], etc. For example, Scheme **70.1** depicts a protection-deprotection sequence in which the steroid side-chain is protected as a bis-methylenedioxy (BMD) moiety. In this sequence, Dexamethasone **70-1** is reacted with paraformaldehyde and an acid catalyst such as hydrochloric acid, as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition (1990), p. 223, to yield the BMD derivative **70-2**. The phosphonate moiety is then introduced, using the procedures described below, to produce the

phosphonate ester **70-3**. The BMD moiety is then hydrolyzed, for example by treatment with 50% aqueous acetic acid, as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition (1990), p. 223, to afford the triol **70-4**.


Preparation of the phosphonate esters 70-7, 70-14, 70-18, 70-20, 70-120, 70-22, and 70-27.

Schemes **70.2-70.6** depicts the preparation of phosphonates in which the phosphonate is attached by means of an imino or iminoxy group and a variable carbon chain. In this procedure, the BMD-protected derivative **70-2** is reacted with an amine or hydroxylamine **70-5**, in which R^2 is an alkyl, alkenyl, cycloalkyl or cycloalkenyl group, optionally incorporating a heteroatom O, S or N, or a functional group such as an amide, ester, oxime, sulfoxide or sulfone etc, or an optionally substituted aryl, heteroaryl or aralkyl group, optionally incorporating a heteroatom O, S or N, and X is either a phosphonate group or a group which is subsequently converted into a phosphonate-containing substituent. For example, X is dialkylphosphono, bromo, hydroxy, amino, carboxy and the like. The reaction is conducted between equimolar amounts of the reactants in an aprotic solvent such as pyridine or xylene, or in an alcoholic solvent such as ethanol, optionally in the presence of an acid catalyst, to give the imine or oxime. The preparation of oximes of steroidal 3-ketones is described in Anal. Bioch., 1978, 86, 133. and in J. Mass. Spectrom., (1995), 30, 497. The BMD-protected side-chain compound **70-6** is then converted, as described in Scheme **70.1**, into the triol **70-7**.

Schemes **70.2-70.6** also illustrates the preparation of hydroxylamine ethers incorporating a phosphonate group. In this procedure, a phosphonate **70-8**, in which Lv is a leaving group such as bromo or trifluoromethylsulfonyloxy, is reacted with BOC-hydroxylamine **70-9** (Aldrich) to produce the ether **70-10**. The reaction is conducted between equimolar amounts of the reactants in a polar solvent such as dimethylformamide or tetrahydrofuran, in the presence of a base such as potassium hydroxide or dimethylaminopyridine. Deprotection, for example by treatment with trifluoroacetic acid, then gives the hydroxylamine ether **70-11**.

Scheme **70.2. Phosphonates A2.**

Method




70-2 **70-6** **70-7**

70-8 **70-10** **70-11**

Scheme **70.3** illustrates the preparation of phosphonates **70-14** in which the phosphonate is attached by means of an iminoxy group. In this procedure, the substrate **70-2** is reacted with a dialkyl phosphonomethyl hydroxylamine **70-12**, prepared as described above from a dialkyl trifluoromethylsulfonyloxymethyl phosphonate (Tet. Lett., 1986, 27, 1477) and BOC-hydroxylamine, to afford the oxime **70-13** which is deprotected to afford the triol **70-14**. The oxime forming reaction is performed at ambient temperature in ethanol-acetic acid solution between equimolar amounts of the reactants. Using the above procedures, but employing, in place of the hydroxylamine ether **70-12**, different oxime ethers **70-5**, the corresponding products **70-7** are obtained.

Scheme **70.3**



70-2 **70-13** **70-14**


Scheme **70.4** illustrates the preparation of compounds **70-18**, **70-20**, and **70-180** in which the phosphonate group is attached by means of a pyridyl methoxy group. In this procedure, the dienone **70-2** is reacted, as described above, with O-(3-bromo-5-pyridylmethyl)hydroxylamine **70-15**, prepared as described above from 3-bromo-5-bromomethylpyridine (WO 95/28400), to give, after deprotection of the side-chain, the oxime **70-16**. The product is then reacted, in the presence of a palladium catalyst, with a dialkyl phosphite **70-17** to

afford the phosphonate **70-18**. The preparation of arylphosphonates by means of a coupling reaction between aryl bromides and dialkyl phosphites is described in J. Med. Chem., 35, 1371, (1992). The reaction is performed in an inert solvent such as toluene, in the presence of a base such as triethylamine and a catalytic amount of tetrakis(triphenylphosphine)palladium(0).

Alternatively, the bromo compound **70-16** is coupled with a dialkyl vinylphosphonate **70-19** (Aldrich) to afford the phosphonate **70-20**. The coupling of aryl halides with olefins by means of the Heck reaction is described, for example, in Advanced Organic Chemistry, by F. A. Carey and R. J. Sundberg, Plenum, (2001), p. 503ff and in Acc. Chem. Res., 12, 146, (1979). The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxan, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate. Optionally, the styrenoid double bond present in the product **70-20** is reduced, for example by reaction with diimide, to produce the saturated analog **70-120**. The reduction of olefinic bonds is described in Comprehensive Organic Transformations, by R. C. Larock, VCH, (1989), p. 6ff. The transformation is effected by means of catalytic hydrogenation, for example using a palladium on carbon catalyst and hydrogen or a hydrogen donor, or by the use of diimide or diborane.

Using the above procedures, but employing, in place of the bromopyridyloxy reagent **70-15**, different bromo-substituted aryl or heteroaryl alkoxy hydroxylamines, and/or different dialkyl alkenyl phosphonates, the products analogous to the compounds **70-18**, **70-20** and **70-120** are obtained.


Scheme **70.4**



Scheme **70.5** depicts the preparation of phosphonates **70-22** in which the phosphonate is attached by means of an imino group. In this procedure, the substrate **70-2** is reacted with a dialkyl 2-aminophenyl phosphonate **70-21**, (Syn., (1999), 1368) to give, after deprotection, the imine product **70-22**. The reaction is conducted in a hydrocarbon solvent such as toluene or xylene, at reflux temperature, in the presence of a basic catalyst such as sodium methoxide, or an acid catalyst such as p-toluenesulfonic acid, under azeotropic conditions.

Using the above procedures, but employing, in place of the 2-aminophenyl phosphonate **70-21** different amino-substituted aryl or heteroaryl phosphonates, products analogous to **70-22** are obtained.

Scheme 70.5



Scheme **70.6** illustrates the preparation of phosphonates **70-27** in which the phosphonate is attached by means of an oximino group and an amide linkage. In this procedure, the dienone **70-2** is reacted with O-(2-carboxyethyl)hydroxylamine **70-23** (J. Med. Chem., 1990, 33, 1423) to yield the


oxime **70-24**. The reaction of steroidal 1,4-dien-3-ones with substituted hydroxylamines is described in J. Steroid Bioch., (1976), 7, 795; the reaction is performed between equimolar amounts of the reactants in a polar organic solvent such as pyridine or methanol, optionally in the presence of acetic acid or sodium acetate. The oxime is then reacted with a dialkyl aminomethyl phosphonate **70-25** (AsInEx), to yield the amide oxime **70-26**. The preparation of amides from carboxylic acids and derivatives is described, for example, in Organic Functional Group Preparations, by S.R.Sandler and W. Karo, Academic Press, (1968), p. 274, and Comprehensive Organic Transformations, by R. C. Larock, VCH, (1989), p. 972ff. The carboxylic acid is reacted with the amine in the presence of an activating agent, such as, for example, dicyclohexylcarbodiimide or diisopropylcarbodiimide, optionally in the presence of, for example, hydroxybenztriazole, N-hydroxysuccinimide or N-hydroxypyridone, in a non-protic solvent such as, for example, pyridine, DMF or dichloromethane, to afford the amide.

Alternatively, the carboxylic acid is first converted into an activated derivative such as the acid chloride, anhydride, mixed anhydride, imidazolide and the like, and then reacted with the amine, in the presence of an organic base such as, for example, pyridine, to afford the amide. The conversion of a carboxylic acid into the corresponding acid chloride is effected by treatment of the carboxylic acid with a reagent such as, for example, thionyl chloride or oxalyl chloride in an inert organic solvent such as dichloromethane, optionally in the presence of a catalytic amount of dimethylformamide.

The amide product **70-26** is then converted, as described in Scheme **70.1**, into the triol **70-27**.

Using the above procedures, but employing, in place of the hydroxylamine **70-25**, different carboxy-substituted hydroxylamines, and/or different amino-substituted phosphonates, the products analogous to **70-27** are obtained.

Scheme **70.6**




Preparation of the phosphonate esters 70-33, 70-35, 70-40, 70-41, 70-47, 70-147, and 70-48.

Schemes **70.7–70.9** illustrates the preparation of the phosphonate esters in which the phosphonate group is attached to the 1' or 2' position of the pyrazole ring, by means of an aromatic or heteroaromatic group, a heteroatom and a variable carbon chain. In this procedure, the BMD-protected dienone **70-2** is reduced to afford the 1,2-dihydro product **70-74**. The catalytic hydrogenation reaction is effected by the use of tris(triphenylphosphine)rhodium (I) chloride, for example as described in J. Med. Chem., (2001), 44, 602. The product is then reacted with ethyl formate and a base such as sodium hydride, in an inert solvent such as toluene or dimethylformamide, as described in J. Am. Chem. Soc., 1964, 86, 1520, to afford the 2-formyl product **70-28**. This compound is then reacted with an alkyl, aralkyl, aryl or heteroaryl hydrazine **70-29**, in which the substituent X is either a phosphonate group or a group which is subsequently transformed into a phosphonate-containing substituent. For example, X is dialkylphosphono, bromo, hydroxy, amino, carboxyl and the like. The reaction yields the isomeric 2'- and 1'-aryl pyrazoles **70-30** and **70-31**. The pyrazole-forming reaction is performed between equimolar amounts of the reactants in an acidic solvent such as acetic acid, as described in J. Am. Chem. Soc., 1964, 86, 1520. The pyrazoles **70-30** and **70-31** are then transformed, for example by the procedures described in Schemes **70.8-70.9**, via the BMD-protected intermediates **70-34** and **70-32**, into the phosphonates **70-35** and **70-33**.

Scheme **70.7. Phosphonates M3 and M4.**

Method




Scheme **70.8** illustrates the preparation of phosphonates and in which the phosphonate is attached by means of a phenyl ring and an alkoxy or an acetylenic linkage. In this procedure, the ketoaldehyde **70-28** is reacted, as described above, with 3-hydroxyphenylhydrazine **70-36** (Japanese patent JP 03011081) to give the pyrazoles **70-70** and **70-37**. The 2'-substituted isomer **70-70** is then reacted in dichloromethane solution at ambient temperature with one molar equivalent of trifluoromethylsulfonyl chloride and dimethylaminopyridine, to yield the triflate **70-39**. The product is then reacted in toluene solution with a dialkyl propynyl phosphonate **70-71** (Syn (1999), 2027), triethylamine and a catalytic amount of tetrakis(triphenylphosphine)palladium (0), to give the acetylenic product **70-73**. The palladium-catalyzed coupling reaction of aryl triflates with terminal acetylenes is described in WO 0230930. The BMD protecting group is then removed to yield the triol **70-41**.

Alternatively, the 1'-substituted pyrazole **70-37** is reacted, in a Mitsonobu reaction, with a dialkyl 2-hydroxyethyl phosphonate **70-72** (Epsilon) to afford the ether **70-38**. The preparation of aromatic ethers by means of the Mitsonobu reaction is described, for example, in Comprehensive Organic Transformations, by R. C. Larock, VCH, 1989, p. 448, and in Advanced Organic Chemistry, Part B, by F.A. Carey and R. J. Sundberg, Plenum, (2001), p. 153-4 and in Org.

React., (1992), 42, 335. The phenol and the alcohol component are reacted together in an aprotic solvent such as, for example, tetrahydrofuran, in the presence of a dialkyl azodicarboxylate and a triarylphosphine, to afford the ether or thioether products. The procedure is also described in Org. React., (1992), 42, 335-656. The product **70-38** is then deprotected to give the triol **70-40**.

Using the above procedures, but employing different acetylenic or hydroxyl-substituted phosphonates, the products analogous to **70-41** and **70-40** are obtained. The functionalization procedures are interchangeable between the pyrazole substrates **70-70** and **70-37**.

Scheme **70.8**




Scheme **70.9** illustrates the preparation of the phosphonates in which the phosphonate group is attached by means of a benzyl group or a benzyl group and a saturated or unsaturated carbon chain. In this procedure, the ketoaldehyde **70-28** is reacted, as described above, with 3-bromobenzyl hydrazine **70-75** (U.S. Patent No. 4,370,339) to produce the pyrazoles **70-42** and **70-43**. The 1'-

substituted isomer **70-42** is coupled, in the presence of a palladium catalyst, with a dialkyl vinylphosphonate **70-76**(Aldrich) to give the phosphonate **70-46**. The product is then deprotected to afford the triol **70-47**. Optionally, the styrenoid double bond present in the product **70-47** is reduced, as described above, to produce the saturated analog **70-147**.

Alternatively, the 2'-substituted pyrazole **70-43** is coupled, in the presence of a palladium catalyst, with a dialkyl phosphite to prepare the phosphonate **70-44** which is deprotected to give the triol **70-48**. The preparation of arylphosphonates by means of a coupling reaction between aryl bromides and dialkyl phosphites is described in J. Med. Chem., 35, 1371, (1992). This reaction is performed in an inert solvent such as toluene, in the presence of a base such as triethylamine and tetrakis(triphenylphosphine)palladium(0).

Using the above procedures, but employing, in place of the bromobenzyl reagent **70-75**, different bromo-substituted aralkyl, aryl or heteroaryl alkoxy hydrazines, and/or different dialkyl alkenyl phosphonates, the products analogous to the compounds **70-47**, **70-147** and **70-48** are obtained.


Scheme **70.9**



Schemes **70.10-70.12** depicts the preparation of the phosphonate esters in which the phosphonate group is attached by means of a variable carbon linkage. In this procedure, the ketoaldehyde **70-28** is reacted with hydrazine, to afford the


pyrazole derivative **70-49**. The reaction of steroidal 2-formyl-3-ketones with hydrazine is described in J. Am. Chem. Soc, 1964, 86, 1520. The reaction is performed in acetic acid at ambient temperature. The pyrazole product is then reacted with a bromomethyl compound **70-77**, in which R^2 and X are as defined above, to yield the alkylation products **70-50** and **70-51**. The alkylation of substituted pyrazoles is described, for example, in Heterocyclic Chemistry, by T. L. Gilchrist, Longman, (1992), p. 309. The reaction is performed between equimolar amounts of the substrates in a polar solvent such as dimethylformamide or tetrahydrofuran, in the presence of a base such as dimethylaminopyridine, lithium hexamethyldisilazide and the like. The products **70-50** and **70-51** are, except in cases where X is dialkylphosphono, converted into the phosphonates **70-52** and **70-53**, using the procedures described herein, and deprotection then affords the triols **70-54** and **70-55**.

Scheme **70.10. Phosphonates M3 and M4.**
Method



As shown in Scheme **70.11**, the pyrazole **70-49** is reacted, as described above, with one molar equivalent of a dialkyl bromoacetonyl phosphonate **70-78** (Tet., 1978, 34, 649) to give the alkylated pyrazoles **70-82** and **70-83**. Deprotection then yields the triols **70-84** and **70-85**.


Scheme **70.11**



As shown in Scheme **70.12**, the pyrazole **70-49** is reacted, as described above, with 1,4-bis(bromomethyl)benzene **70-86** to give the pyrazoles **70-87** and **70-56**. The products are subjected to an Arbuzov reaction, in which the bromomethyl substituent is converted into the dialkyl phosphonomethyl substituent, by reaction with a trialkyl phosphite at 120°, to prepare, after deprotection of the side chain, the phosphonates **70-57** and **70-58**. The Arbuzov reaction is described in Handb. Organophosphorus Chem., (1992), 115-72. In the procedure, the substrate is heated at from 60° to about 160° with a five to fifty-fold molar excess of the trialkyl phosphite.

Using the above procedures, but employing, in place of the dibromide **70-86**, different dibromides, the products analogous to **70-57** and **70-58** are obtained.


Scheme **70.12**



Example 72: Preparation of exemplary compounds of the present invention


Synthetic methodology towards compounds such as these is described by Westwood et al, J. Med. Chem., (1996), 39, 4608-4621, according to the general routes outlined in Scheme **72.1**.

Scheme **72.1**




Examples of the synthesis of suitable phosphonate-containing anilines are shown below.

Scheme **72.2**



72-5 72-7 72-8 72-9

Scheme **72.3**




72-10 72-11 72-12 72-13 72-14 72-15

Example 73: Preparation of exemplary compounds of the present invention

Compounds of the invention can be prepared as generally described by Westwood et al, *J. Med. Chem.*, (1996), *39*, 4608-4621, according to the general route outlined in Scheme **73.1**.


Scheme **73.1**



73-1 73-2


Examples of the synthesis of suitable phosphonate-containing anilines are shown below.

Scheme **73.2**



3-Nitrophenol is alkylated with *E*-1,4-dibromobutene and the resulting monobromide is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid. Finally, the desired aniline is generated by tin (II)-mediated reduction of the nitrobenzene.

Scheme **73.3**




The methyl ester of 3-nitro-4-trifluoromethylbenzoic acid is treated with tin (II) chloride to produce the aniline. The 3-iodobenzoic acid is generated by diazotization and treatment with potassium iodide. A diethylphosphonate ester is attached via an acetylene linker using palladium catalysis, and after saponification of the benzoate ester, Curtius rearrangement of the acyl azide

reveals an aniline suitable for incorporation into the synthesis of teriflunomide analogs.


Example 74: Preparation of exemplary compounds of the present invention

Scheme **74.1**: General access to all compound classes



74-1 74-2


Scheme **74.2**: Specific example for Formula M1



74-1 74-4

The starting carboxylic acid, synthesized according to *J. Am. Chem. Soc.*, (1948), *70*, 1922-1926, is treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or *iso*butyl chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 2-aminoethylphosphonic acid diethyl ester (commercially available) is added. After consumption of the activated species is observed the solvent is removed *in vacuo* and the product is isolated via chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **74.3**:




74-1 74-5

The starting carboxylic acid is treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl

chloroformate and a base such as diisopropylethylamine (DIEA) at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, (2-amino-ethylsulfanylmethyl)-phosphonic acid diethyl ester (made by base-catalyzed coupling of 2-aminoethanethiol with diethyl phosphonomethyltriflate, prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added. After consumption of the activated species is observed the solvent is removed *in vacuo* and the intermediate is isolated by chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The intermediate is then dissolved in a mixture of water, DMF, and acetic acid and is treated with hydrogen peroxide solution (excess). After removal of the solvents the product is isolated by chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.


Scheme **74.4**:



74-1 74-7

The starting carboxylic acid is treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604.). When the activation is complete, (*L*)-2-amino-6-(diethylphosphonato)-hexanoic acid is added. After consumption of the activated species is observed the solvent is removed *in vacuo* and the product is isolated by chromatography. Alternatively, the product can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like.

Scheme **74.5**:




74-1 74-6

The starting carboxylic acid is treated in a solvent such as DMF or NMP with a coupling reagent such as diethyl cyanophosphonate or isobutyl chloroformate and a base such as DIEA at room temperature (*J. Med. Chem.*, (1982), *25*, 960-964 and *J. Med. Chem.*, (1984), *27*, 600-604). When the activation is complete, 4-amino-4-(diethylphosphonato)-butyric acid tert butylester (*J. Am. Chem. Soc.*, (1995), *117*, 10879-10888) is added. After consumption of the activated species is observed the solvent is removed *in vacuo* and the intermediate is isolated by chromatography. Alternatively, the intermediate can be isolated through precipitation from the reaction solution with an organic solvent like diethyl ether or the like. The crude intermediate is then dissolved in DMF and treated with TFA (excess). The product is isolated by chromatography after removal of the solvents. Alternatively, the product can be isolated through precipitation form the reaction solution with an organic solvent like diethyl ether or the like.

Example 75: Preparation of exemplary compounds of the present invention


The phosphorus containing merimepodib analog **75-2** is synthesized from parent compounds by alkylation. Merimepodib **75-1** is obtained by the procedure as described in U.S. Patent No. 6,054,472 and U.S. Patent No. 6,344,465. Schemes **75.1-75.2** shows the procedure for the synthesis of **75-2** and **75-4**. Methoxy group of merimepodib **75-1** is demethylated to phenolic OH using a suitable reagent, such as boron tribromide. The phosphonate moiety is introduced to the phenolic OH in a suitable aprotic solvent such as, DMF and is then treated with the phosphonate reagent **75-40**, **75-41**, bearing a leaving group, for example, bromine, mesyl, tosyl, or trifluoromethanesulfonyl, in the presence of a suitable organic or inorganic base.

Scheme **75.1**



For example, a solution of **75-1** in dichloromethane is treated with boron tribromide to obtain the demethylated compound **75-3**. Compound **75-3** is then treated with cesium carbonate and one equivalent of (trifluoromethanesulfonyloxy)methylphosphonic acid diethyl ester **75-41** to give merimepodib-phosphonate **75-4** in which the linkage is a methylene group as shown in Scheme **75.2**. Using the above procedure but employing different phosphonate reagents **75-40** the corresponding products **75-2** bearing different linking group can be obtained.


Scheme **75.2**



Synthesis of merimepodib analogs **75-2**, **75-12** and **75-13** is shown in Schemes **75.3-75.4**. The imidazole containing intermediate **75-7** is synthesized from an aldehyde **75-6** by the procedure of Shih in *Tetrahedron Lett.* (1993), *34*, 595. Compound **75-6** is prepared by a two-step procedure described in U.S.


Patent No.5,807,876, U.S. Patent No. 6,054,472, and U.S. Patent No. 6,344,465. The imidazole is protected using suitable reagent, for example 2-(trimethylsilyl)ethyoxymethyl (SEM) chloride, and the compound **75-8** is converted to **75-10** by the similar procedure described for the synthesis of **75-1** in U.S. Patent No. 6,054,472 and U.S. Patent No. 6,344,465. After the protecting group on the imidazole of **75-10** is removed, the phosphonate containing moiety is introduced to the imidazole as shown in Schemes **75.4**.

Scheme **75.3**



For example, compound **75-10** is treated with tetrabutylammonium fluoride in THF in reflux condition and the resulting **75-11** is alkylated with **75-41, 75-42** using sodium hydride as a base to obtain two isomers **75-12** and **75-13**, which are separated by chromatography.


Scheme **75.4**




Schemes **75.5-75.6** shows the preparation of merimepodib analog **75-17**. Tetrasubstituted benzene derivatives are obtained by literature procedures (Ichikawa and Ichibagase *Yakugaku Zasshi* (1963), *83*, 103; Norio, A. *et al. Tetrahedron Lett.* (1992), *33(37)*, 5403). After the phenolic OH is protected with a suitable protecting group, for example benzyl group, the compound **75-16** is synthesized by the same procedure of the synthesis of **75-1** as described in U.S. Patent No. 6,054,472, and U.S. Patent No. 6,344,465. After the protecting group is removed, the phosphonate containing moiety is introduced to the phenolic OH using the phosphonate reagent **75-45**, bearing a suitable leaving group.

For example, a solution of **75-18**, which is obtained by the procedure of Norio et al. (*Tetrahedron Lett.* (1992), *33(37)*, 5403), is treated with sodium hydride and one equivalent of benzyl bromide in DMF to get **75-19**. Compound **75-19** is converted to **75-20** by a series of steps reported in U.S. Patent No. 6,054,472, and U.S. Patent No. 6,344,465 for the synthesis of **75-1** from **75-6**. After the benzyl protecting group of **75-20** is removed by catalytic hydrogenation, a phosphonate bearing moiety is attached by alkylation of the resulting phenol in DMF using sodium hydride and one equivalent of (trifluoromethanesulfonyloxy)methylphosphonic acid diethyl ester **75-42** to give **75-21**.

Scheme **75.5**



Scheme **75.6**




Synthesis of merimepodib analog **75-26** is shown in Schemes **75.7-75.8**. Compound **75-22**, an intermediate in the synthesis of **75-1**, is treated with carbonyldiimidazole or triphosgene followed by the compound **75-23**, which has an handle to attach phosphonate moiety. Compound **75-23** bearing an extra substituent is synthesized from the tri subatituted phenol with a cyano and a nitro groups, which is either commercially available or by literature procedures (Zolfigol, M. A. *et. al. Indian J. Chem. Sect. B* (2001), *40*, 1191; De Jongh, R. O. *et al. Recl. Trav. Chim. Pays-Bas* (1968), *87*, 1327). The resulting **75-24** is converted to **75-25** using the procedure described in U.S. Patent No. 6,054,472,


and U.S. Patent No. 6,344,465 for the synthesis of **75-1**. The phosphonate moiety of **75-26** is attached after deprotection of the benzyl group of **75-25**.

For example, the bromine substituent of compound **75-27** is substituted with cyano group by the procedure of De Jongh, R. O. *et al.* (*Recl. Trav. Chim. Pays-Bas* (1968), *87*, 1327) and the methoxy group is converted to benzyloxy group as a protecting group, which affords compound **75-28**. After selective reduction of cyano to aminomethyl group by borane, the amino group is protected with Boc group and then the reduction of the nitro group using tin (II) chloride generates compound **75-29**. This substituted aniline **75-29** is then treated with a reaction mixture of the compound **75-22** and carbonyldiimidazole, as described for the synthesis of **75-1** in U.S. Patent No. 6,054,472, and U.S. Patent No. 6,344,465, to form the urea **75-30**. Compound **75-30** is easily converted to **75-31**, analog of **75-1** bearing benzyloxy group. Deprotection of the benzyl group using catalytic hydrogenation followed by attachment of a phosphonate moiety using **75-41, 75-42** in the presence of cesium carbonate produces **75-32**.

Scheme **75.7**




Scheme **75.8**




Example 76: Preparation of exemplary compounds of the present invention

Preparation of phosphonate prodrugs of tamoxifen and toremifene citrate



Tamoxifen Analog




Toremifene Analog

A number of analogs of tamoxifen have been prepared and tested. A high degree of flexibility is observed at the aminoethyl portion of the compound toward substitution (Meegan *et al. Anti-Cancer Drug Design*, (2001), *16*, 57). Based on the available SAR, this position is chosen as one handle for attachment of the prodrug moiety. A large number of analogs of tamoxifen have been reported, many having favorable profiles. For a review on a number of tamoxifen analogs, see Meegan, M. J., Lloyd, D. G., *Current Medicinal Chemistry*, (2003), *10*, 181. Considering that these analogs are similar to tamoxifen, the prodrug approach on the same site as tamoxifen can be applied to

them. A number of additional sites on the tamoxifen core are available for attachment of the prodrug group. Considering the scale up methods that are well established for tamoxifen, attachment of prodrug through the amino ethanol group on the B ring is one option. The original synthesis of tamoxifen (Harper et al., GB1064629 and Harper et al., GB1013907) has been modified recently (Smyth, T. P., Corby, B. W., *Organic Process Research & Development*, (1997), *1*, 264). This new method was developed for large scale preparation. Additionally, installation of the amino ethyl group attached to the B ring is performed late in the synthesis which is advantageous for one prodrug synthesis.


Scheme **76.1** (all compound numbers in this scheme refer only to this Example)



Synthesis of compounds such as phosphonate **1** (of Scheme **76.1**) are illustrated above. Compounds **1.1** and **1.2** (of Scheme **76.1**) are condensed using trifluoroacetic anhydride as described in Smyth et al., *Organic Process Research & Development*, (1997), *1*, 264. Replacement of the halogen with amino-linker-phosphonate provides compound **1.4** (in Scheme **76.1**). A final Grignard reaction to introduce the last aromatic group, followed by dehydration in acidic medium provides compound **1** (of Scheme **76.1**). The order of the last


two steps can be switched. First, a Grignard reaction can be performed to install the tetrasubstituted olefin followed by displacement of halogen (McCague R., *J. Chem. Res.*, 1986, 0771). The final product is a mixture of cis and trans isomers which are separated by crystallization. Also, further diversity onto the aromatic A ring is incorporated by choice of substitutions attached to the arylbromide that is used in the Grignard reaction.

Scheme **76.2** (all compound numbers in this scheme refer only to this Example)



Specifically, preparation of compound **1.3** (of Scheme **76.2**) is completed as described in literature. Alkylation with amino ethyl phosphonate is performed to replace the chloride in **1.3** to form **1.4** (Scheme **76.2**). A Grignard reaction with bromobenzene gives compound **1.5** (of Scheme **76.2**) which is dehydrated under acidic conditions to provide compound **1** (of Scheme **76.2**) as the HCl salt. The citrate salt is another useful compound. Other salts can also be generated.


Scheme **76.3** (all compound numbers in this scheme refer only to this Example)



Syntheses of a number of analogs of toremifene are described in detail in U.S. Patent No. 4,696,949. Synthesis of prodrugs of toremifene is shown above in Scheme **76.3**. The prodrug is installed early in the synthesis. It is possible to protect the 4-hydroxy benzophenone initially and remove the protecting group near the end of the synthetic sequence. In that case, the prodrug group is installed near the end of the synthesis. The preparation shown in Scheme **76.3** utilizes 4-hydroxy benzophenone as the starting materials. A two carbon linker is attached and subsequently activated toward synthesis of compound **2.3** (of Scheme **76.3**). Introduction of the aminophosphonate **2.1.1** (of Scheme **76.3**)at this stage completes the left half of the molecule. Addition of cinnamaldehyde to lithium aluminium hydride followed by the benzophenone **2.4** yields diol **2.5** (both of Scheme **76.3**). Dehydration of **2.5** and conversion of the 4-OH to chloride is performed by addition of thionyl chloride to provide compound **2.6**

(of Scheme **76.3**). Final product **2** (Scheme **76.3**)is prepared by formation of the desired salt.

Scheme **76.4** (all compound numbers in this scheme refer only to this Example)



Specifically, 4-hydroxy benzophenone is reacted with 1-mesyl ethane diol to yield **2.2** (of Scheme **76.4**) in CH_2Cl_2. Activation of alcohol **2.2** (Scheme **76.4**) to mesylate **2.3** (Scheme **76.4**) is performed using mesyl chloride in CH_2Cl_2 using TEA as a scavenger. Alkylation of mesylate **2.3** with the *N*-methyl amino ethyl phosphonate **2.1.1** (of Scheme **76.4**) in EtOH at 80 °C proceeds well to provide compound **2.4** (Scheme **76.4**). Addition of **2.4** (1 equivalent) to a mixture of cinnamaldehyde (1 equivalent) and lithium aluminum hydride (0.55 equivalent) in THF yields compound **2.5** (of Scheme **76.4**) after 30 minutes of stirring at room temperature. Dehydration of **2.5** (Scheme **76.4**)using thionyl chloride in toluene is complete after 3 hours at 80 °C to provide compound **2.6** (Scheme **76.4**). A variety of salts can be prepared subsequently.

The citrate salt of toremifene is one exemplary compound. Further modification of the phosphonate prodrug can be performed to the phosphonate diester, bisamidate, or monoamidate as illustrated above.

Example 77: Preparation of exemplary compounds of the present invention

Preparation of phosphonate prodrugs of raloxifene hydrochloride

Many structural modifications of raloxifene have been investigated and the SAR of this group of drugs is well established. In brief, the hydroxyl substituents of aryl rings of raloxifene are predictably critical to the potent activity of the compound. The C-6 OH is positioned to bind to the ER residue pair Arg 394/ Glu 343 in the same way as the 3-OH of estradiol. Also, the 4'-OH, which mimics the 17β-OH of estradiol, binds with the His 524 as demonstrated by crystal structure studies (Anzo, et al., *J. Natl. Cancer Inst.*, (1996), *88*, 123). The amine of the piperidine ring is also important in binding to the aspartate 351 of the estrgen receptor. This amine also plays a role in tissue specificity. However, a number of N,N-dialkyl analogs of raloxifene show equipotent activity to the parent compound. Therefore, substitution of the prodrug group at that terminus of the compound is a preferred embodiment of this work.

Three types of substitutions are set forth herein. Two are variations of attachement of prodrug to the tertiary amine region (Scheme **77.1**). Another attachment site on the raloxifene is the carbonyl position. Considering this carbonyl moiety can be easily substituted with a simple oxygen, this position can be used as a potential handle for the phosphonate prodrugs (Palkowitz, et al., *J. Med. Chem.*, (1997), *40*, 10, 1407).

The first phosphonate prodrug is prepared following the general Schemes **77.2-77.3**. An appropriately protected diol is attached on to the phenolic position of 4-hydroxyl benzoic acid methyl ester by Williamson ether synthesis methods. Removal of the protecting group generated compound **77-5**. Turning the hydroxyl group into an appropriate leaving group, such as mesyl, bromide of trifluoromethylsulfonyl, followed by addition of amino phosphonate prodrug moiety gives compound **77-6, 77-50**. Releasing the methyl ester, followed by activation of the acid by formation of the acid chloride proceeds as reported in literature (Jones, et al. *J. Med. Chem.*, 1984, *27*, 1057). Friedal-Crafts aroylation


with compound **77-7, 77-33, 77-25** which is the product of a rearrangement (Kost et al., *Zh. Org. Khim*, 1970, *6*, 1503), (Jones, C. D., EP 0062503) goes smoothly to provide the protected desired compound. Final deprotection provides compound **77-9**. Different salts can be prepared to assist the solubility of the final compound.

A particular example of the general route above is shown in Scheme **77.3**. Compound **77-4** is alkylated with the TMS protected diol **77-23** using K_2CO_3 in DMF. Removal of the silyl protecting group proceeds cleanly with TFA to provide precursor **77-5**. Activation of **77-5** by formation of the mesylate using MsCl and TEA in CH_2Cl_2, followed by addition of the amino ethyl phosphonate **77-22, 77-32** proceeds well to generate amine **77-6, 77-50**. Removal of the methyl ester protecting group of **77-6, 77-50** followed by one-pot two step reactions of Friedal-Crafts aroylation-deprotection using thioethanol proceeds very well to generate HCl salt of the final compound **77-10, 77-35**.


Generation of the piperazyl phosphonate prodrug is performed the same way as for compound **77-10, 77-35**. Synthesis of **77-24, 77-40** proceeds using a mono protected piperazine and the 2-hydroxyethyl phosphonate. Subsequent steps in the synthesis are as described in Schemes **77.2-77.3**. Specifically, addition of **77-24, 77-40** to **77-5** in CH_2Cl_2 using TEA as a scavenger gives **77-12, 77-42**. Deprotection of the methyl ester, activation of the acid with thionyl chloride and the Friedal-Crafts aroylation proceed as before. Compound **77-15, 77-16** is generated by in situ deprotection of the methyl ethers using triethylsilane. Converting the final product into a bis-HCl salt improves solubility.

Generation of phosphonate prodrug **77-18, 77-19** is accomplished from commercial Raloxifene Hydrochloride. A reductive amination with an aminophosphonate generates the desired product. The reaction is carried out using **77-15, 77-16** equivalents of sodium cyanoborohydride in CH_2Cl_2. The two enantiomers generated are separated by chiral chromatography.

Scheme **77.1**




and




77-1 Formula IIa

77-2 Formula IIb




77-3 Formula IIIa


Scheme 77.2


OH
MeO
O
77-4
LO
OP
77-21
Deprotection
L is a leaving group
P represent a protecting group
HO
77-5
Activation
RO
R'O
P-Linker-NH
Me
77-22
RO
R'O
P- Linker
N
Me
MeO
77-6
Hydrolysis
Friedel-Crafts
PO
S
OP
77-7
RO
R'O
P-Linker-NH
Me
PO
77-8
RO
R'O
P-Linker-NH
Me
Deprotection
HO
OH
77-9
X
HX
77-10


Scheme **77.3**


OH
MeO
O
77-4
K_2CO_3, DMF
LO
OTMS
77-23
TFA
HO
O
MeO
O
77-5
MsCl, TEA
Me
RO
P
R'O
O
NH
77-32
RO
P
R'O
O
Me
N
O
MeO
O
77-50
LiOH, THF
RO
P
R'O
O
Me
N
O
HO
O
77-11
1. $SOCl_2$
2. $AlCl_3$, 77-33
3. EtSH
MeO
S
OMe
77-25
RO
P
R'O
O
Cl
NH
O
O
HO
S
OH
77-35


Scheme **77.4**


77-4
77-21
Deprotection
L is a leaving group.
P represents a protecting group.
77-5
Activation
77-24
77-12
Hydrolysis
Friedel-Crafts
77-7
77-13
Deprotection
77-14
HX
77-15


Scheme **77.5**



Scheme **77.6**



Scheme **77.7**



Example 78: Preparation of exemplary compounds of the present invention

Preparation of phosphonate prodrugs of mycophenolate mofetil

Three regions of mycophenolate mofetil are utilized for the attachment of the phosphonate prodrug onto mycophenolic acid as demonstrated by compounds **78-1** to **78-4** (Scheme **78.1**). Also, the carboxylic acid is replaced with a phosphonic acid which is part of the prodrug moiety as in compound **78-3**.

The morpholino ethyl moiety which serves as prodrug to improve bioavailability is replaced with the phosphonate prodrug handle as shown in Schemes **78.2-78.3**. Mycophenolic acid is commercially available, e.g., from Sigma Chemical Company, St. Louis, Mo. Activation of the carboxylic acid **78-5** in the presence of the free phenol followed by addition of an alcohol carrying the phosphonate group results in the formation of the desired product (U.S. Patent No. 4,786,637). Specifically, mycophenolic acid **78-5** is dissolved in dichloromethane. Thionyl chloride is added followed by a catalytic amount of DMF. The reaction mixture is stirred at room temperature for 3 hours, after which the volatile components are removed under vacuum. The phosphonate-alcohol is dissolved in dichloromethane and chilled to 4°C on an ice bath. The mycophenolic acid chloride **78-7** is dissolved in dichloromethane and added to the chilled solution. After stirring for 90 minutes at 4°C, the reaction mixture is washed with water and then with aqueous sodium bicarbonate. The organic solution is dried and evaporated to yield the phosphonate prodrug **78-6, 78-8**.

The C-4 phenol position provides a reactive handle for further analogs (Schemes **78.4-78.5**). Once the carboxylic acid is blocked by morpholino ethyl, such as in compound **78-9**, or a phosphonate prodrug as in compound **78-6, 78-8**, the phenol is alkylated under basic conditions. Bases such as pyridine, potassium carbonate, or triethylamine are utilized. Leaving groups such as trifluoromethylsulfonate, mesylate, bromide, or iodide are attached to the phosphonate prodrug subunit and reacted in the presence of base with compound **78-9**. Compound **78-2, 78-45** can either be used directly, or in the form of a salt. Among the number of salts that can be prepared, chloride and bisulfate salts are of particular interest.

Preparation of compound **78-10, 78-11** is outlined in more detail in Scheme **78.5**. Compound **78-7** is prepared as described in Scheme **78.3**. A

solution of morpholino ethanol in dichloromethane is cooled to 4°C. The mycophenolic acid chloride **78-7** is dissolved in dichloromethane and added to the cooled solution. Stirring this solution for 90 minutes gives compound **78-9**. The reaction mixture is washed with water and dried with sodium sulfate. Removal of the solvent provides compound **78-9**. Alkylation at the phenolic position of **78-9** is achieved by suspending the compound in pyridine. Triflate **78-30** is added to the solution and the mixture is stirred at room temperature for 90 minutes. The reaction mixture is poured into water and the product is extracted with ethyl acetate. Removal of the organic layer provides compound **78-2, 78-45**. Hydrochloride salt of **78-2, 78-45** is also prepared. Compound **78-2, 78-45** is dissolved in isopropanol and the solution is added to a mixture of hydrogen chloride in isopropanol. The hydrochloride salt **78-10, 78-11** is collected by filtration and dried under vacuum.

The carboxylic acid of mycophenolic acid is replaced with a phosphonic acid which serves as the prodrug handle as well. In order to remove the carboxylic acid containing side chain, the acid chloride **78-7** is converted to ester **78-13, 78-33**. Protection of the phenol with a silyl group, followed by dihydroxylation and cleavage of the diol generates aldehyde **78-15, 78-19** (Pankiewicz, et al., *J. Med. Chem.*, (2002), *45*, 703), (Patterson et al., U.S. Patent No. 5,444,072) (Schemes **78.6-78.7**). A wittig reaction with ylide **78-50, 78-31** carrying an appropriately protected phosphonate provides the desired compound **78-16, 78-20**. Final deprotection yields compound **78-17**.

Mycophenolate ester **78-13, 78-33** is prepared by stirring the acid chloride **78-7** with MeOH. Then, the phenol position of mycophenolate ester is protected by a silyl group such as TBS to provide compound **78-14, 78-18**. Once the phenol position is protected, dihydroxylation using osmium tetraoxide followed by periodinate cleavage provides aldehyde **78-15, 78-19**. Aldehyde **78-15, 78-19** and excess of the ylide **78-50, 78-31** are heated in benzene at reflux for 24 hours. The reaction mixture is concentrated and the residue is purified by column chromatography to provide olefin **78-16, 78-20** (Pankiewics et al., *J. Med. Chem.*, (2002), *45*, 703). A final deprotection using HF-pyridine yields the final product **78-17**.


Another attachment point of the compound is unmasked after demethylation of mycophenolate ester **78-9** (Schemes **78.8-78.9**). For this

purpose, 4-OH is masked with a protecting group such as a silyl group. Once the 6-MeO is demethylated and alkylated, the protecting group at position 4 is removed to reveal the final product. The morphonyl ethanol group is installed early and carried through the alkylation steps. A different group serving the role of the protecting group is installed initially and removed later. In that case, the last step is the formation of the morpholinoethyl ester prodrug.


Synthesis of compound **78-4** is shown in Scheme **78.9**. Phenol **78-9** is protected with TBS group in CH_2Cl_2 using imidazole as base. Demethylation is performed using thiolate nucleophiles to generate compound **78-26, 78-22**. A variety of other methods are also available in literature as described in protective groups in organic synthesis by Greene and Wuts. Alklation of the 6-OH using a triflate of the phosphonate prodrug proceeds well using K_2CO_3 or TEA. Final deprotection to remove the TBS group provides product **78-27, 78-24**.

Further manipulations can be performed on the phosphonate moiety prior to the final deprotection. These types of transformations are more extensively described in the following section.


Scheme **78.1**




78-1



78-2




78-3




78-4


Scheme **78.2**




Scheme **78.3**




Scheme **78.4**


1. Activation of the acid
2. HO
78-5
78-9
X–Linker–P–OR
OR'
base
Linker
78-2
HX
78-10


Scheme **78.5**


OH
OH
SO_2Cl_2, CH_2Cl_2, DMF
OH
Cl
78-5
78-7
HO
N
O
, CH_2Cl_2
OH
TfO
P
OR
OR'
78-30
Pyr
78-9
OR
OR'
78-45
HCl, i-PrOH
Cl
NH
78-11


Scheme **78.6**


OH
O
O
O
alkyl
O
Protection
OP
78-13
78-14
Dihydroxylation
Cleavage of the diol
OP
O
78-15
Ph3P
Linker
P
OR
OR'
78-50
OP
Linker
OR'
OR
Deprotection
OH
78-16
78-17

Scheme **78.7**



OH
O
Cl
MeOH
78-7
78-33
TBSCl, Im
CH_2Cl_2
OTBS
OsO_4, $NaIO_4$
78-18
Ph_3P
OR
OR'
78-31
78-19
78-20
HF-pyr
78-17

Scheme **78.8**



78-9 **78-25** **78-26** **78-27**


Scheme **78.9**



Example 79: Preparation of exemplary compounds of the present invention


Derivatization at the C-21 hydroxy group is accomplished through alkylation of dexamethasone **79-1** with the appropriate phosphonate, furnishing analogs of the type **79-2**. (Scheme **79.1**)

Scheme **79.1**



After sodium hydride extraction of the primary hydroxy proton in **79-1**, diethyl phosphonate triflate is added to afford ether **79-3**. (Scheme **79.2**)


Scheme **79.2**



79-1 79-3


Phosphonate appendages linked to the C-11 hydroxy group are attained from utilizing protecting groups on dexamethasone **79-1**. (Scheme **79.3**) Following protection of the primary hydroxy group, protected intermediate **79-4** is alkylated at the more exposed C-11 hydroxy site. Final deprotection provides the desired product **79-6**.

Scheme **79.3**




Dexamethasone **79-1** is protected as its silyl ether using the standard TBSCl and imidazole conditions. (*J. Am. Chem. Soc.* 1972, *94*, 6190) (Scheme **79.4**) After alkylating with the diethyl phosphonate triflate, the resulting intermediate **79-8** is treated with TBAF to give the diol **79-9**.

Scheme **79.4**




Synthesis of C-21 phosphonate analogs of the type **79-12** is shown in Scheme **79.5**. Protection this time of dexamehtasone **79-1** at the two less hindered sites furnishes alcohol **79-10**, which is alkylated at the only exposed hydroxy group with the appropriate phosphonate. Removal of the protecting groups completes the construction of analog **79-12**.

Scheme **79.5**



Again dexamethasone **79-1** is protected as its TBS ether; however, harsher conditions are used for bis-protection. (Scheme **79.6**) After alkylating with the diethyl phosphonate triflate, the resulting intermediate **79-14** is treated with TBAF to give the desired phosphonate **79-15**.


Scheme **79.6**



79-1 79-13 79-14 79-15

Example 81: Preparation of exemplary compounds of the present invention


Experimental results for pro-drugs of phosphonate-containing PNP inhibitors



130-1 130-2

The diacid (100 mg, 0.304 mmol), amino acid (100 mg, 0.651 mmol), phenol (145 mg, 1.54 mmol), and triethylamine (510 µL, 3.66 mmol) were dissolved in pyridine (5 mL). The mixture was heated to 60°C for 5 minutes. To this reaction mixture was added a solution of triphenylphosphine (560 mg, 2.14 mmol) and Aldrithiol(2) (470 mg, 2.13 mmol) dissolved in pyridine (5 mL). The reaction was then heated at 60°C for 12 hours. The reaction mixture was diluted in EtOAc, washed with H_2O, sat'd $NaHCO_3$(aq), and brine. The organic

layer was dried ($MgSO_4$), concentrated and purified by chromatography on silica gel (1% $MeOH/CH_2Cl_2$ → 10% $MeOH/CH_2Cl_2$) to give monoamidate **81-1** (5 mg, 3%) and bisamidate **81-2** (5 mg, 3%). For **81-1**: ^1H NMR (300 MHz, CD_3OD) δ 7.78 (1H, m), 7.35 (2H, m), 7.20 (3H, m), 4.18-3.95 (5H, m), 2.24-1.90 (2H, m), 1.87-1.62 (4H, m), 1.38-1.18 (6H, m), 1.02 (6H, m); ^{31}P NMR (121 MHz, CD_3OD) δ 36.3, 35.3; LC-MS (method: 0.5 min 95% H_2O/5% MeCN → 5 min 0% H_2O/100% MeCN, rt = 2.18 min. MS calc'd for $C_{23}H_{34}N_6O_5P$ (MH^+): 505.2. Found 505.2. For **81-2**: ^1H NMR (300 MHz, CD_3OD) δ 7.77 (1H, s), 4.23-3.92 (8H, m), 2.04-1.50 (6H, m), 1.42 (3H, d), 1.40 (3H, d), 1.28 (3H, t), 1.22 (3H, t), 1.02 (3H, s), 1.01 (3H, s); ^{31}P NMR (121 MHz, CD_3OD) δ 33.9; LC-MS (method: 0.5 min 95% H_2O/5% MeCN → 5 min 0% H_2O/100% MeCN, rt = 1.79 min. MS calc'd for $C_{22}H_{39}N_7O_6P$ (MH^+): 528.3. Found 528.3.



The diacid (25 mg, 0.072 mmol), amino acid (25 mg, 0.16 mmol), phenol (38 mg, 0.40 mmol), and triethylamine (127 μL, 0.911 mmol) were dissolved in pyridine (1.25 mL). The mixture was heated to 60°C for 5 minutes. To this reaction mixture was added a solution of triphenylphosphine (140 mg, 0.534 mmol) and Aldrithiol(2) (119 mg, 0.540 mmol) dissolved in pyridine (1.25 mL). The reaction was then heated at 60°C for 12 hours. Another batch of diacid (12 mg, 0.035 mmol) was treated as described above. The reaction mixtures from both batches were combined and diluted in EtOAc, washed with H_2O, sat'd $NaHCO_3$(aq) and brine. The organic layer was dried ($MgSO_4$), concentrated and purified by chromatography on silica gel (1% $MeOH/CH_2Cl_2$ → 10% $MeOH/CH_2Cl_2$). to give monoamidate **81-3** (3 mg, 8%) and bisamidate **81-4** (8 mg, 20%). For **81-3**: ^1H NMR (300 MHz, CD_3OD) δ 8.38-8.08 (1H, m), 7.78-7.60 (2H, m), 7.50-7.18 (8H, m), 6.67-6.05 (1H, m), 5.60-5.30 (2H, m), 4.63

(1H, bs), 4.25-3.95 (3H, m), 1.37 (3H, m), 1.18 (3H, m); ^{31}P NMR (121 MHz, CD_3OD) δ 21.5, 20.2; LC-MS (method: 0.5 min 95% H_2O/5% MeCN → 5 min 0% H_2O/100% MeCN, rt = 1.98 min. MS calc'd for $C_{25}H_{28}N_6O_5P$ (MH^+): 523.2. Found 523.2. For **81-4**: ^{1}H NMR (300 MHz, CD_3OD) δ 8.15 (1H, dd), 7.72 (1H, s), 7.67 (1H, m), 7.39 (2H, m), 7.28 (1H, m), 6.44 (1H, dd), 5.40 (2H, s), 4.23-3.90 (6H, m), 1.42 (6H, m), 1.27 (3H, t), 1.18 (3H, t); ^{31}P NMR (121 MHz, CD_3OD) δ 19.7; LC-MS (method: 0.5 min 95% H_2O/5% MeCN → 5 min 0% H_2O/100% MeCN, rt = 1.86 min. MS calc'd for $C_{24}H_{33}N_7O_6P$ (MH^+): 546.2. Found 546.2.

Pro-drug cleavage assays

Isolation of PBMC Extracts:

Fresh human PBMCs were obtained from patients undergoing leukophoresis; cells were shipped in plasma and processed within 26 h of draw. Purification was achieved using the Ficoll-Paque method: PBMC cells were harvested by centrifugation at 1200 X g for 5 minutes and washed three times by re-suspension in RBC lysis buffer (155 mM NH_4Cl, 0.1 mM EDTA, 10mM $KHCO_3$). Washed cells were suspended in lysis buffer ($0.2x10^9$ cells in 1 ml of 10 mM Tris, pH 7.4, 150 mM NaCl, 20 mM $CaCl_2$, 1 mM DTT and 1% NP40) and incubated on ice for 20 minutes. The PBMC crude extract was centrifuged at 1000 X g for 30 min to remove unlysed cells and the supernatant at 100,000 X g for 1h. The 100,000 X g supernatant (PBMC Extract: P0) was harvested, snap frozen in liquid nitrogen and stored at –70°C.

Protocol for measurement of cleavage of prodrugs by PBMC Extracts:

Reaction mixtures contained 25mM MesNa (pH 6.5), 100 mM NaCl, 1 mM DTT, 0.1% NP-40, 30 μM substrate, and varying amounts of enzyme in a final volume of 100μl. The enzymatic reaction is performed at 37° C for 10 –120 minutes and stopped at 3-4 individual time points by adding 180 μl of ice cold methanol. Samples are incubated at -20 °C for 30 min, and centrifuged 13,000 RPM for 30 min (at 4 °C). The supernatant is transferred to a 96 well plate and evaporated under vacuum using a speedvac. The precipitate is dissolved in 100

μl of 20 mM CH_3COONH_4+ 5% AcCN. The disappearance of pro-drug is measured by HPLC, monitoring at 260nm. The specific activity of the PBMC Extract against the prodrugs tested is defined as: v (cleavage rate) / μg protein = pmoles / min / μg.


Results

Compound	Human PBMC extract specific activity (pmol/min/μg)
81-1	3.48
81-2	0.65
81-3	4.9
81-4	0.38

Example 82: Preparation of exemplary compounds of the present invention

A series of inhibitors of PNP are rationally designed to mimic the transition state of the enzyme. This class as a whole is called the Immucillins. Depending on the enzyme that is used for the rational design of inhibitors, slightly different structures were proposed and synthesized. A highly potent analog inhibiting the PNP enzyme from *Mycobacterium tuberculosis* (MtPNP) called DADMe-ImmG, structure below, was prepared recently (Lewandowics A. et al., *Biochemistry*, (2003), *42*, 6057).

Scheme **82.1**




DADMe-ImmG

82-9

Reduction of the dose and/or improvement of efficacy is achieved by the use of pro-drugs DADMe-ImmG that, upon cleavage inside the target cell, give rise to agents with increased intracellular half-lives. Such phosphonates pro-drug compounds are shown below (Scheme **82.2**).

Scheme **82.2**:




82-1 **82-2**

General structure of prodrugs of DADMe


Compounds such as **82-1** is made according to the general route outlined in Scheme **82.3**, with an example depicted in Scheme **82.4**.

Scheme **82.3**



82-3 **82-1**

Scheme **82.4**




82-3 **82-4**

Preparation of DADMe-ImmG is reported in Lewandowics A. et al., *Biochemistry*, (2003), *42*, 6057. The tertiary nitrogen of the ring may not interfere with the alkylation of the secondary alcohol and in that case does not need to be protected, although standard protection and deprotection protocols as described in Greene, T. Protective groups in organic synthesis, Wiley-Interscience, (1999) may be used if necessary. Reaction of the primary alcohol **82-3** with base followed by addition of the appropriately activated phosphonate yields the protected product. Global deprotection yields the desired phosphonate **82-4**.

Compounds such as **82-2** is made according to the general route outlined in Scheme **82.5**, with an example depicted in Scheme **82.6**.


Scheme **82.5**



82-5 **82-2**

Preparation of DADMe-ImmG is reported in Lewandowics A. et al., *Biochemistry*, (2003), *42*, 6057. Blocking of the primary alcohol can be achieved by methods described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999). Reaction of the secondary alcohol in base followed by addition of the appropriately activated phosphonate yields the protected desired product. Deprotection yields the desired phosphonate.

Scheme **82.6**




82-7 **82-8**

Specifically, the protected DADMe derivative can be treated with treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonoethylltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, yielding the desired phosphonate ester. Removal of the protecting group can be performed as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, (1999) to provide the desired phosphonate ester.


Example 83: Preparation of exemplary compounds of the present invention
Scheme **83.1**

Parent molecule:



Leflunomide


83-1




Active metabolite

83-2

General target structures:



83-3




83-4

link includes 1 or more atoms; 2 - 8 is preferred

A synthetic scheme towards specific targets **83-8** and **83-9** is outlined below:

Scheme **83.2**



83-5 83-6 83-7


Target 83-8

Target 83-9

Reference for these reactions: *J. Med. Chem.* (1996), *39*, 4608

Additional Compounds: The synthesis of targets **83-13** and **83-14** is set forth below.

Scheme **83.3**



83-5 83-10 83-11 83-12


Target 83-13

Target 83-14

Example 84: Preparation of exemplary compounds of the present invention


Leflunomide (structure below, together with its active metabolite) (see U.S. Patent No. 4,284,786) is a derivative of isoxazole that inhibits various T-lymphocyte functions through the inhibition of dihydroorotate dehydrogenase (Copeland et al, Biochem., (1996), 35, 1270).

Scheme **84.1**




84-1

Leflunomide



84-2

A771726 (active metabolite)




84-3

FK778 (MNA-715)

The active metabolite of leflunomide (A771726, also known as teriflunomide, see U.S. Patent No. 6,288,098) has a very long half-life in humans, and this is a cause for concern given the side effects that have been noted for the compound, which include skin rash, pruritus, diarrhea, abdominal pain, nausea, vomiting, weight loss, hypertension, dizziness, and reversible alopecia. More serious adverse events that have also been reported include several cases of pleural involvement, vasculitis and hepatotoxicity. Rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have also been described.


Reduction of the dose and improvement of efficacy is achieved by the use of pro-drugs of analogs of leflunomide or its metabolite which, upon cleavage inside the target cell, give rise to an agent with an increased intracellular half-life. The same concepts are applicable to FK778 (MNA-715) (see U.S. Patent No. 5,308,865), an agent with a similar mode of action. Such compounds are described below.

Scheme **84.2**




84-4

OR




84-5




84-6


OR



84-7



84-8




84-9

In all cases, link includes 1 or more atoms;
2 - 8 is preferred

Synthetic methodology towards compounds such as these is described by Westwood et al, J. Med. Chem., (1996), 39, 4608-4621, according to the general routes outlined in Schemes **84.3-84.5**.

Scheme **84.3**



84-10


84-22

84-21

84-25


Examples of the synthesis of suitable phosphonate-containing anilines are shown below.

Scheme **84.4**



84-11 84-12 84-13 84-14

Scheme **84.5**




84-15 84-16 84-17 84-18 84-19 84-20

Example 85: Preparation of exemplary compounds of the present invention

Brequinar (structure below; see U.S. Patent No. 4,680,299 and U.S. Patent No. 5,032,597) is an inhibitor of dihydroorotate dehydrogenase (*Biochemical Pharmacology* 1990, 40, 709-714).

Scheme **85.1**




85-1


The compound has been investigated clinically as an immunosuppressant or as an anti-cancer agent, but its efficacy has been disappointing, possibly due to a narrow therapeutic window arising from an excessively long half-life that precludes higher dosing.

These problems are addressed by the use of pro-drugs of analogs of brequinar as well as other quinoline inhibitors of dihydroorotate dehydrogenase which, upon cleavage inside the target cell, give rise to an active entity with a sustained intracellular half-life relative to plasma levels. The therapeutic index of such agents might be significantly improved over brequinar itself. Such compounds are described below.

Scheme **85.2**



85-2 **85-3**



85-4 **85-5**

X, X' = H, F, Cl, CF_3, CN, Me, tBu


In all cases, link includes 1 or more atoms; 2 - 8 is preferred

Link > one atom spacer, best > 2

Link > one atom spacer, best = 3 or greater


Synthetic methodology towards compounds such as these is based on methods described by Batt et al, *Bioorg. Med. Chem. Lett.*, (1995), *5*, 1549. A typical general route is outlined in Schemes **85.3-85.5**.

Scheme **85.3**




Examples of the synthesis of suitable phosphonate-containing analogs are shown below.

Scheme **85.4**




Scheme **85.5**



Example 86: Preparation of exemplary compounds of the present invention


Scheme 86.1: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-methyl)-phosphonic acid diethyl ester



To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (67.0 mg, 177 μmol) in DMF (3.0 mL) was added diethyl cyanophosphonate (34.8 μL, 230 μmol) and diisopropylethylamine (Hunig's Base, DIEA, 30.4 μL, 177 μmol). The solution was stirred at ambient temperature for 4 hours when diethyl(aminomethyl)-phosphonate (45.4 mg, 177 μmol) was added. The solution was stirred for 4

additional hours, when complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount of the product (20 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 12.9 mg (76%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.19 (t, 6H, *J*= 7.2 Hz), 3.21 (s, 3H), 3.70 (m, 2H), 4.00 (q, 4H, *J*= 7.2 Hz), 4.81 (s, 2H), 6.81 (d, 2H, *J*= 9 Hz), 7.71 (d, 2H, *J*= 9 Hz), 8.40 (br s, 1H), 8.61 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 23.4. MS (*m/z*) 475.2 $[M+H]^+$, 597.2 $[M+Na]^+$.


Scheme 86.2: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-methyl)-phosphonic acid



To a solution of crude (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester post silica column chromatography (60 mg, 126 μmol) in dry DMF (0.90 mL) was added trimethylsilyl bromide (bromotrimethylsilane, TMSBr, 130.6 μL, 1,010 μmol) at ambient temperature. The solution was then heated at 70 °C for 4.0 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent volume was reduced to ~ 700 μL *in vacuo* and diluted with H_2O (100 μL). This solution was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 26.8 mg (51%) of the desired compound as a yellow solid. ^{1}H NMR (300 MHz, DMSO-d_6) δ 3.18 (s, 3H), 3.50 (m, 2H),


4.77 (s, 2H), 6.79 (d, 2H, *J*= 9 Hz), 7.79 (d, 2H, *J*= 9 Hz), 8.07 (br s, 1H), 8.56 (s, 1H); MS (*m/z*) 419.2 $[M+H]^+$.

Scheme 86.3: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester




To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (61.2 mg, 161 μmol) in DMF (2.8 mL) were added diethyl cyanophosphonate (31.8 μL, 210 μmol) and DIEA (27.8 μL, 161 μmol). The solution was stirred at ambient temperature for 4 hours, when diethyl(aminoethyl)phosphonate (43.8 mg, 161 μmol) was added. The solution was stirred for 3 additional hours, by which time complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount of the product (32 mg) was re-purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 19 mg (70%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.21 (t, 6H, *J*= 7 Hz), 1.95- 2.05 (m, 2H), 3.20 (s, 3H), 3.13- 3.22 (m, 2H), 3.98 (appt septet, 4H, *J*= 7 Hz), 4.79 (s, 2H), 6.80 (d, 2H, *J*= 9 Hz), 7.65 (d, 2H, *J*= 9 Hz), 8.20 (br s, 1H), 8.60 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 28.9. MS (*m/z*) 489.2 $[M+H]^+$, 511.2 $[M+Na]^+$.

Scheme 86.4: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid



To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester post silica column chromatography (61 mg, 125 μmol) in dry DMF (1.00 mL) was added TMSBr (129.0 μL, 999.2 μmol) at ambient temperature. The solution was then heated at 70 °C for 5.5 hours, when LCMS analysis demonstrated the reaction to be 90% complete. The reaction mixture was allowed to cool to room temperature and stirred for an additional 12 hours. The reaction was worked up by removal of the solvent *in vacuo* and dissolving the residue in DMF / H_2O (800 μL, 1:1) and 1N aqueous NaOH (15 μL). The product was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 29 mg (53%) of the desired compound as a yellow solid. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.67- 1.85 (m, 2H), 3.19 (s, 3H), 3.25- 3.40 (m, 2H), 4.76 (s, 2H), 6.71 (br s, 2H), 5.80 (d, 2H, J= 9 Hz), 7.64 (d, 2H, J= 9 Hz), 7.73 (br s, 2H), 8.15 (br s, 1H), 8.56 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 23.0. MS (*m/z*) 431.3 [M-H]$^-$.


Scheme 86.5: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid diethyl ester



To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (61.2 mg, 161 μmol) in DMF (2.8

mL) were added diethyl cyanophosphonate (31.8 μL, 210 μmol) and DIEA (27.8 μL, 161 μmol). The solution was stirred at ambient temperature for 3 hours, when diethyl(aminopropyl)phosphonate (34.9 mg, 122.6 μmol) was added. The solution was stirred for 2 additional hours, whereupon complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product (65.5 mg) collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount (32.8 mg) was re-purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 23.2 mg (75%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.20 (t, 6H, J= 7.2 Hz), 1.64- 1.75 (m, 4H), 3.22 (s, 3H), 3.41 (m, 2H), 3.98 (appt septet, 4H, J= 7.2 Hz), 4.85 (s, 2H), 6.79 (d, 2H, J= 9 Hz), 7.68 (d, 2H, J= 9 Hz), 8.17 (br s, 1H), 8.70 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 31.9; MS (*m/z*) 503.2 $[M+H]^+$.


Scheme 86.6: (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid



To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid diethyl ester post silica column chromatography (32.2 mg, 66.2 μmol) in dry DMF (0.50 mL) was added TMSBr (68.0 μL, 529.6 μmol) at ambient temperature. The solution was then heated at 70 °C for 1.0 hour, when LCMS analysis demonstrated the reaction to be complete. The reaction mixture was allowed to cool to room temperature, and water (60 μL) and methanol (60 μL) were added. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 11.2 mg (38%) of the desired compound as a yellow solid. ^1H NMR (300 MHz, DMSO-d_6) δ 1.50 (m, 2H), 1.61 (m, 2H), 3.22 (s, 3H), 3.25- 3.40 (m,

2H), 4.84 (s, 2H), 6.80 (d, 2H, *J*= 9 Hz), 7.69 (d, 2H, *J*= 9 Hz), 8.20 (br s, 1H), 8.69 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 26.3. MS (*m/z*) 447.3 [M-H]$^-$.


Scheme 86.7: 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methyl-amino]benzoylamino}-ethyl)phenoxyphosphinoyloxy]propionic acid ethyl ester [diastereomeric mixture at phosphorus]



To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (60.0 mg, 158.3 μmol) in DMF (2.5 mL) were added diethyl cyanophosphonate (31.2 μL, 205.7 μmol) and DIEA (81.8 μL, 474.9 μmol). The solution was stirred at ambient temperature for 3.5 hours, when a solution of (*S*)-2-[(2-aminoethyl)phenoxyphosphinoyloxy]-propionic acid ethyl ester mono acetic acid salt (57.1 mg, 158.3 μmol; mixture of diastereomers at phosphorus) in DMF (200 μL) was added. The solution was stirred for 1.5 additional hours, whereupon complete consumption of the starting materials was observed. The solvent was removed *in vacuo* and the crude material was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). A small amount of the product (24.8 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 15.8 mg (65%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.17 – 1.27 (m, 3H), 1.32 (d,


2H, J = 7.5 Hz), 1.42 (d, 1H, J = 7.5 Hz) 2.27 (m, 2H), 3.19 (s, 3H), 3.53 (m, 2H), 4.08 – 4.14 (m, 2H), 4.77 (s, 2H), 4.98 (m, 1H), 6.72 (br s, 1H), 6.81 (d, 2H, *J*= 9 Hz), 7.21 (m, 3H), 7.36 (m, 2H), 7.66 (d, 2H, *J*= 9 Hz), 8.26 (br s, 1H), 8.56 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.6, 27.4. MS (*m/z*) 609.2 $[M+H]^+$.

Scheme 86.8: 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methyl-amino]benzoylamino}-ethyl)phenoxyphosphinoyloxy]-propionic acid [diastereomeric mixture at phosphorus]




To a solution of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methyl-amino]benzoylamino}ethyl)phenoxy-phosphinoyloxy]propionic acid ethyl ester (mixture of diastereomers at phosphorus; 40.0 mg, 65.7 μmol) in DMF (0.4 mL), acetonitrile (0.2 mL) and water (0.2 mL) was added aqueous sodium hydroxide (1 N, 131.4 μL). The solution was stirred at ambient temperature for 4 hours. The solvents were removed *in vacuo* and the crude product was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 23.7 mg (71.3%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.30 (d, 2H, J = 6.9 Hz), 1.79 (m, 2H), 3.21 (s, 3H), 3.37 (m, 2H), 4.61 (m, 1H), 4.81 (s, 2H), 6.79 (d, 2H, *J*= 8.7 Hz), 7.64 (d, 2H, *J*= 9.7 Hz), 8.25 (br s, 1H), 8.63 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 25.1. MS (*m/z*) 505.2 $[M+H]^+$.

Scheme 86.9: 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]-benzoy-lamino}ethyl)phenoxyphosphinoyloxy]propionic acid ethyl ester [diastereomerically pure at phosphorus]



To a solution of 4-[(2,4-diaminopteridin-6-ylmethyl)-methyl-amino]benzoic acid hemihydrochloride dihydrate (101.9 mg, 268.9 μmol) in DMF (3.3 mL) were added diethyl cyanophosphonate (53.0 μL, 349.5 μmol) and DIEA (138.0 μL, 806.7 μmol). The solution was stirred at ambient temperature for 2.5 hours, whereupon (*S*)-2-[(2-aminoethyl)phenoxyphosphinoyloxy]-propionic acid ethyl ester mono acetic acid salt (diastereomerically pure at phosphorus; 268.9 μmol) in DMF (500 μL) was added. The solution was stirred for 30 additional minutes, whereupon complete consumption of the starting materials was observed. The solvent was removed *in vacuo* and the crude material was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). A small amount of the product (40.0 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 28.7 mg (75.1%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.15 (t, 3H, J = 7.2 Hz), 1.44 (d, 3H, J = 6.9 Hz), 2.26 (m, 2H), 3.23 (s, 3H), 3.51 (m, 2H), 4.09 (q, 2H, J = 7.2 Hz), 4.86 (s, 2H), 5.01 (m, 1H), 6.81 (d, 2H, *J*= 9.3 Hz), 7.21 (m, 3H), 7.35 (m, 2H), 7.68 (d, 2H, *J*= 9.3 Hz), 8.29 (br s, 1H), 8.71 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.6. MS (*m/z*) 609.2 $[M+H]^+$.


Scheme 86.10: 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}-ethyl)-phenoxyphosphinoylamino]propionic acid ethyl ester (mixture of diastereomers at phosphorus)



To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (39.6 mg, 104.0 μmol) in DMF (1.2 mL) were added diethyl cyanophosphonate (20.6 μL, 136.1 μmol) and DIEA (36.0 μL, 209.4 μmol). The solution was stirred at ambient temperature for 3 hours, when (*S*)-2-[(2-aminoethyl)phenoxyphosphinoylamino]propionic acid ethyl ester mono acetic acid salt (mixture of diastereomers at phosphorus; 104.0 μmol) in DMF (200 μL) was added. The solution was stirred for 30 minutes when complete consumption of the starting materials was observed. An aliquot (66%) of the reaction was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%), yielding 27.2 mg of crude product. A small amount of the product (10 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 4.2 mg (26%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.11 (t, 3H, *J*= 6.9 Hz), 1.18 (d, 3H, *J*= 7.2 Hz), 2.06-2.17 (m, 2H), 3.20 (s, 3H), 3.51 (m, 2H), 3.88 (m, 1H), 4.02 (m, 2H), 4.79 (s, 2H), 5.61 (m, 1H), 6.80 (d, 2H, *J*= 9 Hz), 6.98 (br s, 1H), 7.18 (m, 3H), 7.32 (m,


2H), 7.67 (d, 2H, *J*= 9 Hz), 8.20 (br s, 1H), 8.59 (s, 1H) ^{31}P (121.4 MHz, DMSO-d_6) δ 29.5, 30.1. MS (*m/z*) 608.2 $[M+H]^+$.

Scheme 86.11: 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6-(diethoxy-phosphoryl)-hexanoic acid




To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (63.0 mg, 166.2 μmol) in DMF (2.8 mL) were added diethyl cyano phosphonate (30.8 μL, 199.4 μmol) and DIEA (85.8 μL, 498.6 μmol). The solution was stirred at ambient temperature for 3.5 hours when (L)-2-amino-6-diethylphosphonatohexanoic acid (44.3 mg, 166.2 μmol) was added. The solution was stirred for 48 additional hours. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product (87 mg) collected from this chromatography step was sufficiently pure to be carried on to the next reaction. An aliquot of the product (51.0 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 24.7 mg (44%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.18 (t, 6H, *J*= 6.9 Hz), 1.42 (m, 4H), 1.65 (m, 4H), 3.20 (s, 3H), 3.92 (m, 4H), 4.29 (m, 1H), 4.78 (s, 2H), 6.72 (br s, 1H), 6.81 (d, 2H, *J*= 9 Hz), 7.73 (d, 2H, *J*= 9 Hz), 8.14 (d, 1H, *J* = 7.8 Hz), 8.56 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 31.8; MS (*m/z*) 574.3 $[M]^+$.

Scheme 86.12: 2-{4-[(2,4-Diaminopteridin-6-ylmethyl)methylamino]-benzoylamino}-6-(phosphoryl)hexanoic acid



To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino})-2' (*L*)-(6'-(phosphonic acid diethyl ester) hexanoic acid) post silica column chromatography (20 mg, 34.6 μmol) in dry DMF (0.60 mL) was added TMSBr (18.0 μL, 139.2 μmol) at ambient temperature. The solution was then heated at 70 °C for 18 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent was removed *in vacuo* and dissolved in DMF (400 μL) and water (60 μL). This solution was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 8.9 mg (49%) of the product as a yellow solid. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.45 (m, 6H), 1.75 (m, 2H), 3.20 (s, 3H), 4.25 (m, 1H), 4.77 (s, 2H), 6.62 (br s, 1H), 6.80 (d, 2H, *J*= 8.7 Hz), 7.73 (d, 2H, *J*= 8.7 Hz), 8.14 (br s, 1H), 8.55 (s, 1H); MS (*m/z*) 519.2 $[M+H]^+$.


Scheme 86.13: 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)hexanoic acid



The ethyl-TMS ester is hydrolyzed under suitable conditions to provide the corresponding acid of the invention.

The intermediate 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester can be prepared as follows.


a. *(L)*-2- Cbz-Amino-hexanoic acid –6-phosphonic acid.



To a suspension of (*L*)-2-amino-6-(diethoxyphosphonyl)hexanoic acid (106 mg, 396.8 μmol) in dry DMF (2.00 mL) was added TMSBr (307.0 μL, 2,381.0 μmol) at ambient temperature. The solution was then heated at 70 °C for 2 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent was removed *in vacuo*. The crude material was dissolved in water (0.25 mL) and NaOH (1-N, 2.50 mL). Benzyl chloroformate (79.3 μL, 555.5 μmol) was added and stirring at room temperature was

continued. After 2 hours, the solution was washed with ether (2 mL) and the aqueous layer was acidified with aqueous HCl to pH 1. The aqueous layer was extracted with EtOAc (3x 5 mL). The combined organic extracts were dried over sodium sulfate. Filtration and evaporation of solvents yielded a crude product, which was sufficiently pure for further transformations. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.42 – 1.65 (m, 8H), 3.90 (m, 1H), 5.02 (s, 2H), 7.32 (s, 5H), 7.55 (m, 1H), 7.94 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.5; MS (*m/z*) 345.6 $[M+H]^+$.

b. (*L*)-2--Amino-hexanoic acid 2' TMS ethyl ester–6-phosphonic acid mono phenyl ester



To a solution of (*L*)-2-Cbz-amino-hexanoic acid–6-phosphonic acid (137.3 mg, 397.9 μmol) in 2-TMS ethanol (2.5 mL) was added acetyl chloride (50 μL). Stirring at room temperature was continued. After 22 hours complete conversion was observed. The solvents were removed *in vacuo*. The crude material was sufficiently pure for the next step.


One half of the crude material (198.9 μmol) was dissolved in toluene (3.0 mL) at room temperature. Thionyl chloride (167.2 mg, 1,416.0 μmol) was added and the reaction mixture was heated at 70 °C (oil bath). After 4 hours, the reaction was cooled to room temperature and the solvent was removed *in vacuo*. The crude material was re-dissolved in methylene chloride (2.0 mL) and a solution of phenol (36.6 mg, 389.0 μmol) and DIEA (67.0 μL, 389.0 μmol) in methylene chloride (1.0 mL) was added. Stirring at room temperature was continued. After 4 hrs the solvents were removed *in vacuo*.


The crude material was dissolved in tetrahydrofuran (THF) (3.0 mL) and aqueous sodium hydroxide solution (1N, 0.885 mL) was added. Stirring at room

temperature was continued. After 14 hours the solvent was removed *in vacuo* to provide the crude phosphonate mono phenyl ester (63.8 mg). This material was dissolved in 2-TMS ethanol (1.0 mL) and acetyl chloride (20 μL) was added. Stirring at room temperature was continued. After 22 hours complete conversion to the carboxylate ester was observed. The solvents were removed *in vacuo*. The material was sufficiently pure for the next step.

One half of the crude material (75 μmol) was dissolved in ethanol (1.5 mL). Pd/C (5%, 20 mg) was added and the reaction was placed under an atmosphere of hydrogen gas. After 1.5 hours Celite was added and the crude reaction mixture was filtered through Celite. The solvents were removed *in vacuo* and the crude material was used in the next step without further purification.

c. 2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester






To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (22.7 mg, 60.0 μmol) in DMF (0.80 mL) were added diethyl cyano phosphonate (12.4 μL, 78.0 μmol) and DIEA (31.0 μL, 180.0 μmol). The solution was stirred at ambient temperature for one hour when (L)-2-amino-6-monophenoxyphosphonatohexanoic acid 2' TMS

ethyl ester (70.5 μmol), suspended in DMF (0.2 mL), was added. The solution was stirred for 3.5 additional hours. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (5-95%) to provide 19.4 mg (46%) of 2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester. ^{1}H NMR (300 MHz, DMSO-d_6) δ 0.0 (s, 9H), 0.91 (t, 2H, J= 8.1 Hz), 1.42 – 1.53 (m, 4H), 1.67 –1.76 (m, 4H), 3.24 (s, 3H), 4.10 (t, 2H, J= 8.1 Hz), 4.29 (m, 1H), 4.86 (s, 2H), 6.81 (d, 2H, J= 9 Hz), 7.12 (m, 3H), 7. 31 (m, 2H), 7.74 (d, 2H, J= 9 Hz), 8.14 (d, 1H, J = 7.8 Hz), 8.71 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.2; MS (*m/z*) 695.2 $[M]^+$.


Scheme 86.14: 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)methylamino]-benzoylamino}-6'-(mono phenyl mono (S) ethyl lactate-phosphonate)hexanoic acid



The ethyl-TMS ester is hydrolyzed under suitable conditions to provide the corresponding acid of the invention.

The intermediate 2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl mono (S) ethyl lactate-phosphonate)-hexanoic acid TMS ethanol ester can be prepared as follows.

2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl mono (S) ethyl lactate-phosphonate)-hexanoic acid TMS ethanol ester




To a solution of 2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester (14.5 mg, 20.8 μmol, Example 225) in DMF (0.70 mL) was added PyBOP (32.4 mg, 62.4 μmol), DIEA (21.4 mg, 166.4 μmol) and (S) ethyl lactate (19.6 mg, 166.4 μmol). The reaction mixture was stirred at room temperature for one hour. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (5-95%) to provide 13.5 mg (81%) of the pure product as a mixture of diastereomers at phosphorus (~ 4:1). ^1H NMR (300 MHz, $CDCl_3$) δ 0.0 (s, 9H), 1.02 (t, 2H, *J*= 8.7 Hz), 1.23 (t, 3H, *J*= 9.3 Hz), 1.35 (d, 2.4H, *J*= 6.6 Hz), 1.42 – 1.53 (m, 4.6H), 1.67 –1.86 (m, 4H), 3.14 (s, 3H), 4.03 – 4.27 (m, 4H), 4.71 (br s, 3H), 4.98 (m, 0.8H), 5.10 (m, 0.2H), 6.57 (d, 2H, *J*= 7.5 Hz), 7.00 (m, 1H), 7.16 (m, 3H), 7. 30 (m, 2H), 7.63 (d, 2H, *J*= 7.5 Hz), 8.43 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 30.5, 29.2; MS (*m/z*) 795.2 $[M]^+$.

Example 87: Preparation of exemplary compounds of the present invention

A recent PNP inhibitor PNP-405 (also described as PNU-405) was disclosed in the ACS meeting, (2000). This compound inhibits purine nucleotide phosphorylase with an IC_{50} of 20 nM (structure below).

Scheme **87.1**




PNP 405


87-1

Reduction of the dose and/or improvement of efficacy is achieved by the use of pro-drugs PNP-405 that, upon cleavage inside the target cell, give rise to agents with increased intracellular half-lives. Such phosphonates pro-drug compounds are shown below (Scheme **87.2**).

Scheme **87.2**




87-2



87-3

In all cases, linker is 0-8 and preferably 1-6 atoms




87-4

X= C, N, O, S
Y= F, H
Z= H, CH_2-OH


Compounds such as **87-2, 87-5** are made according to the general route outlined in Scheme **87.3**, with an example depicted in Scheme **87.4**.

Scheme **87.3**



PNP 405 87-1 87-5

Scheme **87.4**




PNP 405 87-1 87-6

PNP-405 is prepared according to the method of Littler, B. J. et al., 7th International Conference on Organic Process Research and Development, New Orleans, LA, March 16-19, (2003). PNP-405 is treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, to provide compound **87-6** as the desired product.

Compounds of Scheme **87.2** where X= O, Z= CH_2OH), can be prepared according to the procedure of Littler, B. J. et al., 7th International Conference on Organic Process Research and Development, New Orleans, LA, March 16-19, (2003) (Schemes **87.5** and **87.6**). The starting material, 2-benzyloxyphenylacetic acid (provided by Avocado) can be acylated via the mixed anhydride with the oxazolidinone shown at 80-85 °C, with triethylamine as base. A low-temperature alkylation with bromoacetonitrile results in the formation of compound **87-9** with good diastereomeric ratio. Removal of the chiral auxiliary under reductive conditions yields compound **87-10** without racemization. Protection of the resulting alcohol with the trityl group provides compound **87-11**. Subsequent pyrrole ring construction as well as cyclo-guanidinylation

reaction to prepare the six-membered 2-aminopyrimidone ring can be prepared as illustrated in Scheme **87.6**.

Scheme **87.5**:



87-7 **87-8** **87-9**


87-10 **87-11**

Compounds of Schemes **87.2** (where X= O, Z= H) can be prepared according to the general route illustrated above. The starting material, 3-(2-Benzyloxy-phenyl)-propionitrile, is available by Lewis acid-mediated reaction of phenol with acrylonitrile according to U.S. Patent No. 2,789,995, published in 1954. Intermediate **87-11** can follow the same synthetic steps as outlined here to provide of compounds of Schemes **87.1** and **87.1**.

Pyrrole ring construction can be completed in three steps from 3-(2-Benzyloxy-phenyl)-propionitrile. Formation of 3-hydroxy-acrylonitrile **87-13** can be achieved by exposure of **87-12** to LDA and ethyl formate. Condensation of this product with 2-Amino-malonic acid diethyl ester in EtOH and sodium acetate yields compound **87-14** which undergoes a decarboxylative cyclization in the basic medium of NaOH and EtOH to provide pyrrole **87-15**. In some syntheses, the trityl protecting group on the benzylic alcohol is removed at this stage. Subsequently, guanidinylation reaction using cyanamide provides compound **87-16** which, upon treatment with sodium hydroxide, cyclizes to form the 2-aminopyrimidone ring (compound **87-17**). Removal of the phenolic protecting group under hydrogenolysis conditions provides the free phenol, which is used as the attachment site for the pro-drug group. A variety of linkers may be utilized to attach the pro-drug moiety to the backbone molecule. A particular example in which diethyl phosphonomethyltriflate is used as the starting materials is illustrated below. Therefore, compound **87-18** is treated in a


solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride or cesium carbonate. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, (1986), *27*, 1477) is added, to provide compounds of Scheme **87.2**.

Scheme **87.6**:



Compounds of Schemes **87.2** (where X= O, Y= H, Z= CH_2OH) can be prepared from 4-benzyloxyphenylacetic acid (available from Aldrich). Following a similar sequence to that demonstrated in Scheme **87.7**, intermediate **87-24** can be prepared (Scheme **87.7**). Proceeding with the sequence shown in Schemes **87.6**, **87-24** can be transformed to the desired products of Scheme **87.2**.

Scheme **87.7**:




87-20 **87-21** **87-22** **87-23** **87-24**

Example 88: Preparation of exemplary compounds of the present invention

The phosphorus containing thiazolidinedione derivative **88-2** is synthesized from parent compounds by alkylation. The parent compound **88-1** is obtained by the procedure as described in U.S. Patent 4,572,912. Scheme **88.1** shows the attachment of the phosphonate linkage to the phenolic OH of **88-1** to give compounds of formula **88-2**. Compound **88-1** is dissolved in a suitable aprotic solvent such as, DMF and is then treated with the phosphonate reagent (**88-30**), bearing a leaving group, for example, bromine, mesyl, tosyl, or trifluoromethanesulfonyl, in the presence of a suitable organic or inorganic base. In the schemes of this Example, A^0-LG refers to a phosphonate compound as described is this specification that is attached to a leaving groups, such as, for example, a halogen, a triflate, a mesylate, or a tolunenesulfonate.


Scheme **88.1**



For example, a solution of **88-3** in DMF is treated with cesium carbonate and one equivalent of (trifluoromethanesulfonyloxy)methylphosphonic acid diethyl ester **88-18, 88-25** to give troglitazone-phosphonate **88-4** in which the linkage is a methylene group as shown in Scheme **88.2**. Using the above


procedure but employing a different **88-1** and phosphonate reagents **88-30, 88-40**, the corresponding products **88-2** bearing different substituents and linking groups can be obtained.

Scheme **88.2**




Scheme **88.3** shows the preparation of phosphorus containing thiazolidinedione derivative of type **88-7, 88-20**. The parent compound **88-5** is obtained by the procedure as described in U.S. Patent No. 4,572,912. The phenolic OH and thiazolidinedione unit are protected with suitable protecting group, for example SEM group, and the hydroxyl group at C4 position of chroman alcohol analogs is generated by reduction of the carbonyl group, using suitable reducing agent, for example sodium borohydride. The alcohol **88-6** is then treated with suitable chloroformate ester, for example phenyl chloroformate or *p*-nitrophenyl chloroformate, or carbonate, such as bis(*p*-nitrophenyl)carbonate to generate an active carbonate. The resulting active carbonate is reacted with phosphonate reagents bearing amino group **88-35** and subsequent deprotection of protecting groups produces the phosphonates of type **88-7, 88-20**.

Scheme **88.3**



For example, a solution of **88-8** in THF is treated with diisopropylethylamine and two equivalent of 2-(trimethylsilyl)ethoxymethyl chloride to protect the phenolic OH and thiazolidinedione unit. A solution of the protected product in methanol is then reduced using sodium borohydride to obtain the alcohol **88-9**. The alcohol **88-9** is treated with phenyl chloroformate to provide phenyl carbonate, which is reacted with 2-aminoethylphosphonate diethyl ester **88-12**, to obtain protected phosphonate derivative, which is deprotected by tetrabutylammonium fluoride in THF to result **88-10**. Using the above procedure but employing different **88-5** and phosphonate reagents **88-35** the corresponding products **88-7, 88-20** bearing different substituents and linking groups can be obtained.


Scheme **88.4**



Scheme **88.5** shows the preparation of phosphorus a containing thiazolidinedione derivative. Thiazolidinedione with phosphorus containing moiety **88-13** is generated by the alkylation of thiazolidinedione **88-11** in a suitable aprotic solvent such as, DMF and is then treated with the phosphonate reagent **88-30, 88-40**, bearing a leaving group, for example, bromine, mesyl, tosyl, or trifluoromethanesulfonyl, in the presence of a suitable organic or inorganic base. Compound **88-13** is then reacted with benzaldehyde **88-14** with protected phenol at the para position. The protecting group R^{88} can be any protecting group for phenolic OH, for example alkoxyalkyl groups, such as the methoxymethyl group; aralkyl groups, such as the benzyl group; the 2-tetrahydropyranyl group; and acyl groups, such as the acetyl or benzoyl groups, preferably benzyl group. The reaction is carried out in an aprotic solvent, such as toluene, suitably at an elevated temperature, such as the reflux temperature of the solvent, and preferably in the presence of a suitable catalyst, such as

piperidinium acetate or benzoate. Favorably, the water produced in the reaction is removed from the reaction mixture, for example by means of a Dean and Stark apparatus. The reduction of **88-15** to **88-16** is accomplished by catalytic reduction with suitable catalysts, such as palladium on carbon catalysts, preferably a 10% palladium on charcoal catalyst. (U.S. Patent 6,288,095) The coupling of **88-16** with chroman alcohol homolog **88-17**, which is obtained by the procedure described in J. American Oil Chemical Society (1974), *51*, 200 or in U.S. Patent No. 4,572,912, and in which the alcoholic functional groups are suitably protected as described in U.S. Patent No. 4,572,912, is done using Mitsunobu condition.


Scheme **88.5**



For example, a solution of **88-11** in DMF is treated with sodium hydride and one equivalent of (trifluoromethanesulfonyloxy)methylphosphonic acid diethyl ester **88-18, 88-25** to give thiazolidinedione-phosphonate **88-19** in which the linkage is a methylene group as shown in Scheme **88.6**. The thiazolidinedione-phosphonate **88-19** is then reacted with the benzaldehyde **88-20** bearing benzyloxy substituent in toluene in reflux condition in the presence of catalytic piperidinium acetate with Dean-Stark apparatus, which results **88-21**. The reduction of **88-21** in dioxane by catalytic hydrogenation in the presence of 10% palladium on charcoal provides **88-22**. The reaction between **88-22** and chroman alcohol analogs **88-23** in the presence of diethyl azodicarboxylate and triphenylphosphine followed by deprotection of SEM group by TBAF provides **88-24**. Using the above procedure but employing different chroman alcohol analogs and phosphonate reagents **88-30, 88-40** the

corresponding products **88-2** bearing different substituents and linking groups are obtained.

Scheme **88.6**




Example 89: Preparation of exemplary compounds of the present invention.

Schemes **K2** - **K4** illustrate the syntheses of phosphonate compounds of the invention, **K2** - **K4,** and of the intermediate compounds necessary for their synthesis.

Protection of reactive substituents.

Depending on the reaction conditions employed, it may be necessary to protect certain reactive substituents from unwanted reactions by protection before the described sequence is reacted, and to deprotect the substituents afterwards, according to the knowledge of one skilled in the art. Protection and deprotection of functional groups are described, for example, in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990. The protection and deprotection of steroidal ketones and alcohols is described in Organic Reactions in Steroid Chemistry, Vol. 1, J. Fried and J. A. Edwards, van Nostrand Reinhold, 1972, p. 375ff. Reactive substituents which may be protected are shown in the accompanying schemes as, for example, [OH], [O], etc.

Scheme K1.




For example, Scheme **K1** depicts a protection-deprotection sequence in which the steroid side-chain is protected as a bis-methylenedioxy (BMD) moiety. In this sequence, 6α ,9α-difluoro-16β-methyl-11β,17α,21-

trihydroxypregn-1,4-dien-3,21-dione **K1.1** (US Patent 4,619,921) is reacted with paraformaldehyde and an acid catalyst such as hydrochloric acid, as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 223, to yield the BMD derivative **K1.2**. The phosphonate moiety is then introduced, using the procedures described below, to produce the phosphonate ester **K1.3**. The BMD moiety is then hydrolyzed, for example by treatment with 50% aqueous acetic acid, as described in Protective Groups in Organic Synthesis, by T.W. Greene and P.G.M. Wuts, Wiley, Second Edition 1990, p. 223, to afford the triol **K1.4**. The latter compound is then converted into the 17,21-cyclic orthoester **K1.5** using the procedure described in Chem. Pharm. Bull., 1986, 34, 1613. The substrate is reacted in dimethylformamide at 70°C with two molar equivalents of triethyl orthopropionate and a catalytic amount of p-toluenesulfonic acid. The product is then reacted with an excess of trimethylsilyl chloride in dimethylformamide at ambient temperature to produce the 21-chloro 17-propionate product **K1.6**.

Alternatively, the substrate **K1.4** is converted into the product **K1.6** by means of the method described in *J. Med. Chem.*, (1987), 30: 1581. In this procedure, the 21-hydroxy group is activated by conversion to the 21-mesylate, by reaction with mesyl chloride in pyridine; the mesylate group is then displaced to yield the 21-chloro intermediate, by reaction with lithium chloride in dimethylformamide, and the 17-hydroxyl group is esterified to give the 21-chloro-17-propionate derivative **K1.6**. The selective acylation of the 17α hydroxyl group in the presence of an 11β hydroxyl group is described in *J. Med. Chem.*, (1987), 30: 1581.

Preparation of the phosphonate esters K2.

Scheme K2. Phosphonates K2.




Scheme **K2** depicts the preparation of phosphonates **K2** in which the phosphonate is attached by means of an imino or iminoxy group and a variable carbon chain. In this procedure, the BMD-protected derivative **K1.2** is reacted with an amine or hydroxylamine **K2.1**, in which R^2 is an alkyl, alkenyl, cycloalkyl or cycloalkenyl group, optionally incorporating a heteroatom O, S or N, or a functional group such as an amide, ester, oxime, sulfoxide or sulfone etc, or an optionally substituted aryl, heteroaryl or aralkyl group, optionally incorporating a heteroatom O, S or N, and X is either a phosphonate group or a group which is subsequently converted into a phosphonate-containing substituent. For example, X is dialkylphosphono, bromo, hydroxy, amino, carboxy and the like. The reaction is conducted between equimolar amounts of the reactants in an aprotic solvent such as pyridine or xylene, or in an alcoholic solvent such as ethanol, optionally in the presence of an acid catalyst, to give the imine or oxime. The preparation of oximes of steroidal 3-ketones is described in *Anal. Bioch.*, (1978), 86, 133. and in *J. Mass. Spectrom.*, (1995), 30, 497. The BMD-protected side-chain compound **K2.2** is then converted into the triol **K2.3a**, and then to the 21-chloro 17 propionate product **K2.3b**, as described in Scheme **K1**.

Scheme **K2** also illustrates the preparation of hydroxylamine ethers incorporating a phosphonate group. In this procedure, a phosphonate **K2.4**, in which Lv is a leaving group such as bromo or trifluoromethylsulfonyloxy, is reacted with BOC-hydroxylamine **K2.5** (Aldrich) to produce the ether **K2.6**. The reaction is conducted between equimolar amounts of the reactants in a polar solvent such as dimethylformamide or tetrahydrofuran, in the presence of a base such as potassium hydroxide or dimethylaminopyridine. Deprotection, for example by treatment with trifluoroacetic acid, then gives the hydroxylamine ether **K2.7**.

Scheme K2


Example 89-A



Scheme **K2**, Example **89-A** illustrates the preparation of phosphonates **K2** in which the phosphonate is attached by means of an iminoxy group. In this procedure, the substrate **K1.2** is reacted with a dialkyl phosphonomethyl hydroxylamine **K2.8**, prepared as described above from a dialkyl trifluoromethylsulfonyloxymethyl phosphonate (*Tet. Lett.* 27:1477 (1986)) and BOC-hydroxylamine, to afford the oxime **K2.9**. Deprotection then affords the triol **K2.10a** from which the 21-chloro 17-propionate compound **K2.10b** is prepared. The oxime forming reaction is performed at ambient temperature in ethanol-acetic acid solution between equimolar amounts of the reactants.

Using the above procedures, but employing, in place of the hydroxylamine ether **K2.8**, different oxime ethers **K2.1**, the corresponding products **K2.3b** are obtained.

Scheme K2




Scheme **K2**, Example **89-B** illustrates the preparation of compounds **K2** in which the phosphonate group is attached by means of a thienylmethoxy oxime group. In this procedure, the dienone **K1.2** is reacted, as described above, with O-(4-bromo-2-thienylmethoxy)hydroxylamine **K2.11**, prepared as described above from 4-bromo-2-bromomethylthiophene (WO 9420456) and BOC-protected hydroxylamine, to give, after deprotection of the side-chain, the oxime **K2.12**. The product is then reacted, in the presence of a palladium catalyst, with a dialkyl phosphite **K2.13** to afford the phosphonate **K2.14a**. The preparation of arylphosphonates by means of a coupling reaction between aryl bromides and dialkyl phosphites is described in *J. Med. Chem.* 35:1371 (1992). The reaction is performed in an inert solvent such as toluene, in the presence of a base such as triethylamine and a catalytic amount of tetrakis(triphenylphosphine)palladium(0). The 21-hydroxy compound **K2.14a** is then converted, as described in Scheme **K1**, into the 21-chloro 17-propionate derivative **K2.14b**.

Alternatively, the bromo compound **K2.12** is coupled with a dialkyl butenyl phosphonate **K2.15** (*Org. Lett.* 3:217 (2001)) to afford the phosphonate **K2.16a**. The coupling of aryl halides with olefins by means of the Heck reaction

is described, for example, in F. A. Carey and R. J. Sundberg, Advanced Organic Chemistry 503ff (Plenum, 2001) and in *Acc. Chem. Res.* 12:146 (1979). The aryl bromide and the olefin are coupled in a polar solvent such as dimethylformamide or dioxan, in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or palladium(II) catalyst such as palladium(II) acetate, and optionally in the presence of a base such as triethylamine or potassium carbonate. Optionally, the double bond present in the product **K2.16a** is reduced, for example by reaction with diimide, to produce the saturated analog **K2.17a**. The reduction of olefinic bonds is described in R. C. Larock, Comprehensive Organic Transformations 6ff (VCH 1989). The transformation is effected by means of catalytic hydrogenation, for example using a palladium on carbon catalyst and hydrogen or a hydrogen donor, or by the use of diimide or diborane. The products **K2.16a** and **K2.17a** are then converted into the 21-chloro 17-propionate analogs **K2.16b** and **K2.17b**.

Using the above procedures, but employing, in place of the bromothienylmethoxy reagent **K2.11**, different bromo-substituted aryl or heteroaryl alkoxy hydroxylamines, and/or different dialkyl alkenyl phosphonates, the products analogous to the compounds **K2.14b**, **K2.16b** and **K2.17b** are obtained.

Scheme K2, Example 89-C



K1.2

K2.19a: R^3=OH, R^4=H


K2.19b: R^3=Cl, R^4=COEt

Scheme **K2**, Example **89-C** depicts the preparation of phosphonates **K2** in which the phosphonate is attached by means of an imino group. In this procedure, the substrate **K1.2** is reacted with a dialkyl 4-amino-2-thienyl phosphonate **K2.18**, prepared by the palladium-catalyzed coupling, as described

above, between 4-amino-2-bromothiophene (*Tet.* 43:3295 (1987)) and a dialkyl phosphite, to give, after deprotection, the imine product **K2.19a**. The imine forming reaction is conducted in a hydrocarbon solvent such as toluene or xylene, at reflux temperature, in the presence of a basic catalyst such as sodium methoxide, or an acid catalyst such as p-toluenesulfonic acid, under azeotropic conditions. The product is then converted into the 21-chloro 17-propionate compound **K2.19b**.

Using the above procedures, but employing, in place of the 4-aminothienyl phosphonate **K2.18** different amino-substituted aryl or heteroaryl phosphonates, products analogous to **K2.19b** are obtained.

Scheme K2, Example 89-D




Scheme **K2**, Example **89-D** illustrates the preparation of phosphonates **K2** in which the phosphonate is attached by means of an oximino group and an amide linkage. In this procedure, the dienone **K1.2** is reacted with O-(4-aminobutyl)hydroxylamine **K2.20** (*Pol. J. Chem.* 55:1163 (1981)) to yield the oxime **K2.21**. The reaction of steroidal 1,4-dien-3-ones with substituted hydroxylamines is described in *J. Steroid Bioch.* 7:795 (1976); the reaction is performed between equimolar amounts of the reactants in a polar organic solvent such as pyridine or methanol, optionally in the presence of acetic acid or sodium acetate. The product is then coupled with a dialkyl 2-hydroxyethyl phosphonate **K2.22** (Epsilon) and carbonyl diimidazole, to yield the carbamate oxime **K2.23**.

The preparation of carbamates is described in A. R. Katritzky, Comprehensive Organic Functional Group Transformations, 6:416ff (Pergamon, 1995), and in S. R. Sandler and W. Karo, Organic Functional Group Preparations, 260ff (Academic Press, 1986). In the procedure, the amine is reacted in an inert aprotic solvent such as dichloromethane or tetrahydrofuran, with phosgene or a functional equivalent thereof, such as carbonyl diimidazole, triphosgene, pentafluorophenyl carbonate and the like, to afford the corresponding activated acylamine. The latter compound is then reacted with an alcohol to yield the carbamate. The carbamate product **K2.23** is then converted, as described in Scheme **K1**, into the 21-chloro 17-propionate product **K2.24b**.

Using the above procedures, but employing, in place of the hydroxylamine **K2.22**, different amino-substituted hydroxylamines, and/or different hydroxy-substituted phosphonates, the products analogous to **K2.24b** are obtained.


Preparation of the phosphonate esters K3 and K4.

Scheme K3. Phosphonates K3 and K4.



Scheme **K3** illustrates the preparation of the phosphonate esters **K3** and **K4** in which the phosphonate group is attached to the 1' or 2' position of the pyrazole ring, by means of an aromatic or heteroaromatic group, a heteroatom and/or a variable carbon chain. In this procedure, the BMD-protected dienone **K1.2** is reduced to afford the 1,2-dihydro product **K3.1**. The catalytic hydrogenation reaction is effected by the use of tris(triphenylphosphine)rhodium (I) chloride, for example as described in *J. Med. Chem.* 44:602 (2001). The product is then reacted with ethyl formate and a base such as sodium hydride, in an inert solvent such as toluene or dimethylformamide, as described in *J. Am. Chem. Soc.* 86:1520 (1964), to afford the 2-formyl product **K3.2**. This compound is then reacted with an alkyl, aralkyl, aryl or heteroaryl hydrazine **K3.3**, in which the substituent X is either a phosphonate group or a group which is subsequently transformed into a phosphonate-containing substituent. For example, X is dialkylphosphono, bromo, hydroxy, amino, carboxyl and the like. The reaction yields the isomeric 2'- and 1'-aryl pyrazoles **K3.4** and **K3.5**. The pyrazole-forming reaction is performed between equimolar amounts of the reactants in an acidic solvent such as acetic acid, as described in *J. Am. Chem. Soc.* 86:1520 (1964). The pyrazoles **K3.4** and **K3.5** are then transformed, for example by the procedures described in Examples **89-E** and **89-F**, via the BMD-protected intermediates **K3.6** and **K3.7**, into the 21-chloro 17-propionate phosphonates **K3.8b** and **K3.9b**.

Scheme K3, Example 89-E



Scheme K3, Example **89-E** illustrates the preparation of phosphonates **K3** and **K4** in which the phosphonate is attached by means of an amide linkage. In this procedure, the ketoaldehyde **K3.2** is reacted, as described above, with 3-carboxypropyl hydrazine **K3.10** (*Ind. J. Exp. Biol.* 32:218 (1994)) to give the pyrazoles **K3.11** and **K3.12**. The 2'-substituted isomer **K3.11** is then reacted in dimethylformamide solution at ambient temperature with one molar equivalent of a dialkyl 4-aminophenyl phosphonate **K3.13** (Epsilon) and dicyclohexyl carbodiimide, to yield the amide **K3.14**. The preparation of amides from carboxylic acids and derivatives is described, for example, in S.R.Sandler and W. Karo, Organic Functional Group Preparations, 274 (Academic Press, 1968), and R. C. Larock, Comprehensive Organic Transformations, 972ff (VCH, 1989). The carboxylic acid is reacted with the amine in the presence of an activating agent, such as, for example, dicyclohexylcarbodiimide or diisopropylcarbodiimide, optionally in the presence of, for example, hydroxybenztriazole, N-hydroxysuccinimide or N-hydroxypyridone, in a non-protic solvent such as, for example, pyridine, DMF or dichloromethane, to afford the amide.

Alternatively, the carboxylic acid may first be converted into an activated derivative such as the acid chloride, anhydride, mixed anhydride, imidazolide and the like, and then reacted with the amine, in the presence of an organic base such as, for example, pyridine, to afford the amide.


The conversion of a carboxylic acid into the corresponding acid chloride can be effected by treatment of the carboxylic acid with a reagent such as, for example, thionyl chloride or oxalyl chloride in an inert organic solvent such as dichloromethane, optionally in the presence of a catalytic amount of dimethylformamide.

The BMD protecting group is then removed and the product is converted into the 21-chloro 17-propionate product **K3.16b**.

Alternatively, the 1'-substituted pyrazole **K3.12** is coupled, as described above, with a dialkyl aminomethyl phosphonate **K3.17** (Interchim), to afford the amide **K3.18**. The product **K3.18** is then deprotected to give the triol **K3.19a**, and the latter compound is transformed into the 21-chloro 17-propionate **K3.19b**.

Using the above procedures, but employing different amino-substituted phosphonates, and/or different carboxy-substituted hydrazines, the products analogous to **K3.16b** and **K3.19b** are obtained. The functionalization procedures are interchangeable between the pyrazole substrates **K3.11** and **K3.12**.

Scheme K3 Example 89-F




Scheme **K3**, Example **89-F** illustrates the preparation of the phosphonates **K3** and **K4** in which the phosphonate group is attached by means of an aryl ring and a propenyl linkage. In this procedure, the ketoaldehyde **K3.2** is reacted, as described above, with allyl hydrazine **K3.20** (*Zh. Org. Khim.*, 3:983 (1967)) to produce the pyrazoles **K3.21** and **K3.22**. The 1'-substituted isomer **K3.21** is coupled, as described in Scheme **K2**, with a dialkyl 3-bromophenyl phosphonate **K3.23** (Epsilon) to give the phosphonate **K3.24**. The product is then deprotected to afford the triol **K3.25a** which is converted into the 21-chloro 17-propionate compound **K3.25b**.

Alternatively, the 2'-substituted pyrazole **K3.22** is coupled, as described above, with a dialkyl 5-bromo-2-thienyl phosphonate **K3.26** (*Syn.*, 455 (2003)) to prepare the phosphonate **K3.27** which is deprotected, and the product is converted into the 21-chloro 17-propionate analog **K3.28b**.

Using the above procedures, but employing, in place of the propenyl hydrazine **K3.20**, different alkenyl hydrazines, and/or different dialkyl bromo-substituted phosphonates, the products analogous to the compounds **K3.25b** and **K3.28b** are obtained.

Scheme K4. Phosphonates K3 and K4.


Method




Scheme **K4** depicts the preparation of the phosphonate esters **K3** and **K4** in which the phosphonate group is attached by means of a variable carbon linkage. In this procedure, the ketoaldehyde **K3.2** is reacted with hydrazine, to afford the pyrazole derivative **K4.1**. The reaction of steroidal 2-formyl-3-ketones with hydrazine is described in *J. Am. Chem. Soc*, 86:1520 (1964). The reaction is performed in acetic acid at ambient temperature. The pyrazole product is then reacted with a bromomethyl compound **K4.2**, in which R^2 and X are as defined above, to yield the alkylation products **K4.3** and **K4.4**. The alkylation of substituted pyrazoles is described, for example, in T. L. Gilchrist, Heterocyclic Chemistry, 309 (Longman, 1992). The reaction is performed between equimolar amounts of the substrates in a polar solvent such as dimethylformamide or tetrahydrofuran, in the presence of a base such as dimethylaminopyridine, lithium hexamethyldisilazide and the like. The products **K4.3** and **K4.4** are, except in cases where X is dialkylphosphono, converted into the phosphonates **K4.5** and **K4.6**, using the procedures described herein, and

deprotection/chlorination/acylation then affords the 21-chloro 17-propionate compounds **K4.7b** and **K4.8b**.

Scheme K4



As shown in Scheme **K4**, Example **89-G**, the pyrazole **K4.1** is reacted with 2-bromobenzyl bromide **K4.9** to give the pyrazoles **K4.10** and **K4.11**. The products are then coupled, as described above, with a dialkyl phosphite, to afford after side-chain deprotection and modification, as described above, the 21-chloro 17 propionates **K4.12b** and **K4.13b**.



As shown in Scheme **K4**, Example **89-H**, the pyrazole **K4.1** is reacted in tetrahydrofuran solution, as described above, with 4-bromomethyl cyclohexanone **K4.14** (WO 9737959) to give the alkylation products **K4.14** and **K4.15**. The 1'-substituted isomer **K4.15** is then reacted, in a reductive amination reaction, with a dialkyl aminomethyl phosphonate **K.19** (Interchim) and sodium cyanoborohydride, to yield, after deprotection and side-chain modification, the 21-chloro 17-propionate **K4.17b**.

The preparation of amines by means of reductive amination procedures is described, for example, in R. C. Larock, Comprehensive Organic Transformations, 421 (VCH, 1989), and in F.A. Carey and R. J. Sundberg, Advanced Organic Chemistry, Part B, 269 (Plenum, 2001). In this procedure, the amine component and the aldehyde or ketone component are reacted together in the presence of a reducing agent such as, for example, borane, sodium cyanoborohydride, sodium triacetoxyborohydride or diisobutylaluminum hydride, optionally in the presence of a Lewis acid, such as titanium tetraisopropoxide, as described in *J. Org. Chem.*, 55:2552 (1990).

The 2'-substituted pyrazole **K4.16** is subjected to the same series of reaction to give the amine phosphonate **K4.18b**.

Using the above procedures, but employing different bromomethyl-substituted aldehydes or ketones, and/or different amino-substituted phosphonates, the products analogous to **K4.17b** and **K4.18b** are obtained.

Example 90: Preparation of exemplary compounds of the present invention.

Schemes **1** and **2** illustrate syntheses of phosphonate compounds of this invention, **M1** and **M2**, and of intermediate compounds necessary for their synthesis.


Protection of reactive substituents

Depending on the reaction conditions employed, it may be necessary to protect certain reactive substituents from unwanted reactions by protection before the sequence described, and to deprotect the substituents afterwards,

according to the knowledge of one skilled in the art. Protection and deprotection of functional groups are described, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis (Second Edition, Wiley, 1991). The protection and deprotection of steroidal ketones is described in J. Fried and J. A. Edwards, Organic Reactions in Steroid Chemistry, Vol. 1 375ff (van Nostrand Reinhold, 1972). Reactive substituents which may be protected are shown in the accompanying schemes as, for example, [OH], [O], etc.


Preparation of the phosphonate esters **M1**

Scheme 1



1.1 **1**

Scheme 1, Example 90-A




1.1 **1**

Scheme **1** depicts the preparation of phosphonates **M1** (Compound 1 in Scheme **1**). Scheme **1**, Example **90-A** depicts an example of Scheme **1**. In Scheme **1**, Example **90-A**, the 5-hydroxy-1-β-D-ribofuranosyl-1*H*-imidazole-4-carboxamide **1.1** (prepared according to US Patetn No. 3888843) can be treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, **1986**, *27*, 1477) is added, yielding the desired phosphonate diester **1**.


Preparation of the phosphonate esters **M2**

Scheme 2



Scheme **2** illustrates the preparation of the phosphonate esters **M2** (Compound 2 in Scheme **2**). Compound **2.1**, 5-hydroxy-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-ylmethyl)-1H-imidazole-4-carboxylic acid amide can be prepared by addition of the imidazole base (JP Kokai 76 88965) onto the 3,5-bis-protected 2-deoxy-D-*erythro*-pentofuranosyl chloride (Hayashi, M. et al., *Chem. Pharm. Bull.*, **1975**, *23*, 1, 245; Montgomery, J. A. et al., *J. Med. Chem.*, **1969**, *12*, 3, 498; and Iwamoto, R. H. et al., *J. Med. Chem.*, **1963**, *6*, 684). Compound **2.1** is then protected on the imidazol-4-ol. Oxidation of the 5'-OH followed by elimination provides glycal **2.3** (see the procedure of Zemlicka J. et al., *J. Am. Chem. Soc.*, **1972**, *94*, 9, 3213). Selenoetherification provides the protected phosphonate **2.4** (Kim, C. et al., *J. Org. Chem.*, **1991**, *56*, 2642). Oxidative elimination of the phenylselenide (as described in Kim, C. et al., *J. Org. Chem.*, **1991**, *56*, 2642) followed by stereoselective dihydroxylation provides the diol **2.6**. Finally, the protecting group is removed to provide compound **2**.


Scheme 2, Example 90-C




Scheme **2**, Example **90-C** illustrates the preparation of the phosphonates **M2** (Compound 2 in this example). Specifically, compound **2.1**, 5-hydroxy-1-(4-hydroxy-5-hydroxymethyl-tetrahydrofuran-2-ylmethyl)-1H-imidazole-4-carboxylic acid amide, which can be prepared by addition of the imidazole base (JP Kokai 76 88965; also Schipper, E. et al., *J. Am. Chem. Soc.*, **1952**, *74*, 350) onto the 3,5-bis-protected 2-deoxy-D-*erythro*-pentofuranosyl chloride (Hayashi, M. et al., *Chem. Pharm. Bull.*, **1975**, *23*, 1, 245; Montgomery, J. A. et al., *J. Med. Chem.*, **1969**, *12*, 3, 498; and Iwamoto, R. H. et al., *J. Med. Chem.*, **1963**, *6*, 684) is first protected using a TBS group. Subsequent oxidation with PtO_2 proceeds to provide carboxylic acid **2.2**. Decarboxylative elimination is achieved using dimethylformamide dineopentyl acetal in DMF at high temperature (Zemlicka J. et al., *J. Am. Chem. Soc.*, **1972**, *94*, 9, 3213). Once the furanoid glycal **2.3** is in hand, it is treated with silver perchlorate in the presence of diethyl(hydroxylmethyl)phosphonate (Phillion, D. et al., Tetrahedron Lett., 1986, 27, 1477) to provide the phosphonate **2.4** (Kim, C. et al., *J. Org. Chem.*,

1991, *56*, 2642). Oxidative elimination of the selenide followed by dihydroxylation using osmium tetraoxide provides a diol with the desired stereochemistry. Deprotection of the TBS group can be achieved using TBAF to provide compound **2**.

Example 91: Preparation of exemplary compounds of the present invention.




Scheme I



Example 91-A [2-(4-{4-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phosphonic acid diethyl ester

A mixture of *N*-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide (30 mg, 0.06 mmol, Zimmermann et


al., *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1221), diethyl 2-bromoethylphosphonate (30 μL, 0.12 mmol) and K_2CO3 (20 mg, 0.16 mmol) in 2.5 mL of DMF was heated at 110 °C for 8 hours when most of the starting materials were consumed as judged by LCMS analysis. The solid material was filtered off. The filtrate was diluted with water and then extracted with EtOAc. The organic layer was dried over Na_2SO_4 and concentrated to dryness. The crude material was purified by silica gel chromatography using 10% MeOH/CH_2Cl_2 to provide 28 mg (55%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.32 (t, 6H), 1.92-20.3 (m, 4H), 2.35 (s, 3H), 2.5 (bs, 6H), 2.64 (m, 2H), 3.56 (s, 2H), 4.05-4.14 (m, 4H), 7.07(s, 1H), 7.18 (d, 2H, *J*= 5 Hz), 7.30 (dd, 1H, *J*= 6, 8 Hz), 7.33-7.45 (m, 3H), 7.84 (d, 2H, *J*= 8 Hz), 8.01 (s, 1H), 8.51 (dd, 2H, *J*= 4, 9 Hz), 8.58 (d, 1H, *J*= 2 Hz), 8.70 (dd, 1H, *J*= 2, 5 Hz), 9.25 (s, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 30.5; MS (*m/z*) 644 $[M+H]^+$.




Example 91-B [2-(4-{4-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phosphonic acid

To a solution of [2-(4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phosphonic acid diethyl ester (8 mg, 0.012 mmol) in DMF (1 mL) was added TMSBr (15 μL, 0.12 mmol) at room temperature. The reaction was allowed to proceed at room temperature for 14 hours. Another portion of TMSBr (20 μL) was added and heated at 110 °C for 12 hours when completion of the reaction was detected by LCMS. The reaction was cooled down to room temperature and quenched with addition of MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O- Acetonitrile (5-100%) over 20 minutes to provide 4.2 mg (50%) of the product as mono-TFA salt. ^{1}H NMR (300 MHz, CD_3OD) δ 1.80-1.84 (m, 2H), 2.08-2.02 (m, 2H), 2.23 (s, 3H), 3.07 (bs, 4H), 3.30-3.32 (2H, possible overlap

with solvent), 3.89 (m, 2H), 4.01 (s, 2H), 6.87 (s, 1H), 7.23-7.3 (m, 3H), 7.52-7.60 (m, 3H), 8.01 (d, 2H, *J*= 8 Hz), 8.08 (dd, 1H, *J*= 2, 5 Hz), 8.30 (s, 1H), 8.58 (d, 1H, *J*= 5 Hz), 8.89 (d, 1H, *J*= 2 Hz), 9.22 (dd, 1H, *J*= 2, 5 Hz), 9.63 (s, 1H); ^{31}P (121.4 MHz, CD_3OD) δ 21.9 ; MS (*m/z*) 588 $[M+H]^+$.




Scheme II



Example 91-C 2-{[2-(4-{4-[4-Methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester

A solution of *N*-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide (20 mg, 0.04 mmol) and 2-[(2-oxo-ethyl)-phenoxy-phosphinoyloxy]-propionic acid ethyl ester (60 mg, 0.2 mmol) in 1% Acetic Acid/DMF (1.5 mL) solution was stirred at room temperature for 7 hours followed by an addition of $NaCNBH_3$ (30 mg, 0.24 mmol). The resulting mixture was stirred for additional 30 min when completion of the reaction was observed by LCMS. After evaporation of solvent, the residue was taken up in CH_2Cl_2 and then extracted with saturated aqueous $NaHCO_3$. The organic extracts were dried *in vacuo* and the residue was purified by silica gel chromatography using MeOH-CH_2Cl_2 (7%) to afford 8 mg (26 %) of the product. ^{31}P NMR (121.4 MHz, $CDCl_3$) δ 27.2, 28.6 ; MS (*m/z*) 764 $[M+H]^+$.




Example 91-D 2-{Hydroxy-[2-(4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phosphinoyloxy}-propionic acid

To a solution of 2-{[2-(4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-yl)-ethyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester (6 mg, 0.008 mmol) in 2:1 acetonitrile/water (0.3 mL) was added 1N NaOH (50 μL, 0.048 mmol). The solution was allowed to stir at room temperature for 1 hour when completion of

the reaction was observed by LCMS. The reaction was acidified by 1N HCl (50 μL) solution and purified by RP HPLC using a C18 column with a gradient of H_2O- Acetonitrile (5-100%) over 20 minutes to provide 2 mg (38%) of the product. ^1H NMR (300 MHz, CD_3OD) δ 1.51 (d, 3H, *J*= 7 Hz), 2.04 (m, 2H), 2.33 (s, 3H), 2.96 (bs, 4H), 3.31 (m, 2H), 3.4 (bs, 4H), 3.89 (s, 2H), 4.88 (1H, possible overlap with solvent), 7.30 (m, 2H), 7.48-7.57 (m, 4H), 7.96-7.99 (m, 4H), 8.32 (s, 1H), 8.56 (d, 1H, *J*= 5 Hz), 8.86 (d, 1H, *J*= 2 Hz), 9.10 (dd, 1H, *J*= 2, 5 Hz), 9.59 (s, 1H); ^{31}P (121.4 MHz, CD_3OD) δ 20.0 ; MS (*m/z*) 660 $[M+H]^+$.


Example 92: Preparation of exemplary compounds of the present invention.

Scheme I



Example 92-A 6-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester


To a solution of 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (222 mg, 0.66 mmol), PPh_3 (260 mg, 0.996 mmol), and diethyl azodicarboxylate (173 mg, 0.996 mmol) in THF (3 mL) at 0 °C was added a solution of trimethylsilyl ethanol (142 μL, 0.996 mmol) in THF (3 mL). The resulting yellow solution was allowed to warm up to room temperature and stirred overnight. The reaction was worked up by concentrating the solution to dryness and addition of ether and hexanes. Triphenylphosphine oxide was removed by filtration and the filtrate was concentrated and purified by silica gel chromatography to provide 248 mg of the desired product as a clear oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.18- 1.30 (m, 2H), 1.81 (s, 3H), 2.18 (s, 3H), 2.25- 2.33 (m, 2H), 2.37-2.45 (m, 2H), 3.42 (d, 2H, *J*= 7 Hz), 3.62 (s, 3H), 3.77 (s, 3H), 4.25- 4.35 (m, 2H), 5.13 (s, 2H), 5.12- 5.22 (m, 1H).



Example 92-B [6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde


A solution of 6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester (618 mg, 1.42 mmol) in MeOH (10 mL), CH_2Cl_2 (10 mL) and pyridine (50 μL, 0.618 mmol) was cooled to –70 °C using a dry ice/ acetone bath according to the procedure of Smith, D. B. et al., *J. Org. Chem.*, **1996**, *61*, 6, 2236. A stream of ozone was bubbled through the reaction via a gas dispersion tube until the reaction became blue in color (15 minutes). The ozone line was replaced with a stream of nitrogen and bubbling continued for another 15 minutes when the blue color disappeared. To this solution at –70 °C was added thiourea (75.7 mg, 0.994 mmol) in one portion, and the cooling bath was removed. The reaction was allowed to warm to room temperature and stirred for 15 hours. The reaction

was worked up by filtration to remove solid thiourea S-dioxide, and then partitioned between CH_2Cl_2 and water. The organic layer was removed. The aqueous layer was washed with CH_2Cl_2 one more time and the organic extracts were combined. The organic layer was washed with aqueous 1N HCl, saturated $NaHCO_3$ and brine. The organic extracts were dried *in vacuo* and the residue was purified to by silica gel chromatography to afford 357 mg (75 %) of the product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ -0.01 (s, 9H), 1.05- 1.15 (m, 2H), 2.15 (s, 3H), 3.69 (s, 3H), 3.78 (d, 2H, *J*= 1 Hz), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 9.72 (d, 1H, *J*= 1 Hz).




Example 92-C 4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal

[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (70 mg, 0.21 mmol) in toluene (2 mL) was heated at 100 °C with 2-(triphenylphosphanylidene)-propionaldehyde (72.9 mg, 0.23 mmol) overnight. A second portion of 2-(triphenyl-phosphanylidene)-propionaldehyde (33 mg, 0.11 mmol) was added and the reaction mixture was heated for an additional day. After concentration, the residue was purified by silica gel chromatography to provide 54 mg (83%) of the desired product as a pale yellow oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.10- 1.21 (m, 2H), 1.87 (s, 3H), 2.16 (s, 3H), 3.67- 3.76 (m, 2H), 3.74 (s, 3H), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 6.40- 6.48 (m, 1H), 9.2 (s, 1H).




Example 92-D 6-(4-Hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

A solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (103 mg, 0.27 mmol) in methanol (5 mL) was cooled to 0 °C. A solution of $CeCl_3$ (0.68 mL, MeOH: H_2O, 9:1) was added, followed by $LiBH_4$ (0.14 mL, 0.28 mmol of a 2M solution in THF). The ice bath was removed and the reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for an additional 40 minutes whereupon TLC indicated complete consumption of starting aldehyde. The reaction was worked up by addition of aqueous 1N HCl (0.5 mL) and the product was extracted with CH_2Cl_2. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to provide 100 mg (97%) of the product as a clear liquid. ^1H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.20 (dd, 2H, *J*= 7, 8 Hz), 1.81 (s, 3H), 2.13 (s, 3H), 3.38- 3.50 (m, 2H), 3.74 (s, 3H), 3.95 (s, 2H), 4.27 (dd, 2H, *J*= 7, 8 Hz), 5.08 (s, 2H), 5.17- 5.44 (m, 1H).



Example 92-E Phosphorous acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester


To a solution of 6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (75 mg, 0.20 mmol) and DIEA (49 μL, 0.28 mmol) in dioxane (2 mL) was added 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (56.7 mg, 0.28 mmol) according the procedure of Shadid, B. et al., *Tetrahedron*, **1989**, *45*, 12, 3889. After 10 minutes, another portion of 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (40 mg, 0.20 mmol) and DIEA (35 μL, 0.20 mmol) were added. The reaction was allowed to proceed at room temperature for an additional hour, after which it was quenched by the addition of H_2O. The solution was stirred for another 10 minutes and concentrated *in vacuo* to a small volume. The product was triturated with diethyl ether and coevaporated from acetonitrile (4 x 10 mL) to provide the product. ^1H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.08- 1.30 (m, 2H), 1.84 (br s, 3H), 2.17 (s, 3H), 3.46 (br s, 2H), 3.76 (s, 3H), 4.21- 4.39 (m, 4H), 5.12 (s, 2H), 5.43- 5.60 (m, 1H), 7.83 (br s, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 7.22; MS (*m/z*) 441 $[M-H]^-$.



Example 92-F Phosphoric acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester


A solution of phosphorous acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester (27 mg, 0.06 mmol) in dioxane (1 mL) was stirred with DIEA (21 μL, 0.12 mmol) and N,O-bis(trimethylsilyl)acetamide (29 μL, 0.12 mmol) at room temperature for 3 hours. To the reaction solution was added 2,2'-dipyridyldisulfide (16 mg, 0.072 mmol) and the mixture was allowed to stir for an additional 2 hours at room temperature. The reaction mixture was diluted by addition of H_2O and the solution was stirred for 2 more hours when it was

concentrated. The residue was dissolved in a solution of 10% TFA/ CH_2Cl_2 and stirred at room temperature for 9 hours. The reaction mixture was dried under reduced pressure and the product was purified by reverse-phase HPLC to provide the desired product as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.87 (s, 3H), 2.16 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.79 (s, 3H), 4.28 (d, 2H, *J*= 6 Hz), 5.26 (s, 2H), 5.50- 5.61 (m, 1H); ^{31}P (121.4 MHz, CD_3OD) δ 0.50; MS (*m/z*) 357 [M-H]$^-$.




Example 92-G 6-(2-Hydroxy-ethyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

To a solution of [6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (97 mg, 0.29 mmol) in THF (5 mL) was added an aliquot of a 2 M $LiBH_4$ in THF (150 μL, 0.300 mmol). The reaction mixture was stirred at room temperature for 1 hour when complete consumption of the starting materials was observed by TLC. The reaction mixture was worked up by addition of an aqueous 1N HCl solution and extraction with EtOAc. The organic layer was dried *in vacuo* and the residue was purified by silica gel chromatography to provide the product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.20 (dd, 2H, *J*=7, 9 Hz), 2.07 (br s, 1H), 2.14 (s, 3H), 2.97 (t, 2H, *J*= 6 Hz), 3.76 (t, 2H, *J*= 6 Hz), 3.77 (s, 3H), 4.32 (dd, 2H, *J*= 7, 8 Hz), 5.08 (s, 2H).



Example 92-H {2-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-ethoxymethyl}-phosphonic acid diisopropyl ester


A mixture of 6-(2-hydroxy-ethyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (79 mg, 0.23 mmol) was heated with bromomethylphosphonic acid diisopropyl ester (120 mg, 0.46 mmol) in the presence of lithium *t*-butoxide (22 mg, 0.27 mmol) in DMF (2 mL) at 70 °C overnight. The reaction mixture was purified by reverse-phase HPLC to provide the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.13- 1.25 (m, 2H), 1.26 (t, 12H, *J*= 6 Hz), 2.12 (s, 3H), 2.98 (t, 2H, *J*= 7 Hz), 3.60- 3.73 (m, 4H), 3.77 (s, 3H), 4.05- 4.16 (m, 2H), 4.62- 4.74 (m, 2H), 5.07 (s, 2H); MS (*m/z*) 539 $[M+Na]^+$.




Example 92-I [2-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-ethoxymethyl]-phosphonic acid

To a solution of {2-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-ethoxymethyl}-phosphonic acid diisopropyl ester (7.5 mg, 0.014 mmol) in acetonitrile (2 mL) and 2,6-lutidine (25 μL, 0.21 mmol) was added trimethylsilyl bromide (27 μL, 0.21 mmol) at room temperature. The reaction was allowed to proceed for 18 hours when completion of the reaction was indicated by LCMS. The reaction was quenched by addition of MeOH and concentration. The residue was purified by reverse-phase HPLC using a C18 column. The collected product was dispensed in a solution of 10% TFA/ CH_2Cl_2 to assure complete cleavage of the TMSE group. The reaction mixture was lyophilized to provide the desired product. ^{1}H NMR (300 MHz, CD_3OD) δ 2.12 (s, 3H), 2.98 (t, 2H, *J*= 7 Hz), 3.66- 3.76 (m, 4H), 3.78 (s, 3H), 5.21 (s, 2H); MS (*m/z*) 331 $[M-H]^-$.

A. Scheme II






Example 92-J 6-(4-Bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one


Polymer-supported triphenylphosphine (3 mmol/g, 0.5 g) was soaked in dichloromethane (10mL) for 1 h. 7-Hydroxy-6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-3H-isobenzofuran-1-one (100 mg, 0.36 mmol) and carbon tetrabromide (143 mg, 0.43 mmol) were sequentially added and the mixture was shaken for 1 h at room temperature. More carbon tetrabromide

(143 mg, 0.43 mmol) was added and the mixture was shaken further for 1 h. The mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica gel (0 % to 60 % ethyl acetate / hexanes) to afford 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one as an oil (52 mg, 42 %); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.95 (s, 3H), 2.16 (s, 3H), 3.44 (d, J = 7.2, 2H), 3.78 (s, 3H), 3.98 (s, 2H), 5.21 (s, 2H), 5.68 (t, J = 7.2 Hz, 1H), 7.71 (brs, 1H).




Example 92-K [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid dimethyl ester

A solution of 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one (33 mg, 0.097 mmol) in trimethyl phosphite (1.0 mL, 8.5 mmol) was heated to 100 °C for 1 hour, whereupon complete reaction was indicated by LCMS. The reaction was worked up by removal of the excess of trimethyl phosphite under reduced pressure and the residue was purified by silica gel chromatography using EtOAc-hexanes (20-100%) to provide 20 mg (60%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.90 (s, 3H), 2.09 (s, 3H), 2.48 (d, 2H, J= 22 Hz), 3.38 (t, 2H, J= 6 Hz), 3.64 (d, 6H, J= 11 Hz), 3.72 (s, 3H), 5.14 (s, 2H),5.33 (q, 1H, J= 6 Hz), 7.65 (br s, 1H); MS (m/z) 371 $[M+H]^+$.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid (LC-2095-49): To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid dimethyl ester (18 mg, 0.049 mmol) in acetonitrile

(2 mL) was added TMSBr (63 μL, 0.49 mmol) and 2,6-lutidine (85 μL, 0.73 mmol) at 0 °C. The reaction solution was allowed to warm up to ambient temperature. The solution was stirred at room temperature for 2 hours when completion of the reaction was observed by LCMS. The reaction was cooled down to 0 °C and quenched with addition of MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O-acetonitrile (5-0%) over 20 minutes to provide 12.2 mg (73%) of the product. ^1H NMR (300 MHz, CD_3OD) δ 1.95 (s, 3H), 2.15 (s, 3H), 2.48 (d, 2H, *J*= 22 Hz), 3.44 (t, 2H, *J*= 6 Hz), 3.79 (s, 3H), 5.24 (s, 2H),5.38 (q, 1H, *J*= 7 Hz), 6.87 (br s, 1H); MS (*m/z*) 341 $[M-H]^-$.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester: A mixture of 7-hydroxy-6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-3H-isobenzofuran-1-one (50 mg, 0.18 mmol, Pankiewicz et al., *J. Med. Chem.* 2002, *45*, 703), diisopropyl bromomethylphosphonate (93 mg, 0.36 mmol) and lithium *t*-butoxide (1M in THF, 0.54 mL) in DMF (3 mL) was heated at 70 °C for 5 h. The reaction was quenched with 1N HCl. The mixture was poured into 5 % aqueous lithium chloride, extracted with ethyl acetate, and concentrated. The residue was purified by chromatography on silica gel, affording [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester as an oil (25 mg, 32%); ^1H NMR (300 MHz, $CDCl_3$) δ 1.25 (m, 12H), 1.79 (s, 3H), 2.05 (s, 3H), 3.37 (d, *J* = 6.6 Hz, 2H), 3.58 (d, 2H), 3.77 (s, 3H), 3.97 (m, 2H), 4.68 (m, 2H), 5.19 (s, 2H), 5.45 (t, *J* = 6.6 Hz, 1H), 7.83 (s, 1H).



Example 92-L [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid


To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester (25 mg, 0.055 mmol) and 2,6-lutidine (0.18 mL, 1.65 mmol) in acetonitrile was added trimethylsilyl bromide (0.126 mL, 1.1 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 4 h. The reaction was quenched with methanol at 0 °C, and the resulting mixture was concentrated. The residue was purified by preparative reverse-phase HPLC to afford, after removal of the solvent, [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid as an oil (17 mg, 83 %); ^{1}H NMR (300 MHz, CD_3OD) δ 1.81 (s, 3H), 2.06 (s, 3H), 3.40 (d, J = 6.6 Hz, 2H), 3.50 (d, 2H), 3.77 (s, 3H), 3.97 (s, 2H), 5.20 (s, 2H), 5.47 (t, J = 6.6 Hz, 1H); MS (*m/z*) 371 $[M-H]^-$.



Example 92-M [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester and [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diphenyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid (49 mg, 0.13 mmol) in DMF (0.4 mL) and phenol (62 mg, 0.65 mmol) was added dicyclohexyl carbodiimide (107 mg, 0.52 mmol) and DMAP (8 mg, 0.065 mmol) in DMF (0.6 mL), slowly at 0 °C. The reaction was allowed to warm to room temperature and heated to 140 °C for 10 hours. After cooling to room

temperature the mixture was filtered and extracted with aqueous 1N NaOH solution. The aqueous layer was acidified with aqueous 1N HCl and extracted with EtOAc. The organic layer was dried over Na_2SO_4 and concentrated to dryness. The residue was purified by reverse-phase HPLC to provide 18.5 mg of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester (major product) as a pale yellow solid and 4.1 mg of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diphenyl ester (minor product) also as a pale yellow solid. Major product: ^{1}H NMR (300 MHz, CD_3OD) δ 1.82 (s, 3H), 2.16 (s, 3H), 3.46 (d, 2H, *J*= 7 Hz), 3.70 (d, 2H, *J*= 8 Hz), 3.77 (s, 3H), 3.96 (s, 2H), 5.25 (s, 2H), 5.52 (t, 1H, *J*= 8 Hz), 7.10- 7.21 (m, 3H), 7.30 (t, 2H, *J*= 8 Hz); ^{31}P (121.4 MHz, CD_3OD) δ 17.3; MS (*m/z*) 449.0 $[M+H]^+$, 471.2 $[M+Na]^+$. Minor product: ^{1}H NMR (300 MHz, CD_3OD) δ 1.82 (s, 3H), 2.15 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.77 (s, 3H), 3.98- 4.06 (m, 4H), 5.25 (s, 2H), 5.50- 5.61 (m, 1H), 7.10- 7.25 (m, 6H), 7.30- 7.41 (m, 4H); ^{31}P (121.4 MHz, CD_3OD) δ 16.3; MS (*m/z*) 525.2 $[M+H]^+$, 547.2 $[M+Na]^+$.





Example 92-N 2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester (18.5 mg, 0.040 mmol) and ethyl (S)-(-)-lactate (47 μL, 0.400 mmol) in pyridine (0.5 mL) was added PyBOP (32 mg, 0.060 mmol). The solution was stirred at room temperature for 1 hour, when an additional portion of PyBOP (21 mg, 0.040 mmol) was added. The solution was stirred for another hour and concentrated. The residue was purified by HPLC to provide 7.5 mg of the desired product as a clear oil. ^{1}H NMR (300 MHz, CD_3OD) δ 1.22 and 1.25

(t, 3H, *J*= 7 Hz), 1.42 and 1.50 (d, 3H, *J*= 7 Hz), 1.82 and 1.83 (s, 3H), 2.16 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.78 (s, 3H), 3.89 (d, 1H, *J*= 8 Hz), 3.93- 4.02 (m, 3H), 4.10- 4.22 (m, 2H), 4.94- 5.08 (m, 1H), 5.25 (s, 2H), 5.50-5.60 (m, 1H), 7.15- 7.27 (m, 3H), 7.33- 7.41 (m, 2H); ^{31}P (121.4 MHz, CD_3OD) δ 18.9, 20.3; MS (*m/z*) 549.2 $[M+H]^+$, 571.3 $[M+Na]^+$.

B. Scheme III






Example 92-O [5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester

Butyl lithium (1.6 M in hexanes, 1 mL) was added to an equal volume of THF at –20 °C. A solution of diethyl methylphosphonate (220 mg, 1.45 mmol) in THF (1 mL) was then added dropwise and the mixture was stirred for 30 min. After cooling to –60 °C, the solution was transferred via a cannula to a vial containing copper (I) iodide (276 mg, 1.45 mmol), and the resulting mixture was stirred for 1 h at –30 °C. A solution of 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one (50 mg, 0.15 mmol) in THF (1 mL) was added, and the mixture was allowed to warm to 0 °C for 2 h before saturated aqueous ammonium chloride was added. The reaction mixture


was acidified with 2 N HCl and extracted with ethyl acetate. The ethyl acetate extract was concentrated and the residue was chromatographed on silica gel (40 % to 100 % ethyl acetate / hexanes), affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester as an oil (27 mg, contaminated with the starting diethyl methylphosphonate); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.32 (m, 6H), 1.8-1.9 (m, 5H), 2.18 (s, 3H), 2.25 (m, 2H), 3.42 (d, J = 7.2, 2H), 3.78 (s, 3H), 4.15 (m, 4H), 5.21 (s, 2H), 5.24 (t, J = 7.2 Hz, 1H), 7.65 (s, 1H).



Example 92-P [5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid monoethyl ester


A mixture of [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester (27 mg, 0.066 mmol), LiOH (200 mg), MeOH (3 mL) and water (1 mL) was stirred at 70 °C for 4 h. After cooling, the reaction solution was acidified with 2 N HCl, mixed with brine, and extracted with ethyl acetate / acetonitrle. The organic extract was concentrated and the residue was purified by preparative reverse-phase HPLC (acetonitrile and 0.1% aqueous CF_3COOH), affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid monoethyl ester (7 mg, 28 %); ^{1}H NMR (300 MHz, CD_3OD) δ 1.28 (t, J = 6.9, 3H), 1.7-1.9 (m, 5H), 2.20 (s, 3H), 2.2-2.3 (m, 2H), 3.41 (d, J = 6.6 Hz, 2H), 3.80 (s, 3H), 4.02 (m, 2H), 5.2-5.3 (m, 3H).

II. Scheme IV



Example 92-Q [5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester


To a solution of tetramethylmethylene diphosphonate (102 mg, 0.44 mmol) in THF (2.5 mL) was added a solution of sodium bis(trimethysilyl)amide in THF (1.0 M, 0.44 mL). After stirring for 30 minutes, a solution of 4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enal (30 mg, 0.11 mmol, Pankiewicz, et al., *J. Med. Chem.* 45, 703) in THF (2.5 mL) was added and stirring was continued for an additional 15 minutes. The reaction was quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate. After evaporation of solvent, the residue was purified by chromatography on silica gel eluting with ethyl acetate (50 % to 100 %) / hexanes, affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester (30 mg, 71 %) as an oil; ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.80 (s, 3H), 2.04 (s, 3H), 3.45 (d, J = 6.6 Hz, 2H), 3.76 (s, 3H), 3.88 (d, 6H), 5.20 (s, 3H), 5.55 (m, 1H), 5.95 (m, 1H), 7.05 (m, 1H), 7.65 (s, 1H).




Example 92-R [5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid

To a solution of [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester (22 mg, 0.057 mmol) and 2,6-lutidine (0.22 mL, 1.71 mmol) in acetonitrile was added trimethylsilyl bromide (0.183 mL, 1.71 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 1 h. The reaction was quenched with methanol at 0 °C, and the resulting mixture was concentrated. The residue was purified by preparative reverse-phase HPLC to afford, after removal of the solvent, [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid as a solid (13 mg, 65 %); ^{1}H NMR (300 MHz, CD_3OD) δ 1.91 (s, 3H), 2.10 (s, 3H), 3.55 (d, *J* = 6.6 Hz, 2H), 3.75 (s, 3H), 5.2 (s, 2H), 5.6-5.8 (m, 2H), 6.9 (m, 1H).

III.



Br
Br
NaN(TMS)2
P(OMe)3
LiOH
DEAD
PPh3
CH3CN
TMSBr
2,6-lutidine
reflux
t-BuNH2
t-BuNH2
TBAF
TBAF

Scheme I




Example 92-S 2-(4-Bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester

To a cooled (-78°C) solution of mycophenolic acid methyl ester (138 mg, 0.41 mmol) in THF (2.5 mL) was added a THF solution of sodium bis(trimethysilyl)amide (1.0 M, 0.98 mL). After stirring for 30 minutes, a solution of 1,4-dibromo-2-butene (950 mg, 4.1 mmol) in THF (2.5 mL) was added and stirring was continued for 10 min. The resulting mixture was warmed to –30 °C and stored at this temperature for 16 h. The reaction was quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate to give, after evaporation of the solvent, a residue which was purified by chromatography on silica gel, eluting with ethyl acetate (0 % to 40 %) / hexanes, affording 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (150 mg, 78 %) as an oil; ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.75 (s, 3H), 2.0-2.4 (m, 8H), 2.62 (m, 1H), 3.37 (d, J = 6.6 Hz, 2H), 3.58 (s, 3H), 3.76 (s, 3H), 3.88 (d, J = 4.8 Hz, 2H), 5.1-5.3 (m, 3H), 5.67 (brs, 2H), 7.67 (s, 1H).



Example 92-T 2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester


Under a N_2 atmosphere, a solution of 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (490 mg, 1.05 mmol) in trimethyl phosphite (2.5 mL, 21.1 mmol) was heated at 120 °C for 1 hour. The reaction was allowed to cool to room temperature. The reaction mixture was worked up by removal of the solvent *in vacuo* followed by chromatography using EtOAc-hexanes to provide 460 mg (88%) of the product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.77 (s, 3H), 2.081- 2.31 (m, 4H), 2.15 (s, 3H), 2.52 (d, 1H, *J*= 22 Hz), 2.54 (d, 1H, *J*= 22 Hz), 2.55- 2.63 (m, 1H), 3.36 (d, 2H, *J*= 7 Hz), 3.57 (s, 3H), 3.72 (d, 6H, *J*= 11 Hz), 3.76 (s, 3H), 5.20 (s, 2H), 5.20- 5.26 (m, 1H), 5.36- 5.56 (m, 2H), 7.69 (s, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 30.1; MS (*m/z*) 497.2 $[M+H]^+$, 519.2 $[M+Na]^+$.



Example 92-U 2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid


2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (460 mg, 0.927 mmol) in a solution of 1: 1: 2 of H_2O/MeOH/THF (8 mL) was stirred with LiOH.H_2O (78 mg, 1.86 mmol) at ambient temperature for 12 hours. A second batch of LiOH.H_2O (40 mg, 0.952 mmol) was added.

The reaction mixture was stirred at room temperature for another 16 hours, after which no further progress was observed. The reaction was quenched by addition of a saturated aqueous solution of NH_4Cl. The organic layer was removed *in vacuo* and the product was extracted with EtOAc from the aqueous layer, which had been acidified by addition of 5 drops of 2 N HCl. The product was further purified by chromatography to provide the desired product. ^1H NMR (300 MHz, $CDCl_3$) δ 1.79 (s, 3H), 2.08- 2.38 (m, 4H), 2.15 (s, 3H), 2.53 (d, 1H, *J*= 22 Hz), 2.60 (d, 1H, *J*= 22 Hz), 2.57- 2.64 (m, 1H), 3.38 (d, 2H, *J*= 7 Hz), 3.72 (d, 6H, *J*= 11 Hz) 3.76 (s, 3H), 5.20 (s, 2H), 5.27 (t, 1H, *J*= 6 Hz), 5.36- 5.63 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 30.5; MS (*m/z*) 481.2 $[M-H]^-$.




Example 92-V 2-[4-(2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

To a solution of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid (25 mg, 0.052 mmol) in acetonitrile (2 mL) was added 2,6-lutidine (60 μL, 0.52 mmol) and TMSBr (67 μL, 0.52 mmol). The reaction was allowed to proceed for 45 minutes when it was completed as judged by LCMS. The reaction mixture was concentrated under reduced pressure and quenched with an aqueous NaOH solution (1 mL). The product was purified by reverse-phase HPLC on a C18 column to provide 14.2 mg (60%) of the product as a solid. ^1H NMR (300 MHz, CD_3OD) δ 1.81 (s, 3H), 2.081- 2.31 (m, 4H), 2.16 (s, 3H), 2.45 (d, 1H, *J*= 22 Hz), 2.47 (d, 1H, *J*= 22 Hz), 2.55- 2.63 (m, 1H), 3.38 (d, 2H, *J*= 7 Hz), 3.77 (s, 3H), 5.25 (s, 2H), 5.20- 5.36 (m, 1H), 5.36- 5.56 (m, 2H); ^{31}P (121.4 MHz, CD_3OD) δ 25.4; MS (*m/z*) 453 $[M-H]^-$.




Example 92-W 2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester

A solution of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid (160 mg, 0.332 mmol) and trimethylsilylethanol (160 mg, 1.36 mmol) in THF (8.00 mL) was stirred with triphenylphosphine (345 mg, 1.33 mmol). To this solution was added diethyl azodicarboxylate (230 μL, 1.33 mmol) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 16 hours. Additional triphenylphosphine (180 mg, 0.692 mmol), trimethylsilylethanol (160 mg, 1.36 mmol), and diethyl azodicarboxylate (115 μL, 0.665 mmol) were added and the reaction mixture was stirred for another 1 day at room temperature. The reaction was worked up by removing the solvents *in vacuo* and purifying the residue by silica gel chromatography to provide 192 mg (85%) of the product as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 0.05 (s, 9H), 0.93- 0.96 (m, 2H), 1.20- 1.29 (m, 2H), 1.78 (s, 3H), 2.01- 2.32 (m, 4H), 2.17 (s, 3H), 2.51 (d, 1H, *J*= 22 Hz), 2.58 (d, 1H, *J*= 22 Hz), 2.50- 2.60 (m, 1H), 3.37 (d, 2H, *J*= 7 Hz), 3.72 (d, 6H, *J*= 11 Hz), 3.76 (s, 3H), 4.08 (appt t, 2H, *J*= 8 Hz), 4.30 (appt t, 2H, *J*= 8 Hz), 5.12 (s, 2H), 5.15- 5.25 (m, 1H), 5.36- 5.63 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 29.3; MS (*m/z*) 705.3 $[M+Na]^+$.



Example 92-X 2-[4-(Hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester


A mixture of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (184 mg, 0.270 mmol) in *tert*-butylamine (2.8 mL, 27 mmol) was heated at 60 °C for 24 hours. The solution was allowed to cool down to room temperature and concentrated. The residue was purified by silica gel column chromatography using MeOH/ CH_2Cl_2 (0- 30%) to provide 75 mg of the product as a clear oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.01 (s, 9H), 0.04 (s, 9H), 0.89 (appt t, 2H, *J*= 9 Hz), 1.23 (appt t, 2H, *J*= 9 Hz), 1.77 (s, 3H), 2.01- 2.31 (m, 4H), 2.17 (s, 3H), 2.36 (d, 1H, *J*= 22 Hz), 2.38 (d, 1H, *J*= 22 Hz), 2.52 (septet, 1H, *J*= 9 Hz), 3.39 (d, 2H, *J*= 7 Hz), 3.51 (d, 3H, *J*= 11 Hz), 4.01- 4.08 (m, 2H), 4.30 (dd, 2H, *J*= 8, 9 Hz), 5.11 (s, 2H), 5.19 (br t, 1H, *J*= 6 Hz), 5.33- 5.56 (m, 2H), 8.49 (br s, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 22.1; MS (*m/z*) 667.4 $[M+Na]^+$.



Example 92-Y 2-{4-[(1-Ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester

A solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (67 mg, 0.10 mmol), PyBOP (234 mg, 0.450 mmol) in DMF (1.5 mL) was stirred with ethyl (S)-(-)-lactate (53 mg, 0.45 mmol) and DIEA (174 μL, 1.00 mmol) at ambient temperature for 1 hour when complete consumption of the starting materials was observed. The reaction was worked up by addition of saturated


aqueous sodium chloride and ethyl acetate. The organic layer was separated and washed with 5% aqueous solution of lithium chloride. The organic layer was dried *in vacuo* and the residue was purified by silica gel chromatography using MeOH- CH_2Cl_2 (0- 20%) to provide 57 mg (74%)of the desired product as a clear oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.02 (s, 9H), 0.05 (s, 9H), 0.88- 0.94 (m, 2H), 1.20- 1.30 (m, 2H), 1.29 (t, 3H, *J*= 7 Hz), 1.45 (d, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.01- 2.31 (m, 4H), 2.17 (s, 3H), 2.50- 2.58 (m, 1H), 2.65 (d, 1H, *J*= 22 Hz), 2.67 (d, 1H, *J*= 22 Hz), 3.39 (d, 2H, *J*= 7 Hz), 3.69 and 3.77 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.07 (appt t, 2H, *J*= 7 Hz), 4.20 (dq, 2H, *J*= 3, 7 Hz), 4.29 (appt t, 2H, *J*= 9 Hz), 4.85- 4.99 (m, 1H), 5.12 (s, 2H), 5.19 (br t, 1H, *J*= 6 Hz), 5.33- 5.61 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 28.9, 29.9; MS (*m/z*) 791.4 $[M+Na]^+$.



Example 92-Z 2-{4-[(1-Ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid


A solution of 2-{4-[(1-ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (14 mg, 0.018 mmol) in THF (1 mL) was stirred with a 1M solution of TBAF in THF (55 μL, 0.055 mmol) for 1 hour. The reaction mixture was worked up by concentrating the reaction mixture *in vacuo* and extracting the product from an aqueous 1N HCl solution with EtOAc. The organic layer was washed with brine and dried. The product was purified by silica gel column chromatography EtOH-EtOAc (0-10%). Further purification was performed by dissolving the product in CH_2Cl_2 and passing the compound through a 13 mm Acrodisc syringe filter with a 0.45 μm Nylon membrane to provide 8 mg (77%)

of the product. ^{1}H NMR (300 MHz, $CDCl_3$) 0.92 (t, 3H, *J*= 7 Hz), 1.30 (d, 3H, *J*= 8 Hz), 1.79 (s, 3H), 2.10- 2.39 (m, 4H), 2.15 (s, 3H), 2.53 (d, 1H, *J*= 8 Hz), 2.65 (d, 1H, *J*= 22 Hz), 2.68 (d, 1H, *J*= 22 Hz), 3.38 (d, 2H, *J*= 7 Hz), 3.70 and 3.74 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.07 (m, 2H), 4.96 (dq, 1H, *J*= 7 Hz), 5.20 (s, 2H), 5.27 (br t, 1H, *J*= 7 Hz), 5.33- 5.55 (m, 2H), 7.51- 7.56 (m, 1H), 7.68- 7.74 (m, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 29.0, 30.1; MS (*m/z*) 569.2 $[M+H]^+$, 591.3 $[M+Na]^+$.



Example 92-AA 2-{4-[(1-Carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester


A solution of 2-{4-[(1-ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanylethyl ester (12 mg, 0.016 mmol) in *tert*-butylamine (1 mL, 9.6 mmol) was heated at 65 °C for 16 hours. The solution was allowed to cool down to room temperature and concentrated to provide the crude product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$) 0.03 (s, 9H), 0.04 (s, 9H), 0.86- 0.98 (m, 2H), 1.22- 1.33 (m, 2H), 1.50 (d, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.05- 2.30 (m, 4H), 2.10 (s, 3H), 2.48- 2.63 (m, 3H), 3.40 (d, 2H, *J*= 7 Hz), 3.76 (s, 3H), 4.08 (appt t, 2H, *J*= 9 Hz), 4.25- 4.33 (m, 2H), 4.75- 4.84 (m, 1H), 5.13 (s, 2H), 5.15- 5.23 (m, 1H), 5.33- 5.55 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 28.9; MS (*m/z*) 725.3 $[M-H]^-$.



Example 92-AB 2-{4-[(1-Carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A solution of crude 2-{4-[(1-carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (AC-2101-59) and tetrabutylammonium fluoride in THF (1M, 54 μL, 0.054 mmol) was stirred with THF (1 mL) for 2 hours at ambient temperature when an extra amount of tetrabutylammonium fluoride in THF (54 μL, 0.054 mmol) was added. The reaction was stirred for an additional 16 hours when the reaction was complete. The reaction mixture was concentrated *in vacuo* and the product was purified by reverse-phase HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O, 0.1% TFA- CH_3CN, 0.1% TFA to provide the product (8.0 mg) as a clear oil. ^1H NMR (300 MHz, $CDCl_3$) 1.51 (d, 3H, *J*= 7 Hz), 1.79 (s, 3H), 2.05- 2.40 (m, 4H), 2.11 (s, 3H), 2.49- 2.71 (m, 3H), 3.38 (d, 2H, *J*= 6 Hz), 3.76 (s, 3H), 4.85 (br s, 1H), 5.20 (s, 2H), 5.21-5.30 (m, 1H), 5.33- 5.63 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 27.7; MS (*m/z*) 525.2 $[M-H]^-$.


Scheme II



Example 92-AC 2-{4-[(1-Ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester

A solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (20 mg, 0.030 mmol), PyBOP (62.4 mg, 0.120 mmol) in DMF (1.0 mL) was stirred with L-alanine ethyl ester hydrochloride (18 mg, 0.12 mmol) and DIEA (26 μL, 0.15 mmol) at ambient temperature for 1 hour when complete consumption of the starting materials was observed. The reaction was worked up by addition of water until the reaction solution became cloudy. A minimum amount of DMF was added until the reaction became clear again. The reaction mixture was


filtered through Acrodisc (13 mm syringe filter with a 0.45 μm Nylon membrane) and purified by reverse-phase HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm), eluting with water and acetonitrile. The fractions containing the product were pooled together and dried *in vacuo* to remove the acetonitrile. The aqueous layer was saturated with sodium chloride and extracted with EtOAc and acetonitrile to provide 7.2 mg of the product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 0.05 (s, 9H), 0.923 (appt t, 2H, *J*= 8 Hz), 1.18- 1.31 (m, 5H), 1.41 (t, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.03- 2.36 (m, 4H), 2.18 (s, 3H), 2.43- 2.63 (m, 3H), 3.10- 3.30 (m, 1H), 3.40 (d, 2H, *J*= 7 Hz), 3.62 and 3.65 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.03-4.12 (m, 2H), 4.20 (dq, 2H, *J*= 2, 7 Hz), 4.29 (appt t, 2H, *J*= 8 Hz), 5.12 (s, 2H), 5.18- 5.28 (m, 1H), 5.33- 5.67 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 30.4, 31.2; MS (*m/z*) 790.4 $[M+Na]^+$.



Example 92-AD 2-{4-[(1-Ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

To a solution of 2-{4-[(1-ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (7.2 mg, 9.38 mmol) in THF (1 mL) was added TBAF (40 μL, 1M solution in THF) at room temperature. The reaction mixture was stirred for 20 minutes when the starting materials were completely converted to the desired products as observed by LCMS. The reaction mixture was dried in vacuo and re-dissolved in DMF. The product was purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O-CH_3CN. The fractions containing the desired product were pooled and further purified on Dowex 50WX8-400 packed on a 4.5 cm x 2 cm


column to elute the sodium salt at H_2O- MeOH (1:1) to provide 3.2 mg of the desired product. ^1H NMR (300 MHz, CD_3OD) δ 1.26 (dd, 3H, *J*= 4, 7 Hz), 1.37 (t, 3H, *J*= 8 Hz), 1.80 (s, 3H), 2.00- 2.22 (m, 4H), 2.10 (s, 3H), 2.25- 2.60 (m, 3H), 3.37 (d, 2H, *J*= 7 Hz), 3.60 and 3.65 (d, 3H, *J*= 11 Hz), 3.74 (s, 3H), 3.83- 3.96 (m, 1H), 4.18 (q, 2H, *J*= 8 Hz), 5.15 (s, 2H), 5.25- 5.42 (m, 2H), 5.55- 5.69 (m, 1H); ^{31}P (121.4 MHz, CD_3OD) δ 33.8, 34.2; MS (*m/z*) 568.2 $[M+H]^+$, 590.3 $[M+Na]^+$.



Example 92-AE 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-4-methyl-hex-4-enoic acid

To a solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanylethyl ester (11 mg, 0.016 mmol) in THF (1 mL) was added TBAF (50 μL, 1M solution in THF) at room temperature. The solution was stirred for 16 hours and concentrated. The solution was dried under reduced pressure and re-suspended in DMF (0.8 mL) and water (0.25 mL). The solution was filtered through Acrodisc (13 mm syringe filter with a 0.45 μm Nylon membrane) and purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O, 0.1% TFA-CH_3CN, 0.1% TFA. The product from the column was subjected to ion exchange chromatography (Sodium salt form of Dowex 50WX8-400) using a 2 x 4.5 cm column eluting with H_2O-MeOH (1:1) to provide 7.5 mg of the desired product as an oil. ^1H NMR (300 MHz, $CDCl_3$) 1.80 (s, 3H), 2.01- 2.29 (m, 5H), 2.11 (s, 3H), 2.35 (d, 2H, *J*= 22 Hz), 3.38 (d, 2H, *J*= 7 Hz), 3.53 (d, 3H, *J*= 11 Hz), 3.75 (s, 3H), 5.19 (s, 2H), 5.26 (t, 1H, *J*= 6 Hz), 5.43- 5.54 (m, 2H); ^{31}P (121.4 MHz, $CDCl_3$) δ 23.5; MS (*m/z*) 469.2 $[M+H]^+$, 491.3 $[M+Na]^+$.


Scheme III



Example 92-AF 2-[4-(Diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester:


A solution of 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (140 mg, 0.30 mmol) and triethylphosphite (600 mg, 3.6 mmol) in toluene (30 mL) was stirred at reflux for 20 h. The mixture was concentrated and chromatographed on silica gel eluting with ethyl acetate (60 % to 100 %) /

hexanes, affording 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester as an oil (70 mg, 43 %); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.27 (m, 6H), 1.79 (s, 3H), 2.0-2.7 (m, 8H), 3.37 (d, J = 6.6 Hz), 3.52 (s, 3H), 3.75 (s, 3H), 4.08 (m, 4H), 5.20 m, 3H), 5.45 (m, 2H).



Example 92-AG 2-[4-(Diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A mixture of 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (33 mg, 0.063 mmol) and lithium hydroxide (44 mg) in a mixed solvent of THF (6 mL) and water (1 mL) was stirred at room temperature for 6 h. The organic solvent was removed and the residue was partitioned between ethyl acetate and 5 % aqueous sodium bicarbonate. The aqueous layer was acidified with 2 N HCl and extracted with ethyl acetate. The ethyl acetate extract was concentrated, affording 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid as an oil (30 mg, 100%); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.27 (m, 6H), 1.79 (s, 3H), 2.0-2.7 (m, 8H), 3.37 (d, J = 6.6 Hz), 3.75 (s, 3H), 4.08 (m, 4H), 5.19 (s, 2H), 5.25 (m, 1H), 5.44 (m, 1H), 5.55 (m, 1H), 5.45 (m, 2H).




Example 92-AH 2-[4-(Ethoxy-hydroxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A mixture of 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (25 mg, 0.048 mmol) and lithium hydroxide (200 mg) in a mixed solvent of methanol (3 mL) and water (1 mL) was stirred at 70 °C for 2 h. The organic solvent was removed and then acidified with 2N HCl and extracted with ethyl acetate /acetonitrile. The organic extract was concentrated and the residue was purified by preparative reverse-phase HPLC (acetonitrile and 0.1% aqueous CF_3COOH), affording 22-[4-(ethoxy-hydroxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid as an oil (15 mg, 89%); ^1H NMR (300 MHz, CD_3OD) δ 1.25 (t, J = 6.9 Hz, 3H), 1.81 (s, 3H), 2.1-2.6 (m, 8H), 3.40 (d, J = 6.6 Hz, 2H), 3.77 (s, 3H), 3.97 (m, 2H), 5.1-5.3 (m, 3H), 5.67 (brs, 2H).

Example 93: Preparation of exemplary compounds of the present invention.

Figure 1




1 2 3

Link is 1-8 atoms in length, with 2-6 atoms preferred


Compounds such as **1** can be made according to the general route outlined in Scheme **1**, with an example depicted in Scheme **2**.

Scheme 1:



1.1.1 **1**

Scheme 2:




1.1.1 **1**

The Boc-protected (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol, compound **1.1.1**, is prepared by stirring the (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol (WO 9,919,338 and Evans, G. B. et al., *Tetrahedron*, **2000**, *56*, 3053, also reported in Evans, G. B. et al., *J. Med. Chem.* **2003**, *46*, 3412) with BOC anhydride as described in Greene, T., Protective


groups in organic synthesis, Wiley-Interscience, 1999. Compound **1.1.1** is then treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, **1986**, *27*, 1477) is added, yielding the desired phosphonate **1** after deprotection of the BOC group using trifluoroacetic acid (TFA).

Compounds such as **2** and **3** can be made according to the general route outlined in Scheme 3, with an example depicted in Scheme **4**.

Scheme 3:



Scheme 4:




The Boc-protected (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol, compound **1.1**, is prepared by stirring the (1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol (WO 9,919,338 and Evans, G. B. et al., *Tetrahedron*, **2000**, *56*, 3053, also reported in Evans, G. B. et al., *J. Med. Chem.* **2003**, *46*, 3412) with BOC anhydride as described in Greene, T., Protective groups in organic synthesis, Wiley-Interscience, 1999. Subsequent protection of the primary alcohol using a TBS group can be achieved using TBSCl and imidazole in solvents such as CH_2Cl_2 as described in Greene, T. Protective

groups in organic synthesis, Wiley-Interscience, 1999 to provide compound **1.1**. Compound **1.1** is then treated in a solvent such as tetrahydrofuran or dimethylformamide with a base such as sodium hydride. When bubbling ceases, diethyl phosphonomethyltriflate (prepared according to *Tetrahedron Lett.*, **1986**, *27*, 1477) is added, yielding a mixture of the desired phosphonate diester **2** and **3** after deprotection of the BOC group using trifluoroacetic acid (TFA). Compounds **2** and **3** can be also prepared via a more complicated 2' OH protected analog of **1.1** followed by alkylation using the diethyl phosphonomethyltriflate to provide compound **2** exclusively. Compound **3** can also be prepared by installation of a different protecting group at the 3' OH position, followed by deprotection of 2' OH and alkylation with diethyl phosphonomethyltriflate at the 2' center followed by global deprotection.


Example 94: Preparation of exemplary compounds of the present invention.

IV. **Parent molecule:**



Camptosar


General target structures:



Linker is 1-8 atoms in length, with 2-6 atoms preferred

A synthetic scheme towards a specific target I is outlined below:

Scheme 1




Recommended procedure for O-alkylation: mix the phenol and Cs_2CO_3 (ca. 1:1.2) in DMF and stir well for 30 min at 0 °C. Add the triflate (1.2 eq.). The reaction should be complete within an hour.

Experimental for the trifluoromethanesulfonyloxymethylphosphonate will be provided separately.

Additional Compounds: The following target II will be prepared after an initial biological evaluation of the target I.

Scheme 2




Reference for camptothecin-7-aldehyde: *Chem. Pharm. Bull.* **1991**, *39*, 2574.

Reference for reactions of Wittig ylides with the camptothecin aldehyde: *J. Med. Chem.* **2000**, *43*, 3963.


Example 95: Preparation of exemplary compounds of the present invention.


V. **Parent molecule:**



Idarubicin

General target structures:






Link is 1-8 atoms in length, with 2-6 atoms preferred

A synthetic scheme towards a specific target I is outlined below:

Scheme **1**




Target I

Reference of reductive amination of anthracyclines: *J. Med. Chem.* **1998**, *41*, 965.


Experimental for the aldehyde intermediate from the allyl phosphonate will be provided.

Additional Compounds: The following two targets II and III will be prepared after an initial biological evaluation of the target I.



Target II


Target III



Reference for N-acylation of anthracyclines: *J. Med. Chem.* **1980**, *23*, 1166


Example 96: Preparation of exemplary compounds of the present invention.

Parent molecule:



BAY-43-9006


Target classes:



Link = 1-8 atoms, with 2-6 preferred

A synthetic scheme towards specific targets I and II is outlined below.


Scheme 1



Reference for synthesis of target I: Org. Pro. Res. Dev. web publication will be provided.


Additional Compounds: The following targets III and IV will be prepared after an initial biological evaluation of the targets I and II.

Scheme **2**



Target III


Scheme **3**



Target IV

Mycophenolate

Representative compounds of the invention having the following formulae can be prepared as described in Examples **201-204**.




D **E**

F **G**

For example, three regions of mycophenolate mofetil can be utilized for the attachment of the phosphonate prodrug as demonstrated by compounds **D**, **E**,


and **G** shown above. Also, the carboxylic acid can be replaced with a phosphonic acid as in compound **F**.

Example 201 Preparation of Representative Compounds of Formula 204



201.1 **201.3**

Representative compounds of the invention can be prepared as illustrated above. The morpholino ethyl moiety can serve as a prodrug functionality to improve bioavailability and can be replaced with the phosphonate prodrug handle as shown above. Mycophenolic acid is commercially available, e.g., from Sigma Chemical Company, St. Louis, Mo. Activation of the carboxylic acid **201.1** in the presence of the free phenol, followed by addition of an alcohol carrying the phosphonate group, results in the formation of the desired product **201.3** (US 4,786,637). A specific compound of the invention can be prepared as follows.




201.1 **201.2** **201.3**

Mycophenolic acid **201.1** is dissolved in dichloromethane. Thionyl chloride is added followed by a catalytic amount of DMF. The reaction mixture is stirred at room temperature for 3 hours, after which the volatile components


are removed under vacuum. The phosphonate-alcohol is dissolved in dichloromethane and chilled to about 4 °C on an ice bath. The mycophenolic acid chloride **201.2** is dissolved in dichloromethane and added to the chilled solution. After stirring for 90 minutes at about 4 °C, the reaction mixture is washed with water and then with aqueous sodium bicarbonate. The organic solution is dried and evaporated to yield the phosphonate **201.3**.

Example 202 Preparation of Representative Compounds of Formula 207



Representative compounds of the invention can be prepared as illustrated above. The C-4 phenol position provides a reactive handle for further analogs as illustrated above. Once the carboxylic acid of **202.1** is blocked by morpholino ethyl, such as in compound **202.2** the phenol can be alkylated under basic conditions. Bases such as pyridine, potassium carbonate, or triethylamine are utilized. Leaving groups such as trifluoromethylsulfonate, mesylate, bromide, or iodide are attached to the phosphonate prodrug subunit and reacted, in the presence of base, with compound **202.2**. Compound **202.3** can either be used directly, or in the form of a salt, compound **202.4**. Among the large number of

salts that can be prepared, chloride and bisulfate salts are one particular embodiment of the invention. A specific compound of the invention can be prepared as follows.




202.8


Compound **202.5** is prepared similar to compound **201.2** (described in Example 201). A solution of morpholino ethanol in dichloromethane is cooled to about 4 °C. The mycophenolic acid chloride **202.5** is dissolved in dichloromethane and added to the cooled solution. Stirring this solution for about 90 minutes gives compound **202.2**. The reaction mixture is washed with water and dried with sodium sulfate. Removal of the solvent provides isolated compound **202.2**. Alkylation at the phenolic position of **202.2** is achieved by suspending the compound in pyridine. Triflate **202.6** is added to the solution and the mixture is stirred at room temperature for about 90 minutes. The reaction mixture is poured into water and the product is extracted with ethyl acetate. Removal of the organic layer provides compound **202.7**. Hydrochloride salt of **202.7** can optionally be prepared. Compound **202.7** is dissolved in

isopropanol and the solution is added to a mixture of hydrogen chloride in isopropanol. The hydrochloride salt **202.8** is collected by filtration and dried under vacuum.

Example 203 Preparation of Representative Compounds of Formula 205




Representative compounds of the invention can be prepared as illustrated above. The carboxylic acid of mycophenolic acid can be replaced with a phosphonic acid that may also serves as a prodrug handle. In order to remove the carboxylic acid containing side chain, the acid chloride **202.5** (prepared in Example 202) is converted to ester **203.1**. Protection of the phenol with a silyl group, followed by dihydroxylation and cleavage of the diol generates aldehyde **203.3** (Pankiewicz, et al., *J. Med. Chem.*, 2002, *45*, 703), (Patterson et al., US 5,444,072) (Example 20). A Wittig reaction with ylide **203.4** carrying an appropriately protected phosphonate provides the desired compound **203.5**. Final deprotection yields compound **203.6**. A specific compound of the invention can be prepared as follows.




Mycophenolate ester **203.8** can simply be prepared by stirring the acid chloride **203.7** with MeOH. Then, the phenol position of mycophenolate ester is protected by a silyl group such as TBS to provide compound **203.9**. Once the phenol position is protected, dihydroxylation using osmium tetraoxide followed by periodinate cleavage provides aldehyde **203.10**. Aldehyde **203.10** and excess of the ylide **203.11** are heated in benzene at reflux for about 24 hours. The reaction mixture is concentrated and the residue is purified by column chromatography to provide olefin **203.12** (Pankiewics et al., *J. Med. Chem.*, 2002, *45*, 703). A final deprotection using HF-pyridine yields the final product **203.13**.

Example 204 Preparation of Representative Compounds of Formula 208




204.1 204.2 204.3 204.4

Representative compounds of the invention can be prepared as illustrated above. Another attachement point of the compound can be unmasked after demethylation of mycophenolate ester **204.2** as illustrated above. For this purpose, the 4-OH needs to be masked with a protecting group (P) such as a silyl group. Once the 6-MeO is demethylated and alkylated, the protecting group at position 4 is removed to reveal the final product **204.4**. The morphonyl ethanol group is installed early and carried through the alkylation steps. A different protecting group may be installed initially and removed later. In such the latter type of synthesis, the last step is the formation of the morpholinoethyl ester prodrug. A specific compound of the invention can be prepared as described below.



Phenol **204.5** is protected with TBS group in CH_2Cl_2 using imidazole as base to yield **204.6.** Demethylation is performed using thiolate nucleophiles to generate compound **204.7.** A variety of other methods are also available in literature as described in *Protective Groups in Organic Synthesis* by Greene and Wuts. Alklation of the 6-OH using a triflate of the phosphonate proceeds well using K_2CO_3 or TEA to provide **204.8.** Final deprotection to remove the TBS group provides product **204.9.**

Example 251: Preparation of Representative Compounds of the Invention.



Representative compounds of the invention can be prepared as illustrated above.

[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester

A mixture of 7-hydroxy-6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-3H-isobenzofuran-1-one **1A** (50 mg, 0.18 mmol, Pankiewicz *et al.*, *J. Med. Chem.*, **45**, 703), diisopropyl bromomethylphosphonate (93 mg, 0.36 mmol) and lithium *t*-butoxide (1M in THF, 0.54 mL) in DMF (3 mL) was heated at 70 °C for 5 hours. The reaction was quenched with 1N HCl. The mixture was poured into 5 % aqueous lithium chloride, extracted with ethyl acetate, and concentrated. The residue was purified by chromatography on silica gel, affording [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester **1B** (25 mg, 32%); ^{1}H NMR (300 MHz, $CDCl_3$) δ1.25 (m, 12H), 1.79 (s, 3H), 2.05 (s, 3H), 3.37 (d, J = 6.6 Hz, 2H), 3.58 (d, 2H), 3.77 (s, 3H), 3.97 (m, 2H), 4.68 (m, 2H), 5.19 (s, 2H), 5.45 (t, J = 6.6 Hz, 1H), 7.83 (s, 1H) ppm.


[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid and [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monoisopropyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diisopropyl ester **1B** (25 mg, 0.055 mmol) and 2,6-lutidine (0.18 mL, 1.65 mmol) in acetonitrile was added trimethylsilyl bromide (0.126 mL, 1.1 mmol) at 0°C. The mixture was allowed to warm to room temperature and stirred for 4 hours. The reaction was quenched with methanol at 0°C, and the resulting mixture was concentrated. The residue was purified by preparative reverse-phase HPLC to afford, after removal of the solvent, [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid **1C** as an oil (17 mg, 83 %); ^{1}H NMR (300 MHz, CD_3OD) δ 1.81 (s, 3H), 2.06 (s, 3H), 3.40 (d, J = 6.6 Hz, 2H), 3.50 (d, 2H), 3.77 (s, 3H), 3.97 (s, 2H), 5.20 (s, 2H), 5.47 (t, J = 6.6 Hz, 1H) and [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monoisopropyl ester **1D** as an oil (2 mg, 7 %);

^{1}H NMR (300 MHz, CD_3OD) δ 1.23 (d, 6H), 1.81 (s, 3H), 2.08 (s, 3H), 3.40 (d, J = 6.6 Hz, 2H), 3.50 (d, 2H), 3.77 (s, 3H), 3.90 (s, 2H), 4.50 (m, 1H), 5.20 (s, 2H), 5.47 (t, J = 6.6 Hz, 1H) ppm.

Example 252: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



[5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester


To a solution of tetramethylmethylene diphosphonate (102 mg, 0.44 mmol) in THF (2.5 mL) was added a THF solution of sodium bis(trimethysilyl)amide (1.0 M, 0.44 mL). After stirring for 30 minutes, a solution of 4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enal 2A (30 mg, 0.11 mmol, Pankiewicz *et al.*, *J. Med. Chem.*, 45, 703) in THF (2.5 mL) was added, and stirring was continued for an additional 15 minutes. The reaction was quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate. After evaporation of solvent, the residue was purified by chromatography on silica gel eluting with ethyl acetate (50 % to 100 %) / hexanes, affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester 2B (30 mg, 71 %) as an oil; ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.80 (s, 3H), 2.04 (s, 3H), 3.45 (d, J = 6.6 Hz, 2H), 3.76 (s, 3H), 3.88 (d, 6H), 5.20 (s, 3H), 5.55 (m, 1H), 5.95 (m, 1H), 7.05 (m, 1H), 7.65 (s, 1H) ppm.

[5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid

To a solution of [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid dimethyl ester 2B (22 mg, 0.057 mmol) and 2,6-lutidine (0.22 mL, 1.71 mmol) in acetonitrile was added trimethylsilyl bromide (0.183 mL, 1.71 mmol) at 0°C. The mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was quenched with methanol at 0°C, and the resulting mixture was concentrated. The residue was purified by preparative reverse-phase HPLC to afford, after removal of the solvent, [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-penta-1,3-dienyl]-phosphonic acid 2C as a solid (13 mg, 65 %); ^{1}H NMR (300 MHz, CD_3OD) δ 1.91 (s, 3H), 2.10 (s, 3H), 3.55 (d, J = 6.6 Hz, 2H), 3.75 (s, 3H), 5.2 (s, 2H), 5.6-5.8 (m, 2H), 6.9 (m, 1H) ppm.

Example 253: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



6-(4-Bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one

Polymer-supported triphenylphosphine (3 mmol/g, 0.5 g) was soaked in dichloromethane (10mL) for 1 hour 7-Hydroxy-6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-3H-isobenzofuran-1-one 1A (100 mg, 0.36 mmol) and carbon tetrabromide (143 mg, 0.43 mmol) were sequentially added and the mixture was shaken for 1 hour at room temperature. More carbon tetrabromide

(143 mg, 0.43 mmol) was added and the mixture was shaken further for 1 hour. The mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica gel (0 % to 60 % ethyl acetate / hexanes) to afford 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one 3B as an oil (52 mg, 42 %); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.95 (s, 3H), 2.16 (s, 3H), 3.44 (d, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.98 (s, 2H), 5.21 (s, 2H), 5.68 (t, J = 7.2 Hz, 1H), 7.71 (brs, 1H) ppm.


[5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester

n-Butyl lithium (1.6 M in hexanes, 1 mL) was added to an equal volume of THF at –20°C. A solution of diethyl methylphosphonate (220 mg, 1.45 mmol) in THF (1 mL) was then added dropwise and the solution was stirred for 30 minutes. After cooling at –60°C, the solution was transferred *via* a cannula to a vial containing copper (I) iodide (276 mg, 1.45 mmol), and the resulting mixture was stirred for 1 hour at –30°C. A solution of 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one 3B (50 mg, 0.15 mmol) in THF (1 mL) was added and the mixture was allowed to warm to 0°C for 2 hours before saturated aqueous ammonium chloride was added. The reaction mixture was acidified with 2 N HCl and extracted with ethyl acetate. The ethyl acetate extract was concentrated and the residue was chromatographed on silica gel (40% to 100% ethyl acetate / hexanes), affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester 3C as an oil (27 mg, contaminated with the starting diethyl methylphosphonate); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.32 (m, 6H), 1.8-1.9 (m, 5H), 2.18 (s, 3H), 2.25 (m, 2H), 3.42 (d, J = 7.2 Hz, 2H), 3.78 (s, 3H), 4.15 (m, 4H), 5.21 (s, 2H), 5.24 (t, J = 7.2 Hz, 1H), 7.65 (s, 1H) ppm.

[5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid monoethyl ester

A mixture of [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester 3C (27

mg, 0.066 mmol), LiOH (200 mg), MeOH (3 mL) and water (1 mL) was stirred at 70°C for 4 hours. After cooling, the reaction solution was acidified with 2 N HCl, mixed with brine, and extracted with ethyl acetate / acetonitrle. The organic extract was concentrated and the residue was purified by preparative reverse-phase HPLC (acetonitrile and 0.1% aqueous CF_3COOH), affording [5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid monoethyl ester 3D (7 mg, 28 %); ^1H NMR (300 MHz, CD_3OD) δ 1.28 (t, J = 6.9 Hz, 3H), 1.7-1.9 (m, 5H), 2.20 (s, 3H), 2.2-2.3 (m, 2H), 3.41 (d, J = 6.6 Hz, 2H), 3.80 (s, 3H), 4.02 (m, 2H), 5.2-5.3 (m, 3H) ppm.




[5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid

To a solution of {5-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-sobenzofuran-5-yl]-3-methyl-pent-3-enyl}-phosphonic acid diethyl ester (20 mg, 0.039 mmol) in DMF (0.5 mL) and DCM (0.5 mL) was added TMSBr (50.5μL, 0.39 mmol) followed by 2,6-lutidine (45.3 μL, 0.39 mmol). The reaction was allowed to proceed for one hour when it was complete, as judged by LCMS. The reaction mixture was quenched with MeOH and concentrated to dryness. The residue was purified by preparative reverse-phase HPLC. The fraction containing the desired product was concentrated and treated with 10% TFA/DCM for 5 minutes. After concentration, the residue was purified by preparative reverse-phase HPLC to provide 7 mg (50%) of [5-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid as a solid. ^1H NMR (300 MHz, CD_3OD) δ 1.66-1.78 (m, 5H), 2.10 (s, 3H), 2.16-2.22 (m, 2H), 3.34 (d, J = 7.2 Hz, 2H), 3.72 (s, 3H), 5.16 (s, 2H), 5.20 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 31.57 ppm; MS (*m/z*) 355 $[M-H]^-$, 357 $[M+H]^+$.

Example 254: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



2-(4-Bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester

To a cooled (-78°C) solution of mycophenolic acid methyl ester **4A** (138 mg, 0.41 mmol) in THF (2.5 mL) was added a THF solution of sodium bis(trimethysilyl)amide (1.0 M, 0.98 mL). After stirring for 30 minutes, a solution of 1,4-dibromo-2-butene (950 mg, 4.1 mmol) in THF (2.5 mL) was added and stirring was continued for 10 minutes. The resulting mixture was warmed to –30°C and stored at this temperature for 16 hours. The reaction was quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate to give, after evaporation of the solvent, a residue that was purified by chromatography on silica gel eluting with ethyl acetate (0 % to 40 %) / hexanes, affording 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

methyl ester **4B** (150 mg, 78 %) as an oil; ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.75 (s, 3H), 2.0-2.4 (m, 8H), 2.62 (m, 1H), 3.37 (d, J = 6.6 Hz, 2H), 3.58 (s, 3H), 3.76 (s, 3H), 3.88 (d, J = 4.8 Hz, 2H), 5.1-5.3 (m, 3H), 5.67 (brs, 2H), 7.67 (s, 1H) ppm.

2-[4-(Diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester

A solution of 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester **4B** (140 mg, 0.30 mmol) and triethylphosphite (600 mg, 3.6 mmol) in toluene (30 mL) was stirred at reflux for 20 hours. The mixture was concentrated and chromatographed on silica gel eluting with ethyl acetate (60 % to 100 %) / hexanes, affording 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester **4C** as an oil (70 mg, 43 %); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.27 (m, 6H), 1.79 (s, 3H), 2.0-2.7 (m, 8H), 3.37 (d, J = 6.6 Hz), 3.52 (s, 3H), 3.75 (s, 3H), 4.08 (m, 4H), 5.20 m, 3H), 5.45 (m, 2H) ppm.


2-[4-(Diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A mixture of 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester **4C** (33 mg, 0.063 mmol) and lithium hydroxide (44 mg) in a mixture of THF (6 mL) and water (1 mL) was stirred at room temperature for 6 hours. The organic solvent was removed and the residue was partitioned between ethyl acetate and 5 % aqueous sodium bicarbonate. The aqueous layer was acidified with 2 N HCl and extracted with ethyl acetate. The ethyl acetate extract was concentrated, affording 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid **4D** as an oil (30 mg, 100%); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.27 (m, 6H), 1.79 (s, 3H), 2.0-2.7 (m, 8H), 3.37 (d, J = 6.6 Hz), 3.75 (s, 3H),

4.08 (m, 4H), 5.19 (s, 2H), 5.25 (m, 1H), 5.44 (m, 1H), 5.55 (m, 1H), 5.45 (m, 2H) ppm.

2-[4-(Ethoxy-hydroxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid


A mixture of 2-[4-(diethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester **4C** (25 mg, 0.048 mmol) and lithium hydroxide (200 mg) in a mixture of methanol (3 mL) and water (1 mL) was stirred at 70°C for 2 hours. The organic solvent was evaporated and the residue acidified with 2N HCl and extracted with ethyl acetate /acetonitrile. The organic extract was concentrated, and the residue was purified by preparative reverse-phase HPLC (acetonitrile and 0.1% aqueous CF_3COOH), affording 2-[4-(ethoxy-hydroxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid **4E** as an oil (15 mg, 89%); ^1H NMR (300 MHz, CD_3OD) δ 1.25 (t, J = 6.9 Hz, 3H), 1.81 (s, 3H), 2.1-2.6 (m, 8H), 3.40 (d, J = 6.6 Hz, 2H), 3.77 (s, 3H), 3.97 (m, 2H), 5.1-5.3 (m, 3H), 5.67 (brs, 2H) ppm.



2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester


Under a N_2 atmosphere, a solution of 2-(4-bromo-but-2-enyl)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (490 mg, 1.05 mmol) in trimethylphosphite (2.5 mL, 21.1 mmol) was heated at 120°C for 1 hour. The reaction was allowed to cool to room temperature. The reaction mixture was worked up by removal of

the solvent *in vacuo* followed by chromatography using EtOAc-hexanes to provide 460 mg (88%) of the product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.77 (s, 3H), 2.081- 2.31 (m, 4H), 2.15 (s, 3H), 2.52 (d, 1H, *J*= 22 Hz), 2.54 (d, 1H, *J*= 22 Hz), 2.55- 2.63 (m, 1H), 3.36 (d, 2H, *J*= 7 Hz), 3.57 (s, 3H), 3.72 (d, 6H, *J*= 11 Hz), 3.76 (s, 3H), 5.20 (s, 2H), 5.20- 5.26 (m, 1H), 5.36- 5.56 (m, 2H), 7.69 (s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 30.1 ppm; MS (*m/z*) 497.2 $[M+H]^+$, 519.2 $[M+Na]^+$.




2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (460 mg, 0.927 mmol) in a solution of 1: 1: 2 of H_2O, MeOH, THF (8 mL) was stirred with LiOH.H_2O (78 mg, 1.86 mmol) at ambient temperature for 12 hours. A second batch of LiOH.H_2O (40 mg, 0.952 mmol) was added. The reaction mixture was stirred at room temperature for another 16 hours, after which no further progress was observed. The reaction was quenched by addition of a saturated aqueous solution of NH_4Cl. The organic layer was removed *in vacuo* and the product was extracted with EtOAc from the aqueous layer, which had been acidified by addition of 5 drops of 2 N HCl. The product was further purified by chromatography to provide the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.79 (s, 3H), 2.08- 2.38 (m, 4H), 2.15 (s, 3H), 2.53 (d, 1H, *J*= 22 Hz), 2.60 (d, 1H, *J*= 22 Hz), 2.57- 2.64 (m, 1H), 3.38 (d, 2H, *J*= 7 Hz), 3.72 (d, 6H, *J*= 11 Hz) 3.76 (s, 3H), 5.20 (s, 2H), 5.27 (t, 1H, *J*= 6 Hz), 5.36- 5.63 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 30.5 ppm; MS (*m/z*) 481.2 $[M-H]^-$.



2-[4-(2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid


To a solution of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid (25 mg, 0.052 mmol) in acetonitrile (2 mL) was added 2,6-lutidine (60 μL, 0.52 mmol) and TMSBr (67 μL, 0.52 mmol). The reaction was allowed to proceed for 45 minutes when it was completed as judged by LCMS. The reaction mixture was concentrated under reduced pressure and quenched with an aqueous NaOH solution (1 mL). The product was purified by RP HPLC (using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA) to provide 14.2 mg (60%) of the product as a solid. ^1H NMR (300 MHz, CD_3OD) δ 1.81 (s, 3H), 2.081- 2.31 (m, 4H), 2.16 (s, 3H), 2.45 (d, 1H, *J*= 22 Hz), 2.47 (d, 1H, *J*= 22 Hz), 2.55- 2.63 (m, 1H), 3.38 (d, 2H, *J*= 7 Hz), 3.77 (s, 3H), 5.25 (s, 2H), 5.20- 5.36 (m, 1H), 5.36- 5.56 (m, 2H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 25.4 ppm; MS (*m/z*) 453 $[M-H]^-$.



2-[4-(Dimethoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester

A solution of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid (160 mg, 0.332 mmol) and trimethylsilylethanol (160 mg, 1.36 mmol) in THF (8.00 mL) was stirred with triphenylphosphine (345 mg, 1.33 mmol). To


this solution was added diethyl azodicarboxylate (230 μL, 1.33 mmol) at 0°C. The mixture was allowed to warm to room temperature and stirred for 16 hours. Additional triphenylphosphine (180 mg, 0.692 mmol), trimethylsilylethanol (160 mg, 1.36 mmol), and diethyl azodicarboxylate (115 μL, 0.665 mmol) were added and the reaction mixture was stirred for another 1 day at room temperature. The reaction was worked up by removing the solvents *in vacuo* and purifying the residue by silica gel chromatography to provide 192 mg (85%) of the product as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 0.05 (s, 9H), 0.93- 0.96 (m, 2H), 1.20- 1.29 (m, 2H), 1.78 (s, 3H), 2.01- 2.32 (m, 4H), 2.17 (s, 3H), 2.51 (d, 1H, *J*= 22 Hz), 2.58 (d, 1H, *J*= 22 Hz), 2.50- 2.60 (m, 1H), 3.37 (d, 2H, *J*= 7 Hz), 3.72 (d, 6H, *J*= 11 Hz), 3.76 (s, 3H), 4.08 (appt t, 2H, *J*= 8 Hz), 4.30 (appt t, 2H, *J*= 8 Hz), 5.12 (s, 2H), 5.15- 5.25 (m, 1H), 5.36- 5.63 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 29.3 ppm; MS (*m/z*) 705.3 $[M+Na]^+$.



2-[4-(Hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester


A mixture of 2-[4-(dimethoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (184 mg, 0.270 mmol) in *tert*-butylamine (2.8 mL, 27 mmol) was heated at 60 °C for 24 hours. The solution was allowed to cool to room temperature and concentrated. The residue was purified by silica gel column chromatography using MeOH/ CH_2Cl_2 (0-30%) to provide 75 mg of the product as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.01 (s, 9H), 0.04 (s, 9H), 0.89 (appt t, 2H, *J*= 9 Hz), 1.23 (appt t, 2H, *J*= 9 Hz), 1.77 (s, 3H), 2.01- 2.31 (m, 4H), 2.17 (s, 3H), 2.36 (d, 1H, *J*= 22 Hz), 2.38 (d, 1H, *J*= 22 Hz), 2.52 (septet, 1H, *J*= 9 Hz), 3.39 (d, 2H, *J*= 7 Hz), 3.51 (d, 3H,

J= 11 Hz), 4.01- 4.08 (m, 2H), 4.30 (dd, 2H, *J*= 8, 9 Hz), 5.11 (s, 2H), 5.19 (br t, 1H, *J*= 6 Hz), 5.33- 5.56 (m, 2H), 8.49 (br s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 22.1 ppm; MS (*m/z*) 667.4 $[M+Na]^+$.




2-{4-[(1-Ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester

A solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (67 mg, 0.10 mmol) and PyBOP (234 mg, 0.450 mmol) in DMF (1.5 mL) was stirred with ethyl (S)-(-)-lactate (53 mg, 0.45 mmol) and DIEA (174 μL, 1.00 mmol) at ambient temperature for 1 hour, when complete consumption of the starting materials was observed. The reaction was worked up by addition of saturated aqueous sodium chloride and ethyl acetate. The organic layer was separated and washed with 5% aqueous solution of lithium chloride. The organic layer was dried *in vacuo* and the residue was purified by silica gel chromatography using MeOH-CH_2Cl_2 (0-20%) to provide 57 mg (74%) of the desired product as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.02 (s, 9H), 0.05 (s, 9H), 0.88- 0.94 (m, 2H), 1.20- 1.30 (m, 2H), 1.29 (t, 3H, *J*= 7 Hz), 1.45 (d, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.01- 2.31 (m, 4H), 2.17 (s, 3H), 2.50- 2.58 (m, 1H), 2.65 (d, 1H, *J*= 22 Hz), 2.67 (d, 1H, *J*= 22 Hz), 3.39 (d, 2H, *J*= 7 Hz), 3.69 and 3.77 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.07 (appt t, 2H, *J*= 7 Hz), 4.20 (dq, 2H, *J*= 3, 7 Hz), 4.29 (appt t, 2H, *J*= 9 Hz), 4.85- 4.99 (m, 1H), 5.12 (s, 2H), 5.19 (br t, 1H, *J*= 6 Hz), 5.33- 5.61 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 28.9, 29.9 ppm; MS (*m/z*) 791.4 $[M+Na]^+$.




2-{4-[(1-Ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A solution of 2-{4-[(1-ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (14 mg, 0.018 mmol) in THF (1 mL) was stirred with a 1M solution of TBAF in THF (55 μL, 0.055 mmol) for 1 hour. The reaction mixture was concentrated, acidified with 1N HCl and extracted with EtOAc. The organic layer was washed with brine and dried. The product was purified by silica gel column chromatography EtOH-EtOAc (0-10%). Further purification was performed by dissolving the product in CH_2Cl_2 and passing the compound through a 13 mm Acrodisc syringe filter with a 0.45 μm Nylon membrane to provide 8 mg (77%) of the product. ^1H NMR (300 MHz, $CDCl_3$) δ 0.92 (t, 3H, *J*= 7 Hz), 1.30 (d, 3H, *J*= 8 Hz), 1.79 (s, 3H), 2.10- 2.39 (m, 4H), 2.15 (s, 3H), 2.53 (d, 1H, *J*= 8 Hz), 2.65 (d, 1H, *J*= 22 Hz), 2.68 (d, 1H, *J*= 22 Hz), 3.38 (d, 2H, *J*= 7 Hz), 3.70 and 3.74 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.07 (m, 2H), 4.96 (dq, 1H, *J*= 7 Hz), 5.20 (s, 2H), 5.27 (br t, 1H, *J*= 7 Hz), 5.33- 5.55 (m, 2H), 7.51- 7.56 (m, 1H), 7.68- 7.74 (m, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 29.0, 30.1 ppm; MS (*m/z*) 569.2 $[M+H]^+$, 591.3 $[M+Na]^+$.



2-{4-[(1-Carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester


A solution of 2-{4-[(1-ethoxycarbonyl-ethoxy)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanylethyl ester (12 mg, 0.016 mmol) in *tert*-butylamine (1 mL, 9.6 mmol) was heated at 65°C for 16 hours. The solution was allowed to cool to room temperature and concentrated to provide the crude product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 0.04 (s, 9H), 0.86- 0.98 (m, 2H), 1.22- 1.33 (m, 2H), 1.50 (d, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.05- 2.30 (m, 4H), 2.10 (s, 3H), 2.48- 2.63 (m, 3H), 3.40 (d, 2H, *J*= 7 Hz), 3.76 (s, 3H), 4.08 (appt t, 2H, *J*= 9 Hz), 4.25- 4.33 (m, 2H), 4.75- 4.84 (m, 1H), 5.13 (s, 2H), 5.15- 5.23 (m, 1H), 5.33- 5.55 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 28.9 ppm; MS (*m/z*) 725.3 $[M-H]^-$.



2-{4-[(1-Carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

A solution of crude 2-{4-[(1-carboxy-ethoxy)-hydroxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (AC-2101-59) and tetrabutylammonium fluoride in THF (1M, 54 μL, 0.054 mmol) was stirred with THF (1 mL) for 2 hours at ambient temperature, when more tetrabutylammonium fluoride in THF (54 μL, 0.054 mmol) was added. The reaction was stirred for an additional 16 hours, by which time the reaction was complete. The reaction mixture was concentrated *in vacuo* and the product was purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O, 0.1% TFA-CH_3CN, 0.1% TFA to provide


the product (8.0 mg) as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.51 (d, 3H, *J*= 7 Hz), 1.79 (s, 3H), 2.05- 2.40 (m, 4H), 2.11 (s, 3H), 2.49- 2.71 (m, 3H), 3.38 (d, 2H, *J*= 6 Hz), 3.76 (s, 3H), 4.85 (br s, 1H), 5.20 (s, 2H), 5.21- 5.30 (m, 1H), 5.33- 5.63 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 27.7 ppm; MS (*m/z*) 525.2 [M-H]$^-$.



2-{4-[(1-Ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester


A solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (20 mg, 0.030 mmol), PyBOP (62.4 mg, 0.120 mmol) in DMF (1.0 mL) was stirred with L-alanine ethyl ester hydrochloride (18 mg, 0.12 mmol) and DIEA (26 μL, 0.15 mmol) at ambient temperature for 1 hour, when complete consumption of the starting materials was observed. The reaction was worked up by addition of water until the reaction solution became cloudy. DMF was added dropwise until the mixture became clear again. The reaction mixture was filtered through Acrodisc (13 mm syringe filter with a 0.45 μm Nylon membrane) and purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm), eluting with water and acetonitrile. The fractions containing the product were pooled together and concentrated *in vacuo* to remove the acetonitrile. The remaining solution was saturated with sodium chloride and extracted with EtOAc and acetonitrile to provide 7.2 mg of the product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 0.05 (s, 9H), 0.923 (appt t, 2H, *J*= 8 Hz), 1.18- 1.31 (m, 5H), 1.41 (t, 3H, *J*= 7 Hz), 1.78 (s, 3H), 2.03- 2.36 (m, 4H), 2.18 (s, 3H), 2.43- 2.63 (m, 3H), 3.10- 3.30 (m, 1H), 3.40 (d, 2H, *J*= 7 Hz), 3.62 and 3.65 (d, 3H, *J*= 11 Hz), 3.76 (s, 3H), 4.03-4.12 (m, 2H), 4.20 (dq, 2H, *J*= 2, 7

Hz), 4.29 (appt t, 2H, *J*= 8 Hz), 5.12 (s, 2H), 5.18- 5.28 (m, 1H), 5.33- 5.67 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 30.4, 31.2 ppm; MS (*m/z*) 790.4 $[M+Na]^+$.




2-{4-[(1-Ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid

To a solution of 2-{4-[(1-ethoxycarbonyl-ethylamine)-methoxy-phosphoryl]-but-2-enyl}-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanyl-ethyl ester (7.2 mg, 9.38 mmol) in THF (1 mL) was added TBAF (40 μL, 1M solution in THF) at room temperature. The reaction mixture was stirred for 20 minutes, when the starting material was completely converted to the desired product as judged by LCMS. The reaction mixture was dried *in vacuo* and re-dissolved in DMF. The product was purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O-CH_3CN. The fractions containing the desired product were pooled and further purified on Dowex 50WX8-400 packed on a 4.5 cm x 2 cm column to elute the sodium salt at H_2O- MeOH (1:1), providing 3.2 mg of the desired product. ^{1}H NMR (300 MHz, CD_3OD) δ 1.26 (dd, 3H, *J*= 4, 7 Hz), 1.37 (t, 3H, *J*= 8 Hz), 1.80 (s, 3H), 2.00- 2.22 (m, 4H), 2.10 (s, 3H), 2.25- 2.60 (m, 3H), 3.37 (d, 2H, *J*= 7 Hz), 3.60 and 3.65 (d, 3H, *J*= 11 Hz), 3.74 (s, 3H), 3.83- 3.96 (m, 1H), 4.18 (q, 2H, *J*= 8 Hz), 5.15 (s, 2H), 5.25- 5.42 (m, 2H), 5.55- 5.69 (m, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 33.8, 34.2 ppm; MS (*m/z*) 568.2 $[M+H]^+$, 590.3 $[M+Na]^+$.



6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-4-methyl-hex-4-enoic acid


To a solution of 2-[4-(hydroxy-methoxy-phosphoryl)-but-2-enyl]-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid 2-trimethylsilanylethyl ester (11 mg, 0.016 mmol) in THF (1 mL) was added TBAF (50 μL, 1M solution in THF) at room temperature. The solution was stirred for 16 hours and concentrated. The solution was dried under reduced pressure and re-suspended in DMF (0.8 mL) and water (0.25 mL). The solution was filtered through Acrodisc (13 mm syringe filter with a 0.45 μm Nylon membrane) and purified by RP HPLC using a Phenomenex Synergi 5 μ Hydro RP 80A column (50 x 21.2 mm) with eluents of H_2O, 0.1% TFA-CH_3CN, 0.1% TFA. The product from the column was subjected to ion exchange chromatography (Sodium salt form of Dowex 50WX8-400) using a 2 x 4.5 cm column eluting with H_2O-MeOH (1:1) to provide 7.5 mg of the desired product as an oil. ^1H NMR (300 MHz, $CDCl_3$) δ 1.80 (s, 3H), 2.01- 2.29 (m, 5H), 2.11 (s, 3H), 2.35 (d, 2H, *J*= 22 Hz), 3.38 (d, 2H, *J*= 7 Hz), 3.53 (d, 3H, *J*= 11 Hz), 3.75 (s, 3H), 5.19 (s, 2H), 5.26 (t, 1H, *J*= 6 Hz), 5.43- 5.54 (m, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 23.5 ppm; MS (*m/z*) 469.2 $[M+H]^+$, 491.3 $[M+Na]^+$.



6-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester


To a solution of 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid methyl ester (222 mg, 0.66 mmol), triphenylphosphine (260 mg, 0.996 mmol), and diethyl azodicarboxylate (173 mg, 0.996 mmol) in THF (3 mL) at 0°C was added a solution of 2-trimethylsilylethanol (142 μL, 0.996 mmol) in THF (3 mL). The resulting yellow solution was allowed to warm to room temperature and stirred overnight. The reaction was concentrated to dryness and ether and hexanes were added.

Triphenylphosphine oxide was removed by filtration and the filtrate was concentrated and purified by silica gel chromatography to provide 248 mg of the desired product as a colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.18- 1.30 (m, 2H), 1.81 (s, 3H), 2.18 (s, 3H), 2.25- 2.33 (m, 2H), 2.37- 2.45 (m, 2H), 3.42 (d, 2H, *J*= 7 Hz), 3.62 (s, 3H), 3.77 (s, 3H), 4.25- 4.35 (m, 2H), 5.13 (s, 2H), 5.12- 5.22 (m, 1H) ppm.




[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde

A solution of 6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester (618 mg, 1.42 mmol) in MeOH (10 mL), CH_2Cl_2 (10 mL) and pyridine (50 μL, 0.618 mmol) was cooled to –70°C using a dry ice/ acetone bath according to the procedure of Smith, D. B. *et al.*, *J. Org. Chem.*, **1996**, *61*, 6, 2236. A stream of ozone was bubbled through the reaction *via* a gas dispersion tube until the reaction became blue in color (15 minutes). The ozone line was replaced with a stream of nitrogen and bubbling continued for another 15 minutes, by which time the blue color had disappeared. To this solution, thiourea (75.7 mg, 0.994 mmol) was added in one portion at –70 °C, and the cooling bath was removed. The reaction was allowed to warm to room temperature and stirred for 15 hours. The reaction was worked up by filtration to remove solid thiourea S-dioxide, and then partitioned between CH_2Cl_2 and water. The organic layer was removed. The aqueous layer was washed with CH_2Cl_2 one more time, and the organic extracts were combined. The organic layer was washed with aqueous 1N HCl, saturated $NaHCO_3$ and brine. The organic extracts were dried *in vacuo* and the residue was purified to by silica gel chromatography to afford 357 mg (75 %) of the product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ -0.01 (s, 9H), 1.05- 1.15 (m, 2H), 2.15 (s, 3H), 3.69 (s, 3H), 3.78 (d, 2H, *J*= 1 Hz), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 9.72 (d, 1H, *J*= 1 Hz) ppm.



4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal


[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (70 mg, 0.21 mmol) in toluene (2 mL) was heated at 100 °C with 2-(triphenyl-phosphanylidene)-propionaldehyde (72.9 mg, 0.23 mmol) overnight. A second portion of 2-(triphenyl-phosphanylidene)-propionaldehyde (33 mg, 0.11 mmol) was added and the reaction mixture was heated for an additional day. After concentration, the residue was purified by silica gel chromatography to provide 54 mg (83%) of the desired product as a pale yellow oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.10- 1.21 (m, 2H), 1.87 (s, 3H), 2.16 (s, 3H), 3.67- 3.76 (m, 2H), 3.74 (s, 3H), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 6.40- 6.48 (m, 1H), 9.2 (s, 1H) ppm.



6-(4-Hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one


A solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (103 mg, 0.27 mmol) in methanol (5 mL) was cooled to 0°C. A solution of $CeCl_3$ (0.68 mL, MeOH: H_2O, 9:1) was added, followed by $LiBH_4$ (0.14 mL, 0.28 mmol of a 2M solution in THF). The ice bath was removed and the reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for an additional 40 minutes whereupon TLC indicated complete consumption of starting aldehyde. The reaction was worked up by addition of aqueous 1N HCl

(0.5 mL) and the product was extracted with CH_2Cl_2. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to provide 100 mg (97%) of the product as a clear liquid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.20 (dd, 2H, *J*= 7, 8 Hz), 1.81 (s, 3H), 2.13 (s, 3H), 3.38- 3.50 (m, 2H), 3.74 (s, 3H), 3.95 (s, 2H), 4.27 (dd, 2H, *J*= 7, 8 Hz), 5.08 (s, 2H), 5.17- 5.44 (m, 1H) ppm.



6-(2-Hydroxy-ethyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

To a solution of [6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (97 mg, 0.29 mmol) in THF (5 mL) was added an aliquot of a 2 M $LiBH_4$ in THF (150 μL, 0.300 mmol). The reaction mixture was stirred at room temperature for 1 hour when complete consumption of the starting materials was observed by TLC. The reaction mixture was worked up by addition of an aqueous 1N HCl solution and extraction with EtOAc. The organic layer was dried *in vacuo* and the residue was purified by silica gel chromatography to provide the product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.20 (dd, 2H, *J*=7, 9 Hz), 2.07 (br s, 1H), 2.14 (s, 3H), 2.97 (t, 2H, *J*= 6 Hz), 3.76 (t, 2H, *J*= 6 Hz), 3.77 (s, 3H), 4.32 (dd, 2H, *J*= 7, 8 Hz), 5.08 (s, 2H) ppm.




{2-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-ethoxymethyl}-phosphonic acid diisopropyl ester

A mixture of 6-(2-hydroxy-ethyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (79 mg, 0.23 mmol) was heated with bromomethylphosphonic acid diisopropyl ester (120 mg, 0.46 mmol) in the presence of lithium *t*-butoxide (22 mg, 0.27 mmol) in DMF (2 mL) at 70 °C overnight. The reaction mixture was purified by RP HPLC (acetonitrile and 0.1% aqueous CF_3COOH) to provide the desired product. ^1H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.13- 1.25 (m, 2H), 1.26 (t, 12H, *J*= 6 Hz), 2.12 (s, 3H), 2.98 (t, 2H, *J*= 7 Hz), 3.60- 3.73 (m, 4H), 3.77 (s, 3H), 4.05- 4.16 (m, 2H), 4.62- 4.74 (m, 2H), 5.07 (s, 2H) ppm; MS (*m/z*) 539 $[M+Na]^+$.


Example 255: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[2-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-ethoxymethyl]-phosphonic acid

To a solution of {2-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-ethoxymethyl}-phosphonic acid diisopropyl ester (7.5 mg, 0.014 mmol) in acetonitrile (2 mL) and 2,6-lutidine (25 μL, 0.21 mmol) was added trimethylsilyl bromide (27 μL, 0.21 mmol) at room temperature. The reaction was allowed to proceed for 18 hours when completion of the reaction was indicated by LCMS. The reaction was quenched by addition of MeOH and concentration. The residue was purified by RP-HPLC using a C18 column. The collected product was dissolved in a solution of 10% TFA/ CH_2Cl_2 to assure complete deprotection. The reaction mixture was lyophilized to provide the desired product. ^1H NMR (300 MHz, CD_3OD) δ 2.12 (s, 3H), 2.98 (t, 2H, *J*= 7 Hz), 3.66- 3.76 (m, 4H), 3.78 (s, 3H), 5.21 (s, 2H) ppm; MS (*m/z*) 331 $[M-H]^-$.



Example 256: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



6-(4-Bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one

Polymer-supported triphenylphosphine (3 mmol/g, 0.5 g) was soaked in dichloromethane (10mL) for 1 hour 7-Hydroxy-6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-3H-isobenzofuran-1-one (100 mg, 0.36 mmol) and carbon tetrabromide (143 mg, 0.43 mmol) were added sequentially and the mixture was shaken for 1 hour at room temperature. More carbon tetrabromide (143 mg, 0.43 mmol) was added and the mixture was shaken further for 1 hour The mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica gel (0 % to 60 % ethyl acetate / hexanes) to afford 6-

(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one as an oil (52 mg, 42 %); ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.95 (s, 3H), 2.16 (s, 3H), 3.44 (d, J = 7.2, 2H), 3.78 (s, 3H), 3.98 (s, 2H), 5.21 (s, 2H), 5.68 (t, J = 7.2 Hz, 1H), 7.71 (brs, 1H) ppm.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid dimethyl ester

A solution of 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one (33 mg, 0.097 mmol) in trimethylphosphite (1.0 mL, 8.5 mmol) was heated to 100 °C for 1 hour, whereupon complete reaction was indicated by LCMS. The reaction was worked up by removal of the excess reagent under reduced pressure and the residue was purified by silica gel chromatography using EtOAc-hexanes (20-100%) to provide 20 mg (60%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.90 (s, 3H), 2.09 (s, 3H), 2.48 (d, 2H, J= 22 Hz), 3.38 (t, 2H, J= 6 Hz), 3.64 (d, 6H, J= 11 Hz), 3.72 (s, 3H), 5.14 (s, 2H),5.33 (q, 1H, J= 6 Hz), 7.65 (br s, 1H) ppm; MS (*m/z*) 371 $[M+H]^+$.

Example 257: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phosphonic acid dimethyl ester (18

mg, 0.049 mmol) in acetonitrile (2 mL) was added TMSBr (63 μL, 0.49 mmol) and 2,6-lutidine (85 μL, 0.73 mmol) at 0°C. The reaction solution was allowed to warm to room temperature and stirred for 2 hours when completion of the reaction was observed by LCMS. The reaction was cooled to 0°C and quenched by the addition of MeOH. The reaction mixture was concentrated under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O-acetonitrile (5-0%) over 20 minutes to provide 12.2 mg (73%) of the product. ^1H NMR (300 MHz, CD_3OD) δ 1.95 (s, 3H), 2.15 (s, 3H), 2.48 (d, 2H, *J*= 22 Hz), 3.44 (t, 2H, *J*= 6 Hz), 3.79 (s, 3H), 5.24 (s, 2H),5.38 (q, 1H, *J*= 7 Hz), 6.87 (br s, 1H) ppm; MS (*m/z*) 341 $[M-H]^-$.

Example 258: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester and [4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diphenyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid (49 mg, 0.13 mmol) in DMF (0.4 mL) and phenol (62 mg, 0.65 mmol) was added dicyclohexyl carbodiimide (107 mg, 0.52 mmol) and DMAP (8 mg, 0.065 mmol) in DMF (0.6 mL), slowly at 0°C. The reaction was allowed to warm to room temperature and heated to 140°C for 10 hours. After cooling to room temperature the mixture was filtered and extracted with aqueous 1N NaOH solution. The aqueous layer was acidified with aqueous 1N HCl and extracted

with EtOAc. The organic layer was dried over Na_2SO_4 and concentrated to dryness. The residue was purified by RP HPLC to provide 18.5 mg of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester (major product, Example 8) as a pale yellow solid and 4.1 mg of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diphenyl ester (minor product) also as a pale yellow solid. Major product: ^{1}H NMR (300 MHz, CD_3OD) δ 1.82 (s, 3H), 2.16 (s, 3H), 3.46 (d, 2H, *J*= 7 Hz), 3.70 (d, 2H, *J*= 8 Hz), 3.77 (s, 3H), 3.96 (s, 2H), 5.25 (s, 2H), 5.52 (t, 1H, *J*= 8 Hz), 7.10- 7.21 (m, 3H), 7.30 (t, 2H, *J*= 8 Hz) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 17.3 ppm; MS (*m/z*) 449.0 $[M+H]^+$, 471.2 $[M+Na]^+$. Minor product: ^{1}H NMR (300 MHz, CD_3OD) δ 1.82 (s, 3H), 2.15 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.77 (s, 3H), 3.98- 4.06 (m, 4H), 5.25 (s, 2H), 5.50- 5.61 (m, 1H), 7.10- 7.25 (m, 6H), 7.30- 7.41 (m, 4H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 16.3 ppm; MS (*m/z*) 525.2 $[M+H]^+$, 547.2 $[M+Na]^+$.

Example 259: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester (18.5 mg, 0.040 mmol) and ethyl (S)-(-)-lactate (47 μL, 0.400 mmol) in pyridine (0.5 mL) was added PyBOP (32 mg, 0.060 mmol). The solution was stirred at room temperature for 1 hour, when an additional portion of PyBOP (21 mg, 0.040 mmol) was added. The solution was stirred for another

hour and concentrated. The residue was purified by HPLC to provide 7.5 mg of the desired product as a clear oil. ^{1}H NMR (300 MHz, CD_3OD) δ 1.22 and 1.25 (t, 3H, *J*= 7 Hz), 1.42 and 1.50 (d, 3H, *J*= 7 Hz), 1.82 and 1.83 (s, 3H), 2.16 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.78 (s, 3H), 3.89 (d, 1H, *J*= 8 Hz), 3.93- 4.02 (m, 3H), 4.10- 4.22 (m, 2H), 4.94- 5.08 (m, 1H), 5.25 (s, 2H), 5.50-5.60 (m, 1H), 7.15- 7.27 (m, 3H), 7.33- 7.41 (m, 2H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 18.9, 20.3 ppm (diastereomers at phosphorus); MS (*m/z*) 549.2 $[M+H]^+$, 571.3 $[M+Na]^+$.

Example 260: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phenoxy-phosphinoylamino}-propionic acid ethyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monophenyl ester (20 mg, 0.045 mmol) and L-alanine ethyl ester hydrochloride (68.5mg, 0.45mmol) in pyridine (1.0 mL) was added PyBOP (70mg, 0.14mmol). After stirring overnight, the mixture was concentrated and the residue purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 3.6 mg of the product as a colorless gel. ^{1}H NMR (300 MHz, CD_3OD) δ 1.17-1.3 (m, 6H), 1.8-1.9 (m, 3H), 2.16 (s, 3H), 3.17 (m, 1H), 3.47 (d, 2H), 3.72-3.8 (m, 5H), 3.92-4.2 (m, 4H), 5.25 (s, 2H), 5.54 (m, 1H), 7.18 (m, 3H), 7.33 (m, 2H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 24.1, 25.0 ppm (diastereomers at phosphorus); MS (*m/z*) 546.2 $[M-H]^+$.

Example 261: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid monomethyl ester

To a solution of [4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid diphenyl ester (53 mg, 0.1 mmol) in methanol (0.5 mL) was added an aqueous solution of 1N NaOH (300 μL). After stirring overnight, the mixture was concentrated and the residue purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 5 mg of the product as a colorless gel, together with the phosphonic acid monophenyl ester (7mg) and the phosphonic acid dimethyl ester (14.5mg). ^1H NMR (300 MHz, CD_3OD) δ 1.84 (s, 3H), 2.16 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.6 (d, 2H, *J*= 12 Hz), 3.75 (d, 3H, *J*= 11 Hz), 3.79 (s, 3H), 3.94 (s, 2H), 5.26 (s, 2H), 5.53 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 21.5 ppm; MS (*m/z*) 385.2 $[M-H]^+$, 387.1 $[M+H]^+$.

Example 262: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



(2-{4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester

To a solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (84 mg, 0.22

mmol), (2-amino-ethyl)-phosphonic acid diethyl ester oxalate (91 mg, 0.33 mmol), and sodium triacetoxyborohydride (93 mg, 0.44 mmol) in DMF (1.5 mL) was added acetic acid (60 μL, 1.0 mmol) at room temperature. The solution was stirred for 2 days when it was quenched by addition of saturated aqueous sodium bicarbonate solution and EtOAc. The organic layer was separated and concentrated under reduced pressure. The residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 115 mg (96%) of the product as an oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.04 (s, 9H), 1.16- 1.27 (m, 2H), 1.34 (t, 6H, *J*= 7 Hz), 1.94 (s, 3H), 2.18 (s, 3H), 2.20- 2.31 (m, 2H), 3.13- 3.31 (m, 2H), 3.48 (d, 2H, *J*= 7 Hz), 3.54 (s, 2H), 3.78 (s, 3H), 4.14 (pent, 4H, *J*= 7 Hz), 4.30- 4.37 (m, 2H), 5.13 (s, 2H), 5.65 (t, 1H, *J*= 7 Hz), 6.23 (br s, 2H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 27.8 ppm; MS (*m/z*) 542.3 $[M+H]^+$, 564.2 $[M+Na]^+$.




{2-[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phosphonic acid

A solution of (2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (30 mg, 0.055 mmol), TMSBr (72 μL, 0.55 mmol), and 2,6-lutidine (64 μL, 0.55 mmol) was stirred in CH_2Cl_2 (1 mL) and DMF (0.5 mL) for 1 hour at ambient temperature. The reaction mixture was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 7.8 mg of the product as a white solid. ^1H NMR (300 MHz, CD_3OD) δ 1.96 (s, 3H), 1.95- 2.07 (m, 2H), 2.16 (s, 3H), 3.10-3.24 (m, 2H), 3.51 (d, 2H, *J*= 7 Hz), 3.57 (s, 2H), 3.81 (s, 3H), 5.25 (s, 2H), 5.73 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 20.2 ppm; ^{19}F NMR (282.6 MHz, CD_3OD) δ -74.0 ppm; MS (*m/z*) 386.3 $[M+H]^+$.


Example 263: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



[2-(Methanesulfonyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester

A solution of (2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (45 mg, 0.092 mmol) in CH_2Cl_2 (0.5 mL) was stirred with methanesulfonyl chloride (21 μL, 0.28 mmol) and pyridine (45 μL, 0.55 mmol) at ambient temperature overnight. The reaction was quenched by addition of 2 drops of water. The reaction mixture was concentrated and purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 36 mg of the product (63%) as a clear gel. ^1H NMR (300 MHz, $CDCl_3$) δ 0.05 (s, 9H), 1.18- 1.29 (m, 2H), 1.29 (t, 6H, *J*= 7 Hz), 1.85 (s, 3H), 2.00- 2.13 (m, 2H), 2.19 (s, 3H), 2.85 (s, 3H), 3.32- 3.43 (m, 2H), 3.47 (d, 2H, *J*= 7 Hz), 3.69 (s, 2H), 3.79 (s, 3H), 4.05 (pent, 4H, *J*= 7 Hz), 4.30- 4.37 (m, 2H), 5.13 (s, 2H), 5.45 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, CD_3Cl) δ 27.5 ppm; MS (*m/z*) 642.2 $[M+Na]^+$.




(2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-methanesulfonyl-amino}-ethyl)-phosphonic acid

A solution of [2-(methanesulfonyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester (18 mg, 0.029 mmol) in acetonitrile

(0.5 mL) was stirred with TMSBr (38 μL, 0.29 mmol) and 2,6-lutidine (34 μL, 0.29 mmol) for 2 hours at room temperature. The reaction was worked up by addition of EtOAc and aqueous 1N HCl. The organic layer was washed with brine and the solvent was removed *in vacuo*. The residue was suspended in a solution of 10% TFA-CH_2Cl_2 for 10 minutes before it was dried to provide 9.9 mg of the desired product (73%) as a white solid. ^{1}H NMR (300 MHz, DMSO-*d6*) δ 1.76 (s, 3H), 1.76- 1.88 (m, 2H), 2.10 (s, 3H), 2.87 (s, 3H), 3.24- 3.35 (m, 2H), 3.39 (d, 2H, *J*= 7 Hz), 3.65 (s, 2H), 3.75 (s, 3H), 5.22 (s, 2H), 5.41- 5.48 (m, 1H) ppm; ^{31}P (121.4 MHz, DMSO-*d6*) δ 21.4 ppm; MS (*m/z*) 464.1 $[M+H]^+$.

Example 264: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



[2-(Acetyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester

To a solution of (2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (32 mg, 0.059 mmol) in acetic acid (0.5 mL) was added acetic anhydride (0.5 mL). The solution was stirred at room temperature for 90 minutes when it was quenched by addition of 2 drops of water. The solution was dried *in vacuo* and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 28 mg of the product (81%) as a clear gel. The NMR data of this compound shows two rotamers in a ratio of 70:30. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.05 (s, 9H), 1.17- 1.27 (m, 2H), 1.30 and 1.31 (t, 6H, *J*= 7 Hz), 1.70-1.79 (m, 2H), 1.76 (s, 3H), 2.00 (s, 3H), 2.18 (s, 3H), 3.40- 3.52 (m, 2H), 3.46 (d, 2H, *J*= 7 Hz), 3.77 (s, 3H), 3.79 and 3.93 (s, 3H), 4.07 (pent, 4H, *J*= 7 Hz), 4.27- 4.35

(m, 2H), 5.13 (s, 2H), 5.22- 5.30 (m, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 27.5 and 28.9 ppm; MS (*m/z*) 584.1 $[M+H]^+$, 606.2 $[M+Na]^+$.




(2-{Acetyl-[4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-amino}-ethyl)-phosphonic acid

To a solution of [2-(acetyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester (14 mg, 0.024 mmol) in acetonitrile (0.5 mL) was added TMSBr (31 μL, 0.24 mmol) and 2,6-lutidine (28 μL, 0.24 mmol). The solution was stirred at room temperature for 1 hour. The reaction was quenched by addition of methanol and aqueous 1N HCl. The product was extracted with EtOAc. The combined organic extracts were dried over Na_2SO_4 and concentrated *in vacuo*. The product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 5.4 mg of the product (53%) as a white solid. The NMR data of this compound shows two rotamers. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.67 and 1.73 (s, 3H), 1.85-2.12 (m, 5H), 2.13 (s, 3H), 3.30-3.61 (m, 4H), 3.75 (s, 3H), 3.76 (br s, 2H), 5.17 (s, 2H), 5.31 (br s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 27.5 and 28.8 ppm; MS (*m/z*) 428.2 $[M+H]^+$, 450.2 $[M+Na]^+$.


Example 265: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



[2-(Benzyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester

A solution of (2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (30 mg, 0.055 mmol), benzaldehyde (5.6 μL, 0.055 mmol), and sodium triacetoxyborohydride (23 mg, 0.11 mmol) was stirred with acetic acid (15.7 μL, 0.28 mmol) in DMF (0.5 mL) at room temperature over night. The reaction was quenched with a 10% aqueous Na_2CO_3 solution and the product was extracted with EtOAc. The organic layer was dried and concentrated under reduced pressure. The product was purified purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 15 mg of the product (43%) as a clear gel. ^1H NMR (300 MHz, $CDCl_3$) δ 0.02 (s, 9H), 1.18- 1.25 (m, 2H), 1.24 (t, 6H, *J*= 7 Hz), 1.86 (s, 3H), 1.88- 2.02 (m, 2H), 2.16 (s, 3H), 2.65- 2.74 (m, 2H), 3.93 (s, 2H), 3.46 (br d, 4H, *J*= 7 Hz), 3.76 (s, 3H), 4.00 (pent, 4H, *J*= 7 Hz), 4.25- 4.34 (m, 2H), 5.11 (s, 2H), 5.34- 5.43 (m, 1H), 7.18- 7.33 (m, 5H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 30.9 ppm; MS (*m/z*) 632.4 $[M+H]^+$, 654.3 $[M+Na]^+$.




(2-{Benzyl-[4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-amino}-ethyl)-phosphonic acid

A solution of (2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (15 mg, 0.024 mmol) in acetonitrile (0.5 mL) was treated with TMSBr (31 μL, 0.24 mmol) and 2,6-lutidine (28 μL, 0.24 mmol). The solution was stirred at ambient temperature for 1 hour, when it was quenched with methanol. The solvent was removed under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 11 mg of the product (93%)

as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.89 (s, 3H), 2.03- 2.15 (m, 2H), 2.14 (s, 3H), 3.30- 3.47 (m, 2H), 3.50 (br s, 2H), 3.62 (br s, 2H), 3.79 (s, 3H), 4.28 (s, 2H), 5.23 (s, 2H), 5.76 (br s, 1H), 7.46 (br s, 5H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 20.1 ppm; MS (*m/z*) 476.3 $[M+H]^+$, 498.3 $[M+Na]^+$.


Example 266: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



[2-(Formyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester

To a solution of (2-{4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (74 mg, 0.14 mmol) in formic acid (1 mL) was added formic anhydride (1 mL) and the solution was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the crude product carried onto the next step. The NMR data of this compound shows two rotamers with the ratio of 70:30. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.05 (s, 9H), 1.18- 1.28 (m, 2H), 1.28 and 1.30 (t, 6H, *J*= 7 Hz), 1.74 (s, 3H), 1.84- 2.08 (m, 2H), 2.19 (s, 3H), 3.34- 3.45 (m, 2H), 3.47 (d, 2H, *J*= 7 Hz), 3.72 and 3.87 (s, 2H), 3.78 and 3.79 (s, 3H), 4.06 and 4.07 (pent, 4H, *J*= 7 Hz), 4.26- 4.37 (m, 2H), 5.13 (s, 2H), 5.30-5.46 (m, 1H), 8.03 and 8.19 (s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 27.5 and 28.1 ppm; MS (*m/z*) 570.1 $[M+H]^+$, 592.2 $[M+Na]^+$.




(2-{Formyl-[4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-amino}-ethyl)-phosphonic acid

To a solution of crude [2-(formyl-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-amino)-ethyl]-phosphonic acid diethyl ester (78 mg, 0.14 mmol) in acetonitrile (1 mL) was added TMSBr (177 μL, 1.4 mmol) and 2,6-lutidine (163 μL, 1.4 mmol). The solution was stirred at room temperature for 1 hour when it was quenched by addition of methanol and 1N aqueous HCl. The product was extracted with EtOAc and purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 29 mg of the product as a white solid. The NMR data of this compound shows two rotamers with the ratio of approximately 70:30. ^1H NMR (300 MHz, CD_3OD) δ 1.62 and 1.64 (s, 3H), 1.83- 1.98 (m, 2H), 2.16 (s, 3H), 3.38- 3.55 (m, 4H), 3.78 (s, 3H), 3.80 and 3.91 (s, 2H), 5.22 (s, 2H), 5.39- 5.52 (m, 1H), 8.03 and 8.18 (s, 1H) ppm; MS (*m/z*) 414.2 $[M+H]^+$, 436.2 $[M+Na]^+$.

Example 267: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



({4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-methyl)-phosphonic acid diethyl ester

To a solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (500 mg, 1.33 mmol), (2-aminomethyl)phosphonic acid diethyl ester oxalate (376 mg, 1.46 mmol), sodium triacetoxyborohydride (563 mg, 2.66 mmol) in DMF (10 mL) was added acetic acid (380 μL, 6.65 mmol) at room temperature. The solution was stirred overnight when it was quenched by addition of saturated aqueous

sodium bicarbonate solution and EtOAc. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel chromatography to provide 500 mg (71%) of the product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.13- 1.23 (m, 2H), 1.25 and 1.27 (t, 6H, *J*= 7 Hz), 1.65- 1.75 (m, 2H), 1.77 (s, 3H), 2.13 (s, 3H), 2.80 (s, 1H), 3.14 (s, 2H), 3.41 (d, 2H, *J*= 7 Hz), 3.73 (s, 3H), 4.08 and 4.09 (pent, 4H, *J*= 7 Hz), 4.20- 4.30 (m, 2H), 5.08 (s, 2H), 5.30 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 26.5 ppm; MS (*m/z*) 528.1 $[M+H]^+$, 550.2 $[M+Na]^+$.




{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-methyl}-phosphonic acid

To a solution of ({4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-methyl)-phosphonic acid diethyl ester (20 mg, 0.038 mmol) in DMF (0.5 mL) was added TMSBr (49 μL, 0.38 mmol) and 2,6-lutidine (44 μL, 0.38 mmol). The solution was stirred at room temperature for 1 hour when it was quenched by addition of methanol. The product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 5.6 mg of the product as a white solid. ^{1}H NMR (300 MHz, CD_3OD and $CDCl_3$) δ 1.93 (s, 3H), 2.13 (s, 3H), 2.94 (br d, 2H, *J*= 11 Hz), 3.42-3.53 (m, 2H), 3.60 (s, 2H), 3.78 (s, 3H), 5.22 (s, 2H), 5.71 (br s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 8.5 ppm; MS (*m/z*) 372.2 $[M+H]^+$, 743.2 $[2M+H]^+$.

Example 268: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-({2-[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phenoxy-phosphinoyloxy)-propionic acid ethyl ester

A solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (188 mg, 0.5 mmol) was stirred with 2-[(2-aminoethyl)phenoxy-phosphinoyloxy]-propionic acid ethyl ester acetic acid salt (315.8 mg, 0.75 mmol) in CH_2Cl_2 (3 mL) for 2 hours at ambient temperature. Sodium triacetoxyborohydride (159 mg, 0.75 mmol) was added to the solution and the reaction was allowed to proceed for 1 hour. The reaction was quenched by addition of a saturated aqueous solution of $NaHCO_3$ and the product was extracted with EtOAc. The organic layer was removed under reduced pressure and the residue was resuspended in a 10% TFA/ CH_2Cl_2 for 1 hour. The reaction mixture was concentrated and the product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 198 mg of the product as a white solid. The NMR data of this compound shows two diastereomers at phosphorus in a ratio of approximately 45: 55. ^1H NMR (300 MHz, CD_3OD) δ 1.23 and 1.24 (t, 3H, *J*= 7 Hz), 1.38 and 1.52 (d, 3H, *J*= 7 Hz), 1.97 and 1.98 (s, 3H), 2.14 (s, 3H), 2.44- 2.66 (m, 2H), 3.31- 3.48 (m, 2H), 3.51 (d, 2H, *J*= 7 Hz), 3.66 (d, 2H, *J*= 5 Hz), 3.80 (s, 3H), 4.10- 4.27 (m, 2H), 4.90- 5.10 (m, 1H), 5.20 (s, 2H), 5.73- 5.82 (m, 1H), 7.15- 7.27 (m, 3H), 7.35- 7.45 (m, 2H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 22.6, 24.3 ppm; MS (*m/z*) 561.9 $[M+H]^+$.


Example 269: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-[Hydroxy-(2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphinoyloxy]-propionic acid ethyl ester

A solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (38 mg, 0.1 mmol) was stirred with 2-[(2-aminoethyl)-phenoxy-phosphinoyloxy]-propionic acid ethyl ester acetic acid (63 mg, 0.15 mmol) in CH_2Cl_2 (1 mL) for 2 hours at ambient temperature. Sodium triacetoxyborohydride (32 mg, 0.15 mmol) was added to the solution and the reaction was allowed to proceed for 1 hour. The reaction was quenched by addition of a saturated aqueous solution of $NaHCO_3$ and the product was extracted with EtOAc. The organic layer was removed under reduced pressure and the residue was re-suspended in 10% TFA/ CH_2Cl_2 for 1 hour. The reaction mixture was concentrated and the product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 15 mg of the product (154-2). ^1H NMR (300 MHz, $CDCl_3$) δ 0.04 (s, 9H), 1.15- 1.24 (m, 2H), 1.26 (t, 3H, *J*= 7 Hz), 1.48 (d, 3H, *J*= 7 Hz), 1.93 (s, 3H), 2.10- 2.25 (m, 2H), 2.18 (s, 3H), 3.10- 3.31 (m, 2H), 3.48 (d, 2H, *J*= 7 Hz), 3.48- 3.61 (m, 2H), 3.77 (s, 3H), 4.04- 4.21 (m, 2H), 4.29- 4.40 (m, 2H), 4.81- 4.92 (m, 1H), 5.13 (s, 2H), 5.64 (t, 1H, *J*= 7 Hz), 8.70- 9.11 (m, 3H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 21.9 ppm; MS (*m/z*) 586.3 $[M+H]^+$, 1171.4 $[2M+H]^+$.




2-(Hydroxy-{2-[4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phosphinoyloxy)-propionic acid

A solution of 2-[hydroxy-(2-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphinoyloxy]-propionic acid ethyl ester (15 mg, 0.026 mmol) in 10% TFA-CH_2Cl_2 (1 mL) was stirred at ambient temperature for 10 minutes. The reaction was worked up by removal of the solvent. The residue was dissolved in THF (0.5 mL) and water (0.4 mL) and 1N aqueous NaOH solution (0.1 mL) was added. The solution was stirred at room temperature for 20 minutes when it was acidified with 1N aqueous HCl solution. The resulting solution was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 6.8 mg of the product as a white solid. ^1H NMR (300 MHz, $CDCl_3$) δ 1.38 (d, 3H, *J*= 7 Hz), 1.91 (s, 3H), 2.13 (s, 3H), 2.12- 2.28 (m, 2H), 3.12- 3.33 (m, 2H), 3.41 (d, 2H, *J*= 6 Hz), 3.56 (br s, 2H), 3.75 (s, 3H), 4.71- 4.88 (m, 1H), 5.16 (s, 2H), 5.58- 5.71 (m, 1H), 7.88 (br s, 3H), 8.60 (br s, 1H), 8.78 (br s, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 22.0 ppm; MS (*m/z*) 458.3 $[M+H]^+$, 480.3 $[M+Na]^+$.




Example 270: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



{1-Cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-3-methyl-pent-3-enyl}-phosphonic acid diethyl ester

To a solution of diethyl cyanomethylphosphonate (241 mg, 1.38 mmol) in THF (1 mL) was added a THF solution of sodium bis(trimethysilyl)amide (1.0 M, 1.13 mL, 1.15 mmol). After stirring for 30 minutes, the solution was added dropwise to a solution of 6-(4-bromo-3-methyl-but-2-enyl)-7-hydroxy-5-methoxy-4-methyl-3H-isobenzofuran-1-one (100 mg, 0.23 mmol) in THF (1 mL). The resulting mixture was allowed to stir at room temperature for one hour before saturated aqueous ammonium chloride was added. The reaction mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness. The residue was purified by silica gel column chromatography, affording 110 mg (90 %) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.04 (s, 9H), 1.24 (dd, J= 7, 8 Hz, 2H), 1.36 (t, 6H), 1.86 (s, 3H), 2.17 (s, 3H), 2.43-2.57 (m, 2H), 3.04-3.17 (m, 1H), 3.47 (d, J = 7.2 Hz, 2H), 3.79 (s, 3H), 4.12-4.37 (m, 6H), 5.13 (s, 2H), 5.44 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 18.18 ppm; MS (*m/z*) 560 $[M+Na]^+$.




[1-Cyano-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid diethyl ester

{1-Cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-3-methyl-pent-3-enyl}-phosphonic acid diethyl ester (25mg, 0.047 mmol) was dissolved in a solution of 10% TFA/CH_2Cl_2 (5 mL) and stirred at room temperature for 2 hours. The reaction mixture was dried under reduced pressure and the product was purified by RP-HPLC to provide 16 mg (80%) of the desired product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.38 (t, 6H), 1.86 (s,3H), 2.15 (s, 3H), 2.40-2.58 (m, 2H), 3.01-3.14 (m, 1H), 3.45 (d, J = 7.2 Hz, 2H), 3.79 (s, 3H), 4.18-4.30 (m, 4H), 5.21 (s, 2H), 5.48 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 18.09 ppm; MS (*m/z*) 436 $[M-H]^-$, 438 $[M+H]^+$.

Example 271: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[1-Cyano-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-3-methyl-pent-3-enyl]-phosphonic acid

To a solution of {1-cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-3-methyl-pent-3-enyl}-phosphonic acid diethyl ester (35 mg, 0.065 mmol) in acetonitrile (2 mL) was added TMSBr (180 μL, 1.38 mmol) and 2,6-lutidine (160 μL, 1.38 mmol). The reaction solution was allowed stir at room temperature for one hour before quenching with MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 15 mg (60 %) of the desired product. ^{1}H NMR (300 MHz, CD_3OD) δ 1.86 (s,3H), 2.15 (s, 3H), 2.38-2.57 (m, 2H), 3.17-3.28 (m, 1H), 3.44 (d, J = 7.2 Hz, 2H), 3.80 (s, 3H), 5.25 (s, 2H), 5.47 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 15.28 ppm; MS (*m/z*) 380 $[M-H]^-$, 382 $[M+H]^+$.


Example 272: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




{1-Cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-1,3-dimethyl-pent-3-enyl}-phosphonic acid diethyl ester

To a solution of {1-cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-3-methyl-pent-3-enyl}-phosphonic acid diethyl ester (45 mg, 0.084 mmol) in THF (0.5 mL) was added sodium bis(trimethysilyl)amide (1.0 M, 1.13 mL, 1.15 mmol). After stirring for 20 minutes, iodomethane (52 μL, 0.84 mmol) was added dropwise and the resulting mixture was allowed to stir at room temperature for 2 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness. The residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to afford 6.6 mg (23 %) of the desired product. ^1H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.16 (dd, J= 7, 8 Hz, 2H), 1.31 (t, 6H), 1.38 (d, 3H), 1.92 (s,3H), 2.17 (s, 3H), 2.23 (m, 1H), 2.65 (m, 1H), 3.30-3.42 (m, 2H), 3.73 (s, 3H), 4.14-4.27 (m, 6H), 5.08 (s, 2H), 5.28 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 22.26 ppm; MS (*m/z*) 574 $[M+Na]^+$.




[1-Cyano-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-1,3-dimethyl-pent-3-enyl]-phosphonic acid

To a solution of {1-cyano-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-1,3-dimethyl-pent-3-enyl}-phosphonic acid diethyl ester (18 mg, 0.04 mmol) in DMF (0.5 mL) and DCM (0.5 mL) was added TMSBr (51 μL, 0.4 mmol) and 2,6-lutidine (46 μL, 0.4 mmol). The reaction solution was allowed stir at room temperature overnight before quenching with MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 4.5 mg (33 %) of the desired product. ^1H NMR (300 MHz, CD_3OD) δ 1.37 (d, 3H), 1.87 (s, 3H), 2.13 (s, 3H), 2.26 (m, 1H), 2.64 (m, 1H), 3.39 (m, 2H), 3.75 (s, 3H), 5.18 (s, 2H), 5.34 (m, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 21.47 ppm; MS (*m/z*) 422 $[M-H]^-$, 424 $[M+H]^+$.




Example 273: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



2-Ethyl-4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enal


A solution of [6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (1.5 g, 4.46 mmol) in toluene (14 mL) was heated at 100 °C with 2-(triphenyl-phosphanylidene)-butyraldehyde (1.68g, 5.35 mmol) overnight. A second portion of 2-(triphenyl-phosphanylidene)-butyraldehyde (495 mg, 1.49 mmol) was added and the reaction mixture was heated for an additional day. After concentration, the residue was purified by silica gel chromatography to provide 1.3g (83%) of the desired product as oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.01 (s, 9H), 1.03 (t, 3H), 1.10- 1.21 (m, 2H), 2.15 (s, 3H), 2.15-2.44 (m, 2H), 3.67- 3.76 (m, 2H), 3.74 (s, 3H), 4.31- 4.36 (m, 2H), 5.10 (s, 2H), 6.34- 6.38 (m, 1H), 9.28 (s, 1H) ppm.



6-(3-Hydroxymethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one


A solution of 2-ethyl-4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enal (1.3g, 3.30 mmol) in methanol (10 mL) and THF (10 mL) was cooled to 0 °C. A solution of $CeCl_3$ (8.25 mL, 0.4M, MeOH: H_2O, 9:1) was added, followed by $LiBH_4$ (1.66 mL, 3.30 mmol of a 2M solution in THF). The ice bath was removed and the reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for an additional 40 minutes, whereupon TLC indicated complete consumption of starting aldehyde. The reaction was worked up by addition of aqueous 1N HCl and the product was extracted with EtOAc. The

organic layer was washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to provide 948 mg (73%) of the product as colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.07 (t, 3H), 1.20 (dd, 2H, J= 7, 8 Hz), 2.13 (s, 3H), 2.38- 2.50 (m, 2H), 3.77 (s, 3H), 3.99 (s, 2H), 4.27 (dd, 2H, J= 7, 8 Hz), 5.08 (s, 2H), 5.34 (t, J = 7.2 Hz, 1H) ppm.



6-(3-Bromomethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

Polymer-supported triphenylphosphine (3 mmol/g, 0.66 g) was soaked in dichloromethane (6 mL) for 1 hour 6-(3-Hydroxymethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (260 mg, 0.66 mmol) and carbon tetrabromide (657 mg, 1.98 mmol) were added sequentially and the mixture was shaken for 1 hour at room temperature. The mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography to provide 233 mg (77%) of the product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.08 (t,3H), 1.20 (dd, 2H, J= 7, 8 Hz), 2.14 (s, 3H), 2.35-2.43 (m, 2H), 3.44 (d, J = 7.2, 2H), 3.73 (s, 3H), 3.95 (s, 2H), 4.27 (dd, 2H, J= 7, 8 Hz), 5.08 (s, 2H), 5.53 (t, J = 7.2 Hz, 1H) ppm.




[2-Ethyl-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-but-2-enyl]-phosphonic acid

A solution of 6-(3-bromomethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (230 mg, 0.5 mmol) in

trimethylphosphite (1.5 mL, 12.75 mmol) was heated to 100 °C for 4 hours. The reaction was worked up by removal of excess trimethylphosphite under reduced pressure. The residue was dissolved in acetonitrile (1 mL) and TMSBr (646 μL, 5.0 mmol) and 2,6-lutidine (580 μL, 5.0 mmol) were added at 0 °C. The reaction solution was allowed to warm to room temperature and stirred for 4 hours. The reaction was cooled to 0°C and quenched with addition of MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 77mg (58%) of the product. ^{1}H NMR (300 MHz, CD_3OD) δ 1.08 (t, 3H), 2.16 (s, 3H), 2.43 (m, 2H), 2.48 (d, 2H, *J*= 22 Hz), 3.46 (t, 2H, *J*= 6 Hz), 3.79 (s, 3H), 5.25 (s, 2H), 5.38 (q, 1H, *J*= 7 Hz) ppm.; ^{31}P (121.4 MHz, CD_3OD) δ 25.65 ppm.; MS (*m/z*) 355 $[M-H]^-$, 357 $[M+H]^+$.

Example 274: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



{1-Cyano-3-ethyl-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-pent-3-enyl}-phosphonic acid diethyl ester

To a solution of diethyl cyanomethylphosphonate (233 mg, 1.32 mmol) in THF (1 mL) was added a THF solution of sodium bis(trimethysilyl)amide (1.0 M, 1.21 mL, 1.21 mmol). After stirring for 30 minutes, the solution was added dropwise to a solution of 6-(3-bromomethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (100 mg, 0.22 mmol) in THF (1 mL). The resulting mixture was allowed to stir at room temperature overnight before saturated aqueous ammonium chloride was added. The reaction mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated to dryness. The residue was purified by

preparative reverse-phase HPLC, affording 51 mg (42%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.04 (s, 9H), 1.07 (t,3H), 1.24 (dd, 2H, J= 7, 8 Hz), 1.36 (t, 6H), 2.12 (m, 1H), 2.18 (s, 3H), 2.35-2.47 (m, 2H), 2.67 (m,1H), 3.00-3.14 (m, 1H), 3.44 (d, *J* = 7.2, 2H), 3.79 (s, 3H), 4.12-4.37 (m, 6H), 5.13 (s, 2H), 5.38 (t, *J* = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 18.26 ppm; MS (*m/z*) 574 $[M+Na]^+$.




[1-Cyano-3-ethyl-5-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-pent-3-enyl]-phosphonic acid

{1-Cyano-3-ethyl-5-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-pent-3-enyl}-phosphonic acid diethyl ester (19.5 mg, 0.035 mmol) was dissolved in a solution of 10% TFA/ CH_2Cl_2 (2 mL) and stirred at room temperature for 10 minutes. The reaction mixture was dried under reduced pressure and purified by RP-HPLC to provide 9.5 mg (61%) of the desired product. This material was dissolved in DMF (0.5 mL) and DCM (0.5 mL) and TMSBr (27 μL, 0.2 mmol) and 2,6-lutidine (23 μL, 0.2 mmol) were added. The reaction solution was allowed stir at room temperature overnight before quenching with MeOH. The reaction mixture was dried under reduced pressure and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 5.1 mg (65%) of the desired product as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.10 (t,3H), 2.16 (s, 3H), 2.23-2.52 (m, 3H), 2.67 (m,1H), 3.05-3.20 (m, 1H), 3.48 (d, *J* = 7.2, 2H), 3.81 (s, 3H), 5.26 (s, 2H), 5.43 (t, *J* = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 14.18 ppm; MS (*m/z*) 394 $[M-H]^-$, 396 $[M+H]^+$.


Example 275: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



{2-Ethyl-4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enyloxymethyl}-phosphonic acid diisopropyl ester

To a solution of bromomethylphosphonate diisopropyl ester (680mg, 2.62 mmol) and 6-(3-hydroxymethyl-pent-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (688mg, 1.75 mmol) in DMF (3 mL) was added lithium t-butoxide (1.0M in THF; 2.6mL). The reaction was heated at 70°C for 2 hours. After cooling to ambient temperature, more bromomethylphosphonate diisopropyl ester (680mg, 2.62 mmol) and lithium t-butoxide (1.0M in THF; 2.6mL) were added. The reaction mixture was heated at 70°C for a further hour, cooled, poured into a solution of lithium chloride (5% aqueous) and extracted with ethyl acetate. The organic extract was dried and the product was purified by chromatography on silica gel, eluting with hexane-ethyl acetate to provide 347 mg (35%) of the product as a colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.04 (s, 9H), 1.09 (t, 3H, *J*= 7.5 Hz), 1.20- 1.26 (m, 2H), 1.31 (t, 12H, *J*= 6 Hz), 2.18 (s, 3H), 2.29 (q, 2H, *J*= 7.5 Hz), 3.5 (m, 2H), 3.59 (d, 2H, *J*= 8.7 Hz), 3.78 (s, 3H), 3.98 (s, 2H), 4.28- 4.35 (m, 2H), 4.6-4.8 (m, 2H), 5.13 (s, 2H), 5.4 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 20.26 ppm; MS (*m/z*) 593.3 $[M+Na]^+$.




[2-Ethyl-4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-but-2-enyloxymethyl]-phosphonic acid

To a solution of {2-ethyl-4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-

enyloxymethyl}-phosphonic acid diisopropyl ester (347mg, 0.61mmol) in acetonitrile (5mL) was added 2,6-lutidine (0.71mL, 6.1mmol) and bromotrimethylsilane (0.786mL, 6.1mmol). The mixture was stirred at room temperature for 3 hours, quenched with methanol (5mL), concentrated, and partitioned between ethyl acetate and 1N HCl (aqueous). The organic layer was concentrated to give the free phosphonic acid as a colorless oil (205mg, 70%). This material (20mg) was dissolved in a solution of trifluoroacetic acid (0.3mL) and dichloromethane (2.7mL) and stirred for 30 minutes at ambient temperature. After concentration, the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide the product, after lyophilization, as a white solid (10mg). ^{1}H NMR (300 MHz, $CDCl_3$) δ 1.007 (t, 3H, *J*= 7.5 Hz), 2.13 (s, 3H), 2.32 (q, 2H, *J*= 7.5 Hz), 3.41 (d, 2H, *J*= 6.3 Hz), 3.56 (d, 2H, *J*= 9 Hz), 3.75 (s, 3H), 3.95 (s, 2H), 5.16 (s, 2H), 5.43 (t, 1H, *J*= 6.3 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 22.8 ppm; MS (*m/z*) 385.2 $[M-H]^+$, 387.1 $[M+H]^+$.

Example 276: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



6-Allyloxy-3-methyl-4-trifluoromethanesulfonyloxy-phthalic acid dimethyl ester


To a solution of 6-allyloxy-4-hydroxy-3-methyl-phthalic acid dimethyl ester (8.06 g, 28.8 mmol) [synthesized according to: J. W. Patterson, *Tetrahedron,* **1993**, *49*, 4789-4798] and pyridine (11.4 g, 144.0 mmol) in dichloromethane (DCM) (20 mL) at 0°C was added triflic anhydride (12.19 g,

43.2 mmol). The reaction was stirred at 0°C for 2 hours after which additional triflic anhydride (3 mL) was added. Stirring at 0°C was continued for an additional hour. The reaction mixture was poured into a mixture of DCM and HCl (1N). The layers were separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded a crude product, which was purified by silica gel chromatography to provide 8.39 g of the product as an oil. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 2.32 (s, 3H), 3.89 (s, 6H), 4.60 (m, 2H), 5.33 (d, J = 9.3 Hz, 1H), 5.41 (d, J = 18.6 Hz, 1H), 5.95 (m, 1H), 6.95 (s, 1H) ppm; ^{19}F NMR (282 MHz, $CDCl_3$): δ = -74 ppm.




6-Hydroxy-3-methyl-4-trifluoromethanesulfonyloxy-phthalic acid dimethyl ester

To a solution of 6-allyloxy-3-methyl-4-trifluoromethanesulfonyloxy-phthalic acid dimethyl ester (8.39 g, 20.3 mmol) in toluene (20 mL) was added tetrakistriphenylphosphine palladium (0.47 g, 0.40 mmol) and diethylamine (2.97 g, 40.86 mmol) at room temperature under an atmosphere of nitrogen. Stirring at room temperature was continued until all starting material was consumed. The crude reaction mixture was partitioned between diethyl ether and HCl (0.1 N). The organic layer was washed with brine and dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded a crude material, which was purified by silica gel chromatography to provide 4.16 g (55%) of the desired product as an off-white solid. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 2.20 (s, 3H), 3.93 (s, 3H), 3.95 (s, 3H), 7.01 (s, 1H) ppm; ^{19}F NMR (282 MHz, $CDCl_3$): δ = -74 ppm.




6-Hydroxy-3-methyl-4-vinyl-phthalic acid dimethyl ester

To a solution of 6-hydroxy-3-methyl-4-trifluoromethanesulfonyloxy-phthalic acid dimethyl ester (2.17 g, 5.85 mmol) in *N*-methyl pyrolidinone (15 mL) was added lithium chloride (743 mg, 17.5 mmol) and triphenylarsine (179 mg, 0.585 mmol). Tributylvinyltin (2.04 g, 6.43 mmol) was added followed by tris(tribenzylideneacetone)dipalladium(0)-chloroform adduct (90 mg, 0.087 mmol). The reaction was placed under an atmosphere of nitrogen and heated at 60°C for 18 hours. The reaction was cooled to room temperature and poured onto a mixture of ice (20 g), EtOAc (40 mL), and potassium fluoride (1 g). Stirring was continued for 1 hour. The aqueous layer was extracted with EtOAc and the organic extracts filtered through Celite. The combined organic layers were washed with water and dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded a crude material, which was purified by silica gel chromatography to provide 1.27 g (87%) of the product as an off-white solid. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 2.16 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 5.46 (dd, J = 11.1, 1.2 Hz, 1H), 5.72 (dd, J = 17.1, 0.9 Hz, 1H), 6.86 (dd, J = 17.1, 11.1 Hz, 1H), 7.14 (s, 1H), 10.79 (s, 1H) ppm.




4-Ethyl-6-hydroxy-3-methyl-phthalic acid dimethyl ester

6-Hydroxy-3-methyl-4-vinyl-phthalic acid dimethyl ester (1.27 g, 5.11 mmol) was dissolved in benzene (10 mL) and EtOAc (10 mL). Tristriphenylphosphine rhodium chloride (150 mg) was added and the reaction was placed under an atmosphere of hydrogen. Stirring at room temperature was continued. After 14 hours, the solvents were removed *in vacuo* and the crude material was purified by silica gel chromatography to provide 1.14 g (88%) of the desired product as an off-white solid. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 1.19 (t, J = 7.8 Hz, 3H), 2.10 (s, 3H), 2.60 (q, J = 7.8 Hz, 2H), 3.89 (s, 6H), 6.87 (s, 1H), 10.79 (s, 1H) ppm.




1 6-Allyloxy-4-ethyl-3-methyl-phthalic acid dimethyl ester

4-Ethyl-6-hydroxy-3-methyl-phthalic acid dimethyl ester (1.01 g, 4.02 mmol) was dissolved in DMF (5 mL). Potassium carbonate (3.33 g, 24.14 mmol) was added, followed by allylbromide (2.92 g, 24.14 mmol). The suspension was heated at 60°C. After 14 hours, the reaction was cooled to room temperature and filtered. The solvents were removed *in vacuo* and the crude material was purified by silica gel chromatography to provide 0.976 g (83%) of the desired product as a colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 1.16 (t, J = 7.2 Hz, 3H), 2.20 (s, 3H), 2.62 (q, J = 7.2 Hz, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 4.57 (m, 2H), 5.26 (dd, J = 9.3, 1.5 Hz, 1H), 5.41 (dd, J = 13.5, 1.5 Hz, 1H), 5.98 (m, 1H), 6.82 (s, 1H) ppm.




4-Allyl-5-ethyl-3-hydroxy-6-methyl-phthalic acid dimethyl ester

6-Allyloxy-4-ethyl-3-methyl-phthalic acid dimethyl ester (1.25 g, 4.28 mmol) was heated at 210°C under an atmosphere of nitrogen. After 14 hours, the reaction was cooled to room temperature. The crude material was purified by silica gel chromatography to provide 0.971 g (77%) of the desired product as a colorless oil. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 1.14 (t, J = 7.8 Hz, 3H), 2.17 (s, 3H), 2.68 (q, J = 7.8 Hz, 2H), 3.49 (m, 2H), 3.86 (s, 3H), 3.89 (s, 3H), 4.89 – 5.01 (m, 2H), 5.93 (m, 1H), 11.22 (s, 1H) ppm.



5 6-Allyl-5-ethyl-7-hydroxy-4-methyl-3H-isobenzofuran-1-one


4-Allyl-5-ethyl-3-hydroxy-6-methyl-phthalic acid dimethyl ester (0.971 g, 3.32 mmol) was dissolved in MeOH (8 mL) at room temperature. A solution of sodium hydroxide (0.798 g, 19.95 mmol) in water (10 mL) was added and the suspension was heated at 55°C. After 16 hours, the reaction was cooled to room temperature and washed with diethyl ether. The aqueous layer was acidified (1N HCl) and the suspension was extracted with EtOAc. The combined organic layers were dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded the desired bis acid as a white solid (0.846 g, 98%, $M^+ = 263$). The bis acid was dissolved in acetic acid (6 mL) and HCl (conc., 1.5 mL). The reaction was heated at 80°C. Zn dust (0.635 g, 9.72 mmol, each) was added in portions every hour for 7 hours. Stirring at 80°C was continued for additional 10 hours. The reaction was cooled to room temperature, and water was added. The resultant suspension was extracted with EtOAc. The combined organic extracts were washed with sodium bicarbonate solution and dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded the crude product, which was purified by silica gel chromatography to provide 0.375 g (50%) of the product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$): $\delta = 1.14$ (t, $J = 7.5$ Hz, 3H), 2.18 (s, 3H), 2.71 (q, $J = 7.5$ Hz, 2H), 3.49 (m, 2H), 4.95 (d, $J = 17.1$ Hz, 1H), 5.02 (d, $J = 10.2$ Hz, 1H), 5.23 (s, 2H), 5.98 (m, 1H), 7.66 (s, 1H) ppm.



5 6-Allyl-5-ethyl-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one


To a solution of 6-allyl-5-ethyl-7-hydroxy-4-methyl-3H-isobenzofuran-1-one (199 mg, 0.857 mmol), PPh_3 (337 mg, 1.286 mmol), and 2-trimethylsilylethanol in THF (3 mL) at 0°C was added di*iso*propyl azodicarboxylate (259 mg, 1.286 mmol). The resulting yellow solution was allowed to warm to room temperature and stirred for one hour. The solvent was removed *in vacuo* and the crude material was dissolved in diethyl ether (3 mL).

Hexanes (1.5 mL) were added. Triphenylphosphine oxide was removed by filtration and the filtrate was concentrated and purified by silica gel chromatography to provide the desired product (261 mg, 92 %) as a clear oil. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.15 (t, J = 7.8 Hz, 3H), 1.25 (m, 2H), 2.20 (s, 3H), 2.73 (q, J = 7.8 Hz, 2H), 3.54 (m, 2H), 4.28 (m, 2H), 4.95 (d, J = 17.1 Hz, 1H), 5.02 (d, J = 10.2 Hz, 1H), 5.15 (s, 2H), 5.95 (m, 1H) ppm.




[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde

A solution of 6-allyl-5-ethyl-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (261 mg, 0.788 mmol) in MeOH (5 mL), CH_2Cl_2 (5 mL) and pyridine (50 μL) was cooled to –78°C using a dry ice/acetone bath according to the procedure of Smith, D. B. *et al.*, *J. Org. Chem.*, **1996**, *61*, 6, 2236. A stream of ozone was bubbled through the reaction *via* a gas dispersion tube until the reaction became blue in color (15 minutes). The ozone line was replaced with a stream of nitrogen and bubbling continued for another 15 minutes, by which time the blue color had disappeared. To this solution, at –78°C, was added thiourea (59.9 mg, 0.788 mmol) in one portion, and the cooling bath was removed. The reaction was allowed to warm to room temperature and stirred for 15 hours. The reaction mixture was filtered and then partitioned between CH_2Cl_2 and water. The aqueous layer was extracted with CH_2Cl_2 one more time and the organic extracts were combined, washed with aqueous 1N HCl, saturated $NaHCO_3$ and brine and dried over sodium sulfate. Filtration and evaporation of solvents in vacuo yielded the crude product, which was purified by silica gel chromatography to afford 181 mg (69 %) of the product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.11 (t, J = 7.5 Hz, 3H), 1.19 (m, 2H), 2.21 (s, 3H), 2.66 (q, J = 7.5 Hz, 2H), 3.90 (s, 2H), 4.36 (m, 2H), 5.18 (s, 2H), 9.71 (s, 1H) ppm.



4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal


[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (90 mg, 0.269 mmol) and 2-(triphenyl-phosphorylidene)-propionaldehyde (72.9 mg, 0.23 mmol) in toluene (3 mL) were heated at 100°C. After 15 hours, a second portion of 2-(triphenyl-phosphanylidene)-propionaldehyde (33 mg, 0.11 mmol) was added and the reaction mixture was heated for additional 9 hours. The toluene was removed *in vacuo*, and the residue was purified by silica gel chromatography to provide 77.6 mg (77%) of the desired product as a pale yellow oil. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.03 (s, 9H), 1.15 (t, J = 7.5 Hz, 3H), 1.21 (m, 2H), 1.93 (s, 3H), 2.21 (s, 3H), 2.71 (q, J = 7.5 Hz, 2H), 3.82 (d, J = 6.9 Hz, 2H), 4.34 (m, 2H), 5.18 (s, 2H), 6.38 (m, 1H), 9.35 (s, 1H) ppm.



5-Ethyl-6-(4-hydroxy-3-methyl-but-2-enyl)-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one


4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (77.6 mg, 0.207 mmol) was dissolved in MeOH (4 mL). A solution of $CeCl_3$ (51.1 mg, 0.207 mmol) in MeOH/water (9/1, 0.66 mL) was added and the solution was cooled to 0°C. A solution of lithium borohydride in THF (2M, 0.105 mL) was added dropwise. After 15 minutes, the reaction was quenched with 1N HCl (0.5 mL). The MeOH was removed *in vacuo* and the crude material was partitioned between DCM and water. The aqueous layer was extracted with DCM and the combined organic

layers were washed with sodium bicarbonate solution and dried over sodium sulfate. Filtration and evaporation of solvents yielded a crude oil, which was purified by silica gel chromatography to provide 57.2 mg (73%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.15 (t, J = 7.8 Hz, 3H), 1.26 (m, 2H), 1.86 (s, 3H), 2.19 (s, 3H), 2.72 (q, J = 7.8 Hz, 2H), 3.52 (d, J = 6.3 Hz, 2H), 3.99 (s, 2H), 4.34 (m, 2H), 5.14 (s, 2H), 5.32 (m, 1H) ppm.



6-(4-Bromo-3-methyl-but-2-enyl)-5-ethyl-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

5-Ethyl-6-(4-hydroxy-3-methyl-but-2-enyl)-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (57.2 mg, 0.152 mmol) was dissolved in DCM (3.5 mL). Polymer-bound triphenylphosphine (3 mmol/g, 152.1 mg) was added and the mixture was mechanically stirred at room temperature. Carbon tetrabromide (151.3 mg, 0.456 mmol) was added and the solution was stirred at room temperature. After 2 hours, the reaction was filtered and the solvent was removed *in vacuo*. The crude material was purified by silica gel chromatography to provide 58.0 mg (87%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.15 (t, J = 7.8 Hz, 3H), 1.25 (m, 2H), 1.95 (s, 3H), 2.20 (s, 3H), 2.70 (q, J = 7.8 Hz, 2H), 3.52 (d, J = 6.3 Hz, 2H), 3.94 (s, 2H), 4.28 (m, 2H), 5.14 (s, 2H), 5.50 (m, 1H) ppm.




{4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid

A solution of 4-[6'-ethyl-7'-methyl-3'-oxo-4'-(2''-trimethylsilanyl-ethoxy)-1',3'-dihydro-isobenzofuran-5'-yl]-2-methyl-but-2-enyl bromide (58 mg, 0.132 mmol) in trimethylphosphite (0.8 mL) was heated at 110°C. After 2 hours the reaction was complete. The reaction was cooled to room temperature and the excess trimethylphosphite was removed *in vacuo*. The crude material was used in the next step without further purification.

The crude product of the Arbuzov reaction was dissolved in MeCN (0.8 mL). Trimethylsilyl bromide (202.2 mg, 1.321 mmol) was added and the reaction was stirred at room temperature. After 15 minutes, lutidine (155.7 mg, 1.453 mmol) was added and stirring at room temperature was continued. After 2 hours, additional trimethylsilyl bromide (202.2 mg, 1.321 mmol) was added and stirring at room temperature was continued. After 4 hours, the reaction was quenched with MeOH (2 mL). The solvents were evaporated *in vacuo*, and the crude material was purified by RP-HPLC (eluent: water / MeCN). The product-containing fractions were combined and lyophilized to yield 2.3 mg (5.1%) of the free phosphonic acid. ^{1}H NMR (300 MHz, DMSO-d6): δ = 1.07 (t, J = 7.5 Hz, 3H), 1.84 (s, 3H), 2.14 (s, 3H), 2.64 (q, J = 7.5 Hz, 2H), 3.34 (m, 4H), 5.06 (m, 1H), 5.25 (s, 2H) ppm; ^{31}P NMR (121 MHz, DMSO-d6): δ = 22.19 ppm; MS = 341 [M^{+}+1].


Example 277: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




[2-Ethyl-4-[6-ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enal

[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-acetaldehyde (90 mg, 0.269 mmol) and 2-(triphenyl-phosphorylidene)-butyraldehyde (98.4 mg, 0.296 mmol) in toluene (3 mL) were heated at 100°C. After 15 hours, a second portion of 2-(triphenyl-phosphanylidene)-butyraldehyde (98.4 mg, 0.296 mmol) was added and the reaction mixture was heated for additional 33 hours. After concentration, the residue was purified by silica gel chromatography to provide 50.3 mg (48%) of the desired product as a pale yellow oil.




5-Ethyl-6-(3-hydroxymethyl-pent-2-enyl)-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

2-Ethyl-4-[6-ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enal (50.3 mg, 0.129 mmol) was dissolved in MeOH (3 mL). A solution of $CeCl_3$ (31.9 mg, 0.129 mmol) in MeOH/water (9/1, 0.66 mL) was added and the solution was cooled to 0°C. A solution of lithium borohydride in THF (2M, 0.065 mL) was added dropwise. After 10 minutes, the reaction was quenched with 1N HCl (0.5 mL). The methanol was removed *in vacuo* and the crude material was partitioned between DCM and water. The aqueous layer was extracted with DCM and the combined organic layers were washed with sodium bicarbonate solution and were dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded a crude oil, which was purified by silica gel chromatography to provide 35.4 mg (70%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.10 – 1.19 (m, 6H), 1.26 (m, 2H), 2.19 (s, 3H), 2.32 (q, J = 7.5 Hz, 2H), 2.72 (q, J = 7.5 Hz, 2H), 3.54 (d, J = 6.6 Hz, 2H), 4.05 (s, 2H), 4.26 (m, 2H), 5.14 (s, 2H), 5.27 (m, 1H) ppm.



6-(3-Bromomethyl-pent-2-enyl)-5-ethyl-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one

5-Ethyl-6-(3-hydroxymethyl-pent-2-enyl)-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (35.4 mg, 0.090 mmol) was dissolved in DCM (3.0 mL). Polymer-bound triphenylphosphine (3 mmol/g, 90.7 mg) was added, and the mixture was mechanically stirred at room temperature. Carbon tetrabromide (90.2 mg, 0.272 mmol) was added and the solution was stirred at room temperature. After 2 hours, the reaction was filtered and the solvent was removed *in vacuo*. The crude material was purified by silica gel chromatography to provide 32.0 mg (78%) of the desired product. The material was used in the next step without further characterization.




[2-Ethyl-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-but-2-enyl]-phosphonic acid


A solution of 6-(3-bromomethyl-pent-2-enyl)-5-ethyl-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (32 mg, 0.070 mmol) in trimethylphosphite (0.8 mL) was heated at 110 °C. After 2 hours, the reaction was complete. The reaction was cooled to room temperature and the excess trimethylphosphite was removed *in vacuo*. The crude material was used in the next step without further purification.


The crude product of the Arbuzov reaction was dissolved in MeCN (0.8 mL). Trimethylsilyl bromide (108.0 mg, 0.706 mmol) was added and the reaction was stirred at room temperature. After 2 hours, a second batch of trimethysilyl bromide (108.0 mg, 0.706 mmol) was added. After 3 hours, the reaction was quenched with MeOH (2 mL). The solvents were evaporated *in vacuo* and the crude material was purified by RP-HPLC (eluent: water / MeCN). The product-containing fractions were combined and lyophilized to yield 15.7 mg (63%) of the product. ^{1}H NMR (300 MHz, DMSO-d6): δ = 0.98 - 1.09 (m, 6H), 2.10 (s, 3H), 2.30 (m, 2H), 2.64 (q, J = 7.5 Hz, 2H), 3.38 (m, 4H), 5.03 (m, 1H), 5.25 (s, 2H) ppm; ^{31}P NMR (121 MHz, DMSO-d6): δ = 22.26 ppm; MS = 355 [M^++1].

Example 278: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.







(2-{4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester


4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (19.7 mg, 0.052 mmol) and aminoethylphosphonic acid diethylester oxalate salt (15.6 mg, 0.057 mmol) were dissolved in DMF (0.5 mL). Acetic acid (15.7 mg, 0.263 mmol) was added, followed by sodium triacetoxyborohydride (22.3 mg, 0.105 mmol). After 4 hours, the crude reaction mixture was purified by RP-HPLC (eluent: water/MeCN) to provide 27.7 mg (97%) of the desired product after lyophilization. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.04 (s, 9H), 1.14 (t, J = 7.5 Hz, 3H), 1.26 (m, 2H), 1.30 (t, J = 7.2 Hz, 6H), 1.95 (s, 3H), 2.19 (s, 3H), 2.23 (m, 2H), 2.68 (q, J = 7.5 Hz, 2H), 3.18 (m, 2H), 3.53 (s, 2H), 4.13 (m, 4H), 4.28 (m, 2H), 5.15 (s, 2H), 5.51 (m, 1H) ppm; ^{31}P NMR (121 MHz, $CDCl_3$): δ = 27.39 ppm; MS = 540 [M^++1].





{2-[4-(6-Ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phosphonic acid:

(2-{4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (27.7 mg, 0.051 mmol) was dissolved in DMF (0.5 mL) and DCM (0.5 mL). Trimethylsilyl bromide (78.3 mg, 0.512 mmol) was added and the reaction was stirred at room temperature. After 20 hours, the reaction was quenched with MeOH (0.3 mL). The solvents were evaporated *in vacuo* and the crude material was purified by RP-HPLC (eluent: water/MeCN). The product-containing fractions were combined and lyophilized to yield 14.2 mg (57%) of the free phosphonic acid [MS: 484 M^++1].

The material was dissolved in DCM (0.5 mL). TFA (0.05 mL) was added and stirring at room temperature was continued. After 20 minutes, the solvents were removed *in vacuo* and the crude material was purified by RP-HPLC (eluent: water/MeCN * 0.1% TFA). The product-containing fractions were combined and lyophilized to yield 7.6 mg (52%) of the product as the TFA salt. ^{1}H NMR (300 MHz, DMSO-d6): δ = 1.07 (t, *J* = 7.5 Hz, 3H), 1.84 (s, 3H), 1.90 (m, 2H), 2.11 (s, 3H), 2.63 (q, *J* = 7.5 Hz, 2H), 2.99 (m, 2H), 3.43 (d, J = 6.3 Hz, 2H), 3.51 (s, 2H), 5.26 (s, 2H), 5.45 (m, 1H) ppm; ^{31}P NMR (121 MHz, DMSO-d6): δ = 20.02 ppm; MS = 384 [M^++1].







(2-{2-Ethyl-4-[6-ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester

2-Ethyl-4-[6-ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enal (26.6 mg, 0.068 mmol) and aminoethylphosphonic acid diethylester oxalate salt (20.4 mg, 0.075 mmol) were dissolved in DMF (0.8 mL). Acetic acid (20.5 mg, 0.342 mmol) was added, followed by sodium triacetoxyborohydride (27.6 mg, 0.137 mmol). After 8 hours, the crude reaction mixture was purified by RP-HPLC (eluent: water/MeCN) to provide 24.9 mg (65%) of the desired product after lyophilization. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.05 (s, 9H), 1.10 - 1.24 (m, 8H), 1.35 (t, J = 7.5 Hz, 6H), 2.19 (s, 3H), 2.23 (m, 2H), 2.35 (q, J = 7.8 Hz, 2H), 2.70 (q, J = 7.2 Hz, 2H), 3.25 (m, 2H), 3.56 (m, 4H), 4.15 (m, 4H), 4.29 (m, 2H), 5.15 (s, 2H), 5.47 (m, 1H) ppm; ^{31}P NMR (121 MHz, $CDCl_3$): δ = 27.71 ppm; MS = 554 [M^++1].



{2-[2-Ethyl-4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-but-2-enylamino]-ethyl}-phosphonic acid


(2-{2-Ethyl-4-[6-ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-but-2-enylamino}-ethyl)-phosphonic acid diethyl ester (24.9 mg, 0.045 mmol) was dissolved in DMF (0.5 mL) and DCM (0.5mL). Trimethylsilyl bromide (68.7 mg, 0.449 mmol) was added and the reaction was stirred at room temperature. After 20 hours, the reaction was quenched with MeOH (0.15 mL). The solvents were evaporated *in vacuo* and

the crude material was purified by RP-HPLC (eluent: water/MeCN). The product-containing fractions were combined and lyophilized to yield 8.0 mg of the free phosphonic acid [MS: 498 M^++1].

This material was dissolved in DCM (0.5 mL). TFA (0.05 mL) was added, and stirring at room temperature was continued. After 20 minutes, the solvents were removed *in vacuo* and the crude material was purified by RP-HPLC (eluent: water/MeCN * 0.1% TFA). The product-containing fractions were combined and lyophilized to yield 4.4 mg (54%) of the product as the TFA salt. ^{1}H NMR (300 MHz, DMSO-d6): δ = 1.05 (m, 6H), 1.60 (m, 2H), 2.10 (s, 3H), 2.67 (q, J = 7.5 Hz, 2H), 2.63 (q, J = 6.9 Hz, 2H), 2.93 (m, 2H), 3.45 (m, 4H), 5.24 (s, 2H), 5.36 (m, 1H) ppm.; ^{31}P NMR (121 MHz, DMSO-d6): δ = 16.93 ppm; MS = 398 [M^++1].

Example 279: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-({4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phenoxy-phosphinoylamino)-propionic acid ethyl ester

4-[6'-ethyl-7'-methyl-3'-oxo-4'-(2''-trimethylsilanyl-ethoxy)-1',3'-dihydro-isobenzofuran-5'-yl]-2-methyl-but-2-en-phosphonic acid (44.8 mg, 0.101 mmol), dicyclohexylcarbodiimide (52.6 mg, 0.254 mmol), and phenol (95.8 mg, 1.018 mmol) were dissolved in pyridine (0.3 mL) and heated at 70°C for 4 hours. The reaction mixture was cooled to room temperature and the pyridine was removed *in vacuo*. The crude material was partitioned between DCM and HCl (0.1N). The aqueous layer was extracted with DCM and the combined organic layers were dried over sodium sulfate. Filtration and evaporation of solvents *in vacuo* yielded a crude material, which was used in the next step without further purification.

The crude material was dissolved in MeCN (0.8 mL) and water (0.3 mL). Aqueous sodium hydroxide solution (2N, 0.8 mL) was added in portions (0.2 mL). After all starting material was consumed, the organic solvent was removed *in vacuo* and the crude material was partitioned between chloroform and aqueous HCl (1N). The aqueous layer was extracted with chloroform. The combined organic layers were dried over sodium sulfate. Filtration and evaporation of solvents yielded the crude product as a mixture of mono phenyl ester and the symmetrical anhydride.

The crude material of the previous step and ethyl (*L*)-alanine hydrochloride salt (78.1 mg, 0.509 mmol) were dissolved in DMF (0.4 mL). DMAP (1.2 mg, catalytic) was added, followed by di*iso*propylethylamine (131.3 mg, 1.018 mmol). Stirring at room temperature was continued. After 20 minutes, complete conversion of the anhydride was observed. After 2 hours, PyBOP (101 mg, 0.202 mmol) was added and stirring at room temperature was continued. The reaction was filtered and the crude reaction solution was purified by RP-HPLC (eluent: water/MeCN). The product-containing fractions were combined and lyophilized to yield the product (15.7 mg, 25% over three steps) as a white powder. ^{1}H NMR (300 MHz, $CDCl_3$): δ = 0.03 (s, 9H), 1.13 – 1.28 (m, 8H), 2.03 (s, 3H), 2.19 (s, 3H), 2.62 – 2.74 (m, 4H), 3.38 (m, 1H), 3.53 (t, *J* = 6.3 Hz, 2H), 4.03 (m, 3H), 4.30 (m, 2H), 5.14 (s, 2H), 5.31 (m, 1H), 7.11 –

7.17 (m, 3H), 7.25 – 7.30 (m, 2H) ppm; ^{31}P NMR (121 MHz, $CDCl_3$): δ = 27.04, 27.73 ppm; MS =615 [M^++1].




2-{[4-(6-Ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phenoxy-phosphinoylamino}-propionic acid ethyl ester

2-({4-[6-Ethyl-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phenoxy-phosphinoylamino)-propionic acid ethyl ester (7.5 mg, 0.012 mmol) was dissolved in TFA/DCM (10%, 0.3 mL) at –20°C. The reaction mixture was warmed to 0°C and stirred at this temperature for 45 minutes. Pyridine (0.09 mL) was added the solvents were removed *in vacuo*. The crude material was purified by RP-HPLC (eluent: water/MeCN). The product-containing fractions were combined and lyophilized, yielding a white powder (5.5 mg, 87%). ^{1}H NMR (300 MHz, $CDCl_3$): δ = 1.12 – 1.29 (m, 6H), 2.03 (s, 3H), 2.17 (s, 3H), 2.65 – 2.74 (m, 4H), 3.38 (m, 1H), 3.53 (t, *J* = 6.3 Hz, 2H), 4.03 (m, 3H), 5.22 (s, 2H), 5.36 (m, 1H), 7.11 – 7.16 (m, 3H), 7.24 – 7.30 (m, 2H), 7.72 (m, 1H) ppm; ^{31}P NMR (121 MHz, $CDCl_3$): δ = 27.11, 27.57 ppm; MS =515 [M^++1].


Example 280: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




6-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid

A mixture of 6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester (1.5 g, 3.45 mmol) and sodium hydroxide (552 mg) in a mixture of methanol (20 mL) and water (7 mL) was stirred at room temperature for one hour. The solution was acidified with 1N HCl. The precipitate was collected by suction filtration and washed with water to give the desired product (1.2g, 83%). ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.02 (s, 9H), 1.15- 1.22 (m, 2H), 1.76 (s, 3H), 2.13 (s, 3H), 2.12- 2.28 (m, 2H), 2.35- 2.41 (m, 2H), 3.37 (d, 2H, *J*= 7 Hz), 3.71 (s, 3H), 4.22- 4.28 (m, 2H), 5.07 (s, 2H), 5.13- 5.17 (m, 1H) ppm; MS (*m/z*) 419.3 $[M-H]^-$, 443.2 $[M+Na]^+$.



({6-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoylamino}-methyl)-phosphonic acid diethyl ester

To a solution of 6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid (50 mg, 0.12 mmol) in THF (1 mL) was added isobutyl chloroformate (17 μL, 0.13 mmol) and triethylamine (50 μL, 0.36 mmol) at 0°C. After stirring at 0 °C for 2 hours, diethyl (aminomethyl) phosphonate oxalate (62 mg, 0.26 mmol) was added and stirring was continued at room temperature for 20 minutes. After removal of solvent, the residue was purified by preparative reverse-phase HPLC to afford 54.8 mg (81%) of the desired product. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.15- 1.22 (m, 2H), 1.31 (t, 6H), 1.81 (s, 3H), 2.18 (s, 3H), 2.30 (m, 4H), 3.41 (d, 2H, *J*= 7 Hz), 3.65 (dd, 2H, J= 6, 12 Hz), 3.77 (s, 3H), 3.77-4.16 (m, 4H), 4.26-4.32 (m,2H), 5.12 (s, 2H), 5.17- 5.19 (m, 1H), 5.86 (bs, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 23.01 ppm; MS (*m/z*) 568 $[M-H]^-$, 592 $[M+Na]^+$.




{[6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoylamino]-methyl}-phosphonic acid

To a solution of ({6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoylamino}-methyl)-phosphonic acid diethyl ester (40 mg, 0.07 mmol) in acetonitrile (1 mL) was added TMSBr (91 μL, 0.7 mmol) followed by 2,6-lutidine (81.5 μL, 0.7 mmol). The reaction was allowed to proceed overnight when it was completed as judged by LCMS. The reaction mixture was quenched with MeOH and concentrated to dryness. The residue was purified by preparative reverse-phase HPLC to afford

2.6 mg (9%) of desired product as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.67 (s, 3H), 2.17 (m, 5H), 2.30-2.46 (m, 2H), 2.80- 2.86 (m, 2H), 3.55 (m, 2H), 3.82 (s, 3H), 5.26 (s, 3H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 10.27 ppm; MS (*m/z*) 412 $[M-H]^-$, 414 $[M+H]^+$.


Example 281: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



(2-{6-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoylamino}-ethyl)-phosphonic acid diethyl ester

To a solution of 6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid (50 mg, 0.12 mmol) in THF (1 mL) was added isobutyl chloroformate (17 μL, 0.13 mmol) and triethylamine (50 μL, 0.36 mmol) at 0°C. After stirring at 0°C for 2 hours, diethyl (aminoethyl) phosphonate oxalate (62 mg, 0.26 mmol) was added and stirred at room temperature was continued for one hour. After removal of solvent, the residue was purified by preparative reverse-phase HPLC to afford 37 mg (54%) of the desired product as a white solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.15- 1.22 (m, 2H), 1.31 (t, 6H), 1.81 (s, 3H), 1.85-1.93 (m,2H), 2.18 (s, 3H), 2.30 (m, 4H), 3.41 (d, 2H, *J*= 7 Hz), 3.48-3.54 (m, 2H), 3.77 (s, 3H), 3.77-4.16 (m, 4H), 4.26-4.32 (m,2H), 5.12 (s, 2H), 5.17- 5.19 (m, 1H), 6.30 (bs, 1H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 29.91 ppm; MS (*m/z*) 584 $[M+H]^+$.





{2-[6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-hex-4-enoylamino]-ethyl}-phosphonic acid

To a solution of (2-{6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoylamino}-ethyl)-phosphonic acid diethyl ester (36.6 mg, 0.063 mmol) in acetonitrile (1 mL) was added TMSBr (81 μL, 0.63 mmol) followed by 2,6-lutidine (73 μL, 0.63 mmol). The reaction was allowed to proceed overnight, when it was completed as judged by LCMS. The reaction mixture was quenched with MeOH and concentrated to dryness. The residue was purified by preparative reverse-phase HPLC to afford 5.8 mg (29%) of desired product as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.80 (s, 3H), 2.14 (m, 5H), 2.25 (m, 4H), 3.35 (m, 2H), 3.38-3.38 (m, 2H), 3.75 (s, 3H), 5.23 (s, 3H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 26.03 ppm; MS (*m/z*) 426 $[M-H]^-$, 428 $[M+H]^+$.

Example 282: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.





{4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid diphenyl ester


To a solution of [{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid (260 mg, 0.59 mmol) in DMF (6 mL) and phenol (555 mg, 5.9 mmol) was added dicyclohexyl carbodiimide (1.21 g, 5.9 mmol) and DMAP (36 mg, 0.295 mmol). The reaction mixture was heated to 140°C for 30 minutes. After cooling to room temperature, the mixture was partitioned between EtOAc/Hexane (1:1) and 5% aqueous LiCl solution. The organic layer was washed with 5% aqueous LiCl solution repeatedly, then dried over Na_2SO_4. After removal of solvent, the residue was purified by silica gel chromatography to provide 75 mg (21%) of the desired product. MS (*m/z*) 617 $[M+Na]^+$.



{4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid monophenyl ester


To a solution of {4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid diphenyl ester (75 mg, 0.126 mmol) in THF (5 mL) was added 1N NaOH (0.1 mL) solution. The mixture was allowed to stir at room temperature for 16 hours. EtOAc was added and the resulting mixture was washed with 1H HCl. The organic layer was concentrated to dryness and the residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1%

TFA to provide 24.8 mg (38 %) of the desired product. MS (*m/z*) 517 $[M-H]^-$, 541 $[M+Na]^+$.



2-({4-[6-Methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phenoxy-phosphinoyloxy)-propionic acid ethyl ester

To a solution of {4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid monophenyl ester (25 mg, 0.048 mmol) and ethyl (S)-(-)-lactate (34 mg, 0.288 mmol) in pyridine (1 mL) was added PyBOP (125 mg, 0.24 mmol). The solution was stirred at room temperature for 16 hours and concentrated. The residue was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 24 mg (83%) of the desired product. MS (*m/z*) 641 $[M+Na]^+$.




2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester

To a solution of 2-({4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phenoxy-phosphinoyloxy)-propionic acid ethyl ester (24 mg, 0.039 mmol) in DCM (1 mL) was added TFA (0.5 mL) and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was dried under reduced pressure and the residue was purified by RP-HPLC to provide 18 mg (90%) of the desired product as a clear oil. ^1H NMR (300 MHz, $CDCl_3$) δ 1.18-1.34 (m, 3H), 1.36-

1.48 (dd,3H), 2.02 (m, 3H), 2.17 (s, 3H), 2.78-2.98 (dd, 2H), 3.45 (m, 2H), 3.79 (s, 3H), 4.05-4.25 (m, 2H), 4.97 (m, 1H), 5.21 (s, 2H), 5.48 (t, J = 7.2 Hz, 1H), 7.05-7.18 (m, 5H) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 24.59, 26.13 ppm; MS (*m/z*) 517 $[M-H]^-$, 519 $[M+H]^+$.

Example 283: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phenoxy-phosphinoyloxy}-propionic acid

To a solution of 2-{[4-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phenoxy-phosphinoyloxy}-propionic acid ethyl ester (10 mg, 0.019 mmol) in THF (3 mL) was added 1N NaOH (232 μL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was dried under reduced pressure and the residue was purified by RP-HPLC to provide 6 mg (77 %) of the desired product as a clear oil. ^{1}H NMR (300 MHz, CD_3OD) δ 1.41 (d, J = 7 Hz, 3H), 1.97 (s, 3H), 2.16 (s, 3H), 2.59 (d, J = 22 Hz, 2H), 3.45 (m, 2H), 3.79 (s, 3H), 4.83 (m, 1H), 5.26 (s, 2H), 5.43 (t, J = 7.2 Hz, 1H) ppm; ^{31}P (121.4 MHz, CD_3OD) δ 27.02 ppm; MS (*m/z*) 413 $[M-H]^-$, 415 $[M+H]^+$.

Example 284: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.




2-{[4-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyl]-phenoxy-phosphinoylamino}-propionic acid ethyl ester

{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl}-phosphonic acid monophenyl ester (1 g, ~1.9 mmol) was combined with pyBOP (2 g, 4 mmol) and DMAP (120 mg, 0.96 mmol). A solution of L-alanine ethyl ester hydrochloride salt (2.9 g, 19 mmol) and diisopropylethylamine (6.7 mL, 38 mmol) in pyridine (5 mL) was added to the monoacid mixture and the reaction was stirred at room temperature for 12 hours. The reaction mixture was then concentrated and purified twice by column chromatography (1% $MeOH/CH_2Cl_2$ 3% $MeOH/CH_2Cl_2$). The resulting oil was dissolved in a vigorously-stirred solution of 10% TFA/CH_2Cl_2 (30 mL) at -40°C. The reaction was gradually warmed to 0°C. After about 3 hours, the reaction was complete. Pyridine (4.5 mL) was added, and the reaction mixture was concentrated. The product was purified by preparative TLC (5% $MeOH/CH_2Cl_2$) and concentrated to give 210 mg (21%) of the desired product as a light yellow oil. ^1H NMR (300 MHz, $CDCl_3$) δ 7.83-7.70 (m, 1H), 7.30-7.20 (m, 2H), 7.18-7.03 (m, 3H), 5.60-5.35 (m, 1H), 5.21 (s, 2H), 4.17-3.95 (m, 3H), 3.79 (s, 3H), 3.60-3.40 (m, 3H), 2.80-2.60 (m, 2H), 2.17 (m, 3H), 2.01 (m, 3H), 1.30-1.10 (m, 6H) ppm; ^{31}P NMR (121 MHz, $CDCl_3$) δ 28.0, 27.5 ppm; MS (*m/z*) 516 $[M-H]^-$.


Example 285: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



2-(Dimethoxy-phosphoryl)-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester

To a solution of trimethylphosphonoacetate (63 μL, 0.39 mmol) in THF (1 mL) was added $NaN(TMS)_2$ (0.39 mmol, 0.39 mL) at ambient temperature. After 30 minutes, a solution of 6-(4-bromo-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (69 mg, 0.156 mmol) in THF (1 mL) was added. The reaction mixture was stirred for 2 hours, when a precipitate was observed. The reaction mixture was worked up by addition of a saturated aqueous solution of ammonium chloride and extraction of the product with EtOAc. The organic extract was dried and the product was purified using silica gel chromatography with 0-100% EtOAc-Hexanes to provide 40 mg of the desired product as a colorless oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.05 (s, 9H), 1.20- 1.26 (m, 2H), 1.79 (s, 3H), 2.17 (s, 3H), 2.42- 2.72 (m, 2H), 3.19 (ddd, 1H, *J*= 4, 12, 23 Hz), 3.39 (d, 2H, *J*= 7 Hz), 3.62 (s, 3H), 3.75 (s, 3H), 3.77- 3.84 (m, 6H), 4.27- 4.34 (m, 2H), 5.12 (s, 2H), 5.24 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 25.1 ppm; MS (*m/z*) 565.2 $[M+Na]^+$.




6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-4-methyl-2-phosphono-hex-4-enoic acid methyl ester

To a solution of 2-(dimethoxy-phosphoryl)-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester (30 mg, 0.055 mmol) in acetonitrile (2 mL) was added trimethylsilyl bromide (0.18 mL). After 10 minutes, 2,6-lutidine (0.16 mL) was added to the reaction at ambient temperature. The reaction was allowed to proceed for 16 hours before it was concentrated to dryness. The residue was resuspended in a solution of DMF: H_2O (8: 2, 1 mL) and purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 18 mg of the product as a white powder. ^1H NMR (300

MHz, CD_3OD) δ 1.81 (s, 3H), 2.16 (s, 3H), 2.40-2.49 (m, 1H), 2.63 (dt, 1H, *J*= 6, 17 Hz), 3.07 (ddd, 1H, *J*= 4, 12, 23 Hz), 3.38 (3, 2H, *J*= 7 Hz), 3.52 (s, 3H), 3.77 (s, 3H), 5.25 (s, 2H), 5.28 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 19.5 ppm; MS (*m/z*) 415.2 $[M+H]^+$, 437.2 $[M+Na]^+$.


Example 286: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.



2-(Bis-(2,2,2-trifluoroethoxy)phosphoryl)-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester

To a solution of [bis-(2,2,2-trifluoro-ethoxy)-phosphoryl]-acetic acid methyl ester (186 μL, 0.88 mmol) in anhydrous THF (2 mL) was added a solution of 1N $NaN(TMS)_2$ in THF (0.88 mL, 0.88 mmol). The solution was stirred at room temperature for 30 minutes, whereupon a solution of 6-(4-bromo-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (98 mg, 0.22 mmol) in THF (1 mL) was added. The reaction mixture was stirred overnight when a precipitate was observed. The reaction mixture was worked up by addition of a saturated aqueous solution of ammonium chloride and extraction of the product with EtOAc. The organic extract was dried and the product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 72 mg (48%) of the product as a colorless oil. ^1H NMR (300 MHz, $CDCl_3$) δ 0.05 (s, 9H), 1.22 (t, 3H, *J*= 7 Hz), 1.81 (s, 3H), 2.18 (s, 3H), 2.5- 2.7 (m, 2H), 3.3 (ddd, 1H, *J*= 4, 12, 23 Hz), 3.40 (d, 2H, *J*= 7 Hz), 3.65 (s, 3H), 3.76 (s, 3H), 4.29- 5.13 (m, 6H), 5.13 (s, 2H), 5.28 (t, 1H, *J*= 7 Hz) ppm; MS (*m/z*) 701.2 $[M+Na]^+$.




2-(Bis-(2,2,2-trifluoroethoxy)phosphoryl)-6-[6-methoxy-7-methyl-3-oxo-4-(2-hydroxyoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester

[2-(Bis-(2,2,2-trifluoroethoxy)phosphoryl)-6-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-4-methyl-hex-4-enoic acid methyl ester (70 mg) was dissolved in a solution of 10% trifluoroacetic acid in dichloromethane (5mL). After 10 minutes, the mixture was concentrated and the product was purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 45 mg (75%) of the product as a colorless oil. ^1H NMR (300 MHz, $CDCl_3$) δ 1.81 (s, 3H), 2.16 (s, 3H), 2.5- 2.7 (m, 2H), 3.3 (ddd, 1H), 3.38 (d, 2H, *J*= 7 Hz), 3.65 (s, 3H), 3.77 (s, 3H), 4.33- 4.43 (m, 4H), 5.21 (s, 2H), 5.33 (t, 1H, *J*= 7 Hz) ppm; ^{31}P (121.4 MHz, $CDCl_3$) δ 25.8 ppm; MS (*m/z*) 601.2 $[M+Na]^+$.

Example 287: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.



6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-[hydroxy-(2,2,2-trifluoro-ethoxy)-phosphoryl]-4-methyl-hex-4-enoic acid

To a solution of [bis-(2,2,2-trifluoro-ethoxy)-phosphoryl]-acetic acid methyl ester (186 μL, 0.88 mmol) in anhydrous THF (0.5 mL) was added a solution of 1N NaOH (aqueous; 0.06 mL) and N-methylpyrrolidinone (0.2mL). After 6.5 hours, another aliquot of 1N NaOH (0.06mL) was added and the mixture was stirred overnight. After concentration, the residue was suspended in

DMF (<1mL), neutralized with a few drops of TFA and purified by RP HPLC using a C18 column with a gradient of H_2O, 0.1% TFA-acetonitrile, 0.1% TFA to provide 5.6 mg (72%) of the product as a white powder after lyophilization. ^1H NMR (300 MHz, CD_3OD) δ 1.83 (s, 3H), 2.16 (s, 3H), 2.43-2.51 (m, 1H), 2.59–2.70 (m, 1H), 3.13 (ddd, 1H), 3.40 (d, 2H), 3.76 (s, 3H), 4.36-4.47 (m, 2H), 5.25 (s, 2H), 5.34 (t, 1H, *J*= 7 Hz) ppm; MS (*m/z*) 505.2 $[M+Na]^+$.




Example 288: Preparation of Representative Compounds of the Invention.

Representative compounds of the invention can be prepared as illustrated below.

Phosphorous acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester

To a solution of 6-(4-hydroxy-3-methyl-but-2-enyl)-5-methoxy-4-methyl-7-(2-trimethylsilanyl-ethoxy)-3H-isobenzofuran-1-one (75 mg, 0.20 mmol) and DIEA (49 μL, 0.28 mmol) in dioxane (2 mL) was added 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (56.7 mg, 0.28 mmol) according the procedure of Shadid, B. et al., *Tetrahedron*, **1989**, *45*, 12, 3889. After 10 minutes, another portion of 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one (40 mg, 0.20 mmol) and DIEA (35 μL, 0.20 mmol) were added. The reaction was allowed to proceed at room temperature for an additional hour, after which it was quenched by the addition of H_2O. The solution was stirred for another 10 minutes and concentrated *in vacuo* to a small volume. The product was triturated with diethyl ether and coevaporated from acetonitrile (4 x 10 mL) to provide the product. ^1H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.08- 1.30 (m, 2H), 1.84 (br s, 3H), 2.17 (s, 3H), 3.46 (br s, 2H), 3.76 (s, 3H), 4.21- 4.39 (m,

4H), 5.12 (s, 2H), 5.43- 5.60 (m, 1H), 7.83 (br s, 1H); ^{31}P (121.4 MHz, $CDCl_3$) δ 7.22; MS (*m/z*) 441 [M-H]$^-$.



Example 289: Preparation of Representative Compounds of the Invention.


Representative compounds of the invention can be prepared as illustrated below.

Phosphoric acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester

A solution of phosphorous acid mono-{4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enyl} ester (27 mg, 0.06 mmol) in dioxane (1 mL) was stirred with DIEA (21 μL, 0.12 mmol) and N,O-bis(trimethylsilyl)acetamide (29 μL, 0.12 mmol) at room temperature for 3 hours. To the reaction solution was added 2,2'-dipyridyldisulfide (16 mg, 0.072 mmol) and the mixture was allowed to stir for an additional 2 hours at room temperature. The reaction mixture was diluted by addition of H_2O and the solution was stirred for 2 more hours when it was concentrated. The residue was dissolved in a solution of 10% TFA/ CH_2Cl_2 and stirred at room temperature for 9 hours. The reaction mixture was dried under reduced pressure and the product was purified by reverse-phase HPLC to provide the desired product as a white solid. ^{1}H NMR (300 MHz, CD_3OD) δ 1.87 (s, 3H), 2.16 (s, 3H), 3.47 (d, 2H, *J*= 7 Hz), 3.79 (s, 3H), 4.28 (d, 2H, *J*= 6 Hz), 5.26 (s, 2H), 5.50- 5.61 (m, 1H); ^{31}P (121.4 MHz, CD_3OD) δ 0.50; MS (*m/z*) 357 [M-H]$^-$.


Example 290: Specific Embodiments of the Invention


Several compounds of the invention are presented below.




Example 291: Preparation of Representative Compounds of the Invention

Additional representative compounds of the invention, and intermediates thereof, can be prepared according to the methods presented below.






Linker = 0-8 atoms, preferably 1-6;
R_1 = OMe, OEt, vinyl, Et, cyclopropyl, NHMe, NHCHO
R_2 = Me, Cl, CF_3
R_3 = H, Me, cyclopropyl, Et, vinyl, CF_3
R_4 = H, Cl, Me, Et, cyclopropyl, vinyl, allyl,




Synthesis of phenacetaldehydes with variants at R_1, R_2


The parent compound (R_1 = OMe; R_2 = Me) is accessible by semi-synthesis from mycophenolic acid as follows:



To a solution of mycophenolic acid (500 g, 1.56 mol) in MeOH (4 L) under nitrogen atmosphere was added sulfuric acid (10 mL) dropwise, and the suspension was stirred at room temperature. After 2 hours, the reaction became homogeneous, and soon thereafter a precipitate was formed. The reaction was allowed to stir at room temperature for 10 hours, at which time TLC indicated complete reaction. The reaction was cooled in an ice bath to 10°C and then filtered using a Buchner funnel. The filter cake was washed with ice cold methanol (750 mL) followed by hexanes (750 mL) and then dried to give 497 g (95%) of the desired product as a solid: ^{1}H NMR (300 MHz, $CDCl_3$) δ, 1.81 (s, 3H), 2.18 (s, 3H), 2.15 (s, 3H), 2.37- 2.50 (m, 4H), 3.38 (d, 2H, *J*= 7 Hz), 3.62 (s, 3H), 3.77 (s, 3H), 5.13 (s, 2H), 5.22 (m, 1H), 7.17 (s, 1H).




To a solution (3.99 g, 11.9 mmol), PPh_3 (4.68 g, 17.9 mmol), and diisopropyl azodicarboxylate (3.46 mL, 17.9 mmol) in THF (60 mL) at 0°C was added a solution of 2-trimethylsilylethanol (2.05 mL, 14.3 mmol) in THF (20 mL). The resulting yellow solution was allowed to warm to room temperature and stirred for 4 hours. The reaction was worked up by concentrating the solution to dryness and addition of ether and hexanes. Triphenylphosphine oxide was removed by filtration and the filtrate was concentrated and purified by silica gel chromatography to provide 4.8 g (100%) as a clear oil: ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.03 (s, 9H), 1.18- 1.30 (m, 2H), 1.81 (s, 3H), 2.18 (s, 3H), 2.25- 2.33 (m, 2H), 2.37- 2.45 (m, 2H), 3.42 (d, 2H, *J*= 7 Hz), 3.62 (s, 3H), 3.77 (s, 3H), 4.25- 4.35 (m, 2H), 5.13 (s, 2H), 5.12- 5.22 (m, 1H).




A solution (9.6 g, 22 mmol) in MeOH (90 mL), CH_2Cl_2 (90 mL) and pyridine (0.7 mL) was cooled to –70 °C using a dry ice/ acetone bath. A stream of ozone was bubbled through the reaction *via* a gas dispersion tube until the reaction became blue in color (1.5 hours). The ozone line was replaced with a stream of nitrogen and bubbling continued for another 30 minutes, by which time the blue color had disappeared. To this solution at –70°C was added thiourea (1.2 g, 15.4 mmol) in one portion, and the cooling bath was removed. The reaction was allowed to warm to room temperature and stirred for 15 hours. The reaction was worked up by filtration to remove solid thiourea S-dioxide, and then partitioned between CH_2Cl_2 and water. The organic layer was removed. The aqueous layer was washed with CH_2Cl_2 and the organic extracts were combined, washed with aqueous 1N HCl, saturated $NaHCO_3$ and brine, and dried *in vacuo*. The residue was purified by silica gel chromatography to afford 7.3 g (99 %) as a white solid: ^{1}H NMR (300 MHz, $CDCl_3$) δ -0.01 (s, 9H), 1.05-1.15 (m, 2H), 2.15 (s, 3H), 3.69 (s, 3H), 3.78 (d, 2H, *J*= 1 Hz), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 9.72 (d, 1H, *J*= 1 Hz).


R_1 variants




The starting material, synthesized according to *J. Med. Chem.*, **1996**, *39*, 4181-4196, is transformed to the desired aldehyde using methods analogous to those described above.



The starting material, synthesized according to *J. Med. Chem.*, **1996**, *39*, 4181-4196, is transformed to the desired aldehyde using methods analogous to those described above.



The starting material, synthesized according to *J. Med. Chem.*, **1996**, *39*, 4181-4196, is transformed to the desired aldehyde using methods analogous to those described above.



The aldehyde is dissolved in an organic solvent such as methanol and sodium borohydride is added. At the end of the reaction, aqueous HCl solution is added and the solvent is removed *in vacuo*. Further purification is achieved by chromatography.


The resulting alcohol is dissolved in an organic solvent such as dichloromethane (DCM). Pyridine and acetic anhydride are added and stirring at room temperature is continued. At the end of the reaction additional DCM is added and the solution is washed with aqueous HCl solution, aqueous sodium bicarbonate solution, and dried over sodium sulfate. Filtration and evaporation of the solvent *in vacuo* gives the crude product. Further purification is achieved by chromatography.

The acetate is dissolved in DCM and bromine is added, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction, additional DCM is added and the solution is washed with aqueous sodium thiosulfate solution and brine. The organic layer is dried over sodium sulfate. Filtration and evaporation of solvents yields the crude material. Further purification is achieved by chromatography.

The product of the previous step, lithium chloride, triphenylarsine, tributylvinyltin, and tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct are heated in an organic solvent such as *N*-methylpyrrolidinone at an elevated temperature of approximately 55°C, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction, the mixture is cooled to room temperature and poured into a mixture of ice, potassium fluoride, water, and ethyl acetate. Stirring is continued for one hour. The suspension is filtered through Celite and extracted with ethyl acetate. The combined organic

extracts are dried over sodium sulfate. The solvents are removed *in vacuo* and the crude material is further purified by chromatography.

The product of the previous step is dissolved in an organic solvent such as DCM or THF. 1,1,1-tris(acyloxy)-1,1-dihydro-1,2benziodoxol-3-(1H)-one (Dess-Martin reagent) is added and the solution is stirred at room temperature, according to a procedure from *J. Org. Chem.*, **1984**, *48*, 4155-4156. At the end of the reaction diethyl ether is added, followed by aqueous sodium hydroxide solution. The layers are separated and the organic layer is washed with aqueous sodium hydroxide solution, water, and dried over sodium sulfate. Filtration and evaporation of solvents yields the crude product. Further purification is achieved by chromatography.




The starting material is dissolved in an organic solvent such as toluene. P(*iso*butylNCH$_2$CH$_2$)$_3$N, palladium(II)acetate, sodium *tert.* butoxide, and benzylamine are added and the mixture was heated at 80°C, according to a procedure from *J. Org. Chem.*, **2003**, *68*, 452-459. At the end of the reaction, the mixture is cooled to room temperature and the solvents are removed *in vacuo*. The crude material is purified by chromatography. Any residual acetate is removed by brief treatment with methanolic sodium methoxide.

The benzyl-protected aniline is dissolved in an organic solvent such as DMF. Palladium on carbon is added and the reaction mixture is placed under an atmosphere of hydrogen. At the end of the reaction, the mixture is filtered through Celite. The solvents are removed *in vacuo*. Further purification is achieved by chromatography.

The resulting primary aniline is dissolved in an organic solvent such as THF, acetonitrile, or DMF and is treated with formaldehyde and sodium triacetoxyborohydride as described in *J. Org. Chem*, **1996**, 61, 3849-3862. The reaction is quenched with aqueous sodium bicarbonate and the product is extracted with an organic solvent such as ethyl acetate. The crude material is

treated with di-*t*-butyl dicarbonate in an organic solvent such as dimethylformamide and aqueous sodium hydroxide. The resulting carbamate is purified by chromatography.


The primary alcohol product is dissolved in an organic solvent such as DCM or THF. 1,1,1-tris(acyloxy)-1,1-dihydro-1,2benziodoxol-3-(1H)-one (Dess-Martin reagent) is added and the solution is stirred at room temperature, according to a procedure from *J. Org. Chem.*, **1984**, *48*, 4155-4156. At the end of the reaction diethyl ether is added, followed by aqueous sodium hydroxide solution. The layers are separated and the organic layer is washed with aqueous sodium hydroxide solution, water, and dried over sodium sulfate. Filtration and evaporation of solvents yields the crude product. Further purification is achieved by chromatography.



The starting material is dissolved in an organic solvent such as DCM or THF and is treated with the mixed anhydride of formic and pivalic acids, according to a procedure from *Recl. Trav. Chem. Pay-Bas,* **1982**, *101*, 460. At the end of the reaction, the solvent and all volatiles are removed *in vacuo* and the crude product is further purified by chromatography.


The product is dissolved in an organic solvent such as DCM or THF. 1,1,1-Tris(acyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one (Dess-Martin reagent) is added and the solution was stirred at room temperature, according to a procedure from *J. Org. Chem.*, **1984**, *48*, 4155-4156. At the end of the reaction diethyl ether is added, followed by aqueous sodium hydroxide solution. The layers are separated and the organic layer is washed with aqueous sodium hydroxide solution, water, and dried over sodium sulfate. Filtration and evaporation of solvents yields the crude product. Further purification is achieved by chromatography.

$\underline{R_2 \text{ variants}}$



The starting material is dissolved in an organic solvent such as DMF and reacted with *N*-chlorosuccinimide, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. After the starting material is consumed the reaction mixture is poured into water and the product is extracted with diethyl ether. The combined organic layers are dried over sodium sulfate. Filtration and evaporation of the solvent yields a crude reaction product.

The product of step one is dissolved in a mixture of organic solvents such as methanol, DCM, and pyridine. The solution is cooled to –78°C and ozone is bubbled into the solution until a blue color persists. The excess ozone is removed with a nitrogen stream. The reaction mixture is warmed to room temperature and thiourea is added. Stirring at room temperature is continued. The reaction mixture is filtered and partitioned between DCM and water. The aqueous layer is extracted with DCM and the combined organic layers are washed with HCl (1 N), saturated aqueous sodium bicarbonate solution and brine. The solution is dried over sodium sulfate. Filtration and evaporation of the solvents yields the crude aldehyde. Further purification is achieved by chromatography.




The starting material is dissolved in a mixture of organic solvents such as methanol, DCM, and pyridine. The solution is cooled to –78°C and ozone is bubbled into the solution until a blue color persists. The excess ozone is removed with a nitrogen stream. The reaction mixture is warmed to room temperature and thiourea is added. Stirring at room temperature is continued. The reaction mixture is filtered and partitioned between DCM and water. The aqueous layer is extracted with DCM and the combined organic layers are


washed with HCl (1 N), saturated aqueous sodium bicarbonate solution, and brine. The solution is dried over sodium sulfate. Filtration and evaporation of the solvents yields the crude aldehyde. Further purification is achieved by chromatography.

The product of step one is dissolved in an organic solvent such as benzene. Trifluoromethanesulfonyl chloride and dichlorotris(triphenylphosphine)rhuthenium are added and the solution is degassed. The reaction mixture is heated at 120 °C, according to a procedure from *J. Chem. Soc., Perkin Trans. 1*, **1994**, 1339-1346. At the end of the reaction the mixture is cooled to room temperature and the solvent is removed *in vacuo*. Further product purification is achieved by chromatography.

Synthesis of olefins and linkers to phosphonates




The phenacetaldehyde (5.3 g, 15.8 mmol) in toluene (50 mL) was heated at 100°C with 2-(triphenyl-phosphanylidene)-propionaldehyde (6.8 g, 20.5 mmol) overnight. After concentration, the residue was purified by silica gel chromatography to provide 4.24 g (72%) of the unsaturated aldehyde as a pale yellow solid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.10- 1.21 (m, 2H), 1.87 (s, 3H), 2.16 (s, 3H), 3.67- 3.76 (m, 2H), 3.74 (s, 3H), 4.27- 4.39 (m, 2H), 5.11 (s, 2H), 6.40- 6.48 (m, 1H), 9.2 (s, 1H).




The trimethylsilyethyl protected aldehyde is treated with diethylphosphite in a solvent such as acetonitrile in the presence of a base such as triethylamine to afford the hydroxy phosphonate, according to a procedure such as that reported in *Tetrahedron,* **1995**, *51*, 2099. The hydroxy phosphonate is *O*-akylated and then the protecting group is removed by treatment with either trifluoroacetic acid or tetrabutylammonium fluoride to generate the desired methoxy phosphonate analog.

Alternatively, the aldehyde is mixed with diethyl (2-aminoethyl)phosphonate and treated with a reducing agent such as sodium triacetoxyborohydride to generate the amino phosphonate analog.




A solution of 4-[6-methoxy-7-methyl-3-oxo-4-(2-trimethylsilanyl-ethoxy)-1,3-dihydro-isobenzofuran-5-yl]-2-methyl-but-2-enal (103 mg, 0.27 mmol) in methanol (5 mL) was cooled to 0°C. A solution of $CeCl_3$ (0.68 mL, MeOH: H_2O, 9:1) was added, followed by $LiBH_4$ (0.14 mL, 0.28 mmol of a 2M solution in THF). The ice bath was removed and the reaction mixture was allowed to warm to room temperature. The reaction mixture was stirred for an additional 40 minutes whereupon TLC indicated complete consumption of starting aldehyde. The reaction was worked up by addition of aqueous 1N HCl (0.5 mL) and the product was extracted with CH_2Cl_2. The organic layer was

washed with saturated aqueous sodium bicarbonate solution and brine. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to provide 100 mg (97%) of the product as a clear liquid. ^{1}H NMR (300 MHz, $CDCl_3$) δ 0.00 (s, 9H), 1.20 (dd, 2H, *J*= 7, 8 Hz), 1.81 (s, 3H), 2.13 (s, 3H), 3.38- 3.50 (m, 2H), 3.74 (s, 3H), 3.95 (s, 2H), 4.27 (dd, 2H, *J*= 7, 8 Hz), 5.08 (s, 2H), 5.17- 5.44 (m, 1H).




Polymer-supported triphenylphosphine is soaked in DCM for 1 hour. The allylic alcohol and carbon tetrabromide are sequentially added. When the reaction is complete, the mixture is filtered and the filtrate concentrated. The bromide is purified as necessary by chromatography.




The allylic bromide is treated in an inert organic solvent such as dimethylformamide with an alkali metal salt of ethyl diethoxyphosphorylacetate (prepared by reacting ethyl diethoxyphosphorylacetate with sodium hexamethyldisilazide or sodium hydride) to afford the ethoxycarbonyl phosphonate, according to a procedure such as that described in WO 9522538. The carboxylic ester group is converted to both the carboxylic amide and the hydroxymethyl groups according to the methods conventionally utilized for amide formations and ester reductions. For example, the carboxylic ester is saponified with aqueous lithium hydroxide. The acid is activated with ethyl

chloroformate and reduced with sodium borohydride to generate, after removal of the protecting group, the hydroxymethyl phosphonate analog. The acid is also converted to its acyl chloride and then reacted with ethylamine to afford the amide analog.




The aryl acetaldehyde is coupled with 2-(diethoxyphosphoryl)-but-3-enoic acid ethyl ester to generate the 2-vinyl substituted ester, according to a procedure such as that reported in *Synthesis*, **1999**, 282. The 2-vinyl group is converted to the 2-cyclopropyl group under cyclopropanation conditions such as those described in *Tetrahedron Lett.* **1998**, *39*, 8621. The ester is converted to the alcohol, which, optionally, can be further subjected to reactions such as that described below to generate various phosphonate-containing mycophenolic acid analogues.




The allylic alcohol is treated with bromomethylphosphonic acid diisopropyl ester in the presence of a base such as lithium *t*-butoxide in a solvent


such as dimethylformamide. The phenol protecting group is then removed by treatment with trifluoroacetic acid.



The phenacetaldehyde can alternatively be converted to the allyl phosphonium salt, according to a procedure such as that reported in *J. Org. Chem.* **1987**, *52*, 849. The phosphonium salt is then treated with the commercially available 3,3,3-trifluoro-2-oxo-propionic acid ethyl ester and a base such as sodium hydride to generate the 2-trifluoromethyl substituted ester. The ester is converted to the alcohol, which, optionally, can be further subjected to reactions described earlier to generate mycophenolic acid analogues with various side chains containing the phosphonate group.



Introduction of R_4 variants



The enone (synthesis reviewed in *Tetrahedron*, **1985**, *41*, 4881-4889) and the diene (*Chem. Pharm. Bull.*, **1989**, *37*, 2948-2951) are dissolved in an organic solvent such as toluene, stirred at room temperature for 24 hours and heated to reflux for additional 5 hours, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. The reaction mixture is cooled to room temperature and the solvent removed *in vacuo*. The crude reaction product is further purified by chromatography.


The product of step one is dissolved in an organic solvent such as DCM and *m*-chloroperbenzoic acid is added, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction, the solution is poured into aqueous sodium hydrogen sulfite solution. The organic layer is washed with saturated aqueous sodium bicarbonate solution and is dried over sodium sulfate. Filtration and evaporation of solvents yields the crude product.

The crude product is dissolved in an organic solvent such as toluene and treated with dichlorodicyanoquinone (DDQ), according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction the solvent is removed *in vacuo* and the crude material is further purified by chromatography.


The product is dissolved in an organic solvent such as DCM and treated with boron trichloride at reflux temperature, according to a modified procedure from *J. Med. Chem.*, **1996**, *39*, 46-55. At the end of the reaction the solution is washed with aqueous HCl solution. The solution is dried over sodium sulfate. Removal of the solvent yields the crude reaction product. Further purification is achieved by chromatography.

The product of the previous step and triphenylphosphine are dissolved in an organic solvent such as tetrahydrofuran (THF). Di*iso*propylazodicarboxylate (DIAD) is added dropwise at 0°C. Stirring is continued. A solution of 2-trimethylsilyl ethanol in THF is added and stirring is continued. At the end of the reaction, the solvent is removed *in vacuo*. The crude reaction solid is extracted with a mixture of organic solvents such as hexanes and diethylether.

The washings are combined and the solvents removed *in vacuo*. The desired product is further purified and separated from the undesired regioisomer by chromatography.




The starting material is dissolved in an organic solvent such as dimethylformamide (DMF) and reacted with *N*-chlorosuccinimide, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. After the starting material is consumed the reaction mixture is poured into water and the product is extracted with diethyl ether. The combined organic layers are dried over sodium sulfate. Filtration and evaporation of the solvents yields the crude product. Further purification is achieved by chromatography.



The starting material is dissolved in an organic solvent such as benzene and reacted with dimethyl sulfoxide (DMSO), dicyclohexylcarbodiimide (DCC), and orthophosphoric acid according to a procedure from *J. Am. Chem. Soc.*, **1966**, *88*, 5855-5866. At the end of the reaction, the suspension is filtered and the organic layer washed with aqueous sodium bicarbonate solution and dried over sodium sulfate. Filtration and evaporation of solvents yields the crude material. Further purification is achieved by chromatography.

The product of step one is dissolved in an organic solvent such as DCM or THF and treated with Raney nickel, according to procedures reviewed in *Chem. Rev.*, **1962**, *62*, 347-404. When all starting material is consumed, the


reaction is filtered and the solvent removed *in vacuo*. Further purification is achieved by chromatography.



The starting material is dissolved in an organic solvent such as DCM and bromine is added, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction, additional DCM is added and the solution washed with aqueous sodium thiosulfate solution and brine. The organic layer is dried over sodium sulfate. Filtration and evaporation of solvents yields the crude material. Further purification is achieved by chromatography on silica gel.

The starting material, lithium chloride, triphenylarsine, tributylvinyltin, and tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct are heated in an organic solvent such as *N*-methylpyrrolidinone at an elevated temperature of approximately 55°C, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. At the end of the reaction, the mixture is cooled to room temperature and poured into a mixture of ice, potassium fluoride, water, and ethyl acetate. Stirring is continued for 1 hour. The suspension is filtered through Celite and extracted with ethyl acetate. The combined organic extracts are dried over sodium sulfate. The solvents are removed *in vacuo* and the crude material is further purified by chromatography.

The product of step two is dissolved in a mixture of organic solvents such as benzene and ethyl acetate. Tris(triphenylphosphine)rhodium(I) chloride is added and the reaction is placed under an atmosphere of hydrogen, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. The solvents are removed *in vacuo* and the crude reaction is filtered through silica gel. Further purification is achieved by chromatography.




The starting material is dissolved in an organic solvent such as DMF. Potassium carbonate and allyl bromide are added and stirring at room temperature is continued, according to a procedure from *J. Med. Chem.*, **1996**, *39*, 4181-4196. After all the starting material is consumed, aqueous HCl solution and diethyl ether are added and the organic layer is collected and the solvent is removed *in vacuo*.

The crude material is dissolved in *N,N* diethylaniline and the reaction mixture is heated at an elevated temperature of *ca.* 180°C. At the end of the reaction, the mixture is cooled to room temperature and poured into a mixture of aqueous HCl (2N) and ethyl actetate. The organic layer is washed with aqueous HCl (2N) and dried over sodium sulfate. Filtration and removal of the solvents yields the crude product. Further purification is achieved by chromatography.

The product of step 2 is dissolved in a mixture of organic solvents such as methanol, DCM, and pyridine. The solution is cooled to –78°C and ozone is bubbled into the solution until a blue color persists. The excess ozone is removed with a nitrogen stream. The reaction mixture is warmed to room temperature and thiourea is added. Stirring at room temperature is continued. The reaction mixture is filtered and partitioned between DCM and water. The aqueous layer is extracted with DCM and the combined organic layers are washed with HCl (1 N), saturated aqueous sodium bicarbonate solution and brine. The solution is dried over sodium sulfate. Filtration and evaporation of the solvents yields the crude aldehyde. Further purification is achieved by chromatography.

The aldehyde is dissolved in an organic solvent such as THF and is reacted with triphenylphosphonium *sec.*propyl bromide and potassium *tert.*butoxide, according to procedures reviewed in *Chem. Rev.*, **1989**, *89*, 863-927. At the end of the reaction, the solvent is removed *in vacuo* and the crude material purified by chromatography.


Introduction of linkers to phosphonates



The phenols shown herein may optionally be alkylated with the reagent of choice. Optionally, the phosphonate moiety will be part of such a reagent. Alternatively, it will be introduced in a subsequent step by a variety of means, of which three are illustrated above. For example, an alkyl halide may be heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., "Synthesis of Carbon-phosphorus Bonds," CRC press, 1988). Alternatively, an epoxide may be reacted with the anion of a dialkyl phosphinate. In a further example, the phosphonate reagent may be the electrophile, *e.g.*, an acetylide anion may be condensed with phosphorus oxychloride and the intermediate dichlorophosphonate quenched with ethanol to generate the diethyl ester of the desired phosphonic acid.

Example 316: Preparation of an Additional Representative Mycophenolate Compound of the Invention.

A specific compound of the invention can be prepared as follows.




[4-(6-Ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phosphonic acid

This product was prepared using methods similar to those described herein, *e.g.*, in Examples 251 and 276. MS (negative mode): 369.3 [M^+ - 1].

Example 317: Preparation of an Additional Representative Mycophenolate Compound of the Invention.

A specific compound of the invention can be prepared as follows.




2-{[4-(6-Ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enyloxymethyl]-phenoxy-phosphinoylamino}-propionic acid ethyl ester

Using methods similar to those described herein, *e.g.*, in Example 261, the desired product was prepared, starting from Example 316. MS (positive mode): 546.3 [M^+ + 1] & 568.3 [M^+ + Na].

Example 318: Preparation of an Additional Representative Mycophenolate Compound of the Invention.

A specific compound of the invention can be prepared as follows:




2-({2-[4-(6-Ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phenoxy-phosphinoylamino)-propionic acid ethyl ester

This product was prepared using methods analogous to those described herein, *e.g.*, in Examples 268 and 316, using 2-[(2-amino-ethyl)-phenoxy-phosphinoylamino]-propionic acid ethyl ester in the reductive amination step. MS (positive mode): 559.4 [M^+ + 1] & 581.3 [M^+ + Na].

Example 319: Preparation of an Additional Representative Mycophenolate Compound of the Invention.


A specific compound of the invention can be prepared as follows:



2-((1-Ethoxycarbonyl-ethylamino)-{2-[4-(6-ethyl-4-hydroxy-7-methyl-3-oxo-1,3-dihydro-isobenzofuran-5-yl)-2-methyl-but-2-enylamino]-ethyl}-phosphinoylamino)-propionic acid ethyl ester

This product was prepared by methods analogous to those described herein, *e.g.*, in Example 318, using 2-[(2-aminoethyl)-(1-ethoxycarbonyl-ethylamino)-phosphinoylamino]-propionic acid ethyl ester in the reductive amination step. MS (positive mode): 582.4 [M^+ + 1] & 604.3 [M^+ + Na].

Example 330 Synthesis of Exemplary Compounds of the Invention



330.1 330.2 330.3 330.4

A representative compound of the invention **330.4** can be prepared as illustrated above and as described below.

Compound **330.3** (250 mg, 0.65 mmol) was dissolved in 10 mL of absolute ethanol (15 mL) under an argon atmosphere. Following the addition of NaOH (29 mg, 0.72 mmol), the reaction mixture was stirred overnight at room temperature. TLC ($CHCl_3$/MeOH, 9 : 1) showed completion of reaction. The reaction mixture was concentrated to a solid and dissolved in ethyl acetate (20 mL). The solution was washed with deionized water (2x10 mL) and dried over Na_2SO_4. Concentration gave a solid that was purified by silica gel column chromatography ($CHCl_3$/MeOH, 4 : 1), affording pure compound **330.4** as a solid (188 mg, 75%). ESI-MS *m/z* 383 $[M+H]^+$. ^1H NMR (300 MHz, DMSO-d_6): δ 7.32 (1H, s, ArH), 6.96 (2H, s, ArH), 4.31 (2H, d, J = 9.9 Hz, OCH_2), 4.18-4.08 (4H, m, 2xOCH_2), 2.08 (3H, s, CH_3), 2.00 (3H, s, CH_3), 1.26 (6H, t, J = 7.0 Hz, CH_3). ^{31}P NMR (121.7MHz, DMSO-d_6/ external H_3PO_4) δ ppm 20.0-20.4 (m); HPLC: 93% pure (Sphereclone 5 μL, H_2O : MeCN, 20 min linear from 10-90% MeCN, 1.0 mL/min).

The intermediate compound **330.3** was prepared as follows.


a. Synthesis of Compound 330.1. 2-Methyl-5-nitrophenol (2.00 g, 13.05 mmol) was dissolved in dry DMF (10 mL) under argon atmosphere and cooled to 0 °C. Diethylphosponomethyl-*O*-triflate (4.70 gm, 15.66 mmol) and cesium carbonate (6.38 gm, 19.58 mmol) were added sequentially. The reaction mixture was stirred at 0 °C for 4 hrs. TLC (cyclohexane/EtOAc, 1:1) showed completion of reaction. Deionized water (15 mL) was added and the mixture was extracted

with EtOAC (2x50 mL). The organic layer was washed with 1N HCl (20 mL) followed by water (2x20 mL), dried over Na_2SO_4 and concentrated to a semi-solid. Purification by silica gel column chromatography (cyclohexane/EtOAc, 1 : 1) afforded pure compound **330.1** as an oil (3.86 g, 97%).
ESI-MS *m/z* 304 $[M+H]^+$.

b. Synthesis of Compound 330.2. Compound **330.1** (2.8 g, 9.24 mmol) was dissolved in 15 mL of absolute ethanol (15 mL) and 6N HCl (2 mL) under an argon atmosphere. Following the addition of $SnCl_2 \cdot 2H_2O$ (5.26 g, 27.72 mmol), the reaction mixture was stirred overnight at room temperature. TLC ($CHCl_3$ /MeOH, 9 : 1) showed completion of reaction. The mixture was concentrated to a semi-solid and dissolved in ethyl acetate (30 mL). The ethyl acetate layer was washed with deionized water (10 mL) and satd. $NaHCO_3$ (10 mL) and dried over Na_2SO_4. Concentration gave a solid that was used without purification. ESI-MS *m/z* 274 $[M+H]^+$.


c. Synthesis of Compound 330.3. Crude compound K-105-48 (900 mg, 3.38 mmol) was dissolved in 15 mL of dry THF (15 mL) under an argon atmosphere. Following the addition of 5-methylisoxazole-4-carboxylic acid (381 mg, 3.00 mmol) and diisopropyl carbodiimide (511 µL, 3.30 mmol), the reaction mixture was stirred 6 h at room temperature. TLC ($CHCl_3$ /MeOH, 9 : 1) showed completion of reaction. The reaction mixture was filtered and the filtrate concentrated to give a solid, which was dissolved in ethyl acetate (25 mL). The solution was washed with deionized water (2x10 mL) and dried over Na_2SO_4. Concentration gave a solid that was purified by silica gel column chromatography ($CHCl_3$/MeOH, 95 : 5) to afford pure compound **330.3** as light yellow solid (680 mg, 55%). ESI-MS *m/z* 383 $[M+H]^+$. ^1H NMR (300 MHz, $CDCl_3$): δ 7.11 (1H, s, ArH), 7.06 (2H, s, ArH), 4.29-4.20 (4H, m, OCH_2), 4.14 (2H, d, J = 10.4 Hz, OCH_2), 2.76 (3H, s, CH_3), 2.14 (3H, s, CH_3), 1.37 (6H, t, J = 7.0 Hz, CH_3). ^{31}P NMR (121.7MHz, DMSO-d_6/ external H_3PO_4) δ ppm 19.7-20.0 (m); HPLC: 98 % pure (Sphereclone 5 µL, H_2O : MeCN, 20 min linear from 10-90% MeCN, 1.0 mL/min).

Example 331 Synthesis of Representative Prednisone Compounds of the Invention



331.1 331.2


Representative compounds of the invention can be prepared as illustrated above. Derivatization at the C-21 hydroxy group is accomplished through alkylation of prednisone **331.1** with the appropriate phosphonate to provide compounds of the invention **331.2**. A specific compound of the invention can be prepared as follows.




331.1 331.4

After sodium hydride extraction of the primary hydroxy proton in **331.1**, diethyl phosphonate triflate is added to afford ether **331.4**.

Example 332 Synthesis of Representative Prednisone Compounds of the Invention



Representative compounds of the invention **332.3** can be prepared as illustrated above. Protection of prednisone **332.1** at the less hindered primary site furnishes alcohol **332.5**, which is alkylated at the exposed hydroxy group with the appropriate phosphonate to provide **332.6**. Removal of the protecting group completes the construction of analog **332.3**. A specific compound can be prepared as follows.



Prednisone **332.1** is mono-protected as its TBS ether **332.7**. After alkylating with the diethyl phosphonate triflate, the resulting intermediate **332.8** is treated with TBAF to give the desired phosphonate **332.9**.

Example 500 Synthesis of Exemplary Compounds of the Invention

Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-methyl)-phosphonic acid diethyl ester.


To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (67.0 mg, 177 μmol) in DMF (3.0 mL) was added diethyl cyanophosphonate (34.8 μL, 230 μmol) and diisopropylethylamine (Hunig's Base, DIEA, 30.4 μL, 177 μmol). The solution was stirred at ambient temperature for 4 hours when diethyl(aminomethyl)phosphonate oxalate (45.4 mg, 177 μmol) was added. The solution was stirred for 4 additional hours, when complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount of the product (20 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 12.9 mg (76%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.19 (t, 6H, J= 7.2 Hz), 3.21 (s, 3H), 3.70 (m, 2H), 4.00 (q, 4H, J= 7.2 Hz), 4.81 (s, 2H), 6.81 (d, 2H, J= 9 Hz), 7.71 (d, 2H, J= 9 Hz), 8.40 (br s, 1H), 8.61 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 23.4. MS (*m/z*) 475.2 $[M+H]^+$, 597.2 $[M+Na]^+$.

Example 501 Synthesis of Exemplary Compounds of the Invention

Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-methyl)-phosphonic acid

To a solution of crude (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester post silica column chromatography (60 mg, 126 μmol) in dry DMF (0.90 mL) was added trimethylsilyl bromide (bromotrimethylsilane, TMSBr, 130.6 μL, 1,010 μmol) at ambient temperature. The solution was then heated at 70 °C for 4.0 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent volume was reduced to ~ 700 μL *in vacuo* and diluted with H_2O (100 μL). This solution was purified by RP HPLC on C_{18} column using

H_2O/acetonitrile (2-95%) to provide 26.8 mg (51%) of the desired compound as a yellow solid. ^1H NMR (300 MHz, DMSO-d_6) δ 3.18 (s, 3H), 3.50 (m, 2H), 4.77 (s, 2H), 6.79 (d, 2H, J= 9 Hz), 7.79 (d, 2H, J= 9 Hz), 8.07 (br s, 1H), 8.56 (s, 1H); MS (*m/z*) 419.2 $[M+H]^+$.



Example 502 Synthesis of Exemplary Compounds of the Invention


Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester

To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (61.2 mg, 161 μmol) in DMF (2.8 mL) were added diethyl cyanophosphonate (31.8 μL, 210 μmol) and DIEA (27.8 μL, 161 μmol). The solution was stirred at ambient temperature for 4 hours, when diethyl(aminoethyl)phosphonate oxalate (43.8 mg, 161 μmol) was added. The solution was stirred for 3 additional hours, by which time complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount of the product (32 mg) was re-purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 19 mg (70%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.21 (t, 6H, J= 7 Hz), 1.95-2.05 (m, 2H), 3.20 (s, 3H), 3.13- 3.22 (m, 2H), 3.98 (appt septet, 4H, J= 7 Hz), 4.79 (s, 2H), 6.80 (d, 2H, J= 9 Hz), 7.65 (d, 2H, J= 9 Hz), 8.20 (br s, 1H), 8.60 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 28.9. MS (*m/z*) 489.2 $[M+H]^+$, 511.2 $[M+Na]^+$.

Example 503 Synthesis of Exemplary Compounds of the Invention

Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid

To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-ethyl)-phosphonic acid diethyl ester post silica column chromatography (61 mg, 125 μmol) in dry DMF (1.00 mL) was added TMSBr (129.0 μL, 999.2 μmol) at ambient temperature. The solution was then heated at 70 °C for 5.5 hours, when LCMS analysis demonstrated the reaction to be 90% complete. The reaction mixture was allowed to cool to room temperature and stirred for an additional 12 hours. The reaction was worked up by removal of the solvent *in vacuo* and dissolving the residue in DMF / H_2O (800 μL, 1:1) and 1N aqueous NaOH (15 μL). The product was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 29 mg (53%) of the desired compound as a yellow solid. ^1H NMR (300 MHz, DMSO-d_6) δ 1.67- 1.85 (m, 2H), 3.19 (s, 3H), 3.25- 3.40 (m, 2H), 4.76 (s, 2H), 6.71 (br s, 2H), 5.80 (d, 2H, J= 9 Hz), 7.64 (d, 2H, J= 9 Hz), 7.73 (br s, 2H), 8.15 (br s, 1H), 8.56 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 23.0. MS (m/z) 431.3 $[M-H]^-$.



Example 504 Synthesis of Exemplary Compounds of the Invention

Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid diethyl ester


To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (61.2 mg, 161 μmol) in DMF (2.8 mL) were added diethyl cyanophosphonate (31.8 μL, 210 μmol) and DIEA (27.8 μL, 161 μmol). The solution was stirred at ambient temperature for 3 hours, when diethyl(aminopropyl)phosphonate oxalate (34.9 mg, 122.6 μmol) was

added. The solution was stirred for 2 additional hours, whereupon complete consumption of the starting materials was observed. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product (65.5 mg) collected from this chromatography step was sufficiently pure to be carried on to the next reaction. A small amount (32.8 mg) was re-purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 23.2 mg (75%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.20 (t, 6H, J= 7.2 Hz), 1.64-1.75 (m, 4H), 3.22 (s, 3H), 3.41 (m, 2H), 3.98 (appt septet, 4H, J= 7.2 Hz), 4.85 (s, 2H), 6.79 (d, 2H, J= 9 Hz), 7.68 (d, 2H, J= 9 Hz), 8.17 (br s, 1H), 8.70 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 31.9; MS (*m/z*) 503.2 $[M+H]^+$.

Example 505 Synthesis of Exemplary Compounds of the Invention

Preparation of (2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid

To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-propyl)-phosphonic acid diethyl ester post silica column chromatography (32.2 mg, 66.2 μmol) in dry DMF (0.50 mL) was added TMSBr (68.0 μL, 529.6 μmol) at ambient temperature. The solution was then heated at 70 °C for 1.0 hour, when LCMS analysis demonstrated the reaction to be complete. The reaction mixture was allowed to cool to room temperature, and water (60 μL) and methanol (60 μL) were added. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 11.2 mg (38%) of the desired compound as a yellow solid. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.50 (m, 2H), 1.61 (m, 2H), 3.22 (s, 3H), 3.25- 3.40 (m, 2H), 4.84 (s, 2H), 6.80 (d, 2H, J= 9 Hz), 7.69 (d, 2H, J= 9 Hz), 8.20 (br s, 1H), 8.69 (s, 1H). ^{31}P (121.4 MHz, DMSO-d_6) δ 26.3. MS (*m/z*) 447.3 $[M-H]^-$.




Example 506 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}ethyl)-phenoxyphosphinoyloxy]propionic acid ethyl ester [diastereomeric mixture at phosphorus]

To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (60.0 mg, 158.3 μmol) in DMF (2.5 mL) were added diethyl cyanophosphonate (31.2 μL, 205.7 μmol) and DIEA (81.8 μL, 474.9 μmol). The solution was stirred at ambient temperature for 3.5 hours, when a solution of (*S*)-2-[(2-aminoethyl)phenoxyphosphinoyloxy]propionic acid ethyl ester mono acetic acid salt (57.1 mg, 158.3 μmol; mixture of diastereomers at phosphorus) in DMF (200 μL) was added. The solution was stirred for 1.5 additional hours, whereupon complete consumption of the starting materials was observed. The solvent was removed *in vacuo* and the crude material was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). A small amount of the product (24.8 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 15.8 mg (65%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.17 – 1.27 (m, 3H), 1.32 (d, 2H, J = 7.5 Hz), 1.42 (d, 1H, J = 7.5 Hz) 2.27 (m, 2H), 3.19 (s, 3H), 3.53 (m, 2H), 4.08 – 4.14 (m, 2H), 4.77 (s, 2H), 4.98 (m, 1H), 6.72 (br s, 1H), 6.81 (d, 2H, *J*= 9 Hz), 7.21 (m, 3H), 7.36 (m, 2H),


7.66 (d, 2H, *J*= 9 Hz), 8.26 (br s, 1H), 8.56 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.6, 27.4. MS (*m/z*) 609.2 $[M+H]^+$.



Example 507 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}ethyl)-phenoxyphosphinoyloxy]propionic acid [diastereomeric mixture at phosphorus]


To a solution of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}ethyl)phenoxy-phosphinoyloxy]propionic acid ethyl ester (mixture of diastereomers at phosphorus; 40.0 mg, 65.7 μmol) in DMF (0.4 mL), acetonitrile (0.2 mL) and water (0.2 mL) was added aqueous sodium hydroxide (1 N, 131.4 μL). The solution was stirred at ambient temperature for 4 hours. The solvents were removed *in vacuo* and the crude product was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 23.7 mg (71.3%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.30 (d, 2H, J = 6.9 Hz), 1.79 (m, 2H), 3.21 (s, 3H), 3.37 (m, 2H), 4.61 (m, 1H), 4.81 (s, 2H), 6.79 (d, 2H, *J*= 8.7 Hz), 7.64 (d, 2H, *J*= 9.7 Hz), 8.25 (br s, 1H), 8.63 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 25.1. MS (*m/z*) 505.2 $[M+H]^+$.



Example 508 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}ethyl)-phenoxyphosphinoyloxy]propionic acid ethyl ester [diastereomerically pure at phosphorus]

To a solution of 4-[(2,4-diaminopteridin-6-ylmethyl)-methyl-amino]benzoic acid hemihydrochloride dihydrate (101.9 mg, 268.9 μmol) in DMF (3.3 mL) were added diethyl cyanophosphonate (53.0 μL, 349.5 μmol) and DIEA (138.0 μL, 806.7 μmol). The solution was stirred at ambient temperature for 2.5 hours, whereupon (*S*)-2-[(2-aminoethyl)phenoxyphosphinoyloxy]propionic acid ethyl ester mono acetic acid salt (diastereomerically pure at phosphorus; 268.9 μmol) in DMF (500 μL) was added. The solution was stirred for 30 additional minutes, whereupon complete consumption of the starting materials was observed. The solvent was removed *in vacuo* and the crude material was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). A small amount of the product (40.0 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 28.7 mg (75.1%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.15 (t, 3H, J = 7.2 Hz), 1.44 (d, 3H, J = 6.9 Hz), 2.26 (m, 2H), 3.23 (s, 3H), 3.51 (m, 2H), 4.09 (q, 2H, J = 7.2 Hz), 4.86 (s, 2H), 5.01 (m, 1H), 6.81 (d, 2H, *J*= 9.3 Hz), 7.21 (m, 3H), 7.35 (m, 2H), 7.68 (d, 2H, *J*= 9.3 Hz), 8.29 (br s, 1H), 8.71 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.6. MS (*m/z*) 609.2 $[M+H]^+$.




Example 509 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-[(2-{4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoylamino}ethyl)-phenoxyphosphinoylamino]propionic acid ethyl ester (mixture of diastereomers at phosphorus)

To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (39.6 mg, 104.0 μmol) in DMF (1.2 mL) were added diethyl cyanophosphonate (20.6 μL, 136.1 μmol) and DIEA (36.0 μL, 209.4 μmol). The solution was stirred at ambient temperature for 3 hours, when (*S*)-2-[(2-aminoethyl)phenoxyphosphinoylamino]propionic acid ethyl ester mono acetic acid salt (mixture of diastereomers at phosphorus; 104.0 μmol) in DMF (200 μL) was added. The solution was stirred for 30 minutes when complete consumption of the starting materials was observed. An aliquot (66%) of the reaction was purified by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%), yielding 27.2 mg of crude product. A small amount of the product (10 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 4.2 mg (26%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.11 (t, 3H, *J*= 6.9 Hz), 1.18 (d, 3H, *J*= 7.2 Hz), 2.06-2.17 (m, 2H), 3.20 (s, 3H), 3.51 (m, 2H), 3.88 (m, 1H), 4.02 (m, 2H), 4.79 (s,

2H), 5.61 (m, 1H), 6.80 (d, 2H, *J*= 9 Hz), 6.98 (br s, 1H), 7.18 (m, 3H), 7.32 (m, 2H), 7.67 (d, 2H, *J*= 9 Hz), 8.20 (br s, 1H), 8.59 (s, 1H) ^{31}P (121.4 MHz, DMSO-d_6) δ 29.5, 30.1. MS (*m/z*) 608.2 $[M+H]^+$.



Example 510 Synthesis of Exemplary Compounds of the Invention


Preparation of 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6-(diethoxy-phosphoryl)-hexanoic acid

To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (63.0 mg, 166.2 μmol) in DMF (2.8 mL) were added diethyl cyano phosphonate (30.8 μL, 199.4 μmol) and DIEA (85.8 μL, 498.6 μmol). The solution was stirred at ambient temperature for 3.5 hours when (L)-2-amino-6-diethylphosphonatohexanoic acid (44.3 mg, 166.2 μmol) was added. The solution was stirred for 48 additional hours. The reaction was worked up by removal of the solvent *in vacuo* and purifying the residue by silica gel chromatography using MeOH-CH_2Cl_2 (10-30%). The product (87 mg) collected from this chromatography step was sufficiently pure to be carried on to the next reaction. An aliquot of the product (51.0 mg) was repurified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 24.7 mg (44%) of the pure product. ^1H NMR (300 MHz, DMSO-d_6) δ 1.18 (t, 6H, *J*= 6.9 Hz), 1.42 (m, 4H), 1.65 (m, 4H), 3.20 (s, 3H), 3.92 (m, 4H), 4.29 (m, 1H), 4.78 (s, 2H), 6.72 (br s, 1H), 6.81 (d, 2H, *J*= 9 Hz), 7.73 (d, 2H, *J*= 9 Hz), 8.14 (d, 1H, *J* = 7.8 Hz), 8.56 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 31.8; MS (*m/z*) 574.3 $[M]^+$.

Example 511 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-{4-[(2,4-Diaminopteridin-6-ylmethyl)methylamino]benzoylamino}-6-(phosphoryl)hexanoic acid


To a solution of crude (2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino})-2' (*L*)-(6'-(phosphonic acid diethyl ester) hexanoic acid) post silica column chromatography (20 mg, 34.6 μmol) in dry DMF (0.60 mL) was added TMSBr (18.0 μL, 139.2 μmol) at ambient temperature. The solution was then heated at 70 °C for 18 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent was removed *in vacuo* and dissolved in DMF (400 μL) and water (60 μL). This solution was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (2-95%) to provide 8.9 mg (49%) of the product as a yellow solid. ^1H NMR (300 MHz, DMSO-d_6) δ 1.45 (m, 6H), 1.75 (m, 2H), 3.20 (s, 3H), 4.25 (m, 1H), 4.77 (s, 2H), 6.62 (br s, 1H), 6.80 (d, 2H, *J*= 8.7 Hz), 7.73 (d, 2H, *J*= 8.7 Hz), 8.14 (br s, 1H), 8.55 (s, 1H); MS (*m/z*) 519.2 $[M+H]^+$.



Example 512 Synthesis of Exemplary Compounds of the Invention

Preparation of (*L*)-2- Cbz-Amino-hexanoic acid –6-phosphonic acid

To a suspension of (*L*)-2-amino-6-(diethoxyphosphonyl)hexanoic acid (106 mg, 396.8 μmol) in dry DMF (2.00 mL) was added TMSBr (307.0 μL, 2,381.0 μmol) at ambient temperature. The solution was then heated at 70 °C for 2 hours, after which the reaction mixture was allowed to cool to room temperature. The solvent was removed *in vacuo*. The crude material was dissolved in water (0.25 mL) and NaOH (1-N, 2.50 mL). Benzyl chloroformate (79.3 μL, 555.5 μmol) was added and stirring at room temperature was continued. After 2 hours, the solution was washed with ether (2 mL) and the aqueous layer was acidified with aqueous HCl to pH 1. The aqueous layer was extracted with EtOAc (3x 5 mL). The combined organic extracts were dried over sodium sulfate. Filtration and evaporation of solvents yielded a crude product, which was sufficiently pure for further transformations. ^{1}H NMR (300 MHz, DMSO-d_6) δ 1.42 – 1.65 (m, 8H), 3.90 (m, 1H), 5.02 (s, 2H), 7.32 (s, 5H), 7.55 (m, 1H), 7.94 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.5; MS (*m/z*) 345.6 $[M+H]^+$.



Example 513 Synthesis of Exemplary Compounds of the Invention

Preparation of (*L*)-2--Amino-hexanoic acid 2' TMS ethyl ester–6-phosphonic acid mono phenyl ester


To a solution of (*L*)-2-Cbz-amino-hexanoic acid–6-phosphonic acid (137.3 mg, 397.9 μmol) in 2-TMS ethanol (2.5 mL) was added acetyl chloride (50 μL). Stirring at room temperature was continued. After 22 hours complete conversion was observed. The solvents were removed *in vacuo*. The crude material was sufficiently pure for the next step.

One half of the crude material (198.9 μmol) was dissolved in toluene (3.0 mL) at room temperature. Thionyl chloride (167.2 mg, 1,416.0 μmol) was added and the reaction mixture was heated at 70 °C (oil bath). After 4 hours, the

reaction was cooled to room temperature and the solvent was removed *in vacuo*. The crude material was re-dissolved in methylene chloride (2.0 mL) and a solution of phenol (36.6 mg, 389.0 μmol) and DIEA (67.0 μL, 389.0 μmol) in methylene chloride (1.0 mL) was added. Stirring at room temperature was continued. After 4 hrs the solvents were removed *in vacuo*.

The crude material was dissolved in tetrahydrofuran (THF) (3.0 mL) and aqueous sodium hydroxide solution (1N, 0.885 mL) was added. Stirring at room temperature was continued. After 14 hours the solvent was removed *in vacuo* to provide the crude phosphonate mono phenyl ester (63.8 mg). This material was dissolved in 2-TMS ethanol (1.0 mL) and acetyl chloride (20 μL) was added. Stirring at room temperature was continued. After 22 hours complete conversion to the carboxylate ester was observed. The solvents were removed *in vacuo*. The material was sufficiently pure for the next step.


One half of the crude material (75 μmol) was dissolved in ethanol (1.5 mL). Pd/C (5%, 20 mg) was added and the reaction was placed under an atmosphere of hydrogen gas. After 1.5 hours Celite was added and the crude reaction mixture was filtered through Celite. The solvents were removed *in vacuo* and the crude material was used in the next step without further purification.



Example 514 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester

To a solution of 4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoic acid hemihydrochloride dihydrate (22.7 mg, 60.0 μmol) in DMF (0.80 mL) were added diethyl cyano phosphonate (12.4 μL, 78.0 μmol) and DIEA (31.0 μL, 180.0 μmol). The solution was stirred at ambient temperature for one hour when (L)-2-amino-6-monophenoxyphosphonatohexanoic acid 2' TMS ethyl ester (70.5 μmol), suspended in DMF (0.2 mL), was added. The solution was stirred for 3.5 additional hours. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (5-95%) to provide 19.4 mg (46%) of the pure product. ^{1}H NMR (300 MHz, DMSO-d_6) δ 0.0 (s, 9H), 0.91 (t, 2H, J= 8.1 Hz), 1.42 – 1.53 (m, 4H), 1.67 –1.76 (m, 4H), 3.24 (s, 3H), 4.10 (t, 2H, J= 8.1 Hz), 4.29 (m, 1H), 4.86 (s, 2H), 6.81 (d, 2H, J= 9 Hz), 7.12 (m, 3H), 7. 31 (m, 2H), 7.74 (d, 2H, J= 9 Hz), 8.14 (d, 1H, J = 7.8 Hz), 8.71 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 26.2; MS (m/z) 695.2 $[M]^+$.




Example 515 Synthesis of Exemplary Compounds of the Invention

Preparation of 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl mono (S) ethyl lactate-phosphonate)-hexanoic acid TMS ethanol ester


To a solution of 2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-6'-(mono phenyl-phosphonate)-hexanoic acid TMS ethanol ester (14.5 mg, 20.8 μmol) in DMF (0.70 mL) was added PyBOP (32.4 mg, 62.4

μmol), DIEA (21.4 mg, 166.4 μmol) and (S) ethyl lactate (19.6 mg, 166.4 μmol). The reaction mixture was stirred at room temperature for one hour. The crude reaction mixture was purified by RP HPLC on C_{18} column using H_2O/acetonitrile (5-95%) to provide 13.5 mg (81%) of the pure product as a mixture of diastereomers at phosphorus (~ 4:1). ^1H NMR (300 MHz, $CDCl_3$) δ 0.0 (s, 9H), 1.02 (t, 2H, *J*= 8.7 Hz), 1.23 (t, 3H, *J*= 9.3 Hz), 1.35 (d, 2.4H, *J*= 6.6 Hz), 1.42 – 1.53 (m, 4.6H), 1.67 –1.86 (m, 4H), 3.14 (s, 3H), 4.03 – 4.27 (m, 4H), 4.71 (br s, 3H), 4.98 (m, 0.8H), 5.10 (m, 0.2H), 6.57 (d, 2H, *J*= 7.5 Hz), 7.00 (m, 1H), 7.16 (m, 3H), 7. 30 (m, 2H), 7.63 (d, 2H, *J*= 7.5 Hz), 8.43 (s, 1H); ^{31}P (121.4 MHz, DMSO-d_6) δ 30.5, 29.2; MS (*m/z*) 795.2 $[M]^+$.

Example 516 Synthesis of Exemplary Compounds of the Invention




Compounds of the invention can generally be prepared as illustrated above. For example, a specific compound of the invention can be prepared as follows.




Rofecoxib is treated in a solvent such as dimethylformamide or tetrahydrofuran with a base such as sodium hydride. When bubbling ceases, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The bromide so formed is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of

carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid.

Example 517 Synthesis of Exemplary Compounds of the Invention




Compounds of the invention can generally be prepared as illustrated above (see also, *Ind. J. Chem., Sect B*, **1990**, *10*, 954.) A specific intermediate useful in the above process can be prepared as follows.



Ethyl 4-hydroxyphenylacetate is treated in a solvent such as dimethylformamide or tetrahydrofuran with a base such as sodium hydride. When bubbling ceases, *E*-1,4-dibromobutene is added in excess. After quenching the reaction with aqueous ammonium chloride and extracting the product with an organic solvent such as ethyl acetate, the mono-alkylated product is isolated by chromatography. The bromide so formed is heated with triethylphosphite in a solvent such as toluene (or other Arbuzov reaction conditions: see Engel, R., Synthesis of carbon-phosphorus bonds, CRC press, 1988) to generate the diethyl ester of the desired phosphonic acid.

Example 518 Synthesis of Exemplary Compounds of the Invention

Scheme 518-1



Appropriate oxidant(s) can convert the primary alcohol (5'-hydroxy) shown in **518-1.3** to a carboxylic acid or its corresponding ester. In the case of an ester, an additional deprotection step will give the carboxylic acid, **518-1.4**. A variety of oxidation procedures exist in the literature and can be utilized here. These include but are not limited to the following methods: (i) pyridinium dichromate in Ac_2O, t-BuOH, and dichloromethane producing the t-butyl ester, followed by a deprotection using reagent such as trifluoroacetic acid to convert the ester to the corresponding carboxylic acid (see Classon, et al, *Acta Chem. Scand. Ser. B; 39*; 1985; 501-504. Cristalli, et al; *J. Med. Chem.; 31*; 1988; 1179-1183.); (ii) iodobenzene diacetate and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO) in acetonitrile, producing the carboxylic acid (See Epp, *et al*; *J. Org. Chem. 64*; 1999; 293-295. Jung et al; *J. Org. Chem.; 66*; 2001; 2624-2635.); (iii) sodium periodate, ruthenium(III) chloride in chloroform producing the carboxylic acid (see Kim, et al, *J Med. Chem. 37*; 1994; 4020-4030. Homma, et al; *J. Med. Chem.; 35*; 1992; 2881-2890); (iv) chromium trioxide in acetic acid producing the carboxylic acid (see Olsson et al; *J. Med. Chem.; 29*; 1986; 1683-1689. Gallo-Rodriguez et al; *J. Med. Chem.; 37*; 1994; 636-646); (v) potassium permanganate in aqueous potassium hydroxide producing the carboxylic acid (see Ha, et al; *J. Med. Chem.; 29*; 1986; 1683-1689. Franchetti, et al; *J. Med. Chem.; 41*; 1998; 1708-1715.) (vi) nucleoside oxidase from *S. maltophilia* to give the carboxylic acid (see Mahmoudian, et al; *Tetrahedron; 54*; 1998; 8171-8182.)

The preparation of **518-1.5** from **518-1.4** using lead(IV) tetraacetate (LG = OAc) was described by Teng et al; *J. Org. Chem.; 59*; 1994; 278-280 and

Schultz, et al; *J. Org. Chem.; 48*; 1983; 3408-3412. When lead(IV) tetraacetate is used together with lithium chloride (see Kochi, et al; *J. Am. Chem. Soc.; 87*; 1965; 2052), the corresponding chloride is obtained (1.5, LG = Cl). Lead(IV) tetraacetate in combination with N-chlorosuccinimide can produce the same product (1.5, LG = Cl) (see Wang, et al; *Tet. Asym.; 1*; 1990; 527 and Wilson et al; *Tet. Asym.; 1*; 1990; 525). Alternatively, the acetate leaving group (LG) can also be converted to other leaving group such as bromide by treatment of trimethylsilyl bromide to give **518-1.5** ((see Spencer, et al; *J. Org. Chem.; 64*; 1999; 3987-3995).


The coupling of **518-1.5** (LG = OAc) with a variety of nucleophiles were described by Teng et al; *Synlett*; 1996; 346-348 and US 6,087,482; Column 54 line 64 to Column 55 line 20. Specifically, the coupling between **518-1.5** and diethyl hydroxymethylphosphonate in the presence of trimethylsilyl trifluoromethanesulfonate (TMS-OTf) was described. It can be envisioned that other compounds with the general structure of HO-linker-$POR^{P1}R^{P2}$ can also be used so long as the functional groups in these compounds are compatible with the coupling reaction conditions. There are many examples in the published literature describing the coupling of **518-1.5** (LG = halogen) with a variety of alcohols. The reactions can be facilitated with a number of reagents, such as silver(I) salts (see Kim et al; *J. Org. Chem.; 56*; 1991; 2642-2647, Toikka et al; *J. Chem. Soc. Perkins Trans. 1; 13*; 1999; 1877-1884), mercury(II) salts (see Veeneman et al; *Recl. Trav. Chim. Pays-Bas; 106*; 1987; 129-131), boron trifluoride diethyl etherate (see Kunz et al; *Hel. Chim Acta; 68*; 1985; 283-287), Tin(II) chloride (see O'Leary et al; *J. Org. Chem.; 59*; 1994; 6629-6636), alkoxide (see Shortnacy-Fowler et al; *Nucleosides Nucleotides; 20*; 2001; 1583-1598), and iodine (see Kartha et al; *J. Chem. Soc. Perkins Trans. 1*; 2001; 770-772). These methods can be selectively used in conjunction with different methods in forming **518-1.5** with various leaving groups (LG) to produce **518-1.6**.

The introduction and removal of protecting groups from a compound is a commonly practiced art in organic synthesis. Many sources of information of the art are available in the published literature, e.g. Greene and Wuts, *Protecting Groups in Organic Synthesis*, 3rd Ed., John Wiley & Sons, Inc., 1999. The main purpose is to temporarily transform a functional group so that it will survive a set


of subsequent reaction procedures. Afterwards, the original functional group can be restored by a preconceived deprotection procedure. Therefore, the transformations from **518-1.1** to **518-1.2**, from **518-1.2** to **518-1.3**, and from **518-1.6** to **518-A** are intended to allow the core components of the transformations (from **518-1.3** to **518-1.6**) to occur while preserving the functional groups already exist in the compound structures.

The 5'-hydroxyl group of ribavirin (**518-2**) can be selectively protected by an appropriate protecting group. The product, **518-3**, can be treated with benzoyl chloride, an appropriate base, in the presence of catalytic amount of 4-dimethylaminopyridine, to convert 2'- and 3'-hydroxyl groups to their corresponding benzoyl esters, **518-4**. The 5'-hydroxyl group can be selectively deprotected to give **518-5**. Following procedure described for analogous compound in US6,087,482, Figure 2, **518-4** can be converted to **518-7** in a three-step sequence. Treating **518-7** with a coupling agent, such as trimethylsilyl trifluoromethanesulfonate, in the presence of an appropriate alcohol containing a phosphonate group can produce **518-8**. Lastly, treating **518-8** with aqueous sodium hydroxide can deprotect the 2'- and 3'-hydroxyl groups to give **518-1**. It is important to point out that R^{P1} and R^{P2} in **518-8** and **518-1** do not need to be the same.

A variety of compounds of the general structure **518-1.1** can either be prepared using procedures described in the literature, or be purchased from commercial sources. The following are good sources for information on the art of preparing a variety of compounds of the general structure **518-1.1**, Townsend, Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994; and Vorbruggen and Ruh-Pohlenz, *Handbook of Nucleoside Synthesis*, John Wiley & Sons, Inc., 2001. Some exemplary precursors, starting materials and their commercial sources include:




Available from Aldrich Cat. No. 85729-7



LG = OH, Aldrich Cat. No. R175-7


LG = OAc, R = Benzoyl, Aldrich Cat. No. 15,901-8



About 300 available from various commercial sources based on ACD search

Compound **518-2.1** in Scheme 518-2 is prepared using method described (WO 01/90121, page 115, table). The 5'-hydroxyl in **518-2.1** is protected as t-butyldimethylsilyl (TBDMS) ether. The 2'- and 3'- hydroxyl groups can be protected as benzoyl (Bz) esters to give **518-2.2**. The 5'-hydroxyl can then be deprotected to give **518-2.3**. Oxidation using iodobenzene diacetate and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO) convert the primary alcohol to the corresponding acid **518-2.4**. Further oxidation of **518-2.4** using lead tetraacetate can produce **518-2.5**. Coupling between **518-2.5** and diethyl hydroxymethylphosphonate (available from Sigma-Aldrich, Cat. No. 39,262-6) effected by TMS-OTf can afford **518-2.6**. Treating **518-2.6** with TMS-Br converts the phosphodiester to the corresponding phosphonic acid **518-2.7**. Deprotection of the 2'- and 3'- hydroxyl gives **518-2.8** as an example of the generic structure **518-A**, where Base is an adenine, R^1, R^5, and R^6 are hydrogen, R^2 is methyl group, R^3 and R^4 are hydroxyl groups, linker is a methylene group, and R^{P1} and R^{P2} are both hydroxyl groups.


Scheme 518-2



The phosphonic acids in **518-2.7** and **518-2.8** are used as examples for illustration purpose. Other forms of phosphonates can be access via the phosphonic acid, or other forms, such as the corresponding diesters. See section INTERCONVERSIONS OF PHOSPHONATES for details.

Many compounds of the generic structure **518-1.1** with the sugar moiety in its L-configuration are either commercially available or can be prepared by procedures described in the published literature. The opposite D-configuration enantiomers of the L-nucleoside analogs previously discussed can be prepared from the precursors that are the opposite enantiomers of **518-3.1**, **518-3.2**, and **518-3.3**. Scheme **518-3** describes the preparation of the opposite enantiomers of **518-3.1**, **518-3.2**, and **518-3.3**.


Scheme 518-3



The commercially available starting material **518-4.1** can be converted to **518-4.4**, which is the opposite enantiomer of **518-3.1,** using the sequence of reactions outlined above in Scheme **518-3**. The osmium tetraoxide catalyzed dihydroxylation reaction should introduce the diol selectively in the opposite face to the tert-butyldimethylsilyl (TBDMS) ether of the hydroxymethyl group. The diol in intermediate **518-4.3** can be protected as TBDMS ether. Diisobutylaluminum hydride reduction of the lactone at low temperature should produce **518-4.6**, which can be converted to **518-4.6** by acetylation. Deprotection of **518-4.6** should produce L-ribose (**518-4.7**). Acylation reaction


can convert all hydroxyl groups in **518-4.7** to the corresponding benzoyl esters. Standard coupling reactions with a variety of nucleobases should produce **518-4.10**, which is the opposite enantiomer of **518-3.3**.

Scheme 518-4




The synthesis of 3-cyano-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1,2,4-triazole (**518-2**) is described in US 2002/0156030 A1, page 6, paragraph 0078 to paragraph 0079. Using this starting material, one can synthesize carboxamide compound **518-1** (Scheme **518-4**) or formamidine compound **518-1** (Scheme **518-5**) using the sequences of chemical transformations outlined in Schemes **518-4** and **518-5**, respectively.

Scheme 518-5



Appropriate protection, deprotection procédures (See Greene and Wuts, (1999) *Protective Groups in Organic Synthesis*,) can be employed to prepare **518-3**, in which the 5'-hydroxyl group is protected, while the 2', and 3'-hydroxyl groups are not (Schemes **518-4** and **518-5**). Subsequent protection, depretection procedures can introduce protecting groups such as benzoyl group to the 2'- and 3'-hydroxyl, and leave the 5'-hydroxyl group unprotected as in **518-4**. Oxidation can convert the primary alcohol in **518-4** to the corresponding carboxylic acid or its ester. An optional deprotection of the ester can give the acid **518-5** as product. Further oxidation using oxidant such as lead tetraacetate can convert **518-5** to **518-6**, in which the leaving group is an acetate. Treating **518-6** with an alcohol containing a phosphonate moiety in the presence of appropriate coupling agent, such as trimethylsilyl trifluoromethanesulfonate, will give **518-8** as product. Finally, treating **518-8** with the procedure described in US 2002/0156030 A1, page 6, paragraph 0081, should give **518-1** as product. It is important to point out that R^{P1} and R^{P2} in **518-7, 518-8** and **518-1** do not need to be the same.

Scheme 518-6



A solution of tert-butyl hydroperoxide (t-BuOOH) in benzene (68%, 3 eq) is added dropwise to a solution of allylic alcohol **518-1** (synthesized as described in *Tet. Letters* (1997) 38:2355-58) and $VO(acac)_2$ in benzene (final

concentration 0.1 M) at room temperature (Scheme 518-6). After 1 h of stirring at room temperature, saturated aqueous $Na_2S_2O_3$ is added to the reaction mixture. The resulting solution is extracted with EtOAc, washed with H_2O, and dried over sodium sulfate. After removal of solvent, the crude product **518-2** is purified by column chromatography on silica.

Epoxide **518-2** and p-anisylchlorodiphenylmethane (1.5 eq) is dissolved in anhydrous pyridine (0.17 M) and stirred at 25 °C for 2d. Solvents were removed under reduced pressure and the residue dissolved in EtOAc. The organics were washed with water, saturated aqueous $NaHCO_3$, and dried over sodium sulfate. After removal of solvent, the crude product **518-3** is purified by column chromatography on silica.

To a solution of methyltriphenylphosphonium bromide (2 eq) in anhydrous THF at –78 °C is added n-butyllithium (2.2 eq). The solution is allowed to warm to room temperature and stirred for 20 min. After recooling to –78 °C, this solution is added to fully protected epoxide **518-3** in THF (final concentration 0.06 M). The reaction mixture is allowed to warm to room temperature and stirred for 12 h at which point H_2O is added and extracted with diethyl ether. The combined organics were dried over sodium sulfate. After removal of solvent, the crude product **518-4** is purified by column chromatography on silica.

Sodium hydride (1 eq) and 2-amino-4-chloro-7*H* pyrrolo[2,3-d]pyrimidine (1 eq) were dissolved in anhydrous DMF (0.06 M) and stirred at 120 °C for 10 min. A solution of **518-4** in DMF is then added and the reaction mixture is stirred 12 h at 120 °C at which point the solvents were evaporated under reduced pressure. The residue is dissolved in CH_2Cl_2, washed with H_2O, and dried over sodium sulfate. After removal of solvent, the crude product **518-5** is purified by column chromatography on silica.

Compound **518-5** is dissolved in dichloromethane and added to a solution of 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1*H*)-one (Aldrich, Dess–Martin periodinane, 4 eq) in dichloromethane (final concentration 0.06 M). The reaction mixture is stirred at room temperature for 4 d at which point it is diluted with EtOAc and poured into a solution of sodium thiosulfate in saturated aqueous sodium bicarbonate solution. The organic layer is separated and dried

over sodium sulfate. After removal of solvent, the crude product **518-6** is purified by column chromatography on silica.

A solution of ketone **518-6** in anhydrous THF is added to a solution of methylmagnesium bromide (4 eq) in anhydrous THF (0.1 M) at –78 °C The reaction mixture is stirred for 12 h at –60 °C at which point the reaction is quenched with saturated aqueous NH_4Cl solution. The mixture is filtered over celite and washed with EtOAc. The combined organics were washed with saturated aqueous NH_4Cl, water and dried over sodium sulfate. After removal of solvent, the crude product is purified by column chromatography on silica.

A solution of alcohol **518-7** in anhydrous THF (0.06 M) is treated with a solution of tetrabutylammonium fluoride (1.5 eq) in THF at room temperature. The reaction mixture is stirred for 3 h at which point the solvents were evaporated. The crude desilylated diol **518-8** is purified by column chromatography on silica.


To a solution of diol **518-8** and benzenesulfonic acid diisopropoxy-phosphorylmethyl ester (1.2 eq) in anhydrous DMF (0.1 M) is added magnesium tert-butoxide (1 eq). The reaction mixture is heated to 80 °C for 12 h. After cooling to room temperature, 1 N citric acid is added and extracted with EtOAc. The organics were neutralized with saturated aqueous $NaHCO_3$, washed with saturated aqueous NaCl, and dried over sodium sulfate. After removal of solvent, the crude product **518-9** is purified by column chromatography on silica.

Compound **518-9** is dissolved in 80% acetic acid and stirred 12 h at room temperature. After removal of solvent, the crude product **518-10** is purified by column chromatography on silica.

Phosphonate ester **518-10** and 2,6-lutidine (8eq) is dissolved in CH_3CN and treated with trimethylsilyliodide (8 eq). After stirring for 3 h at room temperature, triethylamine (8 eq) is added followed by methanol. After removal of solvent, the crude product **518-11** is purified by column chromatography on silica.

Phosphonic diacid **518-11** is dissolved in 1,4-dioxane and treated with 4 N NaOH and heated to 100 °C for 4 h. After cooling to room temperature, the reaction mixture is neutralized with 4N HCl. After removal of solvent, the crude product is purified by column chromatography on silica to provide **518-12**.

Scheme 518-7


p-MeOC6H4CH2OCH2Cl
i-Pr2NEt, CH2Cl2
518-13
518-14
1. n-BuLi, HMPA
2. MeI
518-15
DDQ
518-16
PPh3, DIAD
2-amino-6-chloropurine, dioxane
518-17
TBAF, THF
518-18
(i-PrO)2POCH2Br
LiOt-Bu, DMF
518-19
N-methylmorpholine-N-oxide
OsO4, acetone
518-20
TMS-I, MeCN
518-21
NaOH
518-22
518-23

Compound **518-13** (Paquette et al *J. Org. Chem.* (1997) 62:1730-1736) is treated with *p*-methoxybenzyl bromide(1.5 eq.), sodium hydride(1.4 eq) in dry DMF at room temperature (Scheme 518-7). The reaction is monitor by TLC for the disappearance of **518-13**. The reaction is quenched by the addition of a saturated aqueous solution of ammonium chloride. Extraction by diethyl ether affords a crude product, which can be purified by silica gel chromatography to give **518-14**.

A solution of **518-14** in THF is added dropwise to a solution of n-BuLi (1.2 eq) in THF cooled at -78 °C under a nitrogen atmosphere. The solution is stirred for 1 h at -78 °C. Excess of HMPA (1.4 eq) is added. After 10 min, a solution of MeI (5 eq) in THF is added. After another 5 h at -78 °C, 20% aqueous NaH_2PO_4 is added, and the mixture is warmed to room temperature. Extraction with diethyl ether gives a crude product, which is purified by silica gel chromatography to give **518-15**.

Dichlorodicyanoquinone (DDQ) is added to a mixture of compound **518-15** in dichloromethane and water. After stirring at room temperature for 2 h. The mixture is extracted with dichloromethane to give a crude product, which is purified by silica gel chromatography to give **518-16**.

To a solution of **518-16** in dioxane, is added triphenylphosphine (2 eq.), 2-amino-6-chloropurine (2 eq) at room temperature. Diisopropyl azodicarboxylate (2 eq, DIAD) is added dropwise via syringe. The mixture is stirred at room temperature for another 3 h. Water is added to quench the reaction. Extraction with ethyl acetate gives a crude product, which is purified by silica gel chromatography to give **518-17**.

Alternatively, a nucleobase may be added by the methods described in Crimmins, M.T. (1998) *Tetrahedron* 54:9229-9272, such as palladium coupling to a cyclopentyl acetate.

To a solution of compound **518-17** in THF is added a 1 M solution of tetrabutylammonium fluoride (1.2 eq, TBAF) at room temperature. After another few hours, a saturated solution of ammonium chloride is added. Extraction with ethyl acetate gives a crude product, which is purified by silica gel chromatography to give **518-18**.

Compound **518-18**, diethyl bromomethylphosphonate (1.5 eq), and lithium t-butoxide (1.5 eq) are added to DMF sequentially. The mixture is

stirred at 80 °C for several hours. After the mixture is cooled to room temperature, a 1 M solution of KH_2PO_4 is added. Extraction with ethyl acetate gives a crude product, which is purified by silica gel chromatography to give **518-19**.


To a solution of **518-19** in acetone, is added N-methylmorpholine N-oxide (2 eq) and osmium tetraoxide (0.2 eq). The mixture is stirred at room temperature for 16 h. A 1 M aqueous solution of sodium sulfite is added. After stirring at room temperature for another hour, the mixture is evaporated to remove most of acetone. The aqueous residue is frozen and lyophilized to give a crude product, which is purified by reversed phase HPLC to give **518-20**.

Iodotrimethylsilane (8 eq, TMS-I) is added to a mixture of **518-20**, 2,6-lutidine (8 eq) and acetonitrile. After stirring at room temperature for 2 h, the mixture is poured onto ice. The mixture is then frozen and lyophilized to give a residue, which is purified by reversed phase HPLC to give **518-21**.

518-21 is dissolved in 4 N aqueous NaOH and refluxed for several hours. The mixture is cooled to room temperature, neutralized with 4 N HCl, and purified with reversed phase HPLC to give **518-22**.

Compound **518-22** can be converted to the corresponding diphosphophosphonate **518-23**, and prodrugs using known procedures.

Scheme 518-8



3-Cyclopenten-1-ol **518-24**(108 uL, 1.2 mmol, 1.2 eq) is dissolved in 5 mL of dry THF (Scheme 518-8). The solution is cooled to 0 °C. A 1.35 M solution of n-BuLi (0.89 mL, 1.2 mmol, 1.2 eq) is added via syringe. After 10 min, diisopropylphosphonomethyl p-toluenesulfonate (350 mg, 1.0 mmol, 1.0 eq) is added. The mixture is stirred in a 45 °C bath for 3.5 h. The reaction is quenched with a pH 7 aqueous phosphate buffer. Extraction with diethyl ether gave a crude product, which is purified by silica gel chromatography (eluted with 45% ethyl acetate in hexane) to give 178 mg of **518-25** (68%).

To a solution of **518-25** (168 mg, 0.69 mmol, 1 eq) in 12 mL of acetone, is added 273 mg of $NaHCO_3$ in 8 mL of water. The mixture is then cooled to 0 °C. Oxone (519 mg, 0.85 mmol, 1.3 eq) in 4 mL of water is added over 5 min in portions. The mixture is stirred vigorously for 2.5 h. The mixture is then evaporated *in vacuo* to remove most of the acetone. The aqueous residue is extracted with ethyl acetate to give a crude product, which is purified by silica gel chromatography to give **518-26** as a clear oil.

To a solution of **518-26** (21 mg, 0.076 mmol, 1.0 eq) in 0.25 mL of DMF, is added cytosine (13 mg, 1.5 eq) and cesium carbonate (6 mg, 0.25 eq) and magnesium t-butoxide. The mixture is heated to 140 °C for several hours. After cooling to room temperature, the reaction mixture is purified by reversed phase HPLC to give 12.5 mg of **518-27** (42%). ^{1}H NMR (CDCl3): δ 9.60 (br s, 1H), 8.96 (br s, 1H), 7.87 (d, 1H), 6.21 (d, 1H), 4.84 (m, 1H), 4.78 (m, 2H), 4.43 (m, 1H), 4.08 (s, 1H), 3.72 (m, 2H), 2.82 (m, 1H), 2.33 (m, 1H), 1.83 (m, 2H), 1.38 (m, 12H) ppm.


Alternatively, the methods in WO 03/105770 can be applied to add a nucleobase with a nucleophilic amine to a cycopentyl epoxide.

The conversion from **518-27** to **518-28** is described in Scheme **518-2** above. The conversion of **518-28** to the corresponding diphosphophosphonate **518-29** and phosphorus prodrugs, e.g. **518-30** can be accomplished using procedures described herein.

Cyclopentyl intermediate **518-31** may be prepared by procedures analogous to those described in US5206244 and US5340816 (Scheme **518-4**). Diol **518-31** is converted to cyclopentenone **518-32** and treated with IBr in the presence of the appropriate phosphonate alcohol to give **518-33**. Iodide **518-33** is displaced with inversion to give cyclopentanone intermediate **518-34**. Nysted methylenation (US 3865848; *Aldrichim. Acta* (1993) 26:14) provides exocyclic methylene **518-35**, which may be deprotected to give **518-36**.


Cyclopentanone **518-34** may be a versatile intermediate to form other compounds of the invention by reduction to cyclopentyl **518-37**, or Wittig or Grubb olefination to alkenyl **518-38**.

Scheme 518-9




Scheme **518-10** shows intermediate **518-39** is converted to guanosyl cyclopentenone **518-40** (*J. Am. Chem. Soc.* (1972) 94:3213), then treated with IBr and diethyl phosphomethanol to furnish iodide **518-41** (*J. Org. Chem.* (1991) 56:2642) Nucleophilic substitution with AgOAc affords acetate **518-42**. After methylenation using the procedure of Nysted (US3865848; *Aldrichim. Acta* 1993, *26*, 14), to give **518-43**, the acetate group is removed by the addition of sodium methoxide and the resulting alcohol is inverted by the Mitsunobo protocol, and a second acetate deprotection produces **518-44**. Desilylation with tetra-butylammonium fluoride (TBAF) of **518-44** will yield **518-45**.


Scheme 518-10



SPECIFIC EMBODIMENTS




Example 519 Synthesis of Exemplary Compounds of the Invention



Synthesis of **519-1**: To a solution of 3'-deoxyuridine (995 mg, 4.36 mmol) in 8 mL of anhydrous pyridine was added t-butyldiphenylsilyl chloride (TBDPS-Cl, 1.38 g, 5.01 mmol), and 4-dimethylaminopyridine (DMAP, 27 mg, 0.22 mmol). The mixture was stirred at 23 C for 14 h and then cooled to 0 C in a ice-water bath. To this mixture was added benzoyl chloride (735 mg, 0.61 mL, 5.2 mmol). The mixture was warmed to 23 °C and stirred for another 2 h. The mixture was concentrated in vacuo to give a paste, which was partitioned

between water and ethyl acetate. The aqueous later was extracted once with ethyl acetate. The combined ethyl acetate layer was washed sequentially with 1 M aqueous citric acid, saturated sodium bicarbonate, and brine. It was dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude product as a yellow oil. Purification by silica gel chromatography (15 – 65% ethyl acetate in hexane) gave a colorless oil. Yield 1.35 g (54%). ^{1}H NMR (DMSO-d6): δ 11.38 (s, 1H), 8.01 (d, J = 7.9 Hz, 2H), 7.77 (d, J = 8.2 Hz, 1H), 7.70 – 7.40 (m, 13 H), 5.99 (s, 1H), 5.58 (m, 1H), 7.34 (d, J = 8.2 Hz, 1H), 4.47 (m ,1H), 4.03 (m, 1H), 3.84 (m, 1H), 2.43 (m, 1H), 2.21 (m, 1H), 1.03 (s, 9H) ppm. MS (m/z) 571.1 ($M+H^+$), 593.3 ($M+Na^+$).

Example 520 Synthesis of Exemplary Compounds of the Invention




520-2

Synthesis of **520-2:** To a solution of **519-1** (1.31 g, 2.3 mmol) in 5 mL of anhydrous N,N-dimethylformamide was added benzyl chloromethyl ether (0.54 g, 3.45 mmol), N,N-diisopropylethylamine (446 mg, 0.60 mL, 3.45 mmol). The mixture was stirred at 23 °C for 4 h. Water was added. The mixture was extracted with ethyl acetate. The organic layer was washed sequentially with 1 M aqueous citric acid, saturated sodium bicarbonate, and brine. It was dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude product as a yellow oil, which was used in the next step without further purification.

The crude product obtained above was dissolved in 9 mL of THF. The solution was cooled to 0 C. A 1 M solution of TBAF (4.6 mL, 4.6 mmol) was added via syringe. The mixture was warmed to 23 °C and stirred for another 2 h. An additional 2.3 mL of 1 M TBAF was added. The mixture was stirred for another 2 h at 23 C. Saturated aqueous ammonium chloride was added to the solution. The mixture was evaporated in vacuo to remove most of THF. The

aqueous phase was extracted with ethyl acetate. The aqueous layer was washed with brine. It was then dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude product as a yellow oil. Purification by silica gel chromatography (30 – 80% ethyl acetate in hexane) gave a white solid. Yield of **520-2**: 805 mg (77% for two steps). ^{1}H NMR (DMSO-d6): δ 8.04 (m, 3H), 7.67 (t, J = 7.3 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.30 (m, 5H), 5.98 (s, 1H), 5.78 (d, J = 7.9 Hz, 1H), 5.55 (m, 1H), 5.31 (s, 2H), 5.22 (m, 1H), 4.57 (s, 2H), 4.41 (m ,1H), 3.80 (m, 1H), 3.60 (m, 1H), 2.31 (m, 1H), 2.15 (m, 1H) ppm. MS (m/z) 453.1 ($M+H^+$), 475.3 ($M+Na^+$).


Example 521 Synthesis of Exemplary Compounds of the Invention



521-3

Synthesis of **521-3:** To a solution of **520-2** (800 mg, 1.77 mmol) in 3.5 mL of a 1:1 mixture of acetonitrile/water was added iodobenzene diacetate (1.25 g, 3.89 mmol), and TEMPO (55 mg, 0.35 mmol). The mixture was stirred at 23 °C for 14 h. The mixture was then froze in a –78 °C bath and lyophilized to give a solid residue. This residue was purified by silica gel chromatography (0 -15% methanol in dichloromethane). Product **521-3** was obtained as a white solid. Yield: 735 mg (89%). ^{1}H NMR (DMSO-d6): δ 8.13 (d, J = 7.6 Hz, 1H), 8.03 (d, J = 7.7 Hz, 2H), 7.68 (m, 1H), 7.58 (t, J = 7.0 Hz, 2H), 7.29 (m, 5H), 6.04 (s, 1H), 5.85 (d, J = 8.3 Hz, 1H), 5.62 (m, 1H), 5.31 (s, 2H), 4.87 (m, 1H), 4.58 (s, 2H), 2.40 - 2.20 (m, 2H) ppm. MS (m/z) 467.1 ($M+H^+$), 489.3 ($M+Na^+$).


Example 522 Synthesis of Exemplary Compounds of the Invention




522-4

Synthesis of **522-4:** To a deoxygenated solution of **521-3** (730 mg, 1.57 mmol) and pyridine (0.51 mL, 6.26 mmol) in 7 mL of anhydrous DMF, was added lead tetraacetate (3.47 g, 7.83 mmol). The mixture was stirred at 23 °C for 14 h shielded from light. The mixture was diluted with 15 mL of ethyl acetate and 10 mL of water. This mixture filtered through a pad of Celite and separated. The aqueous phase was extracted with another 10 mL of ethyl acetate. The combined ethyl acetate extract was washed with brine, dried over sodium sulfate, and evaporated in vacuo to give the crude product as an oil. The crude product **522-4** was purified by silica gel chromatography (10-50% ethyl acetate in hexane). Products of two diastereomers were obtained as a white foam. Yield: 400 mg (53%). ^{1}H NMR (DMSO-d6): δ 8.01 (m, 2H), 7.82 – 7.63 (m, 2H), 7.57 (m, 2H), 7.31 (m, 5H), 6.58 (m, 1H), 6.17 (m, 1H), 5.83 (m, 1H), 5.65 (m, 1H), 5.31 (s, 2H), 4.59 (s, 2H), 2.76 and 2.28 (m, 1H), 2.10 (m, 1H), 2.07 (s, 3H) ppm. MS (m/z) 481.0 ($M+H^+$), 503.3 ($M+Na^+$).

Example 523 Synthesis of Exemplary Compounds of the Invention



523-5a



523-5b


Synthesis of **523-5a:** To a solution of **522-4** (300 mg, 0.63 mmol) in 6 mL of anhydrous dichloromethane was added diethyl hydroxymethylphosphonate (0.37 mL, 2.5 mmol), followed by trimethylsilyl trifluoromethanesulfonate (0.34 mL, 1.88 mmol). The mixture was stirred at 23

°C for 6 h. Triethylamine (0.44 mL, 3.15 mmol) was added, followed by water. The mixture was extracted with ethyl acetate. The organic layer was washed with 1 M aqueous citric acid, saturated sodium bicarbonate, and brine. It was then dried over anhydrous sodium sulfate, and evaporated in vacuo to give a residue. This crude product was purified by silica gel chromatography (75–95% ethyl acetate in hexane) to give two products, which were diastereomers of each other shown above (**523-5a** and **523-5b**). Yield of **523-5a**: 53 mg (14%). Yield of **523-5b**: 129 mg (35%).

Analytical data for **5a**: ^{1}H NMR (Acetonitrile-d3): δ 8.04 (d, J = 7.0 Hz, 2H), 7.77 (d, J = 7.9 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.53 (m, 2H), 7.33 (m, 5H), 6.38 (d, J = 4.0 Hz, 1H), 5.80 (d, J = 8.2 Hz, 1H), 5.63 (m, 1H), 5.52 (m, 1H), 5.41 (s, 2H), 4.64 (s, 2H), 4.17 (m, 4H), 4.08 (dd, J = 13.8, 10.1 Hz, 1H), 3.92 (dd, J = 13.7, 9.5 Hz, 1H), 2.66 - 2.42 (m, 2H), 1.35 (t, J = 7.0 Hz, 6H) ppm. MS (m/z) 589.2 ($M+H^+$), 611.3 ($M+Na^+$). Stereochemistry of **523-5a** was confirmed by additional 2D NMR experiments.

Analytical data for **523-5b**: ^{1}H NMR (Acetonitrile-d3): δ 8.08 (d, J = 7.3 Hz, 2H), 7.69 (t, J = 7.5 Hz, 1H), 7.55 (m, 2H), 7.43 (d, J = 8.2 Hz, 1H), 7.36 (m, 5H), 6.11 (d, J = 2.4 Hz, 1H), 5.77 (d, J = 8.3 Hz, 1H), 5.57 (m, 2H), 5.41 (s, 2H), 4.66 (s, 2H), 4.12 (m, 5H), 3.88 (dd, J = 14.0, 5.2 Hz, 1H), 2.82 (m, 1H), 2.25 (m, 1H), 1.27 (t, J = 7.0 Hz, 6H) ppm. MS (m/z) 589.0 ($M+H^+$), 611.2 ($M+Na^+$).

Example 524 Synthesis of Exemplary Compounds of the Invention




524-6

Synthesis of **524-6:** To a solution of **523-5a** (110 mg, 0.19 mmol) in in 3 mL of acetonitrile was added 2,6-lutidine (0.43 mL, 3.74 mmol), followed by iodotrimethylsilane (0.53 mL, 3.74 mmol). After stirring at 23 C for 30 min, the mixture was heated to 40 °C and stirred at that temperature for another 4 h. The

reaction mixture was cooled to 23 °C. Triethylamine (0.52 mL, 3.74 mmol) was added, followed by water (10 mL). The aqueous mixture was extracted twice with 5 mL of diethyl ether. The resulting aqueous solution was frozen in a –78 °C bath and was lyophilized to give a yellow solid. This crude product was purified by reversed phase HPLC to give **524-6** as a light yellow solid. Yield 26 mg (34%). MS (m/z) 411.3 ($M-H^-$).

Example 525 Synthesis of Exemplary Compounds of the Invention




525-7

Synthesis of **525-7:** Phosphonate **524-6** (12 mg, 0.029 mmol), carbonyldiimidazole (47 mg, 0.29 mmol), and tri-n-butylamine (5.4 mg, 0.029 mmol) were dissolved in 0.3 mL of anhydrous dimethylformamide (DMF). The mixture was stirred at 23 °C for 4 h. MeOH (0.020 mL) was added and the mixture was stirred for another 30 min. A solution of tributylammonium pyrophosphate (159 mg, 0.29 mmol) in 0.63 mL of anhydrous DMF was added. The resulting mixture was stirred at 23 °C for 14 h. The mixture was evaporated in vacuo to remove most of the DMF. The residue was dissolved in 5 mL of water and was purified by ion-exchange chromatography (DEAE-cellulose resin, 0 – 50% triethylammonium bicarbonate in water) to give a white solid, which was used directly in the next reaction.

The product obtained above was dissolved in 2 mL of water. A 0.3 mL of a 1 M solution of sodium hydroxide in water was added. The mixture was stirred at 23 °C for 40 min. Acetic acid was added to adjust the pH of the solution to 5. The solution was diluted with water and purified with an ion-exchange column (DEAE-cellulose resin, 0–50% triethylammonium bicarbonate in water) to give diphosphophosphonate **525-7** as a white solid, which is the triethylammonium salt of the structure shown above. Yield 10 mg (45% for two steps). ^1H NMR (D_2O): δ 7.79 (d, J = 7.6 Hz, 1H), 5.89 (m, 1H), 5.85 (d, J = 7.6

Hz, 1H), 5.41 (m, 1H), 4.49 (m, 1H), 4.02 –3.65 (m, 2H), 3.06 (m, 18H), 2.20 (m, 2H), 1.14 (m, 27H) ppm. ^{31}P NMR (D_2O): δ 7.46 (d, 1P), -9.45 (d, 1P), -23.11 (t, 1P) ppm. MS (m/z) 467.0 ($M-H^-$).


Example 526 Synthesis of Exemplary Compounds of the Invention




524-6 526-8

Synthesis of **526-8:** To a solution of **524-6** (16 mg, 0.039 mmol) in 0.4 mL of water was added NaOH (7.8 mg, 0.19 mmol). The solution was stirred at 23 °C for 1 h. Acetic acid (0.012 mL) was added to the solution. The mixture was then purified by reversed phase HPLC (eluted with 100% water) to give 4.6 mg of **526-8** as a white solid (38% yield). ^{1}H NMR (D_2O): δ 7.83 (d, J = 8.3 Hz, 1H), 5.86 (d, J = 3.4 Hz, 1H), 5.82 (d, J = 7.9 Hz, 1H), 4.48 (m, 1H), 3.68 (m, 1H), 3.37 (m, 1H), 2.16 (m, 2H) ppm. ^{31}P NMR (D_2O): δ 12.60 (s, 1P) ppm. MS (m/z) 615.1 ($2M-H^-$).

Scheme 526-1





A solution of tert-butyl hydroperoxide (t-BuOOH) in benzene (68%, 3 eq) is added dropwise to a solution of allylic alcohol **526-1** (synthesized as described in Tet. Lett., 38: 2355 (1997)) and $VO(acac)_2$ in benzene (final concentration 0.1 M) at room temperature (Scheme **526-1**). After 1 h of stirring at room temperature, saturated aqueous $Na_2S_2O_3$ is added to the reaction mixture. The resulting solution is extracted with EtOAc, washed with H_2O, and dried over sodium sulfate. After removal of solvent, the crude product **526-2** is purified by column chromatography on silica.

Epoxide **526-2** and p-anisylchlorodiphenylmethane (1.5 eq) is dissolved in anhydrous pyridine (0.17 M) and stirred at 25 °C for 2d. Solvents were removed under reduced pressure and the residue dissolved in EtOAc. The organics were washed with water, saturated aqueous $NaHCO_3$, and dried over sodium sulfate. After removal of solvent, the crude product **526-3** is purified by column chromatography on silica.

To a solution of methyltriphenylphosphonium bromide (2 eq) in anhydrous THF at –78 °C is added n-butyllithium (2.2 eq). The solution is allowed to warm to room temperature and stirred for 20 min. After recooling to –78 °C, this solution is added to fully protected epoxide **526-3** in THF (final concentration 0.06 M). The reaction mixture is allowed to warm to room temperature and stirred for 12 h at which point H_2O is added and extracted with diethyl ether. The combined organics were dried over sodium sulfate. After removal of solvent, the crude product **526-4** is purified by column chromatography on silica.

Sodium hydride (1 eq) and 2-amino-4-chloro-7H pyrrolo[2,3-d]pyrimidine (1 eq) were dissolved in anhydrous DMF (0.06 M) and stirred at 120 °C for 10 min. A solution of **526-4** in DMF is then added and the reaction mixture is stirred 12 h at 120 °C at which point the solvents were evaporated under reduced pressure. The residue is dissolved in CH_2Cl_2, washed with H_2O, and dried over sodium sulfate. After removal of solvent, the crude product **526-5** is purified by column chromatography on silica.

Compound **526-5** is dissolved in dichloromethane and added to a solution of 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1*H*)-one (Aldrich, Dess–Martin periodinane, 4 eq) in dichloromethane (final concentration 0.06 M). The reaction mixture is stirred at room temperature for 4 d at which point it is diluted with EtOAc and poured into a solution of sodium thiosulfate in saturated aqueous sodium bicarbonate solution. The organic layer is separated and dried over sodium sulfate. After removal of solvent, the crude product 6 is purified by column chromatography on silica.

A solution of ketone **526-6** in anhydrous THF is added to a solution of methylmagnesium bromide (4 eq) in anhydrous THF (0.1 M) at –78 °C The reaction mixture is stirred for 12 h at –60 °C at which point the reaction is quenched with saturated aqueous NH_4Cl solution. The mixture is filtered over celite and washed with EtOAc. The combined organics were washed with saturated aqueous NH_4Cl, water and dried over sodium sulfate. After removal of solvent, the crude product **526-7** is purified by column chromatography on silica.

A solution of alcohol 7 in anhydrous THF (0.06 M) is treated with a solution of tetrabutylammonium fluoride (1.5 eq) in THF at room temperature. The reaction mixture is stirred for 3 h at which point the solvents were

evaporated. The crude desilylated diol **526-8** is purified by column chromatography on silica.


To a solution of diol **526-8** and benzenesulfonic acid diisopropoxy-phosphorylmethyl ester (1.2 eq) in anhydrous DMF (0.1 M) is added magnesium tert-butoxide (1 eq). The reaction mixture is heated to 80 °C for 12 h. After cooling to room temperature, 1 N citric acid is added and extracted with EtOAc. The organics were neutralized with saturated aqueous $NaHCO_3$, washed with saturated aqueous NaCl, and dried over sodium sulfate. After removal of solvent, the crude product **526-9** is purified by column chromatography on silica.

Compound **526-9** is dissolved in 80% acetic acid and stirred 12 h at room temperature. After removal of solvent, the crude product **526-10** is purified by column chromatography on silica.


Phosphonate ester **526-10** and 2,6-lutidine (8eq) is dissolved in CH_3CN and treated with trimethylsilyliodide (8 eq). After stirring for 3 h at room temperature, triethylamine (8 eq) is added followed by methanol. After removal of solvent, the crude product **526-11** is purified by column chromatography on silica.

Phosphonic diacid **526-11** is dissolved in 1,4-dioxane and treated with 4 N NaOH and heated to 100 °C for 4 h. After cooling to room temperature, the reaction mixture is neutralized with 4N HCl. After removal of solvent, the crude product is purified by column chromatography on silica to provide **526-12**.


Scheme 526-2




526-13 526-14




526-15 526-16




526-17




526-18 526-19



526-20



526-21 526-22



526-23

Compound **526-13** (Paquette et al in *J. Org. Chem.* (1997) 62:1730-1736) is treated with *p*-methoxybenzyl bromide(1.5 eq.), sodium hydride(1.4 eq) in dry DMF at room temperature (Scheme 526-2). The reaction is monitor by TLC for the disappearance of **526-13**. The reaction is quenched by the addition of a saturated aqueous solution of ammonium chloride. Extraction by diethyl ether affords a crude product, which can be purified by silica gel chromatography to give **526-14**.

A solution of **526-14** in THF is added dropwise to a solution of n-BuLi (1.2 eq) in THF cooled at -78 °C under a nitrogen atmosphere. The solution is stirred for 1 h at -78 °C. Excess of HMPA (1.4 eq) is added. After 10 min, a solution of MeI (5 eq) in THF is added. After another 5 h at -78 °C, 20% aqueous NaH_2PO_4 is added, and the mixture is warmed to room temperature. Extraction with diethyl ether gives a crude product, which is purified by silica gel chromatography to give **526-15**.

Dichlorodicyanoquinone (DDQ) is added to a mixture of compound **526-15** in dichloromethane and water. After stirring at room temperature for 2 h. The mixture is extracted with dichloromethane to give a crude product, which is purified by silica gel chromatography to give **526-16**.

To a solution of **526-16** in dioxane, is added triphenylphosphine (2 eq.), 2-amino-6-chloropurine (2 eq) at room temperature. Diisopropyl azodicarboxylate (2 eq, DIAD) is added dropwise via syringe. The mixture is stirred at room temperature for another 3 h. Water is added to quench the reaction. Extraction with ethyl acetate gives a crude product, which is purified by silica gel chromatography to give **526-17**.

To a solution of compound **526-17** in THF is added a 1 M solution of tetrabutylammonium fluoride (1.2 eq, TBAF) at room temperature. After another few hours, a saturated solution of ammonium chloride is added. Extraction with ethyl acetate gives a crude product, which is purified by silica gel chromatography to give **526-18**.

Compound **526-18**, diethyl bromomethylphosphonate (1.5 eq), and lithium t-butoxide (1.5 eq) are added to DMF sequentially. The mixture is stirred at 80 °C for several hours. After the mixture is cooled to room temperature, a 1 M solution of KH_2PO_4 is added. Extraction with ethyl acetate

gives a crude product, which is purified by silica gel chromatography to give **526-19**.


To a solution of **526-19** in acetone, is added N-methylmorpholine N-oxide (2 eq) and osmium tetraoxide (0.2 eq). The mixture is stirred at room temperature for 16 h. A 1 M aqueous solution of sodium sulfite is added. After stirring at room temperature for another hour, the mixture is evaporated to remove most of acetone. The aqueous residue is frozen and lyophilized to give a crude product, which is purified by reversed phase HPLC to give **526-20**.


Iodotrimethylsilane (8 eq, TMS-I) is added to a mixture of **526-20**, 2,6-lutidine (8 eq) and acetonitrile. After stirring at room temperature for 2 h, the mixture is poured onto ice. The mixture is then frozen and lyophilized to give a residue, which is purified by reversed phase HPLC to give **526-21**.

526-21 is dissolved in 4 N aqueous NaOH and refluxed for several hours. The mixture is cooled to room temperature, neutralized with 4 N HCl, and purified with reversed phase HPLC to give **526-22**.


Compound **526-22** can be converted to the corresponding diphosphophosphonate **526-23**, and prodrugs using known procedures.

Scheme 526-3





526-29



526-30

3-Cyclopenten-1-ol **526-24**(108 uL, 1.2 mmol, 1.2 eq) is dissolved in 5 mL of dry THF The solution is cooled to 0 °C. A 1.35 M solution of n-BuLi (0.89 mL, 1.2 mmol, 1.2 eq) is added via syringe. After 10 min, diisopropylphosphonomethyl p-toluenesulfonate (350 mg, 1.0 mmol, 1.0 eq) is added. The mixture is stirred in a 45 °C bath for 3.5 h. The reaction is quenched with a pH 7 aqueous phosphate buffer. Extraction with diethyl ether gave a crude product, which is purified by silica gel chromatography (eluted with 45% ethyl acetate in hexane) to give 178 mg of **526-25** (68%).

To a solution of **526-25** (168 mg, 0.69 mmol, 1 eq) in 12 mL of acetone, is added 273 mg of $NaHCO_3$ in 8 mL of water. The mixture is then cooled to 0 °C. Oxone (519 mg, 0.85 mmol, 1.3 eq) in 4 mL of water is added over 5 min in portions. The mixture is stirred vigorously for 2.5 h. The mixture is then evaporated *in vacuo* to remove most of the acetone. The aqueous residue is extracted with ethyl acetate to give a crude product, which is purified by silica gel chromatography to give **526-26** as a clear oil.


To a solution of **526-26** (21 mg, 0.076 mmol, 1.0 eq) in 0.25 mL of DMF, is added cytosine (13 mg, 1.5 eq) and cesium carbonate (6 mg, 0.25 eq) and magnesium t-butoxide. The mixture is heated to 140 °C for several hours. After cooling to room temperature, the reaction mixture is purified by reversed phase HPLC to give 12.5 mg of **526-27** (42%). ^{1}H NMR (CDCl3): δ 9.60 (br s, 1H), 8.96 (br s, 1H), 7.87 (d, 1H), 6.21 (d, 1H), 4.84 (m, 1H), 4.78 (m, 2H), 4.43 (m, 1H), 4.08 (s, 1H), 3.72 (m, 2H), 2.82 (m, 1H), 2.33 (m, 1H), 1.83 (m, 2H), 1.38 (m, 12H) ppm.

The conversion from **526-27** to **526-28** is described in Scheme **526-2** above. The conversion of **526-28** to the corresponding diphosphophosphonate **526-29** and phosphorus prodrugs, e.g. **526-30** can be accomplished using procedures described herein.

Cyclopentyl intermediate **526-31** may be prepared by procedures analogous to those described in US5206244 and US5340816 (Scheme 526-4). Diol **526-31** is converted to cyclopentenone **526-32** and treated with IBr in the presence of the appropriate phosphonate alcohol to give **526-33**. Iodide **526-33** is displaced with inversion to give cyclopentanone intermediate **526-34**. Nysted methylenation (US 3865848; *Aldrichim. Acta* (1993) 26:14) provides exocyclic methylene **526-35**, which may be deprotected to give **526-36**.


Cyclopentanone **526-34** may be a versatile intermediate to form other compounds of the invention by reduction to cyclopentyl **526-37**, or Wittig or Grubb olefination to alkenyl **526-38**.

Scheme 526-4




Scheme **526-5** shows intermediate **526-39** is converted to guanosyl cyclopentenone **526-40** (*J. Am. Chem. Soc.* (1972) 94:3213), then treated with IBr and diethyl phosphomethanol to furnish iodide **526-41** (*J. Org. Chem.* (1991) 56:2642) Nucleophilic substitution with AgOAc affords acetate **526-42**. After methylenation using the procedure of Nysted (US3865848; *Aldrichim. Acta* 1993, *26*, 14), to give **526-43**, the acetate group is removed by the addition of sodium methoxide and the resulting alcohol is inverted by the Mitsunobo protocol, and a second acetate deprotection produces **526-44**. Desilylation with tetra-butylammonium fluoride (TBAF) of **526-44** will yield **526-45**.


Scheme 526-5



Synthesis of 2'-C-Me-UP



Example 527 Synthesis of Exemplary Compounds of the Invention




527-1

Synthesis of Compound 527-1: L-Xylose (36.2 g) and anhydrous $CuSO_4$ were placed in a 500 mL round bottomed flask. Acetone (220 mL) was added. To this slurry stirred at room temperature was added 3.6 mL of 96% sulfuric acid. The mixture was stirred for another 24 h at room temperature under a nitrogen atmosphere. The mixture is filtered to remove solid material. The solids were washed with 50 mL of acetone. To the combined filtrate was added 25.3 mL of conc. ammonium hydroxide. The precipitates were removed by filtration. The filtrate was evaporated *in vacuo* to give an oil, which was co-evaporated twice with absolute ethanol to give a yellow oil. The above crude product was stirred with 160 mL of 0.06 M aqueous HCl vigorously at room temperature for 2.5 h. The reaction mixture was homogeneous at the end of the reaction. Solid $NaHCO_3$ (3.26 g) was added in portions. After gas evolution had stopped, the mixture was filtered. The filtrate was frozen and lyophilized overnight to give a syrup, which was dissolved in ethyl acetate and dried over anhydrous Na2SO4 to give the desired diol as a yellow oil. Proton NMR showed the product to be

>95% pure. Yield of this crude product: 44.5 g (96%). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 5.79 (d, J = 3.6 Hz, 1H), 5.13 (d, J = 4.9 Hz, 1H), 4.61 (t, J = 5.6 Hz, 1H), 4.36 (d, J = 3.6 Hz, 1H), 4.10 – 3.91 (m, 2H), 3.60 (m, 1H), 3.51 (m, 1H), 1.37 (s, 3H), 1.22 (s, 3H) ppm


Example 528 Synthesis of Exemplary Compounds of the Invention



528-2

Synthesis of Compound 528-2: 1,2-O-isopropylidene-L-xylose (5 g, 26.3 mmol, 1.0 eq.) and 2-iodobenzoyl chloride (7.01 g, 26.3 mmol) were dissolved in anhydrous dichloromethane (25 mL). The solution was cooled in an ice-water bath. Triethylamine (3.85 mL, 27.6 mmol, 1.05 eq.) was added dropwise via syringe. The mixture was stirred at 0 °C for 30 min and slowly warmed to room temperature over 1 h. Water was added to the reaction mixture. The mixture was washed with 1 M aqueous HCl. The aqueous wash was extracted with 20 mL of dichloromethane. The combined organic extract was washed with a mixture of 20 mL of brine and 5 mL of saturated aqueous sodium bicarbonate. The organic layer was dried over anhydrous Na_2SO_4, filtered, and concentrated *in vacuo* to give a brown oil. This crude product was purified by silica gel chromatography (eluted with 0 – 50% EtOAc in hexane) to give the desired mono-ester as a yellow oil. Yield: 7.6 g (69%). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 8.02 (d, J = 7.3 Hz, 1H), 7.73 (dd, J = 7.8, 1.7 Hz, 1H), 7.52 (t, J = 7.3 Hz, 1H), 7.29 (td, J = 7.7, 1.8 Hz, 1H), 5.88 (d, J = 3.7 Hz, 1H), 5.51 (m, 1H), 4.45 (m, 2H), 4.12 (m, 1H), 1.38 (s, 3H), 1.24 (s, 3H) ppm. MS (m/z): *calculated* 420.01 ($M+H^+$), 443.00 ($M+Na^+$), *found* 420.9 ($M+H^+$), 443.0 ($M+Na^+$).


Example 529 Synthesis of Exemplary Compounds of the Invention



529-3

Synthesis of Compound 529-3: The product obtained in the previous step (7.6 g, 18.1 mmol, 1.0 eq.) was dissolved in 35 mL of anhydrous dichloromethane. Dess-Martin periodinane (9.6 g, 22.6 mmol, 1.25 eq.) was added. The mixture was stirred at room temperature for 14 h. A 1 M solution of sodium sulfite (7.5 mL) was added. The resulting mixture was stirred for another 2 h at room temperature. A saturated solution of $NaHCO_3$ was added in portions to adjust the pH of the aqueous phase to 6. The two layers were separated. The aqueous phase was extracted twice with 15 mL of dichloromethane. The combined organic extract was washed with brine, dried over anhydrous Na_2SO_4 for 4 h with good stirring. It was then filtered, and dried over excess amount of anhydrous $MgSO_4$ overnight with good stirring. The mixture was filtered and concentrated in vacuo to give a clear oil as product, which was used without further purification in the subsequent step. Yield: 6.7 g (89%). ^1H NMR (*DMSO-d_6*, 300MHz): δ 8.02 (d, J = 7.9 Hz, 1H), 7.71 (dd, J = 7.8, 1.7 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.29 (td, J = 7.6, 1.5 Hz, 1H), 6.16 (d, J = 4.6 Hz, 1H), 4.85 (m, 1H), 4.63 (d, J = 4.6 Hz, 1H), 4.54 (dd, J = 12.2, 2.7 Hz, 1H), 4.42 (dd, J = 12.2, 4.3 Hz, 1H), 1.41 (s, 3H), 1.34 (s, 3H) ppm. MS (m/z): *calculated* 458.99 ($M+H_2O+Na^+$), *found* 459.03 ($M+H_2O+Na^+$).

Example 530 Synthesis of Exemplary Compounds of the Invention




530-4

Synthesis of Compound 530-4: The product obtained in the previous step (6.15 g, 14.7 mmol, 1.0 eq.) was dissolved in 29 mL of anhydrous THF. The solution was cooled in an ice-water bath. A 3.0 M solution of methyl magnesium

bromide in diethyl ether (5.39 mL, 16.2 mmol, 1.1 eq.) was added dropwise via syringe. The mixture was stirred at 0 °C for 2 h. Aqueous citric acid solution (1 M, 10 mL) was added to the reaction mixture. The resulting mixture was evaporated *in vacuo* to remove most of THF. The aqueous residue was extracted twice with 10 mL of EtOAc. The organic extract was washed with saturated $NaHCO_3$ and brine. The organic phase was dried over anyhydrous sodium sulfate, filtered, and evaporated in vacuo to give a white solid as product. Yield: 6.11 g (96%). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 8.01 (dd, J = 8.0, 1.0 Hz, 1H), 7.71 (dd, J = 7.8, 1.7 Hz, 1H), 7.52 (td, J = 7.5, 1.0 Hz, 1H), 7.29 (td, J = 7.7, 1.8 Hz, 1H), 5.72 (d, J = 3.7 Hz, 1H), 5.13 (s, 1H), 4.46 (dd, J = 11.6, 2.3 Hz, 1H), 4.20 (dd, J = 11.7, 8.5 Hz, 1H), 4.12 (d, J = 3.6 Hz, 1H), 4.08 (dd, J = 8.5, 2.1 Hz, 1H), 1.45 (s, 3H), 1.26 (s, 3H), 1.06 (s, 3H) ppm. MS (m/z): *calculated* 457.01 ($M+Na^+$), *found* 457.27 ($M+Na^+$).

Example 531 Synthesis of Exemplary Compounds of the Invention




531-5

Synthesis of Compound 531-5: To a solution of **530-4** (6.1 g, 14.1 mmol) in 20 mL of anhydrous pyridine, was added triethylamine (3.13 mL, 22.5 mmol), DMAP (0.343 g, 2.8 mmol), followed by benzoyl chloride (2.61 mL, 22.5 mmol). The mixture was stirred at 70 C for 36 h, and then cooled to room temperature. The mixture was evaporated in vacuo to remove most of the pyridine. The residue was acidified with 1 M aqueous citric acid. The resulting mixture was extracted twice with ethyl acetate. The combined organic layer was washed with saturated $NaHCO_3$, and brine, dried over anhydrous Na_2SO_4, and evaporated in vacuo to give a crude product. This crude product was purified by silica gel chromatography (0-35% ethyl acetate in hexane) to give 7.0 g (92%) of **5**. ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 8.03 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 7.5 Hz, 2H), 7.79 (d, J = 7.7 Hz, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.5 (m, 3H), 7.30 (t, J

= 7.6 Hz, 1H), 5.92 (d, J = 3.7 Hz, 1H), 4.92 (d, J = 3.5 Hz, 1H), 4.63 (m, 1H), 4.46 (m, 2H), 1.50 (s, 3H), 1.39 (s, 3H), 1.25 (s, 3H) ppm. MS (m/z) 589.2 ($M+H^+$), 611.3 ($M+Na^+$). MS (m/z): *calculated* 561.04 ($M+Na^+$), *found* 561.06 ($M+Na^+$).


Example 532 Synthesis of Exemplary Compounds of the Invention



532-6

Synthesis of Compound 532-6: To a solution of **531-5** (7.0 g, 13 mmol) in 26 mL of glacial acetic acid, was added acetic anhydride (7.7 mL). The solution was cooled in an ice-water bath. Concentrated sulfuric acid (1.9 mL) was added dropwise via syringe over 10 min. The cooling bath was removed and the solution was allowed to warm to room temperature and stirred at that temperature for another 20 h. The reaction mixture was poured into a mixture of 75 mL of diethyl ether and 75 g of ice. The layers were separated and the aqueous layer was extracted with 75 mL of diethyl ether. The combined ether extract was stirred with 250 mL of water. Solid NaHCO3 was addedin portions until gas evolution had stopped. The layers were separated. The aqueous layer was extracted with 75 mL of ether. The combined ether extract was washed with brine, dried over anhydrous $MgSO_4$, and concentrated in vacuo to give 6 as a yellow foam. Two diastereomers of the same molucular weight were present in the product mixture, presumably the two anomers. Yield: 6.76 g (89%). This crude product was used without further purification. MS (m/z): *calculated* 605.03 ($M+Na^+$), *found* 604.93 ($M+Na^+$).


Example 533 Synthesis of Exemplary Compounds of the Invention



533-7

Synthesis of Compound 533-7: **532-6** (6.76 g, 11.6 mmol) was dissolved in 22 mL of dichloromethane. The solution was cooled in an ice-water bath. A solution of $SnCl_4$ in dichloromethane (1.0 M, 29 mL, 29 mmol) was added via syringe. The cooling bath was removed and the mixture was warmed to room temperature and stirred for another hour. The mixture was again cooled to 0 °C. Triethylamine (15 mL) was added via syringe. The resulting solution was poured onto a mixture of 75 g of ice and 75 mL of EtOAc. The mixture was filtered through a pad of Celite. The solids were washed thoroughly with EtOAc. The combined filtrate was washed with saturated $NaHCO_3$, brine, dried over Na_2SO_4, and concentrated in vacuo to give a crude product, which was purified by silica gel chromatography (25 – 75% EtOAc in hexane) to give 7 as a light yellow foam. Yield: 6.0 g (75%). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 8.00 (d, J = 7.9 Hz, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 7.9 Hz, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.45 (m, 3H), 7.25 (t, J = 7.3 Hz, 1H), 5.28 (s, 1H), 5.07 (s, 1H), 4.65 (m, 2H), 4.49 (m, 1H), 4.10 – 3.90 (m, 5H), 3.83 (dd, J = 13.9, 9.0 Hz, 1H), 1.88 (s, 3H), 1.69 (s, 3H), 1.18 (t, J = 6.9 Hz, 6H) ppm. MS (m/z): *calculated* 713.06 ($M+Na^+$), *found* 713.08 ($M+Na^+$).

Example 534 Synthesis of Exemplary Compounds of the Invention




534-8

Synthesis of Compound 534-8: To a solution of **533-7** (4.7 g, 6.8 mmol) in 30 mL of dichloromethane was added 27.2 mL of a 1.0 M aqueous solution of KH_2PO_4. A 0.8 M solution of NaOCl in water was added. The mixture was stirred at room temperature for 1 h. Methanol (10 mL) was added. Solid K2CO3 was added in portions until the pH of the aqueous phase reached 9 – 10. The mixture was stirred for another hour at room temperature. An 1 M aqueous solution of Na_2SO_3 (10 mL) was added and the mixture was stirred for another 30 min at room temperature. The two layers were separated. The aqueous layer

was further extracted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and evaporated in vacuo to give **534-8** as a yellow foam, which was used directly in the next step without further purification. ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 7.94 (d, J = 7.8 Hz, 2H), 7.68 (t, J = 7.5 Hz, 1H), 7.54 (t, J = 7.6 Hz, 2H), 5.28 (d, J = 1.0 Hz, 1H), 5.05 (d, J = 1.2 Hz, 1H), 4.98 (t, J = 5.6 Hz, 1H), 4.34 (dd, J = 6.5, 4.6 Hz, 1H), 4.11 – 3.95 (m, 5H), 3.86 (dd, J = 13.7, 8.8 Hz, 1H), 3.76 (m, 1H), 3.63 (m, 1H), 1.93 (s, 3H), 1.64 (s, 3H), 1.25 (t, J = 7.0 Hz, 6H) ppm.
^{31}P NMR (*DMSO-d_6*): δ 20.63 (s, 1P) ppm. MS (m/z): *calculated* 483.14 ($M+Na^+$), *found* 483.30 ($M+Na^+$).


Example 535 Synthesis of Exemplary Compounds of the Invention



535-9

Synthesis of Compound 535-9: To a mixture of **533-8** obtained above and 6.8 mL of acetonitrile and 6.8 mL of water, was added iodobenzene diacetate (4.97 g, 15 mmol), and TEMPO (0.213 g, 1.36 mmol). The mixture was stirred vigorously for 6 h at room temperature. It was then frozen and lyophilized to give a orange colored solid, which was dissolved in dichloromethane and purified by silica gel chromatography (0 – 10% MeOH in CH2Cl2) to give **534-9** as a light yellow solid. Yield: 2.8 g (87% for two steps). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 13.39 (br s, 1H), 7.97 (d, J = 7.8 Hz, 2H), 7.70 (t, J = 7.3 Hz, 1H), 7.56 (t, J = 7.5 Hz, 2H), 5.35 (s, 1H), 5.16 (s, 1H), 4.89 (s, 1H), 4.18 (dd, J = 13.7, 8.8 Hz, 1H), 4.06 (m, 4H), 3.88 (dd, J = 13.4, 9.7 Hz, 1H), 1.86 (s, 3H), 1.69 (s, 3H), 1.24 (dt, J = 7.0, 2.7 Hz, 6H) ppm. ^{31}P NMR (*DMSO-d_6*): δ 20.79 (s, 1P) ppm. MS (m/z): *calculated* 473.12 ($M-H^-$), *found* 472.95 ($M-H^-$).


Example 536 Synthesis of Exemplary Compounds of the Invention



536-10

Synthesis of Compound 536-10: To a solution of **535-9** (474 mg, 1.0 mmol) in 2.0 mL of anhydrous DMF, was added pyridine (238 mg, 3.0 mmol), and lead tetraacetate (1.33 g, 3.0 mmol). The mixture was stirred while shielded from light for 7 h at room temperature. It was then poured into a mixture of 10 g of ice and 10 mL of diethyl ether. The mixture was filtered to remove precipitates. The two layers of the filtrate were separated. The aqueous phase was extracted twice with ether. The combined ether extract was washed with 1 M citric acid, saturated $NaHCO_3$, and brine. After drying with anhydrous MgSO4, the ether solution was concentrated in vacuo to give crude **536-10** as a colorless oil, which was used without further purification. Yield: 255 mg (52%). MS (m/z): *calculated* 511.13 ($M+Na^+$), *found* 511.11 ($M+Na^+$).

Example 537 Synthesis of Exemplary Compounds of the Invention




537-11

Synthesis of Compound 537-11: To a solution of **536-10** (211 mg, 0.43 mmol) in 2.0 mL of anhydrous acetonitrile, was added O,O-bis(trimethylsilyl)uracil (443 mg, 1.73 mmol), and TMS-OTf (384 mg, 1.73 mmol). The mixture was stirred at room temperature for 3 h. An additional 443 mg of O,O-bis(trimethylsilyl)uracil was added, and the mixture was stirred for another 4 h at room temperature. 2, 6-Lutidine (371 mg, 3.46 mmol) was added dropwise via syringe, followed by TMS-I (259 mg, 1.3 mmol). The mixture was stirred for another hour at room temperature and then poured onto 10 g of ice. The mixture frozen and filtered through a pad of Celite. The filtrate was frozen and lyophilized to give a yellow solid, which was dissolved in water and purified by

reversed phase HPLC to give **537-11** as a white solid. Yield: 20 mg (10%). MS (m/z): *calculated* 483.08 ($M-H^-$), *found* 483.34 ($M-H^-$).

Example 538 Synthesis of Exemplary Compounds of the Invention




538-12


Synthesis of Compound 538-12: To a solution of **537-11** (17 mg, 0.035 mmol) in 0.3 mL water, was added NaOH (4.3 mg, 0.11 mmol). After stirring at room temperature for 2 h, the mixture acidified with trifluoroacetic acid and purified by HPLC to give **538-12** as a white powder. Yiled: 5 mg (42%). ^1H NMR (D_2O, 300MHz): δ 7.74 (d, J = 8.2 Hz, 1H), 5.97 (s, 1H), 5.78 (d, J = 8.2 Hz, 1H), 5.10 (d, J = 4.9 Hz, 1H), 3.86 (dd, J = 12.9, 10.0 Hz, 1H), 3.78 (d, J = 4.7 Hz, 1H), 3.65 (dd, J = 12.7, 9.3 Hz, 1H), 1.10 (s, 3H) ppm. ^{31}P NMR (D_2O): δ 14.60 (s, 1P) ppm. MS (m/z): *calculated* 337.04 ($M-H^-$), *found* 337.38 ($M-H^-$).

Example 539: Synthesis of Exemplary Compounds of the Invention

Synthesis of 3'-Deoxy-CP




Example 540 Synthesis of Exemplary Compounds of the Invention



540-2

Synthesis of Compound 540-2 To a stirred solution of **527-1** (50 mg, 0.11 mmol) in 1 mL of acetonitrile under nitrogen was added 2,4,6-triisopropylbenzenesulfonyl chloride (65 mg, 0.21 mmol), DMAP (26 mg, 0.21 mmol), and triethylamine (22 mg, 0.21 mmol). The mixture was stirred at room temperature for 4 h. Aqueous ammonia (29%, 1 mL) was added. The mixture was stirred at room temperature for 2 h. Extraction with EtOAc, followed by purification by silica gel chromatography gave **540-2** as a white solid. MS (m/z): *calculated* 468.15 ($M+H^+$), *found* 468.0 ($M+H^+$).


Example 541 Synthesis of Exemplary Compounds of the Invention



541-3

Synthesis of Compound 541-3: To a solution of **540-2** obtained above in acetonitrile was added 2,6-lutidine (118 mg, 1.10 mmol) and TMS-I (165 mg, 0.84mmol). The mixture was stirred at room temperature for 2 h. Triethylamine was added, followed by water. The mixture was then frozen and lyophilized to give a solid residue. This crude product was purified by reversed phase HPLC to give **541-3** as a white solid. Yiled 44 mg (97% for two steps). MS (m/z): *calculated* 410.1 ($M-H^-$), *found* 410.2 ($M-H^-$).


Example 542 Synthesis of Exemplary Compounds of the Invention



542-4

Synthesis of Compound 542-4: To solution of **541-3** (40 mg, 0.097 mmol) in 0.5 mL of water was added NaOH (20 mg, 0.5 mmol). The solution was stirred at room temperature for 30 min. Reversed phase HPLC purification gave **542-4** as a white solid. Yield: 28 mg (94%). ^{1}H NMR (D_2O, 300 MHz) δ 7.79 (d, J = 7.6 Hz, 1H), 5.95 (d, J = 7.6 Hz, 1H), 5.88 (d, J = 2.8 Hz, 1H), 5.40 (m, 1H), 4.42 (m, 1H), 3.78 (dd, J = 12.8, 9.8 Hz, 1H), 3.55 (dd, J = 13.1, 9.7 Hz, 1H), 2.20–2.05 (m, 2H) ppm. ^{31}P NMR (D_2O, 300 MHz) δ 14.66 ppm. MS (m/z): *calculated* 306.05 ($M-H^-$), *found* 305.8 ($M-H^-$).

Example 543 Synthesis of Exemplary Compounds of the Invention




543-5

Synthesis of Compound 543-5: To phosphonic diacid **542-4** (9 mg, 0.029 mmol) in 0.25 mL of DMF was added tributylamine (5.4 mg, 0.03 mmol) followed by carbonyldiimidazole (48 mg, 0.3 mmol). Reaction mixture was stirred at room temperature for 4 h at which point MeOH (0.010 mL) was added and stirred for an additional 30 min. Tributyl ammonium pyrophosphate (161 mg , 0.3 mmol) in DMF (0.64 mL) was added the reaction mixture stirred for 14 h. After the solvents were evaporated in vacuo, the crude product was purified by ion exchange HPLC (0–40% TEAB) to give the triethylammonium salt of **543-5** as a white solid. Yield: 3 mg. ^{1}H NMR (D_2O, 300 MHz) δ 7.78 (d, J = 7.6 Hz, 1H), 6.02 (d, J = 7.6 Hz, 1H), 5.88 (d, J = 2.9 Hz, 1H), 5.42 (m, 1H), 4.41 (m, 1H), 4.05 – 3.62 (m, 2H), 3.05 (q, J = 7.4 Hz, triethylammonium), 2.23 – 1.95


(m, 2H), 1.13 (t, J = 7.4 Hz, triethylammonium) ppm. ^{31}P NMR (D_2O, 300 MHz) δ 7.58 (d), -8.34 (d), –22.71 (t) ppm. MS (m/z): *calculated* 465.98 (M-H$^-$), *found* 466.16 (M-H$^-$).

Example 544 Synthesis of Exemplary Compounds of the Invention

Synthesis of 3'-Deoxy-CP



Example 545 Synthesis of Exemplary Compounds of the Invention




545-2

Synthesis of Compound 545-2 To a stirred solution of 1-O-methyl-2'-deoxy-D-ribose (23.9 g, 161.41 mmol) in pyridine under nitrogen was added t-butyldiphenylsilyl chloride (48 mL, 186 mmol) dropwise. When the addition was complete N,N-dimethyl-4-aminopyridine was added as a solid. The reaction was stirred at room temperature for 12 hr. and monitored by TLC. When the reaction was complete by TLC the pyridine was removed under vacuum. The oily residue was suspended in ethyl acetate (150 mL) and a white solid formed. The mixture was filtered and the solid was washed with 50 mL additional ethyl acetate. The solid was then discarded. The organic filtrates were combined and

washed with water (2 X 100 mL), 1N HCl(aq) (2x100mL) and sodium bicarbonate(sat'd)(2 x100mL). The organic phase was collected and dried over $MgSO_4$(anh). Evaporation and purification by column chromatography provides the desired mixture of diastereomers **545-2**: yield 31.15 g (50 0%). ^{1}H NMR (CD_3CN, 300MHz): δ 1.08 m, 9H); 1.85 m 1H; 2.27 m 2H; 3.3 s 3H; 3.7 m 2H; 3.90 m 1H; 4.27 m 1H; 5.06 m 1H, 7.45 m 6H; 7.76 m 4H. ppm.


Example 546 Synthesis of Exemplary Compounds of the Invention



546-3

Synthesis of Compound 546-3: The alcohol **545-2** (5.00g, 12.95 mmol) and triphenylphosphine (6.79 g. 25.9 mmol) were dissolved in anhydrous THF (50 mL) under nitrogen at room temperature. To this stirring solution was added dropwise, a mixture of benzoic acid (3.162g, 25.9 mmol) and disopropylazodicarboxylate dissolved in anhydrous THF (30 mL). After the addition was complete the reaction was stirred for 12 hr. at room temperature. After the reaction was complete by TLC, the solvent was removed under vacuum. The residue was suspended in diethyl ether (60 mL). Hexane (120 mL) was added and the solid formed was filtered and discarded. The solvents were removed by rotary evaporation and the products **546-3** were purified by column chromatography (2% to 15% EtOAc in hexane): yield 3.074g (48.4%). ^{1}H NMR (CD_3CN, 300MHz): δ 0.98 m 9H; 2.07 m 1H; 2.42 m 2H; 3.35 s 3H; 3.85 m 1H; 3.99 m 1H; 4.4 m 1H; 5.10 m 1H; 5.69 m 1H; 7.30 m 1H; 7.47 m 5H; 7.65 m 6H; 7.80 m 1H; 7.95 m 1H; 8.22 m 1H ppm.


Example 547 Synthesis of Exemplary Compounds of the Invention



547-4

Synthesis of Compound 547-4: The acetal **546-3** (6.88g, 12.95 mmol) and hydroxymethylphosphonate diethyl ester (7.76 mL, 52.65 mmol) were dissolved in 200 mL of toluene. The toluene was removed by rotary evaporation at 70°C under vacuum to reduce the reaction volume to appoximately 25 mL. The reaction was cooled to room temperature and p-toluene sulfonic acid monohydrate (0.490g, 2.58 mmol) was added as a solid along with toluene (200 mL). The toluene was removed by rotary evaporation at 70 °C under vacuum to reduce the reaction volume once again to appoximately 25 mL. Two additional aliquots of toluene were added and removal by evaporation is repeated each time. The reaction was monitored by TLC and when completed the residue was suspended in ethyl acetate (100mL) The organic layer was washed with sodium bicarbonate (sat'd), brine and then dried over $MgSO_4$ (anh). The desired phosphonate **547-4** was purified by column chromatography (10% to 90% EtOAc in hexane): yield 2.89 g (33%). ^{1}H NMR (*DMSO-d_6*, 300MHz): δ 0.92 s 9H; 1.25 t 6H; 2.35 t 2H; 3.84 m 4H; 4.05 m 4H; 4.32 q 1H; 5.37 t 1H; 5.62 q 1H; 7.26 t 2H; 7.30-7.55 m 8H; 7.60 d 2H; 7.65 t 1H; 7.82 d 2H ppm.

Example 548 Synthesis of Exemplary Compounds of the Invention




548-5

Synthesis of Compound 548-5: The silyl ether **547-4** (2.86g, 4.57 mmol) was dissolved in a minimal amount of methanol (15 mL) and stirred a room temperature under nitrogen. Ammonium fluoride (1.69g, 45.7 mmol) was added as a solid and the reaction was stirred at room temperature for 12 hr. The reaction was monitored by TLC and, when complete the methanol was removed under a stream of nitrogen. Add 6 mL of 1N Acetic acid (aq) and extract the aqueous phase with ethyl acetate (2 x125 mL). Combine the organic extracts and dried over Na_2SO_4(anh). The final product **548-5** was purified by column chromatography (50% to 100% EtOAc in hexane): yield 1.59 g (90%). ^{1}H NMR

(*DMSO-d_6*, 300MHz): δ 1.21 t 6H; 2.35 t 2H; 3.62-3.82 m 4H; 4.05 m 4H; 4.12 q 1H; 5.30 t 1H; 5.49 q 1H; 7.47 t 2H; 7.65 t 1H; 7.90 d 2H.


Example 549 Synthesis of Exemplary Compounds of the Invention



549-6

Synthesis of Compound 549-6: The primary alcohol **548-5** (1.43 g, 3.69 mmol) was dissolved in a 1:1 mixture of acetonitrile and water (10 mL) under nitrogen. Bisacetyliodobenzene (2.61g, 8.12mmol) was added as a solid along with a catalytic amount of TEMPO (0.115g, 0.74 mmol). The reaction was stirred at room temperature for 12 hr. and monitored by TLC. When the reaction was complete, it was frozen and lyphilized. The carboxylic acid **549-6** was purified by column chromatography (0% to 10% methanol in dichloromethane): yield 0.750g (51%). ^{1}H NMR (CD_3CN, 300MHz): δ 1.30 t 6H; 2.45 t 2H; 3.84 m 1H; 4.00-4.20 m 5H; 4.82 d 1H; 5.50 t 1H; 5.82 q 1H; 7.54 t 2H; 7.65 t 1H; 7.96 d 2H.


Example 550 Synthesis of Exemplary Compounds of the Invention



550-7

Synthesis of Compound 550-7 To acid **549-6** (88 mg, 0.22 mmol) in DMF (3.1 mL, 0.07 M) was added anhydrous pyridine (0.027 mL, 0.33 mmol) followed by lead tetraacetate (146 mg, 0.33 mmol). After 14 h at room temperature, Et_2O/H_2O (1:1, 3 mL) was added. The organics were separated, washed with 1M aqueous citric acid, saturated aqueous $NaHCO_3$, saturated aqueous NaCl and dried over sodium sulfate. After removal of solvent, the crude product **7** (50 mg, 54 %) was used directly in the next reaction.


Example 551 Synthesis of Exemplary Compounds of the Invention



551-8

Synthesis of Compound 551-8: N-Acetoxy-diphenylcarbamoyl gaunine (43 mg, 0.11 mmol), synthesized as described in Can. J. Chem. 65: 1436 (1987), in dichloroethane (1.1 mL, 0.1 M) was treated with N,O-bis(trimethylsilyl)acetamide (0.054 mL, 0.22 mmol). The reaction mixture was heated to 80 °C for 20 min after which the solvents were removed in vacuo. The crude silylated protected guanine was combined with phosphonate **550-7** (50 mg, 0.12 mmol) in dichloroethane (1.1 mL, 0.1 M) to which TMSOTf (28 μL, 0.153 mmol) was added. The reaction mixture heated to 60 °C for 5 h after with the reaction was quenched with saturated aqueous $NaHCO_3$. The solution was extracted with CH_2Cl_2, washed with saturated aqueous $NaHCO_3$, and dried over sodium sulfate. After removal of solvent, the crude product was purified by column chromatography on silica (2% $MeOH/CH_2Cl_2$) to provide the phosphonate diester **551-8** (18 mg, 22%). ^1H NMR ($CDCl_3$, 300 MHz) δ 8.30 (s, 1H), 8.15 (s, 1H), 8.02 (s, 1H) 8.00 (s, 1H), 7.35–7.62 (m, 12H), 6.43 (d, 1H), 6.02 (m, 1H), 5.65 (m, 1H), 4.18 (q, 4H), 3.78–4.01 (m, 2H), 2.86 (m, 1H), 2.63 (m, 1H), 2.53 (s, 3H), 1.37 (t, 6H) ppm. ^{31}P NMR ($CDCl_3$, 300 MHz) δ 20.07 (s) ppm. MS (m/z): *calculated* 744.2 ($M+H^+$), *found* 744.9 ($M+H^+$).


Example 552 Synthesis of Exemplary Compounds of the Invention



552-9

Synthesis of Compound 552-9 Phosphonate ester **551-8** (14 mg, 0.02 mmol) was treated with NH_3 in MeOH (2 mL, 2.0 N) at room temperature for 9 h. After solvents were removed in vacuo, the crude product was purified by column chromatography on silica (10% MeOH/CH_2Cl_2) to provide **552-9.** ^{1}H NMR (CD_3OD, 300 MHz) δ 7.89 (s, 1H), 5.96 (d, 1H), 5.45 (m, 1H), 4.10–4.21 (q, 4H), 3.84–4.02 (m, 2H), 2.92–2.47 (m, 2H), 1.33 (t, 6H) ppm. ^{31}P NMR (CD_3OD, 300 MHz) δ 21.75 ppm. MS (m/z): *calculated* 404.1 ($M+H^+$), *found* 404.2 ($M+H^+$).


Example 553 Synthesis of Exemplary Compounds of the Invention



553-10

Synthesis of Compound 553-10: To phosphonate ester guanosine derivative **552-9** (5.8 mg, 0.02 mmol) in anhydrous acetonitrile (0.15 mL, 0.1 M) was added 2,6-lutidine (0.014 mL, 0.12 mmol) followed by iodotrimethylsilane (0.016 mL, 0.12 mmol). After stirring for 15 min, triethylamine (0.12 mmol) and methanol (0.020 mL) were added and solvents were removed in vacuo. The crude product was purified by reverse phase column chromatography on C18 (0–10 % MeOH/H_2O-1% AcOH) to provide the phosphonic diacid **553-10**. ^{1}H NMR (D_2O, 300 MHz) δ 7.91 (s, 1H), 5.86 (d, 1H), 5.41 (m, 1H), 3.42–3.65 (m, 2H), 2.25–2.36 (m, 2H) ppm. ^{31}P NMR (D_2O, 300 MHz) δ 15.16 ppm. MS (m/z): *calculated* 346.1 ($M-H^-$), *found* 346.3 ($M-H^-$).

Example 554 Synthesis of Exemplary Compounds of the Invention



554-11


Synthesis of Compound 554-11: To phosphonic diacid **553-10** (2.5 mg, 7.2 μmol) in DMF (144 μL, 0.05 M) was added tributylamine (0.0086 mL, 0.036 mmol) followed by carbonyldiimidazole (12 mg, 0.072 mmol). Reaction was stirred at room temperature for 12 h at which point MeOH (0.005 mL) was added and stirred for an additional 30 min. Tributyl ammonium pyrophosphate (0.040 mg , 72 mmol) in DMF (0.16 mL) was added the reaction mixture stirred for 1 h. After the solvents were evaporated in vacuo, the crude product was purified by ion exchange HPLC (0–60% TEAB) to provide the diphosphophosphonate **554-11**. ^{1}H NMR (D_2O, 300 MHz) δ 7.94 (s, 1H), 5.85 (d, 1H), 4.47 (m, 1H), 3.71–3.78 (m, 2H), 2.27–2.39 (m, 2H) ppm. ^{31}P NMR (D_2O, 300 MHz) δ 8.09 (d), 7.71 (s), –22.04 (t) ppm. MS (m/z): *calculated* 505.99 (M-H$^-$), *found* 506.2 (M-H$^-$).

Example 555 Synthesis of Exemplary Compounds of the Invention

The following Schemes **555-5** to **555-9** describes a general method of preparing the [3.1.0] bicyclo hexane scaffold of the Formula **555-I** and **555-II** compounds. Exemplary structures, intermediates, substituents, protecting groups, reagents, and synthetic routes chosen for description here are meant to merely illustrate general methods of preparation, and are not intended to any way limit or denote preference to the methods.

The [3.1.0] bicyclo hexane scaffold may be synthesized by intramolecular cyclopropanation of a carbene generated by decomposition of a diazo 1,3-ketoester (Moon etal (2000) *Organic Letters* 2(24):3793-3796). The requisite 1,3-ketoester **555-5.1** may be prepared from acetoacetate ester anion addition to ene-aldehydes, e.g. acrolein (Scheme **555-5a**). For example, ethyl acetoacetate treated with 2 equivalents of lithium diisopropylamide at -78 °C and then one equivalent of acrolein gives the 1,3-ketoester **555-5.1** (Yoshimura etal (2002) *Jour. Org. Chem.* 67:5938-5945). Protection of the hydroxyl may be

accomplished with phenyldimethylsilyl chloride to give **555-5.2** where PG is phenyldimethylsilyl ($PhMe_2Si$–). Other trialkylsilyl protecting groups may be useful. Diazotization with p-toluenesulfonyl azide gives **555-5.3**. Treatment of **555-5.3** with a carbenoid insertion catalyst, e.g. $CuSO_4$ or $Rh(OAc)_2$, gives **555-5.4** as a mixture of diastereomers.




Scheme 555-5a

The ester of **555-5.4** may be hydrolyzed to the hydroxymethyl **555-5.5** or saponified directly to carboxylic acid **555-5.6** (Scheme **555-5b**). Appropriate oxidant(s) can convert the primary alcohol **555-5.5** to carboxylic acid **555-5.6** or its corresponding ester. In the case of an ester, an additional deprotection step will give the carboxylic acid, **555-5.6**. A variety of oxidation procedures exist in the literature and can be utilized here. These include but are not limited to the following methods: (i) pyridinium dichromate in Ac_2O, t-BuOH, and dichloromethane producing the t-butyl ester, followed by a deprotection using reagent such as trifluoroacetic acid to convert the ester to the corresponding carboxylic acid (see Classon, et al, *Acta Chem. Scand. Ser. B; 39*; 1985; 501-504. Cristalli, et al; *J. Med. Chem.; 31*; 1988; 1179-1183.); (ii) iodobenzene diacetate and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO) in acetonitrile, producing the carboxylic acid (See Epp, *et al*; *J. Org. Chem. 64*; 1999; 293-295. Jung et al; *J. Org. Chem.; 66*; 2001; 2624-2635.); (iii) sodium periodate, ruthenium(III) chloride in chloroform producing the carboxylic acid

(see Kim, et al, *J Med. Chem. 37*; 1994; 4020-4030. Homma, et al; *J. Med. Chem.; 35*; 1992; 2881-2890); (iv) chromium trioxide in acetic acid producing the carboxylic acid (see Olsson et al; *J. Med. Chem.; 29*; 1986; 1683-1689. Gallo-Rodriguez et al; *J. Med. Chem.; 37*; 1994; 636-646); (v) potassium permanganate in aqueous potassium hydroxide producing the carboxylic acid (see Ha, et al; *J. Med. Chem.; 29*; 1986; 1683-1689. Franchetti, et al; *J. Med. Chem.; 41*; 1998; 1708-1715.) (vi) nucleoside oxidase from *S. maltophilia* to give the carboxylic acid (see Mahmoudian, et al; *Tetrahedron; 54*; 1998; 8171-8182.)


Carboxylic acid **555-5.6** may be converted by decarboxylation to acetate **555-5.7** using lead(IV) tetraacetate (Teng et al; (1994) *J. Org. Chem.;* 59:278-280; Schultz, et al; *J. Org. Chem.; 48*; 1983; 3408-3412. When lead(IV) tetraacetate is used together with lithium chloride (see Kochi, et al; *J. Am. Chem. Soc.; 87*; 1965; 2052), the corresponding chloride is obtained **555-5.8**. Lead(IV) tetraacetate in combination with N-chlorosuccinimide can also produce **555-5.8** (Wang, et al; *Tet. Asym.; 1*; 1990; 527 and Wilson et al; *Tet. Asym.; 1*; 1990; 525). Alternatively, the acetate can also be converted to other leaving groups such as bromide by treatment of trimethylsilyl bromide (Spencer, et al; *J. Org. Chem.; 64*; 1999; 3987-3995).



Scheme 555-5b

Intermediates **555-5.7** and **555-5.8** may react with a variety of nucleophiles as described by Teng et al; *Synlett*; 1996; 346-348 and US 6087482; Column 54 line 64 to Column 55 line 20. Specifically, **555-5.7** may be reacted with diethyl hydroxymethylphosphonate in the presence of trimethylsilyl

trifluoromethanesulfonate (TMS-OTf) to give **555-5.9** (Scheme **555-5c**). It can be envisioned that other compounds with the general structure of HO-linker-$POR^{P1}R^{P2}$ can also be used so long as the functional groups in these compounds are compatible with the coupling reaction conditions. There are many examples in the published literature describing the coupling of 1' acetyl furanosyl compounds with a variety of alcohols. The reactions can be facilitated with a number of reagents, such as silver(I) salts (see Kim et al (1991) *J. Org. Chem.* 56:2642-2647, Toikka et al (1999) *J. Chem. Soc. Perkins Trans. 1*; 13:1877-1884); mercury(II) salts (see Veeneman et al (1987) *Recl. Trav. Chim. Pays-Bas;* 106:129-131); boron trifluoride diethyl etherate (see Kunz et al (1985) *Hel. Chim Acta;* 68:283-287); tin(II) chloride (see O'Leary et al (1994) *J. Org. Chem.* 59:6629-6636); alkoxide (see Shortnacy-Fowler et al (2001) *Nucleosides & Nucleotides;* 20:1583-1598); and iodine (see Kartha et al (2001) *J. Chem. Soc. Perkins Trans. 1* 770-772). These methods can be selectively used in conjunction with different methods in forming intermediates from **555-5.6** with various leaving groups (LG).




Scheme 555-5c

The introduction and removal of protecting groups (represented in the structures herein as PG) from a compound is common practice art in organic synthesis. Many sources of information of the art are available in the published literature, e.g. Greene and Wuts, *Protecting Groups in Organic Synthesis*, 3rd Ed., John Wiley & Sons, Inc., 1999. The main purpose is to temporarily transform a functional group and mask its reactivity so that it will survive a set of subsequent reaction procedures. Afterwards, the original functional group can be restored by a preconceived deprotection procedure. Therefore, the transformations in Schemes **555-(5a-c)** are intended to build the [3.1.0] scaffold with the appropriate latent functionality or reactivity components.

The keto group of certain intermediates, e.g. **555-5.4** may be elaborated to ribofuranose-type analogs **555-6.1** where Z^1 are for example, each hydroxyl or

protected hydroxyl (Scheme **555-6**). The hydroxyl groups can be protected as benzoyl (Bz) esters to give **555-6.2**. The bridgehead carboxylate ester can then be orthogonally hydrolyzed to give **555-6.3** or reduced to hydroxymethyl **555-6.4**. Oxidation of **555-6.4**, e.g. using iodobenzene diacetate and 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical (TEMPO), converts the primary alcohol to the corresponding acid **555-6.3**. Further oxidation of **555-6.3** using lead tetraacetate can produce acetate **555-6.5**. Coupling between **555-6.5** and hydroxyalkyl dialkylphosponate compounds, e.g. diethyl hydroxymethylphosphonate (available from Sigma-Aldrich, Cat. No. 39,262-6) and TMS-OTf can afford **555-6.6**. Treating **555-6.6** with TMS-Br converts the phosphodiester to the corresponding phosphonic acid **555-6.7**. Deprotection, e.g. NH_3 in methanol, of the 2'- and 3'- hydroxyl gives **555-6.8**.




Scheme 555-6

The phosphonic acids in **555-(6.6-6.8)** are used as examples for illustration purpose. Other forms of phosphonates can be accessed via the


phosphonic acid, or other forms, such as the corresponding diesters. See Schemes **555-A** and **555-(1-4)** for exemplary interconversions of phosphonate moieties.

Compounds such as **555-6.6** can be further elaborated by selective deprotection of PG and introduction of the nucleobase moiety (B). For example, where PG is trialkylsilyl, e.g. triethylsilyl, t-butyldimethylsilyl, or phenyldimethylsilyl, treatment of **555-6.6** with a fluoride reagent, e.g. tetrabutylammonium fluoride in THF, may selectively remove PG. The resulting hydroxyl may be converted to a leaving group (LG) such as chloro or acetate **555-7.1** under Vorbruggen-type reaction conditions, or the hydroxyl **555-7.2** reacted *in situ*, e.g. Mitsunobu conditions, to establish the carbon-nitrogen bond with a nucleobase or protected nucleobase reagent to give **555-7.3** (Scheme **555-7**). Suitable nucleobase or protected nucleobase reagents (B) include thymidine, cytosine, adenine, guanine, and silylated forms thereof. The resulting covalent attachment may be 9-purinyl or 1-pyrimidinyl. Other positional isomers may result and conventional means of separation may be employed to generate pure **555-7.3** compounds. The 2' and 3' protecting groups (Bz = benzoyl) may be removed from intermediate **555-7.3** with aqueous base to give **555-7.4**. The ethyl groups of **555-7.4** may be removed with a dealkylation reagent such as trimethylsilyl bromide to give phosphonic acid **555-7.5** which may be further elaborated according to the reactions shown in Schemes **555-A** and **1-4** to other phosphonate moieties, including diphosphophosphonate and phosphophosphonate compounds.



Scheme 555-7


Scheme **555-8** shows an exemplary route to 2'-β-methyl, 2'-3' hydroxyl bicylco adenine compounds. The 3' and 5' hydroxyl groups of [3.1.0] bicyclo analog of adenosine **555-8.1** (Kim, et al (2002) J. Med. Chem. 45:208-218) may be selectively silylated to give **555-8.2**. The 2' hydroxyl group may be oxidized under Dess-Martin periodinane conditions to give **555-8.3**. The 2' keto of **555-8.3** may be methylenated with a Wittig reagent and desilylated to give **555-8.4**. Epoxidation of **555-8.4** gives **555-8.5**. Hydride attack on the methylene carbon of the epoxide **555-8.5** gives **555-8.6** with the 2',3'-α-dihydroxy, 2'-β-methyl motif. This synthetic route may be versatile in the preparation of a variety of 2',3'-α-dihydroxy, 2'-β-methyl[3.1.0] bicyclo compounds where B = any protected or unprotected nucleobase.



Scheme 555-8


The 5' hydroxymethyl group of 2',3'-α-dihydroxy, 2'-β-methyl [3.1.0] bicyclo compounds, e.g. **555-8.6**, may be elaborated by selective reactions such as those shown in Scheme **555-9**. The 5' carbon may be removed by an oxidative decarboxylation to allow attachment of a phosphonate moiety through an oxygen atom bound directly to the [3.1.0] scaffold. The 5' hydroxyl group of **555-8.6** may be selectively protected as the 5' *tert*-butyldiphenylsilyl ether (TBDPS) and then the 2' and 3' hydroxyls may be protected as methoxymethyl ethers to give **555-9.1**. The 5' TBDPSi group may be removed with tetra-butyl ammonium fluoride (TBAF) and the resulting hydroxymethyll oxidized with the periodinane reagent, $PhI(OAc)_2$ and TEMPO to the carboxylic acid **555-9.2**. Oxidative decarboxylation of **555-9.2** with lead tetracetate and treatment with lithium hydroxide gives **555-9.3**. Alkylation of the hydroxyl of **555-9.3** with bromomethyldiethyl phosphonate gives **555-9.4**. The phosphonate ethyl groups and the 2', 3' methoxymethyl (MOM) protecting groups may be removed with iodotrimethylsilane to give **555-9.5**. The phosphonic acid group of **555-9.5** may be activated, for example with carbonyldiimidazole (CDI) and reacted with pyrophosphate anion to give diphosphophosphonate **555-9.6**. Other phosphonic

acid conversions may be conducted, as described in Schemes **555-A** and **555(1-4)**.




Scheme 555-9

Intermediate **555-8.2** is versatile for the preparation of 2' hydroxyl [3.1.0] bicyclo compounds (Scheme **555-10**). Protection of the 2' hydroxyl with para-methoxybenzyl bromide and silyl removal with TBAF gives **555-10.1**. The 5' hydroxyl is protected with the TBDPSi group to give **555-10.2**. The 3' thioester of **555-10.2** is formed with phenyl chlorothionoformate followed by reduction with tributyl tin hydride with AIBN to give **555-10.3**. Desilyation with TBAF and oxidation with BAIB and TEMPO furnishes the carboxylic acid **555-10.4**.



Scheme 555-10

Oxidative decarboxylation of **555-10.4** with lead tetracetate followed by lithium hydroxide treatment gives the hydroxyl **555-11.1** (Scheme **555-11**). Alkylation of hydroxyl **555-11.1** with bromomethyl diethyl phosphonate gives **555-11.2**. Iodotrimethylsilane cleaves the ethyl groups from the diethylphosphonate and ceric ammonium nitrate deprotects the para-methoxy benzyl group of **555-11.2** to give **555-11.3**. Phosphonate activation with CDI and addition of pyrophosphate gives the 2'-hydroxy diphosphophosphonate [3.1.0] compound **555-11.4**.



Scheme 555-11


Example 556 Synthesis of Exemplary Compounds of the Invention

The following Schemes describe the general method of preparing the 2' fluoro, 2'-3' didehydro nucleosidescaffold of compounds of the present invention.

Methods of introduction of fluorine at the 2' position of ribonucleosides and nucleoside analogs are described in US 5824793; US 5859233; Choo, H. etal *Journal of Medicinal Chemistry* (2003), 46(3), 389-398; Moon, H. etal *Journal of the Chemical Society, Perkin Transactions 1* (2002), (15), 1800-1804; Lee, Kyeong; Choi, Y. etal *Journal of Medicinal Chemistry* (2002), 45(6), 1313-1320; Lee, Kyeong; Choi, Yongseok; Hong, J. etal *Nucleosides & Nucleotides* (1999), 18(4 & 5), 537-540; Lee, K. etal *Journal of Medicinal Chemistry* (1999), 42(7), 1320-1328; Choi, Y. etal *Tetrahedron Letters* (1998), 39(25), 4437-4440; Chen, Shu-Hui etal *Bioorganic & Medicinal Chemistry Letters* (1998), 8(13), 1589-1594; Siddiqui, Maqbool etal *Tetrahedron Letters* (1998), 39(13), 1657-1660; Nakayama, Toshiaki etal *Nucleic Acids Symposium Series* (1991), 25(Symp. Nucleic Acids Chem., 18th,

1991), 191-2; Huang, Jai Tung etal *Journal of Medicinal Chemistry* (1991), 34(5), 1640-6; Sterzycki, Roman Z etal *Journal of Medicinal Chemistry* (1990), 33(8), 2150-7; Martin, Joseph A etal *Journal of Medicinal Chemistry* (1990), 33(8), 2137-45; Watanabe, Kyoichi etal *Journal of Medicinal Chemistry* (1990), 33(8), 2145-50; Zemlicka etal *Journal of the American Chemical Society* (1972) 94(9):3213-3218.

Schemes **556 (A-F)** show the synthetic routes which have been utilized to prepare the exemplary embodiments shown therein.



556-A.1 (-)-adenosine


556-A.2

556-A.3


556-A.4

Scheme 556-A


The (-) enantiomer of adenosine **556-A.1** was tritylated at the N-6 of the adenine exocyclic amine and the 5' hydroxyl with an excess of trityl (Tr, triphenylmethyl, Ph_3C-) chloride with dimethylaminopyridine in pyridine to give bis-trityl **556-A.2** which was treated with triflic anhydride in dichloromethane and DMAP to give **556-A.3** (Scheme 556-A). The 2' triflate group was displaced by fluoride with tetra-butylammonium fluoride in THF at room temperature to give **556-A.4**.


BzO
OBz
BzO
OH
556-B.1
BzO
OBz
BzO
F
556-B.2
BzO
Br
BzO
F
556-B.3
Cl
N
N
N
BzO
O
N
BzO
F
556-B.4
NH2
N
N
N
HO
O
N
HO
F
556-B.5
NH2
N
N
N
HO2C
O
N
HO
F
556-B.6

Scheme 556-B



NH2
HO
HO
F
556-B.5
NHMMT
MMTO
HO
F
556-C.1
NHMMT
MMTO
TBDPSiO
F
556-C.2
NHMMT
MMTO
TBDMSiO
F
556-C.3
NH2
HO
TBDMSiO
F
556-C.4
NH2
HO2C
TBDMSiO
F
556-C.5
NH2
HO2C
HO
F
556-C.6

Scheme 556-C



NMe2
NH2
HO2C
HO
F
556-C.6
556-D.1
556-D.2
556-D.3
EtO
EtO
PhSe
Cl


MeO
MeO
PhSeF
T
F
PhSe
556-D.4
556-D.5

Scheme 556-D


NMe2
EtO
EtO
556-E.1
H2O2
556-D.3
PhSe
F
NH3
NH2
556-E.2
Piv-Cl
NHPiv
556-E.3
556-E.4
H2O2 or O3/CCl4
NaOEt
556-E.5
TMSBr
HO
HO
556-E.6


Scheme 556-E


NMe2
N
N
N
N
Cl
O
N
PhSe
F
556-D.2
NMe2
N
N
N
N
MeO
O
N
PhSe
F
556-F.1
NH2
N
N
N
N
MeO
O
N
PhSe
F
556-F.2

Scheme 556-F

Example 600

By way of example and not limitation, embodiments of the invention are named below in tabular format (Table 100). These embodiments are of the general formula "MBF":



MBF


Each embodiment of MBF is depicted as a substituted nucleus (Sc). Sc is described in formula **1-336** herein, wherein A^0 is the point of covalent attachment of Sc to Lg, as well as in Tables 1.1 to 1.5 below. For those embodiments described in Table 100, Sc is a nucleus designated by a number and each substituent is designated in order by letter or number. Tables 1.1 to 1.5 are a schedule of nuclei used in forming the embodiments of Table 100. Each nucleus (Sc) is given a number designation from Tables 1.1 to 1.5, and this designation appears first in each embodiment name. Similarly, Tables 10.1 to 10.19 and 20.1 to 20.36 list the selected linking groups (Lg) and prodrug (Pd^1 and Pd^2) substituents, again by letter or number designation, respectively. Accordingly, a compound of the formula MBF includes compounds having Sc groups based on formula **1-336** herein as well as compounds according to Table 100 below. In all cases, compounds of the formula MBF have groups Lg, Pd^1 and Pd^2 setforth in the Tables below.

Accordingly, each named embodiment of Table 100 is depicted by a number designating the nucleus from Table 1.1-1.5, followed by a letter designating the linking group (Lg) from Table 10.1-10.19, and two numbers designating the two prodrug groups (Pd^1 and Pd^2) from Table 20.1-20.36. In graphical tabular form, each embodiment of Table 100 appears as a name having the syntax:


$$Sc.Lg.Pd^1.Pd^2$$

Each Sc group is shown having a tilda ("~"). The tilda is the point of covalent attachment of Sc to Lg. Q^1 and Q^2 of the linking groups (Lg), it should be understood, do not represent groups or atoms but are simply connectivity designations. Q^1 is the site of the covalent bond to the nucleus (Sc) and Q^2 is the site of the covalent bond to the phosphorous atom of formula MBF. Each prodrug group (Pd^1 and Pd^2) are covalently bonded to the phosphorous atom of MBF at the tilda symbol ("~"). Some embodiments of Tables 10.1-10.19 and 20.1-20.36 may be designated as a combination of letters and numbers (Table 10.1-10.19) or number and letter (Table 20.1-20.36). For example there are Table 10 entries for BJ1 and BJ2. In any event, entries of Table 10.1-10.19 always begin with a letter and those of Table 20.1-20.36 always begin with a number. When a nucleus (Sc) is shown enclosed within square brackets ("[]") and a covalent bond extends outside the brackets, the point of covalent attachment of Sc to Lg may be at any substitutable site on SC. Selection of the point of attachment is described herein. By way of example and not limitation, the point of attachment is selected from those depicted in the schemes and examples.


Table 1.1




1



2




3




4

Table 1.2




5




6


Table 1.3




7



8




9




10

Table 1.4




11




12

Table 1.5




13



14


Table 10.1




A




B




C




D




E




F




G




H




I




J




K




L



M




N




O


Table 10.2




P




Q




R




S




T




U




V




W




X



Y




Z




AA


Table 10.3




AB




AC




AD




AE




AF




AG




AH




AI




AJ



AK



AL



AM

Table 10.4









Table 10.5



Q1
O
AZ
Q2



Q1
O
BA
CH3
Q2



O
Q2
Q1
BB



Q1
O
BC
Q2



H3C
O
Q2
Q1
BD



Q1
O
Q2
CH3
BE


Q2
Q1
O
BF


Q2
Q1
O
BG
CH3


Q2
O
Q1
BH


O
Q1
BI
Q2


H3C
O
Q1
BJ2
Q2





Q1
O
CH3
BJ1
Q2


Table 10.6




BK




BL




BM



BN




BO




BP


Table 10.7




BQ




BR




BS



BT




BU




BV


Table 10.8




BW




BX




BY



BZ




CA




CB


Table 10.9




CC




CD




CE



CF



CG



CH

Table 10.10







Table 10.11




CU




CV




CW



CX




CY




CZ


Table 10.12




DA




DB




DC



DD




DE




DF


Table 10.13




DG




DH




DI



DJ




DK




DL


Table 10.14




DM




DN




DO



DP




DQ




DR


Table 10.15




DS




DT




DU




DV




DW




DX




DY




DZ




EA



EB




EC




ED


Table 10.16




EE




EF




EG



EH




EI




EJ


Table 10.17




EK




EL




EM



EN




EO




EP


Table 10.18




EQ




ER




ES



ET




EU




EV


Table 10.19




EW




EX




EY



EZ




FA




FB


Table 20.1




1




2




3




4




5



6




8




7


Table 20.2



9




10




11


Table 20.3




12




13




14




15




16



17




19




18


Table 20.4



20




21




22


Table 20.5




23




24




25




26




27



28




30



29

Table 20.6




31


32

33


Table 20.7




34




35




36




37




38



39




40




41


Table 20.8




42




43




44




45




46



47




48




49


Table 20.9




50




51




52




53




54



55




57




56


Table 20.10



58





59





60


Table 20.11



61



62


63


64


65


66


68




67

Table 20.12





69


70


71


Table 20.13



72



73


74


75


76


77


79



78

Table 20.14







Table 20.15




83




84




85




86




87



88





89





90


Table 20.16



91



92


93


94


95


96


97







98


Table 20.17



99



100


101


102


103


104


106




105

Table 20.18





107


108


109


Table 20.19



110



111


112


113


114


115


117




116

Table 20.20





118


119


120


Table 20.21



121



122


123


124


125


126


128



127

Table 20.22







Table 20.23




132




133




134




135




136



137





138





139


Table 20.24



140



141


142


143


144


145


146




147


Table 20.25




148




149




150




151




152




153




154




155




156



157




158




159


Table 20.26




160




161




162




163




164




165




166




167




168



169




170




171


Table 20.27




172




173




174




175




176



177




178




179


Table 20.28




180




181




182



183




184




185


Table 20.29




186




187




188




189




190



191




192




193


Table 20.30




194




195




196



197




198




199

5


Table 20.31




200




201




202




203




204



205




206




207


Table 20.32




208




209




210



211




212




213

5


Table 20.33




214




215




216




217




218



219




220




221

5


Table 20.34




222




223




224



225




226





227


5


Table 20.35



228



229


230


231


232


233


234





235


Table 20.36




236




237




238




239




240



241




242




243


Table 20.37




244



245



246



247

5

Table 100

Prodrugs of 1.B

1.B.228.228; 1.B.228.229; 1.B.228.230; 1.B.228.231; 1.B.228.236; 1.B.228.237; 1.B.228.238; 1.B.228.239; 1.B.228.154; 1.B.228.157; 1.B.228.166; 1.B.228.169; 1.B.228.172; 1.B.228.175; 1.B.228.240; 1.B.228.244; 1.B.229.228; 1.B.229.229; 1.B.229.230; 1.B.229.231; 1.B.229.236; 1.B.229.237; 1.B.229.238; 1.B.229.239; 1.B.229.154; 1.B.229.157; 1.B.229.166; 1.B.229.169; 1.B.229.172; 1.B.229.175; 1.B.229.240; 1.B.229.244; 1.B.230.228; 1.B.230.229; 1.B.230.230; 1.B.230.231; 1.B.230.236; 1.B.230.237; 1.B.230.238; 1.B.230.239; 1.B.230.154; 1.B.230.157; 1.B.230.166; 1.B.230.169; 1.B.230.172; 1.B.230.175; 1.B.230.240; 1.B.230.244; 1.B.231.228; 1.B.231.229; 1.B.231.230; 1.B.231.231; 1.B.231.236; 1.B.231.237; 1.B.231.238; 1.B.231.239; 1.B.231.154; 1.B.231.157; 1.B.231.166; 1.B.231.169; 1.B.231.172; 1.B.231.175; 1.B.231.240; 1.B.231.244; 1.B.236.228; 1.B.236.229; 1.B.236.230; 1.B.236.231; 1.B.236.236; 1.B.236.237; 1.B.236.238; 1.B.236.239; 1.B.236.154; 1.B.236.157; 1.B.236.166; 1.B.236.169; 1.B.236.172; 1.B.236.175; 1.B.236.240; 1.B.236.244; 1.B.237.228; 1.B.237.229; 1.B.237.230; 1.B.237.231; 1.B.237.236; 1.B.237.237; 1.B.237.238; 1.B.237.239; 1.B.237.154; 1.B.237.157; 1.B.237.166; 1.B.237.169; 1.B.237.172; 1.B.237.175; 1.B.237.240; 1.B.237.244; 1.B.238.228; 1.B.238.229; 1.B.238.230; 1.B.238.231; 1.B.238.236; 1.B.238.237; 1.B.238.238; 1.B.238.239; 1.B.238.154; 1.B.238.157; 1.B.238.166; 1.B.238.169; 1.B.238.172; 1.B.238.175; 1.B.238.240; 1.B.238.244; 1.B.239.228; 1.B.239.229; 1.B.239.230; 1.B.239.231; 1.B.239.236; 1.B.239.237; 1.B.239.238; 1.B.239.239; 1.B.239.154; 1.B.239.157; 1.B.239.166; 1.B.239.169; 1.B.239.172; 1.B.239.175; 1.B.239.240; 1.B.239.244; 1.B.154.228; 1.B.154.229; 1.B.154.230; 1.B.154.231; 1.B.154.236; 1.B.154.237; 1.B.154.238; 1.B.154.239; 1.B.154.154; 1.B.154.157; 1.B.154.166; 1.B.154.169; 1.B.154.172; 1.B.154.175; 1.B.154.240; 1.B.154.244; 1.B.157.228; 1.B.157.229; 1.B.157.230; 1.B.157.231; 1.B.157.236; 1.B.157.237; 1.B.157.238; 1.B.157.239; 1.B.157.154; 1.B.157.157; 1.B.157.166; 1.B.157.169; 1.B.157.172; 1.B.157.175; 1.B.157.240; 1.B.157.244; 1.B.166.228; 1.B.166.229; 1.B.166.230; 1.B.166.231; 1.B.166.236; 1.B.166.237; 1.B.166.238; 1.B.166.239; 1.B.166.154; 1.B.166.157; 1.B.166.166; 1.B.166.169; 1.B.166.172; 1.B.166.175; 1.B.166.240; 1.B.166.244; 1.B.169.228; 1.B.169.229; 1.B.169.230; 1.B.169.231; 1.B.169.236; 1.B.169.237; 1.B.169.238; 1.B.169.239; 1.B.169.154; 1.B.169.157; 1.B.169.166; 1.B.169.169; 1.B.169.172; 1.B.169.175; 1.B.169.240; 1.B.169.244; 1.B.172.228; 1.B.172.229; 1.B.172.230; 1.B.172.231; 1.B.172.236; 1.B.172.237; 1.B.172.238; 1.B.172.239; 1.B.172.154; 1.B.172.157; 1.B.172.166;

1.B.172.169; 1.B.172.172; 1.B.172.175; 1.B.172.240; 1.B.172.244; 1.B.175.228; 1.B.175.229; 1.B.175.230; 1.B.175.231; 1.B.175.236; 1.B.175.237; 1.B.175.238; 1.B.175.239; 1.B.175.154; 1.B.175.157; 1.B.175.166; 1.B.175.169; 1.B.175.172; 1.B.175.175; 1.B.175.240; 1.B.175.244; 1.B.240.228; 1.B.240.229; 1.B.240.230; 1.B.240.231; 1.B.240.236; 1.B.240.237; 1.B.240.238; 1.B.240.239; 1.B.240.154; 1.B.240.157; 1.B.240.166; 1.B.240.169; 1.B.240.172; 1.B.240.175; 1.B.240.240; 1.B.240.244; 1.B.244.228; 1.B.244.229; 1.B.244.230; 1.B.244.231; 1.B.244.236; 1.B.244.237; 1.B.244.238; 1.B.244.239; 1.B.244.154; 1.B.244.157; 1.B.244.166; 1.B.244.169; 1.B.244.172; 1.B.244.175; 1.B.244.240; 1.B.244.244;

Prodrugs of 1.D

1.D.228.228; 1.D.228.229; 1.D.228.230; 1.D.228.231; 1.D.228.236; 1.D.228.237; 1.D.228.238; 1.D.228.239; 1.D.228.154; 1.D.228.157; 1.D.228.166; 1.D.228.169; 1.D.228.172; 1.D.228.175; 1.D.228.240; 1.D.228.244; 1.D.229.228; 1.D.229.229; 1.D.229.230; 1.D.229.231; 1.D.229.236; 1.D.229.237; 1.D.229.238; 1.D.229.239; 1.D.229.154; 1.D.229.157; 1.D.229.166; 1.D.229.169; 1.D.229.172; 1.D.229.175; 1.D.229.240; 1.D.229.244; 1.D.230.228; 1.D.230.229; 1.D.230.230; 1.D.230.231; 1.D.230.236; 1.D.230.237; 1.D.230.238; 1.D.230.239; 1.D.230.154; 1.D.230.157; 1.D.230.166; 1.D.230.169; 1.D.230.172; 1.D.230.175; 1.D.230.240; 1.D.230.244; 1.D.231.228; 1.D.231.229; 1.D.231.230; 1.D.231.231; 1.D.231.236; 1.D.231.237; 1.D.231.238; 1.D.231.239; 1.D.231.154; 1.D.231.157; 1.D.231.166; 1.D.231.169; 1.D.231.172; 1.D.231.175; 1.D.231.240; 1.D.231.244; 1.D.236.228; 1.D.236.229; 1.D.236.230; 1.D.236.231; 1.D.236.236; 1.D.236.237; 1.D.236.238; 1.D.236.239; 1.D.236.154; 1.D.236.157; 1.D.236.166; 1.D.236.169; 1.D.236.172; 1.D.236.175; 1.D.236.240; 1.D.236.244; 1.D.237.228; 1.D.237.229; 1.D.237.230; 1.D.237.231; 1.D.237.236; 1.D.237.237; 1.D.237.238; 1.D.237.239; 1.D.237.154; 1.D.237.157; 1.D.237.166; 1.D.237.169; 1.D.237.172; 1.D.237.175; 1.D.237.240; 1.D.237.244; 1.D.238.228; 1.D.238.229; 1.D.238.230; 1.D.238.231; 1.D.238.236; 1.D.238.237; 1.D.238.238; 1.D.238.239; 1.D.238.154; 1.D.238.157; 1.D.238.166; 1.D.238.169; 1.D.238.172; 1.D.238.175; 1.D.238.240; 1.D.238.244; 1.D.239.228; 1.D.239.229; 1.D.239.230; 1.D.239.231; 1.D.239.236; 1.D.239.237; 1.D.239.238; 1.D.239.239; 1.D.239.154; 1.D.239.157; 1.D.239.166; 1.D.239.169; 1.D.239.172; 1.D.239.175; 1.D.239.240; 1.D.239.244; 1.D.154.228; 1.D.154.229;

1.D.154.230; 1.D.154.231; 1.D.154.236; 1.D.154.237; 1.D.154.238; 1.D.154.239; 1.D.154.154; 1.D.154.157; 1.D.154.166; 1.D.154.169; 1.D.154.172; 1.D.154.175; 1.D.154.240; 1.D.154.244; 1.D.157.228; 1.D.157.229; 1.D.157.230; 1.D.157.231; 1.D.157.236; 1.D.157.237; 1.D.157.238; 1.D.157.239; 1.D.157.154; 1.D.157.157; 1.D.157.166; 1.D.157.169; 1.D.157.172; 1.D.157.175; 1.D.157.240; 1.D.157.244; 1.D.166.228; 1.D.166.229; 1.D.166.230; 1.D.166.231; 1.D.166.236; 1.D.166.237; 1.D.166.238; 1.D.166.239; 1.D.166.154; 1.D.166.157; 1.D.166.166; 1.D.166.169; 1.D.166.172; 1.D.166.175; 1.D.166.240; 1.D.166.244; 1.D.169.228; 1.D.169.229; 1.D.169.230; 1.D.169.231; 1.D.169.236; 1.D.169.237; 1.D.169.238; 1.D.169.239; 1.D.169.154; 1.D.169.157; 1.D.169.166; 1.D.169.169; 1.D.169.172; 1.D.169.175; 1.D.169.240; 1.D.169.244; 1.D.172.228; 1.D.172.229; 1.D.172.230; 1.D.172.231; 1.D.172.236; 1.D.172.237; 1.D.172.238; 1.D.172.239; 1.D.172.154; 1.D.172.157; 1.D.172.166; 1.D.172.169; 1.D.172.172; 1.D.172.175; 1.D.172.240; 1.D.172.244; 1.D.175.228; 1.D.175.229; 1.D.175.230; 1.D.175.231; 1.D.175.236; 1.D.175.237; 1.D.175.238; 1.D.175.239; 1.D.175.154; 1.D.175.157; 1.D.175.166; 1.D.175.169; 1.D.175.172; 1.D.175.175; 1.D.175.240; 1.D.175.244; 1.D.240.228; 1.D.240.229; 1.D.240.230; 1.D.240.231; 1.D.240.236; 1.D.240.237; 1.D.240.238; 1.D.240.239; 1.D.240.154; 1.D.240.157; 1.D.240.166; 1.D.240.169; 1.D.240.172; 1.D.240.175; 1.D.240.240; 1.D.240.244; 1.D.244.228; 1.D.244.229; 1.D.244.230; 1.D.244.231; 1.D.244.236; 1.D.244.237; 1.D.244.238; 1.D.244.239; 1.D.244.154; 1.D.244.157; 1.D.244.166; 1.D.244.169; 1.D.244.172; 1.D.244.175; 1.D.244.240; 1.D.244.244;

Prodrugs of 1.E

1.E.228.228; 1.E.228.229; 1.E.228.230; 1.E.228.231; 1.E.228.236; 1.E.228.237; 1.E.228.238; 1.E.228.239; 1.E.228.154; 1.E.228.157; 1.E.228.166; 1.E.228.169; 1.E.228.172; 1.E.228.175; 1.E.228.240; 1.E.228.244; 1.E.229.228; 1.E.229.229; 1.E.229.230; 1.E.229.231; 1.E.229.236; 1.E.229.237; 1.E.229.238; 1.E.229.239; 1.E.229.154; 1.E.229.157; 1.E.229.166; 1.E.229.169; 1.E.229.172; 1.E.229.175; 1.E.229.240; 1.E.229.244; 1.E.230.228; 1.E.230.229; 1.E.230.230; 1.E.230.231; 1.E.230.236; 1.E.230.237; 1.E.230.238; 1.E.230.239; 1.E.230.154; 1.E.230.157; 1.E.230.166; 1.E.230.169; 1.E.230.172; 1.E.230.175; 1.E.230.240; 1.E.230.244; 1.E.231.228; 1.E.231.229; 1.E.231.230; 1.E.231.231; 1.E.231.236;

1.E.231.237; 1.E.231.238; 1.E.231.239; 1.E.231.154; 1.E.231.157; 1.E.231.166; 1.E.231.169; 1.E.231.172; 1.E.231.175; 1.E.231.240; 1.E.231.244; 1.E.236.228; 1.E.236.229; 1.E.236.230; 1.E.236.231; 1.E.236.236; 1.E.236.237; 1.E.236.238; 1.E.236.239; 1.E.236.154; 1.E.236.157; 1.E.236.166; 1.E.236.169; 1.E.236.172; 1.E.236.175; 1.E.236.240; 1.E.236.244; 1.E.237.228; 1.E.237.229; 1.E.237.230; 1.E.237.231; 1.E.237.236; 1.E.237.237; 1.E.237.238; 1.E.237.239; 1.E.237.154; 1.E.237.157; 1.E.237.166; 1.E.237.169; 1.E.237.172; 1.E.237.175; 1.E.237.240; 1.E.237.244; 1.E.238.228; 1.E.238.229; 1.E.238.230; 1.E.238.231; 1.E.238.236; 1.E.238.237; 1.E.238.238; 1.E.238.239; 1.E.238.154; 1.E.238.157; 1.E.238.166; 1.E.238.169; 1.E.238.172; 1.E.238.175; 1.E.238.240; 1.E.238.244; 1.E.239.228; 1.E.239.229; 1.E.239.230; 1.E.239.231; 1.E.239.236; 1.E.239.237; 1.E.239.238; 1.E.239.239; 1.E.239.154; 1.E.239.157; 1.E.239.166; 1.E.239.169; 1.E.239.172; 1.E.239.175; 1.E.239.240; 1.E.239.244; 1.E.154.228; 1.E.154.229; 1.E.154.230; 1.E.154.231; 1.E.154.236; 1.E.154.237; 1.E.154.238; 1.E.154.239; 1.E.154.154; 1.E.154.157; 1.E.154.166; 1.E.154.169; 1.E.154.172; 1.E.154.175; 1.E.154.240; 1.E.154.244; 1.E.157.228; 1.E.157.229; 1.E.157.230; 1.E.157.231; 1.E.157.236; 1.E.157.237; 1.E.157.238; 1.E.157.239; 1.E.157.154; 1.E.157.157; 1.E.157.166; 1.E.157.169; 1.E.157.172; 1.E.157.175; 1.E.157.240; 1.E.157.244; 1.E.166.228; 1.E.166.229; 1.E.166.230; 1.E.166.231; 1.E.166.236; 1.E.166.237; 1.E.166.238; 1.E.166.239; 1.E.166.154; 1.E.166.157; 1.E.166.166; 1.E.166.169; 1.E.166.172; 1.E.166.175; 1.E.166.240; 1.E.166.244; 1.E.169.228; 1.E.169.229; 1.E.169.230; 1.E.169.231; 1.E.169.236; 1.E.169.237; 1.E.169.238; 1.E.169.239; 1.E.169.154; 1.E.169.157; 1.E.169.166; 1.E.169.169; 1.E.169.172; 1.E.169.175; 1.E.169.240; 1.E.169.244; 1.E.172.228; 1.E.172.229; 1.E.172.230; 1.E.172.231; 1.E.172.236; 1.E.172.237; 1.E.172.238; 1.E.172.239; 1.E.172.154; 1.E.172.157; 1.E.172.166; 1.E.172.169; 1.E.172.172; 1.E.172.175; 1.E.172.240; 1.E.172.244; 1.E.175.228; 1.E.175.229; 1.E.175.230; 1.E.175.231; 1.E.175.236; 1.E.175.237; 1.E.175.238; 1.E.175.239; 1.E.175.154; 1.E.175.157; 1.E.175.166; 1.E.175.169; 1.E.175.172; 1.E.175.175; 1.E.175.240; 1.E.175.244; 1.E.240.228; 1.E.240.229; 1.E.240.230; 1.E.240.231; 1.E.240.236; 1.E.240.237; 1.E.240.238; 1.E.240.239; 1.E.240.154; 1.E.240.157; 1.E.240.166; 1.E.240.169; 1.E.240.172; 1.E.240.175; 1.E.240.240; 1.E.240.244; 1.E.244.228; 1.E.244.229; 1.E.244.230; 1.E.244.231; 1.E.244.236; 1.E.244.237; 1.E.244.238; 1.E.244.239; 1.E.244.154; 1.E.244.157; 1.E.244.166; 1.E.244.169; 1.E.244.172; 1.E.244.175; 1.E.244.240; 1.E.244.244;

Prodrugs of 1.G

1.G.228.228; 1.G.228.229; 1.G.228.230; 1.G.228.231; 1.G.228.236; 1.G.228.237; 1.G.228.238; 1.G.228.239; 1.G.228.154; 1.G.228.157; 1.G.228.166; 1.G.228.169; 1.G.228.172; 1.G.228.175; 1.G.228.240; 1.G.228.244; 1.G.229.228; 1.G.229.229; 1.G.229.230; 1.G.229.231; 1.G.229.236; 1.G.229.237; 1.G.229.238; 1.G.229.239; 1.G.229.154; 1.G.229.157; 1.G.229.166; 1.G.229.169; 1.G.229.172; 1.G.229.175; 1.G.229.240; 1.G.229.244; 1.G.230.228; 1.G.230.229; 1.G.230.230; 1.G.230.231; 1.G.230.236; 1.G.230.237; 1.G.230.238; 1.G.230.239; 1.G.230.154; 1.G.230.157; 1.G.230.166; 1.G.230.169; 1.G.230.172; 1.G.230.175; 1.G.230.240; 1.G.230.244; 1.G.231.228; 1.G.231.229; 1.G.231.230; 1.G.231.231; 1.G.231.236; 1.G.231.237; 1.G.231.238; 1.G.231.239; 1.G.231.154; 1.G.231.157; 1.G.231.166; 1.G.231.169; 1.G.231.172; 1.G.231.175; 1.G.231.240; 1.G.231.244; 1.G.236.228; 1.G.236.229; 1.G.236.230; 1.G.236.231; 1.G.236.236; 1.G.236.237; 1.G.236.238; 1.G.236.239; 1.G.236.154; 1.G.236.157; 1.G.236.166; 1.G.236.169; 1.G.236.172; 1.G.236.175; 1.G.236.240; 1.G.236.244; 1.G.237.228; 1.G.237.229; 1.G.237.230; 1.G.237.231; 1.G.237.236; 1.G.237.237; 1.G.237.238; 1.G.237.239; 1.G.237.154; 1.G.237.157; 1.G.237.166; 1.G.237.169; 1.G.237.172; 1.G.237.175; 1.G.237.240; 1.G.237.244; 1.G.238.228; 1.G.238.229; 1.G.238.230; 1.G.238.231; 1.G.238.236; 1.G.238.237; 1.G.238.238; 1.G.238.239; 1.G.238.154; 1.G.238.157; 1.G.238.166; 1.G.238.169; 1.G.238.172; 1.G.238.175; 1.G.238.240; 1.G.238.244; 1.G.239.228; 1.G.239.229; 1.G.239.230; 1.G.239.231; 1.G.239.236; 1.G.239.237; 1.G.239.238; 1.G.239.239; 1.G.239.154; 1.G.239.157; 1.G.239.166; 1.G.239.169; 1.G.239.172; 1.G.239.175; 1.G.239.240; 1.G.239.244; 1.G.154.228; 1.G.154.229; 1.G.154.230; 1.G.154.231; 1.G.154.236; 1.G.154.237; 1.G.154.238; 1.G.154.239; 1.G.154.154; 1.G.154.157; 1.G.154.166; 1.G.154.169; 1.G.154.172; 1.G.154.175; 1.G.154.240; 1.G.154.244; 1.G.157.228; 1.G.157.229; 1.G.157.230; 1.G.157.231; 1.G.157.236; 1.G.157.237; 1.G.157.238; 1.G.157.239; 1.G.157.154; 1.G.157.157; 1.G.157.166; 1.G.157.169; 1.G.157.172; 1.G.157.175; 1.G.157.240; 1.G.157.244; 1.G.166.228; 1.G.166.229; 1.G.166.230; 1.G.166.231; 1.G.166.236; 1.G.166.237; 1.G.166.238; 1.G.166.239; 1.G.166.154; 1.G.166.157; 1.G.166.166; 1.G.166.169; 1.G.166.172; 1.G.166.175; 1.G.166.240; 1.G.166.244; 1.G.169.228; 1.G.169.229; 1.G.169.230; 1.G.169.231; 1.G.169.236; 1.G.169.237; 1.G.169.238; 1.G.169.239; 1.G.169.154;

1.G.169.157; 1.G.169.166; 1.G.169.169; 1.G.169.172; 1.G.169.175; 1.G.169.240; 1.G.169.244; 1.G.172.228; 1.G.172.229; 1.G.172.230; 1.G.172.231; 1.G.172.236; 1.G.172.237; 1.G.172.238; 1.G.172.239; 1.G.172.154; 1.G.172.157; 1.G.172.166; 1.G.172.169; 1.G.172.172; 1.G.172.175; 1.G.172.240; 1.G.172.244; 1.G.175.228; 1.G.175.229; 1.G.175.230; 1.G.175.231; 1.G.175.236; 1.G.175.237; 1.G.175.238; 1.G.175.239; 1.G.175.154; 1.G.175.157; 1.G.175.166; 1.G.175.169; 1.G.175.172; 1.G.175.175; 1.G.175.240; 1.G.175.244; 1.G.240.228; 1.G.240.229; 1.G.240.230; 1.G.240.231; 1.G.240.236; 1.G.240.237; 1.G.240.238; 1.G.240.239; 1.G.240.154; 1.G.240.157; 1.G.240.166; 1.G.240.169; 1.G.240.172; 1.G.240.175; 1.G.240.240; 1.G.240.244; 1.G.244.228; 1.G.244.229; 1.G.244.230; 1.G.244.231; 1.G.244.236; 1.G.244.237; 1.G.244.238; 1.G.244.239; 1.G.244.154; 1.G.244.157; 1.G.244.166; 1.G.244.169; 1.G.244.172; 1.G.244.175; 1.G.244.240; 1.G.244.244;

Prodrugs of 1.I

1.I.228.228; 1.I.228.229; 1.I.228.230; 1.I.228.231; 1.I.228.236; 1.I.228.237; 1.I.228.238; 1.I.228.239; 1.I.228.154; 1.I.228.157; 1.I.228.166; 1.I.228.169; 1.I.228.172; 1.I.228.175; 1.I.228.240; 1.I.228.244; 1.I.229.228; 1.I.229.229; 1.I.229.230; 1.I.229.231; 1.I.229.236; 1.I.229.237; 1.I.229.238; 1.I.229.239; 1.I.229.154; 1.I.229.157; 1.I.229.166; 1.I.229.169; 1.I.229.172; 1.I.229.175; 1.I.229.240; 1.I.229.244; 1.I.230.228; 1.I.230.229; 1.I.230.230; 1.I.230.231; 1.I.230.236; 1.I.230.237; 1.I.230.238; 1.I.230.239; 1.I.230.154; 1.I.230.157; 1.I.230.166; 1.I.230.169; 1.I.230.172; 1.I.230.175; 1.I.230.240; 1.I.230.244; 1.I.231.228; 1.I.231.229; 1.I.231.230; 1.I.231.231; 1.I.231.236; 1.I.231.237; 1.I.231.238; 1.I.231.239; 1.I.231.154; 1.I.231.157; 1.I.231.166; 1.I.231.169; 1.I.231.172; 1.I.231.175; 1.I.231.240; 1.I.231.244; 1.I.236.228; 1.I.236.229; 1.I.236.230; 1.I.236.231; 1.I.236.236; 1.I.236.237; 1.I.236.238; 1.I.236.239; 1.I.236.154; 1.I.236.157; 1.I.236.166; 1.I.236.169; 1.I.236.172; 1.I.236.175; 1.I.236.240; 1.I.236.244; 1.I.237.228; 1.I.237.229; 1.I.237.230; 1.I.237.231; 1.I.237.236; 1.I.237.237; 1.I.237.238; 1.I.237.239; 1.I.237.154; 1.I.237.157; 1.I.237.166; 1.I.237.169; 1.I.237.172; 1.I.237.175; 1.I.237.240; 1.I.237.244; 1.I.238.228; 1.I.238.229; 1.I.238.230; 1.I.238.231; 1.I.238.236; 1.I.238.237; 1.I.238.238; 1.I.238.239; 1.I.238.154; 1.I.238.157; 1.I.238.166; 1.I.238.169; 1.I.238.172; 1.I.238.175; 1.I.238.240; 1.I.238.244; 1.I.239.228; 1.I.239.229; 1.I.239.230; 1.I.239.231; 1.I.239.236; 1.I.239.237; 1.I.239.238; 1.I.239.239;

1.I.239.154; 1.I.239.157; 1.I.239.166; 1.I.239.169; 1.I.239.172; 1.I.239.175; 1.I.239.240; 1.I.239.244; 1.I.154.228; 1.I.154.229; 1.I.154.230; 1.I.154.231; 1.I.154.236; 1.I.154.237; 1.I.154.238; 1.I.154.239; 1.I.154.154; 1.I.154.157; 1.I.154.166; 1.I.154.169; 1.I.154.172; 1.I.154.175; 1.I.154.240; 1.I.154.244; 1.I.157.228; 1.I.157.229; 1.I.157.230; 1.I.157.231; 1.I.157.236; 1.I.157.237; 1.I.157.238; 1.I.157.239; 1.I.157.154; 1.I.157.157; 1.I.157.166; 1.I.157.169; 1.I.157.172; 1.I.157.175; 1.I.157.240; 1.I.157.244; 1.I.166.228; 1.I.166.229; 1.I.166.230; 1.I.166.231; 1.I.166.236; 1.I.166.237; 1.I.166.238; 1.I.166.239; 1.I.166.154; 1.I.166.157; 1.I.166.166; 1.I.166.169; 1.I.166.172; 1.I.166.175; 1.I.166.240; 1.I.166.244; 1.I.169.228; 1.I.169.229; 1.I.169.230; 1.I.169.231; 1.I.169.236; 1.I.169.237; 1.I.169.238; 1.I.169.239; 1.I.169.154; 1.I.169.157; 1.I.169.166; 1.I.169.169; 1.I.169.172; 1.I.169.175; 1.I.169.240; 1.I.169.244; 1.I.172.228; 1.I.172.229; 1.I.172.230; 1.I.172.231; 1.I.172.236; 1.I.172.237; 1.I.172.238; 1.I.172.239; 1.I.172.154; 1.I.172.157; 1.I.172.166; 1.I.172.169; 1.I.172.172; 1.I.172.175; 1.I.172.240; 1.I.172.244; 1.I.175.228; 1.I.175.229; 1.I.175.230; 1.I.175.231; 1.I.175.236; 1.I.175.237; 1.I.175.238; 1.I.175.239; 1.I.175.154; 1.I.175.157; 1.I.175.166; 1.I.175.169; 1.I.175.172; 1.I.175.175; 1.I.175.240; 1.I.175.244; 1.I.240.228; 1.I.240.229; 1.I.240.230; 1.I.240.231; 1.I.240.236; 1.I.240.237; 1.I.240.238; 1.I.240.239; 1.I.240.154; 1.I.240.157; 1.I.240.166; 1.I.240.169; 1.I.240.172; 1.I.240.175; 1.I.240.240; 1.I.240.244; 1.I.244.228; 1.I.244.229; 1.I.244.230; 1.I.244.231; 1.I.244.236; 1.I.244.237; 1.I.244.238; 1.I.244.239; 1.I.244.154; 1.I.244.157; 1.I.244.166; 1.I.244.169; 1.I.244.172; 1.I.244.175; 1.I.244.240; 1.I.244.244;

Prodrugs of 1.J

1.J.228.228; 1.J.228.229; 1.J.228.230; 1.J.228.231; 1.J.228.236; 1.J.228.237; 1.J.228.238; 1.J.228.239; 1.J.228.154; 1.J.228.157; 1.J.228.166; 1.J.228.169; 1.J.228.172; 1.J.228.175; 1.J.228.240; 1.J.228.244; 1.J.229.228; 1.J.229.229; 1.J.229.230; 1.J.229.231; 1.J.229.236; 1.J.229.237; 1.J.229.238; 1.J.229.239; 1.J.229.154; 1.J.229.157; 1.J.229.166; 1.J.229.169; 1.J.229.172; 1.J.229.175; 1.J.229.240; 1.J.229.244; 1.J.230.228; 1.J.230.229; 1.J.230.230; 1.J.230.231; 1.J.230.236; 1.J.230.237; 1.J.230.238; 1.J.230.239; 1.J.230.154; 1.J.230.157; 1.J.230.166; 1.J.230.169; 1.J.230.172; 1.J.230.175; 1.J.230.240; 1.J.230.244; 1.J.231.228; 1.J.231.229; 1.J.231.230; 1.J.231.231; 1.J.231.236; 1.J.231.237; 1.J.231.238; 1.J.231.239; 1.J.231.154; 1.J.231.157; 1.J.231.166; 1.J.231.169; 1.J.231.172; 1.J.231.175; 1.J.231.240; 1.J.231.244; 1.J.236.228; 1.J.236.229; 1.J.236.230; 1.J.236.231; 1.J.236.236; 1.J.236.237; 1.J.236.238; 1.J.236.239;

1.J.236.154; 1.J.236.157; 1.J.236.166; 1.J.236.169; 1.J.236.172; 1.J.236.175; 1.J.236.240; 1.J.236.244; 1.J.237.228; 1.J.237.229; 1.J.237.230; 1.J.237.231; 1.J.237.236; 1.J.237.237; 1.J.237.238; 1.J.237.239; 1.J.237.154; 1.J.237.157; 1.J.237.166; 1.J.237.169; 1.J.237.172; 1.J.237.175; 1.J.237.240; 1.J.237.244; 1.J.238.228; 1.J.238.229; 1.J.238.230; 1.J.238.231; 1.J.238.236; 1.J.238.237; 1.J.238.238; 1.J.238.239; 1.J.238.154; 1.J.238.157; 1.J.238.166; 1.J.238.169; 1.J.238.172; 1.J.238.175; 1.J.238.240; 1.J.238.244; 1.J.239.228; 1.J.239.229; 1.J.239.230; 1.J.239.231; 1.J.239.236; 1.J.239.237; 1.J.239.238; 1.J.239.239; 1.J.239.154; 1.J.239.157; 1.J.239.166; 1.J.239.169; 1.J.239.172; 1.J.239.175; 1.J.239.240; 1.J.239.244; 1.J.154.228; 1.J.154.229; 1.J.154.230; 1.J.154.231; 1.J.154.236; 1.J.154.237; 1.J.154.238; 1.J.154.239; 1.J.154.154; 1.J.154.157; 1.J.154.166; 1.J.154.169; 1.J.154.172; 1.J.154.175; 1.J.154.240; 1.J.154.244; 1.J.157.228; 1.J.157.229; 1.J.157.230; 1.J.157.231; 1.J.157.236; 1.J.157.237; 1.J.157.238; 1.J.157.239; 1.J.157.154; 1.J.157.157; 1.J.157.166; 1.J.157.169; 1.J.157.172; 1.J.157.175; 1.J.157.240; 1.J.157.244; 1.J.166.228; 1.J.166.229; 1.J.166.230; 1.J.166.231; 1.J.166.236; 1.J.166.237; 1.J.166.238; 1.J.166.239; 1.J.166.154; 1.J.166.157; 1.J.166.166; 1.J.166.169; 1.J.166.172; 1.J.166.175; 1.J.166.240; 1.J.166.244; 1.J.169.228; 1.J.169.229; 1.J.169.230; 1.J.169.231; 1.J.169.236; 1.J.169.237; 1.J.169.238; 1.J.169.239; 1.J.169.154; 1.J.169.157; 1.J.169.166; 1.J.169.169; 1.J.169.172; 1.J.169.175; 1.J.169.240; 1.J.169.244; 1.J.172.228; 1.J.172.229; 1.J.172.230; 1.J.172.231; 1.J.172.236; 1.J.172.237; 1.J.172.238; 1.J.172.239; 1.J.172.154; 1.J.172.157; 1.J.172.166; 1.J.172.169; 1.J.172.172; 1.J.172.175; 1.J.172.240; 1.J.172.244; 1.J.175.228; 1.J.175.229; 1.J.175.230; 1.J.175.231; 1.J.175.236; 1.J.175.237; 1.J.175.238; 1.J.175.239; 1.J.175.154; 1.J.175.157; 1.J.175.166; 1.J.175.169; 1.J.175.172; 1.J.175.175; 1.J.175.240; 1.J.175.244; 1.J.240.228; 1.J.240.229; 1.J.240.230; 1.J.240.231; 1.J.240.236; 1.J.240.237; 1.J.240.238; 1.J.240.239; 1.J.240.154; 1.J.240.157; 1.J.240.166; 1.J.240.169; 1.J.240.172; 1.J.240.175; 1.J.240.240; 1.J.240.244; 1.J.244.228; 1.J.244.229; 1.J.244.230; 1.J.244.231; 1.J.244.236; 1.J.244.237; 1.J.244.238; 1.J.244.239; 1.J.244.154; 1.J.244.157; 1.J.244.166; 1.J.244.169; 1.J.244.172; 1.J.244.175; 1.J.244.240; 1.J.244.244;

Prodrugs of 1.L

1.L.228.228; 1.L.228.229; 1.L.228.230; 1.L.228.231; 1.L.228.236; 1.L.228.237; 1.L.228.238; 1.L.228.239; 1.L.228.154; 1.L.228.157; 1.L.228.166; 1.L.228.169; 1.L.228.172; 1.L.228.175; 1.L.228.240; 1.L.228.244; 1.L.229.228; 1.L.229.229; 1.L.229.230; 1.L.229.231; 1.L.229.236; 1.L.229.237; 1.L.229.238;

1.L.229.239; 1.L.229.154; 1.L.229.157; 1.L.229.166; 1.L.229.169; 1.L.229.172; 1.L.229.175; 1.L.229.240; 1.L.229.244; 1.L.230.228; 1.L.230.229; 1.L.230.230; 1.L.230.231; 1.L.230.236; 1.L.230.237; 1.L.230.238; 1.L.230.239; 1.L.230.154; 1.L.230.157; 1.L.230.166; 1.L.230.169; 1.L.230.172; 1.L.230.175; 1.L.230.240; 1.L.230.244; 1.L.231.228; 1.L.231.229; 1.L.231.230; 1.L.231.231; 1.L.231.236; 1.L.231.237; 1.L.231.238; 1.L.231.239; 1.L.231.154; 1.L.231.157; 1.L.231.166; 1.L.231.169; 1.L.231.172; 1.L.231.175; 1.L.231.240; 1.L.231.244; 1.L.236.228; 1.L.236.229; 1.L.236.230; 1.L.236.231; 1.L.236.236; 1.L.236.237; 1.L.236.238; 1.L.236.239; 1.L.236.154; 1.L.236.157; 1.L.236.166; 1.L.236.169; 1.L.236.172; 1.L.236.175; 1.L.236.240; 1.L.236.244; 1.L.237.228; 1.L.237.229; 1.L.237.230; 1.L.237.231; 1.L.237.236; 1.L.237.237; 1.L.237.238; 1.L.237.239; 1.L.237.154; 1.L.237.157; 1.L.237.166; 1.L.237.169; 1.L.237.172; 1.L.237.175; 1.L.237.240; 1.L.237.244; 1.L.238.228; 1.L.238.229; 1.L.238.230; 1.L.238.231; 1.L.238.236; 1.L.238.237; 1.L.238.238; 1.L.238.239; 1.L.238.154; 1.L.238.157; 1.L.238.166; 1.L.238.169; 1.L.238.172; 1.L.238.175; 1.L.238.240; 1.L.238.244; 1.L.239.228; 1.L.239.229; 1.L.239.230; 1.L.239.231; 1.L.239.236; 1.L.239.237; 1.L.239.238; 1.L.239.239; 1.L.239.154; 1.L.239.157; 1.L.239.166; 1.L.239.169; 1.L.239.172; 1.L.239.175; 1.L.239.240; 1.L.239.244; 1.L.154.228; 1.L.154.229; 1.L.154.230; 1.L.154.231; 1.L.154.236; 1.L.154.237; 1.L.154.238; 1.L.154.239; 1.L.154.154; 1.L.154.157; 1.L.154.166; 1.L.154.169; 1.L.154.172; 1.L.154.175; 1.L.154.240; 1.L.154.244; 1.L.157.228; 1.L.157.229; 1.L.157.230; 1.L.157.231; 1.L.157.236; 1.L.157.237; 1.L.157.238; 1.L.157.239; 1.L.157.154; 1.L.157.157; 1.L.157.166; 1.L.157.169; 1.L.157.172; 1.L.157.175; 1.L.157.240; 1.L.157.244; 1.L.166.228; 1.L.166.229; 1.L.166.230; 1.L.166.231; 1.L.166.236; 1.L.166.237; 1.L.166.238; 1.L.166.239; 1.L.166.154; 1.L.166.157; 1.L.166.166; 1.L.166.169; 1.L.166.172; 1.L.166.175; 1.L.166.240; 1.L.166.244; 1.L.169.228; 1.L.169.229; 1.L.169.230; 1.L.169.231; 1.L.169.236; 1.L.169.237; 1.L.169.238; 1.L.169.239; 1.L.169.154; 1.L.169.157; 1.L.169.166; 1.L.169.169; 1.L.169.172; 1.L.169.175; 1.L.169.240; 1.L.169.244; 1.L.172.228; 1.L.172.229; 1.L.172.230; 1.L.172.231; 1.L.172.236; 1.L.172.237; 1.L.172.238; 1.L.172.239; 1.L.172.154; 1.L.172.157; 1.L.172.166; 1.L.172.169; 1.L.172.172; 1.L.172.175; 1.L.172.240; 1.L.172.244; 1.L.175.228; 1.L.175.229; 1.L.175.230; 1.L.175.231; 1.L.175.236; 1.L.175.237; 1.L.175.238; 1.L.175.239; 1.L.175.154; 1.L.175.157; 1.L.175.166; 1.L.175.169; 1.L.175.172; 1.L.175.175; 1.L.175.240; 1.L.175.244; 1.L.240.228; 1.L.240.229; 1.L.240.230; 1.L.240.231; 1.L.240.236; 1.L.240.237; 1.L.240.238; 1.L.240.239; 1.L.240.154; 1.L.240.157; 1.L.240.166; 1.L.240.169; 1.L.240.172; 1.L.240.175; 1.L.240.240; 1.L.240.244; 1.L.244.228; 1.L.244.229; 1.L.244.230; 1.L.244.231; 1.L.244.236;

1.L.244.237; 1.L.244.238; 1.L.244.239; 1.L.244.154; 1.L.244.157; 1.L.244.166; 1.L.244.169; 1.L.244.172; 1.L.244.175; 1.L.244.240; 1.L.244.244;

Prodrugs of 1.O

1.O.228.228; 1.O.228.229; 1.O.228.230; 1.O.228.231; 1.O.228.236; 1.O.228.237; 1.O.228.238; 1.O.228.239; 1.O.228.154; 1.O.228.157; 1.O.228.166; 1.O.228.169; 1.O.228.172; 1.O.228.175; 1.O.228.240; 1.O.228.244; 1.O.229.228; 1.O.229.229; 1.O.229.230; 1.O.229.231; 1.O.229.236; 1.O.229.237; 1.O.229.238; 1.O.229.239; 1.O.229.154; 1.O.229.157; 1.O.229.166; 1.O.229.169; 1.O.229.172; 1.O.229.175; 1.O.229.240; 1.O.229.244; 1.O.230.228; 1.O.230.229; 1.O.230.230; 1.O.230.231; 1.O.230.236; 1.O.230.237; 1.O.230.238; 1.O.230.239; 1.O.230.154; 1.O.230.157; 1.O.230.166; 1.O.230.169; 1.O.230.172; 1.O.230.175; 1.O.230.240; 1.O.230.244; 1.O.231.228; 1.O.231.229; 1.O.231.230; 1.O.231.231; 1.O.231.236; 1.O.231.237; 1.O.231.238; 1.O.231.239; 1.O.231.154; 1.O.231.157; 1.O.231.166; 1.O.231.169; 1.O.231.172; 1.O.231.175; 1.O.231.240; 1.O.231.244; 1.O.236.228; 1.O.236.229; 1.O.236.230; 1.O.236.231; 1.O.236.236; 1.O.236.237; 1.O.236.238; 1.O.236.239; 1.O.236.154; 1.O.236.157; 1.O.236.166; 1.O.236.169; 1.O.236.172; 1.O.236.175; 1.O.236.240; 1.O.236.244; 1.O.237.228; 1.O.237.229; 1.O.237.230; 1.O.237.231; 1.O.237.236; 1.O.237.237; 1.O.237.238; 1.O.237.239; 1.O.237.154; 1.O.237.157; 1.O.237.166; 1.O.237.169; 1.O.237.172; 1.O.237.175; 1.O.237.240; 1.O.237.244; 1.O.238.228; 1.O.238.229; 1.O.238.230; 1.O.238.231; 1.O.238.236; 1.O.238.237; 1.O.238.238; 1.O.238.239; 1.O.238.154; 1.O.238.157; 1.O.238.166; 1.O.238.169; 1.O.238.172; 1.O.238.175; 1.O.238.240; 1.O.238.244; 1.O.239.228; 1.O.239.229; 1.O.239.230; 1.O.239.231; 1.O.239.236; 1.O.239.237; 1.O.239.238; 1.O.239.239; 1.O.239.154; 1.O.239.157; 1.O.239.166; 1.O.239.169; 1.O.239.172; 1.O.239.175; 1.O.239.240; 1.O.239.244; 1.O.154.228; 1.O.154.229; 1.O.154.230; 1.O.154.231; 1.O.154.236; 1.O.154.237; 1.O.154.238; 1.O.154.239; 1.O.154.154; 1.O.154.157; 1.O.154.166; 1.O.154.169; 1.O.154.172; 1.O.154.175; 1.O.154.240; 1.O.154.244; 1.O.157.228; 1.O.157.229; 1.O.157.230; 1.O.157.231; 1.O.157.236; 1.O.157.237; 1.O.157.238; 1.O.157.239; 1.O.157.154; 1.O.157.157; 1.O.157.166; 1.O.157.169; 1.O.157.172; 1.O.157.175; 1.O.157.240; 1.O.157.244; 1.O.166.228; 1.O.166.229; 1.O.166.230; 1.O.166.231; 1.O.166.236;

1.O.166.237; 1.O.166.238; 1.O.166.239; 1.O.166.154; 1.O.166.157; 1.O.166.166; 1.O.166.169; 1.O.166.172; 1.O.166.175; 1.O.166.240; 1.O.166.244; 1.O.169.228; 1.O.169.229; 1.O.169.230; 1.O.169.231; 1.O.169.236; 1.O.169.237; 1.O.169.238; 1.O.169.239; 1.O.169.154; 1.O.169.157; 1.O.169.166; 1.O.169.169; 1.O.169.172; 1.O.169.175; 1.O.169.240; 1.O.169.244; 1.O.172.228; 1.O.172.229; 1.O.172.230; 1.O.172.231; 1.O.172.236; 1.O.172.237; 1.O.172.238; 1.O.172.239; 1.O.172.154; 1.O.172.157; 1.O.172.166; 1.O.172.169; 1.O.172.172; 1.O.172.175; 1.O.172.240; 1.O.172.244; 1.O.175.228; 1.O.175.229; 1.O.175.230; 1.O.175.231; 1.O.175.236; 1.O.175.237; 1.O.175.238; 1.O.175.239; 1.O.175.154; 1.O.175.157; 1.O.175.166; 1.O.175.169; 1.O.175.172; 1.O.175.175; 1.O.175.240; 1.O.175.244; 1.O.240.228; 1.O.240.229; 1.O.240.230; 1.O.240.231; 1.O.240.236; 1.O.240.237; 1.O.240.238; 1.O.240.239; 1.O.240.154; 1.O.240.157; 1.O.240.166; 1.O.240.169; 1.O.240.172; 1.O.240.175; 1.O.240.240; 1.O.240.244; 1.O.244.228; 1.O.244.229; 1.O.244.230; 1.O.244.231; 1.O.244.236; 1.O.244.237; 1.O.244.238; 1.O.244.239; 1.O.244.154; 1.O.244.157; 1.O.244.166; 1.O.244.169; 1.O.244.172; 1.O.244.175; 1.O.244.240; 1.O.244.244;

Prodrugs of 1.P

1.P.228.228; 1.P.228.229; 1.P.228.230; 1.P.228.231; 1.P.228.236; 1.P.228.237; 1.P.228.238; 1.P.228.239; 1.P.228.154; 1.P.228.157; 1.P.228.166; 1.P.228.169; 1.P.228.172; 1.P.228.175; 1.P.228.240; 1.P.228.244; 1.P.229.228; 1.P.229.229; 1.P.229.230; 1.P.229.231; 1.P.229.236; 1.P.229.237; 1.P.229.238; 1.P.229.239; 1.P.229.154; 1.P.229.157; 1.P.229.166; 1.P.229.169; 1.P.229.172; 1.P.229.175; 1.P.229.240; 1.P.229.244; 1.P.230.228; 1.P.230.229; 1.P.230.230; 1.P.230.231; 1.P.230.236; 1.P.230.237; 1.P.230.238; 1.P.230.239; 1.P.230.154; 1.P.230.157; 1.P.230.166; 1.P.230.169; 1.P.230.172; 1.P.230.175; 1.P.230.240; 1.P.230.244; 1.P.231.228; 1.P.231.229; 1.P.231.230; 1.P.231.231; 1.P.231.236; 1.P.231.237; 1.P.231.238; 1.P.231.239; 1.P.231.154; 1.P.231.157; 1.P.231.166; 1.P.231.169; 1.P.231.172; 1.P.231.175; 1.P.231.240; 1.P.231.244; 1.P.236.228; 1.P.236.229; 1.P.236.230; 1.P.236.231; 1.P.236.236; 1.P.236.237; 1.P.236.238; 1.P.236.239; 1.P.236.154; 1.P.236.157; 1.P.236.166; 1.P.236.169; 1.P.236.172; 1.P.236.175; 1.P.236.240; 1.P.236.244; 1.P.237.228; 1.P.237.229; 1.P.237.230; 1.P.237.231; 1.P.237.236; 1.P.237.237; 1.P.237.238; 1.P.237.239; 1.P.237.154; 1.P.237.157; 1.P.237.166; 1.P.237.169; 1.P.237.172; 1.P.237.175; 1.P.237.240;

1.P.237.244; 1.P.238.228; 1.P.238.229; 1.P.238.230; 1.P.238.231; 1.P.238.236; 1.P.238.237; 1.P.238.238; 1.P.238.239; 1.P.238.154; 1.P.238.157; 1.P.238.166; 1.P.238.169; 1.P.238.172; 1.P.238.175; 1.P.238.240; 1.P.238.244; 1.P.239.228; 1.P.239.229; 1.P.239.230; 1.P.239.231; 1.P.239.236; 1.P.239.237; 1.P.239.238; 1.P.239.239; 1.P.239.154; 1.P.239.157; 1.P.239.166; 1.P.239.169; 1.P.239.172; 1.P.239.175; 1.P.239.240; 1.P.239.244; 1.P.154.228; 1.P.154.229; 1.P.154.230; 1.P.154.231; 1.P.154.236; 1.P.154.237; 1.P.154.238; 1.P.154.239; 1.P.154.154; 1.P.154.157; 1.P.154.166; 1.P.154.169; 1.P.154.172; 1.P.154.175; 1.P.154.240; 1.P.154.244; 1.P.157.228; 1.P.157.229; 1.P.157.230; 1.P.157.231; 1.P.157.236; 1.P.157.237; 1.P.157.238; 1.P.157.239; 1.P.157.154; 1.P.157.157; 1.P.157.166; 1.P.157.169; 1.P.157.172; 1.P.157.175; 1.P.157.240; 1.P.157.244; 1.P.166.228; 1.P.166.229; 1.P.166.230; 1.P.166.231; 1.P.166.236; 1.P.166.237; 1.P.166.238; 1.P.166.239; 1.P.166.154; 1.P.166.157; 1.P.166.166; 1.P.166.169; 1.P.166.172; 1.P.166.175; 1.P.166.240; 1.P.166.244; 1.P.169.228; 1.P.169.229; 1.P.169.230; 1.P.169.231; 1.P.169.236; 1.P.169.237; 1.P.169.238; 1.P.169.239; 1.P.169.154; 1.P.169.157; 1.P.169.166; 1.P.169.169; 1.P.169.172; 1.P.169.175; 1.P.169.240; 1.P.169.244; 1.P.172.228; 1.P.172.229; 1.P.172.230; 1.P.172.231; 1.P.172.236; 1.P.172.237; 1.P.172.238; 1.P.172.239; 1.P.172.154; 1.P.172.157; 1.P.172.166; 1.P.172.169; 1.P.172.172; 1.P.172.175; 1.P.172.240; 1.P.172.244; 1.P.175.228; 1.P.175.229; 1.P.175.230; 1.P.175.231; 1.P.175.236; 1.P.175.237; 1.P.175.238; 1.P.175.239; 1.P.175.154; 1.P.175.157; 1.P.175.166; 1.P.175.169; 1.P.175.172; 1.P.175.175; 1.P.175.240; 1.P.175.244; 1.P.240.228; 1.P.240.229; 1.P.240.230; 1.P.240.231; 1.P.240.236; 1.P.240.237; 1.P.240.238; 1.P.240.239; 1.P.240.154; 1.P.240.157; 1.P.240.166; 1.P.240.169; 1.P.240.172; 1.P.240.175; 1.P.240.240; 1.P.240.244; 1.P.244.228; 1.P.244.229; 1.P.244.230; 1.P.244.231; 1.P.244.236; 1.P.244.237; 1.P.244.238; 1.P.244.239; 1.P.244.154; 1.P.244.157; 1.P.244.166; 1.P.244.169; 1.P.244.172; 1.P.244.175; 1.P.244.240; 1.P.244.244;

Prodrugs of 1.U

1.U.228.228; 1.U.228.229; 1.U.228.230; 1.U.228.231; 1.U.228.236; 1.U.228.237; 1.U.228.238; 1.U.228.239; 1.U.228.154; 1.U.228.157; 1.U.228.166; 1.U.228.169; 1.U.228.172; 1.U.228.175; 1.U.228.240; 1.U.228.244; 1.U.229.228; 1.U.229.229; 1.U.229.230; 1.U.229.231; 1.U.229.236; 1.U.229.237; 1.U.229.238; 1.U.229.239; 1.U.229.154; 1.U.229.157; 1.U.229.166; 1.U.229.169; 1.U.229.172; 1.U.229.175; 1.U.229.240; 1.U.229.244; 1.U.230.228; 1.U.230.229; 1.U.230.230; 1.U.230.231; 1.U.230.236; 1.U.230.237; 1.U.230.238; 1.U.230.239;

1.U.230.154; 1.U.230.157; 1.U.230.166; 1.U.230.169; 1.U.230.172; 1.U.230.175; 1.U.230.240; 1.U.230.244; 1.U.231.228; 1.U.231.229; 1.U.231.230; 1.U.231.231; 1.U.231.236; 1.U.231.237; 1.U.231.238; 1.U.231.239; 1.U.231.154; 1.U.231.157; 1.U.231.166; 1.U.231.169; 1.U.231.172; 1.U.231.175; 1.U.231.240; 1.U.231.244; 1.U.236.228; 1.U.236.229; 1.U.236.230; 1.U.236.231; 1.U.236.236; 1.U.236.237; 1.U.236.238; 1.U.236.239; 1.U.236.154; 1.U.236.157; 1.U.236.166; 1.U.236.169; 1.U.236.172; 1.U.236.175; 1.U.236.240; 1.U.236.244; 1.U.237.228; 1.U.237.229; 1.U.237.230; 1.U.237.231; 1.U.237.236; 1.U.237.237; 1.U.237.238; 1.U.237.239; 1.U.237.154; 1.U.237.157; 1.U.237.166; 1.U.237.169; 1.U.237.172; 1.U.237.175; 1.U.237.240; 1.U.237.244; 1.U.238.228; 1.U.238.229; 1.U.238.230; 1.U.238.231; 1.U.238.236; 1.U.238.237; 1.U.238.238; 1.U.238.239; 1.U.238.154; 1.U.238.157; 1.U.238.166; 1.U.238.169; 1.U.238.172; 1.U.238.175; 1.U.238.240; 1.U.238.244; 1.U.239.228; 1.U.239.229; 1.U.239.230; 1.U.239.231; 1.U.239.236; 1.U.239.237; 1.U.239.238; 1.U.239.239; 1.U.239.154; 1.U.239.157; 1.U.239.166; 1.U.239.169; 1.U.239.172; 1.U.239.175; 1.U.239.240; 1.U.239.244; 1.U.154.228; 1.U.154.229; 1.U.154.230; 1.U.154.231; 1.U.154.236; 1.U.154.237; 1.U.154.238; 1.U.154.239; 1.U.154.154; 1.U.154.157; 1.U.154.166; 1.U.154.169; 1.U.154.172; 1.U.154.175; 1.U.154.240; 1.U.154.244; 1.U.157.228; 1.U.157.229; 1.U.157.230; 1.U.157.231; 1.U.157.236; 1.U.157.237; 1.U.157.238; 1.U.157.239; 1.U.157.154; 1.U.157.157; 1.U.157.166; 1.U.157.169; 1.U.157.172; 1.U.157.175; 1.U.157.240; 1.U.157.244; 1.U.166.228; 1.U.166.229; 1.U.166.230; 1.U.166.231; 1.U.166.236; 1.U.166.237; 1.U.166.238; 1.U.166.239; 1.U.166.154; 1.U.166.157; 1.U.166.166; 1.U.166.169; 1.U.166.172; 1.U.166.175; 1.U.166.240; 1.U.166.244; 1.U.169.228; 1.U.169.229; 1.U.169.230; 1.U.169.231; 1.U.169.236; 1.U.169.237; 1.U.169.238; 1.U.169.239; 1.U.169.154; 1.U.169.157; 1.U.169.166; 1.U.169.169; 1.U.169.172; 1.U.169.175; 1.U.169.240; 1.U.169.244; 1.U.172.228; 1.U.172.229; 1.U.172.230; 1.U.172.231; 1.U.172.236; 1.U.172.237; 1.U.172.238; 1.U.172.239; 1.U.172.154; 1.U.172.157; 1.U.172.166; 1.U.172.169; 1.U.172.172; 1.U.172.175; 1.U.172.240; 1.U.172.244; 1.U.175.228; 1.U.175.229; 1.U.175.230; 1.U.175.231; 1.U.175.236; 1.U.175.237; 1.U.175.238; 1.U.175.239; 1.U.175.154; 1.U.175.157; 1.U.175.166; 1.U.175.169; 1.U.175.172; 1.U.175.175; 1.U.175.240; 1.U.175.244; 1.U.240.228;

1.U.240.229; 1.U.240.230; 1.U.240.231; 1.U.240.236; 1.U.240.237; 1.U.240.238; 1.U.240.239; 1.U.240.154; 1.U.240.157; 1.U.240.166; 1.U.240.169; 1.U.240.172; 1.U.240.175; 1.U.240.240; 1.U.240.244; 1.U.244.228; 1.U.244.229; 1.U.244.230; 1.U.244.231; 1.U.244.236; 1.U.244.237; 1.U.244.238; 1.U.244.239; 1.U.244.154; 1.U.244.157; 1.U.244.166; 1.U.244.169; 1.U.244.172; 1.U.244.175; 1.U.244.240; 1.U.244.244;

Prodrugs of 1.W

1.W.228.228; 1.W.228.229; 1.W.228.230; 1.W.228.231; 1.W.228.236; 1.W.228.237; 1.W.228.238; 1.W.228.239; 1.W.228.154; 1.W.228.157; 1.W.228.166; 1.W.228.169; 1.W.228.172; 1.W.228.175; 1.W.228.240; 1.W.228.244; 1.W.229.228; 1.W.229.229; 1.W.229.230; 1.W.229.231; 1.W.229.236; 1.W.229.237; 1.W.229.238; 1.W.229.239; 1.W.229.154; 1.W.229.157; 1.W.229.166; 1.W.229.169; 1.W.229.172; 1.W.229.175; 1.W.229.240; 1.W.229.244; 1.W.230.228; 1.W.230.229; 1.W.230.230; 1.W.230.231; 1.W.230.236; 1.W.230.237; 1.W.230.238; 1.W.230.239; 1.W.230.154; 1.W.230.157; 1.W.230.166; 1.W.230.169; 1.W.230.172; 1.W.230.175; 1.W.230.240; 1.W.230.244; 1.W.231.228; 1.W.231.229; 1.W.231.230; 1.W.231.231; 1.W.231.236; 1.W.231.237; 1.W.231.238; 1.W.231.239; 1.W.231.154; 1.W.231.157; 1.W.231.166; 1.W.231.169; 1.W.231.172; 1.W.231.175; 1.W.231.240; 1.W.231.244; 1.W.236.228; 1.W.236.229; 1.W.236.230; 1.W.236.231; 1.W.236.236; 1.W.236.237; 1.W.236.238; 1.W.236.239; 1.W.236.154; 1.W.236.157; 1.W.236.166; 1.W.236.169; 1.W.236.172; 1.W.236.175; 1.W.236.240; 1.W.236.244; 1.W.237.228; 1.W.237.229; 1.W.237.230; 1.W.237.231; 1.W.237.236; 1.W.237.237; 1.W.237.238; 1.W.237.239; 1.W.237.154; 1.W.237.157; 1.W.237.166; 1.W.237.169; 1.W.237.172; 1.W.237.175; 1.W.237.240; 1.W.237.244; 1.W.238.228; 1.W.238.229; 1.W.238.230; 1.W.238.231; 1.W.238.236; 1.W.238.237; 1.W.238.238; 1.W.238.239; 1.W.238.154; 1.W.238.157; 1.W.238.166; 1.W.238.169; 1.W.238.172; 1.W.238.175; 1.W.238.240; 1.W.238.244; 1.W.239.228; 1.W.239.229; 1.W.239.230; 1.W.239.231; 1.W.239.236; 1.W.239.237; 1.W.239.238; 1.W.239.239; 1.W.239.154; 1.W.239.157; 1.W.239.166; 1.W.239.169; 1.W.239.172; 1.W.239.175; 1.W.239.240; 1.W.239.244; 1.W.154.228; 1.W.154.229; 1.W.154.230; 1.W.154.231; 1.W.154.236; 1.W.154.237; 1.W.154.238; 1.W.154.239; 1.W.154.154; 1.W.154.157; 1.W.154.166; 1.W.154.169;

1.W.154.172; 1.W.154.175; 1.W.154.240; 1.W.154.244; 1.W.157.228; 1.W.157.229; 1.W.157.230; 1.W.157.231; 1.W.157.236; 1.W.157.237; 1.W.157.238; 1.W.157.239; 1.W.157.154; 1.W.157.157; 1.W.157.166; 1.W.157.169; 1.W.157.172; 1.W.157.175; 1.W.157.240; 1.W.157.244; 1.W.166.228; 1.W.166.229; 1.W.166.230; 1.W.166.231; 1.W.166.236; 1.W.166.237; 1.W.166.238; 1.W.166.239; 1.W.166.154; 1.W.166.157; 1.W.166.166; 1.W.166.169; 1.W.166.172; 1.W.166.175; 1.W.166.240; 1.W.166.244; 1.W.169.228; 1.W.169.229; 1.W.169.230; 1.W.169.231; 1.W.169.236; 1.W.169.237; 1.W.169.238; 1.W.169.239; 1.W.169.154; 1.W.169.157; 1.W.169.166; 1.W.169.169; 1.W.169.172; 1.W.169.175; 1.W.169.240; 1.W.169.244; 1.W.172.228; 1.W.172.229; 1.W.172.230; 1.W.172.231; 1.W.172.236; 1.W.172.237; 1.W.172.238; 1.W.172.239; 1.W.172.154; 1.W.172.157; 1.W.172.166; 1.W.172.169; 1.W.172.172; 1.W.172.175; 1.W.172.240; 1.W.172.244; 1.W.175.228; 1.W.175.229; 1.W.175.230; 1.W.175.231; 1.W.175.236; 1.W.175.237; 1.W.175.238; 1.W.175.239; 1.W.175.154; 1.W.175.157; 1.W.175.166; 1.W.175.169; 1.W.175.172; 1.W.175.175; 1.W.175.240; 1.W.175.244; 1.W.240.228; 1.W.240.229; 1.W.240.230; 1.W.240.231; 1.W.240.236; 1.W.240.237; 1.W.240.238; 1.W.240.239; 1.W.240.154; 1.W.240.157; 1.W.240.166; 1.W.240.169; 1.W.240.172; 1.W.240.175; 1.W.240.240; 1.W.240.244; 1.W.244.228; 1.W.244.229; 1.W.244.230; 1.W.244.231; 1.W.244.236; 1.W.244.237; 1.W.244.238; 1.W.244.239; 1.W.244.154; 1.W.244.157; 1.W.244.166; 1.W.244.169; 1.W.244.172; 1.W.244.175; 1.W.244.240; 1.W.244.244;

Prodrugs of 1.Y

1.Y.228.228; 1.Y.228.229; 1.Y.228.230; 1.Y.228.231; 1.Y.228.236; 1.Y.228.237; 1.Y.228.238; 1.Y.228.239; 1.Y.228.154; 1.Y.228.157; 1.Y.228.166; 1.Y.228.169; 1.Y.228.172; 1.Y.228.175; 1.Y.228.240; 1.Y.228.244; 1.Y.229.228; 1.Y.229.229; 1.Y.229.230; 1.Y.229.231; 1.Y.229.236; 1.Y.229.237; 1.Y.229.238; 1.Y.229.239; 1.Y.229.154; 1.Y.229.157; 1.Y.229.166; 1.Y.229.169; 1.Y.229.172; 1.Y.229.175; 1.Y.229.240; 1.Y.229.244; 1.Y.230.228; 1.Y.230.229; 1.Y.230.230; 1.Y.230.231; 1.Y.230.236; 1.Y.230.237; 1.Y.230.238; 1.Y.230.239; 1.Y.230.154; 1.Y.230.157; 1.Y.230.166; 1.Y.230.169; 1.Y.230.172; 1.Y.230.175; 1.Y.230.240; 1.Y.230.244; 1.Y.231.228; 1.Y.231.229; 1.Y.231.230; 1.Y.231.231; 1.Y.231.236; 1.Y.231.237; 1.Y.231.238; 1.Y.231.239; 1.Y.231.154; 1.Y.231.157; 1.Y.231.166; 1.Y.231.169; 1.Y.231.172; 1.Y.231.175; 1.Y.231.240; 1.Y.231.244; 1.Y.236.228;

1.Y.236.229; 1.Y.236.230; 1.Y.236.231; 1.Y.236.236; 1.Y.236.237; 1.Y.236.238; 1.Y.236.239; 1.Y.236.154; 1.Y.236.157; 1.Y.236.166; 1.Y.236.169; 1.Y.236.172; 1.Y.236.175; 1.Y.236.240; 1.Y.236.244; 1.Y.237.228; 1.Y.237.229; 1.Y.237.230; 1.Y.237.231; 1.Y.237.236; 1.Y.237.237; 1.Y.237.238; 1.Y.237.239; 1.Y.237.154; 1.Y.237.157; 1.Y.237.166; 1.Y.237.169; 1.Y.237.172; 1.Y.237.175; 1.Y.237.240; 1.Y.237.244; 1.Y.238.228; 1.Y.238.229; 1.Y.238.230; 1.Y.238.231; 1.Y.238.236; 1.Y.238.237; 1.Y.238.238; 1.Y.238.239; 1.Y.238.154; 1.Y.238.157; 1.Y.238.166; 1.Y.238.169; 1.Y.238.172; 1.Y.238.175; 1.Y.238.240; 1.Y.238.244; 1.Y.239.228; 1.Y.239.229; 1.Y.239.230; 1.Y.239.231; 1.Y.239.236; 1.Y.239.237; 1.Y.239.238; 1.Y.239.239; 1.Y.239.154; 1.Y.239.157; 1.Y.239.166; 1.Y.239.169; 1.Y.239.172; 1.Y.239.175; 1.Y.239.240; 1.Y.239.244; 1.Y.154.228; 1.Y.154.229; 1.Y.154.230; 1.Y.154.231; 1.Y.154.236; 1.Y.154.237; 1.Y.154.238; 1.Y.154.239; 1.Y.154.154; 1.Y.154.157; 1.Y.154.166; 1.Y.154.169; 1.Y.154.172; 1.Y.154.175; 1.Y.154.240; 1.Y.154.244; 1.Y.157.228; 1.Y.157.229; 1.Y.157.230; 1.Y.157.231; 1.Y.157.236; 1.Y.157.237; 1.Y.157.238; 1.Y.157.239; 1.Y.157.154; 1.Y.157.157; 1.Y.157.166; 1.Y.157.169; 1.Y.157.172; 1.Y.157.175; 1.Y.157.240; 1.Y.157.244; 1.Y.166.228; 1.Y.166.229; 1.Y.166.230; 1.Y.166.231; 1.Y.166.236; 1.Y.166.237; 1.Y.166.238; 1.Y.166.239; 1.Y.166.154; 1.Y.166.157; 1.Y.166.166; 1.Y.166.169; 1.Y.166.172; 1.Y.166.175; 1.Y.166.240; 1.Y.166.244; 1.Y.169.228; 1.Y.169.229; 1.Y.169.230; 1.Y.169.231; 1.Y.169.236; 1.Y.169.237; 1.Y.169.238; 1.Y.169.239; 1.Y.169.154; 1.Y.169.157; 1.Y.169.166; 1.Y.169.169; 1.Y.169.172; 1.Y.169.175; 1.Y.169.240; 1.Y.169.244; 1.Y.172.228; 1.Y.172.229; 1.Y.172.230; 1.Y.172.231; 1.Y.172.236; 1.Y.172.237; 1.Y.172.238; 1.Y.172.239; 1.Y.172.154; 1.Y.172.157; 1.Y.172.166; 1.Y.172.169; 1.Y.172.172; 1.Y.172.175; 1.Y.172.240; 1.Y.172.244; 1.Y.175.228; 1.Y.175.229; 1.Y.175.230; 1.Y.175.231; 1.Y.175.236; 1.Y.175.237; 1.Y.175.238; 1.Y.175.239; 1.Y.175.154; 1.Y.175.157; 1.Y.175.166; 1.Y.175.169; 1.Y.175.172; 1.Y.175.175; 1.Y.175.240; 1.Y.175.244; 1.Y.240.228; 1.Y.240.229; 1.Y.240.230; 1.Y.240.231; 1.Y.240.236; 1.Y.240.237; 1.Y.240.238; 1.Y.240.239; 1.Y.240.154; 1.Y.240.157; 1.Y.240.166; 1.Y.240.169; 1.Y.240.172; 1.Y.240.175; 1.Y.240.240; 1.Y.240.244; 1.Y.244.228; 1.Y.244.229; 1.Y.244.230; 1.Y.244.231; 1.Y.244.236; 1.Y.244.237; 1.Y.244.238; 1.Y.244.239; 1.Y.244.154; 1.Y.244.157; 1.Y.244.166; 1.Y.244.169; 1.Y.244.172; 1.Y.244.175; 1.Y.244.240; 1.Y.244.244;

Prodrugs of 2.B

2.B.228.228; 2.B.228.229; 2.B.228.230; 2.B.228.231; 2.B.228.236; 2.B.228.237; 2.B.228.238; 2.B.228.239; 2.B.228.154; 2.B.228.157; 2.B.228.166; 2.B.228.169; 2.B.228.172; 2.B.228.175; 2.B.228.240; 2.B.228.244; 2.B.229.228;

2.B.229.229; 2.B.229.230; 2.B.229.231; 2.B.229.236; 2.B.229.237; 2.B.229.238; 2.B.229.239; 2.B.229.154; 2.B.229.157; 2.B.229.166; 2.B.229.169; 2.B.229.172; 2.B.229.175; 2.B.229.240; 2.B.229.244; 2.B.230.228; 2.B.230.229; 2.B.230.230; 2.B.230.231; 2.B.230.236; 2.B.230.237; 2.B.230.238; 2.B.230.239; 2.B.230.154; 2.B.230.157; 2.B.230.166; 2.B.230.169; 2.B.230.172; 2.B.230.175; 2.B.230.240; 2.B.230.244; 2.B.231.228; 2.B.231.229; 2.B.231.230; 2.B.231.231; 2.B.231.236; 2.B.231.237; 2.B.231.238; 2.B.231.239; 2.B.231.154; 2.B.231.157; 2.B.231.166; 2.B.231.169; 2.B.231.172; 2.B.231.175; 2.B.231.240; 2.B.231.244; 2.B.236.228; 2.B.236.229; 2.B.236.230; 2.B.236.231; 2.B.236.236; 2.B.236.237; 2.B.236.238; 2.B.236.239; 2.B.236.154; 2.B.236.157; 2.B.236.166; 2.B.236.169; 2.B.236.172; 2.B.236.175; 2.B.236.240; 2.B.236.244; 2.B.237.228; 2.B.237.229; 2.B.237.230; 2.B.237.231; 2.B.237.236; 2.B.237.237; 2.B.237.238; 2.B.237.239; 2.B.237.154; 2.B.237.157; 2.B.237.166; 2.B.237.169; 2.B.237.172; 2.B.237.175; 2.B.237.240; 2.B.237.244; 2.B.238.228; 2.B.238.229; 2.B.238.230; 2.B.238.231; 2.B.238.236; 2.B.238.237; 2.B.238.238; 2.B.238.239; 2.B.238.154; 2.B.238.157; 2.B.238.166; 2.B.238.169; 2.B.238.172; 2.B.238.175; 2.B.238.240; 2.B.238.244; 2.B.239.228; 2.B.239.229; 2.B.239.230; 2.B.239.231; 2.B.239.236; 2.B.239.237; 2.B.239.238; 2.B.239.239; 2.B.239.154; 2.B.239.157; 2.B.239.166; 2.B.239.169; 2.B.239.172; 2.B.239.175; 2.B.239.240; 2.B.239.244; 2.B.154.228; 2.B.154.229; 2.B.154.230; 2.B.154.231; 2.B.154.236; 2.B.154.237; 2.B.154.238; 2.B.154.239; 2.B.154.154; 2.B.154.157; 2.B.154.166; 2.B.154.169; 2.B.154.172; 2.B.154.175; 2.B.154.240; 2.B.154.244; 2.B.157.228; 2.B.157.229; 2.B.157.230; 2.B.157.231; 2.B.157.236; 2.B.157.237; 2.B.157.238; 2.B.157.239; 2.B.157.154; 2.B.157.157; 2.B.157.166; 2.B.157.169; 2.B.157.172; 2.B.157.175; 2.B.157.240; 2.B.157.244; 2.B.166.228; 2.B.166.229; 2.B.166.230; 2.B.166.231; 2.B.166.236; 2.B.166.237; 2.B.166.238; 2.B.166.239; 2.B.166.154; 2.B.166.157; 2.B.166.166; 2.B.166.169; 2.B.166.172; 2.B.166.175; 2.B.166.240; 2.B.166.244; 2.B.169.228; 2.B.169.229; 2.B.169.230; 2.B.169.231; 2.B.169.236; 2.B.169.237; 2.B.169.238; 2.B.169.239; 2.B.169.154; 2.B.169.157; 2.B.169.166; 2.B.169.169; 2.B.169.172; 2.B.169.175; 2.B.169.240; 2.B.169.244; 2.B.172.228; 2.B.172.229; 2.B.172.230; 2.B.172.231; 2.B.172.236; 2.B.172.237; 2.B.172.238; 2.B.172.239; 2.B.172.154; 2.B.172.157; 2.B.172.166; 2.B.172.169; 2.B.172.172; 2.B.172.175; 2.B.172.240; 2.B.172.244; 2.B.175.228; 2.B.175.229; 2.B.175.230; 2.B.175.231; 2.B.175.236; 2.B.175.237; 2.B.175.238; 2.B.175.239; 2.B.175.154; 2.B.175.157; 2.B.175.166; 2.B.175.169; 2.B.175.172; 2.B.175.175; 2.B.175.240; 2.B.175.244; 2.B.240.228; 2.B.240.229; 2.B.240.230; 2.B.240.231; 2.B.240.236; 2.B.240.237; 2.B.240.238; 2.B.240.239; 2.B.240.154; 2.B.240.157; 2.B.240.166; 2.B.240.169; 2.B.240.172; 2.B.240.175; 2.B.240.240;

2.B.240.244; 2.B.244.228; 2.B.244.229; 2.B.244.230; 2.B.244.231; 2.B.244.236; 2.B.244.237; 2.B.244.238; 2.B.244.239; 2.B.244.154; 2.B.244.157; 2.B.244.166; 2.B.244.169; 2.B.244.172; 2.B.244.175; 2.B.244.240; 2.B.244.244;

Prodrugs of 2.D

2.D.228.228; 2.D.228.229; 2.D.228.230; 2.D.228.231; 2.D.228.236; 2.D.228.237; 2.D.228.238; 2.D.228.239; 2.D.228.154; 2.D.228.157; 2.D.228.166; 2.D.228.169; 2.D.228.172; 2.D.228.175; 2.D.228.240; 2.D.228.244; 2.D.229.228; 2.D.229.229; 2.D.229.230; 2.D.229.231; 2.D.229.236; 2.D.229.237; 2.D.229.238; 2.D.229.239; 2.D.229.154; 2.D.229.157; 2.D.229.166; 2.D.229.169; 2.D.229.172; 2.D.229.175; 2.D.229.240; 2.D.229.244; 2.D.230.228; 2.D.230.229; 2.D.230.230; 2.D.230.231; 2.D.230.236; 2.D.230.237; 2.D.230.238; 2.D.230.239; 2.D.230.154; 2.D.230.157; 2.D.230.166; 2.D.230.169; 2.D.230.172; 2.D.230.175; 2.D.230.240; 2.D.230.244; 2.D.231.228; 2.D.231.229; 2.D.231.230; 2.D.231.231; 2.D.231.236; 2.D.231.237; 2.D.231.238; 2.D.231.239; 2.D.231.154; 2.D.231.157; 2.D.231.166; 2.D.231.169; 2.D.231.172; 2.D.231.175; 2.D.231.240; 2.D.231.244; 2.D.236.228; 2.D.236.229; 2.D.236.230; 2.D.236.231; 2.D.236.236; 2.D.236.237; 2.D.236.238; 2.D.236.239; 2.D.236.154; 2.D.236.157; 2.D.236.166; 2.D.236.169; 2.D.236.172; 2.D.236.175; 2.D.236.240; 2.D.236.244; 2.D.237.228; 2.D.237.229; 2.D.237.230; 2.D.237.231; 2.D.237.236; 2.D.237.237; 2.D.237.238; 2.D.237.239; 2.D.237.154; 2.D.237.157; 2.D.237.166; 2.D.237.169; 2.D.237.172; 2.D.237.175; 2.D.237.240; 2.D.237.244; 2.D.238.228; 2.D.238.229; 2.D.238.230; 2.D.238.231; 2.D.238.236; 2.D.238.237; 2.D.238.238; 2.D.238.239; 2.D.238.154; 2.D.238.157; 2.D.238.166; 2.D.238.169; 2.D.238.172; 2.D.238.175; 2.D.238.240; 2.D.238.244; 2.D.239.228; 2.D.239.229; 2.D.239.230; 2.D.239.231; 2.D.239.236; 2.D.239.237; 2.D.239.238; 2.D.239.239; 2.D.239.154; 2.D.239.157; 2.D.239.166; 2.D.239.169; 2.D.239.172; 2.D.239.175; 2.D.239.240; 2.D.239.244; 2.D.154.228; 2.D.154.229; 2.D.154.230; 2.D.154.231; 2.D.154.236; 2.D.154.237; 2.D.154.238; 2.D.154.239; 2.D.154.154; 2.D.154.157; 2.D.154.166; 2.D.154.169; 2.D.154.172; 2.D.154.175; 2.D.154.240; 2.D.154.244; 2.D.157.228; 2.D.157.229; 2.D.157.230; 2.D.157.231; 2.D.157.236; 2.D.157.237; 2.D.157.238; 2.D.157.239; 2.D.157.154; 2.D.157.157; 2.D.157.166; 2.D.157.169; 2.D.157.172; 2.D.157.175; 2.D.157.240; 2.D.157.244;

2.D.166.228; 2.D.166.229; 2.D.166.230; 2.D.166.231; 2.D.166.236; 2.D.166.237; 2.D.166.238; 2.D.166.239; 2.D.166.154; 2.D.166.157; 2.D.166.166; 2.D.166.169; 2.D.166.172; 2.D.166.175; 2.D.166.240; 2.D.166.244; 2.D.169.228; 2.D.169.229; 2.D.169.230; 2.D.169.231; 2.D.169.236; 2.D.169.237; 2.D.169.238; 2.D.169.239; 2.D.169.154; 2.D.169.157; 2.D.169.166; 2.D.169.169; 2.D.169.172; 2.D.169.175; 2.D.169.240; 2.D.169.244; 2.D.172.228; 2.D.172.229; 2.D.172.230; 2.D.172.231; 2.D.172.236; 2.D.172.237; 2.D.172.238; 2.D.172.239; 2.D.172.154; 2.D.172.157; 2.D.172.166; 2.D.172.169; 2.D.172.172; 2.D.172.175; 2.D.172.240; 2.D.172.244; 2.D.175.228; 2.D.175.229; 2.D.175.230; 2.D.175.231; 2.D.175.236; 2.D.175.237; 2.D.175.238; 2.D.175.239; 2.D.175.154; 2.D.175.157; 2.D.175.166; 2.D.175.169; 2.D.175.172; 2.D.175.175; 2.D.175.240; 2.D.175.244; 2.D.240.228; 2.D.240.229; 2.D.240.230; 2.D.240.231; 2.D.240.236; 2.D.240.237; 2.D.240.238; 2.D.240.239; 2.D.240.154; 2.D.240.157; 2.D.240.166; 2.D.240.169; 2.D.240.172; 2.D.240.175; 2.D.240.240; 2.D.240.244; 2.D.244.228; 2.D.244.229; 2.D.244.230; 2.D.244.231; 2.D.244.236; 2.D.244.237; 2.D.244.238; 2.D.244.239; 2.D.244.154; 2.D.244.157; 2.D.244.166; 2.D.244.169; 2.D.244.172; 2.D.244.175; 2.D.244.240; 2.D.244.244;

Prodrugs of 2.E

2.E.228.228; 2.E.228.229; 2.E.228.230; 2.E.228.231; 2.E.228.236; 2.E.228.237; 2.E.228.238; 2.E.228.239; 2.E.228.154; 2.E.228.157; 2.E.228.166; 2.E.228.169; 2.E.228.172; 2.E.228.175; 2.E.228.240; 2.E.228.244; 2.E.229.228; 2.E.229.229; 2.E.229.230; 2.E.229.231; 2.E.229.236; 2.E.229.237; 2.E.229.238; 2.E.229.239; 2.E.229.154; 2.E.229.157; 2.E.229.166; 2.E.229.169; 2.E.229.172; 2.E.229.175; 2.E.229.240; 2.E.229.244; 2.E.230.228; 2.E.230.229; 2.E.230.230; 2.E.230.231; 2.E.230.236; 2.E.230.237; 2.E.230.238; 2.E.230.239; 2.E.230.154; 2.E.230.157; 2.E.230.166; 2.E.230.169; 2.E.230.172; 2.E.230.175; 2.E.230.240; 2.E.230.244; 2.E.231.228; 2.E.231.229; 2.E.231.230; 2.E.231.231; 2.E.231.236; 2.E.231.237; 2.E.231.238; 2.E.231.239; 2.E.231.154; 2.E.231.157; 2.E.231.166; 2.E.231.169; 2.E.231.172; 2.E.231.175; 2.E.231.240; 2.E.231.244; 2.E.236.228; 2.E.236.229; 2.E.236.230; 2.E.236.231; 2.E.236.236; 2.E.236.237; 2.E.236.238; 2.E.236.239; 2.E.236.154; 2.E.236.157; 2.E.236.166; 2.E.236.169; 2.E.236.172; 2.E.236.175; 2.E.236.240; 2.E.236.244; 2.E.237.228; 2.E.237.229; 2.E.237.230; 2.E.237.231; 2.E.237.236; 2.E.237.237; 2.E.237.238; 2.E.237.239; 2.E.237.154;

2.E.237.157; 2.E.237.166; 2.E.237.169; 2.E.237.172; 2.E.237.175; 2.E.237.240; 2.E.237.244; 2.E.238.228; 2.E.238.229; 2.E.238.230; 2.E.238.231; 2.E.238.236; 2.E.238.237; 2.E.238.238; 2.E.238.239; 2.E.238.154; 2.E.238.157; 2.E.238.166; 2.E.238.169; 2.E.238.172; 2.E.238.175; 2.E.238.240; 2.E.238.244; 2.E.239.228; 2.E.239.229; 2.E.239.230; 2.E.239.231; 2.E.239.236; 2.E.239.237; 2.E.239.238; 2.E.239.239; 2.E.239.154; 2.E.239.157; 2.E.239.166; 2.E.239.169; 2.E.239.172; 2.E.239.175; 2.E.239.240; 2.E.239.244; 2.E.154.228; 2.E.154.229; 2.E.154.230; 2.E.154.231; 2.E.154.236; 2.E.154.237; 2.E.154.238; 2.E.154.239; 2.E.154.154; 2.E.154.157; 2.E.154.166; 2.E.154.169; 2.E.154.172; 2.E.154.175; 2.E.154.240; 2.E.154.244; 2.E.157.228; 2.E.157.229; 2.E.157.230; 2.E.157.231; 2.E.157.236; 2.E.157.237; 2.E.157.238; 2.E.157.239; 2.E.157.154; 2.E.157.157; 2.E.157.166; 2.E.157.169; 2.E.157.172; 2.E.157.175; 2.E.157.240; 2.E.157.244; 2.E.166.228; 2.E.166.229; 2.E.166.230; 2.E.166.231; 2.E.166.236; 2.E.166.237; 2.E.166.238; 2.E.166.239; 2.E.166.154; 2.E.166.157; 2.E.166.166; 2.E.166.169; 2.E.166.172; 2.E.166.175; 2.E.166.240; 2.E.166.244; 2.E.169.228; 2.E.169.229; 2.E.169.230; 2.E.169.231; 2.E.169.236; 2.E.169.237; 2.E.169.238; 2.E.169.239; 2.E.169.154; 2.E.169.157; 2.E.169.166; 2.E.169.169; 2.E.169.172; 2.E.169.175; 2.E.169.240; 2.E.169.244; 2.E.172.228; 2.E.172.229; 2.E.172.230; 2.E.172.231; 2.E.172.236; 2.E.172.237; 2.E.172.238; 2.E.172.239; 2.E.172.154; 2.E.172.157; 2.E.172.166; 2.E.172.169; 2.E.172.172; 2.E.172.175; 2.E.172.240; 2.E.172.244; 2.E.175.228; 2.E.175.229; 2.E.175.230; 2.E.175.231; 2.E.175.236; 2.E.175.237; 2.E.175.238; 2.E.175.239; 2.E.175.154; 2.E.175.157; 2.E.175.166; 2.E.175.169; 2.E.175.172; 2.E.175.175; 2.E.175.240; 2.E.175.244; 2.E.240.228; 2.E.240.229; 2.E.240.230; 2.E.240.231; 2.E.240.236; 2.E.240.237; 2.E.240.238; 2.E.240.239; 2.E.240.154; 2.E.240.157; 2.E.240.166; 2.E.240.169; 2.E.240.172; 2.E.240.175; 2.E.240.240; 2.E.240.244; 2.E.244.228; 2.E.244.229; 2.E.244.230; 2.E.244.231; 2.E.244.236; 2.E.244.237; 2.E.244.238; 2.E.244.239; 2.E.244.154; 2.E.244.157; 2.E.244.166; 2.E.244.169; 2.E.244.172; 2.E.244.175; 2.E.244.240; 2.E.244.244;

Prodrugs of 2.G

2.G.228.228; 2.G.228.229; 2.G.228.230; 2.G.228.231; 2.G.228.236; 2.G.228.237; 2.G.228.238; 2.G.228.239; 2.G.228.154; 2.G.228.157; 2.G.228.166; 2.G.228.169; 2.G.228.172; 2.G.228.175; 2.G.228.240; 2.G.228.244; 2.G.229.228; 2.G.229.229; 2.G.229.230; 2.G.229.231; 2.G.229.236; 2.G.229.237; 2.G.229.238; 2.G.229.239; 2.G.229.154; 2.G.229.157; 2.G.229.166; 2.G.229.169; 2.G.229.172; 2.G.229.175; 2.G.229.240; 2.G.229.244; 2.G.230.228; 2.G.230.229; 2.G.230.230;

2.G.230.231; 2.G.230.236; 2.G.230.237; 2.G.230.238; 2.G.230.239; 2.G.230.154; 2.G.230.157; 2.G.230.166; 2.G.230.169; 2.G.230.172; 2.G.230.175; 2.G.230.240; 2.G.230.244; 2.G.231.228; 2.G.231.229; 2.G.231.230; 2.G.231.231; 2.G.231.236; 2.G.231.237; 2.G.231.238; 2.G.231.239; 2.G.231.154; 2.G.231.157; 2.G.231.166; 2.G.231.169; 2.G.231.172; 2.G.231.175; 2.G.231.240; 2.G.231.244; 2.G.236.228; 2.G.236.229; 2.G.236.230; 2.G.236.231; 2.G.236.236; 2.G.236.237; 2.G.236.238; 2.G.236.239; 2.G.236.154; 2.G.236.157; 2.G.236.166; 2.G.236.169; 2.G.236.172; 2.G.236.175; 2.G.236.240; 2.G.236.244; 2.G.237.228; 2.G.237.229; 2.G.237.230; 2.G.237.231; 2.G.237.236; 2.G.237.237; 2.G.237.238; 2.G.237.239; 2.G.237.154; 2.G.237.157; 2.G.237.166; 2.G.237.169; 2.G.237.172; 2.G.237.175; 2.G.237.240; 2.G.237.244; 2.G.238.228; 2.G.238.229; 2.G.238.230; 2.G.238.231; 2.G.238.236; 2.G.238.237; 2.G.238.238; 2.G.238.239; 2.G.238.154; 2.G.238.157; 2.G.238.166; 2.G.238.169; 2.G.238.172; 2.G.238.175; 2.G.238.240; 2.G.238.244; 2.G.239.228; 2.G.239.229; 2.G.239.230; 2.G.239.231; 2.G.239.236; 2.G.239.237; 2.G.239.238; 2.G.239.239; 2.G.239.154; 2.G.239.157; 2.G.239.166; 2.G.239.169; 2.G.239.172; 2.G.239.175; 2.G.239.240; 2.G.239.244; 2.G.154.228; 2.G.154.229; 2.G.154.230; 2.G.154.231; 2.G.154.236; 2.G.154.237; 2.G.154.238; 2.G.154.239; 2.G.154.154; 2.G.154.157; 2.G.154.166; 2.G.154.169; 2.G.154.172; 2.G.154.175; 2.G.154.240; 2.G.154.244; 2.G.157.228; 2.G.157.229; 2.G.157.230; 2.G.157.231; 2.G.157.236; 2.G.157.237; 2.G.157.238; 2.G.157.239; 2.G.157.154; 2.G.157.157; 2.G.157.166; 2.G.157.169; 2.G.157.172; 2.G.157.175; 2.G.157.240; 2.G.157.244; 2.G.166.228; 2.G.166.229; 2.G.166.230; 2.G.166.231; 2.G.166.236; 2.G.166.237; 2.G.166.238; 2.G.166.239; 2.G.166.154; 2.G.166.157; 2.G.166.166; 2.G.166.169; 2.G.166.172; 2.G.166.175; 2.G.166.240; 2.G.166.244; 2.G.169.228; 2.G.169.229; 2.G.169.230; 2.G.169.231; 2.G.169.236; 2.G.169.237; 2.G.169.238; 2.G.169.239; 2.G.169.154; 2.G.169.157; 2.G.169.166; 2.G.169.169; 2.G.169.172; 2.G.169.175; 2.G.169.240; 2.G.169.244; 2.G.172.228; 2.G.172.229; 2.G.172.230; 2.G.172.231; 2.G.172.236; 2.G.172.237; 2.G.172.238; 2.G.172.239; 2.G.172.154; 2.G.172.157; 2.G.172.166; 2.G.172.169; 2.G.172.172; 2.G.172.175; 2.G.172.240; 2.G.172.244; 2.G.175.228; 2.G.175.229; 2.G.175.230; 2.G.175.231; 2.G.175.236; 2.G.175.237; 2.G.175.238; 2.G.175.239; 2.G.175.154; 2.G.175.157; 2.G.175.166; 2.G.175.169;

2.G.175.172; 2.G.175.175; 2.G.175.240; 2.G.175.244; 2.G.240.228; 2.G.240.229; 2.G.240.230; 2.G.240.231; 2.G.240.236; 2.G.240.237; 2.G.240.238; 2.G.240.239; 2.G.240.154; 2.G.240.157; 2.G.240.166; 2.G.240.169; 2.G.240.172; 2.G.240.175; 2.G.240.240; 2.G.240.244; 2.G.244.228; 2.G.244.229; 2.G.244.230; 2.G.244.231; 2.G.244.236; 2.G.244.237; 2.G.244.238; 2.G.244.239; 2.G.244.154; 2.G.244.157; 2.G.244.166; 2.G.244.169; 2.G.244.172; 2.G.244.175; 2.G.244.240; 2.G.244.244;

Prodrugs of 2.I

2.I.228.228; 2.I.228.229; 2.I.228.230; 2.I.228.231; 2.I.228.236; 2.I.228.237; 2.I.228.238; 2.I.228.239; 2.I.228.154; 2.I.228.157; 2.I.228.166; 2.I.228.169; 2.I.228.172; 2.I.228.175; 2.I.228.240; 2.I.228.244; 2.I.229.228; 2.I.229.229; 2.I.229.230; 2.I.229.231; 2.I.229.236; 2.I.229.237; 2.I.229.238; 2.I.229.239; 2.I.229.154; 2.I.229.157; 2.I.229.166; 2.I.229.169; 2.I.229.172; 2.I.229.175; 2.I.229.240; 2.I.229.244; 2.I.230.228; 2.I.230.229; 2.I.230.230; 2.I.230.231; 2.I.230.236; 2.I.230.237; 2.I.230.238; 2.I.230.239; 2.I.230.154; 2.I.230.157; 2.I.230.166; 2.I.230.169; 2.I.230.172; 2.I.230.175; 2.I.230.240; 2.I.230.244; 2.I.231.228; 2.I.231.229; 2.I.231.230; 2.I.231.231; 2.I.231.236; 2.I.231.237; 2.I.231.238; 2.I.231.239; 2.I.231.154; 2.I.231.157; 2.I.231.166; 2.I.231.169; 2.I.231.172; 2.I.231.175; 2.I.231.240; 2.I.231.244; 2.I.236.228; 2.I.236.229; 2.I.236.230; 2.I.236.231; 2.I.236.236; 2.I.236.237; 2.I.236.238; 2.I.236.239; 2.I.236.154; 2.I.236.157; 2.I.236.166; 2.I.236.169; 2.I.236.172; 2.I.236.175; 2.I.236.240; 2.I.236.244; 2.I.237.228; 2.I.237.229; 2.I.237.230; 2.I.237.231; 2.I.237.236; 2.I.237.237; 2.I.237.238; 2.I.237.239; 2.I.237.154; 2.I.237.157; 2.I.237.166; 2.I.237.169; 2.I.237.172; 2.I.237.175; 2.I.237.240; 2.I.237.244; 2.I.238.228; 2.I.238.229; 2.I.238.230; 2.I.238.231; 2.I.238.236; 2.I.238.237; 2.I.238.238; 2.I.238.239; 2.I.238.154; 2.I.238.157; 2.I.238.166; 2.I.238.169; 2.I.238.172; 2.I.238.175; 2.I.238.240; 2.I.238.244; 2.I.239.228; 2.I.239.229; 2.I.239.230; 2.I.239.231; 2.I.239.236; 2.I.239.237; 2.I.239.238; 2.I.239.239; 2.I.239.154; 2.I.239.157; 2.I.239.166; 2.I.239.169; 2.I.239.172; 2.I.239.175; 2.I.239.240; 2.I.239.244; 2.I.154.228; 2.I.154.229; 2.I.154.230; 2.I.154.231; 2.I.154.236; 2.I.154.237; 2.I.154.238; 2.I.154.239; 2.I.154.154; 2.I.154.157; 2.I.154.166; 2.I.154.169; 2.I.154.172; 2.I.154.175; 2.I.154.240; 2.I.154.244; 2.I.157.228; 2.I.157.229; 2.I.157.230; 2.I.157.231; 2.I.157.236; 2.I.157.237; 2.I.157.238; 2.I.157.239; 2.I.157.154; 2.I.157.157; 2.I.157.166; 2.I.157.169; 2.I.157.172; 2.I.157.175; 2.I.157.240; 2.I.157.244; 2.I.166.228; 2.I.166.229;

2.I.166.230; 2.I.166.231; 2.I.166.236; 2.I.166.237; 2.I.166.238; 2.I.166.239; 2.I.166.154; 2.I.166.157; 2.I.166.166; 2.I.166.169; 2.I.166.172; 2.I.166.175; 2.I.166.240; 2.I.166.244; 2.I.169.228; 2.I.169.229; 2.I.169.230; 2.I.169.231; 2.I.169.236; 2.I.169.237; 2.I.169.238; 2.I.169.239; 2.I.169.154; 2.I.169.157; 2.I.169.166; 2.I.169.169; 2.I.169.172; 2.I.169.175; 2.I.169.240; 2.I.169.244; 2.I.172.228; 2.I.172.229; 2.I.172.230; 2.I.172.231; 2.I.172.236; 2.I.172.237; 2.I.172.238; 2.I.172.239; 2.I.172.154; 2.I.172.157; 2.I.172.166; 2.I.172.169; 2.I.172.172; 2.I.172.175; 2.I.172.240; 2.I.172.244; 2.I.175.228; 2.I.175.229; 2.I.175.230; 2.I.175.231; 2.I.175.236; 2.I.175.237; 2.I.175.238; 2.I.175.239; 2.I.175.154; 2.I.175.157; 2.I.175.166; 2.I.175.169; 2.I.175.172; 2.I.175.175; 2.I.175.240; 2.I.175.244; 2.I.240.228; 2.I.240.229; 2.I.240.230; 2.I.240.231; 2.I.240.236; 2.I.240.237; 2.I.240.238; 2.I.240.239; 2.I.240.154; 2.I.240.157; 2.I.240.166; 2.I.240.169; 2.I.240.172; 2.I.240.175; 2.I.240.240; 2.I.240.244; 2.I.244.228; 2.I.244.229; 2.I.244.230; 2.I.244.231; 2.I.244.236; 2.I.244.237; 2.I.244.238; 2.I.244.239; 2.I.244.154; 2.I.244.157; 2.I.244.166; 2.I.244.169; 2.I.244.172; 2.I.244.175; 2.I.244.240; 2.I.244.244;

Prodrugs of 2.J

2.J.228.228; 2.J.228.229; 2.J.228.230; 2.J.228.231; 2.J.228.236; 2.J.228.237; 2.J.228.238; 2.J.228.239; 2.J.228.154; 2.J.228.157; 2.J.228.166; 2.J.228.169; 2.J.228.172; 2.J.228.175; 2.J.228.240; 2.J.228.244; 2.J.229.228; 2.J.229.229; 2.J.229.230; 2.J.229.231; 2.J.229.236; 2.J.229.237; 2.J.229.238; 2.J.229.239; 2.J.229.154; 2.J.229.157; 2.J.229.166; 2.J.229.169; 2.J.229.172; 2.J.229.175; 2.J.229.240; 2.J.229.244; 2.J.230.228; 2.J.230.229; 2.J.230.230; 2.J.230.231; 2.J.230.236; 2.J.230.237; 2.J.230.238; 2.J.230.239; 2.J.230.154; 2.J.230.157; 2.J.230.166; 2.J.230.169; 2.J.230.172; 2.J.230.175; 2.J.230.240; 2.J.230.244; 2.J.231.228; 2.J.231.229; 2.J.231.230; 2.J.231.231; 2.J.231.236; 2.J.231.237; 2.J.231.238; 2.J.231.239; 2.J.231.154; 2.J.231.157; 2.J.231.166; 2.J.231.169; 2.J.231.172; 2.J.231.175; 2.J.231.240; 2.J.231.244; 2.J.236.228; 2.J.236.229; 2.J.236.230; 2.J.236.231; 2.J.236.236; 2.J.236.237; 2.J.236.238; 2.J.236.239; 2.J.236.154; 2.J.236.157; 2.J.236.166; 2.J.236.169; 2.J.236.172; 2.J.236.175; 2.J.236.240; 2.J.236.244; 2.J.237.228; 2.J.237.229; 2.J.237.230; 2.J.237.231; 2.J.237.236; 2.J.237.237; 2.J.237.238; 2.J.237.239; 2.J.237.154; 2.J.237.157; 2.J.237.166; 2.J.237.169; 2.J.237.172; 2.J.237.175; 2.J.237.240; 2.J.237.244; 2.J.238.228; 2.J.238.229; 2.J.238.230; 2.J.238.231; 2.J.238.236; 2.J.238.237; 2.J.238.238; 2.J.238.239; 2.J.238.154; 2.J.238.157; 2.J.238.166; 2.J.238.169; 2.J.238.172; 2.J.238.175; 2.J.238.240; 2.J.238.244; 2.J.239.228; 2.J.239.229;

2.J.239.230; 2.J.239.231; 2.J.239.236; 2.J.239.237; 2.J.239.238; 2.J.239.239; 2.J.239.154; 2.J.239.157; 2.J.239.166; 2.J.239.169; 2.J.239.172; 2.J.239.175; 2.J.239.240; 2.J.239.244; 2.J.154.228; 2.J.154.229; 2.J.154.230; 2.J.154.231; 2.J.154.236; 2.J.154.237; 2.J.154.238; 2.J.154.239; 2.J.154.154; 2.J.154.157; 2.J.154.166; 2.J.154.169; 2.J.154.172; 2.J.154.175; 2.J.154.240; 2.J.154.244; 2.J.157.228; 2.J.157.229; 2.J.157.230; 2.J.157.231; 2.J.157.236; 2.J.157.237; 2.J.157.238; 2.J.157.239; 2.J.157.154; 2.J.157.157; 2.J.157.166; 2.J.157.169; 2.J.157.172; 2.J.157.175; 2.J.157.240; 2.J.157.244; 2.J.166.228; 2.J.166.229; 2.J.166.230; 2.J.166.231; 2.J.166.236; 2.J.166.237; 2.J.166.238; 2.J.166.239; 2.J.166.154; 2.J.166.157; 2.J.166.166; 2.J.166.169; 2.J.166.172; 2.J.166.175; 2.J.166.240; 2.J.166.244; 2.J.169.228; 2.J.169.229; 2.J.169.230; 2.J.169.231; 2.J.169.236; 2.J.169.237; 2.J.169.238; 2.J.169.239; 2.J.169.154; 2.J.169.157; 2.J.169.166; 2.J.169.169; 2.J.169.172; 2.J.169.175; 2.J.169.240; 2.J.169.244; 2.J.172.228; 2.J.172.229; 2.J.172.230; 2.J.172.231; 2.J.172.236; 2.J.172.237; 2.J.172.238; 2.J.172.239; 2.J.172.154; 2.J.172.157; 2.J.172.166; 2.J.172.169; 2.J.172.172; 2.J.172.175; 2.J.172.240; 2.J.172.244; 2.J.175.228; 2.J.175.229; 2.J.175.230; 2.J.175.231; 2.J.175.236; 2.J.175.237; 2.J.175.238; 2.J.175.239; 2.J.175.154; 2.J.175.157; 2.J.175.166; 2.J.175.169; 2.J.175.172; 2.J.175.175; 2.J.175.240; 2.J.175.244; 2.J.240.228; 2.J.240.229; 2.J.240.230; 2.J.240.231; 2.J.240.236; 2.J.240.237; 2.J.240.238; 2.J.240.239; 2.J.240.154; 2.J.240.157; 2.J.240.166; 2.J.240.169; 2.J.240.172; 2.J.240.175; 2.J.240.240; 2.J.240.244; 2.J.244.228; 2.J.244.229; 2.J.244.230; 2.J.244.231; 2.J.244.236; 2.J.244.237; 2.J.244.238; 2.J.244.239; 2.J.244.154; 2.J.244.157; 2.J.244.166; 2.J.244.169; 2.J.244.172; 2.J.244.175; 2.J.244.240; 2.J.244.244;

Prodrugs of 2.L

2.L.228.228; 2.L.228.229; 2.L.228.230; 2.L.228.231; 2.L.228.236; 2.L.228.237; 2.L.228.238; 2.L.228.239; 2.L.228.154; 2.L.228.157; 2.L.228.166; 2.L.228.169; 2.L.228.172; 2.L.228.175; 2.L.228.240; 2.L.228.244; 2.L.229.228; 2.L.229.229; 2.L.229.230; 2.L.229.231; 2.L.229.236; 2.L.229.237; 2.L.229.238; 2.L.229.239; 2.L.229.154; 2.L.229.157; 2.L.229.166; 2.L.229.169; 2.L.229.172; 2.L.229.175; 2.L.229.240; 2.L.229.244; 2.L.230.228; 2.L.230.229; 2.L.230.230; 2.L.230.231; 2.L.230.236; 2.L.230.237; 2.L.230.238; 2.L.230.239; 2.L.230.154; 2.L.230.157; 2.L.230.166; 2.L.230.169; 2.L.230.172; 2.L.230.175; 2.L.230.240; 2.L.230.244; 2.L.231.228; 2.L.231.229; 2.L.231.230; 2.L.231.231; 2.L.231.236; 2.L.231.237; 2.L.231.238; 2.L.231.239; 2.L.231.154; 2.L.231.157; 2.L.231.166; 2.L.231.169; 2.L.231.172; 2.L.231.175; 2.L.231.240; 2.L.231.244; 2.L.236.228;

2.L.236.229; 2.L.236.230; 2.L.236.231; 2.L.236.236; 2.L.236.237; 2.L.236.238; 2.L.236.239; 2.L.236.154; 2.L.236.157; 2.L.236.166; 2.L.236.169; 2.L.236.172; 2.L.236.175; 2.L.236.240; 2.L.236.244; 2.L.237.228; 2.L.237.229; 2.L.237.230; 2.L.237.231; 2.L.237.236; 2.L.237.237; 2.L.237.238; 2.L.237.239; 2.L.237.154; 2.L.237.157; 2.L.237.166; 2.L.237.169; 2.L.237.172; 2.L.237.175; 2.L.237.240; 2.L.237.244; 2.L.238.228; 2.L.238.229; 2.L.238.230; 2.L.238.231; 2.L.238.236; 2.L.238.237; 2.L.238.238; 2.L.238.239; 2.L.238.154; 2.L.238.157; 2.L.238.166; 2.L.238.169; 2.L.238.172; 2.L.238.175; 2.L.238.240; 2.L.238.244; 2.L.239.228; 2.L.239.229; 2.L.239.230; 2.L.239.231; 2.L.239.236; 2.L.239.237; 2.L.239.238; 2.L.239.239; 2.L.239.154; 2.L.239.157; 2.L.239.166; 2.L.239.169; 2.L.239.172; 2.L.239.175; 2.L.239.240; 2.L.239.244; 2.L.154.228; 2.L.154.229; 2.L.154.230; 2.L.154.231; 2.L.154.236; 2.L.154.237; 2.L.154.238; 2.L.154.239; 2.L.154.154; 2.L.154.157; 2.L.154.166; 2.L.154.169; 2.L.154.172; 2.L.154.175; 2.L.154.240; 2.L.154.244; 2.L.157.228; 2.L.157.229; 2.L.157.230; 2.L.157.231; 2.L.157.236; 2.L.157.237; 2.L.157.238; 2.L.157.239; 2.L.157.154; 2.L.157.157; 2.L.157.166; 2.L.157.169; 2.L.157.172; 2.L.157.175; 2.L.157.240; 2.L.157.244; 2.L.166.228; 2.L.166.229; 2.L.166.230; 2.L.166.231; 2.L.166.236; 2.L.166.237; 2.L.166.238; 2.L.166.239; 2.L.166.154; 2.L.166.157; 2.L.166.166; 2.L.166.169; 2.L.166.172; 2.L.166.175; 2.L.166.240; 2.L.166.244; 2.L.169.228; 2.L.169.229; 2.L.169.230; 2.L.169.231; 2.L.169.236; 2.L.169.237; 2.L.169.238; 2.L.169.239; 2.L.169.154; 2.L.169.157; 2.L.169.166; 2.L.169.169; 2.L.169.172; 2.L.169.175; 2.L.169.240; 2.L.169.244; 2.L.172.228; 2.L.172.229; 2.L.172.230; 2.L.172.231; 2.L.172.236; 2.L.172.237; 2.L.172.238; 2.L.172.239; 2.L.172.154; 2.L.172.157; 2.L.172.166; 2.L.172.169; 2.L.172.172; 2.L.172.175; 2.L.172.240; 2.L.172.244; 2.L.175.228; 2.L.175.229; 2.L.175.230; 2.L.175.231; 2.L.175.236; 2.L.175.237; 2.L.175.238; 2.L.175.239; 2.L.175.154; 2.L.175.157; 2.L.175.166; 2.L.175.169; 2.L.175.172; 2.L.175.175; 2.L.175.240; 2.L.175.244; 2.L.240.228; 2.L.240.229; 2.L.240.230; 2.L.240.231; 2.L.240.236; 2.L.240.237; 2.L.240.238; 2.L.240.239; 2.L.240.154; 2.L.240.157; 2.L.240.166; 2.L.240.169; 2.L.240.172; 2.L.240.175; 2.L.240.240; 2.L.240.244; 2.L.244.228; 2.L.244.229; 2.L.244.230; 2.L.244.231; 2.L.244.236; 2.L.244.237; 2.L.244.238; 2.L.244.239; 2.L.244.154; 2.L.244.157; 2.L.244.166; 2.L.244.169; 2.L.244.172; 2.L.244.175; 2.L.244.240; 2.L.244.244;

Prodrugs of 2.O

2.O.228.228; 2.O.228.229; 2.O.228.230; 2.O.228.231; 2.O.228.236; 2.O.228.237; 2.O.228.238; 2.O.228.239; 2.O.228.154; 2.O.228.157; 2.O.228.166; 2.O.228.169; 2.O.228.172; 2.O.228.175; 2.O.228.240;

2.O.228.244; 2.O.229.228; 2.O.229.229; 2.O.229.230; 2.O.229.231; 2.O.229.236; 2.O.229.237; 2.O.229.238; 2.O.229.239; 2.O.229.154; 2.O.229.157; 2.O.229.166; 2.O.229.169; 2.O.229.172; 2.O.229.175; 2.O.229.240; 2.O.229.244; 2.O.230.228; 2.O.230.229; 2.O.230.230; 2.O.230.231; 2.O.230.236; 2.O.230.237; 2.O.230.238; 2.O.230.239; 2.O.230.154; 2.O.230.157; 2.O.230.166; 2.O.230.169; 2.O.230.172; 2.O.230.175; 2.O.230.240; 2.O.230.244; 2.O.231.228; 2.O.231.229; 2.O.231.230; 2.O.231.231; 2.O.231.236; 2.O.231.237; 2.O.231.238; 2.O.231.239; 2.O.231.154; 2.O.231.157; 2.O.231.166; 2.O.231.169; 2.O.231.172; 2.O.231.175; 2.O.231.240; 2.O.231.244; 2.O.236.228; 2.O.236.229; 2.O.236.230; 2.O.236.231; 2.O.236.236; 2.O.236.237; 2.O.236.238; 2.O.236.239; 2.O.236.154; 2.O.236.157; 2.O.236.166; 2.O.236.169; 2.O.236.172; 2.O.236.175; 2.O.236.240; 2.O.236.244; 2.O.237.228; 2.O.237.229; 2.O.237.230; 2.O.237.231; 2.O.237.236; 2.O.237.237; 2.O.237.238; 2.O.237.239; 2.O.237.154; 2.O.237.157; 2.O.237.166; 2.O.237.169; 2.O.237.172; 2.O.237.175; 2.O.237.240; 2.O.237.244; 2.O.238.228; 2.O.238.229; 2.O.238.230; 2.O.238.231; 2.O.238.236; 2.O.238.237; 2.O.238.238; 2.O.238.239; 2.O.238.154; 2.O.238.157; 2.O.238.166; 2.O.238.169; 2.O.238.172; 2.O.238.175; 2.O.238.240; 2.O.238.244; 2.O.239.228; 2.O.239.229; 2.O.239.230; 2.O.239.231; 2.O.239.236; 2.O.239.237; 2.O.239.238; 2.O.239.239; 2.O.239.154; 2.O.239.157; 2.O.239.166; 2.O.239.169; 2.O.239.172; 2.O.239.175; 2.O.239.240; 2.O.239.244; 2.O.154.228; 2.O.154.229; 2.O.154.230; 2.O.154.231; 2.O.154.236; 2.O.154.237; 2.O.154.238; 2.O.154.239; 2.O.154.154; 2.O.154.157; 2.O.154.166; 2.O.154.169; 2.O.154.172; 2.O.154.175; 2.O.154.240; 2.O.154.244; 2.O.157.228; 2.O.157.229; 2.O.157.230; 2.O.157.231; 2.O.157.236; 2.O.157.237; 2.O.157.238; 2.O.157.239; 2.O.157.154; 2.O.157.157; 2.O.157.166; 2.O.157.169; 2.O.157.172; 2.O.157.175; 2.O.157.240; 2.O.157.244; 2.O.166.228; 2.O.166.229; 2.O.166.230; 2.O.166.231; 2.O.166.236; 2.O.166.237; 2.O.166.238; 2.O.166.239; 2.O.166.154; 2.O.166.157; 2.O.166.166; 2.O.166.169; 2.O.166.172; 2.O.166.175; 2.O.166.240; 2.O.166.244; 2.O.169.228; 2.O.169.229; 2.O.169.230; 2.O.169.231; 2.O.169.236; 2.O.169.237; 2.O.169.238; 2.O.169.239; 2.O.169.154; 2.O.169.157; 2.O.169.166; 2.O.169.169; 2.O.169.172; 2.O.169.175; 2.O.169.240; 2.O.169.244; 2.O.172.228; 2.O.172.229; 2.O.172.230; 2.O.172.231; 2.O.172.236; 2.O.172.237; 2.O.172.238; 2.O.172.239;

2.O.172.154; 2.O.172.157; 2.O.172.166; 2.O.172.169; 2.O.172.172; 2.O.172.175; 2.O.172.240; 2.O.172.244; 2.O.175.228; 2.O.175.229; 2.O.175.230; 2.O.175.231; 2.O.175.236; 2.O.175.237; 2.O.175.238; 2.O.175.239; 2.O.175.154; 2.O.175.157; 2.O.175.166; 2.O.175.169; 2.O.175.172; 2.O.175.175; 2.O.175.240; 2.O.175.244; 2.O.240.228; 2.O.240.229; 2.O.240.230; 2.O.240.231; 2.O.240.236; 2.O.240.237; 2.O.240.238; 2.O.240.239; 2.O.240.154; 2.O.240.157; 2.O.240.166; 2.O.240.169; 2.O.240.172; 2.O.240.175; 2.O.240.240; 2.O.240.244; 2.O.244.228; 2.O.244.229; 2.O.244.230; 2.O.244.231; 2.O.244.236; 2.O.244.237; 2.O.244.238; 2.O.244.239; 2.O.244.154; 2.O.244.157; 2.O.244.166; 2.O.244.169; 2.O.244.172; 2.O.244.175; 2.O.244.240; 2.O.244.244;

Prodrugs of 2.P

2.P.228.228; 2.P.228.229; 2.P.228.230; 2.P.228.231; 2.P.228.236; 2.P.228.237; 2.P.228.238; 2.P.228.239; 2.P.228.154; 2.P.228.157; 2.P.228.166; 2.P.228.169; 2.P.228.172; 2.P.228.175; 2.P.228.240; 2.P.228.244; 2.P.229.228; 2.P.229.229; 2.P.229.230; 2.P.229.231; 2.P.229.236; 2.P.229.237; 2.P.229.238; 2.P.229.239; 2.P.229.154; 2.P.229.157; 2.P.229.166; 2.P.229.169; 2.P.229.172; 2.P.229.175; 2.P.229.240; 2.P.229.244; 2.P.230.228; 2.P.230.229; 2.P.230.230; 2.P.230.231; 2.P.230.236; 2.P.230.237; 2.P.230.238; 2.P.230.239; 2.P.230.154; 2.P.230.157; 2.P.230.166; 2.P.230.169; 2.P.230.172; 2.P.230.175; 2.P.230.240; 2.P.230.244; 2.P.231.228; 2.P.231.229; 2.P.231.230; 2.P.231.231; 2.P.231.236; 2.P.231.237; 2.P.231.238; 2.P.231.239; 2.P.231.154; 2.P.231.157; 2.P.231.166; 2.P.231.169; 2.P.231.172; 2.P.231.175; 2.P.231.240; 2.P.231.244; 2.P.236.228; 2.P.236.229; 2.P.236.230; 2.P.236.231; 2.P.236.236; 2.P.236.237; 2.P.236.238; 2.P.236.239; 2.P.236.154; 2.P.236.157; 2.P.236.166; 2.P.236.169; 2.P.236.172; 2.P.236.175; 2.P.236.240; 2.P.236.244; 2.P.237.228; 2.P.237.229; 2.P.237.230; 2.P.237.231; 2.P.237.236; 2.P.237.237; 2.P.237.238; 2.P.237.239; 2.P.237.154; 2.P.237.157; 2.P.237.166; 2.P.237.169; 2.P.237.172; 2.P.237.175; 2.P.237.240; 2.P.237.244; 2.P.238.228; 2.P.238.229; 2.P.238.230; 2.P.238.231; 2.P.238.236; 2.P.238.237; 2.P.238.238; 2.P.238.239; 2.P.238.154; 2.P.238.157; 2.P.238.166; 2.P.238.169; 2.P.238.172; 2.P.238.175; 2.P.238.240; 2.P.238.244; 2.P.239.228; 2.P.239.229; 2.P.239.230; 2.P.239.231; 2.P.239.236; 2.P.239.237; 2.P.239.238; 2.P.239.239; 2.P.239.154; 2.P.239.157; 2.P.239.166; 2.P.239.169; 2.P.239.172; 2.P.239.175; 2.P.239.240; 2.P.239.244; 2.P.154.228; 2.P.154.229; 2.P.154.230; 2.P.154.231; 2.P.154.236; 2.P.154.237; 2.P.154.238; 2.P.154.239; 2.P.154.154;

2.P.154.157; 2.P.154.166; 2.P.154.169; 2.P.154.172; 2.P.154.175; 2.P.154.240; 2.P.154.244; 2.P.157.228; 2.P.157.229; 2.P.157.230; 2.P.157.231; 2.P.157.236; 2.P.157.237; 2.P.157.238; 2.P.157.239; 2.P.157.154; 2.P.157.157; 2.P.157.166; 2.P.157.169; 2.P.157.172; 2.P.157.175; 2.P.157.240; 2.P.157.244; 2.P.166.228; 2.P.166.229; 2.P.166.230; 2.P.166.231; 2.P.166.236; 2.P.166.237; 2.P.166.238; 2.P.166.239; 2.P.166.154; 2.P.166.157; 2.P.166.166; 2.P.166.169; 2.P.166.172; 2.P.166.175; 2.P.166.240; 2.P.166.244; 2.P.169.228; 2.P.169.229; 2.P.169.230; 2.P.169.231; 2.P.169.236; 2.P.169.237; 2.P.169.238; 2.P.169.239; 2.P.169.154; 2.P.169.157; 2.P.169.166; 2.P.169.169; 2.P.169.172; 2.P.169.175; 2.P.169.240; 2.P.169.244; 2.P.172.228; 2.P.172.229; 2.P.172.230; 2.P.172.231; 2.P.172.236; 2.P.172.237; 2.P.172.238; 2.P.172.239; 2.P.172.154; 2.P.172.157; 2.P.172.166; 2.P.172.169; 2.P.172.172; 2.P.172.175; 2.P.172.240; 2.P.172.244; 2.P.175.228; 2.P.175.229; 2.P.175.230; 2.P.175.231; 2.P.175.236; 2.P.175.237; 2.P.175.238; 2.P.175.239; 2.P.175.154; 2.P.175.157; 2.P.175.166; 2.P.175.169; 2.P.175.172; 2.P.175.175; 2.P.175.240; 2.P.175.244; 2.P.240.228; 2.P.240.229; 2.P.240.230; 2.P.240.231; 2.P.240.236; 2.P.240.237; 2.P.240.238; 2.P.240.239; 2.P.240.154; 2.P.240.157; 2.P.240.166; 2.P.240.169; 2.P.240.172; 2.P.240.175; 2.P.240.240; 2.P.240.244; 2.P.244.228; 2.P.244.229; 2.P.244.230; 2.P.244.231; 2.P.244.236; 2.P.244.237; 2.P.244.238; 2.P.244.239; 2.P.244.154; 2.P.244.157; 2.P.244.166; 2.P.244.169; 2.P.244.172; 2.P.244.175; 2.P.244.240; 2.P.244.244;

Prodrugs of 2.U

2.U.228.228; 2.U.228.229; 2.U.228.230; 2.U.228.231; 2.U.228.236; 2.U.228.237; 2.U.228.238; 2.U.228.239; 2.U.228.154; 2.U.228.157; 2.U.228.166; 2.U.228.169; 2.U.228.172; 2.U.228.175; 2.U.228.240; 2.U.228.244; 2.U.229.228; 2.U.229.229; 2.U.229.230; 2.U.229.231; 2.U.229.236; 2.U.229.237; 2.U.229.238; 2.U.229.239; 2.U.229.154; 2.U.229.157; 2.U.229.166; 2.U.229.169; 2.U.229.172; 2.U.229.175; 2.U.229.240; 2.U.229.244; 2.U.230.228; 2.U.230.229; 2.U.230.230; 2.U.230.231; 2.U.230.236; 2.U.230.237; 2.U.230.238; 2.U.230.239; 2.U.230.154; 2.U.230.157; 2.U.230.166; 2.U.230.169; 2.U.230.172; 2.U.230.175; 2.U.230.240; 2.U.230.244; 2.U.231.228; 2.U.231.229; 2.U.231.230; 2.U.231.231; 2.U.231.236; 2.U.231.237; 2.U.231.238; 2.U.231.239; 2.U.231.154; 2.U.231.157; 2.U.231.166; 2.U.231.169; 2.U.231.172; 2.U.231.175; 2.U.231.240; 2.U.231.244; 2.U.236.228; 2.U.236.229; 2.U.236.230; 2.U.236.231; 2.U.236.236; 2.U.236.237; 2.U.236.238; 2.U.236.239; 2.U.236.154; 2.U.236.157; 2.U.236.166;

2.U.236.169; 2.U.236.172; 2.U.236.175; 2.U.236.240; 2.U.236.244; 2.U.237.228; 2.U.237.229; 2.U.237.230; 2.U.237.231; 2.U.237.236; 2.U.237.237; 2.U.237.238; 2.U.237.239; 2.U.237.154; 2.U.237.157; 2.U.237.166; 2.U.237.169; 2.U.237.172; 2.U.237.175; 2.U.237.240; 2.U.237.244; 2.U.238.228; 2.U.238.229; 2.U.238.230; 2.U.238.231; 2.U.238.236; 2.U.238.237; 2.U.238.238; 2.U.238.239; 2.U.238.154; 2.U.238.157; 2.U.238.166; 2.U.238.169; 2.U.238.172; 2.U.238.175; 2.U.238.240; 2.U.238.244; 2.U.239.228; 2.U.239.229; 2.U.239.230; 2.U.239.231; 2.U.239.236; 2.U.239.237; 2.U.239.238; 2.U.239.239; 2.U.239.154; 2.U.239.157; 2.U.239.166; 2.U.239.169; 2.U.239.172; 2.U.239.175; 2.U.239.240; 2.U.239.244; 2.U.154.228; 2.U.154.229; 2.U.154.230; 2.U.154.231; 2.U.154.236; 2.U.154.237; 2.U.154.238; 2.U.154.239; 2.U.154.154; 2.U.154.157; 2.U.154.166; 2.U.154.169; 2.U.154.172; 2.U.154.175; 2.U.154.240; 2.U.154.244; 2.U.157.228; 2.U.157.229; 2.U.157.230; 2.U.157.231; 2.U.157.236; 2.U.157.237; 2.U.157.238; 2.U.157.239; 2.U.157.154; 2.U.157.157; 2.U.157.166; 2.U.157.169; 2.U.157.172; 2.U.157.175; 2.U.157.240; 2.U.157.244; 2.U.166.228; 2.U.166.229; 2.U.166.230; 2.U.166.231; 2.U.166.236; 2.U.166.237; 2.U.166.238; 2.U.166.239; 2.U.166.154; 2.U.166.157; 2.U.166.166; 2.U.166.169; 2.U.166.172; 2.U.166.175; 2.U.166.240; 2.U.166.244; 2.U.169.228; 2.U.169.229; 2.U.169.230; 2.U.169.231; 2.U.169.236; 2.U.169.237; 2.U.169.238; 2.U.169.239; 2.U.169.154; 2.U.169.157; 2.U.169.166; 2.U.169.169; 2.U.169.172; 2.U.169.175; 2.U.169.240; 2.U.169.244; 2.U.172.228; 2.U.172.229; 2.U.172.230; 2.U.172.231; 2.U.172.236; 2.U.172.237; 2.U.172.238; 2.U.172.239; 2.U.172.154; 2.U.172.157; 2.U.172.166; 2.U.172.169; 2.U.172.172; 2.U.172.175; 2.U.172.240; 2.U.172.244; 2.U.175.228; 2.U.175.229; 2.U.175.230; 2.U.175.231; 2.U.175.236; 2.U.175.237; 2.U.175.238; 2.U.175.239; 2.U.175.154; 2.U.175.157; 2.U.175.166; 2.U.175.169; 2.U.175.172; 2.U.175.175; 2.U.175.240; 2.U.175.244; 2.U.240.228; 2.U.240.229; 2.U.240.230; 2.U.240.231; 2.U.240.236; 2.U.240.237; 2.U.240.238; 2.U.240.239; 2.U.240.154; 2.U.240.157; 2.U.240.166; 2.U.240.169; 2.U.240.172; 2.U.240.175; 2.U.240.240; 2.U.240.244; 2.U.244.228; 2.U.244.229; 2.U.244.230; 2.U.244.231; 2.U.244.236; 2.U.244.237; 2.U.244.238; 2.U.244.239; 2.U.244.154; 2.U.244.157; 2.U.244.166; 2.U.244.169; 2.U.244.172; 2.U.244.175; 2.U.244.240; 2.U.244.244;

Prodrugs of 2.W

2.W.228.228; 2.W.228.229; 2.W.228.230; 2.W.228.231; 2.W.228.236; 2.W.228.237; 2.W.228.238; 2.W.228.239; 2.W.228.154; 2.W.228.157; 2.W.228.166; 2.W.228.169; 2.W.228.172; 2.W.228.175; 2.W.228.240; 2.W.228.244; 2.W.229.228; 2.W.229.229; 2.W.229.230; 2.W.229.231; 2.W.229.236; 2.W.229.237; 2.W.229.238; 2.W.229.239; 2.W.229.154; 2.W.229.157; 2.W.229.166; 2.W.229.169; 2.W.229.172; 2.W.229.175; 2.W.229.240; 2.W.229.244; 2.W.230.228; 2.W.230.229; 2.W.230.230; 2.W.230.231; 2.W.230.236; 2.W.230.237; 2.W.230.238; 2.W.230.239; 2.W.230.154; 2.W.230.157; 2.W.230.166; 2.W.230.169; 2.W.230.172; 2.W.230.175; 2.W.230.240; 2.W.230.244; 2.W.231.228; 2.W.231.229; 2.W.231.230; 2.W.231.231; 2.W.231.236; 2.W.231.237; 2.W.231.238; 2.W.231.239; 2.W.231.154; 2.W.231.157; 2.W.231.166; 2.W.231.169; 2.W.231.172; 2.W.231.175; 2.W.231.240; 2.W.231.244; 2.W.236.228; 2.W.236.229; 2.W.236.230; 2.W.236.231; 2.W.236.236; 2.W.236.237; 2.W.236.238; 2.W.236.239; 2.W.236.154; 2.W.236.157; 2.W.236.166; 2.W.236.169; 2.W.236.172; 2.W.236.175; 2.W.236.240; 2.W.236.244; 2.W.237.228; 2.W.237.229; 2.W.237.230; 2.W.237.231; 2.W.237.236; 2.W.237.237; 2.W.237.238; 2.W.237.239; 2.W.237.154; 2.W.237.157; 2.W.237.166; 2.W.237.169; 2.W.237.172; 2.W.237.175; 2.W.237.240; 2.W.237.244; 2.W.238.228; 2.W.238.229; 2.W.238.230; 2.W.238.231; 2.W.238.236; 2.W.238.237; 2.W.238.238; 2.W.238.239; 2.W.238.154; 2.W.238.157; 2.W.238.166; 2.W.238.169; 2.W.238.172; 2.W.238.175; 2.W.238.240; 2.W.238.244; 2.W.239.228; 2.W.239.229; 2.W.239.230; 2.W.239.231; 2.W.239.236; 2.W.239.237; 2.W.239.238; 2.W.239.239; 2.W.239.154; 2.W.239.157; 2.W.239.166; 2.W.239.169; 2.W.239.172; 2.W.239.175; 2.W.239.240; 2.W.239.244; 2.W.154.228; 2.W.154.229; 2.W.154.230; 2.W.154.231; 2.W.154.236; 2.W.154.237; 2.W.154.238; 2.W.154.239; 2.W.154.154; 2.W.154.157; 2.W.154.166; 2.W.154.169; 2.W.154.172; 2.W.154.175; 2.W.154.240; 2.W.154.244; 2.W.157.228; 2.W.157.229; 2.W.157.230; 2.W.157.231; 2.W.157.236; 2.W.157.237; 2.W.157.238; 2.W.157.239; 2.W.157.154; 2.W.157.157; 2.W.157.166; 2.W.157.169; 2.W.157.172; 2.W.157.175; 2.W.157.240; 2.W.157.244; 2.W.166.228; 2.W.166.229; 2.W.166.230; 2.W.166.231; 2.W.166.236; 2.W.166.237; 2.W.166.238; 2.W.166.239; 2.W.166.154; 2.W.166.157; 2.W.166.166; 2.W.166.169; 2.W.166.172; 2.W.166.175; 2.W.166.240;

2.W.166.244; 2.W.169.228; 2.W.169.229; 2.W.169.230; 2.W.169.231; 2.W.169.236; 2.W.169.237; 2.W.169.238; 2.W.169.239; 2.W.169.154; 2.W.169.157; 2.W.169.166; 2.W.169.169; 2.W.169.172; 2.W.169.175; 2.W.169.240; 2.W.169.244; 2.W.172.228; 2.W.172.229; 2.W.172.230; 2.W.172.231; 2.W.172.236; 2.W.172.237; 2.W.172.238; 2.W.172.239; 2.W.172.154; 2.W.172.157; 2.W.172.166; 2.W.172.169; 2.W.172.172; 2.W.172.175; 2.W.172.240; 2.W.172.244; 2.W.175.228; 2.W.175.229; 2.W.175.230; 2.W.175.231; 2.W.175.236; 2.W.175.237; 2.W.175.238; 2.W.175.239; 2.W.175.154; 2.W.175.157; 2.W.175.166; 2.W.175.169; 2.W.175.172; 2.W.175.175; 2.W.175.240; 2.W.175.244; 2.W.240.228; 2.W.240.229; 2.W.240.230; 2.W.240.231; 2.W.240.236; 2.W.240.237; 2.W.240.238; 2.W.240.239; 2.W.240.154; 2.W.240.157; 2.W.240.166; 2.W.240.169; 2.W.240.172; 2.W.240.175; 2.W.240.240; 2.W.240.244; 2.W.244.228; 2.W.244.229; 2.W.244.230; 2.W.244.231; 2.W.244.236; 2.W.244.237; 2.W.244.238; 2.W.244.239; 2.W.244.154; 2.W.244.157; 2.W.244.166; 2.W.244.169; 2.W.244.172; 2.W.244.175; 2.W.244.240; 2.W.244.244;

Prodrugs of 2.Y

2.Y.228.228; 2.Y.228.229; 2.Y.228.230; 2.Y.228.231; 2.Y.228.236; 2.Y.228.237; 2.Y.228.238; 2.Y.228.239; 2.Y.228.154; 2.Y.228.157; 2.Y.228.166; 2.Y.228.169; 2.Y.228.172; 2.Y.228.175; 2.Y.228.240; 2.Y.228.244; 2.Y.229.228; 2.Y.229.229; 2.Y.229.230; 2.Y.229.231; 2.Y.229.236; 2.Y.229.237; 2.Y.229.238; 2.Y.229.239; 2.Y.229.154; 2.Y.229.157; 2.Y.229.166; 2.Y.229.169; 2.Y.229.172; 2.Y.229.175; 2.Y.229.240; 2.Y.229.244; 2.Y.230.228; 2.Y.230.229; 2.Y.230.230; 2.Y.230.231; 2.Y.230.236; 2.Y.230.237; 2.Y.230.238; 2.Y.230.239; 2.Y.230.154; 2.Y.230.157; 2.Y.230.166; 2.Y.230.169; 2.Y.230.172; 2.Y.230.175; 2.Y.230.240; 2.Y.230.244; 2.Y.231.228; 2.Y.231.229; 2.Y.231.230; 2.Y.231.231; 2.Y.231.236; 2.Y.231.237; 2.Y.231.238; 2.Y.231.239; 2.Y.231.154; 2.Y.231.157; 2.Y.231.166; 2.Y.231.169; 2.Y.231.172; 2.Y.231.175; 2.Y.231.240; 2.Y.231.244; 2.Y.236.228; 2.Y.236.229; 2.Y.236.230; 2.Y.236.231; 2.Y.236.236; 2.Y.236.237; 2.Y.236.238; 2.Y.236.239; 2.Y.236.154; 2.Y.236.157; 2.Y.236.166; 2.Y.236.169; 2.Y.236.172; 2.Y.236.175; 2.Y.236.240; 2.Y.236.244; 2.Y.237.228; 2.Y.237.229; 2.Y.237.230; 2.Y.237.231; 2.Y.237.236; 2.Y.237.237; 2.Y.237.238; 2.Y.237.239; 2.Y.237.154; 2.Y.237.157; 2.Y.237.166; 2.Y.237.169; 2.Y.237.172; 2.Y.237.175; 2.Y.237.240; 2.Y.237.244; 2.Y.238.228; 2.Y.238.229; 2.Y.238.230; 2.Y.238.231; 2.Y.238.236; 2.Y.238.237; 2.Y.238.238; 2.Y.238.239; 2.Y.238.154; 2.Y.238.157; 2.Y.238.166;

2.Y.238.169; 2.Y.238.172; 2.Y.238.175; 2.Y.238.240; 2.Y.238.244; 2.Y.239.228; 2.Y.239.229; 2.Y.239.230; 2.Y.239.231; 2.Y.239.236; 2.Y.239.237; 2.Y.239.238; 2.Y.239.239; 2.Y.239.154; 2.Y.239.157; 2.Y.239.166; 2.Y.239.169; 2.Y.239.172; 2.Y.239.175; 2.Y.239.240; 2.Y.239.244; 2.Y.154.228; 2.Y.154.229; 2.Y.154.230; 2.Y.154.231; 2.Y.154.236; 2.Y.154.237; 2.Y.154.238; 2.Y.154.239; 2.Y.154.154; 2.Y.154.157; 2.Y.154.166; 2.Y.154.169; 2.Y.154.172; 2.Y.154.175; 2.Y.154.240; 2.Y.154.244; 2.Y.157.228; 2.Y.157.229; 2.Y.157.230; 2.Y.157.231; 2.Y.157.236; 2.Y.157.237; 2.Y.157.238; 2.Y.157.239; 2.Y.157.154; 2.Y.157.157; 2.Y.157.166; 2.Y.157.169; 2.Y.157.172; 2.Y.157.175; 2.Y.157.240; 2.Y.157.244; 2.Y.166.228; 2.Y.166.229; 2.Y.166.230; 2.Y.166.231; 2.Y.166.236; 2.Y.166.237; 2.Y.166.238; 2.Y.166.239; 2.Y.166.154; 2.Y.166.157; 2.Y.166.166; 2.Y.166.169; 2.Y.166.172; 2.Y.166.175; 2.Y.166.240; 2.Y.166.244; 2.Y.169.228; 2.Y.169.229; 2.Y.169.230; 2.Y.169.231; 2.Y.169.236; 2.Y.169.237; 2.Y.169.238; 2.Y.169.239; 2.Y.169.154; 2.Y.169.157; 2.Y.169.166; 2.Y.169.169; 2.Y.169.172; 2.Y.169.175; 2.Y.169.240; 2.Y.169.244; 2.Y.172.228; 2.Y.172.229; 2.Y.172.230; 2.Y.172.231; 2.Y.172.236; 2.Y.172.237; 2.Y.172.238; 2.Y.172.239; 2.Y.172.154; 2.Y.172.157; 2.Y.172.166; 2.Y.172.169; 2.Y.172.172; 2.Y.172.175; 2.Y.172.240; 2.Y.172.244; 2.Y.175.228; 2.Y.175.229; 2.Y.175.230; 2.Y.175.231; 2.Y.175.236; 2.Y.175.237; 2.Y.175.238; 2.Y.175.239; 2.Y.175.154; 2.Y.175.157; 2.Y.175.166; 2.Y.175.169; 2.Y.175.172; 2.Y.175.175; 2.Y.175.240; 2.Y.175.244; 2.Y.240.228; 2.Y.240.229; 2.Y.240.230; 2.Y.240.231; 2.Y.240.236; 2.Y.240.237; 2.Y.240.238; 2.Y.240.239; 2.Y.240.154; 2.Y.240.157; 2.Y.240.166; 2.Y.240.169; 2.Y.240.172; 2.Y.240.175; 2.Y.240.240; 2.Y.240.244; 2.Y.244.228; 2.Y.244.229; 2.Y.244.230; 2.Y.244.231; 2.Y.244.236; 2.Y.244.237; 2.Y.244.238; 2.Y.244.239; 2.Y.244.154; 2.Y.244.157; 2.Y.244.166; 2.Y.244.169; 2.Y.244.172; 2.Y.244.175; 2.Y.244.240; 2.Y.244.244;

Prodrugs of 3.B

3.B.228.228; 3.B.228.229; 3.B.228.230; 3.B.228.231; 3.B.228.236; 3.B.228.237; 3.B.228.238; 3.B.228.239; 3.B.228.154; 3.B.228.157; 3.B.228.166; 3.B.228.169; 3.B.228.172; 3.B.228.175; 3.B.228.240; 3.B.228.244; 3.B.229.228; 3.B.229.229; 3.B.229.230; 3.B.229.231; 3.B.229.236; 3.B.229.237; 3.B.229.238; 3.B.229.239; 3.B.229.154; 3.B.229.157; 3.B.229.166; 3.B.229.169; 3.B.229.172; 3.B.229.175; 3.B.229.240; 3.B.229.244; 3.B.230.228; 3.B.230.229; 3.B.230.230; 3.B.230.231; 3.B.230.236; 3.B.230.237; 3.B.230.238; 3.B.230.239; 3.B.230.154; 3.B.230.157; 3.B.230.166; 3.B.230.169; 3.B.230.172; 3.B.230.175; 3.B.230.240; 3.B.230.244; 3.B.231.228; 3.B.231.229; 3.B.231.230; 3.B.231.231; 3.B.231.236; 3.B.231.237; 3.B.231.238; 3.B.231.239; 3.B.231.154; 3.B.231.157; 3.B.231.166;

3.B.231.169; 3.B.231.172; 3.B.231.175; 3.B.231.240; 3.B.231.244; 3.B.236.228; 3.B.236.229; 3.B.236.230; 3.B.236.231; 3.B.236.236; 3.B.236.237; 3.B.236.238; 3.B.236.239; 3.B.236.154; 3.B.236.157; 3.B.236.166; 3.B.236.169; 3.B.236.172; 3.B.236.175; 3.B.236.240; 3.B.236.244; 3.B.237.228; 3.B.237.229; 3.B.237.230; 3.B.237.231; 3.B.237.236; 3.B.237.237; 3.B.237.238; 3.B.237.239; 3.B.237.154; 3.B.237.157; 3.B.237.166; 3.B.237.169; 3.B.237.172; 3.B.237.175; 3.B.237.240; 3.B.237.244; 3.B.238.228; 3.B.238.229; 3.B.238.230; 3.B.238.231; 3.B.238.236; 3.B.238.237; 3.B.238.238; 3.B.238.239; 3.B.238.154; 3.B.238.157; 3.B.238.166; 3.B.238.169; 3.B.238.172; 3.B.238.175; 3.B.238.240; 3.B.238.244; 3.B.239.228; 3.B.239.229; 3.B.239.230; 3.B.239.231; 3.B.239.236; 3.B.239.237; 3.B.239.238; 3.B.239.239; 3.B.239.154; 3.B.239.157; 3.B.239.166; 3.B.239.169; 3.B.239.172; 3.B.239.175; 3.B.239.240; 3.B.239.244; 3.B.154.228; 3.B.154.229; 3.B.154.230; 3.B.154.231; 3.B.154.236; 3.B.154.237; 3.B.154.238; 3.B.154.239; 3.B.154.154; 3.B.154.157; 3.B.154.166; 3.B.154.169; 3.B.154.172; 3.B.154.175; 3.B.154.240; 3.B.154.244; 3.B.157.228; 3.B.157.229; 3.B.157.230; 3.B.157.231; 3.B.157.236; 3.B.157.237; 3.B.157.238; 3.B.157.239; 3.B.157.154; 3.B.157.157; 3.B.157.166; 3.B.157.169; 3.B.157.172; 3.B.157.175; 3.B.157.240; 3.B.157.244; 3.B.166.228; 3.B.166.229; 3.B.166.230; 3.B.166.231; 3.B.166.236; 3.B.166.237; 3.B.166.238; 3.B.166.239; 3.B.166.154; 3.B.166.157; 3.B.166.166; 3.B.166.169; 3.B.166.172; 3.B.166.175; 3.B.166.240; 3.B.166.244; 3.B.169.228; 3.B.169.229; 3.B.169.230; 3.B.169.231; 3.B.169.236; 3.B.169.237; 3.B.169.238; 3.B.169.239; 3.B.169.154; 3.B.169.157; 3.B.169.166; 3.B.169.169; 3.B.169.172; 3.B.169.175; 3.B.169.240; 3.B.169.244; 3.B.172.228; 3.B.172.229; 3.B.172.230; 3.B.172.231; 3.B.172.236; 3.B.172.237; 3.B.172.238; 3.B.172.239; 3.B.172.154; 3.B.172.157; 3.B.172.166; 3.B.172.169; 3.B.172.172; 3.B.172.175; 3.B.172.240; 3.B.172.244; 3.B.175.228; 3.B.175.229; 3.B.175.230; 3.B.175.231; 3.B.175.236; 3.B.175.237; 3.B.175.238; 3.B.175.239; 3.B.175.154; 3.B.175.157; 3.B.175.166; 3.B.175.169; 3.B.175.172; 3.B.175.175; 3.B.175.240; 3.B.175.244; 3.B.240.228; 3.B.240.229; 3.B.240.230; 3.B.240.231; 3.B.240.236; 3.B.240.237; 3.B.240.238; 3.B.240.239; 3.B.240.154; 3.B.240.157; 3.B.240.166; 3.B.240.169; 3.B.240.172; 3.B.240.175; 3.B.240.240; 3.B.240.244; 3.B.244.228; 3.B.244.229; 3.B.244.230; 3.B.244.231; 3.B.244.236; 3.B.244.237; 3.B.244.238; 3.B.244.239; 3.B.244.154; 3.B.244.157; 3.B.244.166; 3.B.244.169; 3.B.244.172; 3.B.244.175; 3.B.244.240; 3.B.244.244;

Prodrugs of 3.D

3.D.228.228; 3.D.228.229; 3.D.228.230; 3.D.228.231; 3.D.228.236; 3.D.228.237; 3.D.228.238; 3.D.228.239; 3.D.228.154; 3.D.228.157;

3.D.228.166; 3.D.228.169; 3.D.228.172; 3.D.228.175; 3.D.228.240; 3.D.228.244; 3.D.229.228; 3.D.229.229; 3.D.229.230; 3.D.229.231; 3.D.229.236; 3.D.229.237; 3.D.229.238; 3.D.229.239; 3.D.229.154; 3.D.229.157; 3.D.229.166; 3.D.229.169; 3.D.229.172; 3.D.229.175; 3.D.229.240; 3.D.229.244; 3.D.230.228; 3.D.230.229; 3.D.230.230; 3.D.230.231; 3.D.230.236; 3.D.230.237; 3.D.230.238; 3.D.230.239; 3.D.230.154; 3.D.230.157; 3.D.230.166; 3.D.230.169; 3.D.230.172; 3.D.230.175; 3.D.230.240; 3.D.230.244; 3.D.231.228; 3.D.231.229; 3.D.231.230; 3.D.231.231; 3.D.231.236; 3.D.231.237; 3.D.231.238; 3.D.231.239; 3.D.231.154; 3.D.231.157; 3.D.231.166; 3.D.231.169; 3.D.231.172; 3.D.231.175; 3.D.231.240; 3.D.231.244; 3.D.236.228; 3.D.236.229; 3.D.236.230; 3.D.236.231; 3.D.236.236; 3.D.236.237; 3.D.236.238; 3.D.236.239; 3.D.236.154; 3.D.236.157; 3.D.236.166; 3.D.236.169; 3.D.236.172; 3.D.236.175; 3.D.236.240; 3.D.236.244; 3.D.237.228; 3.D.237.229; 3.D.237.230; 3.D.237.231; 3.D.237.236; 3.D.237.237; 3.D.237.238; 3.D.237.239; 3.D.237.154; 3.D.237.157; 3.D.237.166; 3.D.237.169; 3.D.237.172; 3.D.237.175; 3.D.237.240; 3.D.237.244; 3.D.238.228; 3.D.238.229; 3.D.238.230; 3.D.238.231; 3.D.238.236; 3.D.238.237; 3.D.238.238; 3.D.238.239; 3.D.238.154; 3.D.238.157; 3.D.238.166; 3.D.238.169; 3.D.238.172; 3.D.238.175; 3.D.238.240; 3.D.238.244; 3.D.239.228; 3.D.239.229; 3.D.239.230; 3.D.239.231; 3.D.239.236; 3.D.239.237; 3.D.239.238; 3.D.239.239; 3.D.239.154; 3.D.239.157; 3.D.239.166; 3.D.239.169; 3.D.239.172; 3.D.239.175; 3.D.239.240; 3.D.239.244; 3.D.154.228; 3.D.154.229; 3.D.154.230; 3.D.154.231; 3.D.154.236; 3.D.154.237; 3.D.154.238; 3.D.154.239; 3.D.154.154; 3.D.154.157; 3.D.154.166; 3.D.154.169; 3.D.154.172; 3.D.154.175; 3.D.154.240; 3.D.154.244; 3.D.157.228; 3.D.157.229; 3.D.157.230; 3.D.157.231; 3.D.157.236; 3.D.157.237; 3.D.157.238; 3.D.157.239; 3.D.157.154; 3.D.157.157; 3.D.157.166; 3.D.157.169; 3.D.157.172; 3.D.157.175; 3.D.157.240; 3.D.157.244; 3.D.166.228; 3.D.166.229; 3.D.166.230; 3.D.166.231; 3.D.166.236; 3.D.166.237; 3.D.166.238; 3.D.166.239; 3.D.166.154; 3.D.166.157; 3.D.166.166; 3.D.166.169; 3.D.166.172; 3.D.166.175; 3.D.166.240; 3.D.166.244; 3.D.169.228; 3.D.169.229; 3.D.169.230; 3.D.169.231; 3.D.169.236; 3.D.169.237; 3.D.169.238; 3.D.169.239; 3.D.169.154; 3.D.169.157; 3.D.169.166; 3.D.169.169; 3.D.169.172; 3.D.169.175; 3.D.169.240; 3.D.169.244; 3.D.172.228; 3.D.172.229; 3.D.172.230;

3.D.172.231; 3.D.172.236; 3.D.172.237; 3.D.172.238; 3.D.172.239; 3.D.172.154; 3.D.172.157; 3.D.172.166; 3.D.172.169; 3.D.172.172; 3.D.172.175; 3.D.172.240; 3.D.172.244; 3.D.175.228; 3.D.175.229; 3.D.175.230; 3.D.175.231; 3.D.175.236; 3.D.175.237; 3.D.175.238; 3.D.175.239; 3.D.175.154; 3.D.175.157; 3.D.175.166; 3.D.175.169; 3.D.175.172; 3.D.175.175; 3.D.175.240; 3.D.175.244; 3.D.240.228; 3.D.240.229; 3.D.240.230; 3.D.240.231; 3.D.240.236; 3.D.240.237; 3.D.240.238; 3.D.240.239; 3.D.240.154; 3.D.240.157; 3.D.240.166; 3.D.240.169; 3.D.240.172; 3.D.240.175; 3.D.240.240; 3.D.240.244; 3.D.244.228; 3.D.244.229; 3.D.244.230; 3.D.244.231; 3.D.244.236; 3.D.244.237; 3.D.244.238; 3.D.244.239; 3.D.244.154; 3.D.244.157; 3.D.244.166; 3.D.244.169; 3.D.244.172; 3.D.244.175; 3.D.244.240; 3.D.244.244;

Prodrugs of 3.E

3.E.228.228; 3.E.228.229; 3.E.228.230; 3.E.228.231; 3.E.228.236; 3.E.228.237; 3.E.228.238; 3.E.228.239; 3.E.228.154; 3.E.228.157; 3.E.228.166; 3.E.228.169; 3.E.228.172; 3.E.228.175; 3.E.228.240; 3.E.228.244; 3.E.229.228; 3.E.229.229; 3.E.229.230; 3.E.229.231; 3.E.229.236; 3.E.229.237; 3.E.229.238; 3.E.229.239; 3.E.229.154; 3.E.229.157; 3.E.229.166; 3.E.229.169; 3.E.229.172; 3.E.229.175; 3.E.229.240; 3.E.229.244; 3.E.230.228; 3.E.230.229; 3.E.230.230; 3.E.230.231; 3.E.230.236; 3.E.230.237; 3.E.230.238; 3.E.230.239; 3.E.230.154; 3.E.230.157; 3.E.230.166; 3.E.230.169; 3.E.230.172; 3.E.230.175; 3.E.230.240; 3.E.230.244; 3.E.231.228; 3.E.231.229; 3.E.231.230; 3.E.231.231; 3.E.231.236; 3.E.231.237; 3.E.231.238; 3.E.231.239; 3.E.231.154; 3.E.231.157; 3.E.231.166; 3.E.231.169; 3.E.231.172; 3.E.231.175; 3.E.231.240; 3.E.231.244; 3.E.236.228; 3.E.236.229; 3.E.236.230; 3.E.236.231; 3.E.236.236; 3.E.236.237; 3.E.236.238; 3.E.236.239; 3.E.236.154; 3.E.236.157; 3.E.236.166; 3.E.236.169; 3.E.236.172; 3.E.236.175; 3.E.236.240; 3.E.236.244; 3.E.237.228; 3.E.237.229; 3.E.237.230; 3.E.237.231; 3.E.237.236; 3.E.237.237; 3.E.237.238; 3.E.237.239; 3.E.237.154; 3.E.237.157; 3.E.237.166; 3.E.237.169; 3.E.237.172; 3.E.237.175; 3.E.237.240; 3.E.237.244; 3.E.238.228; 3.E.238.229; 3.E.238.230; 3.E.238.231; 3.E.238.236; 3.E.238.237; 3.E.238.238; 3.E.238.239; 3.E.238.154; 3.E.238.157; 3.E.238.166; 3.E.238.169; 3.E.238.172; 3.E.238.175; 3.E.238.240; 3.E.238.244; 3.E.239.228; 3.E.239.229; 3.E.239.230; 3.E.239.231; 3.E.239.236; 3.E.239.237; 3.E.239.238; 3.E.239.239; 3.E.239.154; 3.E.239.157; 3.E.239.166; 3.E.239.169; 3.E.239.172; 3.E.239.175; 3.E.239.240; 3.E.239.244; 3.E.154.228; 3.E.154.229; 3.E.154.230;

3.E.154.231; 3.E.154.236; 3.E.154.237; 3.E.154.238; 3.E.154.239; 3.E.154.154; 3.E.154.157; 3.E.154.166; 3.E.154.169; 3.E.154.172; 3.E.154.175; 3.E.154.240; 3.E.154.244; 3.E.157.228; 3.E.157.229; 3.E.157.230; 3.E.157.231; 3.E.157.236; 3.E.157.237; 3.E.157.238; 3.E.157.239; 3.E.157.154; 3.E.157.157; 3.E.157.166; 3.E.157.169; 3.E.157.172; 3.E.157.175; 3.E.157.240; 3.E.157.244; 3.E.166.228; 3.E.166.229; 3.E.166.230; 3.E.166.231; 3.E.166.236; 3.E.166.237; 3.E.166.238; 3.E.166.239; 3.E.166.154; 3.E.166.157; 3.E.166.166; 3.E.166.169; 3.E.166.172; 3.E.166.175; 3.E.166.240; 3.E.166.244; 3.E.169.228; 3.E.169.229; 3.E.169.230; 3.E.169.231; 3.E.169.236; 3.E.169.237; 3.E.169.238; 3.E.169.239; 3.E.169.154; 3.E.169.157; 3.E.169.166; 3.E.169.169; 3.E.169.172; 3.E.169.175; 3.E.169.240; 3.E.169.244; 3.E.172.228; 3.E.172.229; 3.E.172.230; 3.E.172.231; 3.E.172.236; 3.E.172.237; 3.E.172.238; 3.E.172.239; 3.E.172.154; 3.E.172.157; 3.E.172.166; 3.E.172.169; 3.E.172.172; 3.E.172.175; 3.E.172.240; 3.E.172.244; 3.E.175.228; 3.E.175.229; 3.E.175.230; 3.E.175.231; 3.E.175.236; 3.E.175.237; 3.E.175.238; 3.E.175.239; 3.E.175.154; 3.E.175.157; 3.E.175.166; 3.E.175.169; 3.E.175.172; 3.E.175.175; 3.E.175.240; 3.E.175.244; 3.E.240.228; 3.E.240.229; 3.E.240.230; 3.E.240.231; 3.E.240.236; 3.E.240.237; 3.E.240.238; 3.E.240.239; 3.E.240.154; 3.E.240.157; 3.E.240.166; 3.E.240.169; 3.E.240.172; 3.E.240.175; 3.E.240.240; 3.E.240.244; 3.E.244.228; 3.E.244.229; 3.E.244.230; 3.E.244.231; 3.E.244.236; 3.E.244.237; 3.E.244.238; 3.E.244.239; 3.E.244.154; 3.E.244.157; 3.E.244.166; 3.E.244.169; 3.E.244.172; 3.E.244.175; 3.E.244.240; 3.E.244.244;

Prodrugs of 3.G

3.G.228.228; 3.G.228.229; 3.G.228.230; 3.G.228.231; 3.G.228.236; 3.G.228.237; 3.G.228.238; 3.G.228.239; 3.G.228.154; 3.G.228.157; 3.G.228.166; 3.G.228.169; 3.G.228.172; 3.G.228.175; 3.G.228.240; 3.G.228.244; 3.G.229.228; 3.G.229.229; 3.G.229.230; 3.G.229.231; 3.G.229.236; 3.G.229.237; 3.G.229.238; 3.G.229.239; 3.G.229.154; 3.G.229.157; 3.G.229.166; 3.G.229.169; 3.G.229.172; 3.G.229.175; 3.G.229.240; 3.G.229.244; 3.G.230.228; 3.G.230.229; 3.G.230.230; 3.G.230.231; 3.G.230.236; 3.G.230.237; 3.G.230.238; 3.G.230.239; 3.G.230.154; 3.G.230.157; 3.G.230.166; 3.G.230.169; 3.G.230.172; 3.G.230.175; 3.G.230.240; 3.G.230.244; 3.G.231.228; 3.G.231.229; 3.G.231.230; 3.G.231.231; 3.G.231.236; 3.G.231.237; 3.G.231.238; 3.G.231.239; 3.G.231.154; 3.G.231.157; 3.G.231.166; 3.G.231.169; 3.G.231.172; 3.G.231.175; 3.G.231.240; 3.G.231.244; 3.G.236.228; 3.G.236.229; 3.G.236.230; 3.G.236.231; 3.G.236.236; 3.G.236.237;

3.G.236.238; 3.G.236.239; 3.G.236.154; 3.G.236.157; 3.G.236.166; 3.G.236.169; 3.G.236.172; 3.G.236.175; 3.G.236.240; 3.G.236.244; 3.G.237.228; 3.G.237.229; 3.G.237.230; 3.G.237.231; 3.G.237.236; 3.G.237.237; 3.G.237.238; 3.G.237.239; 3.G.237.154; 3.G.237.157; 3.G.237.166; 3.G.237.169; 3.G.237.172; 3.G.237.175; 3.G.237.240; 3.G.237.244; 3.G.238.228; 3.G.238.229; 3.G.238.230; 3.G.238.231; 3.G.238.236; 3.G.238.237; 3.G.238.238; 3.G.238.239; 3.G.238.154; 3.G.238.157; 3.G.238.166; 3.G.238.169; 3.G.238.172; 3.G.238.175; 3.G.238.240; 3.G.238.244; 3.G.239.228; 3.G.239.229; 3.G.239.230; 3.G.239.231; 3.G.239.236; 3.G.239.237; 3.G.239.238; 3.G.239.239; 3.G.239.154; 3.G.239.157; 3.G.239.166; 3.G.239.169; 3.G.239.172; 3.G.239.175; 3.G.239.240; 3.G.239.244; 3.G.154.228; 3.G.154.229; 3.G.154.230; 3.G.154.231; 3.G.154.236; 3.G.154.237; 3.G.154.238; 3.G.154.239; 3.G.154.154; 3.G.154.157; 3.G.154.166; 3.G.154.169; 3.G.154.172; 3.G.154.175; 3.G.154.240; 3.G.154.244; 3.G.157.228; 3.G.157.229; 3.G.157.230; 3.G.157.231; 3.G.157.236; 3.G.157.237; 3.G.157.238; 3.G.157.239; 3.G.157.154; 3.G.157.157; 3.G.157.166; 3.G.157.169; 3.G.157.172; 3.G.157.175; 3.G.157.240; 3.G.157.244; 3.G.166.228; 3.G.166.229; 3.G.166.230; 3.G.166.231; 3.G.166.236; 3.G.166.237; 3.G.166.238; 3.G.166.239; 3.G.166.154; 3.G.166.157; 3.G.166.166; 3.G.166.169; 3.G.166.172; 3.G.166.175; 3.G.166.240; 3.G.166.244; 3.G.169.228; 3.G.169.229; 3.G.169.230; 3.G.169.231; 3.G.169.236; 3.G.169.237; 3.G.169.238; 3.G.169.239; 3.G.169.154; 3.G.169.157; 3.G.169.166; 3.G.169.169; 3.G.169.172; 3.G.169.175; 3.G.169.240; 3.G.169.244; 3.G.172.228; 3.G.172.229; 3.G.172.230; 3.G.172.231; 3.G.172.236; 3.G.172.237; 3.G.172.238; 3.G.172.239; 3.G.172.154; 3.G.172.157; 3.G.172.166; 3.G.172.169; 3.G.172.172; 3.G.172.175; 3.G.172.240; 3.G.172.244; 3.G.175.228; 3.G.175.229; 3.G.175.230; 3.G.175.231; 3.G.175.236; 3.G.175.237; 3.G.175.238; 3.G.175.239; 3.G.175.154; 3.G.175.157; 3.G.175.166; 3.G.175.169; 3.G.175.172; 3.G.175.175; 3.G.175.240; 3.G.175.244; 3.G.240.228; 3.G.240.229; 3.G.240.230; 3.G.240.231; 3.G.240.236; 3.G.240.237; 3.G.240.238; 3.G.240.239; 3.G.240.154; 3.G.240.157; 3.G.240.166; 3.G.240.169; 3.G.240.172; 3.G.240.175; 3.G.240.240; 3.G.240.244; 3.G.244.228; 3.G.244.229; 3.G.244.230; 3.G.244.231; 3.G.244.236; 3.G.244.237; 3.G.244.238; 3.G.244.239; 3.G.244.154; 3.G.244.157;

3.G.244.166; 3.G.244.169; 3.G.244.172; 3.G.244.175; 3.G.244.240; 3.G.244.244;

Prodrugs of 3.I

3.I.228.228; 3.I.228.229; 3.I.228.230; 3.I.228.231; 3.I.228.236; 3.I.228.237; 3.I.228.238; 3.I.228.239; 3.I.228.154; 3.I.228.157; 3.I.228.166; 3.I.228.169; 3.I.228.172; 3.I.228.175; 3.I.228.240; 3.I.228.244; 3.I.229.228; 3.I.229.229; 3.I.229.230; 3.I.229.231; 3.I.229.236; 3.I.229.237; 3.I.229.238; 3.I.229.239; 3.I.229.154; 3.I.229.157; 3.I.229.166; 3.I.229.169; 3.I.229.172; 3.I.229.175; 3.I.229.240; 3.I.229.244; 3.I.230.228; 3.I.230.229; 3.I.230.230; 3.I.230.231; 3.I.230.236; 3.I.230.237; 3.I.230.238; 3.I.230.239; 3.I.230.154; 3.I.230.157; 3.I.230.166; 3.I.230.169; 3.I.230.172; 3.I.230.175; 3.I.230.240; 3.I.230.244; 3.I.231.228; 3.I.231.229; 3.I.231.230; 3.I.231.231; 3.I.231.236; 3.I.231.237; 3.I.231.238; 3.I.231.239; 3.I.231.154; 3.I.231.157; 3.I.231.166; 3.I.231.169; 3.I.231.172; 3.I.231.175; 3.I.231.240; 3.I.231.244; 3.I.236.228; 3.I.236.229; 3.I.236.230; 3.I.236.231; 3.I.236.236; 3.I.236.237; 3.I.236.238; 3.I.236.239; 3.I.236.154; 3.I.236.157; 3.I.236.166; 3.I.236.169; 3.I.236.172; 3.I.236.175; 3.I.236.240; 3.I.236.244; 3.I.237.228; 3.I.237.229; 3.I.237.230; 3.I.237.231; 3.I.237.236; 3.I.237.237; 3.I.237.238; 3.I.237.239; 3.I.237.154; 3.I.237.157; 3.I.237.166; 3.I.237.169; 3.I.237.172; 3.I.237.175; 3.I.237.240; 3.I.237.244; 3.I.238.228; 3.I.238.229; 3.I.238.230; 3.I.238.231; 3.I.238.236; 3.I.238.237; 3.I.238.238; 3.I.238.239; 3.I.238.154; 3.I.238.157; 3.I.238.166; 3.I.238.169; 3.I.238.172; 3.I.238.175; 3.I.238.240; 3.I.238.244; 3.I.239.228; 3.I.239.229; 3.I.239.230; 3.I.239.231; 3.I.239.236; 3.I.239.237; 3.I.239.238; 3.I.239.239; 3.I.239.154; 3.I.239.157; 3.I.239.166; 3.I.239.169; 3.I.239.172; 3.I.239.175; 3.I.239.240; 3.I.239.244; 3.I.154.228; 3.I.154.229; 3.I.154.230; 3.I.154.231; 3.I.154.236; 3.I.154.237; 3.I.154.238; 3.I.154.239; 3.I.154.154; 3.I.154.157; 3.I.154.166; 3.I.154.169; 3.I.154.172; 3.I.154.175; 3.I.154.240; 3.I.154.244; 3.I.157.228; 3.I.157.229; 3.I.157.230; 3.I.157.231; 3.I.157.236; 3.I.157.237; 3.I.157.238; 3.I.157.239; 3.I.157.154; 3.I.157.157; 3.I.157.166; 3.I.157.169; 3.I.157.172; 3.I.157.175; 3.I.157.240; 3.I.157.244; 3.I.166.228; 3.I.166.229; 3.I.166.230; 3.I.166.231; 3.I.166.236; 3.I.166.237; 3.I.166.238; 3.I.166.239; 3.I.166.154; 3.I.166.157; 3.I.166.166; 3.I.166.169; 3.I.166.172; 3.I.166.175; 3.I.166.240; 3.I.166.244; 3.I.169.228; 3.I.169.229; 3.I.169.230; 3.I.169.231; 3.I.169.236; 3.I.169.237; 3.I.169.238; 3.I.169.239; 3.I.169.154; 3.I.169.157; 3.I.169.166; 3.I.169.169; 3.I.169.172; 3.I.169.175; 3.I.169.240; 3.I.169.244; 3.I.172.228; 3.I.172.229; 3.I.172.230; 3.I.172.231; 3.I.172.236; 3.I.172.237;

3.I.172.238; 3.I.172.239; 3.I.172.154; 3.I.172.157; 3.I.172.166; 3.I.172.169; 3.I.172.172; 3.I.172.175; 3.I.172.240; 3.I.172.244; 3.I.175.228; 3.I.175.229; 3.I.175.230; 3.I.175.231; 3.I.175.236; 3.I.175.237; 3.I.175.238; 3.I.175.239; 3.I.175.154; 3.I.175.157; 3.I.175.166; 3.I.175.169; 3.I.175.172; 3.I.175.175; 3.I.175.240; 3.I.175.244; 3.I.240.228; 3.I.240.229; 3.I.240.230; 3.I.240.231; 3.I.240.236; 3.I.240.237; 3.I.240.238; 3.I.240.239; 3.I.240.154; 3.I.240.157; 3.I.240.166; 3.I.240.169; 3.I.240.172; 3.I.240.175; 3.I.240.240; 3.I.240.244; 3.I.244.228; 3.I.244.229; 3.I.244.230; 3.I.244.231; 3.I.244.236; 3.I.244.237; 3.I.244.238; 3.I.244.239; 3.I.244.154; 3.I.244.157; 3.I.244.166; 3.I.244.169; 3.I.244.172; 3.I.244.175; 3.I.244.240; 3.I.244.244;

Prodrugs of 3.J

3.J.228.228; 3.J.228.229; 3.J.228.230; 3.J.228.231; 3.J.228.236; 3.J.228.237; 3.J.228.238; 3.J.228.239; 3.J.228.154; 3.J.228.157; 3.J.228.166; 3.J.228.169; 3.J.228.172; 3.J.228.175; 3.J.228.240; 3.J.228.244; 3.J.229.228; 3.J.229.229; 3.J.229.230; 3.J.229.231; 3.J.229.236; 3.J.229.237; 3.J.229.238; 3.J.229.239; 3.J.229.154; 3.J.229.157; 3.J.229.166; 3.J.229.169; 3.J.229.172; 3.J.229.175; 3.J.229.240; 3.J.229.244; 3.J.230.228; 3.J.230.229; 3.J.230.230; 3.J.230.231; 3.J.230.236; 3.J.230.237; 3.J.230.238; 3.J.230.239; 3.J.230.154; 3.J.230.157; 3.J.230.166; 3.J.230.169; 3.J.230.172; 3.J.230.175; 3.J.230.240; 3.J.230.244; 3.J.231.228; 3.J.231.229; 3.J.231.230; 3.J.231.231; 3.J.231.236; 3.J.231.237; 3.J.231.238; 3.J.231.239; 3.J.231.154; 3.J.231.157; 3.J.231.166; 3.J.231.169; 3.J.231.172; 3.J.231.175; 3.J.231.240; 3.J.231.244; 3.J.236.228; 3.J.236.229; 3.J.236.230; 3.J.236.231; 3.J.236.236; 3.J.236.237; 3.J.236.238; 3.J.236.239; 3.J.236.154; 3.J.236.157; 3.J.236.166; 3.J.236.169; 3.J.236.172; 3.J.236.175; 3.J.236.240; 3.J.236.244; 3.J.237.228; 3.J.237.229; 3.J.237.230; 3.J.237.231; 3.J.237.236; 3.J.237.237; 3.J.237.238; 3.J.237.239; 3.J.237.154; 3.J.237.157; 3.J.237.166; 3.J.237.169; 3.J.237.172; 3.J.237.175; 3.J.237.240; 3.J.237.244; 3.J.238.228; 3.J.238.229; 3.J.238.230; 3.J.238.231; 3.J.238.236; 3.J.238.237; 3.J.238.238; 3.J.238.239; 3.J.238.154; 3.J.238.157; 3.J.238.166; 3.J.238.169; 3.J.238.172; 3.J.238.175; 3.J.238.240; 3.J.238.244; 3.J.239.228; 3.J.239.229; 3.J.239.230; 3.J.239.231; 3.J.239.236; 3.J.239.237; 3.J.239.238; 3.J.239.239; 3.J.239.154; 3.J.239.157; 3.J.239.166; 3.J.239.169; 3.J.239.172; 3.J.239.175; 3.J.239.240; 3.J.239.244; 3.J.154.228; 3.J.154.229; 3.J.154.230; 3.J.154.231; 3.J.154.236; 3.J.154.237; 3.J.154.238; 3.J.154.239; 3.J.154.154; 3.J.154.157; 3.J.154.166; 3.J.154.169; 3.J.154.172; 3.J.154.175; 3.J.154.240; 3.J.154.244; 3.J.157.228; 3.J.157.229; 3.J.157.230; 3.J.157.231; 3.J.157.236; 3.J.157.237;

3.J.157.238; 3.J.157.239; 3.J.157.154; 3.J.157.157; 3.J.157.166; 3.J.157.169; 3.J.157.172; 3.J.157.175; 3.J.157.240; 3.J.157.244; 3.J.166.228; 3.J.166.229; 3.J.166.230; 3.J.166.231; 3.J.166.236; 3.J.166.237; 3.J.166.238; 3.J.166.239; 3.J.166.154; 3.J.166.157; 3.J.166.166; 3.J.166.169; 3.J.166.172; 3.J.166.175; 3.J.166.240; 3.J.166.244; 3.J.169.228; 3.J.169.229; 3.J.169.230; 3.J.169.231; 3.J.169.236; 3.J.169.237; 3.J.169.238; 3.J.169.239; 3.J.169.154; 3.J.169.157; 3.J.169.166; 3.J.169.169; 3.J.169.172; 3.J.169.175; 3.J.169.240; 3.J.169.244; 3.J.172.228; 3.J.172.229; 3.J.172.230; 3.J.172.231; 3.J.172.236; 3.J.172.237; 3.J.172.238; 3.J.172.239; 3.J.172.154; 3.J.172.157; 3.J.172.166; 3.J.172.169; 3.J.172.172; 3.J.172.175; 3.J.172.240; 3.J.172.244; 3.J.175.228; 3.J.175.229; 3.J.175.230; 3.J.175.231; 3.J.175.236; 3.J.175.237; 3.J.175.238; 3.J.175.239; 3.J.175.154; 3.J.175.157; 3.J.175.166; 3.J.175.169; 3.J.175.172; 3.J.175.175; 3.J.175.240; 3.J.175.244; 3.J.240.228; 3.J.240.229; 3.J.240.230; 3.J.240.231; 3.J.240.236; 3.J.240.237; 3.J.240.238; 3.J.240.239; 3.J.240.154; 3.J.240.157; 3.J.240.166; 3.J.240.169; 3.J.240.172; 3.J.240.175; 3.J.240.240; 3.J.240.244; 3.J.244.228; 3.J.244.229; 3.J.244.230; 3.J.244.231; 3.J.244.236; 3.J.244.237; 3.J.244.238; 3.J.244.239; 3.J.244.154; 3.J.244.157; 3.J.244.166; 3.J.244.169; 3.J.244.172; 3.J.244.175; 3.J.244.240; 3.J.244.244;

Prodrugs of 3.L

3.L.228.228; 3.L.228.229; 3.L.228.230; 3.L.228.231; 3.L.228.236; 3.L.228.237; 3.L.228.238; 3.L.228.239; 3.L.228.154; 3.L.228.157; 3.L.228.166; 3.L.228.169; 3.L.228.172; 3.L.228.175; 3.L.228.240; 3.L.228.244; 3.L.229.228; 3.L.229.229; 3.L.229.230; 3.L.229.231; 3.L.229.236; 3.L.229.237; 3.L.229.238; 3.L.229.239; 3.L.229.154; 3.L.229.157; 3.L.229.166; 3.L.229.169; 3.L.229.172; 3.L.229.175; 3.L.229.240; 3.L.229.244; 3.L.230.228; 3.L.230.229; 3.L.230.230; 3.L.230.231; 3.L.230.236; 3.L.230.237; 3.L.230.238; 3.L.230.239; 3.L.230.154; 3.L.230.157; 3.L.230.166; 3.L.230.169; 3.L.230.172; 3.L.230.175; 3.L.230.240; 3.L.230.244; 3.L.231.228; 3.L.231.229; 3.L.231.230; 3.L.231.231; 3.L.231.236; 3.L.231.237; 3.L.231.238; 3.L.231.239; 3.L.231.154; 3.L.231.157; 3.L.231.166; 3.L.231.169; 3.L.231.172; 3.L.231.175; 3.L.231.240; 3.L.231.244; 3.L.236.228; 3.L.236.229; 3.L.236.230; 3.L.236.231; 3.L.236.236; 3.L.236.237; 3.L.236.238; 3.L.236.239; 3.L.236.154; 3.L.236.157; 3.L.236.166; 3.L.236.169; 3.L.236.172; 3.L.236.175; 3.L.236.240; 3.L.236.244; 3.L.237.228; 3.L.237.229; 3.L.237.230; 3.L.237.231; 3.L.237.236; 3.L.237.237; 3.L.237.238; 3.L.237.239; 3.L.237.154; 3.L.237.157; 3.L.237.166; 3.L.237.169; 3.L.237.172; 3.L.237.175; 3.L.237.240; 3.L.237.244; 3.L.238.228; 3.L.238.229; 3.L.238.230; 3.L.238.231; 3.L.238.236;

3.L.238.237; 3.L.238.238; 3.L.238.239; 3.L.238.154; 3.L.238.157; 3.L.238.166; 3.L.238.169; 3.L.238.172; 3.L.238.175; 3.L.238.240; 3.L.238.244; 3.L.239.228; 3.L.239.229; 3.L.239.230; 3.L.239.231; 3.L.239.236; 3.L.239.237; 3.L.239.238; 3.L.239.239; 3.L.239.154; 3.L.239.157; 3.L.239.166; 3.L.239.169; 3.L.239.172; 3.L.239.175; 3.L.239.240; 3.L.239.244; 3.L.154.228; 3.L.154.229; 3.L.154.230; 3.L.154.231; 3.L.154.236; 3.L.154.237; 3.L.154.238; 3.L.154.239; 3.L.154.154; 3.L.154.157; 3.L.154.166; 3.L.154.169; 3.L.154.172; 3.L.154.175; 3.L.154.240; 3.L.154.244; 3.L.157.228; 3.L.157.229; 3.L.157.230; 3.L.157.231; 3.L.157.236; 3.L.157.237; 3.L.157.238; 3.L.157.239; 3.L.157.154; 3.L.157.157; 3.L.157.166; 3.L.157.169; 3.L.157.172; 3.L.157.175; 3.L.157.240; 3.L.157.244; 3.L.166.228; 3.L.166.229; 3.L.166.230; 3.L.166.231; 3.L.166.236; 3.L.166.237; 3.L.166.238; 3.L.166.239; 3.L.166.154; 3.L.166.157; 3.L.166.166; 3.L.166.169; 3.L.166.172; 3.L.166.175; 3.L.166.240; 3.L.166.244; 3.L.169.228; 3.L.169.229; 3.L.169.230; 3.L.169.231; 3.L.169.236; 3.L.169.237; 3.L.169.238; 3.L.169.239; 3.L.169.154; 3.L.169.157; 3.L.169.166; 3.L.169.169; 3.L.169.172; 3.L.169.175; 3.L.169.240; 3.L.169.244; 3.L.172.228; 3.L.172.229; 3.L.172.230; 3.L.172.231; 3.L.172.236; 3.L.172.237; 3.L.172.238; 3.L.172.239; 3.L.172.154; 3.L.172.157; 3.L.172.166; 3.L.172.169; 3.L.172.172; 3.L.172.175; 3.L.172.240; 3.L.172.244; 3.L.175.228; 3.L.175.229; 3.L.175.230; 3.L.175.231; 3.L.175.236; 3.L.175.237; 3.L.175.238; 3.L.175.239; 3.L.175.154; 3.L.175.157; 3.L.175.166; 3.L.175.169; 3.L.175.172; 3.L.175.175; 3.L.175.240; 3.L.175.244; 3.L.240.228; 3.L.240.229; 3.L.240.230; 3.L.240.231; 3.L.240.236; 3.L.240.237; 3.L.240.238; 3.L.240.239; 3.L.240.154; 3.L.240.157; 3.L.240.166; 3.L.240.169; 3.L.240.172; 3.L.240.175; 3.L.240.240; 3.L.240.244; 3.L.244.228; 3.L.244.229; 3.L.244.230; 3.L.244.231; 3.L.244.236; 3.L.244.237; 3.L.244.238; 3.L.244.239; 3.L.244.154; 3.L.244.157; 3.L.244.166; 3.L.244.169; 3.L.244.172; 3.L.244.175; 3.L.244.240; 3.L.244.244;

Prodrugs of 3.O

3.O.228.228; 3.O.228.229; 3.O.228.230; 3.O.228.231; 3.O.228.236; 3.O.228.237; 3.O.228.238; 3.O.228.239; 3.O.228.154; 3.O.228.157; 3.O.228.166; 3.O.228.169; 3.O.228.172; 3.O.228.175; 3.O.228.240; 3.O.228.244; 3.O.229.228; 3.O.229.229; 3.O.229.230; 3.O.229.231; 3.O.229.236; 3.O.229.237; 3.O.229.238; 3.O.229.239; 3.O.229.154; 3.O.229.157; 3.O.229.166; 3.O.229.169; 3.O.229.172; 3.O.229.175; 3.O.229.240; 3.O.229.244; 3.O.230.228; 3.O.230.229; 3.O.230.230; 3.O.230.231; 3.O.230.236; 3.O.230.237; 3.O.230.238; 3.O.230.239; 3.O.230.154; 3.O.230.157; 3.O.230.166; 3.O.230.169; 3.O.230.172;

3.O.230.175; 3.O.230.240; 3.O.230.244; 3.O.231.228; 3.O.231.229; 3.O.231.230; 3.O.231.231; 3.O.231.236; 3.O.231.237; 3.O.231.238; 3.O.231.239; 3.O.231.154; 3.O.231.157; 3.O.231.166; 3.O.231.169; 3.O.231.172; 3.O.231.175; 3.O.231.240; 3.O.231.244; 3.O.236.228; 3.O.236.229; 3.O.236.230; 3.O.236.231; 3.O.236.236; 3.O.236.237; 3.O.236.238; 3.O.236.239; 3.O.236.154; 3.O.236.157; 3.O.236.166; 3.O.236.169; 3.O.236.172; 3.O.236.175; 3.O.236.240; 3.O.236.244; 3.O.237.228; 3.O.237.229; 3.O.237.230; 3.O.237.231; 3.O.237.236; 3.O.237.237; 3.O.237.238; 3.O.237.239; 3.O.237.154; 3.O.237.157; 3.O.237.166; 3.O.237.169; 3.O.237.172; 3.O.237.175; 3.O.237.240; 3.O.237.244; 3.O.238.228; 3.O.238.229; 3.O.238.230; 3.O.238.231; 3.O.238.236; 3.O.238.237; 3.O.238.238; 3.O.238.239; 3.O.238.154; 3.O.238.157; 3.O.238.166; 3.O.238.169; 3.O.238.172; 3.O.238.175; 3.O.238.240; 3.O.238.244; 3.O.239.228; 3.O.239.229; 3.O.239.230; 3.O.239.231; 3.O.239.236; 3.O.239.237; 3.O.239.238; 3.O.239.239; 3.O.239.154; 3.O.239.157; 3.O.239.166; 3.O.239.169; 3.O.239.172; 3.O.239.175; 3.O.239.240; 3.O.239.244; 3.O.154.228; 3.O.154.229; 3.O.154.230; 3.O.154.231; 3.O.154.236; 3.O.154.237; 3.O.154.238; 3.O.154.239; 3.O.154.154; 3.O.154.157; 3.O.154.166; 3.O.154.169; 3.O.154.172; 3.O.154.175; 3.O.154.240; 3.O.154.244; 3.O.157.228; 3.O.157.229; 3.O.157.230; 3.O.157.231; 3.O.157.236; 3.O.157.237; 3.O.157.238; 3.O.157.239; 3.O.157.154; 3.O.157.157; 3.O.157.166; 3.O.157.169; 3.O.157.172; 3.O.157.175; 3.O.157.240; 3.O.157.244; 3.O.166.228; 3.O.166.229; 3.O.166.230; 3.O.166.231; 3.O.166.236; 3.O.166.237; 3.O.166.238; 3.O.166.239; 3.O.166.154; 3.O.166.157; 3.O.166.166; 3.O.166.169; 3.O.166.172; 3.O.166.175; 3.O.166.240; 3.O.166.244; 3.O.169.228; 3.O.169.229; 3.O.169.230; 3.O.169.231; 3.O.169.236; 3.O.169.237; 3.O.169.238; 3.O.169.239; 3.O.169.154; 3.O.169.157; 3.O.169.166; 3.O.169.169; 3.O.169.172; 3.O.169.175; 3.O.169.240; 3.O.169.244; 3.O.172.228; 3.O.172.229; 3.O.172.230; 3.O.172.231; 3.O.172.236; 3.O.172.237; 3.O.172.238; 3.O.172.239; 3.O.172.154; 3.O.172.157; 3.O.172.166; 3.O.172.169; 3.O.172.172; 3.O.172.175; 3.O.172.240; 3.O.172.244; 3.O.175.228; 3.O.175.229; 3.O.175.230; 3.O.175.231; 3.O.175.236; 3.O.175.237; 3.O.175.238; 3.O.175.239; 3.O.175.154; 3.O.175.157; 3.O.175.166; 3.O.175.169; 3.O.175.172; 3.O.175.175; 3.O.175.240; 3.O.175.244; 3.O.240.228; 3.O.240.229; 3.O.240.230; 3.O.240.231; 3.O.240.236; 3.O.240.237;

3.O.240.238; 3.O.240.239; 3.O.240.154; 3.O.240.157; 3.O.240.166; 3.O.240.169; 3.O.240.172; 3.O.240.175; 3.O.240.240; 3.O.240.244; 3.O.244.228; 3.O.244.229; 3.O.244.230; 3.O.244.231; 3.O.244.236; 3.O.244.237; 3.O.244.238; 3.O.244.239; 3.O.244.154; 3.O.244.157; 3.O.244.166; 3.O.244.169; 3.O.244.172; 3.O.244.175; 3.O.244.240; 3.O.244.244;

Prodrugs of 3.P

3.P.228.228; 3.P.228.229; 3.P.228.230; 3.P.228.231; 3.P.228.236; 3.P.228.237; 3.P.228.238; 3.P.228.239; 3.P.228.154; 3.P.228.157; 3.P.228.166; 3.P.228.169; 3.P.228.172; 3.P.228.175; 3.P.228.240; 3.P.228.244; 3.P.229.228; 3.P.229.229; 3.P.229.230; 3.P.229.231; 3.P.229.236; 3.P.229.237; 3.P.229.238; 3.P.229.239; 3.P.229.154; 3.P.229.157; 3.P.229.166; 3.P.229.169; 3.P.229.172; 3.P.229.175; 3.P.229.240; 3.P.229.244; 3.P.230.228; 3.P.230.229; 3.P.230.230; 3.P.230.231; 3.P.230.236; 3.P.230.237; 3.P.230.238; 3.P.230.239; 3.P.230.154; 3.P.230.157; 3.P.230.166; 3.P.230.169; 3.P.230.172; 3.P.230.175; 3.P.230.240; 3.P.230.244; 3.P.231.228; 3.P.231.229; 3.P.231.230; 3.P.231.231; 3.P.231.236; 3.P.231.237; 3.P.231.238; 3.P.231.239; 3.P.231.154; 3.P.231.157; 3.P.231.166; 3.P.231.169; 3.P.231.172; 3.P.231.175; 3.P.231.240; 3.P.231.244; 3.P.236.228; 3.P.236.229; 3.P.236.230; 3.P.236.231; 3.P.236.236; 3.P.236.237; 3.P.236.238; 3.P.236.239; 3.P.236.154; 3.P.236.157; 3.P.236.166; 3.P.236.169; 3.P.236.172; 3.P.236.175; 3.P.236.240; 3.P.236.244; 3.P.237.228; 3.P.237.229; 3.P.237.230; 3.P.237.231; 3.P.237.236; 3.P.237.237; 3.P.237.238; 3.P.237.239; 3.P.237.154; 3.P.237.157; 3.P.237.166; 3.P.237.169; 3.P.237.172; 3.P.237.175; 3.P.237.240; 3.P.237.244; 3.P.238.228; 3.P.238.229; 3.P.238.230; 3.P.238.231; 3.P.238.236; 3.P.238.237; 3.P.238.238; 3.P.238.239; 3.P.238.154; 3.P.238.157; 3.P.238.166; 3.P.238.169; 3.P.238.172; 3.P.238.175; 3.P.238.240; 3.P.238.244; 3.P.239.228; 3.P.239.229; 3.P.239.230; 3.P.239.231; 3.P.239.236; 3.P.239.237; 3.P.239.238; 3.P.239.239; 3.P.239.154; 3.P.239.157; 3.P.239.166; 3.P.239.169; 3.P.239.172; 3.P.239.175; 3.P.239.240; 3.P.239.244; 3.P.154.228; 3.P.154.229; 3.P.154.230; 3.P.154.231; 3.P.154.236; 3.P.154.237; 3.P.154.238; 3.P.154.239; 3.P.154.154; 3.P.154.157; 3.P.154.166; 3.P.154.169; 3.P.154.172; 3.P.154.175; 3.P.154.240; 3.P.154.244; 3.P.157.228; 3.P.157.229; 3.P.157.230; 3.P.157.231; 3.P.157.236; 3.P.157.237; 3.P.157.238; 3.P.157.239; 3.P.157.154; 3.P.157.157; 3.P.157.166; 3.P.157.169; 3.P.157.172; 3.P.157.175; 3.P.157.240; 3.P.157.244; 3.P.166.228; 3.P.166.229; 3.P.166.230; 3.P.166.231; 3.P.166.236; 3.P.166.237; 3.P.166.238; 3.P.166.239; 3.P.166.154; 3.P.166.157; 3.P.166.166; 3.P.166.169; 3.P.166.172;

3.P.166.175; 3.P.166.240; 3.P.166.244; 3.P.169.228; 3.P.169.229; 3.P.169.230; 3.P.169.231; 3.P.169.236; 3.P.169.237; 3.P.169.238; 3.P.169.239; 3.P.169.154; 3.P.169.157; 3.P.169.166; 3.P.169.169; 3.P.169.172; 3.P.169.175; 3.P.169.240; 3.P.169.244; 3.P.172.228; 3.P.172.229; 3.P.172.230; 3.P.172.231; 3.P.172.236; 3.P.172.237; 3.P.172.238; 3.P.172.239; 3.P.172.154; 3.P.172.157; 3.P.172.166; 3.P.172.169; 3.P.172.172; 3.P.172.175; 3.P.172.240; 3.P.172.244; 3.P.175.228; 3.P.175.229; 3.P.175.230; 3.P.175.231; 3.P.175.236; 3.P.175.237; 3.P.175.238; 3.P.175.239; 3.P.175.154; 3.P.175.157; 3.P.175.166; 3.P.175.169; 3.P.175.172; 3.P.175.175; 3.P.175.240; 3.P.175.244; 3.P.240.228; 3.P.240.229; 3.P.240.230; 3.P.240.231; 3.P.240.236; 3.P.240.237; 3.P.240.238; 3.P.240.239; 3.P.240.154; 3.P.240.157; 3.P.240.166; 3.P.240.169; 3.P.240.172; 3.P.240.175; 3.P.240.240; 3.P.240.244; 3.P.244.228; 3.P.244.229; 3.P.244.230; 3.P.244.231; 3.P.244.236; 3.P.244.237; 3.P.244.238; 3.P.244.239; 3.P.244.154; 3.P.244.157; 3.P.244.166; 3.P.244.169; 3.P.244.172; 3.P.244.175; 3.P.244.240; 3.P.244.244;

Prodrugs of 3.U

3.U.228.228; 3.U.228.229; 3.U.228.230; 3.U.228.231; 3.U.228.236; 3.U.228.237; 3.U.228.238; 3.U.228.239; 3.U.228.154; 3.U.228.157; 3.U.228.166; 3.U.228.169; 3.U.228.172; 3.U.228.175; 3.U.228.240; 3.U.228.244; 3.U.229.228; 3.U.229.229; 3.U.229.230; 3.U.229.231; 3.U.229.236; 3.U.229.237; 3.U.229.238; 3.U.229.239; 3.U.229.154; 3.U.229.157; 3.U.229.166; 3.U.229.169; 3.U.229.172; 3.U.229.175; 3.U.229.240; 3.U.229.244; 3.U.230.228; 3.U.230.229; 3.U.230.230; 3.U.230.231; 3.U.230.236; 3.U.230.237; 3.U.230.238; 3.U.230.239; 3.U.230.154; 3.U.230.157; 3.U.230.166; 3.U.230.169; 3.U.230.172; 3.U.230.175; 3.U.230.240; 3.U.230.244; 3.U.231.228; 3.U.231.229; 3.U.231.230; 3.U.231.231; 3.U.231.236; 3.U.231.237; 3.U.231.238; 3.U.231.239; 3.U.231.154; 3.U.231.157; 3.U.231.166; 3.U.231.169; 3.U.231.172; 3.U.231.175; 3.U.231.240; 3.U.231.244; 3.U.236.228; 3.U.236.229; 3.U.236.230; 3.U.236.231; 3.U.236.236; 3.U.236.237; 3.U.236.238; 3.U.236.239; 3.U.236.154; 3.U.236.157; 3.U.236.166; 3.U.236.169; 3.U.236.172; 3.U.236.175; 3.U.236.240; 3.U.236.244; 3.U.237.228; 3.U.237.229; 3.U.237.230; 3.U.237.231; 3.U.237.236; 3.U.237.237; 3.U.237.238; 3.U.237.239; 3.U.237.154; 3.U.237.157; 3.U.237.166; 3.U.237.169; 3.U.237.172; 3.U.237.175; 3.U.237.240; 3.U.237.244; 3.U.238.228; 3.U.238.229; 3.U.238.230; 3.U.238.231; 3.U.238.236; 3.U.238.237; 3.U.238.238; 3.U.238.239; 3.U.238.154;

3.U.238.157; 3.U.238.166; 3.U.238.169; 3.U.238.172; 3.U.238.175; 3.U.238.240; 3.U.238.244; 3.U.239.228; 3.U.239.229; 3.U.239.230; 3.U.239.231; 3.U.239.236; 3.U.239.237; 3.U.239.238; 3.U.239.239; 3.U.239.154; 3.U.239.157; 3.U.239.166; 3.U.239.169; 3.U.239.172; 3.U.239.175; 3.U.239.240; 3.U.239.244; 3.U.154.228; 3.U.154.229; 3.U.154.230; 3.U.154.231; 3.U.154.236; 3.U.154.237; 3.U.154.238; 3.U.154.239; 3.U.154.154; 3.U.154.157; 3.U.154.166; 3.U.154.169; 3.U.154.172; 3.U.154.175; 3.U.154.240; 3.U.154.244; 3.U.157.228; 3.U.157.229; 3.U.157.230; 3.U.157.231; 3.U.157.236; 3.U.157.237; 3.U.157.238; 3.U.157.239; 3.U.157.154; 3.U.157.157; 3.U.157.166; 3.U.157.169; 3.U.157.172; 3.U.157.175; 3.U.157.240; 3.U.157.244; 3.U.166.228; 3.U.166.229; 3.U.166.230; 3.U.166.231; 3.U.166.236; 3.U.166.237; 3.U.166.238; 3.U.166.239; 3.U.166.154; 3.U.166.157; 3.U.166.166; 3.U.166.169; 3.U.166.172; 3.U.166.175; 3.U.166.240; 3.U.166.244; 3.U.169.228; 3.U.169.229; 3.U.169.230; 3.U.169.231; 3.U.169.236; 3.U.169.237; 3.U.169.238; 3.U.169.239; 3.U.169.154; 3.U.169.157; 3.U.169.166; 3.U.169.169; 3.U.169.172; 3.U.169.175; 3.U.169.240; 3.U.169.244; 3.U.172.228; 3.U.172.229; 3.U.172.230; 3.U.172.231; 3.U.172.236; 3.U.172.237; 3.U.172.238; 3.U.172.239; 3.U.172.154; 3.U.172.157; 3.U.172.166; 3.U.172.169; 3.U.172.172; 3.U.172.175; 3.U.172.240; 3.U.172.244; 3.U.175.228; 3.U.175.229; 3.U.175.230; 3.U.175.231; 3.U.175.236; 3.U.175.237; 3.U.175.238; 3.U.175.239; 3.U.175.154; 3.U.175.157; 3.U.175.166; 3.U.175.169; 3.U.175.172; 3.U.175.175; 3.U.175.240; 3.U.175.244; 3.U.240.228; 3.U.240.229; 3.U.240.230; 3.U.240.231; 3.U.240.236; 3.U.240.237; 3.U.240.238; 3.U.240.239; 3.U.240.154; 3.U.240.157; 3.U.240.166; 3.U.240.169; 3.U.240.172; 3.U.240.175; 3.U.240.240; 3.U.240.244; 3.U.244.228; 3.U.244.229; 3.U.244.230; 3.U.244.231; 3.U.244.236; 3.U.244.237; 3.U.244.238; 3.U.244.239; 3.U.244.154; 3.U.244.157; 3.U.244.166; 3.U.244.169; 3.U.244.172; 3.U.244.175; 3.U.244.240; 3.U.244.244;

Prodrugs of 3.W

3.W.228.228; 3.W.228.229; 3.W.228.230; 3.W.228.231; 3.W.228.236; 3.W.228.237; 3.W.228.238; 3.W.228.239; 3.W.228.154; 3.W.228.157; 3.W.228.166; 3.W.228.169; 3.W.228.172; 3.W.228.175; 3.W.228.240; 3.W.228.244; 3.W.229.228; 3.W.229.229; 3.W.229.230; 3.W.229.231;

3.W.229.236; 3.W.229.237; 3.W.229.238; 3.W.229.239; 3.W.229.154; 3.W.229.157; 3.W.229.166; 3.W.229.169; 3.W.229.172; 3.W.229.175; 3.W.229.240; 3.W.229.244; 3.W.230.228; 3.W.230.229; 3.W.230.230; 3.W.230.231; 3.W.230.236; 3.W.230.237; 3.W.230.238; 3.W.230.239; 3.W.230.154; 3.W.230.157; 3.W.230.166; 3.W.230.169; 3.W.230.172; 3.W.230.175; 3.W.230.240; 3.W.230.244; 3.W.231.228; 3.W.231.229; 3.W.231.230; 3.W.231.231; 3.W.231.236; 3.W.231.237; 3.W.231.238; 3.W.231.239; 3.W.231.154; 3.W.231.157; 3.W.231.166; 3.W.231.169; 3.W.231.172; 3.W.231.175; 3.W.231.240; 3.W.231.244; 3.W.236.228; 3.W.236.229; 3.W.236.230; 3.W.236.231; 3.W.236.236; 3.W.236.237; 3.W.236.238; 3.W.236.239; 3.W.236.154; 3.W.236.157; 3.W.236.166; 3.W.236.169; 3.W.236.172; 3.W.236.175; 3.W.236.240; 3.W.236.244; 3.W.237.228; 3.W.237.229; 3.W.237.230; 3.W.237.231; 3.W.237.236; 3.W.237.237; 3.W.237.238; 3.W.237.239; 3.W.237.154; 3.W.237.157; 3.W.237.166; 3.W.237.169; 3.W.237.172; 3.W.237.175; 3.W.237.240; 3.W.237.244; 3.W.238.228; 3.W.238.229; 3.W.238.230; 3.W.238.231; 3.W.238.236; 3.W.238.237; 3.W.238.238; 3.W.238.239; 3.W.238.154; 3.W.238.157; 3.W.238.166; 3.W.238.169; 3.W.238.172; 3.W.238.175; 3.W.238.240; 3.W.238.244; 3.W.239.228; 3.W.239.229; 3.W.239.230; 3.W.239.231; 3.W.239.236; 3.W.239.237; 3.W.239.238; 3.W.239.239; 3.W.239.154; 3.W.239.157; 3.W.239.166; 3.W.239.169; 3.W.239.172; 3.W.239.175; 3.W.239.240; 3.W.239.244; 3.W.154.228; 3.W.154.229; 3.W.154.230; 3.W.154.231; 3.W.154.236; 3.W.154.237; 3.W.154.238; 3.W.154.239; 3.W.154.154; 3.W.154.157; 3.W.154.166; 3.W.154.169; 3.W.154.172; 3.W.154.175; 3.W.154.240; 3.W.154.244; 3.W.157.228; 3.W.157.229; 3.W.157.230; 3.W.157.231; 3.W.157.236; 3.W.157.237; 3.W.157.238; 3.W.157.239; 3.W.157.154; 3.W.157.157; 3.W.157.166; 3.W.157.169; 3.W.157.172; 3.W.157.175; 3.W.157.240; 3.W.157.244; 3.W.166.228; 3.W.166.229; 3.W.166.230; 3.W.166.231; 3.W.166.236; 3.W.166.237; 3.W.166.238; 3.W.166.239; 3.W.166.154; 3.W.166.157; 3.W.166.166; 3.W.166.169; 3.W.166.172; 3.W.166.175; 3.W.166.240; 3.W.166.244; 3.W.169.228; 3.W.169.229; 3.W.169.230; 3.W.169.231; 3.W.169.236; 3.W.169.237; 3.W.169.238; 3.W.169.239; 3.W.169.154; 3.W.169.157; 3.W.169.166; 3.W.169.169; 3.W.169.172; 3.W.169.175; 3.W.169.240; 3.W.169.244; 3.W.172.228; 3.W.172.229; 3.W.172.230; 3.W.172.231; 3.W.172.236; 3.W.172.237; 3.W.172.238; 3.W.172.239; 3.W.172.154; 3.W.172.157; 3.W.172.166; 3.W.172.169; 3.W.172.172;

3.W.172.175; 3.W.172.240; 3.W.172.244; 3.W.175.228; 3.W.175.229; 3.W.175.230; 3.W.175.231; 3.W.175.236; 3.W.175.237; 3.W.175.238; 3.W.175.239; 3.W.175.154; 3.W.175.157; 3.W.175.166; 3.W.175.169; 3.W.175.172; 3.W.175.175; 3.W.175.240; 3.W.175.244; 3.W.240.228; 3.W.240.229; 3.W.240.230; 3.W.240.231; 3.W.240.236; 3.W.240.237; 3.W.240.238; 3.W.240.239; 3.W.240.154; 3.W.240.157; 3.W.240.166; 3.W.240.169; 3.W.240.172; 3.W.240.175; 3.W.240.240; 3.W.240.244; 3.W.244.228; 3.W.244.229; 3.W.244.230; 3.W.244.231; 3.W.244.236; 3.W.244.237; 3.W.244.238; 3.W.244.239; 3.W.244.154; 3.W.244.157; 3.W.244.166; 3.W.244.169; 3.W.244.172; 3.W.244.175; 3.W.244.240; 3.W.244.244;

Prodrugs of 3.Y

3.Y.228.228; 3.Y.228.229; 3.Y.228.230; 3.Y.228.231; 3.Y.228.236; 3.Y.228.237; 3.Y.228.238; 3.Y.228.239; 3.Y.228.154; 3.Y.228.157; 3.Y.228.166; 3.Y.228.169; 3.Y.228.172; 3.Y.228.175; 3.Y.228.240; 3.Y.228.244; 3.Y.229.228; 3.Y.229.229; 3.Y.229.230; 3.Y.229.231; 3.Y.229.236; 3.Y.229.237; 3.Y.229.238; 3.Y.229.239; 3.Y.229.154; 3.Y.229.157; 3.Y.229.166; 3.Y.229.169; 3.Y.229.172; 3.Y.229.175; 3.Y.229.240; 3.Y.229.244; 3.Y.230.228; 3.Y.230.229; 3.Y.230.230; 3.Y.230.231; 3.Y.230.236; 3.Y.230.237; 3.Y.230.238; 3.Y.230.239; 3.Y.230.154; 3.Y.230.157; 3.Y.230.166; 3.Y.230.169; 3.Y.230.172; 3.Y.230.175; 3.Y.230.240; 3.Y.230.244; 3.Y.231.228; 3.Y.231.229; 3.Y.231.230; 3.Y.231.231; 3.Y.231.236; 3.Y.231.237; 3.Y.231.238; 3.Y.231.239; 3.Y.231.154; 3.Y.231.157; 3.Y.231.166; 3.Y.231.169; 3.Y.231.172; 3.Y.231.175; 3.Y.231.240; 3.Y.231.244; 3.Y.236.228; 3.Y.236.229; 3.Y.236.230; 3.Y.236.231; 3.Y.236.236; 3.Y.236.237; 3.Y.236.238; 3.Y.236.239; 3.Y.236.154; 3.Y.236.157; 3.Y.236.166; 3.Y.236.169; 3.Y.236.172; 3.Y.236.175; 3.Y.236.240; 3.Y.236.244; 3.Y.237.228; 3.Y.237.229; 3.Y.237.230; 3.Y.237.231; 3.Y.237.236; 3.Y.237.237; 3.Y.237.238; 3.Y.237.239; 3.Y.237.154; 3.Y.237.157; 3.Y.237.166; 3.Y.237.169; 3.Y.237.172; 3.Y.237.175; 3.Y.237.240; 3.Y.237.244; 3.Y.238.228; 3.Y.238.229; 3.Y.238.230; 3.Y.238.231; 3.Y.238.236; 3.Y.238.237; 3.Y.238.238; 3.Y.238.239; 3.Y.238.154; 3.Y.238.157; 3.Y.238.166; 3.Y.238.169; 3.Y.238.172; 3.Y.238.175; 3.Y.238.240; 3.Y.238.244; 3.Y.239.228; 3.Y.239.229; 3.Y.239.230; 3.Y.239.231; 3.Y.239.236; 3.Y.239.237; 3.Y.239.238; 3.Y.239.239; 3.Y.239.154; 3.Y.239.157; 3.Y.239.166; 3.Y.239.169; 3.Y.239.172; 3.Y.239.175; 3.Y.239.240; 3.Y.239.244; 3.Y.154.228; 3.Y.154.229; 3.Y.154.230; 3.Y.154.231; 3.Y.154.236; 3.Y.154.237; 3.Y.154.238; 3.Y.154.239; 3.Y.154.154; 3.Y.154.157; 3.Y.154.166; 3.Y.154.169; 3.Y.154.172; 3.Y.154.175; 3.Y.154.240;

3.Y.154.244; 3.Y.157.228; 3.Y.157.229; 3.Y.157.230; 3.Y.157.231; 3.Y.157.236; 3.Y.157.237; 3.Y.157.238; 3.Y.157.239; 3.Y.157.154; 3.Y.157.157; 3.Y.157.166; 3.Y.157.169; 3.Y.157.172; 3.Y.157.175; 3.Y.157.240; 3.Y.157.244; 3.Y.166.228; 3.Y.166.229; 3.Y.166.230; 3.Y.166.231; 3.Y.166.236; 3.Y.166.237; 3.Y.166.238; 3.Y.166.239; 3.Y.166.154; 3.Y.166.157; 3.Y.166.166; 3.Y.166.169; 3.Y.166.172; 3.Y.166.175; 3.Y.166.240; 3.Y.166.244; 3.Y.169.228; 3.Y.169.229; 3.Y.169.230; 3.Y.169.231; 3.Y.169.236; 3.Y.169.237; 3.Y.169.238; 3.Y.169.239; 3.Y.169.154; 3.Y.169.157; 3.Y.169.166; 3.Y.169.169; 3.Y.169.172; 3.Y.169.175; 3.Y.169.240; 3.Y.169.244; 3.Y.172.228; 3.Y.172.229; 3.Y.172.230; 3.Y.172.231; 3.Y.172.236; 3.Y.172.237; 3.Y.172.238; 3.Y.172.239; 3.Y.172.154; 3.Y.172.157; 3.Y.172.166; 3.Y.172.169; 3.Y.172.172; 3.Y.172.175; 3.Y.172.240; 3.Y.172.244; 3.Y.175.228; 3.Y.175.229; 3.Y.175.230; 3.Y.175.231; 3.Y.175.236; 3.Y.175.237; 3.Y.175.238; 3.Y.175.239; 3.Y.175.154; 3.Y.175.157; 3.Y.175.166; 3.Y.175.169; 3.Y.175.172; 3.Y.175.175; 3.Y.175.240; 3.Y.175.244; 3.Y.240.228; 3.Y.240.229; 3.Y.240.230; 3.Y.240.231; 3.Y.240.236; 3.Y.240.237; 3.Y.240.238; 3.Y.240.239; 3.Y.240.154; 3.Y.240.157; 3.Y.240.166; 3.Y.240.169; 3.Y.240.172; 3.Y.240.175; 3.Y.240.240; 3.Y.240.244; 3.Y.244.228; 3.Y.244.229; 3.Y.244.230; 3.Y.244.231; 3.Y.244.236; 3.Y.244.237; 3.Y.244.238; 3.Y.244.239; 3.Y.244.154; 3.Y.244.157; 3.Y.244.166; 3.Y.244.169; 3.Y.244.172; 3.Y.244.175; 3.Y.244.240; 3.Y.244.244;

Prodrugs of 4.B

4.B.228.228; 4.B.228.229; 4.B.228.230; 4.B.228.231; 4.B.228.236; 4.B.228.237; 4.B.228.238; 4.B.228.239; 4.B.228.154; 4.B.228.157; 4.B.228.166; 4.B.228.169; 4.B.228.172; 4.B.228.175; 4.B.228.240; 4.B.228.244; 4.B.229.228; 4.B.229.229; 4.B.229.230; 4.B.229.231; 4.B.229.236; 4.B.229.237; 4.B.229.238; 4.B.229.239; 4.B.229.154; 4.B.229.157; 4.B.229.166; 4.B.229.169; 4.B.229.172; 4.B.229.175; 4.B.229.240; 4.B.229.244; 4.B.230.228; 4.B.230.229; 4.B.230.230; 4.B.230.231; 4.B.230.236; 4.B.230.237; 4.B.230.238; 4.B.230.239; 4.B.230.154; 4.B.230.157; 4.B.230.166; 4.B.230.169; 4.B.230.172; 4.B.230.175; 4.B.230.240; 4.B.230.244; 4.B.231.228; 4.B.231.229; 4.B.231.230; 4.B.231.231; 4.B.231.236; 4.B.231.237; 4.B.231.238; 4.B.231.239; 4.B.231.154; 4.B.231.157; 4.B.231.166; 4.B.231.169; 4.B.231.172; 4.B.231.175; 4.B.231.240; 4.B.231.244; 4.B.236.228; 4.B.236.229; 4.B.236.230; 4.B.236.231; 4.B.236.236; 4.B.236.237; 4.B.236.238; 4.B.236.239; 4.B.236.154; 4.B.236.157; 4.B.236.166; 4.B.236.169; 4.B.236.172; 4.B.236.175; 4.B.236.240; 4.B.236.244; 4.B.237.228; 4.B.237.229; 4.B.237.230; 4.B.237.231; 4.B.237.236; 4.B.237.237; 4.B.237.238; 4.B.237.239; 4.B.237.154; 4.B.237.157; 4.B.237.166; 4.B.237.169; 4.B.237.172; 4.B.237.175; 4.B.237.240;

4.B.237.244; 4.B.238.228; 4.B.238.229; 4.B.238.230; 4.B.238.231; 4.B.238.236; 4.B.238.237; 4.B.238.238; 4.B.238.239; 4.B.238.154; 4.B.238.157; 4.B.238.166; 4.B.238.169; 4.B.238.172; 4.B.238.175; 4.B.238.240; 4.B.238.244; 4.B.239.228; 4.B.239.229; 4.B.239.230; 4.B.239.231; 4.B.239.236; 4.B.239.237; 4.B.239.238; 4.B.239.239; 4.B.239.154; 4.B.239.157; 4.B.239.166; 4.B.239.169; 4.B.239.172; 4.B.239.175; 4.B.239.240; 4.B.239.244; 4.B.154.228; 4.B.154.229; 4.B.154.230; 4.B.154.231; 4.B.154.236; 4.B.154.237; 4.B.154.238; 4.B.154.239; 4.B.154.154; 4.B.154.157; 4.B.154.166; 4.B.154.169; 4.B.154.172; 4.B.154.175; 4.B.154.240; 4.B.154.244; 4.B.157.228; 4.B.157.229; 4.B.157.230; 4.B.157.231; 4.B.157.236; 4.B.157.237; 4.B.157.238; 4.B.157.239; 4.B.157.154; 4.B.157.157; 4.B.157.166; 4.B.157.169; 4.B.157.172; 4.B.157.175; 4.B.157.240; 4.B.157.244; 4.B.166.228; 4.B.166.229; 4.B.166.230; 4.B.166.231; 4.B.166.236; 4.B.166.237; 4.B.166.238; 4.B.166.239; 4.B.166.154; 4.B.166.157; 4.B.166.166; 4.B.166.169; 4.B.166.172; 4.B.166.175; 4.B.166.240; 4.B.166.244; 4.B.169.228; 4.B.169.229; 4.B.169.230; 4.B.169.231; 4.B.169.236; 4.B.169.237; 4.B.169.238; 4.B.169.239; 4.B.169.154; 4.B.169.157; 4.B.169.166; 4.B.169.169; 4.B.169.172; 4.B.169.175; 4.B.169.240; 4.B.169.244; 4.B.172.228; 4.B.172.229; 4.B.172.230; 4.B.172.231; 4.B.172.236; 4.B.172.237; 4.B.172.238; 4.B.172.239; 4.B.172.154; 4.B.172.157; 4.B.172.166; 4.B.172.169; 4.B.172.172; 4.B.172.175; 4.B.172.240; 4.B.172.244; 4.B.175.228; 4.B.175.229; 4.B.175.230; 4.B.175.231; 4.B.175.236; 4.B.175.237; 4.B.175.238; 4.B.175.239; 4.B.175.154; 4.B.175.157; 4.B.175.166; 4.B.175.169; 4.B.175.172; 4.B.175.175; 4.B.175.240; 4.B.175.244; 4.B.240.228; 4.B.240.229; 4.B.240.230; 4.B.240.231; 4.B.240.236; 4.B.240.237; 4.B.240.238; 4.B.240.239; 4.B.240.154; 4.B.240.157; 4.B.240.166; 4.B.240.169; 4.B.240.172; 4.B.240.175; 4.B.240.240; 4.B.240.244; 4.B.244.228; 4.B.244.229; 4.B.244.230; 4.B.244.231; 4.B.244.236; 4.B.244.237; 4.B.244.238; 4.B.244.239; 4.B.244.154; 4.B.244.157; 4.B.244.166; 4.B.244.169; 4.B.244.172; 4.B.244.175; 4.B.244.240; 4.B.244.244;

Prodrugs of 4.D

4.D.228.228; 4.D.228.229; 4.D.228.230; 4.D.228.231; 4.D.228.236; 4.D.228.237; 4.D.228.238; 4.D.228.239; 4.D.228.154; 4.D.228.157; 4.D.228.166; 4.D.228.169; 4.D.228.172; 4.D.228.175; 4.D.228.240; 4.D.228.244; 4.D.229.228; 4.D.229.229; 4.D.229.230; 4.D.229.231; 4.D.229.236; 4.D.229.237; 4.D.229.238; 4.D.229.239; 4.D.229.154; 4.D.229.157; 4.D.229.166; 4.D.229.169; 4.D.229.172; 4.D.229.175; 4.D.229.240; 4.D.229.244; 4.D.230.228; 4.D.230.229; 4.D.230.230; 4.D.230.231; 4.D.230.236; 4.D.230.237; 4.D.230.238; 4.D.230.239;

4.D.230.154; 4.D.230.157; 4.D.230.166; 4.D.230.169; 4.D.230.172; 4.D.230.175; 4.D.230.240; 4.D.230.244; 4.D.231.228; 4.D.231.229; 4.D.231.230; 4.D.231.231; 4.D.231.236; 4.D.231.237; 4.D.231.238; 4.D.231.239; 4.D.231.154; 4.D.231.157; 4.D.231.166; 4.D.231.169; 4.D.231.172; 4.D.231.175; 4.D.231.240; 4.D.231.244; 4.D.236.228; 4.D.236.229; 4.D.236.230; 4.D.236.231; 4.D.236.236; 4.D.236.237; 4.D.236.238; 4.D.236.239; 4.D.236.154; 4.D.236.157; 4.D.236.166; 4.D.236.169; 4.D.236.172; 4.D.236.175; 4.D.236.240; 4.D.236.244; 4.D.237.228; 4.D.237.229; 4.D.237.230; 4.D.237.231; 4.D.237.236; 4.D.237.237; 4.D.237.238; 4.D.237.239; 4.D.237.154; 4.D.237.157; 4.D.237.166; 4.D.237.169; 4.D.237.172; 4.D.237.175; 4.D.237.240; 4.D.237.244; 4.D.238.228; 4.D.238.229; 4.D.238.230; 4.D.238.231; 4.D.238.236; 4.D.238.237; 4.D.238.238; 4.D.238.239; 4.D.238.154; 4.D.238.157; 4.D.238.166; 4.D.238.169; 4.D.238.172; 4.D.238.175; 4.D.238.240; 4.D.238.244; 4.D.239.228; 4.D.239.229; 4.D.239.230; 4.D.239.231; 4.D.239.236; 4.D.239.237; 4.D.239.238; 4.D.239.239; 4.D.239.154; 4.D.239.157; 4.D.239.166; 4.D.239.169; 4.D.239.172; 4.D.239.175; 4.D.239.240; 4.D.239.244; 4.D.154.228; 4.D.154.229; 4.D.154.230; 4.D.154.231; 4.D.154.236; 4.D.154.237; 4.D.154.238; 4.D.154.239; 4.D.154.154; 4.D.154.157; 4.D.154.166; 4.D.154.169; 4.D.154.172; 4.D.154.175; 4.D.154.240; 4.D.154.244; 4.D.157.228; 4.D.157.229; 4.D.157.230; 4.D.157.231; 4.D.157.236; 4.D.157.237; 4.D.157.238; 4.D.157.239; 4.D.157.154; 4.D.157.157; 4.D.157.166; 4.D.157.169; 4.D.157.172; 4.D.157.175; 4.D.157.240; 4.D.157.244; 4.D.166.228; 4.D.166.229; 4.D.166.230; 4.D.166.231; 4.D.166.236; 4.D.166.237; 4.D.166.238; 4.D.166.239; 4.D.166.154; 4.D.166.157; 4.D.166.166; 4.D.166.169; 4.D.166.172; 4.D.166.175; 4.D.166.240; 4.D.166.244; 4.D.169.228; 4.D.169.229; 4.D.169.230; 4.D.169.231; 4.D.169.236; 4.D.169.237; 4.D.169.238; 4.D.169.239; 4.D.169.154; 4.D.169.157; 4.D.169.166; 4.D.169.169; 4.D.169.172; 4.D.169.175; 4.D.169.240; 4.D.169.244; 4.D.172.228; 4.D.172.229; 4.D.172.230; 4.D.172.231; 4.D.172.236; 4.D.172.237; 4.D.172.238; 4.D.172.239; 4.D.172.154; 4.D.172.157; 4.D.172.166; 4.D.172.169; 4.D.172.172; 4.D.172.175; 4.D.172.240; 4.D.172.244; 4.D.175.228; 4.D.175.229; 4.D.175.230; 4.D.175.231; 4.D.175.236; 4.D.175.237; 4.D.175.238; 4.D.175.239; 4.D.175.154; 4.D.175.157; 4.D.175.166; 4.D.175.169; 4.D.175.172; 4.D.175.175; 4.D.175.240; 4.D.175.244; 4.D.240.228;

4.D.240.229; 4.D.240.230; 4.D.240.231; 4.D.240.236; 4.D.240.237; 4.D.240.238; 4.D.240.239; 4.D.240.154; 4.D.240.157; 4.D.240.166; 4.D.240.169; 4.D.240.172; 4.D.240.175; 4.D.240.240; 4.D.240.244; 4.D.244.228; 4.D.244.229; 4.D.244.230; 4.D.244.231; 4.D.244.236; 4.D.244.237; 4.D.244.238; 4.D.244.239; 4.D.244.154; 4.D.244.157; 4.D.244.166; 4.D.244.169; 4.D.244.172; 4.D.244.175; 4.D.244.240; 4.D.244.244;

Prodrugs of 4.E

4.E.228.228; 4.E.228.229; 4.E.228.230; 4.E.228.231; 4.E.228.236; 4.E.228.237; 4.E.228.238; 4.E.228.239; 4.E.228.154; 4.E.228.157; 4.E.228.166; 4.E.228.169; 4.E.228.172; 4.E.228.175; 4.E.228.240; 4.E.228.244; 4.E.229.228; 4.E.229.229; 4.E.229.230; 4.E.229.231; 4.E.229.236; 4.E.229.237; 4.E.229.238; 4.E.229.239; 4.E.229.154; 4.E.229.157; 4.E.229.166; 4.E.229.169; 4.E.229.172; 4.E.229.175; 4.E.229.240; 4.E.229.244; 4.E.230.228; 4.E.230.229; 4.E.230.230; 4.E.230.231; 4.E.230.236; 4.E.230.237; 4.E.230.238; 4.E.230.239; 4.E.230.154; 4.E.230.157; 4.E.230.166; 4.E.230.169; 4.E.230.172; 4.E.230.175; 4.E.230.240; 4.E.230.244; 4.E.231.228; 4.E.231.229; 4.E.231.230; 4.E.231.231; 4.E.231.236; 4.E.231.237; 4.E.231.238; 4.E.231.239; 4.E.231.154; 4.E.231.157; 4.E.231.166; 4.E.231.169; 4.E.231.172; 4.E.231.175; 4.E.231.240; 4.E.231.244; 4.E.236.228; 4.E.236.229; 4.E.236.230; 4.E.236.231; 4.E.236.236; 4.E.236.237; 4.E.236.238; 4.E.236.239; 4.E.236.154; 4.E.236.157; 4.E.236.166; 4.E.236.169; 4.E.236.172; 4.E.236.175; 4.E.236.240; 4.E.236.244; 4.E.237.228; 4.E.237.229; 4.E.237.230; 4.E.237.231; 4.E.237.236; 4.E.237.237; 4.E.237.238; 4.E.237.239; 4.E.237.154; 4.E.237.157; 4.E.237.166; 4.E.237.169; 4.E.237.172; 4.E.237.175; 4.E.237.240; 4.E.237.244; 4.E.238.228; 4.E.238.229; 4.E.238.230; 4.E.238.231; 4.E.238.236; 4.E.238.237; 4.E.238.238; 4.E.238.239; 4.E.238.154; 4.E.238.157; 4.E.238.166; 4.E.238.169; 4.E.238.172; 4.E.238.175; 4.E.238.240; 4.E.238.244; 4.E.239.228; 4.E.239.229; 4.E.239.230; 4.E.239.231; 4.E.239.236; 4.E.239.237; 4.E.239.238; 4.E.239.239; 4.E.239.154; 4.E.239.157; 4.E.239.166; 4.E.239.169; 4.E.239.172; 4.E.239.175; 4.E.239.240; 4.E.239.244; 4.E.154.228; 4.E.154.229; 4.E.154.230; 4.E.154.231; 4.E.154.236; 4.E.154.237; 4.E.154.238; 4.E.154.239; 4.E.154.154; 4.E.154.157; 4.E.154.166; 4.E.154.169; 4.E.154.172; 4.E.154.175; 4.E.154.240; 4.E.154.244; 4.E.157.228; 4.E.157.229; 4.E.157.230; 4.E.157.231; 4.E.157.236; 4.E.157.237; 4.E.157.238; 4.E.157.239; 4.E.157.154; 4.E.157.157; 4.E.157.166; 4.E.157.169; 4.E.157.172; 4.E.157.175; 4.E.157.240; 4.E.157.244; 4.E.166.228; 4.E.166.229; 4.E.166.230; 4.E.166.231; 4.E.166.236; 4.E.166.237; 4.E.166.238;

4.E.166.239; 4.E.166.154; 4.E.166.157; 4.E.166.166; 4.E.166.169; 4.E.166.172; 4.E.166.175; 4.E.166.240; 4.E.166.244; 4.E.169.228; 4.E.169.229; 4.E.169.230; 4.E.169.231; 4.E.169.236; 4.E.169.237; 4.E.169.238; 4.E.169.239; 4.E.169.154; 4.E.169.157; 4.E.169.166; 4.E.169.169; 4.E.169.172; 4.E.169.175; 4.E.169.240; 4.E.169.244; 4.E.172.228; 4.E.172.229; 4.E.172.230; 4.E.172.231; 4.E.172.236; 4.E.172.237; 4.E.172.238; 4.E.172.239; 4.E.172.154; 4.E.172.157; 4.E.172.166; 4.E.172.169; 4.E.172.172; 4.E.172.175; 4.E.172.240; 4.E.172.244; 4.E.175.228; 4.E.175.229; 4.E.175.230; 4.E.175.231; 4.E.175.236; 4.E.175.237; 4.E.175.238; 4.E.175.239; 4.E.175.154; 4.E.175.157; 4.E.175.166; 4.E.175.169; 4.E.175.172; 4.E.175.175; 4.E.175.240; 4.E.175.244; 4.E.240.228; 4.E.240.229; 4.E.240.230; 4.E.240.231; 4.E.240.236; 4.E.240.237; 4.E.240.238; 4.E.240.239; 4.E.240.154; 4.E.240.157; 4.E.240.166; 4.E.240.169; 4.E.240.172; 4.E.240.175; 4.E.240.240; 4.E.240.244; 4.E.244.228; 4.E.244.229; 4.E.244.230; 4.E.244.231; 4.E.244.236; 4.E.244.237; 4.E.244.238; 4.E.244.239; 4.E.244.154; 4.E.244.157; 4.E.244.166; 4.E.244.169; 4.E.244.172; 4.E.244.175; 4.E.244.240; 4.E.244.244;

Prodrugs of 4.G

4.G.228.228; 4.G.228.229; 4.G.228.230; 4.G.228.231; 4.G.228.236; 4.G.228.237; 4.G.228.238; 4.G.228.239; 4.G.228.154; 4.G.228.157; 4.G.228.166; 4.G.228.169; 4.G.228.172; 4.G.228.175; 4.G.228.240; 4.G.228.244; 4.G.229.228; 4.G.229.229; 4.G.229.230; 4.G.229.231; 4.G.229.236; 4.G.229.237; 4.G.229.238; 4.G.229.239; 4.G.229.154; 4.G.229.157; 4.G.229.166; 4.G.229.169; 4.G.229.172; 4.G.229.175; 4.G.229.240; 4.G.229.244; 4.G.230.228; 4.G.230.229; 4.G.230.230; 4.G.230.231; 4.G.230.236; 4.G.230.237; 4.G.230.238; 4.G.230.239; 4.G.230.154; 4.G.230.157; 4.G.230.166; 4.G.230.169; 4.G.230.172; 4.G.230.175; 4.G.230.240; 4.G.230.244; 4.G.231.228; 4.G.231.229; 4.G.231.230; 4.G.231.231; 4.G.231.236; 4.G.231.237; 4.G.231.238; 4.G.231.239; 4.G.231.154; 4.G.231.157; 4.G.231.166; 4.G.231.169; 4.G.231.172; 4.G.231.175; 4.G.231.240; 4.G.231.244; 4.G.236.228; 4.G.236.229; 4.G.236.230; 4.G.236.231; 4.G.236.236; 4.G.236.237; 4.G.236.238; 4.G.236.239; 4.G.236.154; 4.G.236.157; 4.G.236.166; 4.G.236.169; 4.G.236.172; 4.G.236.175; 4.G.236.240; 4.G.236.244; 4.G.237.228; 4.G.237.229; 4.G.237.230; 4.G.237.231; 4.G.237.236; 4.G.237.237; 4.G.237.238; 4.G.237.239; 4.G.237.154; 4.G.237.157; 4.G.237.166; 4.G.237.169; 4.G.237.172; 4.G.237.175; 4.G.237.240; 4.G.237.244; 4.G.238.228; 4.G.238.229; 4.G.238.230; 4.G.238.231;

4.G.238.236; 4.G.238.237; 4.G.238.238; 4.G.238.239; 4.G.238.154; 4.G.238.157; 4.G.238.166; 4.G.238.169; 4.G.238.172; 4.G.238.175; 4.G.238.240; 4.G.238.244; 4.G.239.228; 4.G.239.229; 4.G.239.230; 4.G.239.231; 4.G.239.236; 4.G.239.237; 4.G.239.238; 4.G.239.239; 4.G.239.154; 4.G.239.157; 4.G.239.166; 4.G.239.169; 4.G.239.172; 4.G.239.175; 4.G.239.240; 4.G.239.244; 4.G.154.228; 4.G.154.229; 4.G.154.230; 4.G.154.231; 4.G.154.236; 4.G.154.237; 4.G.154.238; 4.G.154.239; 4.G.154.154; 4.G.154.157; 4.G.154.166; 4.G.154.169; 4.G.154.172; 4.G.154.175; 4.G.154.240; 4.G.154.244; 4.G.157.228; 4.G.157.229; 4.G.157.230; 4.G.157.231; 4.G.157.236; 4.G.157.237; 4.G.157.238; 4.G.157.239; 4.G.157.154; 4.G.157.157; 4.G.157.166; 4.G.157.169; 4.G.157.172; 4.G.157.175; 4.G.157.240; 4.G.157.244; 4.G.166.228; 4.G.166.229; 4.G.166.230; 4.G.166.231; 4.G.166.236; 4.G.166.237; 4.G.166.238; 4.G.166.239; 4.G.166.154; 4.G.166.157; 4.G.166.166; 4.G.166.169; 4.G.166.172; 4.G.166.175; 4.G.166.240; 4.G.166.244; 4.G.169.228; 4.G.169.229; 4.G.169.230; 4.G.169.231; 4.G.169.236; 4.G.169.237; 4.G.169.238; 4.G.169.239; 4.G.169.154; 4.G.169.157; 4.G.169.166; 4.G.169.169; 4.G.169.172; 4.G.169.175; 4.G.169.240; 4.G.169.244; 4.G.172.228; 4.G.172.229; 4.G.172.230; 4.G.172.231; 4.G.172.236; 4.G.172.237; 4.G.172.238; 4.G.172.239; 4.G.172.154; 4.G.172.157; 4.G.172.166; 4.G.172.169; 4.G.172.172; 4.G.172.175; 4.G.172.240; 4.G.172.244; 4.G.175.228; 4.G.175.229; 4.G.175.230; 4.G.175.231; 4.G.175.236; 4.G.175.237; 4.G.175.238; 4.G.175.239; 4.G.175.154; 4.G.175.157; 4.G.175.166; 4.G.175.169; 4.G.175.172; 4.G.175.175; 4.G.175.240; 4.G.175.244; 4.G.240.228; 4.G.240.229; 4.G.240.230; 4.G.240.231; 4.G.240.236; 4.G.240.237; 4.G.240.238; 4.G.240.239; 4.G.240.154; 4.G.240.157; 4.G.240.166; 4.G.240.169; 4.G.240.172; 4.G.240.175; 4.G.240.240; 4.G.240.244; 4.G.244.228; 4.G.244.229; 4.G.244.230; 4.G.244.231; 4.G.244.236; 4.G.244.237; 4.G.244.238; 4.G.244.239; 4.G.244.154; 4.G.244.157; 4.G.244.166; 4.G.244.169; 4.G.244.172; 4.G.244.175; 4.G.244.240; 4.G.244.244;

Prodrugs of 4.I

4.I.228.228; 4.I.228.229; 4.I.228.230; 4.I.228.231; 4.I.228.236; 4.I.228.237; 4.I.228.238; 4.I.228.239; 4.I.228.154; 4.I.228.157; 4.I.228.166; 4.I.228.169; 4.I.228.172; 4.I.228.175; 4.I.228.240; 4.I.228.244; 4.I.229.228; 4.I.229.229;

4.I.229.230; 4.I.229.231; 4.I.229.236; 4.I.229.237; 4.I.229.238; 4.I.229.239; 4.I.229.154; 4.I.229.157; 4.I.229.166; 4.I.229.169; 4.I.229.172; 4.I.229.175; 4.I.229.240; 4.I.229.244; 4.I.230.228; 4.I.230.229; 4.I.230.230; 4.I.230.231; 4.I.230.236; 4.I.230.237; 4.I.230.238; 4.I.230.239; 4.I.230.154; 4.I.230.157; 4.I.230.166; 4.I.230.169; 4.I.230.172; 4.I.230.175; 4.I.230.240; 4.I.230.244; 4.I.231.228; 4.I.231.229; 4.I.231.230; 4.I.231.231; 4.I.231.236; 4.I.231.237; 4.I.231.238; 4.I.231.239; 4.I.231.154; 4.I.231.157; 4.I.231.166; 4.I.231.169; 4.I.231.172; 4.I.231.175; 4.I.231.240; 4.I.231.244; 4.I.236.228; 4.I.236.229; 4.I.236.230; 4.I.236.231; 4.I.236.236; 4.I.236.237; 4.I.236.238; 4.I.236.239; 4.I.236.154; 4.I.236.157; 4.I.236.166; 4.I.236.169; 4.I.236.172; 4.I.236.175; 4.I.236.240; 4.I.236.244; 4.I.237.228; 4.I.237.229; 4.I.237.230; 4.I.237.231; 4.I.237.236; 4.I.237.237; 4.I.237.238; 4.I.237.239; 4.I.237.154; 4.I.237.157; 4.I.237.166; 4.I.237.169; 4.I.237.172; 4.I.237.175; 4.I.237.240; 4.I.237.244; 4.I.238.228; 4.I.238.229; 4.I.238.230; 4.I.238.231; 4.I.238.236; 4.I.238.237; 4.I.238.238; 4.I.238.239; 4.I.238.154; 4.I.238.157; 4.I.238.166; 4.I.238.169; 4.I.238.172; 4.I.238.175; 4.I.238.240; 4.I.238.244; 4.I.239.228; 4.I.239.229; 4.I.239.230; 4.I.239.231; 4.I.239.236; 4.I.239.237; 4.I.239.238; 4.I.239.239; 4.I.239.154; 4.I.239.157; 4.I.239.166; 4.I.239.169; 4.I.239.172; 4.I.239.175; 4.I.239.240; 4.I.239.244; 4.I.154.228; 4.I.154.229; 4.I.154.230; 4.I.154.231; 4.I.154.236; 4.I.154.237; 4.I.154.238; 4.I.154.239; 4.I.154.154; 4.I.154.157; 4.I.154.166; 4.I.154.169; 4.I.154.172; 4.I.154.175; 4.I.154.240; 4.I.154.244; 4.I.157.228; 4.I.157.229; 4.I.157.230; 4.I.157.231; 4.I.157.236; 4.I.157.237; 4.I.157.238; 4.I.157.239; 4.I.157.154; 4.I.157.157; 4.I.157.166; 4.I.157.169; 4.I.157.172; 4.I.157.175; 4.I.157.240; 4.I.157.244; 4.I.166.228; 4.I.166.229; 4.I.166.230; 4.I.166.231; 4.I.166.236; 4.I.166.237; 4.I.166.238; 4.I.166.239; 4.I.166.154; 4.I.166.157; 4.I.166.166; 4.I.166.169; 4.I.166.172; 4.I.166.175; 4.I.166.240; 4.I.166.244; 4.I.169.228; 4.I.169.229; 4.I.169.230; 4.I.169.231; 4.I.169.236; 4.I.169.237; 4.I.169.238; 4.I.169.239; 4.I.169.154; 4.I.169.157; 4.I.169.166; 4.I.169.169; 4.I.169.172; 4.I.169.175; 4.I.169.240; 4.I.169.244; 4.I.172.228; 4.I.172.229; 4.I.172.230; 4.I.172.231; 4.I.172.236; 4.I.172.237; 4.I.172.238; 4.I.172.239; 4.I.172.154; 4.I.172.157; 4.I.172.166; 4.I.172.169; 4.I.172.172; 4.I.172.175; 4.I.172.240; 4.I.172.244; 4.I.175.228; 4.I.175.229; 4.I.175.230; 4.I.175.231; 4.I.175.236; 4.I.175.237; 4.I.175.238; 4.I.175.239; 4.I.175.154; 4.I.175.157; 4.I.175.166; 4.I.175.169; 4.I.175.172; 4.I.175.175; 4.I.175.240; 4.I.175.244; 4.I.240.228; 4.I.240.229; 4.I.240.230; 4.I.240.231; 4.I.240.236; 4.I.240.237; 4.I.240.238; 4.I.240.239; 4.I.240.154; 4.I.240.157; 4.I.240.166; 4.I.240.169; 4.I.240.172; 4.I.240.175; 4.I.240.240; 4.I.240.244;

4.I.244.228; 4.I.244.229; 4.I.244.230; 4.I.244.231; 4.I.244.236; 4.I.244.237; 4.I.244.238; 4.I.244.239; 4.I.244.154; 4.I.244.157; 4.I.244.166; 4.I.244.169; 4.I.244.172; 4.I.244.175; 4.I.244.240; 4.I.244.244;

Prodrugs of 4.J

4.J.228.228; 4.J.228.229; 4.J.228.230; 4.J.228.231; 4.J.228.236; 4.J.228.237; 4.J.228.238; 4.J.228.239; 4.J.228.154; 4.J.228.157; 4.J.228.166; 4.J.228.169; 4.J.228.172; 4.J.228.175; 4.J.228.240; 4.J.228.244; 4.J.229.228; 4.J.229.229; 4.J.229.230; 4.J.229.231; 4.J.229.236; 4.J.229.237; 4.J.229.238; 4.J.229.239; 4.J.229.154; 4.J.229.157; 4.J.229.166; 4.J.229.169; 4.J.229.172; 4.J.229.175; 4.J.229.240; 4.J.229.244; 4.J.230.228; 4.J.230.229; 4.J.230.230; 4.J.230.231; 4.J.230.236; 4.J.230.237; 4.J.230.238; 4.J.230.239; 4.J.230.154; 4.J.230.157; 4.J.230.166; 4.J.230.169; 4.J.230.172; 4.J.230.175; 4.J.230.240; 4.J.230.244; 4.J.231.228; 4.J.231.229; 4.J.231.230; 4.J.231.231; 4.J.231.236; 4.J.231.237; 4.J.231.238; 4.J.231.239; 4.J.231.154; 4.J.231.157; 4.J.231.166; 4.J.231.169; 4.J.231.172; 4.J.231.175; 4.J.231.240; 4.J.231.244; 4.J.236.228; 4.J.236.229; 4.J.236.230; 4.J.236.231; 4.J.236.236; 4.J.236.237; 4.J.236.238; 4.J.236.239; 4.J.236.154; 4.J.236.157; 4.J.236.166; 4.J.236.169; 4.J.236.172; 4.J.236.175; 4.J.236.240; 4.J.236.244; 4.J.237.228; 4.J.237.229; 4.J.237.230; 4.J.237.231; 4.J.237.236; 4.J.237.237; 4.J.237.238; 4.J.237.239; 4.J.237.154; 4.J.237.157; 4.J.237.166; 4.J.237.169; 4.J.237.172; 4.J.237.175; 4.J.237.240; 4.J.237.244; 4.J.238.228; 4.J.238.229; 4.J.238.230; 4.J.238.231; 4.J.238.236; 4.J.238.237; 4.J.238.238; 4.J.238.239; 4.J.238.154; 4.J.238.157; 4.J.238.166; 4.J.238.169; 4.J.238.172; 4.J.238.175; 4.J.238.240; 4.J.238.244; 4.J.239.228; 4.J.239.229; 4.J.239.230; 4.J.239.231; 4.J.239.236; 4.J.239.237; 4.J.239.238; 4.J.239.239; 4.J.239.154; 4.J.239.157; 4.J.239.166; 4.J.239.169; 4.J.239.172; 4.J.239.175; 4.J.239.240; 4.J.239.244; 4.J.154.228; 4.J.154.229; 4.J.154.230; 4.J.154.231; 4.J.154.236; 4.J.154.237; 4.J.154.238; 4.J.154.239; 4.J.154.154; 4.J.154.157; 4.J.154.166; 4.J.154.169; 4.J.154.172; 4.J.154.175; 4.J.154.240; 4.J.154.244; 4.J.157.228; 4.J.157.229; 4.J.157.230; 4.J.157.231; 4.J.157.236; 4.J.157.237; 4.J.157.238; 4.J.157.239; 4.J.157.154; 4.J.157.157; 4.J.157.166; 4.J.157.169; 4.J.157.172; 4.J.157.175; 4.J.157.240; 4.J.157.244; 4.J.166.228; 4.J.166.229; 4.J.166.230; 4.J.166.231; 4.J.166.236; 4.J.166.237; 4.J.166.238; 4.J.166.239; 4.J.166.154; 4.J.166.157; 4.J.166.166; 4.J.166.169; 4.J.166.172; 4.J.166.175; 4.J.166.240; 4.J.166.244; 4.J.169.228; 4.J.169.229; 4.J.169.230; 4.J.169.231; 4.J.169.236; 4.J.169.237; 4.J.169.238; 4.J.169.239; 4.J.169.154; 4.J.169.157; 4.J.169.166; 4.J.169.169; 4.J.169.172; 4.J.169.175; 4.J.169.240; 4.J.169.244;

4.J.172.228; 4.J.172.229; 4.J.172.230; 4.J.172.231; 4.J.172.236; 4.J.172.237; 4.J.172.238; 4.J.172.239; 4.J.172.154; 4.J.172.157; 4.J.172.166; 4.J.172.169; 4.J.172.172; 4.J.172.175; 4.J.172.240; 4.J.172.244; 4.J.175.228; 4.J.175.229; 4.J.175.230; 4.J.175.231; 4.J.175.236; 4.J.175.237; 4.J.175.238; 4.J.175.239; 4.J.175.154; 4.J.175.157; 4.J.175.166; 4.J.175.169; 4.J.175.172; 4.J.175.175; 4.J.175.240; 4.J.175.244; 4.J.240.228; 4.J.240.229; 4.J.240.230; 4.J.240.231; 4.J.240.236; 4.J.240.237; 4.J.240.238; 4.J.240.239; 4.J.240.154; 4.J.240.157; 4.J.240.166; 4.J.240.169; 4.J.240.172; 4.J.240.175; 4.J.240.240; 4.J.240.244; 4.J.244.228; 4.J.244.229; 4.J.244.230; 4.J.244.231; 4.J.244.236; 4.J.244.237; 4.J.244.238; 4.J.244.239; 4.J.244.154; 4.J.244.157; 4.J.244.166; 4.J.244.169; 4.J.244.172; 4.J.244.175; 4.J.244.240; 4.J.244.244;

Prodrugs of 4.L

4.L.228.228; 4.L.228.229; 4.L.228.230; 4.L.228.231; 4.L.228.236; 4.L.228.237; 4.L.228.238; 4.L.228.239; 4.L.228.154; 4.L.228.157; 4.L.228.166; 4.L.228.169; 4.L.228.172; 4.L.228.175; 4.L.228.240; 4.L.228.244; 4.L.229.228; 4.L.229.229; 4.L.229.230; 4.L.229.231; 4.L.229.236; 4.L.229.237; 4.L.229.238; 4.L.229.239; 4.L.229.154; 4.L.229.157; 4.L.229.166; 4.L.229.169; 4.L.229.172; 4.L.229.175; 4.L.229.240; 4.L.229.244; 4.L.230.228; 4.L.230.229; 4.L.230.230; 4.L.230.231; 4.L.230.236; 4.L.230.237; 4.L.230.238; 4.L.230.239; 4.L.230.154; 4.L.230.157; 4.L.230.166; 4.L.230.169; 4.L.230.172; 4.L.230.175; 4.L.230.240; 4.L.230.244; 4.L.231.228; 4.L.231.229; 4.L.231.230; 4.L.231.231; 4.L.231.236; 4.L.231.237; 4.L.231.238; 4.L.231.239; 4.L.231.154; 4.L.231.157; 4.L.231.166; 4.L.231.169; 4.L.231.172; 4.L.231.175; 4.L.231.240; 4.L.231.244; 4.L.236.228; 4.L.236.229; 4.L.236.230; 4.L.236.231; 4.L.236.236; 4.L.236.237; 4.L.236.238; 4.L.236.239; 4.L.236.154; 4.L.236.157; 4.L.236.166; 4.L.236.169; 4.L.236.172; 4.L.236.175; 4.L.236.240; 4.L.236.244; 4.L.237.228; 4.L.237.229; 4.L.237.230; 4.L.237.231; 4.L.237.236; 4.L.237.237; 4.L.237.238; 4.L.237.239; 4.L.237.154; 4.L.237.157; 4.L.237.166; 4.L.237.169; 4.L.237.172; 4.L.237.175; 4.L.237.240; 4.L.237.244; 4.L.238.228; 4.L.238.229; 4.L.238.230; 4.L.238.231; 4.L.238.236; 4.L.238.237; 4.L.238.238; 4.L.238.239; 4.L.238.154; 4.L.238.157; 4.L.238.166; 4.L.238.169; 4.L.238.172; 4.L.238.175; 4.L.238.240; 4.L.238.244; 4.L.239.228; 4.L.239.229; 4.L.239.230; 4.L.239.231; 4.L.239.236; 4.L.239.237; 4.L.239.238; 4.L.239.239; 4.L.239.154; 4.L.239.157; 4.L.239.166; 4.L.239.169; 4.L.239.172; 4.L.239.175; 4.L.239.240; 4.L.239.244; 4.L.154.228; 4.L.154.229; 4.L.154.230; 4.L.154.231; 4.L.154.236; 4.L.154.237; 4.L.154.238; 4.L.154.239; 4.L.154.154; 4.L.154.157; 4.L.154.166; 4.L.154.169; 4.L.154.172; 4.L.154.175; 4.L.154.240;

4.L.154.244; 4.L.157.228; 4.L.157.229; 4.L.157.230; 4.L.157.231; 4.L.157.236; 4.L.157.237; 4.L.157.238; 4.L.157.239; 4.L.157.154; 4.L.157.157; 4.L.157.166; 4.L.157.169; 4.L.157.172; 4.L.157.175; 4.L.157.240; 4.L.157.244; 4.L.166.228; 4.L.166.229; 4.L.166.230; 4.L.166.231; 4.L.166.236; 4.L.166.237; 4.L.166.238; 4.L.166.239; 4.L.166.154; 4.L.166.157; 4.L.166.166; 4.L.166.169; 4.L.166.172; 4.L.166.175; 4.L.166.240; 4.L.166.244; 4.L.169.228; 4.L.169.229; 4.L.169.230; 4.L.169.231; 4.L.169.236; 4.L.169.237; 4.L.169.238; 4.L.169.239; 4.L.169.154; 4.L.169.157; 4.L.169.166; 4.L.169.169; 4.L.169.172; 4.L.169.175; 4.L.169.240; 4.L.169.244; 4.L.172.228; 4.L.172.229; 4.L.172.230; 4.L.172.231; 4.L.172.236; 4.L.172.237; 4.L.172.238; 4.L.172.239; 4.L.172.154; 4.L.172.157; 4.L.172.166; 4.L.172.169; 4.L.172.172; 4.L.172.175; 4.L.172.240; 4.L.172.244; 4.L.175.228; 4.L.175.229; 4.L.175.230; 4.L.175.231; 4.L.175.236; 4.L.175.237; 4.L.175.238; 4.L.175.239; 4.L.175.154; 4.L.175.157; 4.L.175.166; 4.L.175.169; 4.L.175.172; 4.L.175.175; 4.L.175.240; 4.L.175.244; 4.L.240.228; 4.L.240.229; 4.L.240.230; 4.L.240.231; 4.L.240.236; 4.L.240.237; 4.L.240.238; 4.L.240.239; 4.L.240.154; 4.L.240.157; 4.L.240.166; 4.L.240.169; 4.L.240.172; 4.L.240.175; 4.L.240.240; 4.L.240.244; 4.L.244.228; 4.L.244.229; 4.L.244.230; 4.L.244.231; 4.L.244.236; 4.L.244.237; 4.L.244.238; 4.L.244.239; 4.L.244.154; 4.L.244.157; 4.L.244.166; 4.L.244.169; 4.L.244.172; 4.L.244.175; 4.L.244.240; 4.L.244.244;

Prodrugs of 4.O

4.O.228.228; 4.O.228.229; 4.O.228.230; 4.O.228.231; 4.O.228.236; 4.O.228.237; 4.O.228.238; 4.O.228.239; 4.O.228.154; 4.O.228.157; 4.O.228.166; 4.O.228.169; 4.O.228.172; 4.O.228.175; 4.O.228.240; 4.O.228.244; 4.O.229.228; 4.O.229.229; 4.O.229.230; 4.O.229.231; 4.O.229.236; 4.O.229.237; 4.O.229.238; 4.O.229.239; 4.O.229.154; 4.O.229.157; 4.O.229.166; 4.O.229.169; 4.O.229.172; 4.O.229.175; 4.O.229.240; 4.O.229.244; 4.O.230.228; 4.O.230.229; 4.O.230.230; 4.O.230.231; 4.O.230.236; 4.O.230.237; 4.O.230.238; 4.O.230.239; 4.O.230.154; 4.O.230.157; 4.O.230.166; 4.O.230.169; 4.O.230.172; 4.O.230.175; 4.O.230.240; 4.O.230.244; 4.O.231.228; 4.O.231.229; 4.O.231.230; 4.O.231.231; 4.O.231.236; 4.O.231.237; 4.O.231.238; 4.O.231.239; 4.O.231.154; 4.O.231.157; 4.O.231.166; 4.O.231.169; 4.O.231.172; 4.O.231.175; 4.O.231.240; 4.O.231.244; 4.O.236.228; 4.O.236.229; 4.O.236.230; 4.O.236.231; 4.O.236.236; 4.O.236.237; 4.O.236.238; 4.O.236.239; 4.O.236.154; 4.O.236.157; 4.O.236.166; 4.O.236.169; 4.O.236.172; 4.O.236.175; 4.O.236.240; 4.O.236.244;

4.O.237.228; 4.O.237.229; 4.O.237.230; 4.O.237.231; 4.O.237.236; 4.O.237.237; 4.O.237.238; 4.O.237.239; 4.O.237.154; 4.O.237.157; 4.O.237.166; 4.O.237.169; 4.O.237.172; 4.O.237.175; 4.O.237.240; 4.O.237.244; 4.O.238.228; 4.O.238.229; 4.O.238.230; 4.O.238.231; 4.O.238.236; 4.O.238.237; 4.O.238.238; 4.O.238.239; 4.O.238.154; 4.O.238.157; 4.O.238.166; 4.O.238.169; 4.O.238.172; 4.O.238.175; 4.O.238.240; 4.O.238.244; 4.O.239.228; 4.O.239.229; 4.O.239.230; 4.O.239.231; 4.O.239.236; 4.O.239.237; 4.O.239.238; 4.O.239.239; 4.O.239.154; 4.O.239.157; 4.O.239.166; 4.O.239.169; 4.O.239.172; 4.O.239.175; 4.O.239.240; 4.O.239.244; 4.O.154.228; 4.O.154.229; 4.O.154.230; 4.O.154.231; 4.O.154.236; 4.O.154.237; 4.O.154.238; 4.O.154.239; 4.O.154.154; 4.O.154.157; 4.O.154.166; 4.O.154.169; 4.O.154.172; 4.O.154.175; 4.O.154.240; 4.O.154.244; 4.O.157.228; 4.O.157.229; 4.O.157.230; 4.O.157.231; 4.O.157.236; 4.O.157.237; 4.O.157.238; 4.O.157.239; 4.O.157.154; 4.O.157.157; 4.O.157.166; 4.O.157.169; 4.O.157.172; 4.O.157.175; 4.O.157.240; 4.O.157.244; 4.O.166.228; 4.O.166.229; 4.O.166.230; 4.O.166.231; 4.O.166.236; 4.O.166.237; 4.O.166.238; 4.O.166.239; 4.O.166.154; 4.O.166.157; 4.O.166.166; 4.O.166.169; 4.O.166.172; 4.O.166.175; 4.O.166.240; 4.O.166.244; 4.O.169.228; 4.O.169.229; 4.O.169.230; 4.O.169.231; 4.O.169.236; 4.O.169.237; 4.O.169.238; 4.O.169.239; 4.O.169.154; 4.O.169.157; 4.O.169.166; 4.O.169.169; 4.O.169.172; 4.O.169.175; 4.O.169.240; 4.O.169.244; 4.O.172.228; 4.O.172.229; 4.O.172.230; 4.O.172.231; 4.O.172.236; 4.O.172.237; 4.O.172.238; 4.O.172.239; 4.O.172.154; 4.O.172.157; 4.O.172.166; 4.O.172.169; 4.O.172.172; 4.O.172.175; 4.O.172.240; 4.O.172.244; 4.O.175.228; 4.O.175.229; 4.O.175.230; 4.O.175.231; 4.O.175.236; 4.O.175.237; 4.O.175.238; 4.O.175.239; 4.O.175.154; 4.O.175.157; 4.O.175.166; 4.O.175.169; 4.O.175.172; 4.O.175.175; 4.O.175.240; 4.O.175.244; 4.O.240.228; 4.O.240.229; 4.O.240.230; 4.O.240.231; 4.O.240.236; 4.O.240.237; 4.O.240.238; 4.O.240.239; 4.O.240.154; 4.O.240.157; 4.O.240.166; 4.O.240.169; 4.O.240.172; 4.O.240.175; 4.O.240.240; 4.O.240.244; 4.O.244.228; 4.O.244.229; 4.O.244.230; 4.O.244.231; 4.O.244.236; 4.O.244.237; 4.O.244.238; 4.O.244.239; 4.O.244.154; 4.O.244.157; 4.O.244.166; 4.O.244.169; 4.O.244.172; 4.O.244.175; 4.O.244.240; 4.O.244.244;

Prodrugs of 4.P

4.P.228.228; 4.P.228.229; 4.P.228.230; 4.P.228.231; 4.P.228.236; 4.P.228.237; 4.P.228.238; 4.P.228.239; 4.P.228.154; 4.P.228.157; 4.P.228.166; 4.P.228.169; 4.P.228.172; 4.P.228.175; 4.P.228.240; 4.P.228.244; 4.P.229.228; 4.P.229.229; 4.P.229.230; 4.P.229.231; 4.P.229.236; 4.P.229.237; 4.P.229.238; 4.P.229.239; 4.P.229.154; 4.P.229.157; 4.P.229.166; 4.P.229.169; 4.P.229.172; 4.P.229.175; 4.P.229.240; 4.P.229.244; 4.P.230.228; 4.P.230.229; 4.P.230.230; 4.P.230.231; 4.P.230.236; 4.P.230.237; 4.P.230.238; 4.P.230.239; 4.P.230.154; 4.P.230.157; 4.P.230.166; 4.P.230.169; 4.P.230.172; 4.P.230.175; 4.P.230.240; 4.P.230.244; 4.P.231.228; 4.P.231.229; 4.P.231.230; 4.P.231.231; 4.P.231.236; 4.P.231.237; 4.P.231.238; 4.P.231.239; 4.P.231.154; 4.P.231.157; 4.P.231.166; 4.P.231.169; 4.P.231.172; 4.P.231.175; 4.P.231.240; 4.P.231.244; 4.P.236.228; 4.P.236.229; 4.P.236.230; 4.P.236.231; 4.P.236.236; 4.P.236.237; 4.P.236.238; 4.P.236.239; 4.P.236.154; 4.P.236.157; 4.P.236.166; 4.P.236.169; 4.P.236.172; 4.P.236.175; 4.P.236.240; 4.P.236.244; 4.P.237.228; 4.P.237.229; 4.P.237.230; 4.P.237.231; 4.P.237.236; 4.P.237.237; 4.P.237.238; 4.P.237.239; 4.P.237.154; 4.P.237.157; 4.P.237.166; 4.P.237.169; 4.P.237.172; 4.P.237.175; 4.P.237.240; 4.P.237.244; 4.P.238.228; 4.P.238.229; 4.P.238.230; 4.P.238.231; 4.P.238.236; 4.P.238.237; 4.P.238.238; 4.P.238.239; 4.P.238.154; 4.P.238.157; 4.P.238.166; 4.P.238.169; 4.P.238.172; 4.P.238.175; 4.P.238.240; 4.P.238.244; 4.P.239.228; 4.P.239.229; 4.P.239.230; 4.P.239.231; 4.P.239.236; 4.P.239.237; 4.P.239.238; 4.P.239.239; 4.P.239.154; 4.P.239.157; 4.P.239.166; 4.P.239.169; 4.P.239.172; 4.P.239.175; 4.P.239.240; 4.P.239.244; 4.P.154.228; 4.P.154.229; 4.P.154.230; 4.P.154.231; 4.P.154.236; 4.P.154.237; 4.P.154.238; 4.P.154.239; 4.P.154.154; 4.P.154.157; 4.P.154.166; 4.P.154.169; 4.P.154.172; 4.P.154.175; 4.P.154.240; 4.P.154.244; 4.P.157.228; 4.P.157.229; 4.P.157.230; 4.P.157.231; 4.P.157.236; 4.P.157.237; 4.P.157.238; 4.P.157.239; 4.P.157.154; 4.P.157.157; 4.P.157.166; 4.P.157.169; 4.P.157.172; 4.P.157.175; 4.P.157.240; 4.P.157.244; 4.P.166.228; 4.P.166.229; 4.P.166.230; 4.P.166.231; 4.P.166.236; 4.P.166.237; 4.P.166.238; 4.P.166.239; 4.P.166.154; 4.P.166.157; 4.P.166.166; 4.P.166.169; 4.P.166.172; 4.P.166.175; 4.P.166.240; 4.P.166.244; 4.P.169.228; 4.P.169.229; 4.P.169.230; 4.P.169.231; 4.P.169.236; 4.P.169.237; 4.P.169.238; 4.P.169.239; 4.P.169.154; 4.P.169.157; 4.P.169.166; 4.P.169.169; 4.P.169.172; 4.P.169.175; 4.P.169.240; 4.P.169.244; 4.P.172.228; 4.P.172.229; 4.P.172.230; 4.P.172.231; 4.P.172.236; 4.P.172.237; 4.P.172.238; 4.P.172.239; 4.P.172.154; 4.P.172.157; 4.P.172.166; 4.P.172.169; 4.P.172.172; 4.P.172.175; 4.P.172.240; 4.P.172.244; 4.P.175.228; 4.P.175.229; 4.P.175.230; 4.P.175.231; 4.P.175.236; 4.P.175.237; 4.P.175.238;

4.P.175.239; 4.P.175.154; 4.P.175.157; 4.P.175.166; 4.P.175.169; 4.P.175.172; 4.P.175.175; 4.P.175.240; 4.P.175.244; 4.P.240.228; 4.P.240.229; 4.P.240.230; 4.P.240.231; 4.P.240.236; 4.P.240.237; 4.P.240.238; 4.P.240.239; 4.P.240.154; 4.P.240.157; 4.P.240.166; 4.P.240.169; 4.P.240.172; 4.P.240.175; 4.P.240.240; 4.P.240.244; 4.P.244.228; 4.P.244.229; 4.P.244.230; 4.P.244.231; 4.P.244.236; 4.P.244.237; 4.P.244.238; 4.P.244.239; 4.P.244.154; 4.P.244.157; 4.P.244.166; 4.P.244.169; 4.P.244.172; 4.P.244.175; 4.P.244.240; 4.P.244.244;

Prodrugs of 4.U

4.U.228.228; 4.U.228.229; 4.U.228.230; 4.U.228.231; 4.U.228.236; 4.U.228.237; 4.U.228.238; 4.U.228.239; 4.U.228.154; 4.U.228.157; 4.U.228.166; 4.U.228.169; 4.U.228.172; 4.U.228.175; 4.U.228.240; 4.U.228.244; 4.U.229.228; 4.U.229.229; 4.U.229.230; 4.U.229.231; 4.U.229.236; 4.U.229.237; 4.U.229.238; 4.U.229.239; 4.U.229.154; 4.U.229.157; 4.U.229.166; 4.U.229.169; 4.U.229.172; 4.U.229.175; 4.U.229.240; 4.U.229.244; 4.U.230.228; 4.U.230.229; 4.U.230.230; 4.U.230.231; 4.U.230.236; 4.U.230.237; 4.U.230.238; 4.U.230.239; 4.U.230.154; 4.U.230.157; 4.U.230.166; 4.U.230.169; 4.U.230.172; 4.U.230.175; 4.U.230.240; 4.U.230.244; 4.U.231.228; 4.U.231.229; 4.U.231.230; 4.U.231.231; 4.U.231.236; 4.U.231.237; 4.U.231.238; 4.U.231.239; 4.U.231.154; 4.U.231.157; 4.U.231.166; 4.U.231.169; 4.U.231.172; 4.U.231.175; 4.U.231.240; 4.U.231.244; 4.U.236.228; 4.U.236.229; 4.U.236.230; 4.U.236.231; 4.U.236.236; 4.U.236.237; 4.U.236.238; 4.U.236.239; 4.U.236.154; 4.U.236.157; 4.U.236.166; 4.U.236.169; 4.U.236.172; 4.U.236.175; 4.U.236.240; 4.U.236.244; 4.U.237.228; 4.U.237.229; 4.U.237.230; 4.U.237.231; 4.U.237.236; 4.U.237.237; 4.U.237.238; 4.U.237.239; 4.U.237.154; 4.U.237.157; 4.U.237.166; 4.U.237.169; 4.U.237.172; 4.U.237.175; 4.U.237.240; 4.U.237.244; 4.U.238.228; 4.U.238.229; 4.U.238.230; 4.U.238.231; 4.U.238.236; 4.U.238.237; 4.U.238.238; 4.U.238.239; 4.U.238.154; 4.U.238.157; 4.U.238.166; 4.U.238.169; 4.U.238.172; 4.U.238.175; 4.U.238.240; 4.U.238.244; 4.U.239.228; 4.U.239.229; 4.U.239.230; 4.U.239.231; 4.U.239.236; 4.U.239.237; 4.U.239.238; 4.U.239.239; 4.U.239.154; 4.U.239.157; 4.U.239.166; 4.U.239.169; 4.U.239.172; 4.U.239.175; 4.U.239.240; 4.U.239.244; 4.U.154.228; 4.U.154.229; 4.U.154.230; 4.U.154.231; 4.U.154.236; 4.U.154.237; 4.U.154.238; 4.U.154.239; 4.U.154.154; 4.U.154.157; 4.U.154.166; 4.U.154.169;

4.U.154.172; 4.U.154.175; 4.U.154.240; 4.U.154.244; 4.U.157.228; 4.U.157.229; 4.U.157.230; 4.U.157.231; 4.U.157.236; 4.U.157.237; 4.U.157.238; 4.U.157.239; 4.U.157.154; 4.U.157.157; 4.U.157.166; 4.U.157.169; 4.U.157.172; 4.U.157.175; 4.U.157.240; 4.U.157.244; 4.U.166.228; 4.U.166.229; 4.U.166.230; 4.U.166.231; 4.U.166.236; 4.U.166.237; 4.U.166.238; 4.U.166.239; 4.U.166.154; 4.U.166.157; 4.U.166.166; 4.U.166.169; 4.U.166.172; 4.U.166.175; 4.U.166.240; 4.U.166.244; 4.U.169.228; 4.U.169.229; 4.U.169.230; 4.U.169.231; 4.U.169.236; 4.U.169.237; 4.U.169.238; 4.U.169.239; 4.U.169.154; 4.U.169.157; 4.U.169.166; 4.U.169.169; 4.U.169.172; 4.U.169.175; 4.U.169.240; 4.U.169.244; 4.U.172.228; 4.U.172.229; 4.U.172.230; 4.U.172.231; 4.U.172.236; 4.U.172.237; 4.U.172.238; 4.U.172.239; 4.U.172.154; 4.U.172.157; 4.U.172.166; 4.U.172.169; 4.U.172.172; 4.U.172.175; 4.U.172.240; 4.U.172.244; 4.U.175.228; 4.U.175.229; 4.U.175.230; 4.U.175.231; 4.U.175.236; 4.U.175.237; 4.U.175.238; 4.U.175.239; 4.U.175.154; 4.U.175.157; 4.U.175.166; 4.U.175.169; 4.U.175.172; 4.U.175.175; 4.U.175.240; 4.U.175.244; 4.U.240.228; 4.U.240.229; 4.U.240.230; 4.U.240.231; 4.U.240.236; 4.U.240.237; 4.U.240.238; 4.U.240.239; 4.U.240.154; 4.U.240.157; 4.U.240.166; 4.U.240.169; 4.U.240.172; 4.U.240.175; 4.U.240.240; 4.U.240.244; 4.U.244.228; 4.U.244.229; 4.U.244.230; 4.U.244.231; 4.U.244.236; 4.U.244.237; 4.U.244.238; 4.U.244.239; 4.U.244.154; 4.U.244.157; 4.U.244.166; 4.U.244.169; 4.U.244.172; 4.U.244.175; 4.U.244.240; 4.U.244.244;

Prodrugs of 4.W

4.W.228.228; 4.W.228.229; 4.W.228.230; 4.W.228.231; 4.W.228.236; 4.W.228.237; 4.W.228.238; 4.W.228.239; 4.W.228.154; 4.W.228.157; 4.W.228.166; 4.W.228.169; 4.W.228.172; 4.W.228.175; 4.W.228.240; 4.W.228.244; 4.W.229.228; 4.W.229.229; 4.W.229.230; 4.W.229.231; 4.W.229.236; 4.W.229.237; 4.W.229.238; 4.W.229.239; 4.W.229.154; 4.W.229.157; 4.W.229.166; 4.W.229.169; 4.W.229.172; 4.W.229.175; 4.W.229.240; 4.W.229.244; 4.W.230.228; 4.W.230.229; 4.W.230.230; 4.W.230.231; 4.W.230.236; 4.W.230.237; 4.W.230.238; 4.W.230.239; 4.W.230.154; 4.W.230.157; 4.W.230.166; 4.W.230.169; 4.W.230.172; 4.W.230.175; 4.W.230.240; 4.W.230.244; 4.W.231.228; 4.W.231.229; 4.W.231.230; 4.W.231.231; 4.W.231.236; 4.W.231.237; 4.W.231.238;

4.W.231.239; 4.W.231.154; 4.W.231.157; 4.W.231.166; 4.W.231.169; 4.W.231.172; 4.W.231.175; 4.W.231.240; 4.W.231.244; 4.W.236.228; 4.W.236.229; 4.W.236.230; 4.W.236.231; 4.W.236.236; 4.W.236.237; 4.W.236.238; 4.W.236.239; 4.W.236.154; 4.W.236.157; 4.W.236.166; 4.W.236.169; 4.W.236.172; 4.W.236.175; 4.W.236.240; 4.W.236.244; 4.W.237.228; 4.W.237.229; 4.W.237.230; 4.W.237.231; 4.W.237.236; 4.W.237.237; 4.W.237.238; 4.W.237.239; 4.W.237.154; 4.W.237.157; 4.W.237.166; 4.W.237.169; 4.W.237.172; 4.W.237.175; 4.W.237.240; 4.W.237.244; 4.W.238.228; 4.W.238.229; 4.W.238.230; 4.W.238.231; 4.W.238.236; 4.W.238.237; 4.W.238.238; 4.W.238.239; 4.W.238.154; 4.W.238.157; 4.W.238.166; 4.W.238.169; 4.W.238.172; 4.W.238.175; 4.W.238.240; 4.W.238.244; 4.W.239.228; 4.W.239.229; 4.W.239.230; 4.W.239.231; 4.W.239.236; 4.W.239.237; 4.W.239.238; 4.W.239.239; 4.W.239.154; 4.W.239.157; 4.W.239.166; 4.W.239.169; 4.W.239.172; 4.W.239.175; 4.W.239.240; 4.W.239.244; 4.W.154.228; 4.W.154.229; 4.W.154.230; 4.W.154.231; 4.W.154.236; 4.W.154.237; 4.W.154.238; 4.W.154.239; 4.W.154.154; 4.W.154.157; 4.W.154.166; 4.W.154.169; 4.W.154.172; 4.W.154.175; 4.W.154.240; 4.W.154.244; 4.W.157.228; 4.W.157.229; 4.W.157.230; 4.W.157.231; 4.W.157.236; 4.W.157.237; 4.W.157.238; 4.W.157.239; 4.W.157.154; 4.W.157.157; 4.W.157.166; 4.W.157.169; 4.W.157.172; 4.W.157.175; 4.W.157.240; 4.W.157.244; 4.W.166.228; 4.W.166.229; 4.W.166.230; 4.W.166.231; 4.W.166.236; 4.W.166.237; 4.W.166.238; 4.W.166.239; 4.W.166.154; 4.W.166.157; 4.W.166.166; 4.W.166.169; 4.W.166.172; 4.W.166.175; 4.W.166.240; 4.W.166.244; 4.W.169.228; 4.W.169.229; 4.W.169.230; 4.W.169.231; 4.W.169.236; 4.W.169.237; 4.W.169.238; 4.W.169.239; 4.W.169.154; 4.W.169.157; 4.W.169.166; 4.W.169.169; 4.W.169.172; 4.W.169.175; 4.W.169.240; 4.W.169.244; 4.W.172.228; 4.W.172.229; 4.W.172.230; 4.W.172.231; 4.W.172.236; 4.W.172.237; 4.W.172.238; 4.W.172.239; 4.W.172.154; 4.W.172.157; 4.W.172.166; 4.W.172.169; 4.W.172.172; 4.W.172.175; 4.W.172.240; 4.W.172.244; 4.W.175.228; 4.W.175.229; 4.W.175.230; 4.W.175.231; 4.W.175.236; 4.W.175.237; 4.W.175.238; 4.W.175.239; 4.W.175.154; 4.W.175.157; 4.W.175.166; 4.W.175.169; 4.W.175.172; 4.W.175.175; 4.W.175.240; 4.W.175.244; 4.W.240.228; 4.W.240.229; 4.W.240.230; 4.W.240.231; 4.W.240.236; 4.W.240.237; 4.W.240.238; 4.W.240.239; 4.W.240.154; 4.W.240.157; 4.W.240.166; 4.W.240.169; 4.W.240.172; 4.W.240.175; 4.W.240.240; 4.W.240.244;

4.W.244.228; 4.W.244.229; 4.W.244.230; 4.W.244.231; 4.W.244.236; 4.W.244.237; 4.W.244.238; 4.W.244.239; 4.W.244.154; 4.W.244.157; 4.W.244.166; 4.W.244.169; 4.W.244.172; 4.W.244.175; 4.W.244.240; 4.W.244.244;

Prodrugs of 4.Y

4.Y.228.228; 4.Y.228.229; 4.Y.228.230; 4.Y.228.231; 4.Y.228.236; 4.Y.228.237; 4.Y.228.238; 4.Y.228.239; 4.Y.228.154; 4.Y.228.157; 4.Y.228.166; 4.Y.228.169; 4.Y.228.172; 4.Y.228.175; 4.Y.228.240; 4.Y.228.244; 4.Y.229.228; 4.Y.229.229; 4.Y.229.230; 4.Y.229.231; 4.Y.229.236; 4.Y.229.237; 4.Y.229.238; 4.Y.229.239; 4.Y.229.154; 4.Y.229.157; 4.Y.229.166; 4.Y.229.169; 4.Y.229.172; 4.Y.229.175; 4.Y.229.240; 4.Y.229.244; 4.Y.230.228; 4.Y.230.229; 4.Y.230.230; 4.Y.230.231; 4.Y.230.236; 4.Y.230.237; 4.Y.230.238; 4.Y.230.239; 4.Y.230.154; 4.Y.230.157; 4.Y.230.166; 4.Y.230.169; 4.Y.230.172; 4.Y.230.175; 4.Y.230.240; 4.Y.230.244; 4.Y.231.228; 4.Y.231.229; 4.Y.231.230; 4.Y.231.231; 4.Y.231.236; 4.Y.231.237; 4.Y.231.238; 4.Y.231.239; 4.Y.231.154; 4.Y.231.157; 4.Y.231.166; 4.Y.231.169; 4.Y.231.172; 4.Y.231.175; 4.Y.231.240; 4.Y.231.244; 4.Y.236.228; 4.Y.236.229; 4.Y.236.230; 4.Y.236.231; 4.Y.236.236; 4.Y.236.237; 4.Y.236.238; 4.Y.236.239; 4.Y.236.154; 4.Y.236.157; 4.Y.236.166; 4.Y.236.169; 4.Y.236.172; 4.Y.236.175; 4.Y.236.240; 4.Y.236.244; 4.Y.237.228; 4.Y.237.229; 4.Y.237.230; 4.Y.237.231; 4.Y.237.236; 4.Y.237.237; 4.Y.237.238; 4.Y.237.239; 4.Y.237.154; 4.Y.237.157; 4.Y.237.166; 4.Y.237.169; 4.Y.237.172; 4.Y.237.175; 4.Y.237.240; 4.Y.237.244; 4.Y.238.228; 4.Y.238.229; 4.Y.238.230; 4.Y.238.231; 4.Y.238.236; 4.Y.238.237; 4.Y.238.238; 4.Y.238.239; 4.Y.238.154; 4.Y.238.157; 4.Y.238.166; 4.Y.238.169; 4.Y.238.172; 4.Y.238.175; 4.Y.238.240; 4.Y.238.244; 4.Y.239.228; 4.Y.239.229; 4.Y.239.230; 4.Y.239.231; 4.Y.239.236; 4.Y.239.237; 4.Y.239.238; 4.Y.239.239; 4.Y.239.154; 4.Y.239.157; 4.Y.239.166; 4.Y.239.169; 4.Y.239.172; 4.Y.239.175; 4.Y.239.240; 4.Y.239.244; 4.Y.154.228; 4.Y.154.229; 4.Y.154.230; 4.Y.154.231; 4.Y.154.236; 4.Y.154.237; 4.Y.154.238; 4.Y.154.239; 4.Y.154.154; 4.Y.154.157; 4.Y.154.166; 4.Y.154.169; 4.Y.154.172; 4.Y.154.175; 4.Y.154.240; 4.Y.154.244; 4.Y.157.228; 4.Y.157.229; 4.Y.157.230; 4.Y.157.231; 4.Y.157.236; 4.Y.157.237; 4.Y.157.238; 4.Y.157.239; 4.Y.157.154; 4.Y.157.157; 4.Y.157.166; 4.Y.157.169; 4.Y.157.172; 4.Y.157.175; 4.Y.157.240; 4.Y.157.244; 4.Y.166.228; 4.Y.166.229; 4.Y.166.230; 4.Y.166.231; 4.Y.166.236; 4.Y.166.237; 4.Y.166.238; 4.Y.166.239; 4.Y.166.154; 4.Y.166.157; 4.Y.166.166; 4.Y.166.169; 4.Y.166.172; 4.Y.166.175; 4.Y.166.240; 4.Y.166.244; 4.Y.169.228; 4.Y.169.229; 4.Y.169.230; 4.Y.169.231; 4.Y.169.236; 4.Y.169.237; 4.Y.169.238; 4.Y.169.239; 4.Y.169.154;

4.Y.169.157; 4.Y.169.166; 4.Y.169.169; 4.Y.169.172; 4.Y.169.175; 4.Y.169.240; 4.Y.169.244; 4.Y.172.228; 4.Y.172.229; 4.Y.172.230; 4.Y.172.231; 4.Y.172.236; 4.Y.172.237; 4.Y.172.238; 4.Y.172.239; 4.Y.172.154; 4.Y.172.157; 4.Y.172.166; 4.Y.172.169; 4.Y.172.172; 4.Y.172.175; 4.Y.172.240; 4.Y.172.244; 4.Y.175.228; 4.Y.175.229; 4.Y.175.230; 4.Y.175.231; 4.Y.175.236; 4.Y.175.237; 4.Y.175.238; 4.Y.175.239; 4.Y.175.154; 4.Y.175.157; 4.Y.175.166; 4.Y.175.169; 4.Y.175.172; 4.Y.175.175; 4.Y.175.240; 4.Y.175.244; 4.Y.240.228; 4.Y.240.229; 4.Y.240.230; 4.Y.240.231; 4.Y.240.236; 4.Y.240.237; 4.Y.240.238; 4.Y.240.239; 4.Y.240.154; 4.Y.240.157; 4.Y.240.166; 4.Y.240.169; 4.Y.240.172; 4.Y.240.175; 4.Y.240.240; 4.Y.240.244; 4.Y.244.228; 4.Y.244.229; 4.Y.244.230; 4.Y.244.231; 4.Y.244.236; 4.Y.244.237; 4.Y.244.238; 4.Y.244.239; 4.Y.244.154; 4.Y.244.157; 4.Y.244.166; 4.Y.244.169; 4.Y.244.172; 4.Y.244.175; 4.Y.244.240; 4.Y.244.244;

Prodrugs of 5.B

5.B.228.228; 5.B.228.229; 5.B.228.230; 5.B.228.231; 5.B.228.236; 5.B.228.237; 5.B.228.238; 5.B.228.239; 5.B.228.154; 5.B.228.157; 5.B.228.166; 5.B.228.169; 5.B.228.172; 5.B.228.175; 5.B.228.240; 5.B.228.244; 5.B.229.228; 5.B.229.229; 5.B.229.230; 5.B.229.231; 5.B.229.236; 5.B.229.237; 5.B.229.238; 5.B.229.239; 5.B.229.154; 5.B.229.157; 5.B.229.166; 5.B.229.169; 5.B.229.172; 5.B.229.175; 5.B.229.240; 5.B.229.244; 5.B.230.228; 5.B.230.229; 5.B.230.230; 5.B.230.231; 5.B.230.236; 5.B.230.237; 5.B.230.238; 5.B.230.239; 5.B.230.154; 5.B.230.157; 5.B.230.166; 5.B.230.169; 5.B.230.172; 5.B.230.175; 5.B.230.240; 5.B.230.244; 5.B.231.228; 5.B.231.229; 5.B.231.230; 5.B.231.231; 5.B.231.236; 5.B.231.237; 5.B.231.238; 5.B.231.239; 5.B.231.154; 5.B.231.157; 5.B.231.166; 5.B.231.169; 5.B.231.172; 5.B.231.175; 5.B.231.240; 5.B.231.244; 5.B.236.228; 5.B.236.229; 5.B.236.230; 5.B.236.231; 5.B.236.236; 5.B.236.237; 5.B.236.238; 5.B.236.239; 5.B.236.154; 5.B.236.157; 5.B.236.166; 5.B.236.169; 5.B.236.172; 5.B.236.175; 5.B.236.240; 5.B.236.244; 5.B.237.228; 5.B.237.229; 5.B.237.230; 5.B.237.231; 5.B.237.236; 5.B.237.237; 5.B.237.238; 5.B.237.239; 5.B.237.154; 5.B.237.157; 5.B.237.166; 5.B.237.169; 5.B.237.172; 5.B.237.175; 5.B.237.240; 5.B.237.244; 5.B.238.228; 5.B.238.229; 5.B.238.230; 5.B.238.231; 5.B.238.236; 5.B.238.237; 5.B.238.238; 5.B.238.239; 5.B.238.154; 5.B.238.157; 5.B.238.166; 5.B.238.169; 5.B.238.172; 5.B.238.175; 5.B.238.240; 5.B.238.244; 5.B.239.228; 5.B.239.229; 5.B.239.230; 5.B.239.231; 5.B.239.236; 5.B.239.237; 5.B.239.238; 5.B.239.239; 5.B.239.154; 5.B.239.157; 5.B.239.166; 5.B.239.169; 5.B.239.172; 5.B.239.175; 5.B.239.240; 5.B.239.244; 5.B.154.228; 5.B.154.229; 5.B.154.230; 5.B.154.231; 5.B.154.236; 5.B.154.237; 5.B.154.238; 5.B.154.239; 5.B.154.154;

5.B.154.157; 5.B.154.166; 5.B.154.169; 5.B.154.172; 5.B.154.175; 5.B.154.240; 5.B.154.244; 5.B.157.228; 5.B.157.229; 5.B.157.230; 5.B.157.231; 5.B.157.236; 5.B.157.237; 5.B.157.238; 5.B.157.239; 5.B.157.154; 5.B.157.157; 5.B.157.166; 5.B.157.169; 5.B.157.172; 5.B.157.175; 5.B.157.240; 5.B.157.244; 5.B.166.228; 5.B.166.229; 5.B.166.230; 5.B.166.231; 5.B.166.236; 5.B.166.237; 5.B.166.238; 5.B.166.239; 5.B.166.154; 5.B.166.157; 5.B.166.166; 5.B.166.169; 5.B.166.172; 5.B.166.175; 5.B.166.240; 5.B.166.244; 5.B.169.228; 5.B.169.229; 5.B.169.230; 5.B.169.231; 5.B.169.236; 5.B.169.237; 5.B.169.238; 5.B.169.239; 5.B.169.154; 5.B.169.157; 5.B.169.166; 5.B.169.169; 5.B.169.172; 5.B.169.175; 5.B.169.240; 5.B.169.244; 5.B.172.228; 5.B.172.229; 5.B.172.230; 5.B.172.231; 5.B.172.236; 5.B.172.237; 5.B.172.238; 5.B.172.239; 5.B.172.154; 5.B.172.157; 5.B.172.166; 5.B.172.169; 5.B.172.172; 5.B.172.175; 5.B.172.240; 5.B.172.244; 5.B.175.228; 5.B.175.229; 5.B.175.230; 5.B.175.231; 5.B.175.236; 5.B.175.237; 5.B.175.238; 5.B.175.239; 5.B.175.154; 5.B.175.157; 5.B.175.166; 5.B.175.169; 5.B.175.172; 5.B.175.175; 5.B.175.240; 5.B.175.244; 5.B.240.228; 5.B.240.229; 5.B.240.230; 5.B.240.231; 5.B.240.236; 5.B.240.237; 5.B.240.238; 5.B.240.239; 5.B.240.154; 5.B.240.157; 5.B.240.166; 5.B.240.169; 5.B.240.172; 5.B.240.175; 5.B.240.240; 5.B.240.244; 5.B.244.228; 5.B.244.229; 5.B.244.230; 5.B.244.231; 5.B.244.236; 5.B.244.237; 5.B.244.238; 5.B.244.239; 5.B.244.154; 5.B.244.157; 5.B.244.166; 5.B.244.169; 5.B.244.172; 5.B.244.175; 5.B.244.240; 5.B.244.244;

Prodrugs of 5.D

5.D.228.228; 5.D.228.229; 5.D.228.230; 5.D.228.231; 5.D.228.236; 5.D.228.237; 5.D.228.238; 5.D.228.239; 5.D.228.154; 5.D.228.157; 5.D.228.166; 5.D.228.169; 5.D.228.172; 5.D.228.175; 5.D.228.240; 5.D.228.244; 5.D.229.228; 5.D.229.229; 5.D.229.230; 5.D.229.231; 5.D.229.236; 5.D.229.237; 5.D.229.238; 5.D.229.239; 5.D.229.154; 5.D.229.157; 5.D.229.166; 5.D.229.169; 5.D.229.172; 5.D.229.175; 5.D.229.240; 5.D.229.244; 5.D.230.228; 5.D.230.229; 5.D.230.230; 5.D.230.231; 5.D.230.236; 5.D.230.237; 5.D.230.238; 5.D.230.239; 5.D.230.154; 5.D.230.157; 5.D.230.166; 5.D.230.169; 5.D.230.172; 5.D.230.175; 5.D.230.240; 5.D.230.244; 5.D.231.228; 5.D.231.229; 5.D.231.230; 5.D.231.231; 5.D.231.236; 5.D.231.237; 5.D.231.238; 5.D.231.239; 5.D.231.154; 5.D.231.157; 5.D.231.166; 5.D.231.169; 5.D.231.172; 5.D.231.175; 5.D.231.240; 5.D.231.244; 5.D.236.228; 5.D.236.229; 5.D.236.230; 5.D.236.231; 5.D.236.236; 5.D.236.237; 5.D.236.238; 5.D.236.239; 5.D.236.154; 5.D.236.157; 5.D.236.166;

5.D.236.169; 5.D.236.172; 5.D.236.175; 5.D.236.240; 5.D.236.244; 5.D.237.228; 5.D.237.229; 5.D.237.230; 5.D.237.231; 5.D.237.236; 5.D.237.237; 5.D.237.238; 5.D.237.239; 5.D.237.154; 5.D.237.157; 5.D.237.166; 5.D.237.169; 5.D.237.172; 5.D.237.175; 5.D.237.240; 5.D.237.244; 5.D.238.228; 5.D.238.229; 5.D.238.230; 5.D.238.231; 5.D.238.236; 5.D.238.237; 5.D.238.238; 5.D.238.239; 5.D.238.154; 5.D.238.157; 5.D.238.166; 5.D.238.169; 5.D.238.172; 5.D.238.175; 5.D.238.240; 5.D.238.244; 5.D.239.228; 5.D.239.229; 5.D.239.230; 5.D.239.231; 5.D.239.236; 5.D.239.237; 5.D.239.238; 5.D.239.239; 5.D.239.154; 5.D.239.157; 5.D.239.166; 5.D.239.169; 5.D.239.172; 5.D.239.175; 5.D.239.240; 5.D.239.244; 5.D.154.228; 5.D.154.229; 5.D.154.230; 5.D.154.231; 5.D.154.236; 5.D.154.237; 5.D.154.238; 5.D.154.239; 5.D.154.154; 5.D.154.157; 5.D.154.166; 5.D.154.169; 5.D.154.172; 5.D.154.175; 5.D.154.240; 5.D.154.244; 5.D.157.228; 5.D.157.229; 5.D.157.230; 5.D.157.231; 5.D.157.236; 5.D.157.237; 5.D.157.238; 5.D.157.239; 5.D.157.154; 5.D.157.157; 5.D.157.166; 5.D.157.169; 5.D.157.172; 5.D.157.175; 5.D.157.240; 5.D.157.244; 5.D.166.228; 5.D.166.229; 5.D.166.230; 5.D.166.231; 5.D.166.236; 5.D.166.237; 5.D.166.238; 5.D.166.239; 5.D.166.154; 5.D.166.157; 5.D.166.166; 5.D.166.169; 5.D.166.172; 5.D.166.175; 5.D.166.240; 5.D.166.244; 5.D.169.228; 5.D.169.229; 5.D.169.230; 5.D.169.231; 5.D.169.236; 5.D.169.237; 5.D.169.238; 5.D.169.239; 5.D.169.154; 5.D.169.157; 5.D.169.166; 5.D.169.169; 5.D.169.172; 5.D.169.175; 5.D.169.240; 5.D.169.244; 5.D.172.228; 5.D.172.229; 5.D.172.230; 5.D.172.231; 5.D.172.236; 5.D.172.237; 5.D.172.238; 5.D.172.239; 5.D.172.154; 5.D.172.157; 5.D.172.166; 5.D.172.169; 5.D.172.172; 5.D.172.175; 5.D.172.240; 5.D.172.244; 5.D.175.228; 5.D.175.229; 5.D.175.230; 5.D.175.231; 5.D.175.236; 5.D.175.237; 5.D.175.238; 5.D.175.239; 5.D.175.154; 5.D.175.157; 5.D.175.166; 5.D.175.169; 5.D.175.172; 5.D.175.175; 5.D.175.240; 5.D.175.244; 5.D.240.228; 5.D.240.229; 5.D.240.230; 5.D.240.231; 5.D.240.236; 5.D.240.237; 5.D.240.238; 5.D.240.239; 5.D.240.154; 5.D.240.157; 5.D.240.166; 5.D.240.169; 5.D.240.172; 5.D.240.175; 5.D.240.240; 5.D.240.244; 5.D.244.228; 5.D.244.229; 5.D.244.230; 5.D.244.231; 5.D.244.236; 5.D.244.237; 5.D.244.238; 5.D.244.239; 5.D.244.154; 5.D.244.157; 5.D.244.166; 5.D.244.169; 5.D.244.172; 5.D.244.175; 5.D.244.240; 5.D.244.244;

Prodrugs of 5.E

5.E.228.228; 5.E.228.229; 5.E.228.230; 5.E.228.231; 5.E.228.236; 5.E.228.237; 5.E.228.238; 5.E.228.239; 5.E.228.154; 5.E.228.157; 5.E.228.166; 5.E.228.169; 5.E.228.172; 5.E.228.175; 5.E.228.240; 5.E.228.244; 5.E.229.228; 5.E.229.229; 5.E.229.230; 5.E.229.231; 5.E.229.236; 5.E.229.237; 5.E.229.238; 5.E.229.239; 5.E.229.154; 5.E.229.157; 5.E.229.166; 5.E.229.169; 5.E.229.172; 5.E.229.175; 5.E.229.240; 5.E.229.244; 5.E.230.228; 5.E.230.229; 5.E.230.230; 5.E.230.231; 5.E.230.236; 5.E.230.237; 5.E.230.238; 5.E.230.239; 5.E.230.154; 5.E.230.157; 5.E.230.166; 5.E.230.169; 5.E.230.172; 5.E.230.175; 5.E.230.240; 5.E.230.244; 5.E.231.228; 5.E.231.229; 5.E.231.230; 5.E.231.231; 5.E.231.236; 5.E.231.237; 5.E.231.238; 5.E.231.239; 5.E.231.154; 5.E.231.157; 5.E.231.166; 5.E.231.169; 5.E.231.172; 5.E.231.175; 5.E.231.240; 5.E.231.244; 5.E.236.228; 5.E.236.229; 5.E.236.230; 5.E.236.231; 5.E.236.236; 5.E.236.237; 5.E.236.238; 5.E.236.239; 5.E.236.154; 5.E.236.157; 5.E.236.166; 5.E.236.169; 5.E.236.172; 5.E.236.175; 5.E.236.240; 5.E.236.244; 5.E.237.228; 5.E.237.229; 5.E.237.230; 5.E.237.231; 5.E.237.236; 5.E.237.237; 5.E.237.238; 5.E.237.239; 5.E.237.154; 5.E.237.157; 5.E.237.166; 5.E.237.169; 5.E.237.172; 5.E.237.175; 5.E.237.240; 5.E.237.244; 5.E.238.228; 5.E.238.229; 5.E.238.230; 5.E.238.231; 5.E.238.236; 5.E.238.237; 5.E.238.238; 5.E.238.239; 5.E.238.154; 5.E.238.157; 5.E.238.166; 5.E.238.169; 5.E.238.172; 5.E.238.175; 5.E.238.240; 5.E.238.244; 5.E.239.228; 5.E.239.229; 5.E.239.230; 5.E.239.231; 5.E.239.236; 5.E.239.237; 5.E.239.238; 5.E.239.239; 5.E.239.154; 5.E.239.157; 5.E.239.166; 5.E.239.169; 5.E.239.172; 5.E.239.175; 5.E.239.240; 5.E.239.244; 5.E.154.228; 5.E.154.229; 5.E.154.230; 5.E.154.231; 5.E.154.236; 5.E.154.237; 5.E.154.238; 5.E.154.239; 5.E.154.154; 5.E.154.157; 5.E.154.166; 5.E.154.169; 5.E.154.172; 5.E.154.175; 5.E.154.240; 5.E.154.244; 5.E.157.228; 5.E.157.229; 5.E.157.230; 5.E.157.231; 5.E.157.236; 5.E.157.237; 5.E.157.238; 5.E.157.239; 5.E.157.154; 5.E.157.157; 5.E.157.166; 5.E.157.169; 5.E.157.172; 5.E.157.175; 5.E.157.240; 5.E.157.244; 5.E.166.228; 5.E.166.229; 5.E.166.230; 5.E.166.231; 5.E.166.236; 5.E.166.237; 5.E.166.238; 5.E.166.239; 5.E.166.154; 5.E.166.157; 5.E.166.166; 5.E.166.169; 5.E.166.172; 5.E.166.175; 5.E.166.240; 5.E.166.244; 5.E.169.228; 5.E.169.229; 5.E.169.230; 5.E.169.231; 5.E.169.236; 5.E.169.237; 5.E.169.238; 5.E.169.239; 5.E.169.154; 5.E.169.157; 5.E.169.166; 5.E.169.169; 5.E.169.172; 5.E.169.175; 5.E.169.240; 5.E.169.244; 5.E.172.228; 5.E.172.229; 5.E.172.230; 5.E.172.231; 5.E.172.236; 5.E.172.237; 5.E.172.238; 5.E.172.239; 5.E.172.154; 5.E.172.157; 5.E.172.166; 5.E.172.169; 5.E.172.172; 5.E.172.175; 5.E.172.240; 5.E.172.244; 5.E.175.228;

5.E.175.229; 5.E.175.230; 5.E.175.231; 5.E.175.236; 5.E.175.237; 5.E.175.238; 5.E.175.239; 5.E.175.154; 5.E.175.157; 5.E.175.166; 5.E.175.169; 5.E.175.172; 5.E.175.175; 5.E.175.240; 5.E.175.244; 5.E.240.228; 5.E.240.229; 5.E.240.230; 5.E.240.231; 5.E.240.236; 5.E.240.237; 5.E.240.238; 5.E.240.239; 5.E.240.154; 5.E.240.157; 5.E.240.166; 5.E.240.169; 5.E.240.172; 5.E.240.175; 5.E.240.240; 5.E.240.244; 5.E.244.228; 5.E.244.229; 5.E.244.230; 5.E.244.231; 5.E.244.236; 5.E.244.237; 5.E.244.238; 5.E.244.239; 5.E.244.154; 5.E.244.157; 5.E.244.166; 5.E.244.169; 5.E.244.172; 5.E.244.175; 5.E.244.240; 5.E.244.244;

Prodrugs of 5.G

5.G.228.228; 5.G.228.229; 5.G.228.230; 5.G.228.231; 5.G.228.236; 5.G.228.237; 5.G.228.238; 5.G.228.239; 5.G.228.154; 5.G.228.157; 5.G.228.166; 5.G.228.169; 5.G.228.172; 5.G.228.175; 5.G.228.240; 5.G.228.244; 5.G.229.228; 5.G.229.229; 5.G.229.230; 5.G.229.231; 5.G.229.236; 5.G.229.237; 5.G.229.238; 5.G.229.239; 5.G.229.154; 5.G.229.157; 5.G.229.166; 5.G.229.169; 5.G.229.172; 5.G.229.175; 5.G.229.240; 5.G.229.244; 5.G.230.228; 5.G.230.229; 5.G.230.230; 5.G.230.231; 5.G.230.236; 5.G.230.237; 5.G.230.238; 5.G.230.239; 5.G.230.154; 5.G.230.157; 5.G.230.166; 5.G.230.169; 5.G.230.172; 5.G.230.175; 5.G.230.240; 5.G.230.244; 5.G.231.228; 5.G.231.229; 5.G.231.230; 5.G.231.231; 5.G.231.236; 5.G.231.237; 5.G.231.238; 5.G.231.239; 5.G.231.154; 5.G.231.157; 5.G.231.166; 5.G.231.169; 5.G.231.172; 5.G.231.175; 5.G.231.240; 5.G.231.244; 5.G.236.228; 5.G.236.229; 5.G.236.230; 5.G.236.231; 5.G.236.236; 5.G.236.237; 5.G.236.238; 5.G.236.239; 5.G.236.154; 5.G.236.157; 5.G.236.166; 5.G.236.169; 5.G.236.172; 5.G.236.175; 5.G.236.240; 5.G.236.244; 5.G.237.228; 5.G.237.229; 5.G.237.230; 5.G.237.231; 5.G.237.236; 5.G.237.237; 5.G.237.238; 5.G.237.239; 5.G.237.154; 5.G.237.157; 5.G.237.166; 5.G.237.169; 5.G.237.172; 5.G.237.175; 5.G.237.240; 5.G.237.244; 5.G.238.228; 5.G.238.229; 5.G.238.230; 5.G.238.231; 5.G.238.236; 5.G.238.237; 5.G.238.238; 5.G.238.239; 5.G.238.154; 5.G.238.157; 5.G.238.166; 5.G.238.169; 5.G.238.172; 5.G.238.175; 5.G.238.240; 5.G.238.244; 5.G.239.228; 5.G.239.229; 5.G.239.230; 5.G.239.231; 5.G.239.236; 5.G.239.237; 5.G.239.238; 5.G.239.239; 5.G.239.154; 5.G.239.157; 5.G.239.166; 5.G.239.169; 5.G.239.172; 5.G.239.175; 5.G.239.240; 5.G.239.244; 5.G.154.228; 5.G.154.229; 5.G.154.230; 5.G.154.231; 5.G.154.236; 5.G.154.237; 5.G.154.238;

5.G.154.239; 5.G.154.154; 5.G.154.157; 5.G.154.166; 5.G.154.169; 5.G.154.172; 5.G.154.175; 5.G.154.240; 5.G.154.244; 5.G.157.228; 5.G.157.229; 5.G.157.230; 5.G.157.231; 5.G.157.236; 5.G.157.237; 5.G.157.238; 5.G.157.239; 5.G.157.154; 5.G.157.157; 5.G.157.166; 5.G.157.169; 5.G.157.172; 5.G.157.175; 5.G.157.240; 5.G.157.244; 5.G.166.228; 5.G.166.229; 5.G.166.230; 5.G.166.231; 5.G.166.236; 5.G.166.237; 5.G.166.238; 5.G.166.239; 5.G.166.154; 5.G.166.157; 5.G.166.166; 5.G.166.169; 5.G.166.172; 5.G.166.175; 5.G.166.240; 5.G.166.244; 5.G.169.228; 5.G.169.229; 5.G.169.230; 5.G.169.231; 5.G.169.236; 5.G.169.237; 5.G.169.238; 5.G.169.239; 5.G.169.154; 5.G.169.157; 5.G.169.166; 5.G.169.169; 5.G.169.172; 5.G.169.175; 5.G.169.240; 5.G.169.244; 5.G.172.228; 5.G.172.229; 5.G.172.230; 5.G.172.231; 5.G.172.236; 5.G.172.237; 5.G.172.238; 5.G.172.239; 5.G.172.154; 5.G.172.157; 5.G.172.166; 5.G.172.169; 5.G.172.172; 5.G.172.175; 5.G.172.240; 5.G.172.244; 5.G.175.228; 5.G.175.229; 5.G.175.230; 5.G.175.231; 5.G.175.236; 5.G.175.237; 5.G.175.238; 5.G.175.239; 5.G.175.154; 5.G.175.157; 5.G.175.166; 5.G.175.169; 5.G.175.172; 5.G.175.175; 5.G.175.240; 5.G.175.244; 5.G.240.228; 5.G.240.229; 5.G.240.230; 5.G.240.231; 5.G.240.236; 5.G.240.237; 5.G.240.238; 5.G.240.239; 5.G.240.154; 5.G.240.157; 5.G.240.166; 5.G.240.169; 5.G.240.172; 5.G.240.175; 5.G.240.240; 5.G.240.244; 5.G.244.228; 5.G.244.229; 5.G.244.230; 5.G.244.231; 5.G.244.236; 5.G.244.237; 5.G.244.238; 5.G.244.239; 5.G.244.154; 5.G.244.157; 5.G.244.166; 5.G.244.169; 5.G.244.172; 5.G.244.175; 5.G.244.240; 5.G.244.244;

Prodrugs of 5.I

5.I.228.228; 5.I.228.229; 5.I.228.230; 5.I.228.231; 5.I.228.236; 5.I.228.237; 5.I.228.238; 5.I.228.239; 5.I.228.154; 5.I.228.157; 5.I.228.166; 5.I.228.169; 5.I.228.172; 5.I.228.175; 5.I.228.240; 5.I.228.244; 5.I.229.228; 5.I.229.229; 5.I.229.230; 5.I.229.231; 5.I.229.236; 5.I.229.237; 5.I.229.238; 5.I.229.239; 5.I.229.154; 5.I.229.157; 5.I.229.166; 5.I.229.169; 5.I.229.172; 5.I.229.175; 5.I.229.240; 5.I.229.244; 5.I.230.228; 5.I.230.229; 5.I.230.230; 5.I.230.231; 5.I.230.236; 5.I.230.237; 5.I.230.238; 5.I.230.239; 5.I.230.154; 5.I.230.157; 5.I.230.166; 5.I.230.169; 5.I.230.172; 5.I.230.175; 5.I.230.240; 5.I.230.244; 5.I.231.228; 5.I.231.229; 5.I.231.230; 5.I.231.231; 5.I.231.236; 5.I.231.237; 5.I.231.238; 5.I.231.239; 5.I.231.154; 5.I.231.157; 5.I.231.166; 5.I.231.169;

5.I.231.172; 5.I.231.175; 5.I.231.240; 5.I.231.244; 5.I.236.228; 5.I.236.229; 5.I.236.230; 5.I.236.231; 5.I.236.236; 5.I.236.237; 5.I.236.238; 5.I.236.239; 5.I.236.154; 5.I.236.157; 5.I.236.166; 5.I.236.169; 5.I.236.172; 5.I.236.175; 5.I.236.240; 5.I.236.244; 5.I.237.228; 5.I.237.229; 5.I.237.230; 5.I.237.231; 5.I.237.236; 5.I.237.237; 5.I.237.238; 5.I.237.239; 5.I.237.154; 5.I.237.157; 5.I.237.166; 5.I.237.169; 5.I.237.172; 5.I.237.175; 5.I.237.240; 5.I.237.244; 5.I.238.228; 5.I.238.229; 5.I.238.230; 5.I.238.231; 5.I.238.236; 5.I.238.237; 5.I.238.238; 5.I.238.239; 5.I.238.154; 5.I.238.157; 5.I.238.166; 5.I.238.169; 5.I.238.172; 5.I.238.175; 5.I.238.240; 5.I.238.244; 5.I.239.228; 5.I.239.229; 5.I.239.230; 5.I.239.231; 5.I.239.236; 5.I.239.237; 5.I.239.238; 5.I.239.239; 5.I.239.154; 5.I.239.157; 5.I.239.166; 5.I.239.169; 5.I.239.172; 5.I.239.175; 5.I.239.240; 5.I.239.244; 5.I.154.228; 5.I.154.229; 5.I.154.230; 5.I.154.231; 5.I.154.236; 5.I.154.237; 5.I.154.238; 5.I.154.239; 5.I.154.154; 5.I.154.157; 5.I.154.166; 5.I.154.169; 5.I.154.172; 5.I.154.175; 5.I.154.240; 5.I.154.244; 5.I.157.228; 5.I.157.229; 5.I.157.230; 5.I.157.231; 5.I.157.236; 5.I.157.237; 5.I.157.238; 5.I.157.239; 5.I.157.154; 5.I.157.157; 5.I.157.166; 5.I.157.169; 5.I.157.172; 5.I.157.175; 5.I.157.240; 5.I.157.244; 5.I.166.228; 5.I.166.229; 5.I.166.230; 5.I.166.231; 5.I.166.236; 5.I.166.237; 5.I.166.238; 5.I.166.239; 5.I.166.154; 5.I.166.157; 5.I.166.166; 5.I.166.169; 5.I.166.172; 5.I.166.175; 5.I.166.240; 5.I.166.244; 5.I.169.228; 5.I.169.229; 5.I.169.230; 5.I.169.231; 5.I.169.236; 5.I.169.237; 5.I.169.238; 5.I.169.239; 5.I.169.154; 5.I.169.157; 5.I.169.166; 5.I.169.169; 5.I.169.172; 5.I.169.175; 5.I.169.240; 5.I.169.244; 5.I.172.228; 5.I.172.229; 5.I.172.230; 5.I.172.231; 5.I.172.236; 5.I.172.237; 5.I.172.238; 5.I.172.239; 5.I.172.154; 5.I.172.157; 5.I.172.166; 5.I.172.169; 5.I.172.172; 5.I.172.175; 5.I.172.240; 5.I.172.244; 5.I.175.228; 5.I.175.229; 5.I.175.230; 5.I.175.231; 5.I.175.236; 5.I.175.237; 5.I.175.238; 5.I.175.239; 5.I.175.154; 5.I.175.157; 5.I.175.166; 5.I.175.169; 5.I.175.172; 5.I.175.175; 5.I.175.240; 5.I.175.244; 5.I.240.228; 5.I.240.229; 5.I.240.230; 5.I.240.231; 5.I.240.236; 5.I.240.237; 5.I.240.238; 5.I.240.239; 5.I.240.154; 5.I.240.157; 5.I.240.166; 5.I.240.169; 5.I.240.172; 5.I.240.175; 5.I.240.240; 5.I.240.244; 5.I.244.228; 5.I.244.229; 5.I.244.230; 5.I.244.231; 5.I.244.236; 5.I.244.237; 5.I.244.238; 5.I.244.239; 5.I.244.154; 5.I.244.157; 5.I.244.166; 5.I.244.169; 5.I.244.172; 5.I.244.175; 5.I.244.240; 5.I.244.244;

Prodrugs of 5.J

5.J.228.228; 5.J.228.229; 5.J.228.230; 5.J.228.231; 5.J.228.236; 5.J.228.237; 5.J.228.238; 5.J.228.239; 5.J.228.154; 5.J.228.157; 5.J.228.166; 5.J.228.169;

5.J.228.172; 5.J.228.175; 5.J.228.240; 5.J.228.244; 5.J.229.228; 5.J.229.229; 5.J.229.230; 5.J.229.231; 5.J.229.236; 5.J.229.237; 5.J.229.238; 5.J.229.239; 5.J.229.154; 5.J.229.157; 5.J.229.166; 5.J.229.169; 5.J.229.172; 5.J.229.175; 5.J.229.240; 5.J.229.244; 5.J.230.228; 5.J.230.229; 5.J.230.230; 5.J.230.231; 5.J.230.236; 5.J.230.237; 5.J.230.238; 5.J.230.239; 5.J.230.154; 5.J.230.157; 5.J.230.166; 5.J.230.169; 5.J.230.172; 5.J.230.175; 5.J.230.240; 5.J.230.244; 5.J.231.228; 5.J.231.229; 5.J.231.230; 5.J.231.231; 5.J.231.236; 5.J.231.237; 5.J.231.238; 5.J.231.239; 5.J.231.154; 5.J.231.157; 5.J.231.166; 5.J.231.169; 5.J.231.172; 5.J.231.175; 5.J.231.240; 5.J.231.244; 5.J.236.228; 5.J.236.229; 5.J.236.230; 5.J.236.231; 5.J.236.236; 5.J.236.237; 5.J.236.238; 5.J.236.239; 5.J.236.154; 5.J.236.157; 5.J.236.166; 5.J.236.169; 5.J.236.172; 5.J.236.175; 5.J.236.240; 5.J.236.244; 5.J.237.228; 5.J.237.229; 5.J.237.230; 5.J.237.231; 5.J.237.236; 5.J.237.237; 5.J.237.238; 5.J.237.239; 5.J.237.154; 5.J.237.157; 5.J.237.166; 5.J.237.169; 5.J.237.172; 5.J.237.175; 5.J.237.240; 5.J.237.244; 5.J.238.228; 5.J.238.229; 5.J.238.230; 5.J.238.231; 5.J.238.236; 5.J.238.237; 5.J.238.238; 5.J.238.239; 5.J.238.154; 5.J.238.157; 5.J.238.166; 5.J.238.169; 5.J.238.172; 5.J.238.175; 5.J.238.240; 5.J.238.244; 5.J.239.228; 5.J.239.229; 5.J.239.230; 5.J.239.231; 5.J.239.236; 5.J.239.237; 5.J.239.238; 5.J.239.239; 5.J.239.154; 5.J.239.157; 5.J.239.166; 5.J.239.169; 5.J.239.172; 5.J.239.175; 5.J.239.240; 5.J.239.244; 5.J.154.228; 5.J.154.229; 5.J.154.230; 5.J.154.231; 5.J.154.236; 5.J.154.237; 5.J.154.238; 5.J.154.239; 5.J.154.154; 5.J.154.157; 5.J.154.166; 5.J.154.169; 5.J.154.172; 5.J.154.175; 5.J.154.240; 5.J.154.244; 5.J.157.228; 5.J.157.229; 5.J.157.230; 5.J.157.231; 5.J.157.236; 5.J.157.237; 5.J.157.238; 5.J.157.239; 5.J.157.154; 5.J.157.157; 5.J.157.166; 5.J.157.169; 5.J.157.172; 5.J.157.175; 5.J.157.240; 5.J.157.244; 5.J.166.228; 5.J.166.229; 5.J.166.230; 5.J.166.231; 5.J.166.236; 5.J.166.237; 5.J.166.238; 5.J.166.239; 5.J.166.154; 5.J.166.157; 5.J.166.166; 5.J.166.169; 5.J.166.172; 5.J.166.175; 5.J.166.240; 5.J.166.244; 5.J.169.228; 5.J.169.229; 5.J.169.230; 5.J.169.231; 5.J.169.236; 5.J.169.237; 5.J.169.238; 5.J.169.239; 5.J.169.154; 5.J.169.157; 5.J.169.166; 5.J.169.169; 5.J.169.172; 5.J.169.175; 5.J.169.240; 5.J.169.244; 5.J.172.228; 5.J.172.229; 5.J.172.230; 5.J.172.231; 5.J.172.236; 5.J.172.237; 5.J.172.238; 5.J.172.239; 5.J.172.154; 5.J.172.157; 5.J.172.166; 5.J.172.169; 5.J.172.172; 5.J.172.175; 5.J.172.240; 5.J.172.244; 5.J.175.228; 5.J.175.229; 5.J.175.230; 5.J.175.231; 5.J.175.236; 5.J.175.237; 5.J.175.238; 5.J.175.239; 5.J.175.154; 5.J.175.157; 5.J.175.166; 5.J.175.169; 5.J.175.172; 5.J.175.175; 5.J.175.240; 5.J.175.244; 5.J.240.228; 5.J.240.229; 5.J.240.230; 5.J.240.231; 5.J.240.236; 5.J.240.237; 5.J.240.238; 5.J.240.239; 5.J.240.154; 5.J.240.157;

5.J.240.166; 5.J.240.169; 5.J.240.172; 5.J.240.175; 5.J.240.240; 5.J.240.244; 5.J.244.228; 5.J.244.229; 5.J.244.230; 5.J.244.231; 5.J.244.236; 5.J.244.237; 5.J.244.238; 5.J.244.239; 5.J.244.154; 5.J.244.157; 5.J.244.166; 5.J.244.169; 5.J.244.172; 5.J.244.175; 5.J.244.240; 5.J.244.244;

Prodrugs of 5.L

5.L.228.228; 5.L.228.229; 5.L.228.230; 5.L.228.231; 5.L.228.236; 5.L.228.237; 5.L.228.238; 5.L.228.239; 5.L.228.154; 5.L.228.157; 5.L.228.166; 5.L.228.169; 5.L.228.172; 5.L.228.175; 5.L.228.240; 5.L.228.244; 5.L.229.228; 5.L.229.229; 5.L.229.230; 5.L.229.231; 5.L.229.236; 5.L.229.237; 5.L.229.238; 5.L.229.239; 5.L.229.154; 5.L.229.157; 5.L.229.166; 5.L.229.169; 5.L.229.172; 5.L.229.175; 5.L.229.240; 5.L.229.244; 5.L.230.228; 5.L.230.229; 5.L.230.230; 5.L.230.231; 5.L.230.236; 5.L.230.237; 5.L.230.238; 5.L.230.239; 5.L.230.154; 5.L.230.157; 5.L.230.166; 5.L.230.169; 5.L.230.172; 5.L.230.175; 5.L.230.240; 5.L.230.244; 5.L.231.228; 5.L.231.229; 5.L.231.230; 5.L.231.231; 5.L.231.236; 5.L.231.237; 5.L.231.238; 5.L.231.239; 5.L.231.154; 5.L.231.157; 5.L.231.166; 5.L.231.169; 5.L.231.172; 5.L.231.175; 5.L.231.240; 5.L.231.244; 5.L.236.228; 5.L.236.229; 5.L.236.230; 5.L.236.231; 5.L.236.236; 5.L.236.237; 5.L.236.238; 5.L.236.239; 5.L.236.154; 5.L.236.157; 5.L.236.166; 5.L.236.169; 5.L.236.172; 5.L.236.175; 5.L.236.240; 5.L.236.244; 5.L.237.228; 5.L.237.229; 5.L.237.230; 5.L.237.231; 5.L.237.236; 5.L.237.237; 5.L.237.238; 5.L.237.239; 5.L.237.154; 5.L.237.157; 5.L.237.166; 5.L.237.169; 5.L.237.172; 5.L.237.175; 5.L.237.240; 5.L.237.244; 5.L.238.228; 5.L.238.229; 5.L.238.230; 5.L.238.231; 5.L.238.236; 5.L.238.237; 5.L.238.238; 5.L.238.239; 5.L.238.154; 5.L.238.157; 5.L.238.166; 5.L.238.169; 5.L.238.172; 5.L.238.175; 5.L.238.240; 5.L.238.244; 5.L.239.228; 5.L.239.229; 5.L.239.230; 5.L.239.231; 5.L.239.236; 5.L.239.237; 5.L.239.238; 5.L.239.239; 5.L.239.154; 5.L.239.157; 5.L.239.166; 5.L.239.169; 5.L.239.172; 5.L.239.175; 5.L.239.240; 5.L.239.244; 5.L.154.228; 5.L.154.229; 5.L.154.230; 5.L.154.231; 5.L.154.236; 5.L.154.237; 5.L.154.238; 5.L.154.239; 5.L.154.154; 5.L.154.157; 5.L.154.166; 5.L.154.169; 5.L.154.172; 5.L.154.175; 5.L.154.240; 5.L.154.244; 5.L.157.228; 5.L.157.229; 5.L.157.230; 5.L.157.231; 5.L.157.236; 5.L.157.237; 5.L.157.238; 5.L.157.239; 5.L.157.154; 5.L.157.157; 5.L.157.166; 5.L.157.169; 5.L.157.172; 5.L.157.175; 5.L.157.240; 5.L.157.244; 5.L.166.228; 5.L.166.229; 5.L.166.230; 5.L.166.231; 5.L.166.236; 5.L.166.237; 5.L.166.238; 5.L.166.239; 5.L.166.154; 5.L.166.157; 5.L.166.166; 5.L.166.169; 5.L.166.172; 5.L.166.175; 5.L.166.240; 5.L.166.244; 5.L.169.228; 5.L.169.229; 5.L.169.230; 5.L.169.231; 5.L.169.236; 5.L.169.237; 5.L.169.238; 5.L.169.239; 5.L.169.154;

5.L.169.157; 5.L.169.166; 5.L.169.169; 5.L.169.172; 5.L.169.175; 5.L.169.240; 5.L.169.244; 5.L.172.228; 5.L.172.229; 5.L.172.230; 5.L.172.231; 5.L.172.236; 5.L.172.237; 5.L.172.238; 5.L.172.239; 5.L.172.154; 5.L.172.157; 5.L.172.166; 5.L.172.169; 5.L.172.172; 5.L.172.175; 5.L.172.240; 5.L.172.244; 5.L.175.228; 5.L.175.229; 5.L.175.230; 5.L.175.231; 5.L.175.236; 5.L.175.237; 5.L.175.238; 5.L.175.239; 5.L.175.154; 5.L.175.157; 5.L.175.166; 5.L.175.169; 5.L.175.172; 5.L.175.175; 5.L.175.240; 5.L.175.244; 5.L.240.228; 5.L.240.229; 5.L.240.230; 5.L.240.231; 5.L.240.236; 5.L.240.237; 5.L.240.238; 5.L.240.239; 5.L.240.154; 5.L.240.157; 5.L.240.166; 5.L.240.169; 5.L.240.172; 5.L.240.175; 5.L.240.240; 5.L.240.244; 5.L.244.228; 5.L.244.229; 5.L.244.230; 5.L.244.231; 5.L.244.236; 5.L.244.237; 5.L.244.238; 5.L.244.239; 5.L.244.154; 5.L.244.157; 5.L.244.166; 5.L.244.169; 5.L.244.172; 5.L.244.175; 5.L.244.240; 5.L.244.244;

Prodrugs of 5.O

5.O.228.228; 5.O.228.229; 5.O.228.230; 5.O.228.231; 5.O.228.236; 5.O.228.237; 5.O.228.238; 5.O.228.239; 5.O.228.154; 5.O.228.157; 5.O.228.166; 5.O.228.169; 5.O.228.172; 5.O.228.175; 5.O.228.240; 5.O.228.244; 5.O.229.228; 5.O.229.229; 5.O.229.230; 5.O.229.231; 5.O.229.236; 5.O.229.237; 5.O.229.238; 5.O.229.239; 5.O.229.154; 5.O.229.157; 5.O.229.166; 5.O.229.169; 5.O.229.172; 5.O.229.175; 5.O.229.240; 5.O.229.244; 5.O.230.228; 5.O.230.229; 5.O.230.230; 5.O.230.231; 5.O.230.236; 5.O.230.237; 5.O.230.238; 5.O.230.239; 5.O.230.154; 5.O.230.157; 5.O.230.166; 5.O.230.169; 5.O.230.172; 5.O.230.175; 5.O.230.240; 5.O.230.244; 5.O.231.228; 5.O.231.229; 5.O.231.230; 5.O.231.231; 5.O.231.236; 5.O.231.237; 5.O.231.238; 5.O.231.239; 5.O.231.154; 5.O.231.157; 5.O.231.166; 5.O.231.169; 5.O.231.172; 5.O.231.175; 5.O.231.240; 5.O.231.244; 5.O.236.228; 5.O.236.229; 5.O.236.230; 5.O.236.231; 5.O.236.236; 5.O.236.237; 5.O.236.238; 5.O.236.239; 5.O.236.154; 5.O.236.157; 5.O.236.166; 5.O.236.169; 5.O.236.172; 5.O.236.175; 5.O.236.240; 5.O.236.244; 5.O.237.228; 5.O.237.229; 5.O.237.230; 5.O.237.231; 5.O.237.236; 5.O.237.237; 5.O.237.238; 5.O.237.239; 5.O.237.154; 5.O.237.157; 5.O.237.166; 5.O.237.169; 5.O.237.172; 5.O.237.175; 5.O.237.240; 5.O.237.244; 5.O.238.228; 5.O.238.229; 5.O.238.230; 5.O.238.231; 5.O.238.236; 5.O.238.237; 5.O.238.238; 5.O.238.239; 5.O.238.154; 5.O.238.157; 5.O.238.166; 5.O.238.169; 5.O.238.172; 5.O.238.175; 5.O.238.240; 5.O.238.244; 5.O.239.228; 5.O.239.229; 5.O.239.230;

5.O.239.231; 5.O.239.236; 5.O.239.237; 5.O.239.238; 5.O.239.239; 5.O.239.154; 5.O.239.157; 5.O.239.166; 5.O.239.169; 5.O.239.172; 5.O.239.175; 5.O.239.240; 5.O.239.244; 5.O.154.228; 5.O.154.229; 5.O.154.230; 5.O.154.231; 5.O.154.236; 5.O.154.237; 5.O.154.238; 5.O.154.239; 5.O.154.154; 5.O.154.157; 5.O.154.166; 5.O.154.169; 5.O.154.172; 5.O.154.175; 5.O.154.240; 5.O.154.244; 5.O.157.228; 5.O.157.229; 5.O.157.230; 5.O.157.231; 5.O.157.236; 5.O.157.237; 5.O.157.238; 5.O.157.239; 5.O.157.154; 5.O.157.157; 5.O.157.166; 5.O.157.169; 5.O.157.172; 5.O.157.175; 5.O.157.240; 5.O.157.244; 5.O.166.228; 5.O.166.229; 5.O.166.230; 5.O.166.231; 5.O.166.236; 5.O.166.237; 5.O.166.238; 5.O.166.239; 5.O.166.154; 5.O.166.157; 5.O.166.166; 5.O.166.169; 5.O.166.172; 5.O.166.175; 5.O.166.240; 5.O.166.244; 5.O.169.228; 5.O.169.229; 5.O.169.230; 5.O.169.231; 5.O.169.236; 5.O.169.237; 5.O.169.238; 5.O.169.239; 5.O.169.154; 5.O.169.157; 5.O.169.166; 5.O.169.169; 5.O.169.172; 5.O.169.175; 5.O.169.240; 5.O.169.244; 5.O.172.228; 5.O.172.229; 5.O.172.230; 5.O.172.231; 5.O.172.236; 5.O.172.237; 5.O.172.238; 5.O.172.239; 5.O.172.154; 5.O.172.157; 5.O.172.166; 5.O.172.169; 5.O.172.172; 5.O.172.175; 5.O.172.240; 5.O.172.244; 5.O.175.228; 5.O.175.229; 5.O.175.230; 5.O.175.231; 5.O.175.236; 5.O.175.237; 5.O.175.238; 5.O.175.239; 5.O.175.154; 5.O.175.157; 5.O.175.166; 5.O.175.169; 5.O.175.172; 5.O.175.175; 5.O.175.240; 5.O.175.244; 5.O.240.228; 5.O.240.229; 5.O.240.230; 5.O.240.231; 5.O.240.236; 5.O.240.237; 5.O.240.238; 5.O.240.239; 5.O.240.154; 5.O.240.157; 5.O.240.166; 5.O.240.169; 5.O.240.172; 5.O.240.175; 5.O.240.240; 5.O.240.244; 5.O.244.228; 5.O.244.229; 5.O.244.230; 5.O.244.231; 5.O.244.236; 5.O.244.237; 5.O.244.238; 5.O.244.239; 5.O.244.154; 5.O.244.157; 5.O.244.166; 5.O.244.169; 5.O.244.172; 5.O.244.175; 5.O.244.240; 5.O.244.244;

Prodrugs of 5.P

5.P.228.228; 5.P.228.229; 5.P.228.230; 5.P.228.231; 5.P.228.236; 5.P.228.237; 5.P.228.238; 5.P.228.239; 5.P.228.154; 5.P.228.157; 5.P.228.166; 5.P.228.169; 5.P.228.172; 5.P.228.175; 5.P.228.240; 5.P.228.244; 5.P.229.228; 5.P.229.229; 5.P.229.230; 5.P.229.231; 5.P.229.236; 5.P.229.237; 5.P.229.238; 5.P.229.239; 5.P.229.154; 5.P.229.157; 5.P.229.166; 5.P.229.169; 5.P.229.172; 5.P.229.175; 5.P.229.240; 5.P.229.244; 5.P.230.228; 5.P.230.229; 5.P.230.230;

5.P.230.231; 5.P.230.236; 5.P.230.237; 5.P.230.238; 5.P.230.239; 5.P.230.154; 5.P.230.157; 5.P.230.166; 5.P.230.169; 5.P.230.172; 5.P.230.175; 5.P.230.240; 5.P.230.244; 5.P.231.228; 5.P.231.229; 5.P.231.230; 5.P.231.231; 5.P.231.236; 5.P.231.237; 5.P.231.238; 5.P.231.239; 5.P.231.154; 5.P.231.157; 5.P.231.166; 5.P.231.169; 5.P.231.172; 5.P.231.175; 5.P.231.240; 5.P.231.244; 5.P.236.228; 5.P.236.229; 5.P.236.230; 5.P.236.231; 5.P.236.236; 5.P.236.237; 5.P.236.238; 5.P.236.239; 5.P.236.154; 5.P.236.157; 5.P.236.166; 5.P.236.169; 5.P.236.172; 5.P.236.175; 5.P.236.240; 5.P.236.244; 5.P.237.228; 5.P.237.229; 5.P.237.230; 5.P.237.231; 5.P.237.236; 5.P.237.237; 5.P.237.238; 5.P.237.239; 5.P.237.154; 5.P.237.157; 5.P.237.166; 5.P.237.169; 5.P.237.172; 5.P.237.175; 5.P.237.240; 5.P.237.244; 5.P.238.228; 5.P.238.229; 5.P.238.230; 5.P.238.231; 5.P.238.236; 5.P.238.237; 5.P.238.238; 5.P.238.239; 5.P.238.154; 5.P.238.157; 5.P.238.166; 5.P.238.169; 5.P.238.172; 5.P.238.175; 5.P.238.240; 5.P.238.244; 5.P.239.228; 5.P.239.229; 5.P.239.230; 5.P.239.231; 5.P.239.236; 5.P.239.237; 5.P.239.238; 5.P.239.239; 5.P.239.154; 5.P.239.157; 5.P.239.166; 5.P.239.169; 5.P.239.172; 5.P.239.175; 5.P.239.240; 5.P.239.244; 5.P.154.228; 5.P.154.229; 5.P.154.230; 5.P.154.231; 5.P.154.236; 5.P.154.237; 5.P.154.238; 5.P.154.239; 5.P.154.154; 5.P.154.157; 5.P.154.166; 5.P.154.169; 5.P.154.172; 5.P.154.175; 5.P.154.240; 5.P.154.244; 5.P.157.228; 5.P.157.229; 5.P.157.230; 5.P.157.231; 5.P.157.236; 5.P.157.237; 5.P.157.238; 5.P.157.239; 5.P.157.154; 5.P.157.157; 5.P.157.166; 5.P.157.169; 5.P.157.172; 5.P.157.175; 5.P.157.240; 5.P.157.244; 5.P.166.228; 5.P.166.229; 5.P.166.230; 5.P.166.231; 5.P.166.236; 5.P.166.237; 5.P.166.238; 5.P.166.239; 5.P.166.154; 5.P.166.157; 5.P.166.166; 5.P.166.169; 5.P.166.172; 5.P.166.175; 5.P.166.240; 5.P.166.244; 5.P.169.228; 5.P.169.229; 5.P.169.230; 5.P.169.231; 5.P.169.236; 5.P.169.237; 5.P.169.238; 5.P.169.239; 5.P.169.154; 5.P.169.157; 5.P.169.166; 5.P.169.169; 5.P.169.172; 5.P.169.175; 5.P.169.240; 5.P.169.244; 5.P.172.228; 5.P.172.229; 5.P.172.230; 5.P.172.231; 5.P.172.236; 5.P.172.237; 5.P.172.238; 5.P.172.239; 5.P.172.154; 5.P.172.157; 5.P.172.166; 5.P.172.169; 5.P.172.172; 5.P.172.175; 5.P.172.240; 5.P.172.244; 5.P.175.228; 5.P.175.229; 5.P.175.230; 5.P.175.231; 5.P.175.236; 5.P.175.237; 5.P.175.238; 5.P.175.239; 5.P.175.154; 5.P.175.157; 5.P.175.166; 5.P.175.169; 5.P.175.172; 5.P.175.175; 5.P.175.240; 5.P.175.244; 5.P.240.228; 5.P.240.229; 5.P.240.230; 5.P.240.231; 5.P.240.236; 5.P.240.237; 5.P.240.238; 5.P.240.239; 5.P.240.154; 5.P.240.157; 5.P.240.166; 5.P.240.169; 5.P.240.172; 5.P.240.175; 5.P.240.240; 5.P.240.244; 5.P.244.228; 5.P.244.229; 5.P.244.230; 5.P.244.231; 5.P.244.236; 5.P.244.237; 5.P.244.238; 5.P.244.239; 5.P.244.154; 5.P.244.157; 5.P.244.166; 5.P.244.169; 5.P.244.172; 5.P.244.175; 5.P.244.240; 5.P.244.244;

Prodrugs of 5.U

5.U.228.228; 5.U.228.229; 5.U.228.230; 5.U.228.231; 5.U.228.236; 5.U.228.237; 5.U.228.238; 5.U.228.239; 5.U.228.154; 5.U.228.157; 5.U.228.166; 5.U.228.169; 5.U.228.172; 5.U.228.175; 5.U.228.240; 5.U.228.244; 5.U.229.228; 5.U.229.229; 5.U.229.230; 5.U.229.231; 5.U.229.236; 5.U.229.237; 5.U.229.238; 5.U.229.239; 5.U.229.154; 5.U.229.157; 5.U.229.166; 5.U.229.169; 5.U.229.172; 5.U.229.175; 5.U.229.240; 5.U.229.244; 5.U.230.228; 5.U.230.229; 5.U.230.230; 5.U.230.231; 5.U.230.236; 5.U.230.237; 5.U.230.238; 5.U.230.239; 5.U.230.154; 5.U.230.157; 5.U.230.166; 5.U.230.169; 5.U.230.172; 5.U.230.175; 5.U.230.240; 5.U.230.244; 5.U.231.228; 5.U.231.229; 5.U.231.230; 5.U.231.231; 5.U.231.236; 5.U.231.237; 5.U.231.238; 5.U.231.239; 5.U.231.154; 5.U.231.157; 5.U.231.166; 5.U.231.169; 5.U.231.172; 5.U.231.175; 5.U.231.240; 5.U.231.244; 5.U.236.228; 5.U.236.229; 5.U.236.230; 5.U.236.231; 5.U.236.236; 5.U.236.237; 5.U.236.238; 5.U.236.239; 5.U.236.154; 5.U.236.157; 5.U.236.166; 5.U.236.169; 5.U.236.172; 5.U.236.175; 5.U.236.240; 5.U.236.244; 5.U.237.228; 5.U.237.229; 5.U.237.230; 5.U.237.231; 5.U.237.236; 5.U.237.237; 5.U.237.238; 5.U.237.239; 5.U.237.154; 5.U.237.157; 5.U.237.166; 5.U.237.169; 5.U.237.172; 5.U.237.175; 5.U.237.240; 5.U.237.244; 5.U.238.228; 5.U.238.229; 5.U.238.230; 5.U.238.231; 5.U.238.236; 5.U.238.237; 5.U.238.238; 5.U.238.239; 5.U.238.154; 5.U.238.157; 5.U.238.166; 5.U.238.169; 5.U.238.172; 5.U.238.175; 5.U.238.240; 5.U.238.244; 5.U.239.228; 5.U.239.229; 5.U.239.230; 5.U.239.231; 5.U.239.236; 5.U.239.237; 5.U.239.238; 5.U.239.239; 5.U.239.154; 5.U.239.157; 5.U.239.166; 5.U.239.169; 5.U.239.172; 5.U.239.175; 5.U.239.240; 5.U.239.244; 5.U.154.228; 5.U.154.229; 5.U.154.230; 5.U.154.231; 5.U.154.236; 5.U.154.237; 5.U.154.238; 5.U.154.239; 5.U.154.154; 5.U.154.157; 5.U.154.166; 5.U.154.169; 5.U.154.172; 5.U.154.175; 5.U.154.240; 5.U.154.244; 5.U.157.228; 5.U.157.229; 5.U.157.230; 5.U.157.231; 5.U.157.236; 5.U.157.237; 5.U.157.238; 5.U.157.239; 5.U.157.154; 5.U.157.157; 5.U.157.166; 5.U.157.169; 5.U.157.172; 5.U.157.175; 5.U.157.240; 5.U.157.244; 5.U.166.228; 5.U.166.229; 5.U.166.230; 5.U.166.231; 5.U.166.236; 5.U.166.237; 5.U.166.238; 5.U.166.239; 5.U.166.154; 5.U.166.157; 5.U.166.166; 5.U.166.169; 5.U.166.172; 5.U.166.175; 5.U.166.240;

5.U.166.244; 5.U.169.228; 5.U.169.229; 5.U.169.230; 5.U.169.231; 5.U.169.236; 5.U.169.237; 5.U.169.238; 5.U.169.239; 5.U.169.154; 5.U.169.157; 5.U.169.166; 5.U.169.169; 5.U.169.172; 5.U.169.175; 5.U.169.240; 5.U.169.244; 5.U.172.228; 5.U.172.229; 5.U.172.230; 5.U.172.231; 5.U.172.236; 5.U.172.237; 5.U.172.238; 5.U.172.239; 5.U.172.154; 5.U.172.157; 5.U.172.166; 5.U.172.169; 5.U.172.172; 5.U.172.175; 5.U.172.240; 5.U.172.244; 5.U.175.228; 5.U.175.229; 5.U.175.230; 5.U.175.231; 5.U.175.236; 5.U.175.237; 5.U.175.238; 5.U.175.239; 5.U.175.154; 5.U.175.157; 5.U.175.166; 5.U.175.169; 5.U.175.172; 5.U.175.175; 5.U.175.240; 5.U.175.244; 5.U.240.228; 5.U.240.229; 5.U.240.230; 5.U.240.231; 5.U.240.236; 5.U.240.237; 5.U.240.238; 5.U.240.239; 5.U.240.154; 5.U.240.157; 5.U.240.166; 5.U.240.169; 5.U.240.172; 5.U.240.175; 5.U.240.240; 5.U.240.244; 5.U.244.228; 5.U.244.229; 5.U.244.230; 5.U.244.231; 5.U.244.236; 5.U.244.237; 5.U.244.238; 5.U.244.239; 5.U.244.154; 5.U.244.157; 5.U.244.166; 5.U.244.169; 5.U.244.172; 5.U.244.175; 5.U.244.240; 5.U.244.244;

Prodrugs of 5.W

5.W.228.228; 5.W.228.229; 5.W.228.230; 5.W.228.231; 5.W.228.236; 5.W.228.237; 5.W.228.238; 5.W.228.239; 5.W.228.154; 5.W.228.157; 5.W.228.166; 5.W.228.169; 5.W.228.172; 5.W.228.175; 5.W.228.240; 5.W.228.244; 5.W.229.228; 5.W.229.229; 5.W.229.230; 5.W.229.231; 5.W.229.236; 5.W.229.237; 5.W.229.238; 5.W.229.239; 5.W.229.154; 5.W.229.157; 5.W.229.166; 5.W.229.169; 5.W.229.172; 5.W.229.175; 5.W.229.240; 5.W.229.244; 5.W.230.228; 5.W.230.229; 5.W.230.230; 5.W.230.231; 5.W.230.236; 5.W.230.237; 5.W.230.238; 5.W.230.239; 5.W.230.154; 5.W.230.157; 5.W.230.166; 5.W.230.169; 5.W.230.172; 5.W.230.175; 5.W.230.240; 5.W.230.244; 5.W.231.228; 5.W.231.229; 5.W.231.230; 5.W.231.231; 5.W.231.236; 5.W.231.237; 5.W.231.238; 5.W.231.239; 5.W.231.154; 5.W.231.157; 5.W.231.166; 5.W.231.169; 5.W.231.172; 5.W.231.175; 5.W.231.240; 5.W.231.244; 5.W.236.228; 5.W.236.229; 5.W.236.230; 5.W.236.231; 5.W.236.236; 5.W.236.237; 5.W.236.238; 5.W.236.239; 5.W.236.154; 5.W.236.157; 5.W.236.166; 5.W.236.169; 5.W.236.172; 5.W.236.175; 5.W.236.240; 5.W.236.244; 5.W.237.228; 5.W.237.229; 5.W.237.230; 5.W.237.231; 5.W.237.236; 5.W.237.237; 5.W.237.238; 5.W.237.239; 5.W.237.154; 5.W.237.157;

5.W.237.166; 5.W.237.169; 5.W.237.172; 5.W.237.175; 5.W.237.240; 5.W.237.244; 5.W.238.228; 5.W.238.229; 5.W.238.230; 5.W.238.231; 5.W.238.236; 5.W.238.237; 5.W.238.238; 5.W.238.239; 5.W.238.154; 5.W.238.157; 5.W.238.166; 5.W.238.169; 5.W.238.172; 5.W.238.175; 5.W.238.240; 5.W.238.244; 5.W.239.228; 5.W.239.229; 5.W.239.230; 5.W.239.231; 5.W.239.236; 5.W.239.237; 5.W.239.238; 5.W.239.239; 5.W.239.154; 5.W.239.157; 5.W.239.166; 5.W.239.169; 5.W.239.172; 5.W.239.175; 5.W.239.240; 5.W.239.244; 5.W.154.228; 5.W.154.229; 5.W.154.230; 5.W.154.231; 5.W.154.236; 5.W.154.237; 5.W.154.238; 5.W.154.239; 5.W.154.154; 5.W.154.157; 5.W.154.166; 5.W.154.169; 5.W.154.172; 5.W.154.175; 5.W.154.240; 5.W.154.244; 5.W.157.228; 5.W.157.229; 5.W.157.230; 5.W.157.231; 5.W.157.236; 5.W.157.237; 5.W.157.238; 5.W.157.239; 5.W.157.154; 5.W.157.157; 5.W.157.166; 5.W.157.169; 5.W.157.172; 5.W.157.175; 5.W.157.240; 5.W.157.244; 5.W.166.228; 5.W.166.229; 5.W.166.230; 5.W.166.231; 5.W.166.236; 5.W.166.237; 5.W.166.238; 5.W.166.239; 5.W.166.154; 5.W.166.157; 5.W.166.166; 5.W.166.169; 5.W.166.172; 5.W.166.175; 5.W.166.240; 5.W.166.244; 5.W.169.228; 5.W.169.229; 5.W.169.230; 5.W.169.231; 5.W.169.236; 5.W.169.237; 5.W.169.238; 5.W.169.239; 5.W.169.154; 5.W.169.157; 5.W.169.166; 5.W.169.169; 5.W.169.172; 5.W.169.175; 5.W.169.240; 5.W.169.244; 5.W.172.228; 5.W.172.229; 5.W.172.230; 5.W.172.231; 5.W.172.236; 5.W.172.237; 5.W.172.238; 5.W.172.239; 5.W.172.154; 5.W.172.157; 5.W.172.166; 5.W.172.169; 5.W.172.172; 5.W.172.175; 5.W.172.240; 5.W.172.244; 5.W.175.228; 5.W.175.229; 5.W.175.230; 5.W.175.231; 5.W.175.236; 5.W.175.237; 5.W.175.238; 5.W.175.239; 5.W.175.154; 5.W.175.157; 5.W.175.166; 5.W.175.169; 5.W.175.172; 5.W.175.175; 5.W.175.240; 5.W.175.244; 5.W.240.228; 5.W.240.229; 5.W.240.230; 5.W.240.231; 5.W.240.236; 5.W.240.237; 5.W.240.238; 5.W.240.239; 5.W.240.154; 5.W.240.157; 5.W.240.166; 5.W.240.169; 5.W.240.172; 5.W.240.175; 5.W.240.240; 5.W.240.244; 5.W.244.228; 5.W.244.229; 5.W.244.230; 5.W.244.231; 5.W.244.236; 5.W.244.237; 5.W.244.238; 5.W.244.239; 5.W.244.154; 5.W.244.157; 5.W.244.166; 5.W.244.169; 5.W.244.172; 5.W.244.175; 5.W.244.240; 5.W.244.244;

Prodrugs of 5.Y

5.Y.228.228; 5.Y.228.229; 5.Y.228.230; 5.Y.228.231; 5.Y.228.236; 5.Y.228.237; 5.Y.228.238; 5.Y.228.239; 5.Y.228.154; 5.Y.228.157; 5.Y.228.166; 5.Y.228.169; 5.Y.228.172; 5.Y.228.175; 5.Y.228.240; 5.Y.228.244; 5.Y.229.228; 5.Y.229.229; 5.Y.229.230; 5.Y.229.231; 5.Y.229.236; 5.Y.229.237; 5.Y.229.238; 5.Y.229.239; 5.Y.229.154; 5.Y.229.157; 5.Y.229.166; 5.Y.229.169; 5.Y.229.172; 5.Y.229.175; 5.Y.229.240; 5.Y.229.244; 5.Y.230.228; 5.Y.230.229; 5.Y.230.230; 5.Y.230.231; 5.Y.230.236; 5.Y.230.237; 5.Y.230.238; 5.Y.230.239; 5.Y.230.154; 5.Y.230.157; 5.Y.230.166; 5.Y.230.169; 5.Y.230.172; 5.Y.230.175; 5.Y.230.240; 5.Y.230.244; 5.Y.231.228; 5.Y.231.229; 5.Y.231.230; 5.Y.231.231; 5.Y.231.236; 5.Y.231.237; 5.Y.231.238; 5.Y.231.239; 5.Y.231.154; 5.Y.231.157; 5.Y.231.166; 5.Y.231.169; 5.Y.231.172; 5.Y.231.175; 5.Y.231.240; 5.Y.231.244; 5.Y.236.228; 5.Y.236.229; 5.Y.236.230; 5.Y.236.231; 5.Y.236.236; 5.Y.236.237; 5.Y.236.238; 5.Y.236.239; 5.Y.236.154; 5.Y.236.157; 5.Y.236.166; 5.Y.236.169; 5.Y.236.172; 5.Y.236.175; 5.Y.236.240; 5.Y.236.244; 5.Y.237.228; 5.Y.237.229; 5.Y.237.230; 5.Y.237.231; 5.Y.237.236; 5.Y.237.237; 5.Y.237.238; 5.Y.237.239; 5.Y.237.154; 5.Y.237.157; 5.Y.237.166; 5.Y.237.169; 5.Y.237.172; 5.Y.237.175; 5.Y.237.240; 5.Y.237.244; 5.Y.238.228; 5.Y.238.229; 5.Y.238.230; 5.Y.238.231; 5.Y.238.236; 5.Y.238.237; 5.Y.238.238; 5.Y.238.239; 5.Y.238.154; 5.Y.238.157; 5.Y.238.166; 5.Y.238.169; 5.Y.238.172; 5.Y.238.175; 5.Y.238.240; 5.Y.238.244; 5.Y.239.228; 5.Y.239.229; 5.Y.239.230; 5.Y.239.231; 5.Y.239.236; 5.Y.239.237; 5.Y.239.238; 5.Y.239.239; 5.Y.239.154; 5.Y.239.157; 5.Y.239.166; 5.Y.239.169; 5.Y.239.172; 5.Y.239.175; 5.Y.239.240; 5.Y.239.244; 5.Y.154.228; 5.Y.154.229; 5.Y.154.230; 5.Y.154.231; 5.Y.154.236; 5.Y.154.237; 5.Y.154.238; 5.Y.154.239; 5.Y.154.154; 5.Y.154.157; 5.Y.154.166; 5.Y.154.169; 5.Y.154.172; 5.Y.154.175; 5.Y.154.240; 5.Y.154.244; 5.Y.157.228; 5.Y.157.229; 5.Y.157.230; 5.Y.157.231; 5.Y.157.236; 5.Y.157.237; 5.Y.157.238; 5.Y.157.239; 5.Y.157.154; 5.Y.157.157; 5.Y.157.166; 5.Y.157.169; 5.Y.157.172; 5.Y.157.175; 5.Y.157.240; 5.Y.157.244; 5.Y.166.228; 5.Y.166.229; 5.Y.166.230; 5.Y.166.231; 5.Y.166.236; 5.Y.166.237; 5.Y.166.238; 5.Y.166.239; 5.Y.166.154; 5.Y.166.157; 5.Y.166.166; 5.Y.166.169; 5.Y.166.172; 5.Y.166.175; 5.Y.166.240; 5.Y.166.244; 5.Y.169.228; 5.Y.169.229; 5.Y.169.230; 5.Y.169.231; 5.Y.169.236; 5.Y.169.237; 5.Y.169.238; 5.Y.169.239; 5.Y.169.154; 5.Y.169.157; 5.Y.169.166; 5.Y.169.169; 5.Y.169.172; 5.Y.169.175; 5.Y.169.240; 5.Y.169.244; 5.Y.172.228; 5.Y.172.229; 5.Y.172.230; 5.Y.172.231; 5.Y.172.236; 5.Y.172.237; 5.Y.172.238; 5.Y.172.239; 5.Y.172.154; 5.Y.172.157; 5.Y.172.166; 5.Y.172.169; 5.Y.172.172; 5.Y.172.175; 5.Y.172.240; 5.Y.172.244; 5.Y.175.228; 5.Y.175.229; 5.Y.175.230; 5.Y.175.231; 5.Y.175.236; 5.Y.175.237; 5.Y.175.238; 5.Y.175.239; 5.Y.175.154; 5.Y.175.157; 5.Y.175.166; 5.Y.175.169; 5.Y.175.172;

5.Y.175.175; 5.Y.175.240; 5.Y.175.244; 5.Y.240.228; 5.Y.240.229; 5.Y.240.230; 5.Y.240.231; 5.Y.240.236; 5.Y.240.237; 5.Y.240.238; 5.Y.240.239; 5.Y.240.154; 5.Y.240.157; 5.Y.240.166; 5.Y.240.169; 5.Y.240.172; 5.Y.240.175; 5.Y.240.240; 5.Y.240.244; 5.Y.244.228; 5.Y.244.229; 5.Y.244.230; 5.Y.244.231; 5.Y.244.236; 5.Y.244.237; 5.Y.244.238; 5.Y.244.239; 5.Y.244.154; 5.Y.244.157; 5.Y.244.166; 5.Y.244.169; 5.Y.244.172; 5.Y.244.175; 5.Y.244.240; 5.Y.244.244;

Prodrugs of 6.B

6.B.228.228; 6.B.228.229; 6.B.228.230; 6.B.228.231; 6.B.228.236; 6.B.228.237; 6.B.228.238; 6.B.228.239; 6.B.228.154; 6.B.228.157; 6.B.228.166; 6.B.228.169; 6.B.228.172; 6.B.228.175; 6.B.228.240; 6.B.228.244; 6.B.229.228; 6.B.229.229; 6.B.229.230; 6.B.229.231; 6.B.229.236; 6.B.229.237; 6.B.229.238; 6.B.229.239; 6.B.229.154; 6.B.229.157; 6.B.229.166; 6.B.229.169; 6.B.229.172; 6.B.229.175; 6.B.229.240; 6.B.229.244; 6.B.230.228; 6.B.230.229; 6.B.230.230; 6.B.230.231; 6.B.230.236; 6.B.230.237; 6.B.230.238; 6.B.230.239; 6.B.230.154; 6.B.230.157; 6.B.230.166; 6.B.230.169; 6.B.230.172; 6.B.230.175; 6.B.230.240; 6.B.230.244; 6.B.231.228; 6.B.231.229; 6.B.231.230; 6.B.231.231; 6.B.231.236; 6.B.231.237; 6.B.231.238; 6.B.231.239; 6.B.231.154; 6.B.231.157; 6.B.231.166; 6.B.231.169; 6.B.231.172; 6.B.231.175; 6.B.231.240; 6.B.231.244; 6.B.236.228; 6.B.236.229; 6.B.236.230; 6.B.236.231; 6.B.236.236; 6.B.236.237; 6.B.236.238; 6.B.236.239; 6.B.236.154; 6.B.236.157; 6.B.236.166; 6.B.236.169; 6.B.236.172; 6.B.236.175; 6.B.236.240; 6.B.236.244; 6.B.237.228; 6.B.237.229; 6.B.237.230; 6.B.237.231; 6.B.237.236; 6.B.237.237; 6.B.237.238; 6.B.237.239; 6.B.237.154; 6.B.237.157; 6.B.237.166; 6.B.237.169; 6.B.237.172; 6.B.237.175; 6.B.237.240; 6.B.237.244; 6.B.238.228; 6.B.238.229; 6.B.238.230; 6.B.238.231; 6.B.238.236; 6.B.238.237; 6.B.238.238; 6.B.238.239; 6.B.238.154; 6.B.238.157; 6.B.238.166; 6.B.238.169; 6.B.238.172; 6.B.238.175; 6.B.238.240; 6.B.238.244; 6.B.239.228; 6.B.239.229; 6.B.239.230; 6.B.239.231; 6.B.239.236; 6.B.239.237; 6.B.239.238; 6.B.239.239; 6.B.239.154; 6.B.239.157; 6.B.239.166; 6.B.239.169; 6.B.239.172; 6.B.239.175; 6.B.239.240; 6.B.239.244; 6.B.154.228; 6.B.154.229; 6.B.154.230; 6.B.154.231; 6.B.154.236; 6.B.154.237; 6.B.154.238; 6.B.154.239; 6.B.154.154; 6.B.154.157; 6.B.154.166; 6.B.154.169; 6.B.154.172; 6.B.154.175; 6.B.154.240; 6.B.154.244; 6.B.157.228; 6.B.157.229; 6.B.157.230; 6.B.157.231; 6.B.157.236; 6.B.157.237; 6.B.157.238; 6.B.157.239; 6.B.157.154; 6.B.157.157; 6.B.157.166; 6.B.157.169; 6.B.157.172; 6.B.157.175; 6.B.157.240; 6.B.157.244; 6.B.166.228; 6.B.166.229; 6.B.166.230; 6.B.166.231; 6.B.166.236; 6.B.166.237; 6.B.166.238; 6.B.166.239; 6.B.166.154; 6.B.166.157; 6.B.166.166; 6.B.166.169; 6.B.166.172;

6.B.166.175; 6.B.166.240; 6.B.166.244; 6.B.169.228; 6.B.169.229; 6.B.169.230; 6.B.169.231; 6.B.169.236; 6.B.169.237; 6.B.169.238; 6.B.169.239; 6.B.169.154; 6.B.169.157; 6.B.169.166; 6.B.169.169; 6.B.169.172; 6.B.169.175; 6.B.169.240; 6.B.169.244; 6.B.172.228; 6.B.172.229; 6.B.172.230; 6.B.172.231; 6.B.172.236; 6.B.172.237; 6.B.172.238; 6.B.172.239; 6.B.172.154; 6.B.172.157; 6.B.172.166; 6.B.172.169; 6.B.172.172; 6.B.172.175; 6.B.172.240; 6.B.172.244; 6.B.175.228; 6.B.175.229; 6.B.175.230; 6.B.175.231; 6.B.175.236; 6.B.175.237; 6.B.175.238; 6.B.175.239; 6.B.175.154; 6.B.175.157; 6.B.175.166; 6.B.175.169; 6.B.175.172; 6.B.175.175; 6.B.175.240; 6.B.175.244; 6.B.240.228; 6.B.240.229; 6.B.240.230; 6.B.240.231; 6.B.240.236; 6.B.240.237; 6.B.240.238; 6.B.240.239; 6.B.240.154; 6.B.240.157; 6.B.240.166; 6.B.240.169; 6.B.240.172; 6.B.240.175; 6.B.240.240; 6.B.240.244; 6.B.244.228; 6.B.244.229; 6.B.244.230; 6.B.244.231; 6.B.244.236; 6.B.244.237; 6.B.244.238; 6.B.244.239; 6.B.244.154; 6.B.244.157; 6.B.244.166; 6.B.244.169; 6.B.244.172; 6.B.244.175; 6.B.244.240; 6.B.244.244;

Prodrugs of 6.D

6.D.228.228; 6.D.228.229; 6.D.228.230; 6.D.228.231; 6.D.228.236; 6.D.228.237; 6.D.228.238; 6.D.228.239; 6.D.228.154; 6.D.228.157; 6.D.228.166; 6.D.228.169; 6.D.228.172; 6.D.228.175; 6.D.228.240; 6.D.228.244; 6.D.229.228; 6.D.229.229; 6.D.229.230; 6.D.229.231; 6.D.229.236; 6.D.229.237; 6.D.229.238; 6.D.229.239; 6.D.229.154; 6.D.229.157; 6.D.229.166; 6.D.229.169; 6.D.229.172; 6.D.229.175; 6.D.229.240; 6.D.229.244; 6.D.230.228; 6.D.230.229; 6.D.230.230; 6.D.230.231; 6.D.230.236; 6.D.230.237; 6.D.230.238; 6.D.230.239; 6.D.230.154; 6.D.230.157; 6.D.230.166; 6.D.230.169; 6.D.230.172; 6.D.230.175; 6.D.230.240; 6.D.230.244; 6.D.231.228; 6.D.231.229; 6.D.231.230; 6.D.231.231; 6.D.231.236; 6.D.231.237; 6.D.231.238; 6.D.231.239; 6.D.231.154; 6.D.231.157; 6.D.231.166; 6.D.231.169; 6.D.231.172; 6.D.231.175; 6.D.231.240; 6.D.231.244; 6.D.236.228; 6.D.236.229; 6.D.236.230; 6.D.236.231; 6.D.236.236; 6.D.236.237; 6.D.236.238; 6.D.236.239; 6.D.236.154; 6.D.236.157; 6.D.236.166; 6.D.236.169; 6.D.236.172; 6.D.236.175; 6.D.236.240; 6.D.236.244; 6.D.237.228; 6.D.237.229; 6.D.237.230; 6.D.237.231; 6.D.237.236; 6.D.237.237; 6.D.237.238; 6.D.237.239; 6.D.237.154; 6.D.237.157; 6.D.237.166; 6.D.237.169; 6.D.237.172; 6.D.237.175; 6.D.237.240; 6.D.237.244; 6.D.238.228; 6.D.238.229; 6.D.238.230; 6.D.238.231; 6.D.238.236; 6.D.238.237; 6.D.238.238; 6.D.238.239; 6.D.238.154;

6.D.238.157; 6.D.238.166; 6.D.238.169; 6.D.238.172; 6.D.238.175; 6.D.238.240; 6.D.238.244; 6.D.239.228; 6.D.239.229; 6.D.239.230; 6.D.239.231; 6.D.239.236; 6.D.239.237; 6.D.239.238; 6.D.239.239; 6.D.239.154; 6.D.239.157; 6.D.239.166; 6.D.239.169; 6.D.239.172; 6.D.239.175; 6.D.239.240; 6.D.239.244; 6.D.154.228; 6.D.154.229; 6.D.154.230; 6.D.154.231; 6.D.154.236; 6.D.154.237; 6.D.154.238; 6.D.154.239; 6.D.154.154; 6.D.154.157; 6.D.154.166; 6.D.154.169; 6.D.154.172; 6.D.154.175; 6.D.154.240; 6.D.154.244; 6.D.157.228; 6.D.157.229; 6.D.157.230; 6.D.157.231; 6.D.157.236; 6.D.157.237; 6.D.157.238; 6.D.157.239; 6.D.157.154; 6.D.157.157; 6.D.157.166; 6.D.157.169; 6.D.157.172; 6.D.157.175; 6.D.157.240; 6.D.157.244; 6.D.166.228; 6.D.166.229; 6.D.166.230; 6.D.166.231; 6.D.166.236; 6.D.166.237; 6.D.166.238; 6.D.166.239; 6.D.166.154; 6.D.166.157; 6.D.166.166; 6.D.166.169; 6.D.166.172; 6.D.166.175; 6.D.166.240; 6.D.166.244; 6.D.169.228; 6.D.169.229; 6.D.169.230; 6.D.169.231; 6.D.169.236; 6.D.169.237; 6.D.169.238; 6.D.169.239; 6.D.169.154; 6.D.169.157; 6.D.169.166; 6.D.169.169; 6.D.169.172; 6.D.169.175; 6.D.169.240; 6.D.169.244; 6.D.172.228; 6.D.172.229; 6.D.172.230; 6.D.172.231; 6.D.172.236; 6.D.172.237; 6.D.172.238; 6.D.172.239; 6.D.172.154; 6.D.172.157; 6.D.172.166; 6.D.172.169; 6.D.172.172; 6.D.172.175; 6.D.172.240; 6.D.172.244; 6.D.175.228; 6.D.175.229; 6.D.175.230; 6.D.175.231; 6.D.175.236; 6.D.175.237; 6.D.175.238; 6.D.175.239; 6.D.175.154; 6.D.175.157; 6.D.175.166; 6.D.175.169; 6.D.175.172; 6.D.175.175; 6.D.175.240; 6.D.175.244; 6.D.240.228; 6.D.240.229; 6.D.240.230; 6.D.240.231; 6.D.240.236; 6.D.240.237; 6.D.240.238; 6.D.240.239; 6.D.240.154; 6.D.240.157; 6.D.240.166; 6.D.240.169; 6.D.240.172; 6.D.240.175; 6.D.240.240; 6.D.240.244; 6.D.244.228; 6.D.244.229; 6.D.244.230; 6.D.244.231; 6.D.244.236; 6.D.244.237; 6.D.244.238; 6.D.244.239; 6.D.244.154; 6.D.244.157; 6.D.244.166; 6.D.244.169; 6.D.244.172; 6.D.244.175; 6.D.244.240; 6.D.244.244;

Prodrugs of 6.E

6.E.228.228; 6.E.228.229; 6.E.228.230; 6.E.228.231; 6.E.228.236; 6.E.228.237; 6.E.228.238; 6.E.228.239; 6.E.228.154; 6.E.228.157; 6.E.228.166; 6.E.228.169; 6.E.228.172; 6.E.228.175; 6.E.228.240; 6.E.228.244; 6.E.229.228; 6.E.229.229; 6.E.229.230; 6.E.229.231; 6.E.229.236; 6.E.229.237; 6.E.229.238;

6.E.229.239; 6.E.229.154; 6.E.229.157; 6.E.229.166; 6.E.229.169; 6.E.229.172; 6.E.229.175; 6.E.229.240; 6.E.229.244; 6.E.230.228; 6.E.230.229; 6.E.230.230; 6.E.230.231; 6.E.230.236; 6.E.230.237; 6.E.230.238; 6.E.230.239; 6.E.230.154; 6.E.230.157; 6.E.230.166; 6.E.230.169; 6.E.230.172; 6.E.230.175; 6.E.230.240; 6.E.230.244; 6.E.231.228; 6.E.231.229; 6.E.231.230; 6.E.231.231; 6.E.231.236; 6.E.231.237; 6.E.231.238; 6.E.231.239; 6.E.231.154; 6.E.231.157; 6.E.231.166; 6.E.231.169; 6.E.231.172; 6.E.231.175; 6.E.231.240; 6.E.231.244; 6.E.236.228; 6.E.236.229; 6.E.236.230; 6.E.236.231; 6.E.236.236; 6.E.236.237; 6.E.236.238; 6.E.236.239; 6.E.236.154; 6.E.236.157; 6.E.236.166; 6.E.236.169; 6.E.236.172; 6.E.236.175; 6.E.236.240; 6.E.236.244; 6.E.237.228; 6.E.237.229; 6.E.237.230; 6.E.237.231; 6.E.237.236; 6.E.237.237; 6.E.237.238; 6.E.237.239; 6.E.237.154; 6.E.237.157; 6.E.237.166; 6.E.237.169; 6.E.237.172; 6.E.237.175; 6.E.237.240; 6.E.237.244; 6.E.238.228; 6.E.238.229; 6.E.238.230; 6.E.238.231; 6.E.238.236; 6.E.238.237; 6.E.238.238; 6.E.238.239; 6.E.238.154; 6.E.238.157; 6.E.238.166; 6.E.238.169; 6.E.238.172; 6.E.238.175; 6.E.238.240; 6.E.238.244; 6.E.239.228; 6.E.239.229; 6.E.239.230; 6.E.239.231; 6.E.239.236; 6.E.239.237; 6.E.239.238; 6.E.239.239; 6.E.239.154; 6.E.239.157; 6.E.239.166; 6.E.239.169; 6.E.239.172; 6.E.239.175; 6.E.239.240; 6.E.239.244; 6.E.154.228; 6.E.154.229; 6.E.154.230; 6.E.154.231; 6.E.154.236; 6.E.154.237; 6.E.154.238; 6.E.154.239; 6.E.154.154; 6.E.154.157; 6.E.154.166; 6.E.154.169; 6.E.154.172; 6.E.154.175; 6.E.154.240; 6.E.154.244; 6.E.157.228; 6.E.157.229; 6.E.157.230; 6.E.157.231; 6.E.157.236; 6.E.157.237; 6.E.157.238; 6.E.157.239; 6.E.157.154; 6.E.157.157; 6.E.157.166; 6.E.157.169; 6.E.157.172; 6.E.157.175; 6.E.157.240; 6.E.157.244; 6.E.166.228; 6.E.166.229; 6.E.166.230; 6.E.166.231; 6.E.166.236; 6.E.166.237; 6.E.166.238; 6.E.166.239; 6.E.166.154; 6.E.166.157; 6.E.166.166; 6.E.166.169; 6.E.166.172; 6.E.166.175; 6.E.166.240; 6.E.166.244; 6.E.169.228; 6.E.169.229; 6.E.169.230; 6.E.169.231; 6.E.169.236; 6.E.169.237; 6.E.169.238; 6.E.169.239; 6.E.169.154; 6.E.169.157; 6.E.169.166; 6.E.169.169; 6.E.169.172; 6.E.169.175; 6.E.169.240; 6.E.169.244; 6.E.172.228; 6.E.172.229; 6.E.172.230; 6.E.172.231; 6.E.172.236; 6.E.172.237; 6.E.172.238; 6.E.172.239; 6.E.172.154; 6.E.172.157; 6.E.172.166; 6.E.172.169; 6.E.172.172; 6.E.172.175; 6.E.172.240; 6.E.172.244; 6.E.175.228; 6.E.175.229; 6.E.175.230; 6.E.175.231; 6.E.175.236; 6.E.175.237; 6.E.175.238; 6.E.175.239; 6.E.175.154; 6.E.175.157; 6.E.175.166; 6.E.175.169; 6.E.175.172; 6.E.175.175; 6.E.175.240; 6.E.175.244; 6.E.240.228; 6.E.240.229; 6.E.240.230; 6.E.240.231; 6.E.240.236; 6.E.240.237; 6.E.240.238; 6.E.240.239; 6.E.240.154; 6.E.240.157; 6.E.240.166; 6.E.240.169; 6.E.240.172; 6.E.240.175; 6.E.240.240; 6.E.240.244; 6.E.244.228; 6.E.244.229; 6.E.244.230; 6.E.244.231; 6.E.244.236;

6.E.244.237; 6.E.244.238; 6.E.244.239; 6.E.244.154; 6.E.244.157; 6.E.244.166; 6.E.244.169; 6.E.244.172; 6.E.244.175; 6.E.244.240; 6.E.244.244;

Prodrugs of 6.G

6.G.228.228; 6.G.228.229; 6.G.228.230; 6.G.228.231; 6.G.228.236; 6.G.228.237; 6.G.228.238; 6.G.228.239; 6.G.228.154; 6.G.228.157; 6.G.228.166; 6.G.228.169; 6.G.228.172; 6.G.228.175; 6.G.228.240; 6.G.228.244; 6.G.229.228; 6.G.229.229; 6.G.229.230; 6.G.229.231; 6.G.229.236; 6.G.229.237; 6.G.229.238; 6.G.229.239; 6.G.229.154; 6.G.229.157; 6.G.229.166; 6.G.229.169; 6.G.229.172; 6.G.229.175; 6.G.229.240; 6.G.229.244; 6.G.230.228; 6.G.230.229; 6.G.230.230; 6.G.230.231; 6.G.230.236; 6.G.230.237; 6.G.230.238; 6.G.230.239; 6.G.230.154; 6.G.230.157; 6.G.230.166; 6.G.230.169; 6.G.230.172; 6.G.230.175; 6.G.230.240; 6.G.230.244; 6.G.231.228; 6.G.231.229; 6.G.231.230; 6.G.231.231; 6.G.231.236; 6.G.231.237; 6.G.231.238; 6.G.231.239; 6.G.231.154; 6.G.231.157; 6.G.231.166; 6.G.231.169; 6.G.231.172; 6.G.231.175; 6.G.231.240; 6.G.231.244; 6.G.236.228; 6.G.236.229; 6.G.236.230; 6.G.236.231; 6.G.236.236; 6.G.236.237; 6.G.236.238; 6.G.236.239; 6.G.236.154; 6.G.236.157; 6.G.236.166; 6.G.236.169; 6.G.236.172; 6.G.236.175; 6.G.236.240; 6.G.236.244; 6.G.237.228; 6.G.237.229; 6.G.237.230; 6.G.237.231; 6.G.237.236; 6.G.237.237; 6.G.237.238; 6.G.237.239; 6.G.237.154; 6.G.237.157; 6.G.237.166; 6.G.237.169; 6.G.237.172; 6.G.237.175; 6.G.237.240; 6.G.237.244; 6.G.238.228; 6.G.238.229; 6.G.238.230; 6.G.238.231; 6.G.238.236; 6.G.238.237; 6.G.238.238; 6.G.238.239; 6.G.238.154; 6.G.238.157; 6.G.238.166; 6.G.238.169; 6.G.238.172; 6.G.238.175; 6.G.238.240; 6.G.238.244; 6.G.239.228; 6.G.239.229; 6.G.239.230; 6.G.239.231; 6.G.239.236; 6.G.239.237; 6.G.239.238; 6.G.239.239; 6.G.239.154; 6.G.239.157; 6.G.239.166; 6.G.239.169; 6.G.239.172; 6.G.239.175; 6.G.239.240; 6.G.239.244; 6.G.154.228; 6.G.154.229; 6.G.154.230; 6.G.154.231; 6.G.154.236; 6.G.154.237; 6.G.154.238; 6.G.154.239; 6.G.154.154; 6.G.154.157; 6.G.154.166; 6.G.154.169; 6.G.154.172; 6.G.154.175; 6.G.154.240; 6.G.154.244; 6.G.157.228; 6.G.157.229; 6.G.157.230; 6.G.157.231; 6.G.157.236; 6.G.157.237; 6.G.157.238; 6.G.157.239; 6.G.157.154; 6.G.157.157; 6.G.157.166; 6.G.157.169; 6.G.157.172; 6.G.157.175; 6.G.157.240; 6.G.157.244; 6.G.166.228; 6.G.166.229; 6.G.166.230; 6.G.166.231; 6.G.166.236;

6.G.166.237; 6.G.166.238; 6.G.166.239; 6.G.166.154; 6.G.166.157; 6.G.166.166; 6.G.166.169; 6.G.166.172; 6.G.166.175; 6.G.166.240; 6.G.166.244; 6.G.169.228; 6.G.169.229; 6.G.169.230; 6.G.169.231; 6.G.169.236; 6.G.169.237; 6.G.169.238; 6.G.169.239; 6.G.169.154; 6.G.169.157; 6.G.169.166; 6.G.169.169; 6.G.169.172; 6.G.169.175; 6.G.169.240; 6.G.169.244; 6.G.172.228; 6.G.172.229; 6.G.172.230; 6.G.172.231; 6.G.172.236; 6.G.172.237; 6.G.172.238; 6.G.172.239; 6.G.172.154; 6.G.172.157; 6.G.172.166; 6.G.172.169; 6.G.172.172; 6.G.172.175; 6.G.172.240; 6.G.172.244; 6.G.175.228; 6.G.175.229; 6.G.175.230; 6.G.175.231; 6.G.175.236; 6.G.175.237; 6.G.175.238; 6.G.175.239; 6.G.175.154; 6.G.175.157; 6.G.175.166; 6.G.175.169; 6.G.175.172; 6.G.175.175; 6.G.175.240; 6.G.175.244; 6.G.240.228; 6.G.240.229; 6.G.240.230; 6.G.240.231; 6.G.240.236; 6.G.240.237; 6.G.240.238; 6.G.240.239; 6.G.240.154; 6.G.240.157; 6.G.240.166; 6.G.240.169; 6.G.240.172; 6.G.240.175; 6.G.240.240; 6.G.240.244; 6.G.244.228; 6.G.244.229; 6.G.244.230; 6.G.244.231; 6.G.244.236; 6.G.244.237; 6.G.244.238; 6.G.244.239; 6.G.244.154; 6.G.244.157; 6.G.244.166; 6.G.244.169; 6.G.244.172; 6.G.244.175; 6.G.244.240; 6.G.244.244;

Prodrugs of 6.I

6.I.228.228; 6.I.228.229; 6.I.228.230; 6.I.228.231; 6.I.228.236; 6.I.228.237; 6.I.228.238; 6.I.228.239; 6.I.228.154; 6.I.228.157; 6.I.228.166; 6.I.228.169; 6.I.228.172; 6.I.228.175; 6.I.228.240; 6.I.228.244; 6.I.229.228; 6.I.229.229; 6.I.229.230; 6.I.229.231; 6.I.229.236; 6.I.229.237; 6.I.229.238; 6.I.229.239; 6.I.229.154; 6.I.229.157; 6.I.229.166; 6.I.229.169; 6.I.229.172; 6.I.229.175; 6.I.229.240; 6.I.229.244; 6.I.230.228; 6.I.230.229; 6.I.230.230; 6.I.230.231; 6.I.230.236; 6.I.230.237; 6.I.230.238; 6.I.230.239; 6.I.230.154; 6.I.230.157; 6.I.230.166; 6.I.230.169; 6.I.230.172; 6.I.230.175; 6.I.230.240; 6.I.230.244; 6.I.231.228; 6.I.231.229; 6.I.231.230; 6.I.231.231; 6.I.231.236; 6.I.231.237; 6.I.231.238; 6.I.231.239; 6.I.231.154; 6.I.231.157; 6.I.231.166; 6.I.231.169; 6.I.231.172; 6.I.231.175; 6.I.231.240; 6.I.231.244; 6.I.236.228; 6.I.236.229; 6.I.236.230; 6.I.236.231; 6.I.236.236; 6.I.236.237; 6.I.236.238; 6.I.236.239; 6.I.236.154; 6.I.236.157; 6.I.236.166; 6.I.236.169; 6.I.236.172; 6.I.236.175; 6.I.236.240; 6.I.236.244; 6.I.237.228; 6.I.237.229; 6.I.237.230; 6.I.237.231; 6.I.237.236; 6.I.237.237; 6.I.237.238; 6.I.237.239; 6.I.237.154; 6.I.237.157; 6.I.237.166; 6.I.237.169; 6.I.237.172; 6.I.237.175; 6.I.237.240; 6.I.237.244;

6.I.238.228; 6.I.238.229; 6.I.238.230; 6.I.238.231; 6.I.238.236; 6.I.238.237; 6.I.238.238; 6.I.238.239; 6.I.238.154; 6.I.238.157; 6.I.238.166; 6.I.238.169; 6.I.238.172; 6.I.238.175; 6.I.238.240; 6.I.238.244; 6.I.239.228; 6.I.239.229; 6.I.239.230; 6.I.239.231; 6.I.239.236; 6.I.239.237; 6.I.239.238; 6.I.239.239; 6.I.239.154; 6.I.239.157; 6.I.239.166; 6.I.239.169; 6.I.239.172; 6.I.239.175; 6.I.239.240; 6.I.239.244; 6.I.154.228; 6.I.154.229; 6.I.154.230; 6.I.154.231; 6.I.154.236; 6.I.154.237; 6.I.154.238; 6.I.154.239; 6.I.154.154; 6.I.154.157; 6.I.154.166; 6.I.154.169; 6.I.154.172; 6.I.154.175; 6.I.154.240; 6.I.154.244; 6.I.157.228; 6.I.157.229; 6.I.157.230; 6.I.157.231; 6.I.157.236; 6.I.157.237; 6.I.157.238; 6.I.157.239; 6.I.157.154; 6.I.157.157; 6.I.157.166; 6.I.157.169; 6.I.157.172; 6.I.157.175; 6.I.157.240; 6.I.157.244; 6.I.166.228; 6.I.166.229; 6.I.166.230; 6.I.166.231; 6.I.166.236; 6.I.166.237; 6.I.166.238; 6.I.166.239; 6.I.166.154; 6.I.166.157; 6.I.166.166; 6.I.166.169; 6.I.166.172; 6.I.166.175; 6.I.166.240; 6.I.166.244; 6.I.169.228; 6.I.169.229; 6.I.169.230; 6.I.169.231; 6.I.169.236; 6.I.169.237; 6.I.169.238; 6.I.169.239; 6.I.169.154; 6.I.169.157; 6.I.169.166; 6.I.169.169; 6.I.169.172; 6.I.169.175; 6.I.169.240; 6.I.169.244; 6.I.172.228; 6.I.172.229; 6.I.172.230; 6.I.172.231; 6.I.172.236; 6.I.172.237; 6.I.172.238; 6.I.172.239; 6.I.172.154; 6.I.172.157; 6.I.172.166; 6.I.172.169; 6.I.172.172; 6.I.172.175; 6.I.172.240; 6.I.172.244; 6.I.175.228; 6.I.175.229; 6.I.175.230; 6.I.175.231; 6.I.175.236; 6.I.175.237; 6.I.175.238; 6.I.175.239; 6.I.175.154; 6.I.175.157; 6.I.175.166; 6.I.175.169; 6.I.175.172; 6.I.175.175; 6.I.175.240; 6.I.175.244; 6.I.240.228; 6.I.240.229; 6.I.240.230; 6.I.240.231; 6.I.240.236; 6.I.240.237; 6.I.240.238; 6.I.240.239; 6.I.240.154; 6.I.240.157; 6.I.240.166; 6.I.240.169; 6.I.240.172; 6.I.240.175; 6.I.240.240; 6.I.240.244; 6.I.244.228; 6.I.244.229; 6.I.244.230; 6.I.244.231; 6.I.244.236; 6.I.244.237; 6.I.244.238; 6.I.244.239; 6.I.244.154; 6.I.244.157; 6.I.244.166; 6.I.244.169; 6.I.244.172; 6.I.244.175; 6.I.244.240; 6.I.244.244;

Prodrugs of 6.J

6.J.228.228; 6.J.228.229; 6.J.228.230; 6.J.228.231; 6.J.228.236; 6.J.228.237; 6.J.228.238; 6.J.228.239; 6.J.228.154; 6.J.228.157; 6.J.228.166; 6.J.228.169; 6.J.228.172; 6.J.228.175; 6.J.228.240; 6.J.228.244; 6.J.229.228; 6.J.229.229; 6.J.229.230; 6.J.229.231; 6.J.229.236; 6.J.229.237; 6.J.229.238; 6.J.229.239; 6.J.229.154; 6.J.229.157; 6.J.229.166; 6.J.229.169; 6.J.229.172; 6.J.229.175; 6.J.229.240; 6.J.229.244; 6.J.230.228; 6.J.230.229; 6.J.230.230; 6.J.230.231; 6.J.230.236; 6.J.230.237; 6.J.230.238; 6.J.230.239; 6.J.230.154; 6.J.230.157; 6.J.230.166; 6.J.230.169; 6.J.230.172; 6.J.230.175; 6.J.230.240; 6.J.230.244;

6.J.231.228; 6.J.231.229; 6.J.231.230; 6.J.231.231; 6.J.231.236; 6.J.231.237; 6.J.231.238; 6.J.231.239; 6.J.231.154; 6.J.231.157; 6.J.231.166; 6.J.231.169; 6.J.231.172; 6.J.231.175; 6.J.231.240; 6.J.231.244; 6.J.236.228; 6.J.236.229; 6.J.236.230; 6.J.236.231; 6.J.236.236; 6.J.236.237; 6.J.236.238; 6.J.236.239; 6.J.236.154; 6.J.236.157; 6.J.236.166; 6.J.236.169; 6.J.236.172; 6.J.236.175; 6.J.236.240; 6.J.236.244; 6.J.237.228; 6.J.237.229; 6.J.237.230; 6.J.237.231; 6.J.237.236; 6.J.237.237; 6.J.237.238; 6.J.237.239; 6.J.237.154; 6.J.237.157; 6.J.237.166; 6.J.237.169; 6.J.237.172; 6.J.237.175; 6.J.237.240; 6.J.237.244; 6.J.238.228; 6.J.238.229; 6.J.238.230; 6.J.238.231; 6.J.238.236; 6.J.238.237; 6.J.238.238; 6.J.238.239; 6.J.238.154; 6.J.238.157; 6.J.238.166; 6.J.238.169; 6.J.238.172; 6.J.238.175; 6.J.238.240; 6.J.238.244; 6.J.239.228; 6.J.239.229; 6.J.239.230; 6.J.239.231; 6.J.239.236; 6.J.239.237; 6.J.239.238; 6.J.239.239; 6.J.239.154; 6.J.239.157; 6.J.239.166; 6.J.239.169; 6.J.239.172; 6.J.239.175; 6.J.239.240; 6.J.239.244; 6.J.154.228; 6.J.154.229; 6.J.154.230; 6.J.154.231; 6.J.154.236; 6.J.154.237; 6.J.154.238; 6.J.154.239; 6.J.154.154; 6.J.154.157; 6.J.154.166; 6.J.154.169; 6.J.154.172; 6.J.154.175; 6.J.154.240; 6.J.154.244; 6.J.157.228; 6.J.157.229; 6.J.157.230; 6.J.157.231; 6.J.157.236; 6.J.157.237; 6.J.157.238; 6.J.157.239; 6.J.157.154; 6.J.157.157; 6.J.157.166; 6.J.157.169; 6.J.157.172; 6.J.157.175; 6.J.157.240; 6.J.157.244; 6.J.166.228; 6.J.166.229; 6.J.166.230; 6.J.166.231; 6.J.166.236; 6.J.166.237; 6.J.166.238; 6.J.166.239; 6.J.166.154; 6.J.166.157; 6.J.166.166; 6.J.166.169; 6.J.166.172; 6.J.166.175; 6.J.166.240; 6.J.166.244; 6.J.169.228; 6.J.169.229; 6.J.169.230; 6.J.169.231; 6.J.169.236; 6.J.169.237; 6.J.169.238; 6.J.169.239; 6.J.169.154; 6.J.169.157; 6.J.169.166; 6.J.169.169; 6.J.169.172; 6.J.169.175; 6.J.169.240; 6.J.169.244; 6.J.172.228; 6.J.172.229; 6.J.172.230; 6.J.172.231; 6.J.172.236; 6.J.172.237; 6.J.172.238; 6.J.172.239; 6.J.172.154; 6.J.172.157; 6.J.172.166; 6.J.172.169; 6.J.172.172; 6.J.172.175; 6.J.172.240; 6.J.172.244; 6.J.175.228; 6.J.175.229; 6.J.175.230; 6.J.175.231; 6.J.175.236; 6.J.175.237; 6.J.175.238; 6.J.175.239; 6.J.175.154; 6.J.175.157; 6.J.175.166; 6.J.175.169; 6.J.175.172; 6.J.175.175; 6.J.175.240; 6.J.175.244; 6.J.240.228; 6.J.240.229; 6.J.240.230; 6.J.240.231; 6.J.240.236; 6.J.240.237; 6.J.240.238; 6.J.240.239; 6.J.240.154; 6.J.240.157; 6.J.240.166; 6.J.240.169; 6.J.240.172; 6.J.240.175; 6.J.240.240; 6.J.240.244; 6.J.244.228; 6.J.244.229; 6.J.244.230; 6.J.244.231; 6.J.244.236; 6.J.244.237; 6.J.244.238; 6.J.244.239; 6.J.244.154; 6.J.244.157; 6.J.244.166; 6.J.244.169; 6.J.244.172; 6.J.244.175; 6.J.244.240; 6.J.244.244;

Prodrugs of 6.L

6.L.228.228; 6.L.228.229; 6.L.228.230; 6.L.228.231; 6.L.228.236; 6.L.228.237; 6.L.228.238; 6.L.228.239; 6.L.228.154; 6.L.228.157; 6.L.228.166; 6.L.228.169; 6.L.228.172; 6.L.228.175; 6.L.228.240; 6.L.228.244; 6.L.229.228; 6.L.229.229; 6.L.229.230; 6.L.229.231; 6.L.229.236; 6.L.229.237; 6.L.229.238; 6.L.229.239; 6.L.229.154; 6.L.229.157; 6.L.229.166; 6.L.229.169; 6.L.229.172; 6.L.229.175; 6.L.229.240; 6.L.229.244; 6.L.230.228; 6.L.230.229; 6.L.230.230; 6.L.230.231; 6.L.230.236; 6.L.230.237; 6.L.230.238; 6.L.230.239; 6.L.230.154; 6.L.230.157; 6.L.230.166; 6.L.230.169; 6.L.230.172; 6.L.230.175; 6.L.230.240; 6.L.230.244; 6.L.231.228; 6.L.231.229; 6.L.231.230; 6.L.231.231; 6.L.231.236; 6.L.231.237; 6.L.231.238; 6.L.231.239; 6.L.231.154; 6.L.231.157; 6.L.231.166; 6.L.231.169; 6.L.231.172; 6.L.231.175; 6.L.231.240; 6.L.231.244; 6.L.236.228; 6.L.236.229; 6.L.236.230; 6.L.236.231; 6.L.236.236; 6.L.236.237; 6.L.236.238; 6.L.236.239; 6.L.236.154; 6.L.236.157; 6.L.236.166; 6.L.236.169; 6.L.236.172; 6.L.236.175; 6.L.236.240; 6.L.236.244; 6.L.237.228; 6.L.237.229; 6.L.237.230; 6.L.237.231; 6.L.237.236; 6.L.237.237; 6.L.237.238; 6.L.237.239; 6.L.237.154; 6.L.237.157; 6.L.237.166; 6.L.237.169; 6.L.237.172; 6.L.237.175; 6.L.237.240; 6.L.237.244; 6.L.238.228; 6.L.238.229; 6.L.238.230; 6.L.238.231; 6.L.238.236; 6.L.238.237; 6.L.238.238; 6.L.238.239; 6.L.238.154; 6.L.238.157; 6.L.238.166; 6.L.238.169; 6.L.238.172; 6.L.238.175; 6.L.238.240; 6.L.238.244; 6.L.239.228; 6.L.239.229; 6.L.239.230; 6.L.239.231; 6.L.239.236; 6.L.239.237; 6.L.239.238; 6.L.239.239; 6.L.239.154; 6.L.239.157; 6.L.239.166; 6.L.239.169; 6.L.239.172; 6.L.239.175; 6.L.239.240; 6.L.239.244; 6.L.154.228; 6.L.154.229; 6.L.154.230; 6.L.154.231; 6.L.154.236; 6.L.154.237; 6.L.154.238; 6.L.154.239; 6.L.154.154; 6.L.154.157; 6.L.154.166; 6.L.154.169; 6.L.154.172; 6.L.154.175; 6.L.154.240; 6.L.154.244; 6.L.157.228; 6.L.157.229; 6.L.157.230; 6.L.157.231; 6.L.157.236; 6.L.157.237; 6.L.157.238; 6.L.157.239; 6.L.157.154; 6.L.157.157; 6.L.157.166; 6.L.157.169; 6.L.157.172; 6.L.157.175; 6.L.157.240; 6.L.157.244; 6.L.166.228; 6.L.166.229; 6.L.166.230; 6.L.166.231; 6.L.166.236; 6.L.166.237; 6.L.166.238; 6.L.166.239; 6.L.166.154; 6.L.166.157; 6.L.166.166; 6.L.166.169; 6.L.166.172; 6.L.166.175; 6.L.166.240; 6.L.166.244; 6.L.169.228; 6.L.169.229; 6.L.169.230; 6.L.169.231; 6.L.169.236; 6.L.169.237; 6.L.169.238; 6.L.169.239; 6.L.169.154; 6.L.169.157; 6.L.169.166; 6.L.169.169; 6.L.169.172; 6.L.169.175; 6.L.169.240; 6.L.169.244; 6.L.172.228; 6.L.172.229; 6.L.172.230; 6.L.172.231; 6.L.172.236; 6.L.172.237; 6.L.172.238; 6.L.172.239; 6.L.172.154; 6.L.172.157; 6.L.172.166; 6.L.172.169; 6.L.172.172; 6.L.172.175; 6.L.172.240; 6.L.172.244; 6.L.175.228; 6.L.175.229; 6.L.175.230; 6.L.175.231; 6.L.175.236; 6.L.175.237; 6.L.175.238; 6.L.175.239; 6.L.175.154; 6.L.175.157; 6.L.175.166; 6.L.175.169; 6.L.175.172;

6.L.175.175; 6.L.175.240; 6.L.175.244; 6.L.240.228; 6.L.240.229; 6.L.240.230; 6.L.240.231; 6.L.240.236; 6.L.240.237; 6.L.240.238; 6.L.240.239; 6.L.240.154; 6.L.240.157; 6.L.240.166; 6.L.240.169; 6.L.240.172; 6.L.240.175; 6.L.240.240; 6.L.240.244; 6.L.244.228; 6.L.244.229; 6.L.244.230; 6.L.244.231; 6.L.244.236; 6.L.244.237; 6.L.244.238; 6.L.244.239; 6.L.244.154; 6.L.244.157; 6.L.244.166; 6.L.244.169; 6.L.244.172; 6.L.244.175; 6.L.244.240; 6.L.244.244;

Prodrugs of 6.O

6.O.228.228; 6.O.228.229; 6.O.228.230; 6.O.228.231; 6.O.228.236; 6.O.228.237; 6.O.228.238; 6.O.228.239; 6.O.228.154; 6.O.228.157; 6.O.228.166; 6.O.228.169; 6.O.228.172; 6.O.228.175; 6.O.228.240; 6.O.228.244; 6.O.229.228; 6.O.229.229; 6.O.229.230; 6.O.229.231; 6.O.229.236; 6.O.229.237; 6.O.229.238; 6.O.229.239; 6.O.229.154; 6.O.229.157; 6.O.229.166; 6.O.229.169; 6.O.229.172; 6.O.229.175; 6.O.229.240; 6.O.229.244; 6.O.230.228; 6.O.230.229; 6.O.230.230; 6.O.230.231; 6.O.230.236; 6.O.230.237; 6.O.230.238; 6.O.230.239; 6.O.230.154; 6.O.230.157; 6.O.230.166; 6.O.230.169; 6.O.230.172; 6.O.230.175; 6.O.230.240; 6.O.230.244; 6.O.231.228; 6.O.231.229; 6.O.231.230; 6.O.231.231; 6.O.231.236; 6.O.231.237; 6.O.231.238; 6.O.231.239; 6.O.231.154; 6.O.231.157; 6.O.231.166; 6.O.231.169; 6.O.231.172; 6.O.231.175; 6.O.231.240; 6.O.231.244; 6.O.236.228; 6.O.236.229; 6.O.236.230; 6.O.236.231; 6.O.236.236; 6.O.236.237; 6.O.236.238; 6.O.236.239; 6.O.236.154; 6.O.236.157; 6.O.236.166; 6.O.236.169; 6.O.236.172; 6.O.236.175; 6.O.236.240; 6.O.236.244; 6.O.237.228; 6.O.237.229; 6.O.237.230; 6.O.237.231; 6.O.237.236; 6.O.237.237; 6.O.237.238; 6.O.237.239; 6.O.237.154; 6.O.237.157; 6.O.237.166; 6.O.237.169; 6.O.237.172; 6.O.237.175; 6.O.237.240; 6.O.237.244; 6.O.238.228; 6.O.238.229; 6.O.238.230; 6.O.238.231; 6.O.238.236; 6.O.238.237; 6.O.238.238; 6.O.238.239; 6.O.238.154; 6.O.238.157; 6.O.238.166; 6.O.238.169; 6.O.238.172; 6.O.238.175; 6.O.238.240; 6.O.238.244; 6.O.239.228; 6.O.239.229; 6.O.239.230; 6.O.239.231; 6.O.239.236; 6.O.239.237; 6.O.239.238; 6.O.239.239; 6.O.239.154; 6.O.239.157; 6.O.239.166; 6.O.239.169; 6.O.239.172; 6.O.239.175; 6.O.239.240; 6.O.239.244; 6.O.154.228; 6.O.154.229; 6.O.154.230; 6.O.154.231; 6.O.154.236; 6.O.154.237; 6.O.154.238; 6.O.154.239; 6.O.154.154; 6.O.154.157; 6.O.154.166; 6.O.154.169; 6.O.154.172; 6.O.154.175; 6.O.154.240; 6.O.154.244; 6.O.157.228;

6.O.157.229; 6.O.157.230; 6.O.157.231; 6.O.157.236; 6.O.157.237; 6.O.157.238; 6.O.157.239; 6.O.157.154; 6.O.157.157; 6.O.157.166; 6.O.157.169; 6.O.157.172; 6.O.157.175; 6.O.157.240; 6.O.157.244; 6.O.166.228; 6.O.166.229; 6.O.166.230; 6.O.166.231; 6.O.166.236; 6.O.166.237; 6.O.166.238; 6.O.166.239; 6.O.166.154; 6.O.166.157; 6.O.166.166; 6.O.166.169; 6.O.166.172; 6.O.166.175; 6.O.166.240; 6.O.166.244; 6.O.169.228; 6.O.169.229; 6.O.169.230; 6.O.169.231; 6.O.169.236; 6.O.169.237; 6.O.169.238; 6.O.169.239; 6.O.169.154; 6.O.169.157; 6.O.169.166; 6.O.169.169; 6.O.169.172; 6.O.169.175; 6.O.169.240; 6.O.169.244; 6.O.172.228; 6.O.172.229; 6.O.172.230; 6.O.172.231; 6.O.172.236; 6.O.172.237; 6.O.172.238; 6.O.172.239; 6.O.172.154; 6.O.172.157; 6.O.172.166; 6.O.172.169; 6.O.172.172; 6.O.172.175; 6.O.172.240; 6.O.172.244; 6.O.175.228; 6.O.175.229; 6.O.175.230; 6.O.175.231; 6.O.175.236; 6.O.175.237; 6.O.175.238; 6.O.175.239; 6.O.175.154; 6.O.175.157; 6.O.175.166; 6.O.175.169; 6.O.175.172; 6.O.175.175; 6.O.175.240; 6.O.175.244; 6.O.240.228; 6.O.240.229; 6.O.240.230; 6.O.240.231; 6.O.240.236; 6.O.240.237; 6.O.240.238; 6.O.240.239; 6.O.240.154; 6.O.240.157; 6.O.240.166; 6.O.240.169; 6.O.240.172; 6.O.240.175; 6.O.240.240; 6.O.240.244; 6.O.244.228; 6.O.244.229; 6.O.244.230; 6.O.244.231; 6.O.244.236; 6.O.244.237; 6.O.244.238; 6.O.244.239; 6.O.244.154; 6.O.244.157; 6.O.244.166; 6.O.244.169; 6.O.244.172; 6.O.244.175; 6.O.244.240; 6.O.244.244;

Prodrugs of 6.P

6.P.228.228; 6.P.228.229; 6.P.228.230; 6.P.228.231; 6.P.228.236; 6.P.228.237; 6.P.228.238; 6.P.228.239; 6.P.228.154; 6.P.228.157; 6.P.228.166; 6.P.228.169; 6.P.228.172; 6.P.228.175; 6.P.228.240; 6.P.228.244; 6.P.229.228; 6.P.229.229; 6.P.229.230; 6.P.229.231; 6.P.229.236; 6.P.229.237; 6.P.229.238; 6.P.229.239; 6.P.229.154; 6.P.229.157; 6.P.229.166; 6.P.229.169; 6.P.229.172; 6.P.229.175; 6.P.229.240; 6.P.229.244; 6.P.230.228; 6.P.230.229; 6.P.230.230; 6.P.230.231; 6.P.230.236; 6.P.230.237; 6.P.230.238; 6.P.230.239; 6.P.230.154; 6.P.230.157; 6.P.230.166; 6.P.230.169; 6.P.230.172; 6.P.230.175; 6.P.230.240; 6.P.230.244; 6.P.231.228; 6.P.231.229; 6.P.231.230; 6.P.231.231; 6.P.231.236; 6.P.231.237; 6.P.231.238; 6.P.231.239; 6.P.231.154; 6.P.231.157; 6.P.231.166; 6.P.231.169; 6.P.231.172; 6.P.231.175; 6.P.231.240; 6.P.231.244; 6.P.236.228; 6.P.236.229; 6.P.236.230; 6.P.236.231; 6.P.236.236; 6.P.236.237; 6.P.236.238;

6.P.236.239; 6.P.236.154; 6.P.236.157; 6.P.236.166; 6.P.236.169; 6.P.236.172; 6.P.236.175; 6.P.236.240; 6.P.236.244; 6.P.237.228; 6.P.237.229; 6.P.237.230; 6.P.237.231; 6.P.237.236; 6.P.237.237; 6.P.237.238; 6.P.237.239; 6.P.237.154; 6.P.237.157; 6.P.237.166; 6.P.237.169; 6.P.237.172; 6.P.237.175; 6.P.237.240; 6.P.237.244; 6.P.238.228; 6.P.238.229; 6.P.238.230; 6.P.238.231; 6.P.238.236; 6.P.238.237; 6.P.238.238; 6.P.238.239; 6.P.238.154; 6.P.238.157; 6.P.238.166; 6.P.238.169; 6.P.238.172; 6.P.238.175; 6.P.238.240; 6.P.238.244; 6.P.239.228; 6.P.239.229; 6.P.239.230; 6.P.239.231; 6.P.239.236; 6.P.239.237; 6.P.239.238; 6.P.239.239; 6.P.239.154; 6.P.239.157; 6.P.239.166; 6.P.239.169; 6.P.239.172; 6.P.239.175; 6.P.239.240; 6.P.239.244; 6.P.154.228; 6.P.154.229; 6.P.154.230; 6.P.154.231; 6.P.154.236; 6.P.154.237; 6.P.154.238; 6.P.154.239; 6.P.154.154; 6.P.154.157; 6.P.154.166; 6.P.154.169; 6.P.154.172; 6.P.154.175; 6.P.154.240; 6.P.154.244; 6.P.157.228; 6.P.157.229; 6.P.157.230; 6.P.157.231; 6.P.157.236; 6.P.157.237; 6.P.157.238; 6.P.157.239; 6.P.157.154; 6.P.157.157; 6.P.157.166; 6.P.157.169; 6.P.157.172; 6.P.157.175; 6.P.157.240; 6.P.157.244; 6.P.166.228; 6.P.166.229; 6.P.166.230; 6.P.166.231; 6.P.166.236; 6.P.166.237; 6.P.166.238; 6.P.166.239; 6.P.166.154; 6.P.166.157; 6.P.166.166; 6.P.166.169; 6.P.166.172; 6.P.166.175; 6.P.166.240; 6.P.166.244; 6.P.169.228; 6.P.169.229; 6.P.169.230; 6.P.169.231; 6.P.169.236; 6.P.169.237; 6.P.169.238; 6.P.169.239; 6.P.169.154; 6.P.169.157; 6.P.169.166; 6.P.169.169; 6.P.169.172; 6.P.169.175; 6.P.169.240; 6.P.169.244; 6.P.172.228; 6.P.172.229; 6.P.172.230; 6.P.172.231; 6.P.172.236; 6.P.172.237; 6.P.172.238; 6.P.172.239; 6.P.172.154; 6.P.172.157; 6.P.172.166; 6.P.172.169; 6.P.172.172; 6.P.172.175; 6.P.172.240; 6.P.172.244; 6.P.175.228; 6.P.175.229; 6.P.175.230; 6.P.175.231; 6.P.175.236; 6.P.175.237; 6.P.175.238; 6.P.175.239; 6.P.175.154; 6.P.175.157; 6.P.175.166; 6.P.175.169; 6.P.175.172; 6.P.175.175; 6.P.175.240; 6.P.175.244; 6.P.240.228; 6.P.240.229; 6.P.240.230; 6.P.240.231; 6.P.240.236; 6.P.240.237; 6.P.240.238; 6.P.240.239; 6.P.240.154; 6.P.240.157; 6.P.240.166; 6.P.240.169; 6.P.240.172; 6.P.240.175; 6.P.240.240; 6.P.240.244; 6.P.244.228; 6.P.244.229; 6.P.244.230; 6.P.244.231; 6.P.244.236; 6.P.244.237; 6.P.244.238; 6.P.244.239; 6.P.244.154; 6.P.244.157; 6.P.244.166; 6.P.244.169; 6.P.244.172; 6.P.244.175; 6.P.244.240; 6.P.244.244;

Prodrugs of 6.U

6.U.228.228; 6.U.228.229; 6.U.228.230; 6.U.228.231; 6.U.228.236; 6.U.228.237; 6.U.228.238; 6.U.228.239; 6.U.228.154; 6.U.228.157; 6.U.228.166; 6.U.228.169; 6.U.228.172; 6.U.228.175; 6.U.228.240; 6.U.228.244; 6.U.229.228; 6.U.229.229; 6.U.229.230; 6.U.229.231;

6.U.229.236; 6.U.229.237; 6.U.229.238; 6.U.229.239; 6.U.229.154; 6.U.229.157; 6.U.229.166; 6.U.229.169; 6.U.229.172; 6.U.229.175; 6.U.229.240; 6.U.229.244; 6.U.230.228; 6.U.230.229; 6.U.230.230; 6.U.230.231; 6.U.230.236; 6.U.230.237; 6.U.230.238; 6.U.230.239; 6.U.230.154; 6.U.230.157; 6.U.230.166; 6.U.230.169; 6.U.230.172; 6.U.230.175; 6.U.230.240; 6.U.230.244; 6.U.231.228; 6.U.231.229; 6.U.231.230; 6.U.231.231; 6.U.231.236; 6.U.231.237; 6.U.231.238; 6.U.231.239; 6.U.231.154; 6.U.231.157; 6.U.231.166; 6.U.231.169; 6.U.231.172; 6.U.231.175; 6.U.231.240; 6.U.231.244; 6.U.236.228; 6.U.236.229; 6.U.236.230; 6.U.236.231; 6.U.236.236; 6.U.236.237; 6.U.236.238; 6.U.236.239; 6.U.236.154; 6.U.236.157; 6.U.236.166; 6.U.236.169; 6.U.236.172; 6.U.236.175; 6.U.236.240; 6.U.236.244; 6.U.237.228; 6.U.237.229; 6.U.237.230; 6.U.237.231; 6.U.237.236; 6.U.237.237; 6.U.237.238; 6.U.237.239; 6.U.237.154; 6.U.237.157; 6.U.237.166; 6.U.237.169; 6.U.237.172; 6.U.237.175; 6.U.237.240; 6.U.237.244; 6.U.238.228; 6.U.238.229; 6.U.238.230; 6.U.238.231; 6.U.238.236; 6.U.238.237; 6.U.238.238; 6.U.238.239; 6.U.238.154; 6.U.238.157; 6.U.238.166; 6.U.238.169; 6.U.238.172; 6.U.238.175; 6.U.238.240; 6.U.238.244; 6.U.239.228; 6.U.239.229; 6.U.239.230; 6.U.239.231; 6.U.239.236; 6.U.239.237; 6.U.239.238; 6.U.239.239; 6.U.239.154; 6.U.239.157; 6.U.239.166; 6.U.239.169; 6.U.239.172; 6.U.239.175; 6.U.239.240; 6.U.239.244; 6.U.154.228; 6.U.154.229; 6.U.154.230; 6.U.154.231; 6.U.154.236; 6.U.154.237; 6.U.154.238; 6.U.154.239; 6.U.154.154; 6.U.154.157; 6.U.154.166; 6.U.154.169; 6.U.154.172; 6.U.154.175; 6.U.154.240; 6.U.154.244; 6.U.157.228; 6.U.157.229; 6.U.157.230; 6.U.157.231; 6.U.157.236; 6.U.157.237; 6.U.157.238; 6.U.157.239; 6.U.157.154; 6.U.157.157; 6.U.157.166; 6.U.157.169; 6.U.157.172; 6.U.157.175; 6.U.157.240; 6.U.157.244; 6.U.166.228; 6.U.166.229; 6.U.166.230; 6.U.166.231; 6.U.166.236; 6.U.166.237; 6.U.166.238; 6.U.166.239; 6.U.166.154; 6.U.166.157; 6.U.166.166; 6.U.166.169; 6.U.166.172; 6.U.166.175; 6.U.166.240; 6.U.166.244; 6.U.169.228; 6.U.169.229; 6.U.169.230; 6.U.169.231; 6.U.169.236; 6.U.169.237; 6.U.169.238; 6.U.169.239; 6.U.169.154; 6.U.169.157; 6.U.169.166; 6.U.169.169; 6.U.169.172; 6.U.169.175; 6.U.169.240; 6.U.169.244; 6.U.172.228; 6.U.172.229; 6.U.172.230; 6.U.172.231; 6.U.172.236; 6.U.172.237; 6.U.172.238; 6.U.172.239; 6.U.172.154; 6.U.172.157; 6.U.172.166; 6.U.172.169; 6.U.172.172;

6.U.172.175; 6.U.172.240; 6.U.172.244; 6.U.175.228; 6.U.175.229; 6.U.175.230; 6.U.175.231; 6.U.175.236; 6.U.175.237; 6.U.175.238; 6.U.175.239; 6.U.175.154; 6.U.175.157; 6.U.175.166; 6.U.175.169; 6.U.175.172; 6.U.175.175; 6.U.175.240; 6.U.175.244; 6.U.240.228; 6.U.240.229; 6.U.240.230; 6.U.240.231; 6.U.240.236; 6.U.240.237; 6.U.240.238; 6.U.240.239; 6.U.240.154; 6.U.240.157; 6.U.240.166; 6.U.240.169; 6.U.240.172; 6.U.240.175; 6.U.240.240; 6.U.240.244; 6.U.244.228; 6.U.244.229; 6.U.244.230; 6.U.244.231; 6.U.244.236; 6.U.244.237; 6.U.244.238; 6.U.244.239; 6.U.244.154; 6.U.244.157; 6.U.244.166; 6.U.244.169; 6.U.244.172; 6.U.244.175; 6.U.244.240; 6.U.244.244;

Prodrugs of 6.W

6.W.228.228; 6.W.228.229; 6.W.228.230; 6.W.228.231; 6.W.228.236; 6.W.228.237; 6.W.228.238; 6.W.228.239; 6.W.228.154; 6.W.228.157; 6.W.228.166; 6.W.228.169; 6.W.228.172; 6.W.228.175; 6.W.228.240; 6.W.228.244; 6.W.229.228; 6.W.229.229; 6.W.229.230; 6.W.229.231; 6.W.229.236; 6.W.229.237; 6.W.229.238; 6.W.229.239; 6.W.229.154; 6.W.229.157; 6.W.229.166; 6.W.229.169; 6.W.229.172; 6.W.229.175; 6.W.229.240; 6.W.229.244; 6.W.230.228; 6.W.230.229; 6.W.230.230; 6.W.230.231; 6.W.230.236; 6.W.230.237; 6.W.230.238; 6.W.230.239; 6.W.230.154; 6.W.230.157; 6.W.230.166; 6.W.230.169; 6.W.230.172; 6.W.230.175; 6.W.230.240; 6.W.230.244; 6.W.231.228; 6.W.231.229; 6.W.231.230; 6.W.231.231; 6.W.231.236; 6.W.231.237; 6.W.231.238; 6.W.231.239; 6.W.231.154; 6.W.231.157; 6.W.231.166; 6.W.231.169; 6.W.231.172; 6.W.231.175; 6.W.231.240; 6.W.231.244; 6.W.236.228; 6.W.236.229; 6.W.236.230; 6.W.236.231; 6.W.236.236; 6.W.236.237; 6.W.236.238; 6.W.236.239; 6.W.236.154; 6.W.236.157; 6.W.236.166; 6.W.236.169; 6.W.236.172; 6.W.236.175; 6.W.236.240; 6.W.236.244; 6.W.237.228; 6.W.237.229; 6.W.237.230; 6.W.237.231; 6.W.237.236; 6.W.237.237; 6.W.237.238; 6.W.237.239; 6.W.237.154; 6.W.237.157; 6.W.237.166; 6.W.237.169; 6.W.237.172; 6.W.237.175; 6.W.237.240; 6.W.237.244; 6.W.238.228; 6.W.238.229; 6.W.238.230; 6.W.238.231; 6.W.238.236; 6.W.238.237; 6.W.238.238; 6.W.238.239; 6.W.238.154; 6.W.238.157; 6.W.238.166; 6.W.238.169; 6.W.238.172; 6.W.238.175; 6.W.238.240; 6.W.238.244; 6.W.239.228; 6.W.239.229; 6.W.239.230; 6.W.239.231; 6.W.239.236; 6.W.239.237; 6.W.239.238; 6.W.239.239;

6.W.239.154; 6.W.239.157; 6.W.239.166; 6.W.239.169; 6.W.239.172; 6.W.239.175; 6.W.239.240; 6.W.239.244; 6.W.154.228; 6.W.154.229; 6.W.154.230; 6.W.154.231; 6.W.154.236; 6.W.154.237; 6.W.154.238; 6.W.154.239; 6.W.154.154; 6.W.154.157; 6.W.154.166; 6.W.154.169; 6.W.154.172; 6.W.154.175; 6.W.154.240; 6.W.154.244; 6.W.157.228; 6.W.157.229; 6.W.157.230; 6.W.157.231; 6.W.157.236; 6.W.157.237; 6.W.157.238; 6.W.157.239; 6.W.157.154; 6.W.157.157; 6.W.157.166; 6.W.157.169; 6.W.157.172; 6.W.157.175; 6.W.157.240; 6.W.157.244; 6.W.166.228; 6.W.166.229; 6.W.166.230; 6.W.166.231; 6.W.166.236; 6.W.166.237; 6.W.166.238; 6.W.166.239; 6.W.166.154; 6.W.166.157; 6.W.166.166; 6.W.166.169; 6.W.166.172; 6.W.166.175; 6.W.166.240; 6.W.166.244; 6.W.169.228; 6.W.169.229; 6.W.169.230; 6.W.169.231; 6.W.169.236; 6.W.169.237; 6.W.169.238; 6.W.169.239; 6.W.169.154; 6.W.169.157; 6.W.169.166; 6.W.169.169; 6.W.169.172; 6.W.169.175; 6.W.169.240; 6.W.169.244; 6.W.172.228; 6.W.172.229; 6.W.172.230; 6.W.172.231; 6.W.172.236; 6.W.172.237; 6.W.172.238; 6.W.172.239; 6.W.172.154; 6.W.172.157; 6.W.172.166; 6.W.172.169; 6.W.172.172; 6.W.172.175; 6.W.172.240; 6.W.172.244; 6.W.175.228; 6.W.175.229; 6.W.175.230; 6.W.175.231; 6.W.175.236; 6.W.175.237; 6.W.175.238; 6.W.175.239; 6.W.175.154; 6.W.175.157; 6.W.175.166; 6.W.175.169; 6.W.175.172; 6.W.175.175; 6.W.175.240; 6.W.175.244; 6.W.240.228; 6.W.240.229; 6.W.240.230; 6.W.240.231; 6.W.240.236; 6.W.240.237; 6.W.240.238; 6.W.240.239; 6.W.240.154; 6.W.240.157; 6.W.240.166; 6.W.240.169; 6.W.240.172; 6.W.240.175; 6.W.240.240; 6.W.240.244; 6.W.244.228; 6.W.244.229; 6.W.244.230; 6.W.244.231; 6.W.244.236; 6.W.244.237; 6.W.244.238; 6.W.244.239; 6.W.244.154; 6.W.244.157; 6.W.244.166; 6.W.244.169; 6.W.244.172; 6.W.244.175; 6.W.244.240; 6.W.244.244;

Prodrugs of 6.Y

6.Y.228.228; 6.Y.228.229; 6.Y.228.230; 6.Y.228.231; 6.Y.228.236; 6.Y.228.237; 6.Y.228.238; 6.Y.228.239; 6.Y.228.154; 6.Y.228.157; 6.Y.228.166; 6.Y.228.169; 6.Y.228.172; 6.Y.228.175; 6.Y.228.240; 6.Y.228.244; 6.Y.229.228; 6.Y.229.229; 6.Y.229.230; 6.Y.229.231; 6.Y.229.236; 6.Y.229.237; 6.Y.229.238; 6.Y.229.239; 6.Y.229.154; 6.Y.229.157; 6.Y.229.166; 6.Y.229.169; 6.Y.229.172; 6.Y.229.175;

6.Y.229.240; 6.Y.229.244; 6.Y.230.228; 6.Y.230.229; 6.Y.230.230; 6.Y.230.231; 6.Y.230.236; 6.Y.230.237; 6.Y.230.238; 6.Y.230.239; 6.Y.230.154; 6.Y.230.157; 6.Y.230.166; 6.Y.230.169; 6.Y.230.172; 6.Y.230.175; 6.Y.230.240; 6.Y.230.244; 6.Y.231.228; 6.Y.231.229; 6.Y.231.230; 6.Y.231.231; 6.Y.231.236; 6.Y.231.237; 6.Y.231.238; 6.Y.231.239; 6.Y.231.154; 6.Y.231.157; 6.Y.231.166; 6.Y.231.169; 6.Y.231.172; 6.Y.231.175; 6.Y.231.240; 6.Y.231.244; 6.Y.236.228; 6.Y.236.229; 6.Y.236.230; 6.Y.236.231; 6.Y.236.236; 6.Y.236.237; 6.Y.236.238; 6.Y.236.239; 6.Y.236.154; 6.Y.236.157; 6.Y.236.166; 6.Y.236.169; 6.Y.236.172; 6.Y.236.175; 6.Y.236.240; 6.Y.236.244; 6.Y.237.228; 6.Y.237.229; 6.Y.237.230; 6.Y.237.231; 6.Y.237.236; 6.Y.237.237; 6.Y.237.238; 6.Y.237.239; 6.Y.237.154; 6.Y.237.157; 6.Y.237.166; 6.Y.237.169; 6.Y.237.172; 6.Y.237.175; 6.Y.237.240; 6.Y.237.244; 6.Y.238.228; 6.Y.238.229; 6.Y.238.230; 6.Y.238.231; 6.Y.238.236; 6.Y.238.237; 6.Y.238.238; 6.Y.238.239; 6.Y.238.154; 6.Y.238.157; 6.Y.238.166; 6.Y.238.169; 6.Y.238.172; 6.Y.238.175; 6.Y.238.240; 6.Y.238.244; 6.Y.239.228; 6.Y.239.229; 6.Y.239.230; 6.Y.239.231; 6.Y.239.236; 6.Y.239.237; 6.Y.239.238; 6.Y.239.239; 6.Y.239.154; 6.Y.239.157; 6.Y.239.166; 6.Y.239.169; 6.Y.239.172; 6.Y.239.175; 6.Y.239.240; 6.Y.239.244; 6.Y.154.228; 6.Y.154.229; 6.Y.154.230; 6.Y.154.231; 6.Y.154.236; 6.Y.154.237; 6.Y.154.238; 6.Y.154.239; 6.Y.154.154; 6.Y.154.157; 6.Y.154.166; 6.Y.154.169; 6.Y.154.172; 6.Y.154.175; 6.Y.154.240; 6.Y.154.244; 6.Y.157.228; 6.Y.157.229; 6.Y.157.230; 6.Y.157.231; 6.Y.157.236; 6.Y.157.237; 6.Y.157.238; 6.Y.157.239; 6.Y.157.154; 6.Y.157.157; 6.Y.157.166; 6.Y.157.169; 6.Y.157.172; 6.Y.157.175; 6.Y.157.240; 6.Y.157.244; 6.Y.166.228; 6.Y.166.229; 6.Y.166.230; 6.Y.166.231; 6.Y.166.236; 6.Y.166.237; 6.Y.166.238; 6.Y.166.239; 6.Y.166.154; 6.Y.166.157; 6.Y.166.166; 6.Y.166.169; 6.Y.166.172; 6.Y.166.175; 6.Y.166.240; 6.Y.166.244; 6.Y.169.228; 6.Y.169.229; 6.Y.169.230; 6.Y.169.231; 6.Y.169.236; 6.Y.169.237; 6.Y.169.238; 6.Y.169.239; 6.Y.169.154; 6.Y.169.157; 6.Y.169.166; 6.Y.169.169; 6.Y.169.172; 6.Y.169.175; 6.Y.169.240; 6.Y.169.244; 6.Y.172.228; 6.Y.172.229; 6.Y.172.230;

6.Y.172.231; 6.Y.172.236; 6.Y.172.237; 6.Y.172.238; 6.Y.172.239; 6.Y.172.154; 6.Y.172.157; 6.Y.172.166; 6.Y.172.169; 6.Y.172.172; 6.Y.172.175; 6.Y.172.240; 6.Y.172.244; 6.Y.175.228; 6.Y.175.229; 6.Y.175.230; 6.Y.175.231; 6.Y.175.236; 6.Y.175.237; 6.Y.175.238; 6.Y.175.239; 6.Y.175.154; 6.Y.175.157; 6.Y.175.166; 6.Y.175.169; 6.Y.175.172; 6.Y.175.175; 6.Y.175.240; 6.Y.175.244; 6.Y.240.228; 6.Y.240.229; 6.Y.240.230; 6.Y.240.231; 6.Y.240.236; 6.Y.240.237; 6.Y.240.238; 6.Y.240.239; 6.Y.240.154; 6.Y.240.157; 6.Y.240.166; 6.Y.240.169; 6.Y.240.172; 6.Y.240.175; 6.Y.240.240; 6.Y.240.244; 6.Y.244.228; 6.Y.244.229; 6.Y.244.230; 6.Y.244.231; 6.Y.244.236; 6.Y.244.237; 6.Y.244.238; 6.Y.244.239; 6.Y.244.154; 6.Y.244.157; 6.Y.244.166; 6.Y.244.169; 6.Y.244.172; 6.Y.244.175; 6.Y.244.240; 6.Y.244.244;

Prodrugs of 7.AH

7.AH.4.157; 7.AH.4.158; 7.AH.4.196; 7.AH.4.223; 7.AH.4.240; 7.AH.4.244; 7.AH.4.243; 7.AH.4.247; 7.AH.5.157; 7.AH.5.158; 7.AH.5.196; 7.AH.5.223; 7.AH.5.240; 7.AH.5.244; 7.AH.5.243; 7.AH.5.247; 7.AH.7.157; 7.AH.7.158; 7.AH.7.196; 7.AH.7.223; 7.AH.7.240; 7.AH.7.244; 7.AH.7.243; 7.AH.7.247; 7.AH.15.157; 7.AH.15.158; 7.AH.15.196; 7.AH.15.223; 7.AH.15.240; 7.AH.15.244; 7.AH.15.243; 7.AH.15.247; 7.AH.16.157; 7.AH.16.158; 7.AH.16.196; 7.AH.16.223; 7.AH.16.240; 7.AH.16.244; 7.AH.16.243; 7.AH.16.247; 7.AH.18.157; 7.AH.18.158; 7.AH.18.196; 7.AH.18.223; 7.AH.18.240; 7.AH.18.244; 7.AH.18.243; 7.AH.18.247; 7.AH.26.157; 7.AH.26.158; 7.AH.26.196; 7.AH.26.223; 7.AH.26.240; 7.AH.26.244; 7.AH.26.243; 7.AH.26.247; 7.AH.27.157; 7.AH.27.158; 7.AH.27.196; 7.AH.27.223; 7.AH.27.240; 7.AH.27.244; 7.AH.27.243; 7.AH.27.247; 7.AH.29.157; 7.AH.29.158; 7.AH.29.196; 7.AH.29.223; 7.AH.29.240; 7.AH.29.244; 7.AH.29.243; 7.AH.29.247; 7.AH.54.157; 7.AH.54.158; 7.AH.54.196; 7.AH.54.223; 7.AH.54.240; 7.AH.54.244; 7.AH.54.243; 7.AH.54.247; 7.AH.55.157; 7.AH.55.158; 7.AH.55.196; 7.AH.55.223; 7.AH.55.240; 7.AH.55.244; 7.AH.55.243; 7.AH.55.247; 7.AH.56.157; 7.AH.56.158; 7.AH.56.196; 7.AH.56.223; 7.AH.56.240; 7.AH.56.244;

7.AH.56.243; 7.AH.56.247; 7.AH.157.157; 7.AH.157.158; 7.AH.157.196; 7.AH.157.223; 7.AH.157.240; 7.AH.157.244; 7.AH.157.243; 7.AH.157.247; 7.AH.196.157; 7.AH.196.158; 7.AH.196.196; 7.AH.196.223; 7.AH.196.240; 7.AH.196.244; 7.AH.196.243; 7.AH.196.247; 7.AH.223.157; 7.AH.223.158; 7.AH.223.196; 7.AH.223.223; 7.AH.223.240; 7.AH.223.244; 7.AH.223.243; 7.AH.223.247; 7.AH.240.157; 7.AH.240.158; 7.AH.240.196; 7.AH.240.223; 7.AH.240.240; 7.AH.240.244; 7.AH.240.243; 7.AH.240.247; 7.AH.244.157; 7.AH.244.158; 7.AH.244.196; 7.AH.244.223; 7.AH.244.240; 7.AH.244.244; 7.AH.244.243; 7.AH.244.247; 7.AH.247.157; 7.AH.247.158; 7.AH.247.196; 7.AH.247.223; 7.AH.247.240; 7.AH.247.244; 7.AH.247.243; 7.AH.247.247;

Prodrugs of 7.AJ

7.AJ.4.157; 7.AJ.4.158; 7.AJ.4.196; 7.AJ.4.223; 7.AJ.4.240; 7.AJ.4.244; 7.AJ.4.243; 7.AJ.4.247; 7.AJ.5.157; 7.AJ.5.158; 7.AJ.5.196; 7.AJ.5.223; 7.AJ.5.240; 7.AJ.5.244; 7.AJ.5.243; 7.AJ.5.247; 7.AJ.7.157; 7.AJ.7.158; 7.AJ.7.196; 7.AJ.7.223; 7.AJ.7.240; 7.AJ.7.244; 7.AJ.7.243; 7.AJ.7.247; 7.AJ.15.157; 7.AJ.15.158; 7.AJ.15.196; 7.AJ.15.223; 7.AJ.15.240; 7.AJ.15.244; 7.AJ.15.243; 7.AJ.15.247; 7.AJ.16.157; 7.AJ.16.158; 7.AJ.16.196; 7.AJ.16.223; 7.AJ.16.240; 7.AJ.16.244; 7.AJ.16.243; 7.AJ.16.247; 7.AJ.18.157; 7.AJ.18.158; 7.AJ.18.196; 7.AJ.18.223; 7.AJ.18.240; 7.AJ.18.244; 7.AJ.18.243; 7.AJ.18.247; 7.AJ.26.157; 7.AJ.26.158; 7.AJ.26.196; 7.AJ.26.223; 7.AJ.26.240; 7.AJ.26.244; 7.AJ.26.243; 7.AJ.26.247; 7.AJ.27.157; 7.AJ.27.158; 7.AJ.27.196; 7.AJ.27.223; 7.AJ.27.240; 7.AJ.27.244; 7.AJ.27.243; 7.AJ.27.247; 7.AJ.29.157; 7.AJ.29.158; 7.AJ.29.196; 7.AJ.29.223; 7.AJ.29.240; 7.AJ.29.244; 7.AJ.29.243; 7.AJ.29.247; 7.AJ.54.157; 7.AJ.54.158; 7.AJ.54.196; 7.AJ.54.223; 7.AJ.54.240; 7.AJ.54.244; 7.AJ.54.243; 7.AJ.54.247; 7.AJ.55.157; 7.AJ.55.158; 7.AJ.55.196; 7.AJ.55.223; 7.AJ.55.240; 7.AJ.55.244; 7.AJ.55.243; 7.AJ.55.247; 7.AJ.56.157; 7.AJ.56.158; 7.AJ.56.196; 7.AJ.56.223; 7.AJ.56.240; 7.AJ.56.244; 7.AJ.56.243; 7.AJ.56.247; 7.AJ.157.157; 7.AJ.157.158; 7.AJ.157.196; 7.AJ.157.223; 7.AJ.157.240; 7.AJ.157.244; 7.AJ.157.243; 7.AJ.157.247; 7.AJ.196.157; 7.AJ.196.158; 7.AJ.196.196; 7.AJ.196.223; 7.AJ.196.240; 7.AJ.196.244; 7.AJ.196.243; 7.AJ.196.247; 7.AJ.223.157; 7.AJ.223.158; 7.AJ.223.196; 7.AJ.223.223; 7.AJ.223.240; 7.AJ.223.244; 7.AJ.223.243; 7.AJ.223.247; 7.AJ.240.157;

7.AJ.240.158; 7.AJ.240.196; 7.AJ.240.223; 7.AJ.240.240; 7.AJ.240.244; 7.AJ.240.243; 7.AJ.240.247; 7.AJ.244.157; 7.AJ.244.158; 7.AJ.244.196; 7.AJ.244.223; 7.AJ.244.240; 7.AJ.244.244; 7.AJ.244.243; 7.AJ.244.247; 7.AJ.247.157; 7.AJ.247.158; 7.AJ.247.196; 7.AJ.247.223; 7.AJ.247.240; 7.AJ.247.244; 7.AJ.247.243; 7.AJ.247.247;

Prodrugs of 7.AN

7.AN.4.157; 7.AN.4.158; 7.AN.4.196; 7.AN.4.223; 7.AN.4.240; 7.AN.4.244; 7.AN.4.243; 7.AN.4.247; 7.AN.5.157; 7.AN.5.158; 7.AN.5.196; 7.AN.5.223; 7.AN.5.240; 7.AN.5.244; 7.AN.5.243; 7.AN.5.247; 7.AN.7.157; 7.AN.7.158; 7.AN.7.196; 7.AN.7.223; 7.AN.7.240; 7.AN.7.244; 7.AN.7.243; 7.AN.7.247; 7.AN.15.157; 7.AN.15.158; 7.AN.15.196; 7.AN.15.223; 7.AN.15.240; 7.AN.15.244; 7.AN.15.243; 7.AN.15.247; 7.AN.16.157; 7.AN.16.158; 7.AN.16.196; 7.AN.16.223; 7.AN.16.240; 7.AN.16.244; 7.AN.16.243; 7.AN.16.247; 7.AN.18.157; 7.AN.18.158; 7.AN.18.196; 7.AN.18.223; 7.AN.18.240; 7.AN.18.244; 7.AN.18.243; 7.AN.18.247; 7.AN.26.157; 7.AN.26.158; 7.AN.26.196; 7.AN.26.223; 7.AN.26.240; 7.AN.26.244; 7.AN.26.243; 7.AN.26.247; 7.AN.27.157; 7.AN.27.158; 7.AN.27.196; 7.AN.27.223; 7.AN.27.240; 7.AN.27.244; 7.AN.27.243; 7.AN.27.247; 7.AN.29.157; 7.AN.29.158; 7.AN.29.196; 7.AN.29.223; 7.AN.29.240; 7.AN.29.244; 7.AN.29.243; 7.AN.29.247; 7.AN.54.157; 7.AN.54.158; 7.AN.54.196; 7.AN.54.223; 7.AN.54.240; 7.AN.54.244; 7.AN.54.243; 7.AN.54.247; 7.AN.55.157; 7.AN.55.158; 7.AN.55.196; 7.AN.55.223; 7.AN.55.240; 7.AN.55.244; 7.AN.55.243; 7.AN.55.247; 7.AN.56.157; 7.AN.56.158; 7.AN.56.196; 7.AN.56.223; 7.AN.56.240; 7.AN.56.244; 7.AN.56.243; 7.AN.56.247; 7.AN.157.157; 7.AN.157.158; 7.AN.157.196; 7.AN.157.223; 7.AN.157.240; 7.AN.157.244; 7.AN.157.243; 7.AN.157.247; 7.AN.196.157; 7.AN.196.158; 7.AN.196.196; 7.AN.196.223; 7.AN.196.240; 7.AN.196.244; 7.AN.196.243; 7.AN.196.247; 7.AN.223.157; 7.AN.223.158; 7.AN.223.196; 7.AN.223.223; 7.AN.223.240; 7.AN.223.244; 7.AN.223.243; 7.AN.223.247; 7.AN.240.157; 7.AN.240.158; 7.AN.240.196; 7.AN.240.223; 7.AN.240.240; 7.AN.240.244; 7.AN.240.243; 7.AN.240.247; 7.AN.244.157; 7.AN.244.158; 7.AN.244.196; 7.AN.244.223; 7.AN.244.240; 7.AN.244.244;

7.AN.244.243; 7.AN.244.247; 7.AN.247.157; 7.AN.247.158; 7.AN.247.196; 7.AN.247.223; 7.AN.247.240; 7.AN.247.244; 7.AN.247.243; 7.AN.247.247;

Prodrugs of 7.AP

7.AP.4.157; 7.AP.4.158; 7.AP.4.196; 7.AP.4.223; 7.AP.4.240; 7.AP.4.244; 7.AP.4.243; 7.AP.4.247; 7.AP.5.157; 7.AP.5.158; 7.AP.5.196; 7.AP.5.223; 7.AP.5.240; 7.AP.5.244; 7.AP.5.243; 7.AP.5.247; 7.AP.7.157; 7.AP.7.158; 7.AP.7.196; 7.AP.7.223; 7.AP.7.240; 7.AP.7.244; 7.AP.7.243; 7.AP.7.247; 7.AP.15.157; 7.AP.15.158; 7.AP.15.196; 7.AP.15.223; 7.AP.15.240; 7.AP.15.244; 7.AP.15.243; 7.AP.15.247; 7.AP.16.157; 7.AP.16.158; 7.AP.16.196; 7.AP.16.223; 7.AP.16.240; 7.AP.16.244; 7.AP.16.243; 7.AP.16.247; 7.AP.18.157; 7.AP.18.158; 7.AP.18.196; 7.AP.18.223; 7.AP.18.240; 7.AP.18.244; 7.AP.18.243; 7.AP.18.247; 7.AP.26.157; 7.AP.26.158; 7.AP.26.196; 7.AP.26.223; 7.AP.26.240; 7.AP.26.244; 7.AP.26.243; 7.AP.26.247; 7.AP.27.157; 7.AP.27.158; 7.AP.27.196; 7.AP.27.223; 7.AP.27.240; 7.AP.27.244; 7.AP.27.243; 7.AP.27.247; 7.AP.29.157; 7.AP.29.158; 7.AP.29.196; 7.AP.29.223; 7.AP.29.240; 7.AP.29.244; 7.AP.29.243; 7.AP.29.247; 7.AP.54.157; 7.AP.54.158; 7.AP.54.196; 7.AP.54.223; 7.AP.54.240; 7.AP.54.244; 7.AP.54.243; 7.AP.54.247; 7.AP.55.157; 7.AP.55.158; 7.AP.55.196; 7.AP.55.223; 7.AP.55.240; 7.AP.55.244; 7.AP.55.243; 7.AP.55.247; 7.AP.56.157; 7.AP.56.158; 7.AP.56.196; 7.AP.56.223; 7.AP.56.240; 7.AP.56.244; 7.AP.56.243; 7.AP.56.247; 7.AP.157.157; 7.AP.157.158; 7.AP.157.196; 7.AP.157.223; 7.AP.157.240; 7.AP.157.244; 7.AP.157.243; 7.AP.157.247; 7.AP.196.157; 7.AP.196.158; 7.AP.196.196; 7.AP.196.223; 7.AP.196.240; 7.AP.196.244; 7.AP.196.243; 7.AP.196.247; 7.AP.223.157; 7.AP.223.158; 7.AP.223.196; 7.AP.223.223; 7.AP.223.240; 7.AP.223.244; 7.AP.223.243; 7.AP.223.247; 7.AP.240.157; 7.AP.240.158; 7.AP.240.196; 7.AP.240.223; 7.AP.240.240; 7.AP.240.244; 7.AP.240.243; 7.AP.240.247; 7.AP.244.157; 7.AP.244.158; 7.AP.244.196; 7.AP.244.223; 7.AP.244.240; 7.AP.244.244; 7.AP.244.243; 7.AP.244.247; 7.AP.247.157; 7.AP.247.158; 7.AP.247.196; 7.AP.247.223; 7.AP.247.240; 7.AP.247.244; 7.AP.247.243; 7.AP.247.247;

Prodrugs of 7.AZ

7.AZ.4.157; 7.AZ.4.158; 7.AZ.4.196; 7.AZ.4.223; 7.AZ.4.240; 7.AZ.4.244; 7.AZ.4.243; 7.AZ.4.247; 7.AZ.5.157; 7.AZ.5.158; 7.AZ.5.196; 7.AZ.5.223; 7.AZ.5.240; 7.AZ.5.244; 7.AZ.5.243; 7.AZ.5.247; 7.AZ.7.157; 7.AZ.7.158; 7.AZ.7.196; 7.AZ.7.223; 7.AZ.7.240; 7.AZ.7.244; 7.AZ.7.243; 7.AZ.7.247; 7.AZ.15.157; 7.AZ.15.158; 7.AZ.15.196; 7.AZ.15.223; 7.AZ.15.240; 7.AZ.15.244; 7.AZ.15.243; 7.AZ.15.247; 7.AZ.16.157; 7.AZ.16.158; 7.AZ.16.196; 7.AZ.16.223; 7.AZ.16.240; 7.AZ.16.244; 7.AZ.16.243; 7.AZ.16.247; 7.AZ.18.157; 7.AZ.18.158; 7.AZ.18.196; 7.AZ.18.223; 7.AZ.18.240; 7.AZ.18.244; 7.AZ.18.243; 7.AZ.18.247; 7.AZ.26.157; 7.AZ.26.158; 7.AZ.26.196; 7.AZ.26.223; 7.AZ.26.240; 7.AZ.26.244; 7.AZ.26.243; 7.AZ.26.247; 7.AZ.27.157; 7.AZ.27.158; 7.AZ.27.196; 7.AZ.27.223; 7.AZ.27.240; 7.AZ.27.244; 7.AZ.27.243; 7.AZ.27.247; 7.AZ.29.157; 7.AZ.29.158; 7.AZ.29.196; 7.AZ.29.223; 7.AZ.29.240; 7.AZ.29.244; 7.AZ.29.243; 7.AZ.29.247; 7.AZ.54.157; 7.AZ.54.158; 7.AZ.54.196; 7.AZ.54.223; 7.AZ.54.240; 7.AZ.54.244; 7.AZ.54.243; 7.AZ.54.247; 7.AZ.55.157; 7.AZ.55.158; 7.AZ.55.196; 7.AZ.55.223; 7.AZ.55.240; 7.AZ.55.244; 7.AZ.55.243; 7.AZ.55.247; 7.AZ.56.157; 7.AZ.56.158; 7.AZ.56.196; 7.AZ.56.223; 7.AZ.56.240; 7.AZ.56.244; 7.AZ.56.243; 7.AZ.56.247; 7.AZ.157.157; 7.AZ.157.158; 7.AZ.157.196; 7.AZ.157.223; 7.AZ.157.240; 7.AZ.157.244; 7.AZ.157.243; 7.AZ.157.247; 7.AZ.196.157; 7.AZ.196.158; 7.AZ.196.196; 7.AZ.196.223; 7.AZ.196.240; 7.AZ.196.244; 7.AZ.196.243; 7.AZ.196.247; 7.AZ.223.157; 7.AZ.223.158; 7.AZ.223.196; 7.AZ.223.223; 7.AZ.223.240; 7.AZ.223.244; 7.AZ.223.243; 7.AZ.223.247; 7.AZ.240.157; 7.AZ.240.158; 7.AZ.240.196; 7.AZ.240.223; 7.AZ.240.240; 7.AZ.240.244; 7.AZ.240.243; 7.AZ.240.247; 7.AZ.244.157; 7.AZ.244.158; 7.AZ.244.196; 7.AZ.244.223; 7.AZ.244.240; 7.AZ.244.244; 7.AZ.244.243; 7.AZ.244.247; 7.AZ.247.157; 7.AZ.247.158; 7.AZ.247.196; 7.AZ.247.223; 7.AZ.247.240; 7.AZ.247.244; 7.AZ.247.243; 7.AZ.247.247;

Prodrugs of 7.BF

7.BF.4.157; 7.BF.4.158; 7.BF.4.196; 7.BF.4.223; 7.BF.4.240; 7.BF.4.244; 7.BF.4.243; 7.BF.4.247; 7.BF.5.157; 7.BF.5.158; 7.BF.5.196; 7.BF.5.223;

7.BF.5.240; 7.BF.5.244; 7.BF.5.243; 7.BF.5.247; 7.BF.7.157; 7.BF.7.158; 7.BF.7.196; 7.BF.7.223; 7.BF.7.240; 7.BF.7.244; 7.BF.7.243; 7.BF.7.247; 7.BF.15.157; 7.BF.15.158; 7.BF.15.196; 7.BF.15.223; 7.BF.15.240; 7.BF.15.244; 7.BF.15.243; 7.BF.15.247; 7.BF.16.157; 7.BF.16.158; 7.BF.16.196; 7.BF.16.223; 7.BF.16.240; 7.BF.16.244; 7.BF.16.243; 7.BF.16.247; 7.BF.18.157; 7.BF.18.158; 7.BF.18.196; 7.BF.18.223; 7.BF.18.240; 7.BF.18.244; 7.BF.18.243; 7.BF.18.247; 7.BF.26.157; 7.BF.26.158; 7.BF.26.196; 7.BF.26.223; 7.BF.26.240; 7.BF.26.244; 7.BF.26.243; 7.BF.26.247; 7.BF.27.157; 7.BF.27.158; 7.BF.27.196; 7.BF.27.223; 7.BF.27.240; 7.BF.27.244; 7.BF.27.243; 7.BF.27.247; 7.BF.29.157; 7.BF.29.158; 7.BF.29.196; 7.BF.29.223; 7.BF.29.240; 7.BF.29.244; 7.BF.29.243; 7.BF.29.247; 7.BF.54.157; 7.BF.54.158; 7.BF.54.196; 7.BF.54.223; 7.BF.54.240; 7.BF.54.244; 7.BF.54.243; 7.BF.54.247; 7.BF.55.157; 7.BF.55.158; 7.BF.55.196; 7.BF.55.223; 7.BF.55.240; 7.BF.55.244; 7.BF.55.243; 7.BF.55.247; 7.BF.56.157; 7.BF.56.158; 7.BF.56.196; 7.BF.56.223; 7.BF.56.240; 7.BF.56.244; 7.BF.56.243; 7.BF.56.247; 7.BF.157.157; 7.BF.157.158; 7.BF.157.196; 7.BF.157.223; 7.BF.157.240; 7.BF.157.244; 7.BF.157.243; 7.BF.157.247; 7.BF.196.157; 7.BF.196.158; 7.BF.196.196; 7.BF.196.223; 7.BF.196.240; 7.BF.196.244; 7.BF.196.243; 7.BF.196.247; 7.BF.223.157; 7.BF.223.158; 7.BF.223.196; 7.BF.223.223; 7.BF.223.240; 7.BF.223.244; 7.BF.223.243; 7.BF.223.247; 7.BF.240.157; 7.BF.240.158; 7.BF.240.196; 7.BF.240.223; 7.BF.240.240; 7.BF.240.244; 7.BF.240.243; 7.BF.240.247; 7.BF.244.157; 7.BF.244.158; 7.BF.244.196; 7.BF.244.223; 7.BF.244.240; 7.BF.244.244; 7.BF.244.243; 7.BF.244.247; 7.BF.247.157; 7.BF.247.158; 7.BF.247.196; 7.BF.247.223; 7.BF.247.240; 7.BF.247.244; 7.BF.247.243; 7.BF.247.247;

Prodrugs of 7.CI

7.CI.4.157; 7.CI.4.158; 7.CI.4.196; 7.CI.4.223; 7.CI.4.240; 7.CI.4.244; 7.CI.4.243; 7.CI.4.247; 7.CI.5.157; 7.CI.5.158; 7.CI.5.196; 7.CI.5.223; 7.CI.5.240; 7.CI.5.244; 7.CI.5.243; 7.CI.5.247; 7.CI.7.157; 7.CI.7.158; 7.CI.7.196; 7.CI.7.223; 7.CI.7.240; 7.CI.7.244; 7.CI.7.243; 7.CI.7.247; 7.CI.15.157; 7.CI.15.158; 7.CI.15.196; 7.CI.15.223; 7.CI.15.240; 7.CI.15.244;

7.CI.15.243; 7.CI.15.247; 7.CI.16.157; 7.CI.16.158; 7.CI.16.196; 7.CI.16.223; 7.CI.16.240; 7.CI.16.244; 7.CI.16.243; 7.CI.16.247; 7.CI.18.157; 7.CI.18.158; 7.CI.18.196; 7.CI.18.223; 7.CI.18.240; 7.CI.18.244; 7.CI.18.243; 7.CI.18.247; 7.CI.26.157; 7.CI.26.158; 7.CI.26.196; 7.CI.26.223; 7.CI.26.240; 7.CI.26.244; 7.CI.26.243; 7.CI.26.247; 7.CI.27.157; 7.CI.27.158; 7.CI.27.196; 7.CI.27.223; 7.CI.27.240; 7.CI.27.244; 7.CI.27.243; 7.CI.27.247; 7.CI.29.157; 7.CI.29.158; 7.CI.29.196; 7.CI.29.223; 7.CI.29.240; 7.CI.29.244; 7.CI.29.243; 7.CI.29.247; 7.CI.54.157; 7.CI.54.158; 7.CI.54.196; 7.CI.54.223; 7.CI.54.240; 7.CI.54.244; 7.CI.54.243; 7.CI.54.247; 7.CI.55.157; 7.CI.55.158; 7.CI.55.196; 7.CI.55.223; 7.CI.55.240; 7.CI.55.244; 7.CI.55.243; 7.CI.55.247; 7.CI.56.157; 7.CI.56.158; 7.CI.56.196; 7.CI.56.223; 7.CI.56.240; 7.CI.56.244; 7.CI.56.243; 7.CI.56.247; 7.CI.157.157; 7.CI.157.158; 7.CI.157.196; 7.CI.157.223; 7.CI.157.240; 7.CI.157.244; 7.CI.157.243; 7.CI.157.247; 7.CI.196.157; 7.CI.196.158; 7.CI.196.196; 7.CI.196.223; 7.CI.196.240; 7.CI.196.244; 7.CI.196.243; 7.CI.196.247; 7.CI.223.157; 7.CI.223.158; 7.CI.223.196; 7.CI.223.223; 7.CI.223.240; 7.CI.223.244; 7.CI.223.243; 7.CI.223.247; 7.CI.240.157; 7.CI.240.158; 7.CI.240.196; 7.CI.240.223; 7.CI.240.240; 7.CI.240.244; 7.CI.240.243; 7.CI.240.247; 7.CI.244.157; 7.CI.244.158; 7.CI.244.196; 7.CI.244.223; 7.CI.244.240; 7.CI.244.244; 7.CI.244.243; 7.CI.244.247; 7.CI.247.157; 7.CI.247.158; 7.CI.247.196; 7.CI.247.223; 7.CI.247.240; 7.CI.247.244; 7.CI.247.243; 7.CI.247.247;

Prodrugs of 7.CO

7.CO.4.157; 7.CO.4.158; 7.CO.4.196; 7.CO.4.223; 7.CO.4.240; 7.CO.4.244; 7.CO.4.243; 7.CO.4.247; 7.CO.5.157; 7.CO.5.158; 7.CO.5.196; 7.CO.5.223; 7.CO.5.240; 7.CO.5.244; 7.CO.5.243; 7.CO.5.247; 7.CO.7.157; 7.CO.7.158; 7.CO.7.196; 7.CO.7.223; 7.CO.7.240; 7.CO.7.244; 7.CO.7.243; 7.CO.7.247; 7.CO.15.157; 7.CO.15.158; 7.CO.15.196; 7.CO.15.223; 7.CO.15.240; 7.CO.15.244; 7.CO.15.243; 7.CO.15.247; 7.CO.16.157; 7.CO.16.158; 7.CO.16.196; 7.CO.16.223; 7.CO.16.240; 7.CO.16.244; 7.CO.16.243; 7.CO.16.247; 7.CO.18.157; 7.CO.18.158; 7.CO.18.196; 7.CO.18.223; 7.CO.18.240; 7.CO.18.244; 7.CO.18.243; 7.CO.18.247; 7.CO.26.157; 7.CO.26.158; 7.CO.26.196; 7.CO.26.223; 7.CO.26.240; 7.CO.26.244;

7.CO.26.243; 7.CO.26.247; 7.CO.27.157; 7.CO.27.158; 7.CO.27.196; 7.CO.27.223; 7.CO.27.240; 7.CO.27.244; 7.CO.27.243; 7.CO.27.247; 7.CO.29.157; 7.CO.29.158; 7.CO.29.196; 7.CO.29.223; 7.CO.29.240; 7.CO.29.244; 7.CO.29.243; 7.CO.29.247; 7.CO.54.157; 7.CO.54.158; 7.CO.54.196; 7.CO.54.223; 7.CO.54.240; 7.CO.54.244; 7.CO.54.243; 7.CO.54.247; 7.CO.55.157; 7.CO.55.158; 7.CO.55.196; 7.CO.55.223; 7.CO.55.240; 7.CO.55.244; 7.CO.55.243; 7.CO.55.247; 7.CO.56.157; 7.CO.56.158; 7.CO.56.196; 7.CO.56.223; 7.CO.56.240; 7.CO.56.244; 7.CO.56.243; 7.CO.56.247; 7.CO.157.157; 7.CO.157.158; 7.CO.157.196; 7.CO.157.223; 7.CO.157.240; 7.CO.157.244; 7.CO.157.243; 7.CO.157.247; 7.CO.196.157; 7.CO.196.158; 7.CO.196.196; 7.CO.196.223; 7.CO.196.240; 7.CO.196.244; 7.CO.196.243; 7.CO.196.247; 7.CO.223.157; 7.CO.223.158; 7.CO.223.196; 7.CO.223.223; 7.CO.223.240; 7.CO.223.244; 7.CO.223.243; 7.CO.223.247; 7.CO.240.157; 7.CO.240.158; 7.CO.240.196; 7.CO.240.223; 7.CO.240.240; 7.CO.240.244; 7.CO.240.243; 7.CO.240.247; 7.CO.244.157; 7.CO.244.158; 7.CO.244.196; 7.CO.244.223; 7.CO.244.240; 7.CO.244.244; 7.CO.244.243; 7.CO.244.247; 7.CO.4.157; 7.CO.4.158; 7.CO.4.196; 7.CO.4.223; 7.CO.4.240; 7.CO.4.244; 7.CO.4.243; 7.CO.4.247;

<u>Prodrugs of 8.AH</u>

8.AH.4.157; 8.AH.4.158; 8.AH.4.196; 8.AH.4.223; 8.AH.4.240; 8.AH.4.244; 8.AH.4.243; 8.AH.4.247; 8.AH.5.157; 8.AH.5.158; 8.AH.5.196; 8.AH.5.223; 8.AH.5.240; 8.AH.5.244; 8.AH.5.243; 8.AH.5.247; 8.AH.7.157; 8.AH.7.158; 8.AH.7.196; 8.AH.7.223; 8.AH.7.240; 8.AH.7.244; 8.AH.7.243; 8.AH.7.247; 8.AH.15.157; 8.AH.15.158; 8.AH.15.196; 8.AH.15.223; 8.AH.15.240; 8.AH.15.244; 8.AH.15.243; 8.AH.15.247; 8.AH.16.157; 8.AH.16.158; 8.AH.16.196; 8.AH.16.223; 8.AH.16.240; 8.AH.16.244; 8.AH.16.243; 8.AH.16.247; 8.AH.18.157; 8.AH.18.158; 8.AH.18.196; 8.AH.18.223; 8.AH.18.240; 8.AH.18.244; 8.AH.18.243; 8.AH.18.247; 8.AH.26.157; 8.AH.26.158; 8.AH.26.196; 8.AH.26.223; 8.AH.26.240; 8.AH.26.244; 8.AH.26.243; 8.AH.26.247; 8.AH.27.157; 8.AH.27.158; 8.AH.27.196; 8.AH.27.223; 8.AH.27.240; 8.AH.27.244; 8.AH.27.243; 8.AH.27.247; 8.AH.29.157; 8.AH.29.158; 8.AH.29.196; 8.AH.29.223; 8.AH.29.240;

8.AH.29.244; 8.AH.29.243; 8.AH.29.247; 8.AH.54.157; 8.AH.54.158; 8.AH.54.196; 8.AH.54.223; 8.AH.54.240; 8.AH.54.244; 8.AH.54.243; 8.AH.54.247; 8.AH.55.157; 8.AH.55.158; 8.AH.55.196; 8.AH.55.223; 8.AH.55.240; 8.AH.55.244; 8.AH.55.243; 8.AH.55.247; 8.AH.56.157; 8.AH.56.158; 8.AH.56.196; 8.AH.56.223; 8.AH.56.240; 8.AH.56.244; 8.AH.56.243; 8.AH.56.247; 8.AH.157.157; 8.AH.157.158; 8.AH.157.196; 8.AH.157.223; 8.AH.157.240; 8.AH.157.244; 8.AH.157.243; 8.AH.157.247; 8.AH.196.157; 8.AH.196.158; 8.AH.196.196; 8.AH.196.223; 8.AH.196.240; 8.AH.196.244; 8.AH.196.243; 8.AH.196.247; 8.AH.223.157; 8.AH.223.158; 8.AH.223.196; 8.AH.223.223; 8.AH.223.240; 8.AH.223.244; 8.AH.223.243; 8.AH.223.247; 8.AH.240.157; 8.AH.240.158; 8.AH.240.196; 8.AH.240.223; 8.AH.240.240; 8.AH.240.244; 8.AH.240.243; 8.AH.240.247; 8.AH.244.157; 8.AH.244.158; 8.AH.244.196; 8.AH.244.223; 8.AH.244.240; 8.AH.244.244; 8.AH.244.243; 8.AH.244.247; 8.AH.247.157; 8.AH.247.158; 8.AH.247.196; 8.AH.247.223; 8.AH.247.240; 8.AH.247.244; 8.AH.247.243; 8.AH.247.247;

Prodrugs of 8.AJ

8.AJ.4.157; 8.AJ.4.158; 8.AJ.4.196; 8.AJ.4.223; 8.AJ.4.240; 8.AJ.4.244; 8.AJ.4.243; 8.AJ.4.247; 8.AJ.5.157; 8.AJ.5.158; 8.AJ.5.196; 8.AJ.5.223; 8.AJ.5.240; 8.AJ.5.244; 8.AJ.5.243; 8.AJ.5.247; 8.AJ.7.157; 8.AJ.7.158; 8.AJ.7.196; 8.AJ.7.223; 8.AJ.7.240; 8.AJ.7.244; 8.AJ.7.243; 8.AJ.7.247; 8.AJ.15.157; 8.AJ.15.158; 8.AJ.15.196; 8.AJ.15.223; 8.AJ.15.240; 8.AJ.15.244; 8.AJ.15.243; 8.AJ.15.247; 8.AJ.16.157; 8.AJ.16.158; 8.AJ.16.196; 8.AJ.16.223; 8.AJ.16.240; 8.AJ.16.244; 8.AJ.16.243; 8.AJ.16.247; 8.AJ.18.157; 8.AJ.18.158; 8.AJ.18.196; 8.AJ.18.223; 8.AJ.18.240; 8.AJ.18.244; 8.AJ.18.243; 8.AJ.18.247; 8.AJ.26.157; 8.AJ.26.158; 8.AJ.26.196; 8.AJ.26.223; 8.AJ.26.240; 8.AJ.26.244; 8.AJ.26.243; 8.AJ.26.247; 8.AJ.27.157; 8.AJ.27.158; 8.AJ.27.196; 8.AJ.27.223; 8.AJ.27.240; 8.AJ.27.244; 8.AJ.27.243; 8.AJ.27.247; 8.AJ.29.157; 8.AJ.29.158; 8.AJ.29.196; 8.AJ.29.223; 8.AJ.29.240; 8.AJ.29.244; 8.AJ.29.243; 8.AJ.29.247; 8.AJ.54.157; 8.AJ.54.158; 8.AJ.54.196; 8.AJ.54.223; 8.AJ.54.240; 8.AJ.54.244; 8.AJ.54.243; 8.AJ.54.247; 8.AJ.55.157; 8.AJ.55.158; 8.AJ.55.196; 8.AJ.55.223; 8.AJ.55.240; 8.AJ.55.244; 8.AJ.55.243; 8.AJ.55.247; 8.AJ.56.157; 8.AJ.56.158; 8.AJ.56.196; 8.AJ.56.223; 8.AJ.56.240; 8.AJ.56.244; 8.AJ.56.243; 8.AJ.56.247;

8.AJ.157.157; 8.AJ.157.158; 8.AJ.157.196; 8.AJ.157.223; 8.AJ.157.240; 8.AJ.157.244; 8.AJ.157.243; 8.AJ.157.247; 8.AJ.196.157; 8.AJ.196.158; 8.AJ.196.196; 8.AJ.196.223; 8.AJ.196.240; 8.AJ.196.244; 8.AJ.196.243; 8.AJ.196.247; 8.AJ.223.157; 8.AJ.223.158; 8.AJ.223.196; 8.AJ.223.223; 8.AJ.223.240; 8.AJ.223.244; 8.AJ.223.243; 8.AJ.223.247; 8.AJ.240.157; 8.AJ.240.158; 8.AJ.240.196; 8.AJ.240.223; 8.AJ.240.240; 8.AJ.240.244; 8.AJ.240.243; 8.AJ.240.247; 8.AJ.244.157; 8.AJ.244.158; 8.AJ.244.196; 8.AJ.244.223; 8.AJ.244.240; 8.AJ.244.244; 8.AJ.244.243; 8.AJ.244.247; 8.AJ.247.157; 8.AJ.247.158; 8.AJ.247.196; 8.AJ.247.223; 8.AJ.247.240; 8.AJ.247.244; 8.AJ.247.243; 8.AJ.247.247;

Prodrugs of 8.AN

8.AN.4.157; 8.AN.4.158; 8.AN.4.196; 8.AN.4.223; 8.AN.4.240; 8.AN.4.244; 8.AN.4.243; 8.AN.4.247; 8.AN.5.157; 8.AN.5.158; 8.AN.5.196; 8.AN.5.223; 8.AN.5.240; 8.AN.5.244; 8.AN.5.243; 8.AN.5.247; 8.AN.7.157; 8.AN.7.158; 8.AN.7.196; 8.AN.7.223; 8.AN.7.240; 8.AN.7.244; 8.AN.7.243; 8.AN.7.247; 8.AN.15.157; 8.AN.15.158; 8.AN.15.196; 8.AN.15.223; 8.AN.15.240; 8.AN.15.244; 8.AN.15.243; 8.AN.15.247; 8.AN.16.157; 8.AN.16.158; 8.AN.16.196; 8.AN.16.223; 8.AN.16.240; 8.AN.16.244; 8.AN.16.243; 8.AN.16.247; 8.AN.18.157; 8.AN.18.158; 8.AN.18.196; 8.AN.18.223; 8.AN.18.240; 8.AN.18.244; 8.AN.18.243; 8.AN.18.247; 8.AN.26.157; 8.AN.26.158; 8.AN.26.196; 8.AN.26.223; 8.AN.26.240; 8.AN.26.244; 8.AN.26.243; 8.AN.26.247; 8.AN.27.157; 8.AN.27.158; 8.AN.27.196; 8.AN.27.223; 8.AN.27.240; 8.AN.27.244; 8.AN.27.243; 8.AN.27.247; 8.AN.29.157; 8.AN.29.158; 8.AN.29.196; 8.AN.29.223; 8.AN.29.240; 8.AN.29.244; 8.AN.29.243; 8.AN.29.247; 8.AN.54.157; 8.AN.54.158; 8.AN.54.196; 8.AN.54.223; 8.AN.54.240; 8.AN.54.244; 8.AN.54.243; 8.AN.54.247; 8.AN.55.157; 8.AN.55.158; 8.AN.55.196; 8.AN.55.223; 8.AN.55.240; 8.AN.55.244; 8.AN.55.243; 8.AN.55.247; 8.AN.56.157; 8.AN.56.158; 8.AN.56.196; 8.AN.56.223; 8.AN.56.240; 8.AN.56.244; 8.AN.56.243; 8.AN.56.247; 8.AN.157.157; 8.AN.157.158; 8.AN.157.196; 8.AN.157.223; 8.AN.157.240; 8.AN.157.244; 8.AN.157.243; 8.AN.157.247; 8.AN.196.157; 8.AN.196.158; 8.AN.196.196; 8.AN.196.223; 8.AN.196.240;

8.AN.196.244; 8.AN.196.243; 8.AN.196.247; 8.AN.223.157; 8.AN.223.158; 8.AN.223.196; 8.AN.223.223; 8.AN.223.240; 8.AN.223.244; 8.AN.223.243; 8.AN.223.247; 8.AN.240.157; 8.AN.240.158; 8.AN.240.196; 8.AN.240.223; 8.AN.240.240; 8.AN.240.244; 8.AN.240.243; 8.AN.240.247; 8.AN.244.157; 8.AN.244.158; 8.AN.244.196; 8.AN.244.223; 8.AN.244.240; 8.AN.244.244; 8.AN.244.243; 8.AN.244.247; 8.AN.247.157; 8.AN.247.158; 8.AN.247.196; 8.AN.247.223; 8.AN.247.240; 8.AN.247.244; 8.AN.247.243; 8.AN.247.247;

Prodrugs of 8.AP

8.AP.4.157; 8.AP.4.158; 8.AP.4.196; 8.AP.4.223; 8.AP.4.240; 8.AP.4.244; 8.AP.4.243; 8.AP.4.247; 8.AP.5.157; 8.AP.5.158; 8.AP.5.196; 8.AP.5.223; 8.AP.5.240; 8.AP.5.244; 8.AP.5.243; 8.AP.5.247; 8.AP.7.157; 8.AP.7.158; 8.AP.7.196; 8.AP.7.223; 8.AP.7.240; 8.AP.7.244; 8.AP.7.243; 8.AP.7.247; 8.AP.15.157; 8.AP.15.158; 8.AP.15.196; 8.AP.15.223; 8.AP.15.240; 8.AP.15.244; 8.AP.15.243; 8.AP.15.247; 8.AP.16.157; 8.AP.16.158; 8.AP.16.196; 8.AP.16.223; 8.AP.16.240; 8.AP.16.244; 8.AP.16.243; 8.AP.16.247; 8.AP.18.157; 8.AP.18.158; 8.AP.18.196; 8.AP.18.223; 8.AP.18.240; 8.AP.18.244; 8.AP.18.243; 8.AP.18.247; 8.AP.26.157; 8.AP.26.158; 8.AP.26.196; 8.AP.26.223; 8.AP.26.240; 8.AP.26.244; 8.AP.26.243; 8.AP.26.247; 8.AP.27.157; 8.AP.27.158; 8.AP.27.196; 8.AP.27.223; 8.AP.27.240; 8.AP.27.244; 8.AP.27.243; 8.AP.27.247; 8.AP.29.157; 8.AP.29.158; 8.AP.29.196; 8.AP.29.223; 8.AP.29.240; 8.AP.29.244; 8.AP.29.243; 8.AP.29.247; 8.AP.54.157; 8.AP.54.158; 8.AP.54.196; 8.AP.54.223; 8.AP.54.240; 8.AP.54.244; 8.AP.54.243; 8.AP.54.247; 8.AP.55.157; 8.AP.55.158; 8.AP.55.196; 8.AP.55.223; 8.AP.55.240; 8.AP.55.244; 8.AP.55.243; 8.AP.55.247; 8.AP.56.157; 8.AP.56.158; 8.AP.56.196; 8.AP.56.223; 8.AP.56.240; 8.AP.56.244; 8.AP.56.243; 8.AP.56.247; 8.AP.157.157; 8.AP.157.158; 8.AP.157.196; 8.AP.157.223; 8.AP.157.240; 8.AP.157.244; 8.AP.157.243; 8.AP.157.247; 8.AP.196.157; 8.AP.196.158; 8.AP.196.196; 8.AP.196.223; 8.AP.196.240; 8.AP.196.244; 8.AP.196.243; 8.AP.196.247; 8.AP.223.157; 8.AP.223.158; 8.AP.223.196; 8.AP.223.223; 8.AP.223.240; 8.AP.223.244; 8.AP.223.243; 8.AP.223.247; 8.AP.240.157; 8.AP.240.158; 8.AP.240.196; 8.AP.240.223;

8.AP.240.240; 8.AP.240.244; 8.AP.240.243; 8.AP.240.247; 8.AP.244.157; 8.AP.244.158; 8.AP.244.196; 8.AP.244.223; 8.AP.244.240; 8.AP.244.244; 8.AP.244.243; 8.AP.244.247; 8.AP.247.157; 8.AP.247.158; 8.AP.247.196; 8.AP.247.223; 8.AP.247.240; 8.AP.247.244; 8.AP.247.243; 8.AP.247.247;

Prodrugs of 8.AZ

8.AZ.4.157; 8.AZ.4.158; 8.AZ.4.196; 8.AZ.4.223; 8.AZ.4.240; 8.AZ.4.244; 8.AZ.4.243; 8.AZ.4.247; 8.AZ.5.157; 8.AZ.5.158; 8.AZ.5.196; 8.AZ.5.223; 8.AZ.5.240; 8.AZ.5.244; 8.AZ.5.243; 8.AZ.5.247; 8.AZ.7.157; 8.AZ.7.158; 8.AZ.7.196; 8.AZ.7.223; 8.AZ.7.240; 8.AZ.7.244; 8.AZ.7.243; 8.AZ.7.247; 8.AZ.15.157; 8.AZ.15.158; 8.AZ.15.196; 8.AZ.15.223; 8.AZ.15.240; 8.AZ.15.244; 8.AZ.15.243; 8.AZ.15.247; 8.AZ.16.157; 8.AZ.16.158; 8.AZ.16.196; 8.AZ.16.223; 8.AZ.16.240; 8.AZ.16.244; 8.AZ.16.243; 8.AZ.16.247; 8.AZ.18.157; 8.AZ.18.158; 8.AZ.18.196; 8.AZ.18.223; 8.AZ.18.240; 8.AZ.18.244; 8.AZ.18.243; 8.AZ.18.247; 8.AZ.26.157; 8.AZ.26.158; 8.AZ.26.196; 8.AZ.26.223; 8.AZ.26.240; 8.AZ.26.244; 8.AZ.26.243; 8.AZ.26.247; 8.AZ.27.157; 8.AZ.27.158; 8.AZ.27.196; 8.AZ.27.223; 8.AZ.27.240; 8.AZ.27.244; 8.AZ.27.243; 8.AZ.27.247; 8.AZ.29.157; 8.AZ.29.158; 8.AZ.29.196; 8.AZ.29.223; 8.AZ.29.240; 8.AZ.29.244; 8.AZ.29.243; 8.AZ.29.247; 8.AZ.54.157; 8.AZ.54.158; 8.AZ.54.196; 8.AZ.54.223; 8.AZ.54.240; 8.AZ.54.244; 8.AZ.54.243; 8.AZ.54.247; 8.AZ.55.157; 8.AZ.55.158; 8.AZ.55.196; 8.AZ.55.223; 8.AZ.55.240; 8.AZ.55.244; 8.AZ.55.243; 8.AZ.55.247; 8.AZ.56.157; 8.AZ.56.158; 8.AZ.56.196; 8.AZ.56.223; 8.AZ.56.240; 8.AZ.56.244; 8.AZ.56.243; 8.AZ.56.247; 8.AZ.157.157; 8.AZ.157.158; 8.AZ.157.196; 8.AZ.157.223; 8.AZ.157.240; 8.AZ.157.244; 8.AZ.157.243; 8.AZ.157.247; 8.AZ.196.157; 8.AZ.196.158; 8.AZ.196.196; 8.AZ.196.223; 8.AZ.196.240; 8.AZ.196.244; 8.AZ.196.243; 8.AZ.196.247; 8.AZ.223.157; 8.AZ.223.158; 8.AZ.223.196; 8.AZ.223.223; 8.AZ.223.240; 8.AZ.223.244; 8.AZ.223.243; 8.AZ.223.247; 8.AZ.240.157; 8.AZ.240.158; 8.AZ.240.196; 8.AZ.240.223; 8.AZ.240.240; 8.AZ.240.244; 8.AZ.240.243; 8.AZ.240.247; 8.AZ.244.157; 8.AZ.244.158; 8.AZ.244.196; 8.AZ.244.223; 8.AZ.244.240; 8.AZ.244.244;

8.AZ.244.243; 8.AZ.244.247; 8.AZ.247.157; 8.AZ.247.158; 8.AZ.247.196; 8.AZ.247.223; 8.AZ.247.240; 8.AZ.247.244; 8.AZ.247.243; 8.AZ.247.247;

Prodrugs of 8.BF

8.BF.4.157; 8.BF.4.158; 8.BF.4.196; 8.BF.4.223; 8.BF.4.240; 8.BF.4.244; 8.BF.4.243; 8.BF.4.247; 8.BF.5.157; 8.BF.5.158; 8.BF.5.196; 8.BF.5.223; 8.BF.5.240; 8.BF.5.244; 8.BF.5.243; 8.BF.5.247; 8.BF.7.157; 8.BF.7.158; 8.BF.7.196; 8.BF.7.223; 8.BF.7.240; 8.BF.7.244; 8.BF.7.243; 8.BF.7.247; 8.BF.15.157; 8.BF.15.158; 8.BF.15.196; 8.BF.15.223; 8.BF.15.240; 8.BF.15.244; 8.BF.15.243; 8.BF.15.247; 8.BF.16.157; 8.BF.16.158; 8.BF.16.196; 8.BF.16.223; 8.BF.16.240; 8.BF.16.244; 8.BF.16.243; 8.BF.16.247; 8.BF.18.157; 8.BF.18.158; 8.BF.18.196; 8.BF.18.223; 8.BF.18.240; 8.BF.18.244; 8.BF.18.243; 8.BF.18.247; 8.BF.26.157; 8.BF.26.158; 8.BF.26.196; 8.BF.26.223; 8.BF.26.240; 8.BF.26.244; 8.BF.26.243; 8.BF.26.247; 8.BF.27.157; 8.BF.27.158; 8.BF.27.196; 8.BF.27.223; 8.BF.27.240; 8.BF.27.244; 8.BF.27.243; 8.BF.27.247; 8.BF.29.157; 8.BF.29.158; 8.BF.29.196; 8.BF.29.223; 8.BF.29.240; 8.BF.29.244; 8.BF.29.243; 8.BF.29.247; 8.BF.54.157; 8.BF.54.158; 8.BF.54.196; 8.BF.54.223; 8.BF.54.240; 8.BF.54.244; 8.BF.54.243; 8.BF.54.247; 8.BF.55.157; 8.BF.55.158; 8.BF.55.196; 8.BF.55.223; 8.BF.55.240; 8.BF.55.244; 8.BF.55.243; 8.BF.55.247; 8.BF.56.157; 8.BF.56.158; 8.BF.56.196; 8.BF.56.223; 8.BF.56.240; 8.BF.56.244; 8.BF.56.243; 8.BF.56.247; 8.BF.157.157; 8.BF.157.158; 8.BF.157.196; 8.BF.157.223; 8.BF.157.240; 8.BF.157.244; 8.BF.157.243; 8.BF.157.247; 8.BF.196.157; 8.BF.196.158; 8.BF.196.196; 8.BF.196.223; 8.BF.196.240; 8.BF.196.244; 8.BF.196.243; 8.BF.196.247; 8.BF.223.157; 8.BF.223.158; 8.BF.223.196; 8.BF.223.223; 8.BF.223.240; 8.BF.223.244; 8.BF.223.243; 8.BF.223.247; 8.BF.240.157; 8.BF.240.158; 8.BF.240.196; 8.BF.240.223; 8.BF.240.240; 8.BF.240.244; 8.BF.240.243; 8.BF.240.247; 8.BF.244.157; 8.BF.244.158; 8.BF.244.196; 8.BF.244.223; 8.BF.244.240; 8.BF.244.244; 8.BF.244.243; 8.BF.244.247; 8.BF.247.157; 8.BF.247.158; 8.BF.247.196; 8.BF.247.223; 8.BF.247.240; 8.BF.247.244; 8.BF.247.243; 8.BF.247.247;

Prodrugs of 8.CI

8.CI.4.157; 8.CI.4.158; 8.CI.4.196; 8.CI.4.223; 8.CI.4.240; 8.CI.4.244; 8.CI.4.243; 8.CI.4.247; 8.CI.5.157; 8.CI.5.158; 8.CI.5.196; 8.CI.5.223; 8.CI.5.240; 8.CI.5.244; 8.CI.5.243; 8.CI.5.247; 8.CI.7.157; 8.CI.7.158; 8.CI.7.196; 8.CI.7.223; 8.CI.7.240; 8.CI.7.244; 8.CI.7.243; 8.CI.7.247; 8.CI.15.157; 8.CI.15.158; 8.CI.15.196; 8.CI.15.223; 8.CI.15.240; 8.CI.15.244; 8.CI.15.243; 8.CI.15.247; 8.CI.16.157; 8.CI.16.158; 8.CI.16.196; 8.CI.16.223; 8.CI.16.240; 8.CI.16.244; 8.CI.16.243; 8.CI.16.247; 8.CI.18.157; 8.CI.18.158; 8.CI.18.196; 8.CI.18.223; 8.CI.18.240; 8.CI.18.244; 8.CI.18.243; 8.CI.18.247; 8.CI.26.157; 8.CI.26.158; 8.CI.26.196; 8.CI.26.223; 8.CI.26.240; 8.CI.26.244; 8.CI.26.243; 8.CI.26.247; 8.CI.27.157; 8.CI.27.158; 8.CI.27.196; 8.CI.27.223; 8.CI.27.240; 8.CI.27.244; 8.CI.27.243; 8.CI.27.247; 8.CI.29.157; 8.CI.29.158; 8.CI.29.196; 8.CI.29.223; 8.CI.29.240; 8.CI.29.244; 8.CI.29.243; 8.CI.29.247; 8.CI.54.157; 8.CI.54.158; 8.CI.54.196; 8.CI.54.223; 8.CI.54.240; 8.CI.54.244; 8.CI.54.243; 8.CI.54.247; 8.CI.55.157; 8.CI.55.158; 8.CI.55.196; 8.CI.55.223; 8.CI.55.240; 8.CI.55.244; 8.CI.55.243; 8.CI.55.247; 8.CI.56.157; 8.CI.56.158; 8.CI.56.196; 8.CI.56.223; 8.CI.56.240; 8.CI.56.244; 8.CI.56.243; 8.CI.56.247; 8.CI.157.157; 8.CI.157.158; 8.CI.157.196; 8.CI.157.223; 8.CI.157.240; 8.CI.157.244; 8.CI.157.243; 8.CI.157.247; 8.CI.196.157; 8.CI.196.158; 8.CI.196.196; 8.CI.196.223; 8.CI.196.240; 8.CI.196.244; 8.CI.196.243; 8.CI.196.247; 8.CI.223.157; 8.CI.223.158; 8.CI.223.196; 8.CI.223.223; 8.CI.223.240; 8.CI.223.244; 8.CI.223.243; 8.CI.223.247; 8.CI.240.157; 8.CI.240.158; 8.CI.240.196; 8.CI.240.223; 8.CI.240.240; 8.CI.240.244; 8.CI.240.243; 8.CI.240.247; 8.CI.244.157; 8.CI.244.158; 8.CI.244.196; 8.CI.244.223; 8.CI.244.240; 8.CI.244.244; 8.CI.244.243; 8.CI.244.247; 8.CI.247.157; 8.CI.247.158; 8.CI.247.196; 8.CI.247.223; 8.CI.247.240; 8.CI.247.244; 8.CI.247.243; 8.CI.247.247;

Prodrugs of 8.CO

8.CO.4.157; 8.CO.4.158; 8.CO.4.196; 8.CO.4.223; 8.CO.4.240; 8.CO.4.244; 8.CO.4.243; 8.CO.4.247; 8.CO.5.157; 8.CO.5.158; 8.CO.5.196; 8.CO.5.223; 8.CO.5.240; 8.CO.5.244; 8.CO.5.243; 8.CO.5.247; 8.CO.7.157; 8.CO.7.158; 8.CO.7.196; 8.CO.7.223; 8.CO.7.240; 8.CO.7.244; 8.CO.7.243; 8.CO.7.247;

8.CO.15.157; 8.CO.15.158; 8.CO.15.196; 8.CO.15.223; 8.CO.15.240; 8.CO.15.244; 8.CO.15.243; 8.CO.15.247; 8.CO.16.157; 8.CO.16.158; 8.CO.16.196; 8.CO.16.223; 8.CO.16.240; 8.CO.16.244; 8.CO.16.243; 8.CO.16.247; 8.CO.18.157; 8.CO.18.158; 8.CO.18.196; 8.CO.18.223; 8.CO.18.240; 8.CO.18.244; 8.CO.18.243; 8.CO.18.247; 8.CO.26.157; 8.CO.26.158; 8.CO.26.196; 8.CO.26.223; 8.CO.26.240; 8.CO.26.244; 8.CO.26.243; 8.CO.26.247; 8.CO.27.157; 8.CO.27.158; 8.CO.27.196; 8.CO.27.223; 8.CO.27.240; 8.CO.27.244; 8.CO.27.243; 8.CO.27.247; 8.CO.29.157; 8.CO.29.158; 8.CO.29.196; 8.CO.29.223; 8.CO.29.240; 8.CO.29.244; 8.CO.29.243; 8.CO.29.247; 8.CO.54.157; 8.CO.54.158; 8.CO.54.196; 8.CO.54.223; 8.CO.54.240; 8.CO.54.244; 8.CO.54.243; 8.CO.54.247; 8.CO.55.157; 8.CO.55.158; 8.CO.55.196; 8.CO.55.223; 8.CO.55.240; 8.CO.55.244; 8.CO.55.243; 8.CO.55.247; 8.CO.56.157; 8.CO.56.158; 8.CO.56.196; 8.CO.56.223; 8.CO.56.240; 8.CO.56.244; 8.CO.56.243; 8.CO.56.247; 8.CO.157.157; 8.CO.157.158; 8.CO.157.196; 8.CO.157.223; 8.CO.157.240; 8.CO.157.244; 8.CO.157.243; 8.CO.157.247; 8.CO.196.157; 8.CO.196.158; 8.CO.196.196; 8.CO.196.223; 8.CO.196.240; 8.CO.196.244; 8.CO.196.243; 8.CO.196.247; 8.CO.223.157; 8.CO.223.158; 8.CO.223.196; 8.CO.223.223; 8.CO.223.240; 8.CO.223.244; 8.CO.223.243; 8.CO.223.247; 8.CO.240.157; 8.CO.240.158; 8.CO.240.196; 8.CO.240.223; 8.CO.240.240; 8.CO.240.244; 8.CO.240.243; 8.CO.240.247; 8.CO.244.157; 8.CO.244.158; 8.CO.244.196; 8.CO.244.223; 8.CO.244.240; 8.CO.244.244; 8.CO.244.243; 8.CO.244.247; 8.CO.247.157; 8.CO.247.158; 8.CO.247.196; 8.CO.247.223; 8.CO.247.240; 8.CO.247.244; 8.CO.247.243; 8.CO.247.247;

Prodrugs of 9.AH

9.AH.4.157; 9.AH.4.158; 9.AH.4.196; 9.AH.4.223; 9.AH.4.240; 9.AH.4.244; 9.AH.4.243; 9.AH.4.247; 9.AH.5.157; 9.AH.5.158; 9.AH.5.196; 9.AH.5.223; 9.AH.5.240; 9.AH.5.244; 9.AH.5.243; 9.AH.5.247; 9.AH.7.157; 9.AH.7.158; 9.AH.7.196; 9.AH.7.223; 9.AH.7.240; 9.AH.7.244; 9.AH.7.243; 9.AH.7.247; 9.AH.15.157; 9.AH.15.158; 9.AH.15.196; 9.AH.15.223; 9.AH.15.240; 9.AH.15.244; 9.AH.15.243; 9.AH.15.247; 9.AH.16.157; 9.AH.16.158; 9.AH.16.196; 9.AH.16.223; 9.AH.16.240; 9.AH.16.244; 9.AH.16.243;

9.AH.16.247; 9.AH.18.157; 9.AH.18.158; 9.AH.18.196; 9.AH.18.223; 9.AH.18.240; 9.AH.18.244; 9.AH.18.243; 9.AH.18.247; 9.AH.26.157; 9.AH.26.158; 9.AH.26.196; 9.AH.26.223; 9.AH.26.240; 9.AH.26.244; 9.AH.26.243; 9.AH.26.247; 9.AH.27.157; 9.AH.27.158; 9.AH.27.196; 9.AH.27.223; 9.AH.27.240; 9.AH.27.244; 9.AH.27.243; 9.AH.27.247; 9.AH.29.157; 9.AH.29.158; 9.AH.29.196; 9.AH.29.223; 9.AH.29.240; 9.AH.29.244; 9.AH.29.243; 9.AH.29.247; 9.AH.54.157; 9.AH.54.158; 9.AH.54.196; 9.AH.54.223; 9.AH.54.240; 9.AH.54.244; 9.AH.54.243; 9.AH.54.247; 9.AH.55.157; 9.AH.55.158; 9.AH.55.196; 9.AH.55.223; 9.AH.55.240; 9.AH.55.244; 9.AH.55.243; 9.AH.55.247; 9.AH.56.157; 9.AH.56.158; 9.AH.56.196; 9.AH.56.223; 9.AH.56.240; 9.AH.56.244; 9.AH.56.243; 9.AH.56.247; 9.AH.157.157; 9.AH.157.158; 9.AH.157.196; 9.AH.157.223; 9.AH.157.240; 9.AH.157.244; 9.AH.157.243; 9.AH.157.247; 9.AH.196.157; 9.AH.196.158; 9.AH.196.196; 9.AH.196.223; 9.AH.196.240; 9.AH.196.244; 9.AH.196.243; 9.AH.196.247; 9.AH.223.157; 9.AH.223.158; 9.AH.223.196; 9.AH.223.223; 9.AH.223.240; 9.AH.223.244; 9.AH.223.243; 9.AH.223.247; 9.AH.240.157; 9.AH.240.158; 9.AH.240.196; 9.AH.240.223; 9.AH.240.240; 9.AH.240.244; 9.AH.240.243; 9.AH.240.247; 9.AH.244.157; 9.AH.244.158; 9.AH.244.196; 9.AH.244.223; 9.AH.244.240; 9.AH.244.244; 9.AH.244.243; 9.AH.244.247; 9.AH.247.157; 9.AH.247.158; 9.AH.247.196; 9.AH.247.223; 9.AH.247.240; 9.AH.247.244; 9.AH.247.243; 9.AH.247.247;

Prodrugs of 9.AJ

9.AJ.4.157; 9.AJ.4.158; 9.AJ.4.196; 9.AJ.4.223; 9.AJ.4.240; 9.AJ.4.244; 9.AJ.4.243; 9.AJ.4.247; 9.AJ.5.157; 9.AJ.5.158; 9.AJ.5.196; 9.AJ.5.223; 9.AJ.5.240; 9.AJ.5.244; 9.AJ.5.243; 9.AJ.5.247; 9.AJ.7.157; 9.AJ.7.158; 9.AJ.7.196; 9.AJ.7.223; 9.AJ.7.240; 9.AJ.7.244; 9.AJ.7.243; 9.AJ.7.247; 9.AJ.15.157; 9.AJ.15.158; 9.AJ.15.196; 9.AJ.15.223; 9.AJ.15.240; 9.AJ.15.244; 9.AJ.15.243; 9.AJ.15.247; 9.AJ.16.157; 9.AJ.16.158; 9.AJ.16.196; 9.AJ.16.223; 9.AJ.16.240; 9.AJ.16.244; 9.AJ.16.243; 9.AJ.16.247; 9.AJ.18.157; 9.AJ.18.158; 9.AJ.18.196; 9.AJ.18.223; 9.AJ.18.240; 9.AJ.18.244; 9.AJ.18.243; 9.AJ.18.247; 9.AJ.26.157; 9.AJ.26.158; 9.AJ.26.196; 9.AJ.26.223; 9.AJ.26.240; 9.AJ.26.244; 9.AJ.26.243; 9.AJ.26.247; 9.AJ.27.157; 9.AJ.27.158; 9.AJ.27.196; 9.AJ.27.223;

9.AJ.27.240; 9.AJ.27.244; 9.AJ.27.243; 9.AJ.27.247; 9.AJ.29.157; 9.AJ.29.158; 9.AJ.29.196; 9.AJ.29.223; 9.AJ.29.240; 9.AJ.29.244; 9.AJ.29.243; 9.AJ.29.247; 9.AJ.54.157; 9.AJ.54.158; 9.AJ.54.196; 9.AJ.54.223; 9.AJ.54.240; 9.AJ.54.244; 9.AJ.54.243; 9.AJ.54.247; 9.AJ.55.157; 9.AJ.55.158; 9.AJ.55.196; 9.AJ.55.223; 9.AJ.55.240; 9.AJ.55.244; 9.AJ.55.243; 9.AJ.55.247; 9.AJ.56.157; 9.AJ.56.158; 9.AJ.56.196; 9.AJ.56.223; 9.AJ.56.240; 9.AJ.56.244; 9.AJ.56.243; 9.AJ.56.247; 9.AJ.157.157; 9.AJ.157.158; 9.AJ.157.196; 9.AJ.157.223; 9.AJ.157.240; 9.AJ.157.244; 9.AJ.157.243; 9.AJ.157.247; 9.AJ.196.157; 9.AJ.196.158; 9.AJ.196.196; 9.AJ.196.223; 9.AJ.196.240; 9.AJ.196.244; 9.AJ.196.243; 9.AJ.196.247; 9.AJ.223.157; 9.AJ.223.158; 9.AJ.223.196; 9.AJ.223.223; 9.AJ.223.240; 9.AJ.223.244; 9.AJ.223.243; 9.AJ.223.247; 9.AJ.240.157; 9.AJ.240.158; 9.AJ.240.196; 9.AJ.240.223; 9.AJ.240.240; 9.AJ.240.244; 9.AJ.240.243; 9.AJ.240.247; 9.AJ.244.157; 9.AJ.244.158; 9.AJ.244.196; 9.AJ.244.223; 9.AJ.244.240; 9.AJ.244.244; 9.AJ.244.243; 9.AJ.244.247; 9.AJ.247.157; 9.AJ.247.158; 9.AJ.247.196; 9.AJ.247.223; 9.AJ.247.240; 9.AJ.247.244; 9.AJ.247.243; 9.AJ.247.247;

Prodrugs of 9.AN

9.AN.4.157; 9.AN.4.158; 9.AN.4.196; 9.AN.4.223; 9.AN.4.240; 9.AN.4.244; 9.AN.4.243; 9.AN.4.247; 9.AN.5.157; 9.AN.5.158; 9.AN.5.196; 9.AN.5.223; 9.AN.5.240; 9.AN.5.244; 9.AN.5.243; 9.AN.5.247; 9.AN.7.157; 9.AN.7.158; 9.AN.7.196; 9.AN.7.223; 9.AN.7.240; 9.AN.7.244; 9.AN.7.243; 9.AN.7.247; 9.AN.15.157; 9.AN.15.158; 9.AN.15.196; 9.AN.15.223; 9.AN.15.240; 9.AN.15.244; 9.AN.15.243; 9.AN.15.247; 9.AN.16.157; 9.AN.16.158; 9.AN.16.196; 9.AN.16.223; 9.AN.16.240; 9.AN.16.244; 9.AN.16.243; 9.AN.16.247; 9.AN.18.157; 9.AN.18.158; 9.AN.18.196; 9.AN.18.223; 9.AN.18.240; 9.AN.18.244; 9.AN.18.243; 9.AN.18.247; 9.AN.26.157; 9.AN.26.158; 9.AN.26.196; 9.AN.26.223; 9.AN.26.240; 9.AN.26.244; 9.AN.26.243; 9.AN.26.247; 9.AN.27.157; 9.AN.27.158; 9.AN.27.196; 9.AN.27.223; 9.AN.27.240; 9.AN.27.244; 9.AN.27.243; 9.AN.27.247; 9.AN.29.157; 9.AN.29.158; 9.AN.29.196; 9.AN.29.223; 9.AN.29.240; 9.AN.29.244; 9.AN.29.243; 9.AN.29.247; 9.AN.54.157; 9.AN.54.158; 9.AN.54.196; 9.AN.54.223; 9.AN.54.240; 9.AN.54.244; 9.AN.54.243;

9.AN.54.247; 9.AN.55.157; 9.AN.55.158; 9.AN.55.196; 9.AN.55.223; 9.AN.55.240; 9.AN.55.244; 9.AN.55.243; 9.AN.55.247; 9.AN.56.157; 9.AN.56.158; 9.AN.56.196; 9.AN.56.223; 9.AN.56.240; 9.AN.56.244; 9.AN.56.243; 9.AN.56.247; 9.AN.157.157; 9.AN.157.158; 9.AN.157.196; 9.AN.157.223; 9.AN.157.240; 9.AN.157.244; 9.AN.157.243; 9.AN.157.247; 9.AN.196.157; 9.AN.196.158; 9.AN.196.196; 9.AN.196.223; 9.AN.196.240; 9.AN.196.244; 9.AN.196.243; 9.AN.196.247; 9.AN.223.157; 9.AN.223.158; 9.AN.223.196; 9.AN.223.223; 9.AN.223.240; 9.AN.223.244; 9.AN.223.243; 9.AN.223.247; 9.AN.240.157; 9.AN.240.158; 9.AN.240.196; 9.AN.240.223; 9.AN.240.240; 9.AN.240.244; 9.AN.240.243; 9.AN.240.247; 9.AN.244.157; 9.AN.244.158; 9.AN.244.196; 9.AN.244.223; 9.AN.244.240; 9.AN.244.244; 9.AN.244.243; 9.AN.244.247; 9.AN.247.157; 9.AN.247.158; 9.AN.247.196; 9.AN.247.223; 9.AN.247.240; 9.AN.247.244; 9.AN.247.243; 9.AN.247.247;

Prodrugs of 9.AP

9.AP.4.157; 9.AP.4.158; 9.AP.4.196; 9.AP.4.223; 9.AP.4.240; 9.AP.4.244; 9.AP.4.243; 9.AP.4.247; 9.AP.5.157; 9.AP.5.158; 9.AP.5.196; 9.AP.5.223; 9.AP.5.240; 9.AP.5.244; 9.AP.5.243; 9.AP.5.247; 9.AP.7.157; 9.AP.7.158; 9.AP.7.196; 9.AP.7.223; 9.AP.7.240; 9.AP.7.244; 9.AP.7.243; 9.AP.7.247; 9.AP.15.157; 9.AP.15.158; 9.AP.15.196; 9.AP.15.223; 9.AP.15.240; 9.AP.15.244; 9.AP.15.243; 9.AP.15.247; 9.AP.16.157; 9.AP.16.158; 9.AP.16.196; 9.AP.16.223; 9.AP.16.240; 9.AP.16.244; 9.AP.16.243; 9.AP.16.247; 9.AP.18.157; 9.AP.18.158; 9.AP.18.196; 9.AP.18.223; 9.AP.18.240; 9.AP.18.244; 9.AP.18.243; 9.AP.18.247; 9.AP.26.157; 9.AP.26.158; 9.AP.26.196; 9.AP.26.223; 9.AP.26.240; 9.AP.26.244; 9.AP.26.243; 9.AP.26.247; 9.AP.27.157; 9.AP.27.158; 9.AP.27.196; 9.AP.27.223; 9.AP.27.240; 9.AP.27.244; 9.AP.27.243; 9.AP.27.247; 9.AP.29.157; 9.AP.29.158; 9.AP.29.196; 9.AP.29.223; 9.AP.29.240; 9.AP.29.244; 9.AP.29.243; 9.AP.29.247; 9.AP.54.157; 9.AP.54.158; 9.AP.54.196; 9.AP.54.223; 9.AP.54.240; 9.AP.54.244; 9.AP.54.243; 9.AP.54.247; 9.AP.55.157; 9.AP.55.158; 9.AP.55.196; 9.AP.55.223; 9.AP.55.240; 9.AP.55.244; 9.AP.55.243; 9.AP.55.247; 9.AP.56.157; 9.AP.56.158; 9.AP.56.196; 9.AP.56.223; 9.AP.56.240; 9.AP.56.244;

9.AP.56.243; 9.AP.56.247; 9.AP.157.157; 9.AP.157.158; 9.AP.157.196; 9.AP.157.223; 9.AP.157.240; 9.AP.157.244; 9.AP.157.243; 9.AP.157.247; 9.AP.196.157; 9.AP.196.158; 9.AP.196.196; 9.AP.196.223; 9.AP.196.240; 9.AP.196.244; 9.AP.196.243; 9.AP.196.247; 9.AP.223.157; 9.AP.223.158; 9.AP.223.196; 9.AP.223.223; 9.AP.223.240; 9.AP.223.244; 9.AP.223.243; 9.AP.223.247; 9.AP.240.157; 9.AP.240.158; 9.AP.240.196; 9.AP.240.223; 9.AP.240.240; 9.AP.240.244; 9.AP.240.243; 9.AP.240.247; 9.AP.244.157; 9.AP.244.158; 9.AP.244.196; 9.AP.244.223; 9.AP.244.240; 9.AP.244.244; 9.AP.244.243; 9.AP.244.247; 9.AP.247.157; 9.AP.247.158; 9.AP.247.196; 9.AP.247.223; 9.AP.247.240; 9.AP.247.244; 9.AP.247.243; 9.AP.247.247;

Prodrugs of 9.AZ

9.AZ.4.157; 9.AZ.4.158; 9.AZ.4.196; 9.AZ.4.223; 9.AZ.4.240; 9.AZ.4.244; 9.AZ.4.243; 9.AZ.4.247; 9.AZ.5.157; 9.AZ.5.158; 9.AZ.5.196; 9.AZ.5.223; 9.AZ.5.240; 9.AZ.5.244; 9.AZ.5.243; 9.AZ.5.247; 9.AZ.7.157; 9.AZ.7.158; 9.AZ.7.196; 9.AZ.7.223; 9.AZ.7.240; 9.AZ.7.244; 9.AZ.7.243; 9.AZ.7.247; 9.AZ.15.157; 9.AZ.15.158; 9.AZ.15.196; 9.AZ.15.223; 9.AZ.15.240; 9.AZ.15.244; 9.AZ.15.243; 9.AZ.15.247; 9.AZ.16.157; 9.AZ.16.158; 9.AZ.16.196; 9.AZ.16.223; 9.AZ.16.240; 9.AZ.16.244; 9.AZ.16.243; 9.AZ.16.247; 9.AZ.18.157; 9.AZ.18.158; 9.AZ.18.196; 9.AZ.18.223; 9.AZ.18.240; 9.AZ.18.244; 9.AZ.18.243; 9.AZ.18.247; 9.AZ.26.157; 9.AZ.26.158; 9.AZ.26.196; 9.AZ.26.223; 9.AZ.26.240; 9.AZ.26.244; 9.AZ.26.243; 9.AZ.26.247; 9.AZ.27.157; 9.AZ.27.158; 9.AZ.27.196; 9.AZ.27.223; 9.AZ.27.240; 9.AZ.27.244; 9.AZ.27.243; 9.AZ.27.247; 9.AZ.29.157; 9.AZ.29.158; 9.AZ.29.196; 9.AZ.29.223; 9.AZ.29.240; 9.AZ.29.244; 9.AZ.29.243; 9.AZ.29.247; 9.AZ.54.157; 9.AZ.54.158; 9.AZ.54.196; 9.AZ.54.223; 9.AZ.54.240; 9.AZ.54.244; 9.AZ.54.243; 9.AZ.54.247; 9.AZ.55.157; 9.AZ.55.158; 9.AZ.55.196; 9.AZ.55.223; 9.AZ.55.240; 9.AZ.55.244; 9.AZ.55.243; 9.AZ.55.247; 9.AZ.56.157; 9.AZ.56.158; 9.AZ.56.196; 9.AZ.56.223; 9.AZ.56.240; 9.AZ.56.244; 9.AZ.56.243; 9.AZ.56.247; 9.AZ.157.157; 9.AZ.157.158; 9.AZ.157.196; 9.AZ.157.223; 9.AZ.157.240; 9.AZ.157.244; 9.AZ.157.243; 9.AZ.157.247; 9.AZ.196.157; 9.AZ.196.158; 9.AZ.196.196; 9.AZ.196.223; 9.AZ.196.240;

9.AZ.196.244; 9.AZ.196.243; 9.AZ.196.247; 9.AZ.223.157; 9.AZ.223.158; 9.AZ.223.196; 9.AZ.223.223; 9.AZ.223.240; 9.AZ.223.244; 9.AZ.223.243; 9.AZ.223.247; 9.AZ.240.157; 9.AZ.240.158; 9.AZ.240.196; 9.AZ.240.223; 9.AZ.240.240; 9.AZ.240.244; 9.AZ.240.243; 9.AZ.240.247; 9.AZ.244.157; 9.AZ.244.158; 9.AZ.244.196; 9.AZ.244.223; 9.AZ.244.240; 9.AZ.244.244; 9.AZ.244.243; 9.AZ.244.247; 9.AZ.247.157; 9.AZ.247.158; 9.AZ.247.196; 9.AZ.247.223; 9.AZ.247.240; 9.AZ.247.244; 9.AZ.247.243; 9.AZ.247.247;

Prodrugs of 9.BF

9.BF.4.157; 9.BF.4.158; 9.BF.4.196; 9.BF.4.223; 9.BF.4.240; 9.BF.4.244; 9.BF.4.243; 9.BF.4.247; 9.BF.5.157; 9.BF.5.158; 9.BF.5.196; 9.BF.5.223; 9.BF.5.240; 9.BF.5.244; 9.BF.5.243; 9.BF.5.247; 9.BF.7.157; 9.BF.7.158; 9.BF.7.196; 9.BF.7.223; 9.BF.7.240; 9.BF.7.244; 9.BF.7.243; 9.BF.7.247; 9.BF.15.157; 9.BF.15.158; 9.BF.15.196; 9.BF.15.223; 9.BF.15.240; 9.BF.15.244; 9.BF.15.243; 9.BF.15.247; 9.BF.16.157; 9.BF.16.158; 9.BF.16.196; 9.BF.16.223; 9.BF.16.240; 9.BF.16.244; 9.BF.16.243; 9.BF.16.247; 9.BF.18.157; 9.BF.18.158; 9.BF.18.196; 9.BF.18.223; 9.BF.18.240; 9.BF.18.244; 9.BF.18.243; 9.BF.18.247; 9.BF.26.157; 9.BF.26.158; 9.BF.26.196; 9.BF.26.223; 9.BF.26.240; 9.BF.26.244; 9.BF.26.243; 9.BF.26.247; 9.BF.27.157; 9.BF.27.158; 9.BF.27.196; 9.BF.27.223; 9.BF.27.240; 9.BF.27.244; 9.BF.27.243; 9.BF.27.247; 9.BF.29.157; 9.BF.29.158; 9.BF.29.196; 9.BF.29.223; 9.BF.29.240; 9.BF.29.244; 9.BF.29.243; 9.BF.29.247; 9.BF.54.157; 9.BF.54.158; 9.BF.54.196; 9.BF.54.223; 9.BF.54.240; 9.BF.54.244; 9.BF.54.243; 9.BF.54.247; 9.BF.55.157; 9.BF.55.158; 9.BF.55.196; 9.BF.55.223; 9.BF.55.240; 9.BF.55.244; 9.BF.55.243; 9.BF.55.247; 9.BF.56.157; 9.BF.56.158; 9.BF.56.196; 9.BF.56.223; 9.BF.56.240; 9.BF.56.244; 9.BF.56.243; 9.BF.56.247; 9.BF.157.157; 9.BF.157.158; 9.BF.157.196; 9.BF.157.223; 9.BF.157.240; 9.BF.157.244; 9.BF.157.243; 9.BF.157.247; 9.BF.196.157; 9.BF.196.158; 9.BF.196.196; 9.BF.196.223; 9.BF.196.240; 9.BF.196.244; 9.BF.196.243; 9.BF.196.247; 9.BF.223.157; 9.BF.223.158; 9.BF.223.196; 9.BF.223.223; 9.BF.223.240; 9.BF.223.244; 9.BF.223.243; 9.BF.223.247; 9.BF.240.157; 9.BF.240.158; 9.BF.240.196; 9.BF.240.223;

9.BF.240.240; 9.BF.240.244; 9.BF.240.243; 9.BF.240.247; 9.BF.244.157; 9.BF.244.158; 9.BF.244.196; 9.BF.244.223; 9.BF.244.240; 9.BF.244.244; 9.BF.244.243; 9.BF.244.247; 9.BF.247.157; 9.BF.247.158; 9.BF.247.196; 9.BF.247.223; 9.BF.247.240; 9.BF.247.244; 9.BF.247.243; 9.BF.247.247;

Prodrugs of 9.CI

9.CI.4.157; 9.CI.4.158; 9.CI.4.196; 9.CI.4.223; 9.CI.4.240; 9.CI.4.244; 9.CI.4.243; 9.CI.4.247; 9.CI.5.157; 9.CI.5.158; 9.CI.5.196; 9.CI.5.223; 9.CI.5.240; 9.CI.5.244; 9.CI.5.243; 9.CI.5.247; 9.CI.7.157; 9.CI.7.158; 9.CI.7.196; 9.CI.7.223; 9.CI.7.240; 9.CI.7.244; 9.CI.7.243; 9.CI.7.247; 9.CI.15.157; 9.CI.15.158; 9.CI.15.196; 9.CI.15.223; 9.CI.15.240; 9.CI.15.244; 9.CI.15.243; 9.CI.15.247; 9.CI.16.157; 9.CI.16.158; 9.CI.16.196; 9.CI.16.223; 9.CI.16.240; 9.CI.16.244; 9.CI.16.243; 9.CI.16.247; 9.CI.18.157; 9.CI.18.158; 9.CI.18.196; 9.CI.18.223; 9.CI.18.240; 9.CI.18.244; 9.CI.18.243; 9.CI.18.247; 9.CI.26.157; 9.CI.26.158; 9.CI.26.196; 9.CI.26.223; 9.CI.26.240; 9.CI.26.244; 9.CI.26.243; 9.CI.26.247; 9.CI.27.157; 9.CI.27.158; 9.CI.27.196; 9.CI.27.223; 9.CI.27.240; 9.CI.27.244; 9.CI.27.243; 9.CI.27.247; 9.CI.29.157; 9.CI.29.158; 9.CI.29.196; 9.CI.29.223; 9.CI.29.240; 9.CI.29.244; 9.CI.29.243; 9.CI.29.247; 9.CI.54.157; 9.CI.54.158; 9.CI.54.196; 9.CI.54.223; 9.CI.54.240; 9.CI.54.244; 9.CI.54.243; 9.CI.54.247; 9.CI.55.157; 9.CI.55.158; 9.CI.55.196; 9.CI.55.223; 9.CI.55.240; 9.CI.55.244; 9.CI.55.243; 9.CI.55.247; 9.CI.56.157; 9.CI.56.158; 9.CI.56.196; 9.CI.56.223; 9.CI.56.240; 9.CI.56.244; 9.CI.56.243; 9.CI.56.247; 9.CI.157.157; 9.CI.157.158; 9.CI.157.196; 9.CI.157.223; 9.CI.157.240; 9.CI.157.244; 9.CI.157.243; 9.CI.157.247; 9.CI.196.157; 9.CI.196.158; 9.CI.196.196; 9.CI.196.223; 9.CI.196.240; 9.CI.196.244; 9.CI.196.243; 9.CI.196.247; 9.CI.223.157; 9.CI.223.158; 9.CI.223.196; 9.CI.223.223; 9.CI.223.240; 9.CI.223.244; 9.CI.223.243; 9.CI.223.247; 9.CI.240.157; 9.CI.240.158; 9.CI.240.196; 9.CI.240.223; 9.CI.240.240; 9.CI.240.244; 9.CI.240.243; 9.CI.240.247; 9.CI.244.157; 9.CI.244.158; 9.CI.244.196; 9.CI.244.223; 9.CI.244.240; 9.CI.244.244; 9.CI.244.243; 9.CI.244.247; 9.CI.247.157; 9.CI.247.158; 9.CI.247.196; 9.CI.247.223; 9.CI.247.240; 9.CI.247.244; 9.CI.247.243; 9.CI.247.247;

Prodrugs of 9.CO

9.CO.4.157; 9.CO.4.158; 9.CO.4.196; 9.CO.4.223; 9.CO.4.240; 9.CO.4.244; 9.CO.4.243; 9.CO.4.247; 9.CO.5.157; 9.CO.5.158; 9.CO.5.196; 9.CO.5.223; 9.CO.5.240; 9.CO.5.244; 9.CO.5.243; 9.CO.5.247; 9.CO.7.157; 9.CO.7.158; 9.CO.7.196; 9.CO.7.223; 9.CO.7.240; 9.CO.7.244; 9.CO.7.243; 9.CO.7.247; 9.CO.15.157; 9.CO.15.158; 9.CO.15.196; 9.CO.15.223; 9.CO.15.240; 9.CO.15.244; 9.CO.15.243; 9.CO.15.247; 9.CO.16.157; 9.CO.16.158; 9.CO.16.196; 9.CO.16.223; 9.CO.16.240; 9.CO.16.244; 9.CO.16.243; 9.CO.16.247; 9.CO.18.157; 9.CO.18.158; 9.CO.18.196; 9.CO.18.223; 9.CO.18.240; 9.CO.18.244; 9.CO.18.243; 9.CO.18.247; 9.CO.26.157; 9.CO.26.158; 9.CO.26.196; 9.CO.26.223; 9.CO.26.240; 9.CO.26.244; 9.CO.26.243; 9.CO.26.247; 9.CO.27.157; 9.CO.27.158; 9.CO.27.196; 9.CO.27.223; 9.CO.27.240; 9.CO.27.244; 9.CO.27.243; 9.CO.27.247; 9.CO.29.157; 9.CO.29.158; 9.CO.29.196; 9.CO.29.223; 9.CO.29.240; 9.CO.29.244; 9.CO.29.243; 9.CO.29.247; 9.CO.54.157; 9.CO.54.158; 9.CO.54.196; 9.CO.54.223; 9.CO.54.240; 9.CO.54.244; 9.CO.54.243; 9.CO.54.247; 9.CO.55.157; 9.CO.55.158; 9.CO.55.196; 9.CO.55.223; 9.CO.55.240; 9.CO.55.244; 9.CO.55.243; 9.CO.55.247; 9.CO.56.157; 9.CO.56.158; 9.CO.56.196; 9.CO.56.223; 9.CO.56.240; 9.CO.56.244; 9.CO.56.243; 9.CO.56.247; 9.CO.157.157; 9.CO.157.158; 9.CO.157.196; 9.CO.157.223; 9.CO.157.240; 9.CO.157.244; 9.CO.157.243; 9.CO.157.247; 9.CO.196.157; 9.CO.196.158; 9.CO.196.196; 9.CO.196.223; 9.CO.196.240; 9.CO.196.244; 9.CO.196.243; 9.CO.196.247; 9.CO.223.157; 9.CO.223.158; 9.CO.223.196; 9.CO.223.223; 9.CO.223.240; 9.CO.223.244; 9.CO.223.243; 9.CO.223.247; 9.CO.240.157; 9.CO.240.158; 9.CO.240.196; 9.CO.240.223; 9.CO.240.240; 9.CO.240.244; 9.CO.240.243; 9.CO.240.247; 9.CO.244.157; 9.CO.244.158; 9.CO.244.196; 9.CO.244.223; 9.CO.244.240; 9.CO.244.244; 9.CO.244.243; 9.CO.244.247; 9.CO.247.157; 9.CO.247.158; 9.CO.247.196; 9.CO.247.223; 9.CO.247.240; 9.CO.247.244; 9.CO.247.243; 9.CO.247.247;

Prodrugs of 10.AH

10.AH.4.157; 10.AH.4.158; 10.AH.4.196; 10.AH.4.223; 10.AH.4.240; 10.AH.4.244; 10.AH.4.243; 10.AH.4.247; 10.AH.5.157; 10.AH.5.158;

10.AH.5.196; 10.AH.5.223; 10.AH.5.240; 10.AH.5.244; 10.AH.5.243; 10.AH.5.247; 10.AH.7.157; 10.AH.7.158; 10.AH.7.196; 10.AH.7.223; 10.AH.7.240; 10.AH.7.244; 10.AH.7.243; 10.AH.7.247; 10.AH.15.157; 10.AH.15.158; 10.AH.15.196; 10.AH.15.223; 10.AH.15.240; 10.AH.15.244; 10.AH.15.243; 10.AH.15.247; 10.AH.16.157; 10.AH.16.158; 10.AH.16.196; 10.AH.16.223; 10.AH.16.240; 10.AH.16.244; 10.AH.16.243; 10.AH.16.247; 10.AH.18.157; 10.AH.18.158; 10.AH.18.196; 10.AH.18.223; 10.AH.18.240; 10.AH.18.244; 10.AH.18.243; 10.AH.18.247; 10.AH.26.157; 10.AH.26.158; 10.AH.26.196; 10.AH.26.223; 10.AH.26.240; 10.AH.26.244; 10.AH.26.243; 10.AH.26.247; 10.AH.27.157; 10.AH.27.158; 10.AH.27.196; 10.AH.27.223; 10.AH.27.240; 10.AH.27.244; 10.AH.27.243; 10.AH.27.247; 10.AH.29.157; 10.AH.29.158; 10.AH.29.196; 10.AH.29.223; 10.AH.29.240; 10.AH.29.244; 10.AH.29.243; 10.AH.29.247; 10.AH.54.157; 10.AH.54.158; 10.AH.54.196; 10.AH.54.223; 10.AH.54.240; 10.AH.54.244; 10.AH.54.243; 10.AH.54.247; 10.AH.55.157; 10.AH.55.158; 10.AH.55.196; 10.AH.55.223; 10.AH.55.240; 10.AH.55.244; 10.AH.55.243; 10.AH.55.247; 10.AH.56.157; 10.AH.56.158; 10.AH.56.196; 10.AH.56.223; 10.AH.56.240; 10.AH.56.244; 10.AH.56.243; 10.AH.56.247; 10.AH.157.157; 10.AH.157.158; 10.AH.157.196; 10.AH.157.223; 10.AH.157.240; 10.AH.157.244; 10.AH.157.243; 10.AH.157.247; 10.AH.196.157; 10.AH.196.158; 10.AH.196.196; 10.AH.196.223; 10.AH.196.240; 10.AH.196.244; 10.AH.196.243; 10.AH.196.247; 10.AH.223.157; 10.AH.223.158; 10.AH.223.196; 10.AH.223.223; 10.AH.223.240; 10.AH.223.244; 10.AH.223.243; 10.AH.223.247; 10.AH.240.157; 10.AH.240.158; 10.AH.240.196; 10.AH.240.223; 10.AH.240.240; 10.AH.240.244; 10.AH.240.243; 10.AH.240.247; 10.AH.244.157; 10.AH.244.158; 10.AH.244.196; 10.AH.244.223; 10.AH.244.240; 10.AH.244.244; 10.AH.244.243; 10.AH.244.247; 10.AH.247.157; 10.AH.247.158; 10.AH.247.196; 10.AH.247.223; 10.AH.247.240; 10.AH.247.244; 10.AH.247.243; 10.AH.247.247;

Prodrugs of 10.AJ

10.AJ.4.157; 10.AJ.4.158; 10.AJ.4.196; 10.AJ.4.223; 10.AJ.4.240; 10.AJ.4.244; 10.AJ.4.243; 10.AJ.4.247; 10.AJ.5.157; 10.AJ.5.158; 10.AJ.5.196; 10.AJ.5.223; 10.AJ.5.240; 10.AJ.5.244; 10.AJ.5.243; 10.AJ.5.247; 10.AJ.7.157; 10.AJ.7.158; 10.AJ.7.196; 10.AJ.7.223; 10.AJ.7.240; 10.AJ.7.244; 10.AJ.7.243; 10.AJ.7.247; 10.AJ.15.157; 10.AJ.15.158; 10.AJ.15.196; 10.AJ.15.223; 10.AJ.15.240; 10.AJ.15.244; 10.AJ.15.243; 10.AJ.15.247; 10.AJ.16.157; 10.AJ.16.158; 10.AJ.16.196; 10.AJ.16.223; 10.AJ.16.240; 10.AJ.16.244; 10.AJ.16.243; 10.AJ.16.247; 10.AJ.18.157; 10.AJ.18.158; 10.AJ.18.196; 10.AJ.18.223; 10.AJ.18.240; 10.AJ.18.244; 10.AJ.18.243; 10.AJ.18.247; 10.AJ.26.157; 10.AJ.26.158; 10.AJ.26.196; 10.AJ.26.223; 10.AJ.26.240; 10.AJ.26.244; 10.AJ.26.243; 10.AJ.26.247; 10.AJ.27.157; 10.AJ.27.158; 10.AJ.27.196; 10.AJ.27.223; 10.AJ.27.240; 10.AJ.27.244; 10.AJ.27.243; 10.AJ.27.247; 10.AJ.29.157; 10.AJ.29.158; 10.AJ.29.196; 10.AJ.29.223; 10.AJ.29.240; 10.AJ.29.244; 10.AJ.29.243; 10.AJ.29.247; 10.AJ.54.157; 10.AJ.54.158; 10.AJ.54.196; 10.AJ.54.223; 10.AJ.54.240; 10.AJ.54.244; 10.AJ.54.243; 10.AJ.54.247; 10.AJ.55.157; 10.AJ.55.158; 10.AJ.55.196; 10.AJ.55.223; 10.AJ.55.240; 10.AJ.55.244; 10.AJ.55.243; 10.AJ.55.247; 10.AJ.56.157; 10.AJ.56.158; 10.AJ.56.196; 10.AJ.56.223; 10.AJ.56.240; 10.AJ.56.244; 10.AJ.56.243; 10.AJ.56.247; 10.AJ.157.157; 10.AJ.157.158; 10.AJ.157.196; 10.AJ.157.223; 10.AJ.157.240; 10.AJ.157.244; 10.AJ.157.243; 10.AJ.157.247; 10.AJ.196.157; 10.AJ.196.158; 10.AJ.196.196; 10.AJ.196.223; 10.AJ.196.240; 10.AJ.196.244; 10.AJ.196.243; 10.AJ.196.247; 10.AJ.223.157; 10.AJ.223.158; 10.AJ.223.196; 10.AJ.223.223; 10.AJ.223.240; 10.AJ.223.244; 10.AJ.223.243; 10.AJ.223.247; 10.AJ.240.157; 10.AJ.240.158; 10.AJ.240.196; 10.AJ.240.223; 10.AJ.240.240; 10.AJ.240.244; 10.AJ.240.243; 10.AJ.240.247; 10.AJ.244.157; 10.AJ.244.158; 10.AJ.244.196; 10.AJ.244.223; 10.AJ.244.240; 10.AJ.244.244; 10.AJ.244.243; 10.AJ.244.247; 10.AJ.247.157; 10.AJ.247.158; 10.AJ.247.196; 10.AJ.247.223; 10.AJ.247.240; 10.AJ.247.244; 10.AJ.247.243; 10.AJ.247.247;

Prodrugs of 10.AN

10.AN.4.157; 10.AN.4.158; 10.AN.4.196; 10.AN.4.223; 10.AN.4.240; 10.AN.4.244; 10.AN.4.243; 10.AN.4.247; 10.AN.5.157; 10.AN.5.158;

10.AN.5.196; 10.AN.5.223; 10.AN.5.240; 10.AN.5.244; 10.AN.5.243; 10.AN.5.247; 10.AN.7.157; 10.AN.7.158; 10.AN.7.196; 10.AN.7.223; 10.AN.7.240; 10.AN.7.244; 10.AN.7.243; 10.AN.7.247; 10.AN.15.157; 10.AN.15.158; 10.AN.15.196; 10.AN.15.223; 10.AN.15.240; 10.AN.15.244; 10.AN.15.243; 10.AN.15.247; 10.AN.16.157; 10.AN.16.158; 10.AN.16.196; 10.AN.16.223; 10.AN.16.240; 10.AN.16.244; 10.AN.16.243; 10.AN.16.247; 10.AN.18.157; 10.AN.18.158; 10.AN.18.196; 10.AN.18.223; 10.AN.18.240; 10.AN.18.244; 10.AN.18.243; 10.AN.18.247; 10.AN.26.157; 10.AN.26.158; 10.AN.26.196; 10.AN.26.223; 10.AN.26.240; 10.AN.26.244; 10.AN.26.243; 10.AN.26.247; 10.AN.27.157; 10.AN.27.158; 10.AN.27.196; 10.AN.27.223; 10.AN.27.240; 10.AN.27.244; 10.AN.27.243; 10.AN.27.247; 10.AN.29.157; 10.AN.29.158; 10.AN.29.196; 10.AN.29.223; 10.AN.29.240; 10.AN.29.244; 10.AN.29.243; 10.AN.29.247; 10.AN.54.157; 10.AN.54.158; 10.AN.54.196; 10.AN.54.223; 10.AN.54.240; 10.AN.54.244; 10.AN.54.243; 10.AN.54.247; 10.AN.55.157; 10.AN.55.158; 10.AN.55.196; 10.AN.55.223; 10.AN.55.240; 10.AN.55.244; 10.AN.55.243; 10.AN.55.247; 10.AN.56.157; 10.AN.56.158; 10.AN.56.196; 10.AN.56.223; 10.AN.56.240; 10.AN.56.244; 10.AN.56.243; 10.AN.56.247; 10.AN.157.157; 10.AN.157.158; 10.AN.157.196; 10.AN.157.223; 10.AN.157.240; 10.AN.157.244; 10.AN.157.243; 10.AN.157.247; 10.AN.196.157; 10.AN.196.158; 10.AN.196.196; 10.AN.196.223; 10.AN.196.240; 10.AN.196.244; 10.AN.196.243; 10.AN.196.247; 10.AN.223.157; 10.AN.223.158; 10.AN.223.196; 10.AN.223.223; 10.AN.223.240; 10.AN.223.244; 10.AN.223.243; 10.AN.223.247; 10.AN.240.157; 10.AN.240.158; 10.AN.240.196; 10.AN.240.223; 10.AN.240.240; 10.AN.240.244; 10.AN.240.243; 10.AN.240.247; 10.AN.244.157; 10.AN.244.158; 10.AN.244.196; 10.AN.244.223; 10.AN.244.240; 10.AN.244.244; 10.AN.244.243; 10.AN.244.247; 10.AN.247.157; 10.AN.247.158; 10.AN.247.196; 10.AN.247.223; 10.AN.247.240; 10.AN.247.244; 10.AN.247.243; 10.AN.247.247;

Prodrugs of 10.AP

10.AP.4.157; 10.AP.4.158; 10.AP.4.196; 10.AP.4.223; 10.AP.4.240; 10.AP.4.244; 10.AP.4.243; 10.AP.4.247; 10.AP.5.157; 10.AP.5.158; 10.AP.5.196; 10.AP.5.223; 10.AP.5.240; 10.AP.5.244; 10.AP.5.243; 10.AP.5.247; 10.AP.7.157; 10.AP.7.158; 10.AP.7.196; 10.AP.7.223; 10.AP.7.240; 10.AP.7.244; 10.AP.7.243; 10.AP.7.247; 10.AP.15.157; 10.AP.15.158; 10.AP.15.196; 10.AP.15.223; 10.AP.15.240; 10.AP.15.244; 10.AP.15.243; 10.AP.15.247; 10.AP.16.157; 10.AP.16.158; 10.AP.16.196; 10.AP.16.223; 10.AP.16.240; 10.AP.16.244; 10.AP.16.243; 10.AP.16.247; 10.AP.18.157; 10.AP.18.158; 10.AP.18.196; 10.AP.18.223; 10.AP.18.240; 10.AP.18.244; 10.AP.18.243; 10.AP.18.247; 10.AP.26.157; 10.AP.26.158; 10.AP.26.196; 10.AP.26.223; 10.AP.26.240; 10.AP.26.244; 10.AP.26.243; 10.AP.26.247; 10.AP.27.157; 10.AP.27.158; 10.AP.27.196; 10.AP.27.223; 10.AP.27.240; 10.AP.27.244; 10.AP.27.243; 10.AP.27.247; 10.AP.29.157; 10.AP.29.158; 10.AP.29.196; 10.AP.29.223; 10.AP.29.240; 10.AP.29.244; 10.AP.29.243; 10.AP.29.247; 10.AP.54.157; 10.AP.54.158; 10.AP.54.196; 10.AP.54.223; 10.AP.54.240; 10.AP.54.244; 10.AP.54.243; 10.AP.54.247; 10.AP.55.157; 10.AP.55.158; 10.AP.55.196; 10.AP.55.223; 10.AP.55.240; 10.AP.55.244; 10.AP.55.243; 10.AP.55.247; 10.AP.56.157; 10.AP.56.158; 10.AP.56.196; 10.AP.56.223; 10.AP.56.240; 10.AP.56.244; 10.AP.56.243; 10.AP.56.247; 10.AP.157.157; 10.AP.157.158; 10.AP.157.196; 10.AP.157.223; 10.AP.157.240; 10.AP.157.244; 10.AP.157.243; 10.AP.157.247; 10.AP.196.157; 10.AP.196.158; 10.AP.196.196; 10.AP.196.223; 10.AP.196.240; 10.AP.196.244; 10.AP.196.243; 10.AP.196.247; 10.AP.223.157; 10.AP.223.158; 10.AP.223.196; 10.AP.223.223; 10.AP.223.240; 10.AP.223.244; 10.AP.223.243; 10.AP.223.247; 10.AP.240.157; 10.AP.240.158; 10.AP.240.196; 10.AP.240.223; 10.AP.240.240; 10.AP.240.244; 10.AP.240.243; 10.AP.240.247; 10.AP.244.157; 10.AP.244.158; 10.AP.244.196; 10.AP.244.223; 10.AP.244.240; 10.AP.244.244; 10.AP.244.243; 10.AP.244.247; 10.AP.247.157; 10.AP.247.158; 10.AP.247.196; 10.AP.247.223; 10.AP.247.240; 10.AP.247.244; 10.AP.247.243; 10.AP.247.247;

Prodrugs of 10.AZ

10.AZ.4.157; 10.AZ.4.158; 10.AZ.4.196; 10.AZ.4.223; 10.AZ.4.240; 10.AZ.4.244; 10.AZ.4.243; 10.AZ.4.247; 10.AZ.5.157; 10.AZ.5.158; 10.AZ.5.196; 10.AZ.5.223; 10.AZ.5.240; 10.AZ.5.244; 10.AZ.5.243; 10.AZ.5.247; 10.AZ.7.157; 10.AZ.7.158; 10.AZ.7.196; 10.AZ.7.223; 10.AZ.7.240; 10.AZ.7.244; 10.AZ.7.243; 10.AZ.7.247; 10.AZ.15.157; 10.AZ.15.158; 10.AZ.15.196; 10.AZ.15.223; 10.AZ.15.240; 10.AZ.15.244; 10.AZ.15.243; 10.AZ.15.247; 10.AZ.16.157; 10.AZ.16.158; 10.AZ.16.196; 10.AZ.16.223; 10.AZ.16.240; 10.AZ.16.244; 10.AZ.16.243; 10.AZ.16.247; 10.AZ.18.157; 10.AZ.18.158; 10.AZ.18.196; 10.AZ.18.223; 10.AZ.18.240; 10.AZ.18.244; 10.AZ.18.243; 10.AZ.18.247; 10.AZ.26.157; 10.AZ.26.158; 10.AZ.26.196; 10.AZ.26.223; 10.AZ.26.240; 10.AZ.26.244; 10.AZ.26.243; 10.AZ.26.247; 10.AZ.27.157; 10.AZ.27.158; 10.AZ.27.196; 10.AZ.27.223; 10.AZ.27.240; 10.AZ.27.244; 10.AZ.27.243; 10.AZ.27.247; 10.AZ.29.157; 10.AZ.29.158; 10.AZ.29.196; 10.AZ.29.223; 10.AZ.29.240; 10.AZ.29.244; 10.AZ.29.243; 10.AZ.29.247; 10.AZ.54.157; 10.AZ.54.158; 10.AZ.54.196; 10.AZ.54.223; 10.AZ.54.240; 10.AZ.54.244; 10.AZ.54.243; 10.AZ.54.247; 10.AZ.55.157; 10.AZ.55.158; 10.AZ.55.196; 10.AZ.55.223; 10.AZ.55.240; 10.AZ.55.244; 10.AZ.55.243; 10.AZ.55.247; 10.AZ.56.157; 10.AZ.56.158; 10.AZ.56.196; 10.AZ.56.223; 10.AZ.56.240; 10.AZ.56.244; 10.AZ.56.243; 10.AZ.56.247; 10.AZ.157.157; 10.AZ.157.158; 10.AZ.157.196; 10.AZ.157.223; 10.AZ.157.240; 10.AZ.157.244; 10.AZ.157.243; 10.AZ.157.247; 10.AZ.196.157; 10.AZ.196.158; 10.AZ.196.196; 10.AZ.196.223; 10.AZ.196.240; 10.AZ.196.244; 10.AZ.196.243; 10.AZ.196.247; 10.AZ.223.157; 10.AZ.223.158; 10.AZ.223.196; 10.AZ.223.223; 10.AZ.223.240; 10.AZ.223.244; 10.AZ.223.243; 10.AZ.223.247; 10.AZ.240.157; 10.AZ.240.158; 10.AZ.240.196; 10.AZ.240.223; 10.AZ.240.240; 10.AZ.240.244; 10.AZ.240.243; 10.AZ.240.247; 10.AZ.244.157; 10.AZ.244.158; 10.AZ.244.196; 10.AZ.244.223; 10.AZ.244.240; 10.AZ.244.244; 10.AZ.244.243; 10.AZ.244.247; 10.AZ.247.157; 10.AZ.247.158; 10.AZ.247.196; 10.AZ.247.223; 10.AZ.247.240; 10.AZ.247.244; 10.AZ.247.243; 10.AZ.247.247;

Prodrugs of 10.BF

10.BF.4.157; 10.BF.4.158; 10.BF.4.196; 10.BF.4.223; 10.BF.4.240; 10.BF.4.244; 10.BF.4.243; 10.BF.4.247; 10.BF.5.157; 10.BF.5.158; 10.BF.5.196; 10.BF.5.223; 10.BF.5.240; 10.BF.5.244; 10.BF.5.243; 10.BF.5.247; 10.BF.7.157; 10.BF.7.158; 10.BF.7.196; 10.BF.7.223; 10.BF.7.240; 10.BF.7.244; 10.BF.7.243; 10.BF.7.247; 10.BF.15.157; 10.BF.15.158; 10.BF.15.196; 10.BF.15.223; 10.BF.15.240; 10.BF.15.244; 10.BF.15.243; 10.BF.15.247; 10.BF.16.157; 10.BF.16.158; 10.BF.16.196; 10.BF.16.223; 10.BF.16.240; 10.BF.16.244; 10.BF.16.243; 10.BF.16.247; 10.BF.18.157; 10.BF.18.158; 10.BF.18.196; 10.BF.18.223; 10.BF.18.240; 10.BF.18.244; 10.BF.18.243; 10.BF.18.247; 10.BF.26.157; 10.BF.26.158; 10.BF.26.196; 10.BF.26.223; 10.BF.26.240; 10.BF.26.244; 10.BF.26.243; 10.BF.26.247; 10.BF.27.157; 10.BF.27.158; 10.BF.27.196; 10.BF.27.223; 10.BF.27.240; 10.BF.27.244; 10.BF.27.243; 10.BF.27.247; 10.BF.29.157; 10.BF.29.158; 10.BF.29.196; 10.BF.29.223; 10.BF.29.240; 10.BF.29.244; 10.BF.29.243; 10.BF.29.247; 10.BF.54.157; 10.BF.54.158; 10.BF.54.196; 10.BF.54.223; 10.BF.54.240; 10.BF.54.244; 10.BF.54.243; 10.BF.54.247; 10.BF.55.157; 10.BF.55.158; 10.BF.55.196; 10.BF.55.223; 10.BF.55.240; 10.BF.55.244; 10.BF.55.243; 10.BF.55.247; 10.BF.56.157; 10.BF.56.158; 10.BF.56.196; 10.BF.56.223; 10.BF.56.240; 10.BF.56.244; 10.BF.56.243; 10.BF.56.247; 10.BF.157.157; 10.BF.157.158; 10.BF.157.196; 10.BF.157.223; 10.BF.157.240; 10.BF.157.244; 10.BF.157.243; 10.BF.157.247; 10.BF.196.157; 10.BF.196.158; 10.BF.196.196; 10.BF.196.223; 10.BF.196.240; 10.BF.196.244; 10.BF.196.243; 10.BF.196.247; 10.BF.223.157; 10.BF.223.158; 10.BF.223.196; 10.BF.223.223; 10.BF.223.240; 10.BF.223.244; 10.BF.223.243; 10.BF.223.247; 10.BF.240.157; 10.BF.240.158; 10.BF.240.196; 10.BF.240.223; 10.BF.240.240; 10.BF.240.244; 10.BF.240.243; 10.BF.240.247; 10.BF.244.157; 10.BF.244.158; 10.BF.244.196; 10.BF.244.223; 10.BF.244.240; 10.BF.244.244; 10.BF.244.243; 10.BF.244.247; 10.BF.247.157; 10.BF.247.158; 10.BF.247.196; 10.BF.247.223; 10.BF.247.240; 10.BF.247.244; 10.BF.247.243; 10.BF.247.247;

Prodrugs of 10.CI

10.CI.4.157; 10.CI.4.158; 10.CI.4.196; 10.CI.4.223; 10.CI.4.240; 10.CI.4.244; 10.CI.4.243; 10.CI.4.247; 10.CI.5.157; 10.CI.5.158; 10.CI.5.196;

10.CI.5.223; 10.CI.5.240; 10.CI.5.244; 10.CI.5.243; 10.CI.5.247; 10.CI.7.157; 10.CI.7.158; 10.CI.7.196; 10.CI.7.223; 10.CI.7.240; 10.CI.7.244; 10.CI.7.243; 10.CI.7.247; 10.CI.15.157; 10.CI.15.158; 10.CI.15.196; 10.CI.15.223; 10.CI.15.240; 10.CI.15.244; 10.CI.15.243; 10.CI.15.247; 10.CI.16.157; 10.CI.16.158; 10.CI.16.196; 10.CI.16.223; 10.CI.16.240; 10.CI.16.244; 10.CI.16.243; 10.CI.16.247; 10.CI.18.157; 10.CI.18.158; 10.CI.18.196; 10.CI.18.223; 10.CI.18.240; 10.CI.18.244; 10.CI.18.243; 10.CI.18.247; 10.CI.26.157; 10.CI.26.158; 10.CI.26.196; 10.CI.26.223; 10.CI.26.240; 10.CI.26.244; 10.CI.26.243; 10.CI.26.247; 10.CI.27.157; 10.CI.27.158; 10.CI.27.196; 10.CI.27.223; 10.CI.27.240; 10.CI.27.244; 10.CI.27.243; 10.CI.27.247; 10.CI.29.157; 10.CI.29.158; 10.CI.29.196; 10.CI.29.223; 10.CI.29.240; 10.CI.29.244; 10.CI.29.243; 10.CI.29.247; 10.CI.54.157; 10.CI.54.158; 10.CI.54.196; 10.CI.54.223; 10.CI.54.240; 10.CI.54.244; 10.CI.54.243; 10.CI.54.247; 10.CI.55.157; 10.CI.55.158; 10.CI.55.196; 10.CI.55.223; 10.CI.55.240; 10.CI.55.244; 10.CI.55.243; 10.CI.55.247; 10.CI.56.157; 10.CI.56.158; 10.CI.56.196; 10.CI.56.223; 10.CI.56.240; 10.CI.56.244; 10.CI.56.243; 10.CI.56.247; 10.CI.157.157; 10.CI.157.158; 10.CI.157.196; 10.CI.157.223; 10.CI.157.240; 10.CI.157.244; 10.CI.157.243; 10.CI.157.247; 10.CI.196.157; 10.CI.196.158; 10.CI.196.196; 10.CI.196.223; 10.CI.196.240; 10.CI.196.244; 10.CI.196.243; 10.CI.196.247; 10.CI.223.157; 10.CI.223.158; 10.CI.223.196; 10.CI.223.223; 10.CI.223.240; 10.CI.223.244; 10.CI.223.243; 10.CI.223.247; 10.CI.240.157; 10.CI.240.158; 10.CI.240.196; 10.CI.240.223; 10.CI.240.240; 10.CI.240.244; 10.CI.240.243; 10.CI.240.247; 10.CI.244.157; 10.CI.244.158; 10.CI.244.196; 10.CI.244.223; 10.CI.244.240; 10.CI.244.244; 10.CI.244.243; 10.CI.244.247; 10.CI.247.157; 10.CI.247.158; 10.CI.247.196; 10.CI.247.223; 10.CI.247.240; 10.CI.247.244; 10.CI.247.243; 10.CI.247.247;

Prodrugs of 10.CO

10.CO.4.157; 10.CO.4.158; 10.CO.4.196; 10.CO.4.223; 10.CO.4.240; 10.CO.4.244; 10.CO.4.243; 10.CO.4.247; 10.CO.5.157; 10.CO.5.158; 10.CO.5.196; 10.CO.5.223; 10.CO.5.240; 10.CO.5.244; 10.CO.5.243; 10.CO.5.247; 10.CO.7.157; 10.CO.7.158; 10.CO.7.196; 10.CO.7.223;

10.CO.7.240; 10.CO.7.244; 10.CO.7.243; 10.CO.7.247; 10.CO.15.157; 10.CO.15.158; 10.CO.15.196; 10.CO.15.223; 10.CO.15.240; 10.CO.15.244; 10.CO.15.243; 10.CO.15.247; 10.CO.16.157; 10.CO.16.158; 10.CO.16.196; 10.CO.16.223; 10.CO.16.240; 10.CO.16.244; 10.CO.16.243; 10.CO.16.247; 10.CO.18.157; 10.CO.18.158; 10.CO.18.196; 10.CO.18.223; 10.CO.18.240; 10.CO.18.244; 10.CO.18.243; 10.CO.18.247; 10.CO.26.157; 10.CO.26.158; 10.CO.26.196; 10.CO.26.223; 10.CO.26.240; 10.CO.26.244; 10.CO.26.243; 10.CO.26.247; 10.CO.27.157; 10.CO.27.158; 10.CO.27.196; 10.CO.27.223; 10.CO.27.240; 10.CO.27.244; 10.CO.27.243; 10.CO.27.247; 10.CO.29.157; 10.CO.29.158; 10.CO.29.196; 10.CO.29.223; 10.CO.29.240; 10.CO.29.244; 10.CO.29.243; 10.CO.29.247; 10.CO.54.157; 10.CO.54.158; 10.CO.54.196; 10.CO.54.223; 10.CO.54.240; 10.CO.54.244; 10.CO.54.243; 10.CO.54.247; 10.CO.55.157; 10.CO.55.158; 10.CO.55.196; 10.CO.55.223; 10.CO.55.240; 10.CO.55.244; 10.CO.55.243; 10.CO.55.247; 10.CO.56.157; 10.CO.56.158; 10.CO.56.196; 10.CO.56.223; 10.CO.56.240; 10.CO.56.244; 10.CO.56.243; 10.CO.56.247; 10.CO.157.157; 10.CO.157.158; 10.CO.157.196; 10.CO.157.223; 10.CO.157.240; 10.CO.157.244; 10.CO.157.243; 10.CO.157.247; 10.CO.196.157; 10.CO.196.158; 10.CO.196.196; 10.CO.196.223; 10.CO.196.240; 10.CO.196.244; 10.CO.196.243; 10.CO.196.247; 10.CO.223.157; 10.CO.223.158; 10.CO.223.196; 10.CO.223.223; 10.CO.223.240; 10.CO.223.244; 10.CO.223.243; 10.CO.223.247; 10.CO.240.157; 10.CO.240.158; 10.CO.240.196; 10.CO.240.223; 10.CO.240.240; 10.CO.240.244; 10.CO.240.243; 10.CO.240.247; 10.CO.244.157; 10.CO.244.158; 10.CO.244.196; 10.CO.244.223; 10.CO.244.240; 10.CO.244.244; 10.CO.244.243; 10.CO.244.247; 10.CO.247.157; 10.CO.247.158; 10.CO.247.196; 10.CO.247.223; 10.CO.247.240; 10.CO.247.244; 10.CO.247.243; 10.CO.247.247;

Prodrugs of 11.AH

11.AH.4.157; 11.AH.4.158; 11.AH.4.196; 11.AH.4.223; 11.AH.4.240; 11.AH.4.244; 11.AH.4.243; 11.AH.4.247; 11.AH.5.157; 11.AH.5.158; 11.AH.5.196; 11.AH.5.223; 11.AH.5.240; 11.AH.5.244; 11.AH.5.243;

11.AH.5.247; 11.AH.7.157; 11.AH.7.158; 11.AH.7.196; 11.AH.7.223; 11.AH.7.240; 11.AH.7.244; 11.AH.7.243; 11.AH.7.247; 11.AH.15.157; 11.AH.15.158; 11.AH.15.196; 11.AH.15.223; 11.AH.15.240; 11.AH.15.244; 11.AH.15.243; 11.AH.15.247; 11.AH.16.157; 11.AH.16.158; 11.AH.16.196; 11.AH.16.223; 11.AH.16.240; 11.AH.16.244; 11.AH.16.243; 11.AH.16.247; 11.AH.18.157; 11.AH.18.158; 11.AH.18.196; 11.AH.18.223; 11.AH.18.240; 11.AH.18.244; 11.AH.18.243; 11.AH.18.247; 11.AH.26.157; 11.AH.26.158; 11.AH.26.196; 11.AH.26.223; 11.AH.26.240; 11.AH.26.244; 11.AH.26.243; 11.AH.26.247; 11.AH.27.157; 11.AH.27.158; 11.AH.27.196; 11.AH.27.223; 11.AH.27.240; 11.AH.27.244; 11.AH.27.243; 11.AH.27.247; 11.AH.29.157; 11.AH.29.158; 11.AH.29.196; 11.AH.29.223; 11.AH.29.240; 11.AH.29.244; 11.AH.29.243; 11.AH.29.247; 11.AH.54.157; 11.AH.54.158; 11.AH.54.196; 11.AH.54.223; 11.AH.54.240; 11.AH.54.244; 11.AH.54.243; 11.AH.54.247; 11.AH.55.157; 11.AH.55.158; 11.AH.55.196; 11.AH.55.223; 11.AH.55.240; 11.AH.55.244; 11.AH.55.243; 11.AH.55.247; 11.AH.56.157; 11.AH.56.158; 11.AH.56.196; 11.AH.56.223; 11.AH.56.240; 11.AH.56.244; 11.AH.56.243; 11.AH.56.247; 11.AH.157.157; 11.AH.157.158; 11.AH.157.196; 11.AH.157.223; 11.AH.157.240; 11.AH.157.244; 11.AH.157.243; 11.AH.157.247; 11.AH.196.157; 11.AH.196.158; 11.AH.196.196; 11.AH.196.223; 11.AH.196.240; 11.AH.196.244; 11.AH.196.243; 11.AH.196.247; 11.AH.223.157; 11.AH.223.158; 11.AH.223.196; 11.AH.223.223; 11.AH.223.240; 11.AH.223.244; 11.AH.223.243; 11.AH.223.247; 11.AH.240.157; 11.AH.240.158; 11.AH.240.196; 11.AH.240.223; 11.AH.240.240; 11.AH.240.244; 11.AH.240.243; 11.AH.240.247; 11.AH.244.157; 11.AH.244.158; 11.AH.244.196; 11.AH.244.223; 11.AH.244.240; 11.AH.244.244; 11.AH.244.243; 11.AH.244.247; 11.AH.247.157; 11.AH.247.158; 11.AH.247.196; 11.AH.247.223; 11.AH.247.240; 11.AH.247.244; 11.AH.247.243; 11.AH.247.247;

Prodrugs of 11.AJ

11.AJ.4.157; 11.AJ.4.158; 11.AJ.4.196; 11.AJ.4.223; 11.AJ.4.240; 11.AJ.4.244; 11.AJ.4.243; 11.AJ.4.247; 11.AJ.5.157; 11.AJ.5.158; 11.AJ.5.196;

11.AJ.5.223; 11.AJ.5.240; 11.AJ.5.244; 11.AJ.5.243; 11.AJ.5.247; 11.AJ.7.157; 11.AJ.7.158; 11.AJ.7.196; 11.AJ.7.223; 11.AJ.7.240; 11.AJ.7.244; 11.AJ.7.243; 11.AJ.7.247; 11.AJ.15.157; 11.AJ.15.158; 11.AJ.15.196; 11.AJ.15.223; 11.AJ.15.240; 11.AJ.15.244; 11.AJ.15.243; 11.AJ.15.247; 11.AJ.16.157; 11.AJ.16.158; 11.AJ.16.196; 11.AJ.16.223; 11.AJ.16.240; 11.AJ.16.244; 11.AJ.16.243; 11.AJ.16.247; 11.AJ.18.157; 11.AJ.18.158; 11.AJ.18.196; 11.AJ.18.223; 11.AJ.18.240; 11.AJ.18.244; 11.AJ.18.243; 11.AJ.18.247; 11.AJ.26.157; 11.AJ.26.158; 11.AJ.26.196; 11.AJ.26.223; 11.AJ.26.240; 11.AJ.26.244; 11.AJ.26.243; 11.AJ.26.247; 11.AJ.27.157; 11.AJ.27.158; 11.AJ.27.196; 11.AJ.27.223; 11.AJ.27.240; 11.AJ.27.244; 11.AJ.27.243; 11.AJ.27.247; 11.AJ.29.157; 11.AJ.29.158; 11.AJ.29.196; 11.AJ.29.223; 11.AJ.29.240; 11.AJ.29.244; 11.AJ.29.243; 11.AJ.29.247; 11.AJ.54.157; 11.AJ.54.158; 11.AJ.54.196; 11.AJ.54.223; 11.AJ.54.240; 11.AJ.54.244; 11.AJ.54.243; 11.AJ.54.247; 11.AJ.55.157; 11.AJ.55.158; 11.AJ.55.196; 11.AJ.55.223; 11.AJ.55.240; 11.AJ.55.244; 11.AJ.55.243; 11.AJ.55.247; 11.AJ.56.157; 11.AJ.56.158; 11.AJ.56.196; 11.AJ.56.223; 11.AJ.56.240; 11.AJ.56.244; 11.AJ.56.243; 11.AJ.56.247; 11.AJ.157.157; 11.AJ.157.158; 11.AJ.157.196; 11.AJ.157.223; 11.AJ.157.240; 11.AJ.157.244; 11.AJ.157.243; 11.AJ.157.247; 11.AJ.196.157; 11.AJ.196.158; 11.AJ.196.196; 11.AJ.196.223; 11.AJ.196.240; 11.AJ.196.244; 11.AJ.196.243; 11.AJ.196.247; 11.AJ.223.157; 11.AJ.223.158; 11.AJ.223.196; 11.AJ.223.223; 11.AJ.223.240; 11.AJ.223.244; 11.AJ.223.243; 11.AJ.223.247; 11.AJ.240.157; 11.AJ.240.158; 11.AJ.240.196; 11.AJ.240.223; 11.AJ.240.240; 11.AJ.240.244; 11.AJ.240.243; 11.AJ.240.247; 11.AJ.244.157; 11.AJ.244.158; 11.AJ.244.196; 11.AJ.244.223; 11.AJ.244.240; 11.AJ.244.244; 11.AJ.244.243; 11.AJ.244.247; 11.AJ.247.157; 11.AJ.247.158; 11.AJ.247.196; 11.AJ.247.223; 11.AJ.247.240; 11.AJ.247.244; 11.AJ.247.243; 11.AJ.247.247;

Prodrugs of 11.AN

11.AN.4.157; 11.AN.4.158; 11.AN.4.196; 11.AN.4.223; 11.AN.4.240; 11.AN.4.244; 11.AN.4.243; 11.AN.4.247; 11.AN.5.157; 11.AN.5.158; 11.AN.5.196; 11.AN.5.223; 11.AN.5.240; 11.AN.5.244; 11.AN.5.243; 11.AN.5.247; 11.AN.7.157; 11.AN.7.158; 11.AN.7.196; 11.AN.7.223;

11.AN.7.240; 11.AN.7.244; 11.AN.7.243; 11.AN.7.247; 11.AN.15.157; 11.AN.15.158; 11.AN.15.196; 11.AN.15.223; 11.AN.15.240; 11.AN.15.244; 11.AN.15.243; 11.AN.15.247; 11.AN.16.157; 11.AN.16.158; 11.AN.16.196; 11.AN.16.223; 11.AN.16.240; 11.AN.16.244; 11.AN.16.243; 11.AN.16.247; 11.AN.18.157; 11.AN.18.158; 11.AN.18.196; 11.AN.18.223; 11.AN.18.240; 11.AN.18.244; 11.AN.18.243; 11.AN.18.247; 11.AN.26.157; 11.AN.26.158; 11.AN.26.196; 11.AN.26.223; 11.AN.26.240; 11.AN.26.244; 11.AN.26.243; 11.AN.26.247; 11.AN.27.157; 11.AN.27.158; 11.AN.27.196; 11.AN.27.223; 11.AN.27.240; 11.AN.27.244; 11.AN.27.243; 11.AN.27.247; 11.AN.29.157; 11.AN.29.158; 11.AN.29.196; 11.AN.29.223; 11.AN.29.240; 11.AN.29.244; 11.AN.29.243; 11.AN.29.247; 11.AN.54.157; 11.AN.54.158; 11.AN.54.196; 11.AN.54.223; 11.AN.54.240; 11.AN.54.244; 11.AN.54.243; 11.AN.54.247; 11.AN.55.157; 11.AN.55.158; 11.AN.55.196; 11.AN.55.223; 11.AN.55.240; 11.AN.55.244; 11.AN.55.243; 11.AN.55.247; 11.AN.56.157; 11.AN.56.158; 11.AN.56.196; 11.AN.56.223; 11.AN.56.240; 11.AN.56.244; 11.AN.56.243; 11.AN.56.247; 11.AN.157.157; 11.AN.157.158; 11.AN.157.196; 11.AN.157.223; 11.AN.157.240; 11.AN.157.244; 11.AN.157.243; 11.AN.157.247; 11.AN.196.157; 11.AN.196.158; 11.AN.196.196; 11.AN.196.223; 11.AN.196.240; 11.AN.196.244; 11.AN.196.243; 11.AN.196.247; 11.AN.223.157; 11.AN.223.158; 11.AN.223.196; 11.AN.223.223; 11.AN.223.240; 11.AN.223.244; 11.AN.223.243; 11.AN.223.247; 11.AN.240.157; 11.AN.240.158; 11.AN.240.196; 11.AN.240.223; 11.AN.240.240; 11.AN.240.244; 11.AN.240.243; 11.AN.240.247; 11.AN.244.157; 11.AN.244.158; 11.AN.244.196; 11.AN.244.223; 11.AN.244.240; 11.AN.244.244; 11.AN.244.243; 11.AN.244.247; 11.AN.247.157; 11.AN.247.158; 11.AN.247.196; 11.AN.247.223; 11.AN.247.240; 11.AN.247.244; 11.AN.247.243; 11.AN.247.247;

Prodrugs of 11.AP

11.AP.4.157; 11.AP.4.158; 11.AP.4.196; 11.AP.4.223; 11.AP.4.240; 11.AP.4.244; 11.AP.4.243; 11.AP.4.247; 11.AP.5.157; 11.AP.5.158; 11.AP.5.196; 11.AP.5.223; 11.AP.5.240; 11.AP.5.244; 11.AP.5.243;

11.AP.5.247; 11.AP.7.157; 11.AP.7.158; 11.AP.7.196; 11.AP.7.223; 11.AP.7.240; 11.AP.7.244; 11.AP.7.243; 11.AP.7.247; 11.AP.15.157; 11.AP.15.158; 11.AP.15.196; 11.AP.15.223; 11.AP.15.240; 11.AP.15.244; 11.AP.15.243; 11.AP.15.247; 11.AP.16.157; 11.AP.16.158; 11.AP.16.196; 11.AP.16.223; 11.AP.16.240; 11.AP.16.244; 11.AP.16.243; 11.AP.16.247; 11.AP.18.157; 11.AP.18.158; 11.AP.18.196; 11.AP.18.223; 11.AP.18.240; 11.AP.18.244; 11.AP.18.243; 11.AP.18.247; 11.AP.26.157; 11.AP.26.158; 11.AP.26.196; 11.AP.26.223; 11.AP.26.240; 11.AP.26.244; 11.AP.26.243; 11.AP.26.247; 11.AP.27.157; 11.AP.27.158; 11.AP.27.196; 11.AP.27.223; 11.AP.27.240; 11.AP.27.244; 11.AP.27.243; 11.AP.27.247; 11.AP.29.157; 11.AP.29.158; 11.AP.29.196; 11.AP.29.223; 11.AP.29.240; 11.AP.29.244; 11.AP.29.243; 11.AP.29.247; 11.AP.54.157; 11.AP.54.158; 11.AP.54.196; 11.AP.54.223; 11.AP.54.240; 11.AP.54.244; 11.AP.54.243; 11.AP.54.247; 11.AP.55.157; 11.AP.55.158; 11.AP.55.196; 11.AP.55.223; 11.AP.55.240; 11.AP.55.244; 11.AP.55.243; 11.AP.55.247; 11.AP.56.157; 11.AP.56.158; 11.AP.56.196; 11.AP.56.223; 11.AP.56.240; 11.AP.56.244; 11.AP.56.243; 11.AP.56.247; 11.AP.157.157; 11.AP.157.158; 11.AP.157.196; 11.AP.157.223; 11.AP.157.240; 11.AP.157.244; 11.AP.157.243; 11.AP.157.247; 11.AP.196.157; 11.AP.196.158; 11.AP.196.196; 11.AP.196.223; 11.AP.196.240; 11.AP.196.244; 11.AP.196.243; 11.AP.196.247; 11.AP.223.157; 11.AP.223.158; 11.AP.223.196; 11.AP.223.223; 11.AP.223.240; 11.AP.223.244; 11.AP.223.243; 11.AP.223.247; 11.AP.240.157; 11.AP.240.158; 11.AP.240.196; 11.AP.240.223; 11.AP.240.240; 11.AP.240.244; 11.AP.240.243; 11.AP.240.247; 11.AP.244.157; 11.AP.244.158; 11.AP.244.196; 11.AP.244.223; 11.AP.244.240; 11.AP.244.244; 11.AP.244.243; 11.AP.244.247; 11.AP.247.157; 11.AP.247.158; 11.AP.247.196; 11.AP.247.223; 11.AP.247.240; 11.AP.247.244; 11.AP.247.243; 11.AP.247.247;

Prodrugs of 11.AZ

11.AZ.4.157; 11.AZ.4.158; 11.AZ.4.196; 11.AZ.4.223; 11.AZ.4.240; 11.AZ.4.244; 11.AZ.4.243; 11.AZ.4.247; 11.AZ.5.157; 11.AZ.5.158; 11.AZ.5.196; 11.AZ.5.223; 11.AZ.5.240; 11.AZ.5.244; 11.AZ.5.243;

11.AZ.5.247; 11.AZ.7.157; 11.AZ.7.158; 11.AZ.7.196; 11.AZ.7.223; 11.AZ.7.240; 11.AZ.7.244; 11.AZ.7.243; 11.AZ.7.247; 11.AZ.15.157; 11.AZ.15.158; 11.AZ.15.196; 11.AZ.15.223; 11.AZ.15.240; 11.AZ.15.244; 11.AZ.15.243; 11.AZ.15.247; 11.AZ.16.157; 11.AZ.16.158; 11.AZ.16.196; 11.AZ.16.223; 11.AZ.16.240; 11.AZ.16.244; 11.AZ.16.243; 11.AZ.16.247; 11.AZ.18.157; 11.AZ.18.158; 11.AZ.18.196; 11.AZ.18.223; 11.AZ.18.240; 11.AZ.18.244; 11.AZ.18.243; 11.AZ.18.247; 11.AZ.26.157; 11.AZ.26.158; 11.AZ.26.196; 11.AZ.26.223; 11.AZ.26.240; 11.AZ.26.244; 11.AZ.26.243; 11.AZ.26.247; 11.AZ.27.157; 11.AZ.27.158; 11.AZ.27.196; 11.AZ.27.223; 11.AZ.27.240; 11.AZ.27.244; 11.AZ.27.243; 11.AZ.27.247; 11.AZ.29.157; 11.AZ.29.158; 11.AZ.29.196; 11.AZ.29.223; 11.AZ.29.240; 11.AZ.29.244; 11.AZ.29.243; 11.AZ.29.247; 11.AZ.54.157; 11.AZ.54.158; 11.AZ.54.196; 11.AZ.54.223; 11.AZ.54.240; 11.AZ.54.244; 11.AZ.54.243; 11.AZ.54.247; 11.AZ.55.157; 11.AZ.55.158; 11.AZ.55.196; 11.AZ.55.223; 11.AZ.55.240; 11.AZ.55.244; 11.AZ.55.243; 11.AZ.55.247; 11.AZ.56.157; 11.AZ.56.158; 11.AZ.56.196; 11.AZ.56.223; 11.AZ.56.240; 11.AZ.56.244; 11.AZ.56.243; 11.AZ.56.247; 11.AZ.157.157; 11.AZ.157.158; 11.AZ.157.196; 11.AZ.157.223; 11.AZ.157.240; 11.AZ.157.244; 11.AZ.157.243; 11.AZ.157.247; 11.AZ.196.157; 11.AZ.196.158; 11.AZ.196.196; 11.AZ.196.223; 11.AZ.196.240; 11.AZ.196.244; 11.AZ.196.243; 11.AZ.196.247; 11.AZ.223.157; 11.AZ.223.158; 11.AZ.223.196; 11.AZ.223.223; 11.AZ.223.240; 11.AZ.223.244; 11.AZ.223.243; 11.AZ.223.247; 11.AZ.240.157; 11.AZ.240.158; 11.AZ.240.196; 11.AZ.240.223; 11.AZ.240.240; 11.AZ.240.244; 11.AZ.240.243; 11.AZ.240.247; 11.AZ.244.157; 11.AZ.244.158; 11.AZ.244.196; 11.AZ.244.223; 11.AZ.244.240; 11.AZ.244.244; 11.AZ.244.243; 11.AZ.244.247; 11.AZ.247.157; 11.AZ.247.158; 11.AZ.247.196; 11.AZ.247.223; 11.AZ.247.240; 11.AZ.247.244; 11.AZ.247.243; 11.AZ.247.247;

Prodrugs of 11.BF

11.BF.4.157; 11.BF.4.158; 11.BF.4.196; 11.BF.4.223; 11.BF.4.240; 11.BF.4.244; 11.BF.4.243; 11.BF.4.247; 11.BF.5.157; 11.BF.5.158; 11.BF.5.196; 11.BF.5.223; 11.BF.5.240; 11.BF.5.244; 11.BF.5.243;

11.BF.5.247; 11.BF.7.157; 11.BF.7.158; 11.BF.7.196; 11.BF.7.223; 11.BF.7.240; 11.BF.7.244; 11.BF.7.243; 11.BF.7.247; 11.BF.15.157; 11.BF.15.158; 11.BF.15.196; 11.BF.15.223; 11.BF.15.240; 11.BF.15.244; 11.BF.15.243; 11.BF.15.247; 11.BF.16.157; 11.BF.16.158; 11.BF.16.196; 11.BF.16.223; 11.BF.16.240; 11.BF.16.244; 11.BF.16.243; 11.BF.16.247; 11.BF.18.157; 11.BF.18.158; 11.BF.18.196; 11.BF.18.223; 11.BF.18.240; 11.BF.18.244; 11.BF.18.243; 11.BF.18.247; 11.BF.26.157; 11.BF.26.158; 11.BF.26.196; 11.BF.26.223; 11.BF.26.240; 11.BF.26.244; 11.BF.26.243; 11.BF.26.247; 11.BF.27.157; 11.BF.27.158; 11.BF.27.196; 11.BF.27.223; 11.BF.27.240; 11.BF.27.244; 11.BF.27.243; 11.BF.27.247; 11.BF.29.157; 11.BF.29.158; 11.BF.29.196; 11.BF.29.223; 11.BF.29.240; 11.BF.29.244; 11.BF.29.243; 11.BF.29.247; 11.BF.54.157; 11.BF.54.158; 11.BF.54.196; 11.BF.54.223; 11.BF.54.240; 11.BF.54.244; 11.BF.54.243; 11.BF.54.247; 11.BF.55.157; 11.BF.55.158; 11.BF.55.196; 11.BF.55.223; 11.BF.55.240; 11.BF.55.244; 11.BF.55.243; 11.BF.55.247; 11.BF.56.157; 11.BF.56.158; 11.BF.56.196; 11.BF.56.223; 11.BF.56.240; 11.BF.56.244; 11.BF.56.243; 11.BF.56.247; 11.BF.157.157; 11.BF.157.158; 11.BF.157.196; 11.BF.157.223; 11.BF.157.240; 11.BF.157.244; 11.BF.157.243; 11.BF.157.247; 11.BF.196.157; 11.BF.196.158; 11.BF.196.196; 11.BF.196.223; 11.BF.196.240; 11.BF.196.244; 11.BF.196.243; 11.BF.196.247; 11.BF.223.157; 11.BF.223.158; 11.BF.223.196; 11.BF.223.223; 11.BF.223.240; 11.BF.223.244; 11.BF.223.243; 11.BF.223.247; 11.BF.240.157; 11.BF.240.158; 11.BF.240.196; 11.BF.240.223; 11.BF.240.240; 11.BF.240.244; 11.BF.240.243; 11.BF.240.247; 11.BF.244.157; 11.BF.244.158; 11.BF.244.196; 11.BF.244.223; 11.BF.244.240; 11.BF.244.244; 11.BF.244.243; 11.BF.244.247; 11.BF.247.157; 11.BF.247.158; 11.BF.247.196; 11.BF.247.223; 11.BF.247.240; 11.BF.247.244; 11.BF.247.243; 11.BF.247.247;

Prodrugs of 11.CI

11.CI.4.157; 11.CI.4.158; 11.CI.4.196; 11.CI.4.223; 11.CI.4.240; 11.CI.4.244; 11.CI.4.243; 11.CI.4.247; 11.CI.5.157; 11.CI.5.158; 11.CI.5.196; 11.CI.5.223; 11.CI.5.240; 11.CI.5.244; 11.CI.5.243; 11.CI.5.247; 11.CI.7.157; 11.CI.7.158; 11.CI.7.196; 11.CI.7.223; 11.CI.7.240; 11.CI.7.244; 11.CI.7.243; 11.CI.7.247; 11.CI.15.157; 11.CI.15.158; 11.CI.15.196; 11.CI.15.223;

11.CI.15.240; 11.CI.15.244; 11.CI.15.243; 11.CI.15.247; 11.CI.16.157; 11.CI.16.158; 11.CI.16.196; 11.CI.16.223; 11.CI.16.240; 11.CI.16.244; 11.CI.16.243; 11.CI.16.247; 11.CI.18.157; 11.CI.18.158; 11.CI.18.196; 11.CI.18.223; 11.CI.18.240; 11.CI.18.244; 11.CI.18.243; 11.CI.18.247; 11.CI.26.157; 11.CI.26.158; 11.CI.26.196; 11.CI.26.223; 11.CI.26.240; 11.CI.26.244; 11.CI.26.243; 11.CI.26.247; 11.CI.27.157; 11.CI.27.158; 11.CI.27.196; 11.CI.27.223; 11.CI.27.240; 11.CI.27.244; 11.CI.27.243; 11.CI.27.247; 11.CI.29.157; 11.CI.29.158; 11.CI.29.196; 11.CI.29.223; 11.CI.29.240; 11.CI.29.244; 11.CI.29.243; 11.CI.29.247; 11.CI.54.157; 11.CI.54.158; 11.CI.54.196; 11.CI.54.223; 11.CI.54.240; 11.CI.54.244; 11.CI.54.243; 11.CI.54.247; 11.CI.55.157; 11.CI.55.158; 11.CI.55.196; 11.CI.55.223; 11.CI.55.240; 11.CI.55.244; 11.CI.55.243; 11.CI.55.247; 11.CI.56.157; 11.CI.56.158; 11.CI.56.196; 11.CI.56.223; 11.CI.56.240; 11.CI.56.244; 11.CI.56.243; 11.CI.56.247; 11.CI.157.157; 11.CI.157.158; 11.CI.157.196; 11.CI.157.223; 11.CI.157.240; 11.CI.157.244; 11.CI.157.243; 11.CI.157.247; 11.CI.196.157; 11.CI.196.158; 11.CI.196.196; 11.CI.196.223; 11.CI.196.240; 11.CI.196.244; 11.CI.196.243; 11.CI.196.247; 11.CI.223.157; 11.CI.223.158; 11.CI.223.196; 11.CI.223.223; 11.CI.223.240; 11.CI.223.244; 11.CI.223.243; 11.CI.223.247; 11.CI.240.157; 11.CI.240.158; 11.CI.240.196; 11.CI.240.223; 11.CI.240.240; 11.CI.240.244; 11.CI.240.243; 11.CI.240.247; 11.CI.244.157; 11.CI.244.158; 11.CI.244.196; 11.CI.244.223; 11.CI.244.240; 11.CI.244.244; 11.CI.244.243; 11.CI.244.247; 11.CI.247.157; 11.CI.247.158; 11.CI.247.196; 11.CI.247.223; 11.CI.247.240; 11.CI.247.244; 11.CI.247.243; 11.CI.247.247;

Prodrugs of 11.CO

11.CO.4.157; 11.CO.4.158; 11.CO.4.196; 11.CO.4.223; 11.CO.4.240; 11.CO.4.244; 11.CO.4.243; 11.CO.4.247; 11.CO.5.157; 11.CO.5.158; 11.CO.5.196; 11.CO.5.223; 11.CO.5.240; 11.CO.5.244; 11.CO.5.243; 11.CO.5.247; 11.CO.7.157; 11.CO.7.158; 11.CO.7.196; 11.CO.7.223; 11.CO.7.240; 11.CO.7.244; 11.CO.7.243; 11.CO.7.247; 11.CO.15.157; 11.CO.15.158; 11.CO.15.196; 11.CO.15.223; 11.CO.15.240; 11.CO.15.244; 11.CO.15.243; 11.CO.15.247; 11.CO.16.157; 11.CO.16.158; 11.CO.16.196;

11.CO.16.223; 11.CO.16.240; 11.CO.16.244; 11.CO.16.243; 11.CO.16.247; 11.CO.18.157; 11.CO.18.158; 11.CO.18.196; 11.CO.18.223; 11.CO.18.240; 11.CO.18.244; 11.CO.18.243; 11.CO.18.247; 11.CO.26.157; 11.CO.26.158; 11.CO.26.196; 11.CO.26.223; 11.CO.26.240; 11.CO.26.244; 11.CO.26.243; 11.CO.26.247; 11.CO.27.157; 11.CO.27.158; 11.CO.27.196; 11.CO.27.223; 11.CO.27.240; 11.CO.27.244; 11.CO.27.243; 11.CO.27.247; 11.CO.29.157; 11.CO.29.158; 11.CO.29.196; 11.CO.29.223; 11.CO.29.240; 11.CO.29.244; 11.CO.29.243; 11.CO.29.247; 11.CO.54.157; 11.CO.54.158; 11.CO.54.196; 11.CO.54.223; 11.CO.54.240; 11.CO.54.244; 11.CO.54.243; 11.CO.54.247; 11.CO.55.157; 11.CO.55.158; 11.CO.55.196; 11.CO.55.223; 11.CO.55.240; 11.CO.55.244; 11.CO.55.243; 11.CO.55.247; 11.CO.56.157; 11.CO.56.158; 11.CO.56.196; 11.CO.56.223; 11.CO.56.240; 11.CO.56.244; 11.CO.56.243; 11.CO.56.247; 11.CO.157.157; 11.CO.157.158; 11.CO.157.196; 11.CO.157.223; 11.CO.157.240; 11.CO.157.244; 11.CO.157.243; 11.CO.157.247; 11.CO.196.157; 11.CO.196.158; 11.CO.196.196; 11.CO.196.223; 11.CO.196.240; 11.CO.196.244; 11.CO.196.243; 11.CO.196.247; 11.CO.223.157; 11.CO.223.158; 11.CO.223.196; 11.CO.223.223; 11.CO.223.240; 11.CO.223.244; 11.CO.223.243; 11.CO.223.247; 11.CO.240.157; 11.CO.240.158; 11.CO.240.196; 11.CO.240.223; 11.CO.240.240; 11.CO.240.244; 11.CO.240.243; 11.CO.240.247; 11.CO.244.157; 11.CO.244.158; 11.CO.244.196; 11.CO.244.223; 11.CO.244.240; 11.CO.244.244; 11.CO.244.243; 11.CO.244.247; 11.CO.247.157; 11.CO.247.158; 11.CO.247.196; 11.CO.247.223; 11.CO.247.240; 11.CO.247.244; 11.CO.247.243; 11.CO.247.247;

Prodrugs of 12.AH

12.AH.4.157; 12.AH.4.158; 12.AH.4.196; 12.AH.4.223; 12.AH.4.240; 12.AH.4.244; 12.AH.4.243; 12.AH.4.247; 12.AH.5.157; 12.AH.5.158; 12.AH.5.196; 12.AH.5.223; 12.AH.5.240; 12.AH.5.244; 12.AH.5.243; 12.AH.5.247; 12.AH.7.157; 12.AH.7.158; 12.AH.7.196; 12.AH.7.223; 12.AH.7.240; 12.AH.7.244; 12.AH.7.243; 12.AH.7.247; 12.AH.15.157; 12.AH.15.158; 12.AH.15.196; 12.AH.15.223; 12.AH.15.240; 12.AH.15.244;

12.AH.15.243; 12.AH.15.247; 12.AH.16.157; 12.AH.16.158; 12.AH.16.196; 12.AH.16.223; 12.AH.16.240; 12.AH.16.244; 12.AH.16.243; 12.AH.16.247; 12.AH.18.157; 12.AH.18.158; 12.AH.18.196; 12.AH.18.223; 12.AH.18.240; 12.AH.18.244; 12.AH.18.243; 12.AH.18.247; 12.AH.26.157; 12.AH.26.158; 12.AH.26.196; 12.AH.26.223; 12.AH.26.240; 12.AH.26.244; 12.AH.26.243; 12.AH.26.247; 12.AH.27.157; 12.AH.27.158; 12.AH.27.196; 12.AH.27.223; 12.AH.27.240; 12.AH.27.244; 12.AH.27.243; 12.AH.27.247; 12.AH.29.157; 12.AH.29.158; 12.AH.29.196; 12.AH.29.223; 12.AH.29.240; 12.AH.29.244; 12.AH.29.243; 12.AH.29.247; 12.AH.54.157; 12.AH.54.158; 12.AH.54.196; 12.AH.54.223; 12.AH.54.240; 12.AH.54.244; 12.AH.54.243; 12.AH.54.247; 12.AH.55.157; 12.AH.55.158; 12.AH.55.196; 12.AH.55.223; 12.AH.55.240; 12.AH.55.244; 12.AH.55.243; 12.AH.55.247; 12.AH.56.157; 12.AH.56.158; 12.AH.56.196; 12.AH.56.223; 12.AH.56.240; 12.AH.56.244; 12.AH.56.243; 12.AH.56.247; 12.AH.157.157; 12.AH.157.158; 12.AH.157.196; 12.AH.157.223; 12.AH.157.240; 12.AH.157.244; 12.AH.157.243; 12.AH.157.247; 12.AH.196.157; 12.AH.196.158; 12.AH.196.196; 12.AH.196.223; 12.AH.196.240; 12.AH.196.244; 12.AH.196.243; 12.AH.196.247; 12.AH.223.157; 12.AH.223.158; 12.AH.223.196; 12.AH.223.223; 12.AH.223.240; 12.AH.223.244; 12.AH.223.243; 12.AH.223.247; 12.AH.240.157; 12.AH.240.158; 12.AH.240.196; 12.AH.240.223; 12.AH.240.240; 12.AH.240.244; 12.AH.240.243; 12.AH.240.247; 12.AH.244.157; 12.AH.244.158; 12.AH.244.196; 12.AH.244.223; 12.AH.244.240; 12.AH.244.244; 12.AH.244.243; 12.AH.244.247; 12.AH.247.157; 12.AH.247.158; 12.AH.247.196; 12.AH.247.223; 12.AH.247.240; 12.AH.247.244; 12.AH.247.243; 12.AH.247.247;

Prodrugs of 12.AJ

12.AJ.4.157; 12.AJ.4.158; 12.AJ.4.196; 12.AJ.4.223; 12.AJ.4.240; 12.AJ.4.244; 12.AJ.4.243; 12.AJ.4.247; 12.AJ.5.157; 12.AJ.5.158; 12.AJ.5.196; 12.AJ.5.223; 12.AJ.5.240; 12.AJ.5.244; 12.AJ.5.243; 12.AJ.5.247; 12.AJ.7.157; 12.AJ.7.158; 12.AJ.7.196; 12.AJ.7.223; 12.AJ.7.240; 12.AJ.7.244; 12.AJ.7.243; 12.AJ.7.247; 12.AJ.15.157; 12.AJ.15.158; 12.AJ.15.196; 12.AJ.15.223;

12.AJ.15.240; 12.AJ.15.244; 12.AJ.15.243; 12.AJ.15.247; 12.AJ.16.157; 12.AJ.16.158; 12.AJ.16.196; 12.AJ.16.223; 12.AJ.16.240; 12.AJ.16.244; 12.AJ.16.243; 12.AJ.16.247; 12.AJ.18.157; 12.AJ.18.158; 12.AJ.18.196; 12.AJ.18.223; 12.AJ.18.240; 12.AJ.18.244; 12.AJ.18.243; 12.AJ.18.247; 12.AJ.26.157; 12.AJ.26.158; 12.AJ.26.196; 12.AJ.26.223; 12.AJ.26.240; 12.AJ.26.244; 12.AJ.26.243; 12.AJ.26.247; 12.AJ.27.157; 12.AJ.27.158; 12.AJ.27.196; 12.AJ.27.223; 12.AJ.27.240; 12.AJ.27.244; 12.AJ.27.243; 12.AJ.27.247; 12.AJ.29.157; 12.AJ.29.158; 12.AJ.29.196; 12.AJ.29.223; 12.AJ.29.240; 12.AJ.29.244; 12.AJ.29.243; 12.AJ.29.247; 12.AJ.54.157; 12.AJ.54.158; 12.AJ.54.196; 12.AJ.54.223; 12.AJ.54.240; 12.AJ.54.244; 12.AJ.54.243; 12.AJ.54.247; 12.AJ.55.157; 12.AJ.55.158; 12.AJ.55.196; 12.AJ.55.223; 12.AJ.55.240; 12.AJ.55.244; 12.AJ.55.243; 12.AJ.55.247; 12.AJ.56.157; 12.AJ.56.158; 12.AJ.56.196; 12.AJ.56.223; 12.AJ.56.240; 12.AJ.56.244; 12.AJ.56.243; 12.AJ.56.247; 12.AJ.157.157; 12.AJ.157.158; 12.AJ.157.196; 12.AJ.157.223; 12.AJ.157.240; 12.AJ.157.244; 12.AJ.157.243; 12.AJ.157.247; 12.AJ.196.157; 12.AJ.196.158; 12.AJ.196.196; 12.AJ.196.223; 12.AJ.196.240; 12.AJ.196.244; 12.AJ.196.243; 12.AJ.196.247; 12.AJ.223.157; 12.AJ.223.158; 12.AJ.223.196; 12.AJ.223.223; 12.AJ.223.240; 12.AJ.223.244; 12.AJ.223.243; 12.AJ.223.247; 12.AJ.240.157; 12.AJ.240.158; 12.AJ.240.196; 12.AJ.240.223; 12.AJ.240.240; 12.AJ.240.244; 12.AJ.240.243; 12.AJ.240.247; 12.AJ.244.157; 12.AJ.244.158; 12.AJ.244.196; 12.AJ.244.223; 12.AJ.244.240; 12.AJ.244.244; 12.AJ.244.243; 12.AJ.244.247; 12.AJ.247.157; 12.AJ.247.158; 12.AJ.247.196; 12.AJ.247.223; 12.AJ.247.240; 12.AJ.247.244; 12.AJ.247.243; 12.AJ.247.247;

Prodrugs of 12.AN

12.AN.4.157; 12.AN.4.158; 12.AN.4.196; 12.AN.4.223; 12.AN.4.240; 12.AN.4.244; 12.AN.4.243; 12.AN.4.247; 12.AN.5.157; 12.AN.5.158; 12.AN.5.196; 12.AN.5.223; 12.AN.5.240; 12.AN.5.244; 12.AN.5.243; 12.AN.5.247; 12.AN.7.157; 12.AN.7.158; 12.AN.7.196; 12.AN.7.223; 12.AN.7.240; 12.AN.7.244; 12.AN.7.243; 12.AN.7.247; 12.AN.15.157; 12.AN.15.158; 12.AN.15.196; 12.AN.15.223; 12.AN.15.240; 12.AN.15.244; 12.AN.15.243; 12.AN.15.247; 12.AN.16.157; 12.AN.16.158; 12.AN.16.196;

12.AN.16.223; 12.AN.16.240; 12.AN.16.244; 12.AN.16.243; 12.AN.16.247; 12.AN.18.157; 12.AN.18.158; 12.AN.18.196; 12.AN.18.223; 12.AN.18.240; 12.AN.18.244; 12.AN.18.243; 12.AN.18.247; 12.AN.26.157; 12.AN.26.158; 12.AN.26.196; 12.AN.26.223; 12.AN.26.240; 12.AN.26.244; 12.AN.26.243; 12.AN.26.247; 12.AN.27.157; 12.AN.27.158; 12.AN.27.196; 12.AN.27.223; 12.AN.27.240; 12.AN.27.244; 12.AN.27.243; 12.AN.27.247; 12.AN.29.157; 12.AN.29.158; 12.AN.29.196; 12.AN.29.223; 12.AN.29.240; 12.AN.29.244; 12.AN.29.243; 12.AN.29.247; 12.AN.54.157; 12.AN.54.158; 12.AN.54.196; 12.AN.54.223; 12.AN.54.240; 12.AN.54.244; 12.AN.54.243; 12.AN.54.247; 12.AN.55.157; 12.AN.55.158; 12.AN.55.196; 12.AN.55.223; 12.AN.55.240; 12.AN.55.244; 12.AN.55.243; 12.AN.55.247; 12.AN.56.157; 12.AN.56.158; 12.AN.56.196; 12.AN.56.223; 12.AN.56.240; 12.AN.56.244; 12.AN.56.243; 12.AN.56.247; 12.AN.157.157; 12.AN.157.158; 12.AN.157.196; 12.AN.157.223; 12.AN.157.240; 12.AN.157.244; 12.AN.157.243; 12.AN.157.247; 12.AN.196.157; 12.AN.196.158; 12.AN.196.196; 12.AN.196.223; 12.AN.196.240; 12.AN.196.244; 12.AN.196.243; 12.AN.196.247; 12.AN.223.157; 12.AN.223.158; 12.AN.223.196; 12.AN.223.223; 12.AN.223.240; 12.AN.223.244; 12.AN.223.243; 12.AN.223.247; 12.AN.240.157; 12.AN.240.158; 12.AN.240.196; 12.AN.240.223; 12.AN.240.240; 12.AN.240.244; 12.AN.240.243; 12.AN.240.247; 12.AN.244.157; 12.AN.244.158; 12.AN.244.196; 12.AN.244.223; 12.AN.244.240; 12.AN.244.244; 12.AN.244.243; 12.AN.244.247; 12.AN.247.157; 12.AN.247.158; 12.AN.247.196; 12.AN.247.223; 12.AN.247.240; 12.AN.247.244; 12.AN.247.243; 12.AN.247.247;

Prodrugs of 12.AP

12.AP.4.157; 12.AP.4.158; 12.AP.4.196; 12.AP.4.223; 12.AP.4.240; 12.AP.4.244; 12.AP.4.243; 12.AP.4.247; 12.AP.5.157; 12.AP.5.158; 12.AP.5.196; 12.AP.5.223; 12.AP.5.240; 12.AP.5.244; 12.AP.5.243; 12.AP.5.247; 12.AP.7.157; 12.AP.7.158; 12.AP.7.196; 12.AP.7.223; 12.AP.7.240; 12.AP.7.244; 12.AP.7.243; 12.AP.7.247; 12.AP.15.157; 12.AP.15.158; 12.AP.15.196; 12.AP.15.223; 12.AP.15.240; 12.AP.15.244;

12.AP.15.243; 12.AP.15.247; 12.AP.16.157; 12.AP.16.158; 12.AP.16.196; 12.AP.16.223; 12.AP.16.240; 12.AP.16.244; 12.AP.16.243; 12.AP.16.247; 12.AP.18.157; 12.AP.18.158; 12.AP.18.196; 12.AP.18.223; 12.AP.18.240; 12.AP.18.244; 12.AP.18.243; 12.AP.18.247; 12.AP.26.157; 12.AP.26.158; 12.AP.26.196; 12.AP.26.223; 12.AP.26.240; 12.AP.26.244; 12.AP.26.243; 12.AP.26.247; 12.AP.27.157; 12.AP.27.158; 12.AP.27.196; 12.AP.27.223; 12.AP.27.240; 12.AP.27.244; 12.AP.27.243; 12.AP.27.247; 12.AP.29.157; 12.AP.29.158; 12.AP.29.196; 12.AP.29.223; 12.AP.29.240; 12.AP.29.244; 12.AP.29.243; 12.AP.29.247; 12.AP.54.157; 12.AP.54.158; 12.AP.54.196; 12.AP.54.223; 12.AP.54.240; 12.AP.54.244; 12.AP.54.243; 12.AP.54.247; 12.AP.55.157; 12.AP.55.158; 12.AP.55.196; 12.AP.55.223; 12.AP.55.240; 12.AP.55.244; 12.AP.55.243; 12.AP.55.247; 12.AP.56.157; 12.AP.56.158; 12.AP.56.196; 12.AP.56.223; 12.AP.56.240; 12.AP.56.244; 12.AP.56.243; 12.AP.56.247; 12.AP.157.157; 12.AP.157.158; 12.AP.157.196; 12.AP.157.223; 12.AP.157.240; 12.AP.157.244; 12.AP.157.243; 12.AP.157.247; 12.AP.196.157; 12.AP.196.158; 12.AP.196.196; 12.AP.196.223; 12.AP.196.240; 12.AP.196.244; 12.AP.196.243; 12.AP.196.247; 12.AP.223.157; 12.AP.223.158; 12.AP.223.196; 12.AP.223.223; 12.AP.223.240; 12.AP.223.244; 12.AP.223.243; 12.AP.223.247; 12.AP.240.157; 12.AP.240.158; 12.AP.240.196; 12.AP.240.223; 12.AP.240.240; 12.AP.240.244; 12.AP.240.243; 12.AP.240.247; 12.AP.244.157; 12.AP.244.158; 12.AP.244.196; 12.AP.244.223; 12.AP.244.240; 12.AP.244.244; 12.AP.244.243; 12.AP.244.247; 12.AP.247.157; 12.AP.247.158; 12.AP.247.196; 12.AP.247.223; 12.AP.247.240; 12.AP.247.244; 12.AP.247.243; 12.AP.247.247;

Prodrugs of 12.AZ

12.AZ.4.157; 12.AZ.4.158; 12.AZ.4.196; 12.AZ.4.223; 12.AZ.4.240; 12.AZ.4.244; 12.AZ.4.243; 12.AZ.4.247; 12.AZ.5.157; 12.AZ.5.158; 12.AZ.5.196; 12.AZ.5.223; 12.AZ.5.240; 12.AZ.5.244; 12.AZ.5.243; 12.AZ.5.247; 12.AZ.7.157; 12.AZ.7.158; 12.AZ.7.196; 12.AZ.7.223; 12.AZ.7.240; 12.AZ.7.244; 12.AZ.7.243; 12.AZ.7.247; 12.AZ.15.157; 12.AZ.15.158; 12.AZ.15.196; 12.AZ.15.223; 12.AZ.15.240; 12.AZ.15.244;

12.AZ.15.243; 12.AZ.15.247; 12.AZ.16.157; 12.AZ.16.158; 12.AZ.16.196; 12.AZ.16.223; 12.AZ.16.240; 12.AZ.16.244; 12.AZ.16.243; 12.AZ.16.247; 12.AZ.18.157; 12.AZ.18.158; 12.AZ.18.196; 12.AZ.18.223; 12.AZ.18.240; 12.AZ.18.244; 12.AZ.18.243; 12.AZ.18.247; 12.AZ.26.157; 12.AZ.26.158; 12.AZ.26.196; 12.AZ.26.223; 12.AZ.26.240; 12.AZ.26.244; 12.AZ.26.243; 12.AZ.26.247; 12.AZ.27.157; 12.AZ.27.158; 12.AZ.27.196; 12.AZ.27.223; 12.AZ.27.240; 12.AZ.27.244; 12.AZ.27.243; 12.AZ.27.247; 12.AZ.29.157; 12.AZ.29.158; 12.AZ.29.196; 12.AZ.29.223; 12.AZ.29.240; 12.AZ.29.244; 12.AZ.29.243; 12.AZ.29.247; 12.AZ.54.157; 12.AZ.54.158; 12.AZ.54.196; 12.AZ.54.223; 12.AZ.54.240; 12.AZ.54.244; 12.AZ.54.243; 12.AZ.54.247; 12.AZ.55.157; 12.AZ.55.158; 12.AZ.55.196; 12.AZ.55.223; 12.AZ.55.240; 12.AZ.55.244; 12.AZ.55.243; 12.AZ.55.247; 12.AZ.56.157; 12.AZ.56.158; 12.AZ.56.196; 12.AZ.56.223; 12.AZ.56.240; 12.AZ.56.244; 12.AZ.56.243; 12.AZ.56.247; 12.AZ.157.157; 12.AZ.157.158; 12.AZ.157.196; 12.AZ.157.223; 12.AZ.157.240; 12.AZ.157.244; 12.AZ.157.243; 12.AZ.157.247; 12.AZ.196.157; 12.AZ.196.158; 12.AZ.196.196; 12.AZ.196.223; 12.AZ.196.240; 12.AZ.196.244; 12.AZ.196.243; 12.AZ.196.247; 12.AZ.223.157; 12.AZ.223.158; 12.AZ.223.196; 12.AZ.223.223; 12.AZ.223.240; 12.AZ.223.244; 12.AZ.223.243; 12.AZ.223.247; 12.AZ.240.157; 12.AZ.240.158; 12.AZ.240.196; 12.AZ.240.223; 12.AZ.240.240; 12.AZ.240.244; 12.AZ.240.243; 12.AZ.240.247; 12.AZ.244.157; 12.AZ.244.158; 12.AZ.244.196; 12.AZ.244.223; 12.AZ.244.240; 12.AZ.244.244; 12.AZ.244.243; 12.AZ.244.247; 12.AZ.247.157; 12.AZ.247.158; 12.AZ.247.196; 12.AZ.247.223; 12.AZ.247.240; 12.AZ.247.244; 12.AZ.247.243; 12.AZ.247.247;

Prodrugs of 12.BF

12.BF.4.157; 12.BF.4.158; 12.BF.4.196; 12.BF.4.223; 12.BF.4.240; 12.BF.4.244; 12.BF.4.243; 12.BF.4.247; 12.BF.5.157; 12.BF.5.158; 12.BF.5.196; 12.BF.5.223; 12.BF.5.240; 12.BF.5.244; 12.BF.5.243; 12.BF.5.247; 12.BF.7.157; 12.BF.7.158; 12.BF.7.196; 12.BF.7.223; 12.BF.7.240; 12.BF.7.244; 12.BF.7.243; 12.BF.7.247; 12.BF.15.157; 12.BF.15.158; 12.BF.15.196; 12.BF.15.223; 12.BF.15.240; 12.BF.15.244;

12.BF.15.243; 12.BF.15.247; 12.BF.16.157; 12.BF.16.158; 12.BF.16.196; 12.BF.16.223; 12.BF.16.240; 12.BF.16.244; 12.BF.16.243; 12.BF.16.247; 12.BF.18.157; 12.BF.18.158; 12.BF.18.196; 12.BF.18.223; 12.BF.18.240; 12.BF.18.244; 12.BF.18.243; 12.BF.18.247; 12.BF.26.157; 12.BF.26.158; 12.BF.26.196; 12.BF.26.223; 12.BF.26.240; 12.BF.26.244; 12.BF.26.243; 12.BF.26.247; 12.BF.27.157; 12.BF.27.158; 12.BF.27.196; 12.BF.27.223; 12.BF.27.240; 12.BF.27.244; 12.BF.27.243; 12.BF.27.247; 12.BF.29.157; 12.BF.29.158; 12.BF.29.196; 12.BF.29.223; 12.BF.29.240; 12.BF.29.244; 12.BF.29.243; 12.BF.29.247; 12.BF.54.157; 12.BF.54.158; 12.BF.54.196; 12.BF.54.223; 12.BF.54.240; 12.BF.54.244; 12.BF.54.243; 12.BF.54.247; 12.BF.55.157; 12.BF.55.158; 12.BF.55.196; 12.BF.55.223; 12.BF.55.240; 12.BF.55.244; 12.BF.55.243; 12.BF.55.247; 12.BF.56.157; 12.BF.56.158; 12.BF.56.196; 12.BF.56.223; 12.BF.56.240; 12.BF.56.244; 12.BF.56.243; 12.BF.56.247; 12.BF.157.157; 12.BF.157.158; 12.BF.157.196; 12.BF.157.223; 12.BF.157.240; 12.BF.157.244; 12.BF.157.243; 12.BF.157.247; 12.BF.196.157; 12.BF.196.158; 12.BF.196.196; 12.BF.196.223; 12.BF.196.240; 12.BF.196.244; 12.BF.196.243; 12.BF.196.247; 12.BF.223.157; 12.BF.223.158; 12.BF.223.196; 12.BF.223.223; 12.BF.223.240; 12.BF.223.244; 12.BF.223.243; 12.BF.223.247; 12.BF.240.157; 12.BF.240.158; 12.BF.240.196; 12.BF.240.223; 12.BF.240.240; 12.BF.240.244; 12.BF.240.243; 12.BF.240.247; 12.BF.244.157; 12.BF.244.158; 12.BF.244.196; 12.BF.244.223; 12.BF.244.240; 12.BF.244.244; 12.BF.244.243; 12.BF.244.247; 12.BF.247.157; 12.BF.247.158; 12.BF.247.196; 12.BF.247.223; 12.BF.247.240; 12.BF.247.244; 12.BF.247.243; 12.BF.247.247;

Prodrugs of 12.CI

12.CI.4.157; 12.CI.4.158; 12.CI.4.196; 12.CI.4.223; 12.CI.4.240; 12.CI.4.244; 12.CI.4.243; 12.CI.4.247; 12.CI.5.157; 12.CI.5.158; 12.CI.5.196; 12.CI.5.223; 12.CI.5.240; 12.CI.5.244; 12.CI.5.243; 12.CI.5.247; 12.CI.7.157; 12.CI.7.158; 12.CI.7.196; 12.CI.7.223; 12.CI.7.240; 12.CI.7.244; 12.CI.7.243; 12.CI.7.247; 12.CI.15.157; 12.CI.15.158; 12.CI.15.196; 12.CI.15.223; 12.CI.15.240; 12.CI.15.244; 12.CI.15.243; 12.CI.15.247; 12.CI.16.157; 12.CI.16.158; 12.CI.16.196; 12.CI.16.223; 12.CI.16.240; 12.CI.16.244; 12.CI.16.243; 12.CI.16.247; 12.CI.18.157; 12.CI.18.158; 12.CI.18.196;

12.CI.18.223; 12.CI.18.240; 12.CI.18.244; 12.CI.18.243; 12.CI.18.247; 12.CI.26.157; 12.CI.26.158; 12.CI.26.196; 12.CI.26.223; 12.CI.26.240; 12.CI.26.244; 12.CI.26.243; 12.CI.26.247; 12.CI.27.157; 12.CI.27.158; 12.CI.27.196; 12.CI.27.223; 12.CI.27.240; 12.CI.27.244; 12.CI.27.243; 12.CI.27.247; 12.CI.29.157; 12.CI.29.158; 12.CI.29.196; 12.CI.29.223; 12.CI.29.240; 12.CI.29.244; 12.CI.29.243; 12.CI.29.247; 12.CI.54.157; 12.CI.54.158; 12.CI.54.196; 12.CI.54.223; 12.CI.54.240; 12.CI.54.244; 12.CI.54.243; 12.CI.54.247; 12.CI.55.157; 12.CI.55.158; 12.CI.55.196; 12.CI.55.223; 12.CI.55.240; 12.CI.55.244; 12.CI.55.243; 12.CI.55.247; 12.CI.56.157; 12.CI.56.158; 12.CI.56.196; 12.CI.56.223; 12.CI.56.240; 12.CI.56.244; 12.CI.56.243; 12.CI.56.247; 12.CI.157.157; 12.CI.157.158; 12.CI.157.196; 12.CI.157.223; 12.CI.157.240; 12.CI.157.244; 12.CI.157.243; 12.CI.157.247; 12.CI.196.157; 12.CI.196.158; 12.CI.196.196; 12.CI.196.223; 12.CI.196.240; 12.CI.196.244; 12.CI.196.243; 12.CI.196.247; 12.CI.223.157; 12.CI.223.158; 12.CI.223.196; 12.CI.223.223; 12.CI.223.240; 12.CI.223.244; 12.CI.223.243; 12.CI.223.247; 12.CI.240.157; 12.CI.240.158; 12.CI.240.196; 12.CI.240.223; 12.CI.240.240; 12.CI.240.244; 12.CI.240.243; 12.CI.240.247; 12.CI.244.157; 12.CI.244.158; 12.CI.244.196; 12.CI.244.223; 12.CI.244.240; 12.CI.244.244; 12.CI.244.243; 12.CI.244.247; 12.CI.247.157; 12.CI.247.158; 12.CI.247.196; 12.CI.247.223; 12.CI.247.240; 12.CI.247.244; 12.CI.247.243; 12.CI.247.247;

Prodrugs of 12.CO

12.CO.4.157; 12.CO.4.158; 12.CO.4.196; 12.CO.4.223; 12.CO.4.240; 12.CO.4.244; 12.CO.4.243; 12.CO.4.247; 12.CO.5.157; 12.CO.5.158; 12.CO.5.196; 12.CO.5.223; 12.CO.5.240; 12.CO.5.244; 12.CO.5.243; 12.CO.5.247; 12.CO.7.157; 12.CO.7.158; 12.CO.7.196; 12.CO.7.223; 12.CO.7.240; 12.CO.7.244; 12.CO.7.243; 12.CO.7.247; 12.CO.15.157; 12.CO.15.158; 12.CO.15.196; 12.CO.15.223; 12.CO.15.240; 12.CO.15.244; 12.CO.15.243; 12.CO.15.247; 12.CO.16.157; 12.CO.16.158; 12.CO.16.196; 12.CO.16.223; 12.CO.16.240; 12.CO.16.244; 12.CO.16.243; 12.CO.16.247; 12.CO.18.157; 12.CO.18.158; 12.CO.18.196; 12.CO.18.223; 12.CO.18.240; 12.CO.18.244; 12.CO.18.243; 12.CO.18.247; 12.CO.26.157; 12.CO.26.158;

12.CO.26.196; 12.CO.26.223; 12.CO.26.240; 12.CO.26.244; 12.CO.26.243; 12.CO.26.247; 12.CO.27.157; 12.CO.27.158; 12.CO.27.196; 12.CO.27.223; 12.CO.27.240; 12.CO.27.244; 12.CO.27.243; 12.CO.27.247; 12.CO.29.157; 12.CO.29.158; 12.CO.29.196; 12.CO.29.223; 12.CO.29.240; 12.CO.29.244; 12.CO.29.243; 12.CO.29.247; 12.CO.54.157; 12.CO.54.158; 12.CO.54.196; 12.CO.54.223; 12.CO.54.240; 12.CO.54.244; 12.CO.54.243; 12.CO.54.247; 12.CO.55.157; 12.CO.55.158; 12.CO.55.196; 12.CO.55.223; 12.CO.55.240; 12.CO.55.244; 12.CO.55.243; 12.CO.55.247; 12.CO.56.157; 12.CO.56.158; 12.CO.56.196; 12.CO.56.223; 12.CO.56.240; 12.CO.56.244; 12.CO.56.243; 12.CO.56.247; 12.CO.157.157; 12.CO.157.158; 12.CO.157.196; 12.CO.157.223; 12.CO.157.240; 12.CO.157.244; 12.CO.157.243; 12.CO.157.247; 12.CO.196.157; 12.CO.196.158; 12.CO.196.196; 12.CO.196.223; 12.CO.196.240; 12.CO.196.244; 12.CO.196.243; 12.CO.196.247; 12.CO.223.157; 12.CO.223.158; 12.CO.223.196; 12.CO.223.223; 12.CO.223.240; 12.CO.223.244; 12.CO.223.243; 12.CO.223.247; 12.CO.240.157; 12.CO.240.158; 12.CO.240.196; 12.CO.240.223; 12.CO.240.240; 12.CO.240.244; 12.CO.240.243; 12.CO.240.247; 12.CO.244.157; 12.CO.244.158; 12.CO.244.196; 12.CO.244.223; 12.CO.244.240; 12.CO.244.244; 12.CO.244.243; 12.CO.244.247; 12.CO.247.157; 12.CO.247.158; 12.CO.247.196; 12.CO.247.223; 12.CO.247.240; 12.CO.247.244; 12.CO.247.243; 12.CO.247.247.

Prodrugs of 13.B

13.B.228.228; 13.B.228.229; 13.B.228.230; 13.B.228.231; 13.B.228.236; 13.B.228.237; 13.B.228.238; 13.B.228.239; 13.B.228.154; 13.B.228.157; 13.B.228.166; 13.B.228.169; 13.B.228.172; 13.B.228.175; 13.B.228.240; 13.B.228.244; 13.B.229.228; 13.B.229.229; 13.B.229.230; 13.B.229.231; 13.B.229.236; 13.B.229.237; 13.B.229.238; 13.B.229.239; 13.B.229.154; 13.B.229.157; 13.B.229.166; 13.B.229.169; 13.B.229.172; 13.B.229.175; 13.B.229.240; 13.B.229.244; 13.B.230.228; 13.B.230.229; 13.B.230.230; 13.B.230.231; 13.B.230.236; 13.B.230.237; 13.B.230.238; 13.B.230.239; 13.B.230.154; 13.B.230.157; 13.B.230.166; 13.B.230.169; 13.B.230.172; 13.B.230.175; 13.B.230.240; 13.B.230.244; 13.B.231.228; 13.B.231.229;

13.B.231.230; 13.B.231.231; 13.B.231.236; 13.B.231.237; 13.B.231.238; 13.B.231.239; 13.B.231.154; 13.B.231.157; 13.B.231.166; 13.B.231.169; 13.B.231.172; 13.B.231.175; 13.B.231.240; 13.B.231.244; 13.B.236.228; 13.B.236.229; 13.B.236.230; 13.B.236.231; 13.B.236.236; 13.B.236.237; 13.B.236.238; 13.B.236.239; 13.B.236.154; 13.B.236.157; 13.B.236.166; 13.B.236.169; 13.B.236.172; 13.B.236.175; 13.B.236.240; 13.B.236.244; 13.B.237.228; 13.B.237.229; 13.B.237.230; 13.B.237.231; 13.B.237.236; 13.B.237.237; 13.B.237.238; 13.B.237.239; 13.B.237.154; 13.B.237.157; 13.B.237.166; 13.B.237.169; 13.B.237.172; 13.B.237.175; 13.B.237.240; 13.B.237.244; 13.B.238.228; 13.B.238.229; 13.B.238.230; 13.B.238.231; 13.B.238.236; 13.B.238.237; 13.B.238.238; 13.B.238.239; 13.B.238.154; 13.B.238.157; 13.B.238.166; 13.B.238.169; 13.B.238.172; 13.B.238.175; 13.B.238.240; 13.B.238.244; 13.B.239.228; 13.B.239.229; 13.B.239.230; 13.B.239.231; 13.B.239.236; 13.B.239.237; 13.B.239.238; 13.B.239.239; 13.B.239.154; 13.B.239.157; 13.B.239.166; 13.B.239.169; 13.B.239.172; 13.B.239.175; 13.B.239.240; 13.B.239.244; 13.B.154.228; 13.B.154.229; 13.B.154.230; 13.B.154.231; 13.B.154.236; 13.B.154.237; 13.B.154.238; 13.B.154.239; 13.B.154.154; 13.B.154.157; 13.B.154.166; 13.B.154.169; 13.B.154.172; 13.B.154.175; 13.B.154.240; 13.B.154.244; 13.B.157.228; 13.B.157.229; 13.B.157.230; 13.B.157.231; 13.B.157.236; 13.B.157.237; 13.B.157.238; 13.B.157.239; 13.B.157.154; 13.B.157.157; 13.B.157.166; 13.B.157.169; 13.B.157.172; 13.B.157.175; 13.B.157.240; 13.B.157.244; 13.B.166.228; 13.B.166.229; 13.B.166.230; 13.B.166.231; 13.B.166.236; 13.B.166.237; 13.B.166.238; 13.B.166.239; 13.B.166.154; 13.B.166.157; 13.B.166.166; 13.B.166.169; 13.B.166.172; 13.B.166.175; 13.B.166.240; 13.B.166.244; 13.B.169.228; 13.B.169.229; 13.B.169.230; 13.B.169.231; 13.B.169.236; 13.B.169.237; 13.B.169.238; 13.B.169.239; 13.B.169.154; 13.B.169.157; 13.B.169.166; 13.B.169.169; 13.B.169.172; 13.B.169.175; 13.B.169.240; 13.B.169.244; 13.B.172.228; 13.B.172.229; 13.B.172.230; 13.B.172.231; 13.B.172.236; 13.B.172.237; 13.B.172.238; 13.B.172.239; 13.B.172.154; 13.B.172.157; 13.B.172.166; 13.B.172.169; 13.B.172.172; 13.B.172.175; 13.B.172.240; 13.B.172.244; 13.B.175.228; 13.B.175.229; 13.B.175.230; 13.B.175.231; 13.B.175.236; 13.B.175.237; 13.B.175.238; 13.B.175.239; 13.B.175.154; 13.B.175.157; 13.B.175.166; 13.B.175.169; 13.B.175.172; 13.B.175.175; 13.B.175.240; 13.B.175.244; 13.B.240.228; 13.B.240.229; 13.B.240.230; 13.B.240.231; 13.B.240.236; 13.B.240.237; 13.B.240.238; 13.B.240.239; 13.B.240.154; 13.B.240.157; 13.B.240.166;

13.B.240.169; 13.B.240.172; 13.B.240.175; 13.B.240.240; 13.B.240.244; 13.B.244.228; 13.B.244.229; 13.B.244.230; 13.B.244.231; 13.B.244.236; 13.B.244.237; 13.B.244.238; 13.B.244.239; 13.B.244.154; 13.B.244.157; 13.B.244.166; 13.B.244.169; 13.B.244.172; 13.B.244.175; 13.B.244.240; 13.B.244.244;

Prodrugs of 13.D

13.D.228.228; 13.D.228.229; 13.D.228.230; 13.D.228.231; 13.D.228.236; 13.D.228.237; 13.D.228.238; 13.D.228.239; 13.D.228.154; 13.D.228.157; 13.D.228.166; 13.D.228.169; 13.D.228.172; 13.D.228.175; 13.D.228.240; 13.D.228.244; 13.D.229.228; 13.D.229.229; 13.D.229.230; 13.D.229.231; 13.D.229.236; 13.D.229.237; 13.D.229.238; 13.D.229.239; 13.D.229.154; 13.D.229.157; 13.D.229.166; 13.D.229.169; 13.D.229.172; 13.D.229.175; 13.D.229.240; 13.D.229.244; 13.D.230.228; 13.D.230.229; 13.D.230.230; 13.D.230.231; 13.D.230.236; 13.D.230.237; 13.D.230.238; 13.D.230.239; 13.D.230.154; 13.D.230.157; 13.D.230.166; 13.D.230.169; 13.D.230.172; 13.D.230.175; 13.D.230.240; 13.D.230.244; 13.D.231.228; 13.D.231.229; 13.D.231.230; 13.D.231.231; 13.D.231.236; 13.D.231.237; 13.D.231.238; 13.D.231.239; 13.D.231.154; 13.D.231.157; 13.D.231.166; 13.D.231.169; 13.D.231.172; 13.D.231.175; 13.D.231.240; 13.D.231.244; 13.D.236.228; 13.D.236.229; 13.D.236.230; 13.D.236.231; 13.D.236.236; 13.D.236.237; 13.D.236.238; 13.D.236.239; 13.D.236.154; 13.D.236.157; 13.D.236.166; 13.D.236.169; 13.D.236.172; 13.D.236.175; 13.D.236.240; 13.D.236.244; 13.D.237.228; 13.D.237.229; 13.D.237.230; 13.D.237.231; 13.D.237.236; 13.D.237.237; 13.D.237.238; 13.D.237.239; 13.D.237.154; 13.D.237.157; 13.D.237.166; 13.D.237.169; 13.D.237.172; 13.D.237.175; 13.D.237.240; 13.D.237.244; 13.D.238.228; 13.D.238.229; 13.D.238.230; 13.D.238.231; 13.D.238.236; 13.D.238.237; 13.D.238.238; 13.D.238.239; 13.D.238.154; 13.D.238.157; 13.D.238.166; 13.D.238.169; 13.D.238.172; 13.D.238.175; 13.D.238.240; 13.D.238.244; 13.D.239.228; 13.D.239.229; 13.D.239.230; 13.D.239.231; 13.D.239.236; 13.D.239.237; 13.D.239.238; 13.D.239.239; 13.D.239.154; 13.D.239.157; 13.D.239.166; 13.D.239.169; 13.D.239.172; 13.D.239.175; 13.D.239.240; 13.D.239.244; 13.D.154.228; 13.D.154.229; 13.D.154.230; 13.D.154.231; 13.D.154.236; 13.D.154.237; 13.D.154.238; 13.D.154.239; 13.D.154.154; 13.D.154.157; 13.D.154.166; 13.D.154.169; 13.D.154.172; 13.D.154.175; 13.D.154.240; 13.D.154.244; 13.D.157.228; 13.D.157.229; 13.D.157.230; 13.D.157.231; 13.D.157.236; 13.D.157.237;

13.D.157.238; 13.D.157.239; 13.D.157.154; 13.D.157.157; 13.D.157.166; 13.D.157.169; 13.D.157.172; 13.D.157.175; 13.D.157.240; 13.D.157.244; 13.D.166.228; 13.D.166.229; 13.D.166.230; 13.D.166.231; 13.D.166.236; 13.D.166.237; 13.D.166.238; 13.D.166.239; 13.D.166.154; 13.D.166.157; 13.D.166.166; 13.D.166.169; 13.D.166.172; 13.D.166.175; 13.D.166.240; 13.D.166.244; 13.D.169.228; 13.D.169.229; 13.D.169.230; 13.D.169.231; 13.D.169.236; 13.D.169.237; 13.D.169.238; 13.D.169.239; 13.D.169.154; 13.D.169.157; 13.D.169.166; 13.D.169.169; 13.D.169.172; 13.D.169.175; 13.D.169.240; 13.D.169.244; 13.D.172.228; 13.D.172.229; 13.D.172.230; 13.D.172.231; 13.D.172.236; 13.D.172.237; 13.D.172.238; 13.D.172.239; 13.D.172.154; 13.D.172.157; 13.D.172.166; 13.D.172.169; 13.D.172.172; 13.D.172.175; 13.D.172.240; 13.D.172.244; 13.D.175.228; 13.D.175.229; 13.D.175.230; 13.D.175.231; 13.D.175.236; 13.D.175.237; 13.D.175.238; 13.D.175.239; 13.D.175.154; 13.D.175.157; 13.D.175.166; 13.D.175.169; 13.D.175.172; 13.D.175.175; 13.D.175.240; 13.D.175.244; 13.D.240.228; 13.D.240.229; 13.D.240.230; 13.D.240.231; 13.D.240.236; 13.D.240.237; 13.D.240.238; 13.D.240.239; 13.D.240.154; 13.D.240.157; 13.D.240.166; 13.D.240.169; 13.D.240.172; 13.D.240.175; 13.D.240.240; 13.D.240.244; 13.D.244.228; 13.D.244.229; 13.D.244.230; 13.D.244.231; 13.D.244.236; 13.D.244.237; 13.D.244.238; 13.D.244.239; 13.D.244.154; 13.D.244.157; 13.D.244.166; 13.D.244.169; 13.D.244.172; 13.D.244.175; 13.D.244.240; 13.D.244.244;

Prodrugs of 13.E

13.E.228.228; 13.E.228.229; 13.E.228.230; 13.E.228.231; 13.E.228.236; 13.E.228.237; 13.E.228.238; 13.E.228.239; 13.E.228.154; 13.E.228.157; 13.E.228.166; 13.E.228.169; 13.E.228.172; 13.E.228.175; 13.E.228.240; 13.E.228.244; 13.E.229.228; 13.E.229.229; 13.E.229.230; 13.E.229.231; 13.E.229.236; 13.E.229.237; 13.E.229.238; 13.E.229.239; 13.E.229.154; 13.E.229.157; 13.E.229.166; 13.E.229.169; 13.E.229.172; 13.E.229.175; 13.E.229.240; 13.E.229.244; 13.E.230.228; 13.E.230.229; 13.E.230.230; 13.E.230.231; 13.E.230.236; 13.E.230.237; 13.E.230.238; 13.E.230.239; 13.E.230.154; 13.E.230.157; 13.E.230.166; 13.E.230.169; 13.E.230.172; 13.E.230.175; 13.E.230.240; 13.E.230.244; 13.E.231.228; 13.E.231.229; 13.E.231.230; 13.E.231.231; 13.E.231.236; 13.E.231.237; 13.E.231.238; 13.E.231.239; 13.E.231.154; 13.E.231.157; 13.E.231.166; 13.E.231.169; 13.E.231.172; 13.E.231.175; 13.E.231.240; 13.E.231.244; 13.E.236.228;

13.E.236.229; 13.E.236.230; 13.E.236.231; 13.E.236.236; 13.E.236.237; 13.E.236.238; 13.E.236.239; 13.E.236.154; 13.E.236.157; 13.E.236.166; 13.E.236.169; 13.E.236.172; 13.E.236.175; 13.E.236.240; 13.E.236.244; 13.E.237.228; 13.E.237.229; 13.E.237.230; 13.E.237.231; 13.E.237.236; 13.E.237.237; 13.E.237.238; 13.E.237.239; 13.E.237.154; 13.E.237.157; 13.E.237.166; 13.E.237.169; 13.E.237.172; 13.E.237.175; 13.E.237.240; 13.E.237.244; 13.E.238.228; 13.E.238.229; 13.E.238.230; 13.E.238.231; 13.E.238.236; 13.E.238.237; 13.E.238.238; 13.E.238.239; 13.E.238.154; 13.E.238.157; 13.E.238.166; 13.E.238.169; 13.E.238.172; 13.E.238.175; 13.E.238.240; 13.E.238.244; 13.E.239.228; 13.E.239.229; 13.E.239.230; 13.E.239.231; 13.E.239.236; 13.E.239.237; 13.E.239.238; 13.E.239.239; 13.E.239.154; 13.E.239.157; 13.E.239.166; 13.E.239.169; 13.E.239.172; 13.E.239.175; 13.E.239.240; 13.E.239.244; 13.E.154.228; 13.E.154.229; 13.E.154.230; 13.E.154.231; 13.E.154.236; 13.E.154.237; 13.E.154.238; 13.E.154.239; 13.E.154.154; 13.E.154.157; 13.E.154.166; 13.E.154.169; 13.E.154.172; 13.E.154.175; 13.E.154.240; 13.E.154.244; 13.E.157.228; 13.E.157.229; 13.E.157.230; 13.E.157.231; 13.E.157.236; 13.E.157.237; 13.E.157.238; 13.E.157.239; 13.E.157.154; 13.E.157.157; 13.E.157.166; 13.E.157.169; 13.E.157.172; 13.E.157.175; 13.E.157.240; 13.E.157.244; 13.E.166.228; 13.E.166.229; 13.E.166.230; 13.E.166.231; 13.E.166.236; 13.E.166.237; 13.E.166.238; 13.E.166.239; 13.E.166.154; 13.E.166.157; 13.E.166.166; 13.E.166.169; 13.E.166.172; 13.E.166.175; 13.E.166.240; 13.E.166.244; 13.E.169.228; 13.E.169.229; 13.E.169.230; 13.E.169.231; 13.E.169.236; 13.E.169.237; 13.E.169.238; 13.E.169.239; 13.E.169.154; 13.E.169.157; 13.E.169.166; 13.E.169.169; 13.E.169.172; 13.E.169.175; 13.E.169.240; 13.E.169.244; 13.E.172.228; 13.E.172.229; 13.E.172.230; 13.E.172.231; 13.E.172.236; 13.E.172.237; 13.E.172.238; 13.E.172.239; 13.E.172.154; 13.E.172.157; 13.E.172.166; 13.E.172.169; 13.E.172.172; 13.E.172.175; 13.E.172.240; 13.E.172.244; 13.E.175.228; 13.E.175.229; 13.E.175.230; 13.E.175.231; 13.E.175.236; 13.E.175.237; 13.E.175.238; 13.E.175.239; 13.E.175.154; 13.E.175.157; 13.E.175.166; 13.E.175.169; 13.E.175.172; 13.E.175.175; 13.E.175.240; 13.E.175.244; 13.E.240.228; 13.E.240.229; 13.E.240.230; 13.E.240.231; 13.E.240.236; 13.E.240.237; 13.E.240.238; 13.E.240.239; 13.E.240.154; 13.E.240.157; 13.E.240.166; 13.E.240.169; 13.E.240.172; 13.E.240.175; 13.E.240.240; 13.E.240.244; 13.E.244.228; 13.E.244.229; 13.E.244.230; 13.E.244.231; 13.E.244.236; 13.E.244.237; 13.E.244.238; 13.E.244.239; 13.E.244.154; 13.E.244.157;

13.E.244.166; 13.E.244.169; 13.E.244.172; 13.E.244.175; 13.E.244.240; 13.E.244.244;

Prodrugs of 13.G

13.G.228.228; 13.G.228.229; 13.G.228.230; 13.G.228.231; 13.G.228.236; 13.G.228.237; 13.G.228.238; 13.G.228.239; 13.G.228.154; 13.G.228.157; 13.G.228.166; 13.G.228.169; 13.G.228.172; 13.G.228.175; 13.G.228.240; 13.G.228.244; 13.G.229.228; 13.G.229.229; 13.G.229.230; 13.G.229.231; 13.G.229.236; 13.G.229.237; 13.G.229.238; 13.G.229.239; 13.G.229.154; 13.G.229.157; 13.G.229.166; 13.G.229.169; 13.G.229.172; 13.G.229.175; 13.G.229.240; 13.G.229.244; 13.G.230.228; 13.G.230.229; 13.G.230.230; 13.G.230.231; 13.G.230.236; 13.G.230.237; 13.G.230.238; 13.G.230.239; 13.G.230.154; 13.G.230.157; 13.G.230.166; 13.G.230.169; 13.G.230.172; 13.G.230.175; 13.G.230.240; 13.G.230.244; 13.G.231.228; 13.G.231.229; 13.G.231.230; 13.G.231.231; 13.G.231.236; 13.G.231.237; 13.G.231.238; 13.G.231.239; 13.G.231.154; 13.G.231.157; 13.G.231.166; 13.G.231.169; 13.G.231.172; 13.G.231.175; 13.G.231.240; 13.G.231.244; 13.G.236.228; 13.G.236.229; 13.G.236.230; 13.G.236.231; 13.G.236.236; 13.G.236.237; 13.G.236.238; 13.G.236.239; 13.G.236.154; 13.G.236.157; 13.G.236.166; 13.G.236.169; 13.G.236.172; 13.G.236.175; 13.G.236.240; 13.G.236.244; 13.G.237.228; 13.G.237.229; 13.G.237.230; 13.G.237.231; 13.G.237.236; 13.G.237.237; 13.G.237.238; 13.G.237.239; 13.G.237.154; 13.G.237.157; 13.G.237.166; 13.G.237.169; 13.G.237.172; 13.G.237.175; 13.G.237.240; 13.G.237.244; 13.G.238.228; 13.G.238.229; 13.G.238.230; 13.G.238.231; 13.G.238.236; 13.G.238.237; 13.G.238.238; 13.G.238.239; 13.G.238.154; 13.G.238.157; 13.G.238.166; 13.G.238.169; 13.G.238.172; 13.G.238.175; 13.G.238.240; 13.G.238.244; 13.G.239.228; 13.G.239.229; 13.G.239.230; 13.G.239.231; 13.G.239.236; 13.G.239.237; 13.G.239.238; 13.G.239.239; 13.G.239.154; 13.G.239.157; 13.G.239.166; 13.G.239.169; 13.G.239.172; 13.G.239.175; 13.G.239.240; 13.G.239.244; 13.G.154.228; 13.G.154.229; 13.G.154.230; 13.G.154.231; 13.G.154.236; 13.G.154.237; 13.G.154.238; 13.G.154.239; 13.G.154.154; 13.G.154.157; 13.G.154.166; 13.G.154.169; 13.G.154.172; 13.G.154.175; 13.G.154.240; 13.G.154.244; 13.G.157.228; 13.G.157.229; 13.G.157.230; 13.G.157.231; 13.G.157.236; 13.G.157.237; 13.G.157.238; 13.G.157.239; 13.G.157.154; 13.G.157.157; 13.G.157.166; 13.G.157.169; 13.G.157.172; 13.G.157.175; 13.G.157.240; 13.G.157.244; 13.G.166.228; 13.G.166.229; 13.G.166.230; 13.G.166.231; 13.G.166.236;

13.G.166.237; 13.G.166.238; 13.G.166.239; 13.G.166.154; 13.G.166.157; 13.G.166.166; 13.G.166.169; 13.G.166.172; 13.G.166.175; 13.G.166.240; 13.G.166.244; 13.G.169.228; 13.G.169.229; 13.G.169.230; 13.G.169.231; 13.G.169.236; 13.G.169.237; 13.G.169.238; 13.G.169.239; 13.G.169.154; 13.G.169.157; 13.G.169.166; 13.G.169.169; 13.G.169.172; 13.G.169.175; 13.G.169.240; 13.G.169.244; 13.G.172.228; 13.G.172.229; 13.G.172.230; 13.G.172.231; 13.G.172.236; 13.G.172.237; 13.G.172.238; 13.G.172.239; 13.G.172.154; 13.G.172.157; 13.G.172.166; 13.G.172.169; 13.G.172.172; 13.G.172.175; 13.G.172.240; 13.G.172.244; 13.G.175.228; 13.G.175.229; 13.G.175.230; 13.G.175.231; 13.G.175.236; 13.G.175.237; 13.G.175.238; 13.G.175.239; 13.G.175.154; 13.G.175.157; 13.G.175.166; 13.G.175.169; 13.G.175.172; 13.G.175.175; 13.G.175.240; 13.G.175.244; 13.G.240.228; 13.G.240.229; 13.G.240.230; 13.G.240.231; 13.G.240.236; 13.G.240.237; 13.G.240.238; 13.G.240.239; 13.G.240.154; 13.G.240.157; 13.G.240.166; 13.G.240.169; 13.G.240.172; 13.G.240.175; 13.G.240.240; 13.G.240.244; 13.G.244.228; 13.G.244.229; 13.G.244.230; 13.G.244.231; 13.G.244.236; 13.G.244.237; 13.G.244.238; 13.G.244.239; 13.G.244.154; 13.G.244.157; 13.G.244.166; 13.G.244.169; 13.G.244.172; 13.G.244.175; 13.G.244.240; 13.G.244.244;

Prodrugs of 13.I

13.I.228.228; 13.I.228.229; 13.I.228.230; 13.I.228.231; 13.I.228.236; 13.I.228.237; 13.I.228.238; 13.I.228.239; 13.I.228.154; 13.I.228.157; 13.I.228.166; 13.I.228.169; 13.I.228.172; 13.I.228.175; 13.I.228.240; 13.I.228.244; 13.I.229.228; 13.I.229.229; 13.I.229.230; 13.I.229.231; 13.I.229.236; 13.I.229.237; 13.I.229.238; 13.I.229.239; 13.I.229.154; 13.I.229.157; 13.I.229.166; 13.I.229.169; 13.I.229.172; 13.I.229.175; 13.I.229.240; 13.I.229.244; 13.I.230.228; 13.I.230.229; 13.I.230.230; 13.I.230.231; 13.I.230.236; 13.I.230.237; 13.I.230.238; 13.I.230.239; 13.I.230.154; 13.I.230.157; 13.I.230.166; 13.I.230.169; 13.I.230.172; 13.I.230.175; 13.I.230.240; 13.I.230.244; 13.I.231.228; 13.I.231.229; 13.I.231.230; 13.I.231.231; 13.I.231.236; 13.I.231.237; 13.I.231.238; 13.I.231.239; 13.I.231.154; 13.I.231.157; 13.I.231.166; 13.I.231.169; 13.I.231.172; 13.I.231.175; 13.I.231.240; 13.I.231.244; 13.I.236.228; 13.I.236.229; 13.I.236.230; 13.I.236.231; 13.I.236.236; 13.I.236.237; 13.I.236.238; 13.I.236.239; 13.I.236.154; 13.I.236.157; 13.I.236.166; 13.I.236.169; 13.I.236.172; 13.I.236.175; 13.I.236.240; 13.I.236.244;

13.I.237.228; 13.I.237.229; 13.I.237.230; 13.I.237.231; 13.I.237.236; 13.I.237.237; 13.I.237.238; 13.I.237.239; 13.I.237.154; 13.I.237.157; 13.I.237.166; 13.I.237.169; 13.I.237.172; 13.I.237.175; 13.I.237.240; 13.I.237.244; 13.I.238.228; 13.I.238.229; 13.I.238.230; 13.I.238.231; 13.I.238.236; 13.I.238.237; 13.I.238.238; 13.I.238.239; 13.I.238.154; 13.I.238.157; 13.I.238.166; 13.I.238.169; 13.I.238.172; 13.I.238.175; 13.I.238.240; 13.I.238.244; 13.I.239.228; 13.I.239.229; 13.I.239.230; 13.I.239.231; 13.I.239.236; 13.I.239.237; 13.I.239.238; 13.I.239.239; 13.I.239.154; 13.I.239.157; 13.I.239.166; 13.I.239.169; 13.I.239.172; 13.I.239.175; 13.I.239.240; 13.I.239.244; 13.I.154.228; 13.I.154.229; 13.I.154.230; 13.I.154.231; 13.I.154.236; 13.I.154.237; 13.I.154.238; 13.I.154.239; 13.I.154.154; 13.I.154.157; 13.I.154.166; 13.I.154.169; 13.I.154.172; 13.I.154.175; 13.I.154.240; 13.I.154.244; 13.I.157.228; 13.I.157.229; 13.I.157.230; 13.I.157.231; 13.I.157.236; 13.I.157.237; 13.I.157.238; 13.I.157.239; 13.I.157.154; 13.I.157.157; 13.I.157.166; 13.I.157.169; 13.I.157.172; 13.I.157.175; 13.I.157.240; 13.I.157.244; 13.I.166.228; 13.I.166.229; 13.I.166.230; 13.I.166.231; 13.I.166.236; 13.I.166.237; 13.I.166.238; 13.I.166.239; 13.I.166.154; 13.I.166.157; 13.I.166.166; 13.I.166.169; 13.I.166.172; 13.I.166.175; 13.I.166.240; 13.I.166.244; 13.I.169.228; 13.I.169.229; 13.I.169.230; 13.I.169.231; 13.I.169.236; 13.I.169.237; 13.I.169.238; 13.I.169.239; 13.I.169.154; 13.I.169.157; 13.I.169.166; 13.I.169.169; 13.I.169.172; 13.I.169.175; 13.I.169.240; 13.I.169.244; 13.I.172.228; 13.I.172.229; 13.I.172.230; 13.I.172.231; 13.I.172.236; 13.I.172.237; 13.I.172.238; 13.I.172.239; 13.I.172.154; 13.I.172.157; 13.I.172.166; 13.I.172.169; 13.I.172.172; 13.I.172.175; 13.I.172.240; 13.I.172.244; 13.I.175.228; 13.I.175.229; 13.I.175.230; 13.I.175.231; 13.I.175.236; 13.I.175.237; 13.I.175.238; 13.I.175.239; 13.I.175.154; 13.I.175.157; 13.I.175.166; 13.I.175.169; 13.I.175.172; 13.I.175.175; 13.I.175.240; 13.I.175.244; 13.I.240.228; 13.I.240.229; 13.I.240.230; 13.I.240.231; 13.I.240.236; 13.I.240.237; 13.I.240.238; 13.I.240.239; 13.I.240.154; 13.I.240.157; 13.I.240.166; 13.I.240.169; 13.I.240.172; 13.I.240.175; 13.I.240.240; 13.I.240.244; 13.I.244.228; 13.I.244.229; 13.I.244.230; 13.I.244.231; 13.I.244.236; 13.I.244.237; 13.I.244.238; 13.I.244.239; 13.I.244.154; 13.I.244.157; 13.I.244.166; 13.I.244.169; 13.I.244.172; 13.I.244.175; 13.I.244.240; 13.I.244.244;

Prodrugs of 13.J

13.J.228.228; 13.J.228.229; 13.J.228.230; 13.J.228.231; 13.J.228.236; 13.J.228.237; 13.J.228.238; 13.J.228.239; 13.J.228.154; 13.J.228.157; 13.J.228.166; 13.J.228.169; 13.J.228.172; 13.J.228.175; 13.J.228.240; 13.J.228.244; 13.J.229.228; 13.J.229.229; 13.J.229.230; 13.J.229.231; 13.J.229.236; 13.J.229.237; 13.J.229.238; 13.J.229.239; 13.J.229.154; 13.J.229.157; 13.J.229.166; 13.J.229.169; 13.J.229.172; 13.J.229.175; 13.J.229.240; 13.J.229.244; 13.J.230.228; 13.J.230.229; 13.J.230.230; 13.J.230.231; 13.J.230.236; 13.J.230.237; 13.J.230.238; 13.J.230.239; 13.J.230.154; 13.J.230.157; 13.J.230.166; 13.J.230.169; 13.J.230.172; 13.J.230.175; 13.J.230.240; 13.J.230.244; 13.J.231.228; 13.J.231.229; 13.J.231.230; 13.J.231.231; 13.J.231.236; 13.J.231.237; 13.J.231.238; 13.J.231.239; 13.J.231.154; 13.J.231.157; 13.J.231.166; 13.J.231.169; 13.J.231.172; 13.J.231.175; 13.J.231.240; 13.J.231.244; 13.J.236.228; 13.J.236.229; 13.J.236.230; 13.J.236.231; 13.J.236.236; 13.J.236.237; 13.J.236.238; 13.J.236.239; 13.J.236.154; 13.J.236.157; 13.J.236.166; 13.J.236.169; 13.J.236.172; 13.J.236.175; 13.J.236.240; 13.J.236.244; 13.J.237.228; 13.J.237.229; 13.J.237.230; 13.J.237.231; 13.J.237.236; 13.J.237.237; 13.J.237.238; 13.J.237.239; 13.J.237.154; 13.J.237.157; 13.J.237.166; 13.J.237.169; 13.J.237.172; 13.J.237.175; 13.J.237.240; 13.J.237.244; 13.J.238.228; 13.J.238.229; 13.J.238.230; 13.J.238.231; 13.J.238.236; 13.J.238.237; 13.J.238.238; 13.J.238.239; 13.J.238.154; 13.J.238.157; 13.J.238.166; 13.J.238.169; 13.J.238.172; 13.J.238.175; 13.J.238.240; 13.J.238.244; 13.J.239.228; 13.J.239.229; 13.J.239.230; 13.J.239.231; 13.J.239.236; 13.J.239.237; 13.J.239.238; 13.J.239.239; 13.J.239.154; 13.J.239.157; 13.J.239.166; 13.J.239.169; 13.J.239.172; 13.J.239.175; 13.J.239.240; 13.J.239.244; 13.J.154.228; 13.J.154.229; 13.J.154.230; 13.J.154.231; 13.J.154.236; 13.J.154.237; 13.J.154.238; 13.J.154.239; 13.J.154.154; 13.J.154.157; 13.J.154.166; 13.J.154.169; 13.J.154.172; 13.J.154.175; 13.J.154.240; 13.J.154.244; 13.J.157.228; 13.J.157.229; 13.J.157.230; 13.J.157.231; 13.J.157.236; 13.J.157.237; 13.J.157.238; 13.J.157.239; 13.J.157.154; 13.J.157.157; 13.J.157.166; 13.J.157.169; 13.J.157.172; 13.J.157.175; 13.J.157.240; 13.J.157.244; 13.J.166.228; 13.J.166.229; 13.J.166.230; 13.J.166.231; 13.J.166.236; 13.J.166.237; 13.J.166.238; 13.J.166.239; 13.J.166.154; 13.J.166.157; 13.J.166.166; 13.J.166.169; 13.J.166.172; 13.J.166.175; 13.J.166.240; 13.J.166.244; 13.J.169.228; 13.J.169.229; 13.J.169.230; 13.J.169.231;

13.J.169.236; 13.J.169.237; 13.J.169.238; 13.J.169.239; 13.J.169.154; 13.J.169.157; 13.J.169.166; 13.J.169.169; 13.J.169.172; 13.J.169.175; 13.J.169.240; 13.J.169.244; 13.J.172.228; 13.J.172.229; 13.J.172.230; 13.J.172.231; 13.J.172.236; 13.J.172.237; 13.J.172.238; 13.J.172.239; 13.J.172.154; 13.J.172.157; 13.J.172.166; 13.J.172.169; 13.J.172.172; 13.J.172.175; 13.J.172.240; 13.J.172.244; 13.J.175.228; 13.J.175.229; 13.J.175.230; 13.J.175.231; 13.J.175.236; 13.J.175.237; 13.J.175.238; 13.J.175.239; 13.J.175.154; 13.J.175.157; 13.J.175.166; 13.J.175.169; 13.J.175.172; 13.J.175.175; 13.J.175.240; 13.J.175.244; 13.J.240.228; 13.J.240.229; 13.J.240.230; 13.J.240.231; 13.J.240.236; 13.J.240.237; 13.J.240.238; 13.J.240.239; 13.J.240.154; 13.J.240.157; 13.J.240.166; 13.J.240.169; 13.J.240.172; 13.J.240.175; 13.J.240.240; 13.J.240.244; 13.J.244.228; 13.J.244.229; 13.J.244.230; 13.J.244.231; 13.J.244.236; 13.J.244.237; 13.J.244.238; 13.J.244.239; 13.J.244.154; 13.J.244.157; 13.J.244.166; 13.J.244.169; 13.J.244.172; 13.J.244.175; 13.J.244.240; 13.J.244.244;

Prodrugs of 13.L

13.L.228.228; 13.L.228.229; 13.L.228.230; 13.L.228.231; 13.L.228.236; 13.L.228.237; 13.L.228.238; 13.L.228.239; 13.L.228.154; 13.L.228.157; 13.L.228.166; 13.L.228.169; 13.L.228.172; 13.L.228.175; 13.L.228.240; 13.L.228.244; 13.L.229.228; 13.L.229.229; 13.L.229.230; 13.L.229.231; 13.L.229.236; 13.L.229.237; 13.L.229.238; 13.L.229.239; 13.L.229.154; 13.L.229.157; 13.L.229.166; 13.L.229.169; 13.L.229.172; 13.L.229.175; 13.L.229.240; 13.L.229.244; 13.L.230.228; 13.L.230.229; 13.L.230.230; 13.L.230.231; 13.L.230.236; 13.L.230.237; 13.L.230.238; 13.L.230.239; 13.L.230.154; 13.L.230.157; 13.L.230.166; 13.L.230.169; 13.L.230.172; 13.L.230.175; 13.L.230.240; 13.L.230.244; 13.L.231.228; 13.L.231.229; 13.L.231.230; 13.L.231.231; 13.L.231.236; 13.L.231.237; 13.L.231.238; 13.L.231.239; 13.L.231.154; 13.L.231.157; 13.L.231.166; 13.L.231.169; 13.L.231.172; 13.L.231.175; 13.L.231.240; 13.L.231.244; 13.L.236.228; 13.L.236.229; 13.L.236.230; 13.L.236.231; 13.L.236.236; 13.L.236.237; 13.L.236.238; 13.L.236.239; 13.L.236.154; 13.L.236.157; 13.L.236.166; 13.L.236.169; 13.L.236.172; 13.L.236.175; 13.L.236.240; 13.L.236.244; 13.L.237.228; 13.L.237.229; 13.L.237.230; 13.L.237.231; 13.L.237.236; 13.L.237.237; 13.L.237.238; 13.L.237.239; 13.L.237.154; 13.L.237.157; 13.L.237.166; 13.L.237.169; 13.L.237.172; 13.L.237.175; 13.L.237.240;

13.L.237.244; 13.L.238.228; 13.L.238.229; 13.L.238.230; 13.L.238.231; 13.L.238.236; 13.L.238.237; 13.L.238.238; 13.L.238.239; 13.L.238.154; 13.L.238.157; 13.L.238.166; 13.L.238.169; 13.L.238.172; 13.L.238.175; 13.L.238.240; 13.L.238.244; 13.L.239.228; 13.L.239.229; 13.L.239.230; 13.L.239.231; 13.L.239.236; 13.L.239.237; 13.L.239.238; 13.L.239.239; 13.L.239.154; 13.L.239.157; 13.L.239.166; 13.L.239.169; 13.L.239.172; 13.L.239.175; 13.L.239.240; 13.L.239.244; 13.L.154.228; 13.L.154.229; 13.L.154.230; 13.L.154.231; 13.L.154.236; 13.L.154.237; 13.L.154.238; 13.L.154.239; 13.L.154.154; 13.L.154.157; 13.L.154.166; 13.L.154.169; 13.L.154.172; 13.L.154.175; 13.L.154.240; 13.L.154.244; 13.L.157.228; 13.L.157.229; 13.L.157.230; 13.L.157.231; 13.L.157.236; 13.L.157.237; 13.L.157.238; 13.L.157.239; 13.L.157.154; 13.L.157.157; 13.L.157.166; 13.L.157.169; 13.L.157.172; 13.L.157.175; 13.L.157.240; 13.L.157.244; 13.L.166.228; 13.L.166.229; 13.L.166.230; 13.L.166.231; 13.L.166.236; 13.L.166.237; 13.L.166.238; 13.L.166.239; 13.L.166.154; 13.L.166.157; 13.L.166.166; 13.L.166.169; 13.L.166.172; 13.L.166.175; 13.L.166.240; 13.L.166.244; 13.L.169.228; 13.L.169.229; 13.L.169.230; 13.L.169.231; 13.L.169.236; 13.L.169.237; 13.L.169.238; 13.L.169.239; 13.L.169.154; 13.L.169.157; 13.L.169.166; 13.L.169.169; 13.L.169.172; 13.L.169.175; 13.L.169.240; 13.L.169.244; 13.L.172.228; 13.L.172.229; 13.L.172.230; 13.L.172.231; 13.L.172.236; 13.L.172.237; 13.L.172.238; 13.L.172.239; 13.L.172.154; 13.L.172.157; 13.L.172.166; 13.L.172.169; 13.L.172.172; 13.L.172.175; 13.L.172.240; 13.L.172.244; 13.L.175.228; 13.L.175.229; 13.L.175.230; 13.L.175.231; 13.L.175.236; 13.L.175.237; 13.L.175.238; 13.L.175.239; 13.L.175.154; 13.L.175.157; 13.L.175.166; 13.L.175.169; 13.L.175.172; 13.L.175.175; 13.L.175.240; 13.L.175.244; 13.L.240.228; 13.L.240.229; 13.L.240.230; 13.L.240.231; 13.L.240.236; 13.L.240.237; 13.L.240.238; 13.L.240.239; 13.L.240.154; 13.L.240.157; 13.L.240.166; 13.L.240.169; 13.L.240.172; 13.L.240.175; 13.L.240.240; 13.L.240.244; 13.L.244.228; 13.L.244.229; 13.L.244.230; 13.L.244.231; 13.L.244.236; 13.L.244.237; 13.L.244.238; 13.L.244.239; 13.L.244.154; 13.L.244.157; 13.L.244.166; 13.L.244.169; 13.L.244.172; 13.L.244.175; 13.L.244.240; 13.L.244.244;

Prodrugs of 13.O

13.O.228.228; 13.O.228.229; 13.O.228.230; 13.O.228.231; 13.O.228.236; 13.O.228.237; 13.O.228.238; 13.O.228.239; 13.O.228.154; 13.O.228.157;

13.O.228.166; 13.O.228.169; 13.O.228.172; 13.O.228.175; 13.O.228.240; 13.O.228.244; 13.O.229.228; 13.O.229.229; 13.O.229.230; 13.O.229.231; 13.O.229.236; 13.O.229.237; 13.O.229.238; 13.O.229.239; 13.O.229.154; 13.O.229.157; 13.O.229.166; 13.O.229.169; 13.O.229.172; 13.O.229.175; 13.O.229.240; 13.O.229.244; 13.O.230.228; 13.O.230.229; 13.O.230.230; 13.O.230.231; 13.O.230.236; 13.O.230.237; 13.O.230.238; 13.O.230.239; 13.O.230.154; 13.O.230.157; 13.O.230.166; 13.O.230.169; 13.O.230.172; 13.O.230.175; 13.O.230.240; 13.O.230.244; 13.O.231.228; 13.O.231.229; 13.O.231.230; 13.O.231.231; 13.O.231.236; 13.O.231.237; 13.O.231.238; 13.O.231.239; 13.O.231.154; 13.O.231.157; 13.O.231.166; 13.O.231.169; 13.O.231.172; 13.O.231.175; 13.O.231.240; 13.O.231.244; 13.O.236.228; 13.O.236.229; 13.O.236.230; 13.O.236.231; 13.O.236.236; 13.O.236.237; 13.O.236.238; 13.O.236.239; 13.O.236.154; 13.O.236.157; 13.O.236.166; 13.O.236.169; 13.O.236.172; 13.O.236.175; 13.O.236.240; 13.O.236.244; 13.O.237.228; 13.O.237.229; 13.O.237.230; 13.O.237.231; 13.O.237.236; 13.O.237.237; 13.O.237.238; 13.O.237.239; 13.O.237.154; 13.O.237.157; 13.O.237.166; 13.O.237.169; 13.O.237.172; 13.O.237.175; 13.O.237.240; 13.O.237.244; 13.O.238.228; 13.O.238.229; 13.O.238.230; 13.O.238.231; 13.O.238.236; 13.O.238.237; 13.O.238.238; 13.O.238.239; 13.O.238.154; 13.O.238.157; 13.O.238.166; 13.O.238.169; 13.O.238.172; 13.O.238.175; 13.O.238.240; 13.O.238.244; 13.O.239.228; 13.O.239.229; 13.O.239.230; 13.O.239.231; 13.O.239.236; 13.O.239.237; 13.O.239.238; 13.O.239.239; 13.O.239.154; 13.O.239.157; 13.O.239.166; 13.O.239.169; 13.O.239.172; 13.O.239.175; 13.O.239.240; 13.O.239.244; 13.O.154.228; 13.O.154.229; 13.O.154.230; 13.O.154.231; 13.O.154.236; 13.O.154.237; 13.O.154.238; 13.O.154.239; 13.O.154.154; 13.O.154.157; 13.O.154.166; 13.O.154.169; 13.O.154.172; 13.O.154.175; 13.O.154.240; 13.O.154.244; 13.O.157.228; 13.O.157.229; 13.O.157.230; 13.O.157.231; 13.O.157.236; 13.O.157.237; 13.O.157.238; 13.O.157.239; 13.O.157.154; 13.O.157.157; 13.O.157.166; 13.O.157.169; 13.O.157.172; 13.O.157.175; 13.O.157.240; 13.O.157.244; 13.O.166.228; 13.O.166.229; 13.O.166.230; 13.O.166.231; 13.O.166.236; 13.O.166.237; 13.O.166.238; 13.O.166.239; 13.O.166.154; 13.O.166.157; 13.O.166.166; 13.O.166.169; 13.O.166.172; 13.O.166.175; 13.O.166.240; 13.O.166.244; 13.O.169.228; 13.O.169.229; 13.O.169.230; 13.O.169.231; 13.O.169.236; 13.O.169.237; 13.O.169.238; 13.O.169.239; 13.O.169.154; 13.O.169.157; 13.O.169.166; 13.O.169.169; 13.O.169.172; 13.O.169.175; 13.O.169.240; 13.O.169.244; 13.O.172.228; 13.O.172.229; 13.O.172.230;

13.O.172.231; 13.O.172.236; 13.O.172.237; 13.O.172.238; 13.O.172.239; 13.O.172.154; 13.O.172.157; 13.O.172.166; 13.O.172.169; 13.O.172.172; 13.O.172.175; 13.O.172.240; 13.O.172.244; 13.O.175.228; 13.O.175.229; 13.O.175.230; 13.O.175.231; 13.O.175.236; 13.O.175.237; 13.O.175.238; 13.O.175.239; 13.O.175.154; 13.O.175.157; 13.O.175.166; 13.O.175.169; 13.O.175.172; 13.O.175.175; 13.O.175.240; 13.O.175.244; 13.O.240.228; 13.O.240.229; 13.O.240.230; 13.O.240.231; 13.O.240.236; 13.O.240.237; 13.O.240.238; 13.O.240.239; 13.O.240.154; 13.O.240.157; 13.O.240.166; 13.O.240.169; 13.O.240.172; 13.O.240.175; 13.O.240.240; 13.O.240.244; 13.O.244.228; 13.O.244.229; 13.O.244.230; 13.O.244.231; 13.O.244.236; 13.O.244.237; 13.O.244.238; 13.O.244.239; 13.O.244.154; 13.O.244.157; 13.O.244.166; 13.O.244.169; 13.O.244.172; 13.O.244.175; 13.O.244.240; 13.O.244.244;

Prodrugs of 13.P

13.P.228.228; 13.P.228.229; 13.P.228.230; 13.P.228.231; 13.P.228.236; 13.P.228.237; 13.P.228.238; 13.P.228.239; 13.P.228.154; 13.P.228.157; 13.P.228.166; 13.P.228.169; 13.P.228.172; 13.P.228.175; 13.P.228.240; 13.P.228.244; 13.P.229.228; 13.P.229.229; 13.P.229.230; 13.P.229.231; 13.P.229.236; 13.P.229.237; 13.P.229.238; 13.P.229.239; 13.P.229.154; 13.P.229.157; 13.P.229.166; 13.P.229.169; 13.P.229.172; 13.P.229.175; 13.P.229.240; 13.P.229.244; 13.P.230.228; 13.P.230.229; 13.P.230.230; 13.P.230.231; 13.P.230.236; 13.P.230.237; 13.P.230.238; 13.P.230.239; 13.P.230.154; 13.P.230.157; 13.P.230.166; 13.P.230.169; 13.P.230.172; 13.P.230.175; 13.P.230.240; 13.P.230.244; 13.P.231.228; 13.P.231.229; 13.P.231.230; 13.P.231.231; 13.P.231.236; 13.P.231.237; 13.P.231.238; 13.P.231.239; 13.P.231.154; 13.P.231.157; 13.P.231.166; 13.P.231.169; 13.P.231.172; 13.P.231.175; 13.P.231.240; 13.P.231.244; 13.P.236.228; 13.P.236.229; 13.P.236.230; 13.P.236.231; 13.P.236.236; 13.P.236.237; 13.P.236.238; 13.P.236.239; 13.P.236.154; 13.P.236.157; 13.P.236.166; 13.P.236.169; 13.P.236.172; 13.P.236.175; 13.P.236.240; 13.P.236.244; 13.P.237.228; 13.P.237.229; 13.P.237.230; 13.P.237.231; 13.P.237.236; 13.P.237.237; 13.P.237.238; 13.P.237.239; 13.P.237.154; 13.P.237.157; 13.P.237.166; 13.P.237.169; 13.P.237.172; 13.P.237.175; 13.P.237.240; 13.P.237.244; 13.P.238.228; 13.P.238.229; 13.P.238.230; 13.P.238.231; 13.P.238.236; 13.P.238.237; 13.P.238.238; 13.P.238.239; 13.P.238.154; 13.P.238.157; 13.P.238.166; 13.P.238.169; 13.P.238.172; 13.P.238.175;

13.P.238.240; 13.P.238.244; 13.P.239.228; 13.P.239.229; 13.P.239.230; 13.P.239.231; 13.P.239.236; 13.P.239.237; 13.P.239.238; 13.P.239.239; 13.P.239.154; 13.P.239.157; 13.P.239.166; 13.P.239.169; 13.P.239.172; 13.P.239.175; 13.P.239.240; 13.P.239.244; 13.P.154.228; 13.P.154.229; 13.P.154.230; 13.P.154.231; 13.P.154.236; 13.P.154.237; 13.P.154.238; 13.P.154.239; 13.P.154.154; 13.P.154.157; 13.P.154.166; 13.P.154.169; 13.P.154.172; 13.P.154.175; 13.P.154.240; 13.P.154.244; 13.P.157.228; 13.P.157.229; 13.P.157.230; 13.P.157.231; 13.P.157.236; 13.P.157.237; 13.P.157.238; 13.P.157.239; 13.P.157.154; 13.P.157.157; 13.P.157.166; 13.P.157.169; 13.P.157.172; 13.P.157.175; 13.P.157.240; 13.P.157.244; 13.P.166.228; 13.P.166.229; 13.P.166.230; 13.P.166.231; 13.P.166.236; 13.P.166.237; 13.P.166.238; 13.P.166.239; 13.P.166.154; 13.P.166.157; 13.P.166.166; 13.P.166.169; 13.P.166.172; 13.P.166.175; 13.P.166.240; 13.P.166.244; 13.P.169.228; 13.P.169.229; 13.P.169.230; 13.P.169.231; 13.P.169.236; 13.P.169.237; 13.P.169.238; 13.P.169.239; 13.P.169.154; 13.P.169.157; 13.P.169.166; 13.P.169.169; 13.P.169.172; 13.P.169.175; 13.P.169.240; 13.P.169.244; 13.P.172.228; 13.P.172.229; 13.P.172.230; 13.P.172.231; 13.P.172.236; 13.P.172.237; 13.P.172.238; 13.P.172.239; 13.P.172.154; 13.P.172.157; 13.P.172.166; 13.P.172.169; 13.P.172.172; 13.P.172.175; 13.P.172.240; 13.P.172.244; 13.P.175.228; 13.P.175.229; 13.P.175.230; 13.P.175.231; 13.P.175.236; 13.P.175.237; 13.P.175.238; 13.P.175.239; 13.P.175.154; 13.P.175.157; 13.P.175.166; 13.P.175.169; 13.P.175.172; 13.P.175.175; 13.P.175.240; 13.P.175.244; 13.P.240.228; 13.P.240.229; 13.P.240.230; 13.P.240.231; 13.P.240.236; 13.P.240.237; 13.P.240.238; 13.P.240.239; 13.P.240.154; 13.P.240.157; 13.P.240.166; 13.P.240.169; 13.P.240.172; 13.P.240.175; 13.P.240.240; 13.P.240.244; 13.P.244.228; 13.P.244.229; 13.P.244.230; 13.P.244.231; 13.P.244.236; 13.P.244.237; 13.P.244.238; 13.P.244.239; 13.P.244.154; 13.P.244.157; 13.P.244.166; 13.P.244.169; 13.P.244.172; 13.P.244.175; 13.P.244.240; 13.P.244.244;

Prodrugs of 13.U

13.U.228.228; 13.U.228.229; 13.U.228.230; 13.U.228.231; 13.U.228.236; 13.U.228.237; 13.U.228.238; 13.U.228.239; 13.U.228.154; 13.U.228.157; 13.U.228.166; 13.U.228.169; 13.U.228.172; 13.U.228.175; 13.U.228.240; 13.U.228.244; 13.U.229.228; 13.U.229.229; 13.U.229.230; 13.U.229.231; 13.U.229.236; 13.U.229.237; 13.U.229.238; 13.U.229.239; 13.U.229.154;

13.U.229.157; 13.U.229.166; 13.U.229.169; 13.U.229.172; 13.U.229.175; 13.U.229.240; 13.U.229.244; 13.U.230.228; 13.U.230.229; 13.U.230.230; 13.U.230.231; 13.U.230.236; 13.U.230.237; 13.U.230.238; 13.U.230.239; 13.U.230.154; 13.U.230.157; 13.U.230.166; 13.U.230.169; 13.U.230.172; 13.U.230.175; 13.U.230.240; 13.U.230.244; 13.U.231.228; 13.U.231.229; 13.U.231.230; 13.U.231.231; 13.U.231.236; 13.U.231.237; 13.U.231.238; 13.U.231.239; 13.U.231.154; 13.U.231.157; 13.U.231.166; 13.U.231.169; 13.U.231.172; 13.U.231.175; 13.U.231.240; 13.U.231.244; 13.U.236.228; 13.U.236.229; 13.U.236.230; 13.U.236.231; 13.U.236.236; 13.U.236.237; 13.U.236.238; 13.U.236.239; 13.U.236.154; 13.U.236.157; 13.U.236.166; 13.U.236.169; 13.U.236.172; 13.U.236.175; 13.U.236.240; 13.U.236.244; 13.U.237.228; 13.U.237.229; 13.U.237.230; 13.U.237.231; 13.U.237.236; 13.U.237.237; 13.U.237.238; 13.U.237.239; 13.U.237.154; 13.U.237.157; 13.U.237.166; 13.U.237.169; 13.U.237.172; 13.U.237.175; 13.U.237.240; 13.U.237.244; 13.U.238.228; 13.U.238.229; 13.U.238.230; 13.U.238.231; 13.U.238.236; 13.U.238.237; 13.U.238.238; 13.U.238.239; 13.U.238.154; 13.U.238.157; 13.U.238.166; 13.U.238.169; 13.U.238.172; 13.U.238.175; 13.U.238.240; 13.U.238.244; 13.U.239.228; 13.U.239.229; 13.U.239.230; 13.U.239.231; 13.U.239.236; 13.U.239.237; 13.U.239.238; 13.U.239.239; 13.U.239.154; 13.U.239.157; 13.U.239.166; 13.U.239.169; 13.U.239.172; 13.U.239.175; 13.U.239.240; 13.U.239.244; 13.U.154.228; 13.U.154.229; 13.U.154.230; 13.U.154.231; 13.U.154.236; 13.U.154.237; 13.U.154.238; 13.U.154.239; 13.U.154.154; 13.U.154.157; 13.U.154.166; 13.U.154.169; 13.U.154.172; 13.U.154.175; 13.U.154.240; 13.U.154.244; 13.U.157.228; 13.U.157.229; 13.U.157.230; 13.U.157.231; 13.U.157.236; 13.U.157.237; 13.U.157.238; 13.U.157.239; 13.U.157.154; 13.U.157.157; 13.U.157.166; 13.U.157.169; 13.U.157.172; 13.U.157.175; 13.U.157.240; 13.U.157.244; 13.U.166.228; 13.U.166.229; 13.U.166.230; 13.U.166.231; 13.U.166.236; 13.U.166.237; 13.U.166.238; 13.U.166.239; 13.U.166.154; 13.U.166.157; 13.U.166.166; 13.U.166.169; 13.U.166.172; 13.U.166.175; 13.U.166.240; 13.U.166.244; 13.U.169.228; 13.U.169.229; 13.U.169.230; 13.U.169.231; 13.U.169.236; 13.U.169.237; 13.U.169.238; 13.U.169.239; 13.U.169.154; 13.U.169.157; 13.U.169.166; 13.U.169.169; 13.U.169.172; 13.U.169.175; 13.U.169.240; 13.U.169.244; 13.U.172.228; 13.U.172.229; 13.U.172.230; 13.U.172.231; 13.U.172.236; 13.U.172.237; 13.U.172.238; 13.U.172.239; 13.U.172.154; 13.U.172.157; 13.U.172.166; 13.U.172.169; 13.U.172.172; 13.U.172.175; 13.U.172.240; 13.U.172.244; 13.U.175.228; 13.U.175.229;

13.U.175.230; 13.U.175.231; 13.U.175.236; 13.U.175.237; 13.U.175.238; 13.U.175.239; 13.U.175.154; 13.U.175.157; 13.U.175.166; 13.U.175.169; 13.U.175.172; 13.U.175.175; 13.U.175.240; 13.U.175.244; 13.U.240.228; 13.U.240.229; 13.U.240.230; 13.U.240.231; 13.U.240.236; 13.U.240.237; 13.U.240.238; 13.U.240.239; 13.U.240.154; 13.U.240.157; 13.U.240.166; 13.U.240.169; 13.U.240.172; 13.U.240.175; 13.U.240.240; 13.U.240.244; 13.U.244.228; 13.U.244.229; 13.U.244.230; 13.U.244.231; 13.U.244.236; 13.U.244.237; 13.U.244.238; 13.U.244.239; 13.U.244.154; 13.U.244.157; 13.U.244.166; 13.U.244.169; 13.U.244.172; 13.U.244.175; 13.U.244.240; 13.U.244.244;

Prodrugs of 13.W

13.W.228.228; 13.W.228.229; 13.W.228.230; 13.W.228.231; 13.W.228.236; 13.W.228.237; 13.W.228.238; 13.W.228.239; 13.W.228.154; 13.W.228.157; 13.W.228.166; 13.W.228.169; 13.W.228.172; 13.W.228.175; 13.W.228.240; 13.W.228.244; 13.W.229.228; 13.W.229.229; 13.W.229.230; 13.W.229.231; 13.W.229.236; 13.W.229.237; 13.W.229.238; 13.W.229.239; 13.W.229.154; 13.W.229.157; 13.W.229.166; 13.W.229.169; 13.W.229.172; 13.W.229.175; 13.W.229.240; 13.W.229.244; 13.W.230.228; 13.W.230.229; 13.W.230.230; 13.W.230.231; 13.W.230.236; 13.W.230.237; 13.W.230.238; 13.W.230.239; 13.W.230.154; 13.W.230.157; 13.W.230.166; 13.W.230.169; 13.W.230.172; 13.W.230.175; 13.W.230.240; 13.W.230.244; 13.W.231.228; 13.W.231.229; 13.W.231.230; 13.W.231.231; 13.W.231.236; 13.W.231.237; 13.W.231.238; 13.W.231.239; 13.W.231.154; 13.W.231.157; 13.W.231.166; 13.W.231.169; 13.W.231.172; 13.W.231.175; 13.W.231.240; 13.W.231.244; 13.W.236.228; 13.W.236.229; 13.W.236.230; 13.W.236.231; 13.W.236.236; 13.W.236.237; 13.W.236.238; 13.W.236.239; 13.W.236.154; 13.W.236.157; 13.W.236.166; 13.W.236.169; 13.W.236.172; 13.W.236.175; 13.W.236.240; 13.W.236.244; 13.W.237.228; 13.W.237.229; 13.W.237.230; 13.W.237.231; 13.W.237.236; 13.W.237.237; 13.W.237.238; 13.W.237.239; 13.W.237.154; 13.W.237.157; 13.W.237.166; 13.W.237.169; 13.W.237.172; 13.W.237.175; 13.W.237.240; 13.W.237.244; 13.W.238.228; 13.W.238.229; 13.W.238.230; 13.W.238.231; 13.W.238.236; 13.W.238.237; 13.W.238.238; 13.W.238.239; 13.W.238.154; 13.W.238.157; 13.W.238.166; 13.W.238.169; 13.W.238.172; 13.W.238.175; 13.W.238.240; 13.W.238.244; 13.W.239.228; 13.W.239.229; 13.W.239.230; 13.W.239.231; 13.W.239.236; 13.W.239.237; 13.W.239.238; 13.W.239.239; 13.W.239.154; 13.W.239.157; 13.W.239.166; 13.W.239.169; 13.W.239.172;

13.W.239.175; 13.W.239.240; 13.W.239.244; 13.W.154.228; 13.W.154.229; 13.W.154.230; 13.W.154.231; 13.W.154.236; 13.W.154.237; 13.W.154.238; 13.W.154.239; 13.W.154.154; 13.W.154.157; 13.W.154.166; 13.W.154.169; 13.W.154.172; 13.W.154.175; 13.W.154.240; 13.W.154.244; 13.W.157.228; 13.W.157.229; 13.W.157.230; 13.W.157.231; 13.W.157.236; 13.W.157.237; 13.W.157.238; 13.W.157.239; 13.W.157.154; 13.W.157.157; 13.W.157.166; 13.W.157.169; 13.W.157.172; 13.W.157.175; 13.W.157.240; 13.W.157.244; 13.W.166.228; 13.W.166.229; 13.W.166.230; 13.W.166.231; 13.W.166.236; 13.W.166.237; 13.W.166.238; 13.W.166.239; 13.W.166.154; 13.W.166.157; 13.W.166.166; 13.W.166.169; 13.W.166.172; 13.W.166.175; 13.W.166.240; 13.W.166.244; 13.W.169.228; 13.W.169.229; 13.W.169.230; 13.W.169.231; 13.W.169.236; 13.W.169.237; 13.W.169.238; 13.W.169.239; 13.W.169.154; 13.W.169.157; 13.W.169.166; 13.W.169.169; 13.W.169.172; 13.W.169.175; 13.W.169.240; 13.W.169.244; 13.W.172.228; 13.W.172.229; 13.W.172.230; 13.W.172.231; 13.W.172.236; 13.W.172.237; 13.W.172.238; 13.W.172.239; 13.W.172.154; 13.W.172.157; 13.W.172.166; 13.W.172.169; 13.W.172.172; 13.W.172.175; 13.W.172.240; 13.W.172.244; 13.W.175.228; 13.W.175.229; 13.W.175.230; 13.W.175.231; 13.W.175.236; 13.W.175.237; 13.W.175.238; 13.W.175.239; 13.W.175.154; 13.W.175.157; 13.W.175.166; 13.W.175.169; 13.W.175.172; 13.W.175.175; 13.W.175.240; 13.W.175.244; 13.W.240.228; 13.W.240.229; 13.W.240.230; 13.W.240.231; 13.W.240.236; 13.W.240.237; 13.W.240.238; 13.W.240.239; 13.W.240.154; 13.W.240.157; 13.W.240.166; 13.W.240.169; 13.W.240.172; 13.W.240.175; 13.W.240.240; 13.W.240.244; 13.W.244.228; 13.W.244.229; 13.W.244.230; 13.W.244.231; 13.W.244.236; 13.W.244.237; 13.W.244.238; 13.W.244.239; 13.W.244.154; 13.W.244.157; 13.W.244.166; 13.W.244.169; 13.W.244.172; 13.W.244.175; 13.W.244.240; 13.W.244.244;

Prodrugs of 13.Y

13.Y.228.228; 13.Y.228.229; 13.Y.228.230; 13.Y.228.231; 13.Y.228.236; 13.Y.228.237; 13.Y.228.238; 13.Y.228.239; 13.Y.228.154; 13.Y.228.157; 13.Y.228.166; 13.Y.228.169; 13.Y.228.172; 13.Y.228.175; 13.Y.228.240; 13.Y.228.244; 13.Y.229.228; 13.Y.229.229; 13.Y.229.230; 13.Y.229.231; 13.Y.229.236; 13.Y.229.237; 13.Y.229.238; 13.Y.229.239; 13.Y.229.154; 13.Y.229.157; 13.Y.229.166; 13.Y.229.169; 13.Y.229.172; 13.Y.229.175; 13.Y.229.240; 13.Y.229.244; 13.Y.230.228; 13.Y.230.229; 13.Y.230.230; 13.Y.230.231; 13.Y.230.236; 13.Y.230.237; 13.Y.230.238; 13.Y.230.239;

13.Y.230.154; 13.Y.230.157; 13.Y.230.166; 13.Y.230.169; 13.Y.230.172; 13.Y.230.175; 13.Y.230.240; 13.Y.230.244; 13.Y.231.228; 13.Y.231.229; 13.Y.231.230; 13.Y.231.231; 13.Y.231.236; 13.Y.231.237; 13.Y.231.238; 13.Y.231.239; 13.Y.231.154; 13.Y.231.157; 13.Y.231.166; 13.Y.231.169; 13.Y.231.172; 13.Y.231.175; 13.Y.231.240; 13.Y.231.244; 13.Y.236.228; 13.Y.236.229; 13.Y.236.230; 13.Y.236.231; 13.Y.236.236; 13.Y.236.237; 13.Y.236.238; 13.Y.236.239; 13.Y.236.154; 13.Y.236.157; 13.Y.236.166; 13.Y.236.169; 13.Y.236.172; 13.Y.236.175; 13.Y.236.240; 13.Y.236.244; 13.Y.237.228; 13.Y.237.229; 13.Y.237.230; 13.Y.237.231; 13.Y.237.236; 13.Y.237.237; 13.Y.237.238; 13.Y.237.239; 13.Y.237.154; 13.Y.237.157; 13.Y.237.166; 13.Y.237.169; 13.Y.237.172; 13.Y.237.175; 13.Y.237.240; 13.Y.237.244; 13.Y.238.228; 13.Y.238.229; 13.Y.238.230; 13.Y.238.231; 13.Y.238.236; 13.Y.238.237; 13.Y.238.238; 13.Y.238.239; 13.Y.238.154; 13.Y.238.157; 13.Y.238.166; 13.Y.238.169; 13.Y.238.172; 13.Y.238.175; 13.Y.238.240; 13.Y.238.244; 13.Y.239.228; 13.Y.239.229; 13.Y.239.230; 13.Y.239.231; 13.Y.239.236; 13.Y.239.237; 13.Y.239.238; 13.Y.239.239; 13.Y.239.154; 13.Y.239.157; 13.Y.239.166; 13.Y.239.169; 13.Y.239.172; 13.Y.239.175; 13.Y.239.240; 13.Y.239.244; 13.Y.154.228; 13.Y.154.229; 13.Y.154.230; 13.Y.154.231; 13.Y.154.236; 13.Y.154.237; 13.Y.154.238; 13.Y.154.239; 13.Y.154.154; 13.Y.154.157; 13.Y.154.166; 13.Y.154.169; 13.Y.154.172; 13.Y.154.175; 13.Y.154.240; 13.Y.154.244; 13.Y.157.228; 13.Y.157.229; 13.Y.157.230; 13.Y.157.231; 13.Y.157.236; 13.Y.157.237; 13.Y.157.238; 13.Y.157.239; 13.Y.157.154; 13.Y.157.157; 13.Y.157.166; 13.Y.157.169; 13.Y.157.172; 13.Y.157.175; 13.Y.157.240; 13.Y.157.244; 13.Y.166.228; 13.Y.166.229; 13.Y.166.230; 13.Y.166.231; 13.Y.166.236; 13.Y.166.237; 13.Y.166.238; 13.Y.166.239; 13.Y.166.154; 13.Y.166.157; 13.Y.166.166; 13.Y.166.169; 13.Y.166.172; 13.Y.166.175; 13.Y.166.240; 13.Y.166.244; 13.Y.169.228; 13.Y.169.229; 13.Y.169.230; 13.Y.169.231; 13.Y.169.236; 13.Y.169.237; 13.Y.169.238; 13.Y.169.239; 13.Y.169.154; 13.Y.169.157; 13.Y.169.166; 13.Y.169.169; 13.Y.169.172; 13.Y.169.175; 13.Y.169.240; 13.Y.169.244; 13.Y.172.228; 13.Y.172.229; 13.Y.172.230; 13.Y.172.231; 13.Y.172.236; 13.Y.172.237; 13.Y.172.238; 13.Y.172.239; 13.Y.172.154; 13.Y.172.157; 13.Y.172.166; 13.Y.172.169; 13.Y.172.172; 13.Y.172.175; 13.Y.172.240; 13.Y.172.244; 13.Y.175.228; 13.Y.175.229; 13.Y.175.230; 13.Y.175.231; 13.Y.175.236; 13.Y.175.237; 13.Y.175.238; 13.Y.175.239; 13.Y.175.154; 13.Y.175.157; 13.Y.175.166; 13.Y.175.169; 13.Y.175.172; 13.Y.175.175; 13.Y.175.240; 13.Y.175.244; 13.Y.240.228;

13.Y.240.229; 13.Y.240.230; 13.Y.240.231; 13.Y.240.236; 13.Y.240.237; 13.Y.240.238; 13.Y.240.239; 13.Y.240.154; 13.Y.240.157; 13.Y.240.166; 13.Y.240.169; 13.Y.240.172; 13.Y.240.175; 13.Y.240.240; 13.Y.240.244; 13.Y.244.228; 13.Y.244.229; 13.Y.244.230; 13.Y.244.231; 13.Y.244.236; 13.Y.244.237; 13.Y.244.238; 13.Y.244.239; 13.Y.244.154; 13.Y.244.157; 13.Y.244.166; 13.Y.244.169; 13.Y.244.172; 13.Y.244.175; 13.Y.244.240; 13.Y.244.244;

Prodrugs of 14.AH

14.AH.4.157; 14.AH.4.158; 14.AH.4.196; 14.AH.4.223; 14.AH.4.240; 14.AH.4.244; 14.AH.4.243; 14.AH.4.247; 14.AH.5.157; 14.AH.5.158; 14.AH.5.196; 14.AH.5.223; 14.AH.5.240; 14.AH.5.244; 14.AH.5.243; 14.AH.5.247; 14.AH.7.157; 14.AH.7.158; 14.AH.7.196; 14.AH.7.223; 14.AH.7.240; 14.AH.7.244; 14.AH.7.243; 14.AH.7.247; 14.AH.15.157; 14.AH.15.158; 14.AH.15.196; 14.AH.15.223; 14.AH.15.240; 14.AH.15.244; 14.AH.15.243; 14.AH.15.247; 14.AH.16.157; 14.AH.16.158; 14.AH.16.196; 14.AH.16.223; 14.AH.16.240; 14.AH.16.244; 14.AH.16.243; 14.AH.16.247; 14.AH.18.157; 14.AH.18.158; 14.AH.18.196; 14.AH.18.223; 14.AH.18.240; 14.AH.18.244; 14.AH.18.243; 14.AH.18.247; 14.AH.26.157; 14.AH.26.158; 14.AH.26.196; 14.AH.26.223; 14.AH.26.240; 14.AH.26.244; 14.AH.26.243; 14.AH.26.247; 14.AH.27.157; 14.AH.27.158; 14.AH.27.196; 14.AH.27.223; 14.AH.27.240; 14.AH.27.244; 14.AH.27.243; 14.AH.27.247; 14.AH.29.157; 14.AH.29.158; 14.AH.29.196; 14.AH.29.223; 14.AH.29.240; 14.AH.29.244; 14.AH.29.243; 14.AH.29.247; 14.AH.54.157; 14.AH.54.158; 14.AH.54.196; 14.AH.54.223; 14.AH.54.240; 14.AH.54.244; 14.AH.54.243; 14.AH.54.247; 14.AH.55.157; 14.AH.55.158; 14.AH.55.196; 14.AH.55.223; 14.AH.55.240; 14.AH.55.244; 14.AH.55.243; 14.AH.55.247; 14.AH.56.157; 14.AH.56.158; 14.AH.56.196; 14.AH.56.223; 14.AH.56.240; 14.AH.56.244; 14.AH.56.243; 14.AH.56.247; 14.AH.157.157; 14.AH.157.158; 14.AH.157.196; 14.AH.157.223; 14.AH.157.240; 14.AH.157.244; 14.AH.157.243; 14.AH.157.247; 14.AH.196.157; 14.AH.196.158; 14.AH.196.196; 14.AH.196.223; 14.AH.196.240; 14.AH.196.244; 14.AH.196.243; 14.AH.196.247; 14.AH.223.157; 14.AH.223.158; 14.AH.223.196; 14.AH.223.223; 14.AH.223.240; 14.AH.223.244; 14.AH.223.243;

14.AH.223.247; 14.AH.240.157; 14.AH.240.158; 14.AH.240.196; 14.AH.240.223; 14.AH.240.240; 14.AH.240.244; 14.AH.240.243; 14.AH.240.247; 14.AH.244.157; 14.AH.244.158; 14.AH.244.196; 14.AH.244.223; 14.AH.244.240; 14.AH.244.244; 14.AH.244.243; 14.AH.244.247; 14.AH.247.157; 14.AH.247.158; 14.AH.247.196; 14.AH.247.223; 14.AH.247.240; 14.AH.247.244; 14.AH.247.243; 14.AH.247.247;

Prodrugs of 14.AJ

14.AJ.4.157; 14.AJ.4.158; 14.AJ.4.196; 14.AJ.4.223; 14.AJ.4.240; 14.AJ.4.244; 14.AJ.4.243; 14.AJ.4.247; 14.AJ.5.157; 14.AJ.5.158; 14.AJ.5.196; 14.AJ.5.223; 14.AJ.5.240; 14.AJ.5.244; 14.AJ.5.243; 14.AJ.5.247; 14.AJ.7.157; 14.AJ.7.158; 14.AJ.7.196; 14.AJ.7.223; 14.AJ.7.240; 14.AJ.7.244; 14.AJ.7.243; 14.AJ.7.247; 14.AJ.15.157; 14.AJ.15.158; 14.AJ.15.196; 14.AJ.15.223; 14.AJ.15.240; 14.AJ.15.244; 14.AJ.15.243; 14.AJ.15.247; 14.AJ.16.157; 14.AJ.16.158; 14.AJ.16.196; 14.AJ.16.223; 14.AJ.16.240; 14.AJ.16.244; 14.AJ.16.243; 14.AJ.16.247; 14.AJ.18.157; 14.AJ.18.158; 14.AJ.18.196; 14.AJ.18.223; 14.AJ.18.240; 14.AJ.18.244; 14.AJ.18.243; 14.AJ.18.247; 14.AJ.26.157; 14.AJ.26.158; 14.AJ.26.196; 14.AJ.26.223; 14.AJ.26.240; 14.AJ.26.244; 14.AJ.26.243; 14.AJ.26.247; 14.AJ.27.157; 14.AJ.27.158; 14.AJ.27.196; 14.AJ.27.223; 14.AJ.27.240; 14.AJ.27.244; 14.AJ.27.243; 14.AJ.27.247; 14.AJ.29.157; 14.AJ.29.158; 14.AJ.29.196; 14.AJ.29.223; 14.AJ.29.240; 14.AJ.29.244; 14.AJ.29.243; 14.AJ.29.247; 14.AJ.54.157; 14.AJ.54.158; 14.AJ.54.196; 14.AJ.54.223; 14.AJ.54.240; 14.AJ.54.244; 14.AJ.54.243; 14.AJ.54.247; 14.AJ.55.157; 14.AJ.55.158; 14.AJ.55.196; 14.AJ.55.223; 14.AJ.55.240; 14.AJ.55.244; 14.AJ.55.243; 14.AJ.55.247; 14.AJ.56.157; 14.AJ.56.158; 14.AJ.56.196; 14.AJ.56.223; 14.AJ.56.240; 14.AJ.56.244; 14.AJ.56.243; 14.AJ.56.247; 14.AJ.157.157; 14.AJ.157.158; 14.AJ.157.196; 14.AJ.157.223; 14.AJ.157.240; 14.AJ.157.244; 14.AJ.157.243; 14.AJ.157.247; 14.AJ.196.157; 14.AJ.196.158; 14.AJ.196.196; 14.AJ.196.223; 14.AJ.196.240; 14.AJ.196.244; 14.AJ.196.243; 14.AJ.196.247; 14.AJ.223.157; 14.AJ.223.158; 14.AJ.223.196; 14.AJ.223.223; 14.AJ.223.240; 14.AJ.223.244; 14.AJ.223.243; 14.AJ.223.247; 14.AJ.240.157; 14.AJ.240.158; 14.AJ.240.196;

14.AJ.240.223; 14.AJ.240.240; 14.AJ.240.244; 14.AJ.240.243; 14.AJ.240.247; 14.AJ.244.157; 14.AJ.244.158; 14.AJ.244.196; 14.AJ.244.223; 14.AJ.244.240; 14.AJ.244.244; 14.AJ.244.243; 14.AJ.244.247; 14.AJ.247.157; 14.AJ.247.158; 14.AJ.247.196; 14.AJ.247.223; 14.AJ.247.240; 14.AJ.247.244; 14.AJ.247.243; 14.AJ.247.247;

Prodrugs of 14.AN

14.AN.4.157; 14.AN.4.158; 14.AN.4.196; 14.AN.4.223; 14.AN.4.240; 14.AN.4.244; 14.AN.4.243; 14.AN.4.247; 14.AN.5.157; 14.AN.5.158; 14.AN.5.196; 14.AN.5.223; 14.AN.5.240; 14.AN.5.244; 14.AN.5.243; 14.AN.5.247; 14.AN.7.157; 14.AN.7.158; 14.AN.7.196; 14.AN.7.223; 14.AN.7.240; 14.AN.7.244; 14.AN.7.243; 14.AN.7.247; 14.AN.15.157; 14.AN.15.158; 14.AN.15.196; 14.AN.15.223; 14.AN.15.240; 14.AN.15.244; 14.AN.15.243; 14.AN.15.247; 14.AN.16.157; 14.AN.16.158; 14.AN.16.196; 14.AN.16.223; 14.AN.16.240; 14.AN.16.244; 14.AN.16.243; 14.AN.16.247; 14.AN.18.157; 14.AN.18.158; 14.AN.18.196; 14.AN.18.223; 14.AN.18.240; 14.AN.18.244; 14.AN.18.243; 14.AN.18.247; 14.AN.26.157; 14.AN.26.158; 14.AN.26.196; 14.AN.26.223; 14.AN.26.240; 14.AN.26.244; 14.AN.26.243; 14.AN.26.247; 14.AN.27.157; 14.AN.27.158; 14.AN.27.196; 14.AN.27.223; 14.AN.27.240; 14.AN.27.244; 14.AN.27.243; 14.AN.27.247; 14.AN.29.157; 14.AN.29.158; 14.AN.29.196; 14.AN.29.223; 14.AN.29.240; 14.AN.29.244; 14.AN.29.243; 14.AN.29.247; 14.AN.54.157; 14.AN.54.158; 14.AN.54.196; 14.AN.54.223; 14.AN.54.240; 14.AN.54.244; 14.AN.54.243; 14.AN.54.247; 14.AN.55.157; 14.AN.55.158; 14.AN.55.196; 14.AN.55.223; 14.AN.55.240; 14.AN.55.244; 14.AN.55.243; 14.AN.55.247; 14.AN.56.157; 14.AN.56.158; 14.AN.56.196; 14.AN.56.223; 14.AN.56.240; 14.AN.56.244; 14.AN.56.243; 14.AN.56.247; 14.AN.157.157; 14.AN.157.158; 14.AN.157.196; 14.AN.157.223; 14.AN.157.240; 14.AN.157.244; 14.AN.157.243; 14.AN.157.247; 14.AN.196.157; 14.AN.196.158; 14.AN.196.196; 14.AN.196.223; 14.AN.196.240; 14.AN.196.244; 14.AN.196.243; 14.AN.196.247; 14.AN.223.157; 14.AN.223.158; 14.AN.223.196; 14.AN.223.223; 14.AN.223.240; 14.AN.223.244; 14.AN.223.243; 14.AN.223.247; 14.AN.240.157; 14.AN.240.158; 14.AN.240.196;

14.AN.240.223; 14.AN.240.240; 14.AN.240.244; 14.AN.240.243; 14.AN.240.247; 14.AN.244.157; 14.AN.244.158; 14.AN.244.196; 14.AN.244.223; 14.AN.244.240; 14.AN.244.244; 14.AN.244.243; 14.AN.244.247; 14.AN.247.157; 14.AN.247.158; 14.AN.247.196; 14.AN.247.223; 14.AN.247.240; 14.AN.247.244; 14.AN.247.243; 14.AN.247.247;

Prodrugs of 14.AP

14.AP.4.157; 14.AP.4.158; 14.AP.4.196; 14.AP.4.223; 14.AP.4.240; 14.AP.4.244; 14.AP.4.243; 14.AP.4.247; 14.AP.5.157; 14.AP.5.158; 14.AP.5.196; 14.AP.5.223; 14.AP.5.240; 14.AP.5.244; 14.AP.5.243; 14.AP.5.247; 14.AP.7.157; 14.AP.7.158; 14.AP.7.196; 14.AP.7.223; 14.AP.7.240; 14.AP.7.244; 14.AP.7.243; 14.AP.7.247; 14.AP.15.157; 14.AP.15.158; 14.AP.15.196; 14.AP.15.223; 14.AP.15.240; 14.AP.15.244; 14.AP.15.243; 14.AP.15.247; 14.AP.16.157; 14.AP.16.158; 14.AP.16.196; 14.AP.16.223; 14.AP.16.240; 14.AP.16.244; 14.AP.16.243; 14.AP.16.247; 14.AP.18.157; 14.AP.18.158; 14.AP.18.196; 14.AP.18.223; 14.AP.18.240; 14.AP.18.244; 14.AP.18.243; 14.AP.18.247; 14.AP.26.157; 14.AP.26.158; 14.AP.26.196; 14.AP.26.223; 14.AP.26.240; 14.AP.26.244; 14.AP.26.243; 14.AP.26.247; 14.AP.27.157; 14.AP.27.158; 14.AP.27.196; 14.AP.27.223; 14.AP.27.240; 14.AP.27.244; 14.AP.27.243; 14.AP.27.247; 14.AP.29.157; 14.AP.29.158; 14.AP.29.196; 14.AP.29.223; 14.AP.29.240; 14.AP.29.244; 14.AP.29.243; 14.AP.29.247; 14.AP.54.157; 14.AP.54.158; 14.AP.54.196; 14.AP.54.223; 14.AP.54.240; 14.AP.54.244; 14.AP.54.243; 14.AP.54.247; 14.AP.55.157; 14.AP.55.158; 14.AP.55.196; 14.AP.55.223; 14.AP.55.240; 14.AP.55.244; 14.AP.55.243; 14.AP.55.247; 14.AP.56.157; 14.AP.56.158; 14.AP.56.196; 14.AP.56.223; 14.AP.56.240; 14.AP.56.244; 14.AP.56.243; 14.AP.56.247; 14.AP.157.157; 14.AP.157.158; 14.AP.157.196; 14.AP.157.223; 14.AP.157.240; 14.AP.157.244; 14.AP.157.243; 14.AP.157.247; 14.AP.196.157; 14.AP.196.158; 14.AP.196.196; 14.AP.196.223; 14.AP.196.240; 14.AP.196.244; 14.AP.196.243; 14.AP.196.247; 14.AP.223.157; 14.AP.223.158; 14.AP.223.196; 14.AP.223.223; 14.AP.223.240; 14.AP.223.244; 14.AP.223.243; 14.AP.223.247;

14.AP.240.157; 14.AP.240.158; 14.AP.240.196; 14.AP.240.223;
14.AP.240.240; 14.AP.240.244; 14.AP.240.243; 14.AP.240.247;
14.AP.244.157; 14.AP.244.158; 14.AP.244.196; 14.AP.244.223;
14.AP.244.240; 14.AP.244.244; 14.AP.244.243; 14.AP.244.247;
14.AP.247.157; 14.AP.247.158; 14.AP.247.196; 14.AP.247.223;
14.AP.247.240; 14.AP.247.244; 14.AP.247.243; 14.AP.247.247;

Prodrugs of 14.AZ

14.AZ.4.157; 14.AZ.4.158; 14.AZ.4.196; 14.AZ.4.223; 14.AZ.4.240;
14.AZ.4.244; 14.AZ.4.243; 14.AZ.4.247; 14.AZ.5.157; 14.AZ.5.158;
14.AZ.5.196; 14.AZ.5.223; 14.AZ.5.240; 14.AZ.5.244; 14.AZ.5.243;
14.AZ.5.247; 14.AZ.7.157; 14.AZ.7.158; 14.AZ.7.196; 14.AZ.7.223;
14.AZ.7.240; 14.AZ.7.244; 14.AZ.7.243; 14.AZ.7.247; 14.AZ.15.157;
14.AZ.15.158; 14.AZ.15.196; 14.AZ.15.223; 14.AZ.15.240; 14.AZ.15.244;
14.AZ.15.243; 14.AZ.15.247; 14.AZ.16.157; 14.AZ.16.158; 14.AZ.16.196;
14.AZ.16.223; 14.AZ.16.240; 14.AZ.16.244; 14.AZ.16.243; 14.AZ.16.247;
14.AZ.18.157; 14.AZ.18.158; 14.AZ.18.196; 14.AZ.18.223; 14.AZ.18.240;
14.AZ.18.244; 14.AZ.18.243; 14.AZ.18.247; 14.AZ.26.157; 14.AZ.26.158;
14.AZ.26.196; 14.AZ.26.223; 14.AZ.26.240; 14.AZ.26.244; 14.AZ.26.243;
14.AZ.26.247; 14.AZ.27.157; 14.AZ.27.158; 14.AZ.27.196; 14.AZ.27.223;
14.AZ.27.240; 14.AZ.27.244; 14.AZ.27.243; 14.AZ.27.247; 14.AZ.29.157;
14.AZ.29.158; 14.AZ.29.196; 14.AZ.29.223; 14.AZ.29.240; 14.AZ.29.244;
14.AZ.29.243; 14.AZ.29.247; 14.AZ.54.157; 14.AZ.54.158; 14.AZ.54.196;
14.AZ.54.223; 14.AZ.54.240; 14.AZ.54.244; 14.AZ.54.243; 14.AZ.54.247;
14.AZ.55.157; 14.AZ.55.158; 14.AZ.55.196; 14.AZ.55.223; 14.AZ.55.240;
14.AZ.55.244; 14.AZ.55.243; 14.AZ.55.247; 14.AZ.56.157; 14.AZ.56.158;
14.AZ.56.196; 14.AZ.56.223; 14.AZ.56.240; 14.AZ.56.244; 14.AZ.56.243;
14.AZ.56.247; 14.AZ.157.157; 14.AZ.157.158; 14.AZ.157.196; 14.AZ.157.223;
14.AZ.157.240; 14.AZ.157.244; 14.AZ.157.243; 14.AZ.157.247;
14.AZ.196.157; 14.AZ.196.158; 14.AZ.196.196; 14.AZ.196.223;
14.AZ.196.240; 14.AZ.196.244; 14.AZ.196.243; 14.AZ.196.247;
14.AZ.223.157; 14.AZ.223.158; 14.AZ.223.196; 14.AZ.223.223;
14.AZ.223.240; 14.AZ.223.244; 14.AZ.223.243; 14.AZ.223.247;

14.AZ.240.157; 14.AZ.240.158; 14.AZ.240.196; 14.AZ.240.223; 14.AZ.240.240; 14.AZ.240.244; 14.AZ.240.243; 14.AZ.240.247; 14.AZ.244.157; 14.AZ.244.158; 14.AZ.244.196; 14.AZ.244.223; 14.AZ.244.240; 14.AZ.244.244; 14.AZ.244.243; 14.AZ.244.247; 14.AZ.247.157; 14.AZ.247.158; 14.AZ.247.196; 14.AZ.247.223; 14.AZ.247.240; 14.AZ.247.244; 14.AZ.247.243; 14.AZ.247.247;

Prodrugs of 14.BF

14.BF.4.157; 14.BF.4.158; 14.BF.4.196; 14.BF.4.223; 14.BF.4.240; 14.BF.4.244; 14.BF.4.243; 14.BF.4.247; 14.BF.5.157; 14.BF.5.158; 14.BF.5.196; 14.BF.5.223; 14.BF.5.240; 14.BF.5.244; 14.BF.5.243; 14.BF.5.247; 14.BF.7.157; 14.BF.7.158; 14.BF.7.196; 14.BF.7.223; 14.BF.7.240; 14.BF.7.244; 14.BF.7.243; 14.BF.7.247; 14.BF.15.157; 14.BF.15.158; 14.BF.15.196; 14.BF.15.223; 14.BF.15.240; 14.BF.15.244; 14.BF.15.243; 14.BF.15.247; 14.BF.16.157; 14.BF.16.158; 14.BF.16.196; 14.BF.16.223; 14.BF.16.240; 14.BF.16.244; 14.BF.16.243; 14.BF.16.247; 14.BF.18.157; 14.BF.18.158; 14.BF.18.196; 14.BF.18.223; 14.BF.18.240; 14.BF.18.244; 14.BF.18.243; 14.BF.18.247; 14.BF.26.157; 14.BF.26.158; 14.BF.26.196; 14.BF.26.223; 14.BF.26.240; 14.BF.26.244; 14.BF.26.243; 14.BF.26.247; 14.BF.27.157; 14.BF.27.158; 14.BF.27.196; 14.BF.27.223; 14.BF.27.240; 14.BF.27.244; 14.BF.27.243; 14.BF.27.247; 14.BF.29.157; 14.BF.29.158; 14.BF.29.196; 14.BF.29.223; 14.BF.29.240; 14.BF.29.244; 14.BF.29.243; 14.BF.29.247; 14.BF.54.157; 14.BF.54.158; 14.BF.54.196; 14.BF.54.223; 14.BF.54.240; 14.BF.54.244; 14.BF.54.243; 14.BF.54.247; 14.BF.55.157; 14.BF.55.158; 14.BF.55.196; 14.BF.55.223; 14.BF.55.240; 14.BF.55.244; 14.BF.55.243; 14.BF.55.247; 14.BF.56.157; 14.BF.56.158; 14.BF.56.196; 14.BF.56.223; 14.BF.56.240; 14.BF.56.244; 14.BF.56.243; 14.BF.56.247; 14.BF.157.157; 14.BF.157.158; 14.BF.157.196; 14.BF.157.223; 14.BF.157.240; 14.BF.157.244; 14.BF.157.243; 14.BF.157.247; 14.BF.196.157; 14.BF.196.158; 14.BF.196.196; 14.BF.196.223; 14.BF.196.240; 14.BF.196.244; 14.BF.196.243; 14.BF.196.247; 14.BF.223.157; 14.BF.223.158; 14.BF.223.196; 14.BF.223.223; 14.BF.223.240; 14.BF.223.244; 14.BF.223.243; 14.BF.223.247; 14.BF.240.157; 14.BF.240.158; 14.BF.240.196; 14.BF.240.223; 14.BF.240.240;

14.BF.240.244; 14.BF.240.243; 14.BF.240.247; 14.BF.244.157; 14.BF.244.158; 14.BF.244.196; 14.BF.244.223; 14.BF.244.240; 14.BF.244.244; 14.BF.244.243; 14.BF.244.247; 14.BF.247.157; 14.BF.247.158; 14.BF.247.196; 14.BF.247.223; 14.BF.247.240; 14.BF.247.244; 14.BF.247.243; 14.BF.247.247;

Prodrugs of 14.CI

14.CI.4.157; 14.CI.4.158; 14.CI.4.196; 14.CI.4.223; 14.CI.4.240; 14.CI.4.244; 14.CI.4.243; 14.CI.4.247; 14.CI.5.157; 14.CI.5.158; 14.CI.5.196; 14.CI.5.223; 14.CI.5.240; 14.CI.5.244; 14.CI.5.243; 14.CI.5.247; 14.CI.7.157; 14.CI.7.158; 14.CI.7.196; 14.CI.7.223; 14.CI.7.240; 14.CI.7.244; 14.CI.7.243; 14.CI.7.247; 14.CI.15.157; 14.CI.15.158; 14.CI.15.196; 14.CI.15.223; 14.CI.15.240; 14.CI.15.244; 14.CI.15.243; 14.CI.15.247; 14.CI.16.157; 14.CI.16.158; 14.CI.16.196; 14.CI.16.223; 14.CI.16.240; 14.CI.16.244; 14.CI.16.243; 14.CI.16.247; 14.CI.18.157; 14.CI.18.158; 14.CI.18.196; 14.CI.18.223; 14.CI.18.240; 14.CI.18.244; 14.CI.18.243; 14.CI.18.247; 14.CI.26.157; 14.CI.26.158; 14.CI.26.196; 14.CI.26.223; 14.CI.26.240; 14.CI.26.244; 14.CI.26.243; 14.CI.26.247; 14.CI.27.157; 14.CI.27.158; 14.CI.27.196; 14.CI.27.223; 14.CI.27.240; 14.CI.27.244; 14.CI.27.243; 14.CI.27.247; 14.CI.29.157; 14.CI.29.158; 14.CI.29.196; 14.CI.29.223; 14.CI.29.240; 14.CI.29.244; 14.CI.29.243; 14.CI.29.247; 14.CI.54.157; 14.CI.54.158; 14.CI.54.196; 14.CI.54.223; 14.CI.54.240; 14.CI.54.244; 14.CI.54.243; 14.CI.54.247; 14.CI.55.157; 14.CI.55.158; 14.CI.55.196; 14.CI.55.223; 14.CI.55.240; 14.CI.55.244; 14.CI.55.243; 14.CI.55.247; 14.CI.56.157; 14.CI.56.158; 14.CI.56.196; 14.CI.56.223; 14.CI.56.240; 14.CI.56.244; 14.CI.56.243; 14.CI.56.247; 14.CI.157.157; 14.CI.157.158; 14.CI.157.196; 14.CI.157.223; 14.CI.157.240; 14.CI.157.244; 14.CI.157.243; 14.CI.157.247; 14.CI.196.157; 14.CI.196.158; 14.CI.196.196; 14.CI.196.223; 14.CI.196.240; 14.CI.196.244; 14.CI.196.243; 14.CI.196.247; 14.CI.223.157; 14.CI.223.158; 14.CI.223.196; 14.CI.223.223; 14.CI.223.240; 14.CI.223.244; 14.CI.223.243; 14.CI.223.247; 14.CI.240.157; 14.CI.240.158; 14.CI.240.196; 14.CI.240.223; 14.CI.240.240; 14.CI.240.244; 14.CI.240.243; 14.CI.240.247; 14.CI.244.157; 14.CI.244.158; 14.CI.244.196; 14.CI.244.223; 14.CI.244.240; 14.CI.244.244; 14.CI.244.243; 14.CI.244.247; 14.CI.247.157; 14.CI.247.158;

14.CI.247.196; 14.CI.247.223; 14.CI.247.240; 14.CI.247.244; 14.CI.247.243; 14.CI.247.247;

Prodrugs of 14.CO

14.CO.4.157; 14.CO.4.158; 14.CO.4.196; 14.CO.4.223; 14.CO.4.240; 14.CO.4.244; 14.CO.4.243; 14.CO.4.247; 14.CO.5.157; 14.CO.5.158; 14.CO.5.196; 14.CO.5.223; 14.CO.5.240; 14.CO.5.244; 14.CO.5.243; 14.CO.5.247; 14.CO.7.157; 14.CO.7.158; 14.CO.7.196; 14.CO.7.223; 14.CO.7.240; 14.CO.7.244; 14.CO.7.243; 14.CO.7.247; 14.CO.15.157; 14.CO.15.158; 14.CO.15.196; 14.CO.15.223; 14.CO.15.240; 14.CO.15.244; 14.CO.15.243; 14.CO.15.247; 14.CO.16.157; 14.CO.16.158; 14.CO.16.196; 14.CO.16.223; 14.CO.16.240; 14.CO.16.244; 14.CO.16.243; 14.CO.16.247; 14.CO.18.157; 14.CO.18.158; 14.CO.18.196; 14.CO.18.223; 14.CO.18.240; 14.CO.18.244; 14.CO.18.243; 14.CO.18.247; 14.CO.26.157; 14.CO.26.158; 14.CO.26.196; 14.CO.26.223; 14.CO.26.240; 14.CO.26.244; 14.CO.26.243; 14.CO.26.247; 14.CO.27.157; 14.CO.27.158; 14.CO.27.196; 14.CO.27.223; 14.CO.27.240; 14.CO.27.244; 14.CO.27.243; 14.CO.27.247; 14.CO.29.157; 14.CO.29.158; 14.CO.29.196; 14.CO.29.223; 14.CO.29.240; 14.CO.29.244; 14.CO.29.243; 14.CO.29.247; 14.CO.54.157; 14.CO.54.158; 14.CO.54.196; 14.CO.54.223; 14.CO.54.240; 14.CO.54.244; 14.CO.54.243; 14.CO.54.247; 14.CO.55.157; 14.CO.55.158; 14.CO.55.196; 14.CO.55.223; 14.CO.55.240; 14.CO.55.244; 14.CO.55.243; 14.CO.55.247; 14.CO.56.157; 14.CO.56.158; 14.CO.56.196; 14.CO.56.223; 14.CO.56.240; 14.CO.56.244; 14.CO.56.243; 14.CO.56.247; 14.CO.157.157; 14.CO.157.158; 14.CO.157.196; 14.CO.157.223; 14.CO.157.240; 14.CO.157.244; 14.CO.157.243; 14.CO.157.247; 14.CO.196.157; 14.CO.196.158; 14.CO.196.196; 14.CO.196.223; 14.CO.196.240; 14.CO.196.244; 14.CO.196.243; 14.CO.196.247; 14.CO.223.157; 14.CO.223.158; 14.CO.223.196; 14.CO.223.223; 14.CO.223.240; 14.CO.223.244; 14.CO.223.243; 14.CO.223.247; 14.CO.240.157; 14.CO.240.158; 14.CO.240.196; 14.CO.240.223; 14.CO.240.240; 14.CO.240.244; 14.CO.240.243; 14.CO.240.247; 14.CO.244.157; 14.CO.244.158; 14.CO.244.196; 14.CO.244.223; 14.CO.244.240; 14.CO.244.244; 14.CO.244.243;

14.CO.244.247; 14.CO.4.157; 14.CO.4.158; 14.CO.4.196; 14.CO.4.223; 14.CO.4.240; 14.CO.4.244; 14.CO.4.243; 14.CO.4.247.

All literature and patent citations above are hereby expressly incorporated by reference at the locations of their citation. Specifically cited sections or pages of the above cited works are incorporated by reference with specificity. The invention has been described in detail sufficient to allow one of ordinary skill in the art to make and use the subject matter of the following Claims. It is apparent that certain modifications of the methods and compositions of the following Claims can be made within the scope and spirit of the invention.

In the claims hereinbelow, the subscript and superscripts of a given variable are distinct. For example, R_1 is distinct from R^1.

Claims

We claim:


1. A conjugate comprising an anti-cancer compound linked to one or more phosphonate groups; or a pharmaceutically acceptable salt or solvate thereof.

2. The conjugate of claim 1, or a pharmaceutically acceptable salt or solvate thereof, that is a compound of any one of formulae **500-601** substituted with one or more groups A^0,

wherein:


A^0 is A^1, A^2 or W^3 with the proviso that the conjugate includes at least one A^1;

A^1 is:




;

A^2 is:



;

A^3 is:




;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$; and when Y^2 joins two phosphorous atoms Y^2 can also be $C(R^2)(R^2)$;

R^x is independently H, R^1, R^2, W^3, a protecting group, or the formula:



;

wherein:

R^y is independently H, W^3, R^2 or a protecting group;

R^1 is independently H or alkyl of 1 to 18 carbon atoms;

R^2 is independently H, R^1, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups or taken together at a carbon atom, two R^2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_{M2}R^5$, or $-SO_{M2}W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

W^6 is W^3 independently substituted with 1, 2, or 3 A^3 groups;

M2 is 0, 1 or 2;

M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

M1a, M1c, and M1d are independently 0 or 1; and

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.

3. The conjugate of claim 2, or a pharmaceutically acceptable salt or solvate thereof, which has the formula:

$$[DRUG]\text{-}(A^0)_{nn};$$


wherein:

DRUG is a compound of any one of formulae **500-601**; and


nn is 1, 2, or 3.

4. The conjugate of claim 2 which has any one of formulae **1-336** wherein: one A^0 is A^1 X^{50} is H F, or Cl; and X^{51} is H or Cl.


5. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




6. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




7. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



8. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



9. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




;


wherein: W^{5a} is a carbocycle or a heterocycle where W^{5a} is independently substituted with 0 or 1 R^2 groups.

10. The conjugate of any one of claims 2-4, wherein M12a is 1.


11. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



12. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




13. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



;

wherein: W^{5a} is a carbocycle independently substituted with 0 or 1 R^2 groups.

14. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




;

wherein:

Y^{2b} is O or $N(R^2)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


15. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



;

wherein: W^{5a} is a carbocycle independently substituted with 0 or 1 R^2 groups.


16. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:



;

wherein: W^{5a} is a carbocycle or heterocycle where W^{5a} is independently substituted with 0 or 1 R^2 groups.

17. The conjugate of any one of claims 2-4, wherein each A^1 is of the formula:




;

wherein:

Y^{2b} is O or $N(R^2)$; and


M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

18. The conjugate of any one of claims 2-17 wherein each A^2 is of the formula:



.

19. The conjugate of any one of claims 2-17 wherein each A^2 is of the formula:




.

20. The conjugate of any one of claims 2-17 wherein each M12b is 1.

21. The conjugate of claim 20 where M12b is 0, Y^2 is a bond and W^5 is a carbocycle or heterocycle where W^5 is optionally and independently substituted with 1, 2, or 3 R^2 groups.

22. The conjugate of any one of claims 2-17 wherein each A^2 is of the formula:




M12a ;

wherein: W^{5a} is a carbocycle or heterocycle where W^{5a} is optionally and independently substituted with 1, 2, or 3 R^2 groups.


23. The conjugate of claim 22 wherein M12a is 1.

24. The conjugate of any one of claims 2-17 wherein each A^2 is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, pyridyl and substituted pyridyl.

25. The conjugate of any one of claims 2-17 wherein each A^2 is of the formula:




26. The conjugate of any one of claims 2-17 wherein each A^2 is of the formula:




27. The conjugate of claim 26 wherein M12b is 1.


28. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



29. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



30. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{1a} is O or S; and

Y^{2a} is O, N(R^x) or S.


31. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein Y^{2b} is O or N(R^x).

32. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{2b} is O or N(R^x); and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

33. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;


wherein:

Y^{2b} is O or N(R^x); and


M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

34. The conjugate of claim 33 wherein M12d is 1.

35. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




36. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



37. The conjugate of claim 36 wherein W^5 is a carbocycle.


38. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



39. The conjugate of claim 38 wherein W^5 is phenyl.

40. The conjugate of claim 39 wherein M12b is 1.

41. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{1a} is O or S; and

Y^{2a} is O, N(R^x) or S.


42. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein Y^{2b} is O or N(R^x).

43. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein:


Y^{2b} is O or $N(R^x)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

44. The conjugate of claim 43 wherein R^1 is H.

45. The conjugate of claim 44 wherein M12d is 1.


46. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.


47. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;


wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R^2 groups.

48. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




.

49. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




.

50. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



2 .

51. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



M12a


2 ;

wherein:

Y^{1a} is O or S; and

Y^{2a} is O, $N(R^2)$ or S.

52. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



M12a

2;


wherein:

Y^{1a} is O or S;

Y^{2b} is O or $N(R^2)$; and

Y^{2c} is O, $N(R^y)$ or S.

53. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein:


Y^{1a} is O or S;

Y^{2b} is O or $N(R^2)$;

Y^{2d} is O or $N(R^y)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

54. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{2b} is O or $N(R^2)$; and


M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

55. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




wherein Y^{2b} is O or $N(R^2)$.


56. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



57. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



58. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{1a} is O or S; and

Y^{2a} is O, N(R^2) or S.

59. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;


wherein:

Y^{1a} is O or S;

Y^{2b} is O or N(R^2); and

Y^{2c} is O, N(R^y) or S.

60. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein:


Y^{1a} is O or S;

Y^{2b} is O or $N(R^2)$;

Y^{2d} is O or $N(R^y)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.

61. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:




;

wherein:

Y^{2b} is O or $N(R^2)$; and

M12d is 1, 2, 3, 4, 5, 6, 7 or 8.


62. The conjugate of any one of claims 2-27 wherein each A^3 is of the formula:



;

wherein Y^{2b} is O or $N(R^2)$.


63. The conjugate of claim 3 wherein A^0 is of the formula:



;

wherein each R is independently alkyl.

64. The conjugate of claim 1, 2, 3, or 4 which has the formula:



or a pharmaceutically acceptable salt or solvate thereof,


wherein:

DRUG is an anti-cancer compound;

Y^1 is independently O, S, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, or $N(N(R^x)(R^x))$;

Y^2 is independently a bond, O, $N(R^x)$, $N(O)(R^x)$, $N(OR^x)$, $N(O)(OR^x)$, $N(N(R^x)(R^x))$, $-S(O)_{M2}-$, or $-S(O)_{M2}-S(O)_{M2}-$;

R^x is independently H, R^2, W^3, a protecting group, or the formula:



M1a M12c M1c M1d

;

R^y is independently H, W^3, R^2 or a protecting group;

R^2 is independently H, R^3 or R^4 wherein each R^4 is independently substituted with 0 to 3 R^3 groups;

R^3 is R^{3a}, R^{3b}, R^{3c} or R^{3d}, provided that when R^3 is bound to a heteroatom, then R^3 is R^{3c} or R^{3d};

R^{3a} is F, Cl, Br, I, -CN, N_3 or $-NO_2$;

R^{3b} is Y^1;

R^{3c} is $-R^x$, $-N(R^x)(R^x)$, $-SR^x$, $-S(O)R^x$, $-S(O)_2R^x$, $-S(O)(OR^x)$, $-S(O)_2(OR^x)$, $-OC(Y^1)R^x$, $-OC(Y^1)OR^x$, $-OC(Y^1)(N(R^x)(R^x))$, $-SC(Y^1)R^x$, $-SC(Y^1)OR^x$, $-SC(Y^1)(N(R^x)(R^x))$, $-N(R^x)C(Y^1)R^x$, $-N(R^x)C(Y^1)OR^x$, or $-N(R^x)C(Y^1)(N(R^x)(R^x))$;

R^{3d} is $-C(Y^1)R^x$, $-C(Y^1)OR^x$ or $-C(Y^1)(N(R^x)(R^x))$;

R^4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;

R^5 is R^4 wherein each R^4 is substituted with 0 to 3 R^3 groups;

W^3 is W^4 or W^5;

W^4 is R^5, $-C(Y^1)R^5$, $-C(Y^1)W^5$, $-SO_2R^5$, or $-SO_2W^5$;

W^5 is carbocycle or heterocycle wherein W^5 is independently substituted with 0 to 3 R^2 groups;

M2 is 1, 2, or 3;


M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;

nn is 1, 2, or 3; and

L is a direct bond or a linking group.

65. The conjugate of claim 64 wherein each R^x is of the formula:




;

wherein,

Y^{1a} is O or S; and

Y^{2c} is O, $N(R^y)$ or S.

66. The conjugate of claim 64 wherein each R^x is of the formula:




;

wherein,

Y^{1a} is O or S; and

Y^{2d} is O or N(R^y).


67. The conjugate of claim 64 wherein each R^x is of the formula:



.


68. The conjugate of any one of claims 65-67 wherein each R^y is independently H or alkyl of 1 to 10 carbons.

69. The conjugate of claim 64 wherein each R^x is of the formula:



.


70. The conjugate of claim 64 wherein each R^x is of the formula:



M12a

.

71. The conjugate of claim 64 wherein each R^x is of the formula:



72. The conjugate of claim 64 wherein each Y^1 is O or S.

73. The conjugate of claim 64 wherein each Y^2 is O, $N(R^y)$ or S.

74. The conjugate of any one of claims 64-73 wherein nn is 1.

75. The conjugate of any one of claims 64-73 wherein nn is 2.

76. The conjugate of any one of claims 64-73 wherein nn is 3.

77. The conjugate of claim 64 wherein the anti-cancer compound is a compound of any one of formulae **500-601**.

78. The conjugate of claim 77 wherein each L has a molecular weight of from about 20 daltons to about 400 daltons.

79. The conjugate of claim 77 wherein each L has a length of about 5 angstroms to about 300 angstroms.

80. The conjugate of claim 77 wherein each L separates the compound of any one of formulae **500-601** and the phosphorous of the phosphonate group by about 5 angstroms to about 200 angstroms, inclusive.

81. The conjugate of claim 77 wherein each L is a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 2 to 25 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by (-O-), and wherein the chain is optionally substituted on carbon with one or more substituents selected from (C_1-C_6)alkoxy, (C_3-C_6)cycloalkyl, (C_1-C_6)alkanoyl, (C_1-C_6)alkanoyloxy, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylthio, azido, cyano, nitro, halo, hydroxy, oxo (=O), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy.

82. The conjugate of claim 77 wherein each L is of the formula W-A wherein A is (C_1-C_{24})alkylene, (C_2-C_{24})alkenylene, (C_2-C_{24})alkynylene, (C_3-C_8)cycloalkylene, (C_6-C_{10})aryl or a combination thereof, wherein each W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -N(R)-, -C(=O)-, -N(R)C=N(R)-N(R)-, -C(R)=N(R)-, -$S(O)_{M2}$-N(R)-, -N(R)-$S(O)_{M2}$-, or a direct bond; wherein each R is independently H or alkyl of 1 to 10 carbons.

83. The conjugate of claim 82 wherein each A is alkylene of 1 to 10 carbons.

84. The conjugate of claim 77 wherein each L is a divalent radical formed from a peptide.

85. The conjugate of claim 77 wherein each L is a divalent radical formed from an amino acid.

86. The conjugate of claim 77 wherein each L is a divalent radical formed from poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-lysine or poly-L-lysine-L-tyrosine.

87. The conjugate of claim 77 wherein each L is of the formula W-$(CH_2)_n$ wherein, n is between about 1 and about 10; and W is -N(R)C(=O)-, -

C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -$S(O)_2$-, -C(=O)-, -N(R)-, -N(R)C=N(R)-N(R)-, -C(R)=N(R)-, -$S(O)_{M2}$-N(R)-, -N(R)-$S(O)_{M2}$-, or a direct bond; wherein each R is independently H or (C_1-C_6)alkyl.

88. The conjugate of claim 77 wherein each L is methylene, ethylene, or propylene.

89. The conjugate of claim 77 wherein each L is linked to P at a carbon atom of L.

90. The conjugate as described in any one of claims 1-89, which is isolated and purified.

91. The conjugate of any one of claims 1-90 which is not an anti-inflammatory compound.

92. The conjugate of any one of claims 1-99 which is not an anti-infective.

93. The conjugate of any one of claims 1-92 which is not a compound that is active against immune-mediated conditions.

94. The conjugate of any one of claims 1-93 which is not a compound that is active against metabolic diseases.

95. The conjugate of any one of claims 1-94 which is not an antiviral agent.

96. The conjugate of any one of claims 1-95 which is not a nucleoside.

97. The conjugate of any one of claims 1-96 which is not an IMPDH inhibitor.

98. The conjugate of any one of claims 1-97 which is not an antimetabolite.

99. The conjugate of any one of claims 1-98 which is not a PNP inhibitor.

100. The conjugate of any one of claims 1-100 wherein the anti-cancer compound is not a compound of any one of formula **501**, **519**, **597**, **541**, **518**, **558**, **591**, **593**, **592**, **503**, **504**, **505**, **506**, **542**, **544**, **545**, **546**, **516**, or **512**.

101. An anti-cancer conjugate as described herein.

102. A compound of the formula MBF.

103. A compound of claim 102 selected from Table 100.

104. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103.

105. A unit dosage form comprising a conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 and a pharmaceutically acceptable excipient.

106. A method of inhibiting tumor growth *in vitro* or *in vivo* comprising the step of contacting a sample in need of such treatment with a conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103.

107. The method of claim 106 wherein the contacting is *in vivo*.

108. The method of any one of claims 106-107 wherein the tumor is located in the breast, lung, thyroid, lymph node, genitourinary system, kidney, ureter, bladder, ovary, testis, prostate, musculoskeletal system, bone, skeletal muscle, bone marrow, gastrointestinal tract, stomach, esophagus, small bowel, colon,

rectum, pancreas, liver, smooth muscle, central or peripheral nervous system, brain, spinal cord, nerves, head, neck, ear, eye, nasopharynx, oropharynx, salivary gland, cardiovascular system, oral cavity, tongue, larynx, hypopharynx, soft tissues, skin, cervix, anus, retina, and/or heart of a mammal.

109. A method of treating the symptoms or effects of cancer in an animal which comprises administering to said animal a compound as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 to the mammal.

110. A method of inhibiting neoplastic diseases, in a mammal in need of such treatment comprising administering to said animal a compound as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 to the mammal.

111. The method of claim 110 wherein the neoplasm is from acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, hairy-cell leukemia or non-Hodgkin's lymphoma.

112. The method of any one of claims 106-111 wherein the compound is formulated with a pharmaceutically acceptable carrier.

113. The method of claim 112 wherein the formulation further comprises a second active ingredient.

114. A conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 for use in medical therapy.


115. The use of a conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 to prepare a medicament for inhibiting tumor growth in an animal.

116. The use of claim 115 wherein the tumor is located in the breast, lung, thyroid, lymph node, genitourinary system, kidney, ureter, bladder, ovary, testis, prostate, musculoskeletal system, bone, skeletal muscle, bone marrow, gastrointestinal tract, stomach, esophagus, small bowel, colon, rectum, pancreas, liver, smooth muscle, central or peripheral nervous system, brain, spinal cord, nerves, head, neck, ear, eye, nasopharynx, oropharynx, salivary gland, cardiovascular system, oral cavity, tongue, larynx, hypopharynx, soft tissues, skin, cervix, anus, retina, and/or heart of a mammal.

117. The use of a conjugate as described in any one of claims 1-89 and 91-101 or a compound as described in claim 102 or 103 to prepare a medicament for inhibiting a neoplastic disease in a mammal.

118. The use of claim 117 wherein the neoplasm is from acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, hairy-cell leukemia or non-Hodgkin's lymphoma.

119. The conjugate of claim 1 having the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-

chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-d]pyrimidine;

X is selected from O, $C(R^y)_2$, $C=C(R^y)_2$, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,

Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or $N–NR_2$;


Y^2 is independently a bond, O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, $N–NR_2$, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, R, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, $-SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($–NH_2$), ammonium ($–NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone ($–SO_2R$), arylsulfone ($–SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($–SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($–C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($–N_3$), nitro ($–NO_2$), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group

(PG), or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



;

wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and


R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

120. The conjugate of claim 119 wherein C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, -NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, -SOAr, -SAr, $-SO_2NR_2$, -SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, -CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

121. The conjugate of claim 119 wherein the protecting group is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

122. The conjugate of claim 119 wherein W^5 is selected from the structures:



123. The conjugate of claim 119 wherein X is O and R^y is H.


124. The conjugate of claim 119 wherein X is $C=CH_2$ and R^y is H.

125. The conjugate of claim 119 wherein Z^1 is OH.


126. The conjugate of claim 119 wherein Z^2 is C_1–C_8 alkyl or substituted C_1–C_8alkyl.

127. The conjugate of claim 126 wherein Z^2 is CH_3.


128. The conjugate of claim 119 having the following formula:




129. The conjugate of claim 119 having the following formula:



130. The conjugate of claim 119 having the following formula:




131. The conjugate of claim 119 having the following formula:




5


132. The conjugate of claim 119 having the following formula:




133. The conjugate of claim 119 having the following formula:




134. The conjugate of claim 119 having the following formula:



135. The conjugate of claim 119 having the following formula:



136. The conjugate of claim 119 having the following formula:




137. The conjugate of claim 136 wherein Z^1 is OH.


138. The conjugate of claim 136 wherein Z^2 is C_1–C_8 alkyl or C_1–C_8 substituted alkyl.

139. The conjugate of claim 138 wherein Z^2 is CH_3.


140. The conjugate of claim 119 having the following formula:




141. The conjugate of claim 119 having the following formula:




142. The conjugate of claim 119 having the following formula:




143. The conjugate of claim 119 having the following formula:




144. The conjugate of claim 119 having the following formula:




145. The conjugate of claim 119 having the following formula:




146. The conjugate of claim 119 having the following formula:



147. The conjugate of claim 119 having the following formula:




148. The conjugate of claim 147 having the following formula:




;

wherein R^2 is H or C_1–C_8 alkyl.

149. The conjugate of claim 148 having the following formula:




150. The conjugate of claim 148 having the following formula:



;

wherein Y^{2c} is O, $N(R^y)$ or S.

151. The conjugate of claim 150 having the following formula:




.

152. The conjugate of claim 151 wherein Y^{2c} is O.


153. The conjugate of claim 151 wherein Y^{2c} is $N(CH_3)$.

154. The conjugate of claim 151 wherein R^y is H or C_1–C_8 alkyl.

155. The conjugate of claim 119 wherein substituted triazole has the structure:



156. A composition having the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-d]pyrimidine;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


R^y is independently H, F, Cl, Br, I, OH, R, -C(=Y^1)R, -C(=Y^1)OR, -C(=Y^1)N(R_2), -N(R_2), -$^+$N(R_3), -SR, -S(O)R, -$S(O)_2$R, -S(O)(OR), -$S(O)_2$(OR), -OC(=Y^1)R, -OC(=Y^1)OR, -OC(=Y^1)(N(R_2)), -SC(=Y^1)R, -SC(=Y^1)OR, -SC(=Y^1)(N(R_2)), -N(R)C(=Y^1)R, -N(R)C(=Y^1)OR, or -N(R)C(=Y^1)N(R_2),

amino ($-NH_2$), ammonium ($-NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1-C_8 alkyl, C_1-C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1-C_8 alkylsulfonate, C_1-C_8 alkylamino, 4-dialkylaminopyridinium, C_1-C_8 alkylhydroxyl, C_1-C_8 alkylthiol, alkylsulfone ($-SO_2R$), arylsulfone ($-SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($-SO_2NR_2$), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido ($-C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($-N_3$), nitro ($-NO_2$), C_1-C_8 alkoxy (–OR), C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_1-C_8 alkenyl, C_1-C_8 substituted alkenyl, C_1-C_8 alkynyl, C_1-C_8 substituted alkynyl, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heterocycle, C_2-C_{20} substituted heterocycle, polyethyleneoxy, a protecting group (PG), or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1-C_8 alkyl, C_1-C_8 substituted alkyl, C_1-C_8 alkenyl, C_1-C_8 substituted alkenyl, C_1-C_8 alkynyl, C_1-C_8 substituted alkynyl, C_6-C_{20} aryl, C_6-C_{20} substituted aryl, C_2-C_{20} heterocycle, C_2-C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

157. The composition of claim 156 having the following formula:



;

wherein PG is a protecting group selected from an ether-forming group, a thioether-forming group, an ester-forming group, a thioester-forming group, a

silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, a urea-forming group, an amino acid conjugate, and a polypeptide conjugate

158. A conjugate of claim 119 which is capable of accumulating in human PBMC.

159. The conjugate of claim 158 wherein the bioavailability of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to an analog of the conjugate not having the prodrug moiety (the phosphonate group(s)).

160. The conjugate of claim 158 wherein the intracellular half-life of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to the analog of the conjugate not having the prodrug moiety.

161. The conjugate of claim 160 wherein the half-life is improved by at least about 50%.

162. The conjugate of claim 160 wherein the half-life is improved by at least about 100%.

163. The conjugate of claim 158 wherein the intracellular half-life of a metabolite of the conjugate in human PBMC is improved when compared to an analog of the metabolite not having the prodrug moiety.


164. The conjugate of claim 158 wherein the half-life is improved by at least about 50%.

165. The conjugate of claim 158 wherein the half-life is improved by at least about 100%.

166. The conjugate of claim 158 wherein the half-life is improved by greater than 100%.

167. A pharmaceutical composition comprising a therapeutically effective amount of a conjugate of claim 119, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

168. The conjugate of claim 1 having the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-

methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or N–NR_2;

Y^2 is independently a bond, O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, N–NR_2, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, R, -C(=Y^1)R, -C(=Y^1)OR, -C(=Y^1)N$(R)_2$, -N$(R)_2$, -$^+$N$(R)_3$, -SR, -S(O)R, -S$(O)_2$R, -S(O)(OR), -S$(O)_2$(OR), -OC(=Y^1)R, -OC(=Y^1)OR, -OC(=Y^1)(N$(R)_2$), -SC(=Y^1)R, -SC(=Y^1)OR, -SC(=Y^1)(N$(R)_2$), -N(R)C(=Y^1)R, -N(R)C(=Y^1)OR, or -N(R)C(=Y^1)N$(R)_2$, amino (–NH_2), ammonium (–NH_3^+), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone (–SO_2R), arylsulfone (–SO_2Ar), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide (–SO_2NR_2), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido (–C(=O)NR_2), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido (–N_3), nitro (–NO_2), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



;

wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and


W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

169. The conjugate of claim 168 wherein C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, -NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, -SOAr, -SAr, $-SO_2NR_2$, -SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, -CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.

170. The conjugate of claim 168 wherein protecting group is selected from a


carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

171. The conjugate of claim 168 wherein W^5 is selected from the structures:




172. The conjugate of claim 168 wherein X is O and R^y is H.

173. The conjugate of claim 168 having the formula:




174. The conjugate of claim 168 having the structure:



175. The conjugate of claim 174 wherein Z^1 is OH.


176. The conjugate of claim 174 wherein Z^2 is CH_3.

177. The conjugate of claim 173 having the structure:




178. The conjugate of claim 177 wherein Z^2 is C_1–C_8 alkyl or C_1–C_8 substituted alkyl.


179. The conjugate of claim 177 having the structure:




180. The conjugate of claim 177 having the structure:




181. The conjugate of claim 173 having the structure:




182. The conjugate of claim 181 having the structure:




183. The conjugate of claim 182 having the structure:



184. The conjugate of claim 183 having the structure:




185. The conjugate of claim 184 having the structure:




wherein R^2 is H or C_1–C_8 alkyl.

186 The conjugate of claim 185 having the structure:




187. The conjugate of claim 186 having the structure:



wherein Y^{2c} is O, $N(R^y)$ or S.


188. The conjugate of claim 187 having the structure:




189. The conjugate of claim 188 wherein Y^{2c} is O.

190. The conjugate of claim 188 wherein Y^{2c} is $N(CH_3)$.

191. The conjugate of claim 168 wherein substituted triazole has the structure:



192. The conjugate of claim 1 having the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-D]pyrimidine;

X^a is selected from O, NR and S;

Z^1 is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Z^2 is selected from H, C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, and C_1–C_8 substituted alkynyl,


R^y is independently H, F, Cl, Br, I, OH, R, -C(=Y^1)R, -C(=Y^1)OR, -C(=Y^1)N(R)$_2$, -N(R)$_2$, -$^+$N(R)$_3$, -SR, -S(O)R, -S(O)$_2$R, -S(O)(OR), -S(O)$_2$(OR), -OC(=Y^1)R, -OC(=Y^1)OR, -OC(=Y^1)(N(R)$_2$), -SC(=Y^1)R, -SC(=Y^1)OR, -SC(=Y^1)(N(R)$_2$), -N(R)C(=Y^1)R, -N(R)C(=Y^1)OR, or -N(R)C(=Y^1)N(R)$_2$, amino (–NH_2), ammonium (–NH_3^+), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone (–SO_2R), arylsulfone (–SO_2Ar), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide (–SO_2NR_2), alkylsulfoxide (–SOR), ester (–C(=O)OR), amido (–C(=O)NR_2), 5-7 membered ring lactam, 5-7 membered ring lactone,

nitrile (–CN), azido ($–N_3$), nitro ($–NO_2$), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, a protecting group, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

193. The conjugate of claim 192 having Formula IIa:



IIa ;

wherein PG is a protecting group selected from an ether-forming group, a thioether-forming group, an ester-forming group, a thioester-forming group, a silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, a urea-forming group, an amino acid conjugate, and a polypeptide conjugate

194. A conjugate of claim 168 or a pharmaceutically acceptable salt or solvate thereof; which is capable of accumulating in human PBMC.

195. The conjugate of claim 194 wherein the bioavailability of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to the analog of the conjugate not having the prodrug moiety (phosphonate group(s)).

196. The conjugate of claim 194 wherein the intracellular half-life of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to the analog of the conjugate not having the prodrug moiety.

197. The conjugate of claim 196 wherein the half-life is improved by at least about 50%.

198. The conjugate of claim 196 wherein the half-life is improved by at least about 100%.

199. The conjugate of claim 194 wherein the intracellular half-life of a metabolite of the conjugate in human PBMC is improved when compared to an analog of the metabolite not having the prodrug moiety.


200. The conjugate of claim 199 wherein the half-life is improved by at least about 50%.

201. The conjugate of claim 199 wherein the half-life is improved by at least about 100%.

202. The conjugate of claim 199 wherein the half-life is improved by greater than 100%.

203. A pharmaceutical composition comprising a therapeutically effective amount of a conjugate of claim 168, or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable excipient.

204. The conjugate of claim 1 that has the following formula:



or a pharmaceutically acceptable salt or solvate thereof;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-d]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;


Y^1 is independently O, S, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, or $N–NR_2$;

Y^2 is independently O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, $N–NR_2$, S, S–S, S(O), or $S(O)_2$;

M2 is 0, 1 or 2;

R^y is independently H, F, Cl, Br, I, OH, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, $-SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($-NH_2$), ammonium ($-NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone ($-SO_2R$), arylsulfone ($-SO_2Ar$), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide ($-SO_2NR_2$), alkylsulfoxide (–SOR), ester ($-C(=O)OR$), amido ($-C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido ($-N_3$), nitro ($-NO_2$), C_1–C_8 alkoxy (–OR), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R^x is independently R^y, a protecting group, or the formula:



;

wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and


R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

W^3 is W^4 or W^5, where W^4 is R, $-C(Y^1)R^y$, $-C(Y^1)W^5$, $-SO_2R^y$, or $-SO_2W^5$; and W^5 is a carbocycle or a heterocycle wherein W^5 is independently substituted with 0 to 3 R^y groups.

205. The conjugate of claim 204 wherein C_1–C_8 substituted alkyl, C_1–C_8 substituted alkenyl, C_1–C_8 substituted alkynyl, C_6–C_{20} substituted aryl, and C_2–C_{20} substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, $-NH_2$, $-NH_3^+$, –NHR, $-NR_2$, $-NR_3^+$, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, $-SO_2R$, $-SO_2Ar$, –SOAr, –SAr, $-SO_2NR_2$, –SOR, $-CO_2R$, $-C(=O)NR_2$, 5-7 membered ring lactam, 5-7 membered ring lactone, –CN, $-N_3$, $-NO_2$, C_1–C_8 alkoxy, C_1–C_8 trifluoroalkyl, C_1–C_8 alkyl, C_3–C_{12} carbocycle, C_6–C_{20} aryl, C_2–C_{20} heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety.


206. The conjugate of claim 204 wherein protecting group is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate.

207. The conjugate of claim 204 wherein W^5 is selected from the structures:




208. The conjugate of claim 204 wherein X is O and each R^y is H.


209. The conjugate of claim 204 wherein the conjugate is a resolved enantiomer having the structure:




210. The conjugate of claim 204 wherein the conjugate is a resolved enantiomer having the structure:




211. The conjugate of claim 209 having the structure:




212. The conjugate of claim 209 having the structure:




213. The conjugate of claim 212 having the structure:




214. The conjugate of claim 213 having the structure:



215. The conjugate of claim 214 having the structure:




216. The conjugate of claim 215 having the structure:



;


wherein R^2 is H or C_1–C_8 alkyl.

217. The conjugate of claim 216 having the structure:



.

218. The conjugate of claim 217 having the structure:




.

219. The conjugate of claim 217 wherein Z is H.

220. The conjugate of claim 217 wherein B is adenine.


221. The conjugate of claim 217 having the structure:



;

wherein Y^{2c} is O, N(R^y) or S.

222. The conjugate of claim 221 having the structure:




.


223. The conjugate of claim 222 wherein Y^{2c} is O.

224. The conjugate of claim 222 wherein Y^{2c} is N(CH_3).

225. The conjugate of claim 204 wherein substituted triazole has the structure:



226. The conjugate of claim 1 having the following formula:



;

wherein:

B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O^6-methylguanine, N^6-methyladenine, O^4-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-d]pyrimidine;

X is selected from O, $C(R^y)_2$, $OC(R^y)_2$, NR and S;

Z is independently selected from H, OH, OR, NR_2, CN, NO_2, SH, SR, F, Cl, Br, and I;

Y^2 is independently O, CR_2, NR, $^+N(O)(R)$, N(OR), $^+N(O)(OR)$, N–NR_2, S, S–S, S(O), or $S(O)_2$;

R^y is independently H, F, Cl, Br, I, OH, $-C(=Y^1)R$, $-C(=Y^1)OR$, $-C(=Y^1)N(R)_2$, $-N(R)_2$, $-^+N(R)_3$, -SR, -S(O)R, $-S(O)_2R$, -S(O)(OR), $-S(O)_2(OR)$, $-OC(=Y^1)R$, $-OC(=Y^1)OR$, $-OC(=Y^1)(N(R)_2)$, $-SC(=Y^1)R$, $-SC(=Y^1)OR$, -

$SC(=Y^1)(N(R)_2)$, $-N(R)C(=Y^1)R$, $-N(R)C(=Y^1)OR$, or $-N(R)C(=Y^1)N(R)_2$, amino ($-NH_2$), ammonium ($-NH_3^+$), alkylamino, dialkylamino, trialkylammonium, C_1–C_8 alkyl, C_1–C_8 alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C_1–C_8 alkylsulfonate, C_1–C_8 alkylamino, 4-dialkylaminopyridinium, C_1–C_8 alkylhydroxyl, C_1–C_8 alkylthiol, alkylsulfone ($-SO_2R$), arylsulfone ($-SO_2Ar$), arylsulfoxide ($-SOAr$), arylthio ($-SAr$), sulfonamide ($-SO_2NR_2$), alkylsulfoxide ($-SOR$), ester ($-C(=O)OR$), amido ($-C(=O)NR_2$), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ($-CN$), azido ($-N_3$), nitro ($-NO_2$), C_1–C_8 alkoxy ($-OR$), C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, polyethyleneoxy, or W^3; or when taken together, R^y forms a carbocyclic ring of 3 to 7 carbon atoms;

R is C_1–C_8 alkyl, C_1–C_8 substituted alkyl, C_1–C_8 alkenyl, C_1–C_8 substituted alkenyl, C_1–C_8 alkynyl, C_1–C_8 substituted alkynyl, C_6–C_{20} aryl, C_6–C_{20} substituted aryl, C_2–C_{20} heterocycle, C_2–C_{20} substituted heterocycle, or a protecting group; and

PG is a protecting group selected from an ether-forming group, an ester-forming group, a silyl-ether forming group, an amide-forming group, an acetal-forming group, a ketal-forming group, a carbonate-forming group, a carbamate-forming group, an amino acid, and a polypeptide.

227. A conjugate of claim 204 or a pharmaceutically acceptable salt or solvate thereof; which is capable of accumulating in human PBMC.

228. The conjugate of claim 227 wherein the bioavailability of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to the analog of the conjugate not having the prodrug moiety.

229. The conjugate of claim 227 wherein the intracellular half-life of the conjugate or an intracellular metabolite of the conjugate in human PBMC is improved when compared to the analog of the conjugate not having the prodrug moiety.

230. The conjugate of claim 229 wherein the half-life is improved by at least about 50%.

231. The conjugate of claim 229 wherein the half-life is improved by at least about 100%.

232. The conjugate of claim 227 wherein the intracellular half-life of a metabolite of the conjugate in human PBMC is improved when compared to an analog of the metabolite not having the prodrug moiety.

233. The conjugate of claim 232 wherein the half-life is improved by at least about 50%.

234. The conjugate of claim 232 wherein the half-life is improved by at least about 100%.

235. The conjugate of claim 232 wherein the half-life is improved by greater than 100%.

236. A pharmaceutical composition comprising a therapeutically effective amount of a conjugate of claim 204 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable excipient.

237. A method of inhibiting tumor growth *in vitro* or *in vivo* comprising the step of contacting a sample in need of such treatment with a conjugate as described in any one of claims 119-235.

238. The method of claim 237 wherein the contacting is *in vivo*.

239. The method of claim 237 wherein the tumor is located in the breast, lung, thyroid, lymph node, genitourinary system, kidney, ureter, bladder, ovary, testis, prostate, musculoskeletal system, bone, skeletal muscle, bone marrow, gastrointestinal tract, stomach, esophagus, small bowel, colon, rectum, pancreas, liver, smooth muscle, central or peripheral nervous system, brain, spinal cord, nerves, head, neck, ear, eye, nasopharynx, oropharynx, salivary gland, cardiovascular system, oral cavity, tongue, larynx, hypopharynx, soft tissues, skin, cervix, anus, retina, and/or heart of a mammal.

240. A method of treating the symptoms or effects of cancer in an animal which comprises administering to said animal a conjugate as described in any one of claims 119-235.

241. A method of inhibiting neoplastic diseases, in a mammal in need of such treatment comprising administering to said animal a conjugate as described in any one of claims 119-235.

242. The method of claim 241 wherein the neoplasm is from acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, hairy-cell leukemia or non-Hodgkin's lymphoma.

243. The method of claim 242 wherein the compound is formulated with a pharmaceutically acceptable carrier.

244. The method of claim 243 wherein the formulation further comprises a second active ingredient.

245. A conjugate as described in any one of claims 119-235 for use in medical therapy.

246. The use of a conjugate as described in any one of claims 119-235 to prepare a medicament for inhibiting tumor growth in an animal.

247. The use of a conjugate as described in claim 246 wherein the tumor is located in the breast, lung, thyroid, lymph node, genitourinary system, kidney, ureter, bladder, ovary, testis, prostate, musculoskeletal system, bone, skeletal muscle, bone marrow, gastrointestinal tract, stomach, esophagus, small bowel, colon, rectum, pancreas, liver, smooth muscle, central or peripheral nervous system, brain, spinal cord, nerves, head, neck, ear, eye, nasopharynx, oropharynx, salivary gland, cardiovascular system, oral cavity, tongue, larynx, hypopharynx, soft tissues, skin, cervix, anus, retina, and/or heart of a mammal.

248. The use of a conjugate as described in any one of claims 119-235 to prepare a medicament for inhibiting a neoplastic disease in a mammal.

249. The use of a conjugate as described in claim 248 wherein the neoplasm is from acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, cutaneous T-cell lymphoma, hairy-cell leukemia or non-Hodgkin's lymphoma.